FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Menendez, ME
Bot, AGJ
Hageman, MGJS
Neuhaus, V
Mudgal, CS
Ring, D
AF Menendez, Mariano E.
Bot, Arjan G. J.
Hageman, Michiel G. J. S.
Neuhaus, Valentin
Mudgal, Chaitanya S.
Ring, David
TI Computerized Adaptive Testing of Psychological Factors: Relation to
Upper-Extremity Disability
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Editorial Material
C1 [Menendez, Mariano E.; Bot, Arjan G. J.; Hageman, Michiel G. J. S.; Neuhaus, Valentin; Mudgal, Chaitanya S.; Ring, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Menendez, ME (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0021-9355
EI 1535-1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD OCT 16
PY 2013
VL 95A
IS 20
BP 1844
EP 1844
PG 1
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 244DQ
UT WOS:000326367700005
ER
PT J
AU Devor, A
Bandettini, PA
Boas, DA
Bower, JM
Buxton, RB
Cohen, LB
Dale, AM
Einevoll, GT
Fox, PT
Franceschini, MA
Friston, KJ
Fujimoto, JG
Geyer, MA
Greenberg, JH
Halgren, E
Hamalainen, MS
Helmchen, F
Hyman, BT
Jasanoff, A
Jernigan, TL
Judd, LL
Kim, SG
Kleinfeld, D
Kopell, NJ
Kutas, M
Kwong, KK
Larkum, ME
Lo, EH
Magistretti, PJ
Mandeville, JB
Masliah, E
Mitra, PP
Mobley, WC
Moskowitz, MA
Nimmerjahn, A
Reynolds, JH
Rosen, BR
Salzberg, BM
Schaffer, CB
Silva, GA
So, PTC
Spitzer, NC
Toote, RB
Van Essen, DC
Vanduffel, W
Vinogradov, SA
Wald, LL
Wang, LV
Weber, B
Yodh, AG
AF Devor, Anna
Bandettini, Peter A.
Boas, David A.
Bower, James M.
Buxton, Richard B.
Cohen, Lawrence B.
Dale, Anders M.
Einevoll, Gaute T.
Fox, Peter T.
Franceschini, Maria Angela
Friston, Karl J.
Fujimoto, James G.
Geyer, Mark A.
Greenberg, Joel H.
Halgren, Eric
Haemaelaeinen, Math S.
Helmchen, Fritjof
Hyman, Bradley T.
Jasanoff, Alan
Jernigan, Terry L.
Judd, Lewis L.
Kim, Seong-Gi
Kleinfeld, David
Kopell, Nancy J.
Kutas, Marta
Kwong, Kenneth K.
Larkum, Matthew E.
Lo, Eng H.
Magistretti, Pierre J.
Mandeville, Joseph B.
Masliah, Eliezer
Mitra, Partha P.
Mobley, William C.
Moskowitz, Michael A.
Nimmerjahn, Axel
Reynolds, John H.
Rosen, Bruce R.
Salzberg, Brian M.
Schaffer, Chris B.
Silva, Gabriel A.
So, Peter T. C.
Spitzer, Nicholas C.
Toote, Roger B.
Van Essen, David C.
Vanduffel, Wim
Vinogradov, Sergei A.
Wald, Lawrence L.
Wang, Lihong V.
Weber, Bruno
Yodh, Arjun G.
TI The Challenge of Connecting the Dots in the BRAIN
SO NEURON
LA English
DT Editorial Material
AB The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative has focused scientific attention on the necessary tools to understand the human brain and mind. Here, we outline our collective vision for what we can achieve within a decade with properly targeted efforts and discuss likely technological deliverables and neuroscience progress.
C1 [Devor, Anna; Dale, Anders M.; Halgren, Eric; Kutas, Marta; Masliah, Eliezer; Mobley, William C.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Devor, Anna; Buxton, Richard B.; Dale, Anders M.; Halgren, Eric; Jernigan, Terry L.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA.
[Devor, Anna; Boas, David A.; Franceschini, Maria Angela; Haemaelaeinen, Math S.; Kwong, Kenneth K.; Mandeville, Joseph B.; Rosen, Bruce R.; Toote, Roger B.; Vanduffel, Wim; Wald, Lawrence L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Bandettini, Peter A.] NIH, Sect Funct Imaging Methods, Lab Brain & Cognit, Bethesda, MD 20892 USA.
[Bandettini, Peter A.] NIMH, Funct MRI Facil, NIH, Bethesda, MD 20892 USA.
[Bower, James M.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Cohen, Lawrence B.] Korea Inst Sci & Technol, Ctr Funct Connect, Seoul 139791, South Korea.
[Cohen, Lawrence B.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA.
[Einevoll, Gaute T.] Norwegian Univ Life Sci, Dept Math Sci & Technol, N-1432 As, Norway.
[Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Fox, Peter T.] Audie L Murphy South Texas Vet Adm Med Ctr, San Antonio, TX 78229 USA.
[Friston, Karl J.] Wellcome Trust Ctr Neuroimaging, London WC1N 3BG, England.
[Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
[Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
[Geyer, Mark A.; Jernigan, Terry L.; Judd, Lewis L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Greenberg, Joel H.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Helmchen, Fritjof] Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland.
[Helmchen, Fritjof; Weber, Bruno] Univ Zurich, Neurosci Ctr Zurich, CH-8057 Zurich, Switzerland.
[Helmchen, Fritjof; Weber, Bruno] ETH, CH-8092 Zurich, Switzerland.
[Hyman, Bradley T.] Harvard Univ, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Dept Neurol,Alzheimers Dis Res Lab,Med Sch, Charlestown, MA 02129 USA.
[Jasanoff, Alan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Jasanoff, Alan] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Jasanoff, Alan] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Jasanoff, Alan] MIT, Dept Nucl Sci & Engn, Cambridge, MA 02139 USA.
[Jernigan, Terry L.] Univ Calif San Diego, Ctr Human Dev, La Jolla, CA 92093 USA.
[Jernigan, Terry L.; Kutas, Marta] Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA.
[Kim, Seong-Gi] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15203 USA.
[Kim, Seong-Gi] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15203 USA.
[Kleinfeld, David] Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA.
[Kleinfeld, David] Univ Calif San Diego, Neurobiol Sect, La Jolla, CA 92093 USA.
[Kopell, Nancy J.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Kutas, Marta] Univ Calif San Diego, Ctr Res Language, La Jolla, CA 92093 USA.
[Larkum, Matthew E.] Charite, Neurosci Res Ctr NWFZ, D-10117 Berlin, Germany.
[Lo, Eng H.; Moskowitz, Michael A.] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Neurosci Ctr,Med Sch, Boston, MA 02129 USA.
[Lo, Eng H.; Moskowitz, Michael A.] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Neurosci Ctr,Med Sch, Boston, MA 02129 USA.
[Magistretti, Pierre J.] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Neuroenerget & Cellular Dynam, CH-1015 Lausanne, Switzerland.
[Magistretti, Pierre J.] Univ Lausanne, CH-1015 Lausanne, Switzerland.
[Mitra, Partha P.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
[Nimmerjahn, Axel] Salk Inst Biol Studies, Waitt Adv Biophoton Ctr, La Jolla, CA 92037 USA.
[Reynolds, John H.] Salk Inst Biol Studies, Syst Neurobiol Labs, La Jolla, CA 92037 USA.
[Salzberg, Brian M.] Univ Penn, Perelman Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.
[Salzberg, Brian M.] Univ Penn, Perelman Sch Med, Dept Physiol, Philadelphia, PA 19104 USA.
[Schaffer, Chris B.] Cornell Univ, Dept Biomed Engn, Ithaca, NY 14850 USA.
[Silva, Gabriel A.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
[Silva, Gabriel A.] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
[So, Peter T. C.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[So, Peter T. C.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Spitzer, Nicholas C.] Univ Calif San Diego, Div Biol Sci, Kavli Inst Brain & Mind, Neurobiol Sect, La Jolla, CA 92093 USA.
[Toote, Roger B.] NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA.
[Van Essen, David C.] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.
[Vanduffel, Wim] Katholieke Univ Leuven, Sch Med, Lab Neuro & Psychofysiol, B-3000 Louvain, Belgium.
[Vinogradov, Sergei A.] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.
[Wang, Lihong V.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA.
[Weber, Bruno] Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland.
[Yodh, Arjun G.] Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA.
RP Devor, A (reprint author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
EM adevor@ucsd.edu
RI Hamalainen, Matti/C-8507-2013; Schaffer, Chris/A-7409-2008; Friston,
Karl/D-9230-2011; Fox, Peter/B-4725-2010; Weber, Bruno/E-4400-2013;
Wald, Lawrence/D-4151-2009
OI Schaffer, Chris/0000-0002-7800-9596; Friston, Karl/0000-0001-7984-8909;
Fox, Peter/0000-0002-0465-2028;
FU NEI NIH HHS [R01 EY022096]; NIBIB NIH HHS [P41 EB015871, R01 EB000790,
R01 EB003832]; NICHD NIH HHS [R01 HD022614]; NIDA NIH HHS [R01
DA029706]; NIH HHS [DP1 OD006831]; NINDS NIH HHS [DP1 NS082097, R01
NS040966, R01 NS057198, R01 NS058668]; Wellcome Trust [091593, 088130]
NR 1
TC 30
Z9 30
U1 4
U2 53
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD OCT 16
PY 2013
VL 80
IS 2
BP 270
EP 274
DI 10.1016/j.neuron.2013.09.008
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 241VI
UT WOS:000326196400009
PM 24139032
ER
PT J
AU Suh, J
Choi, SH
Romano, DM
Gannon, MA
Lesinski, AN
Kim, DY
Tanzi, RE
AF Suh, Jaehong
Choi, Se Hoon
Romano, Donna M.
Gannon, Moira A.
Lesinski, Andrea N.
Kim, Doo Yeon
Tanzi, Rudolph E.
TI ADAM10 Missense Mutations Potentiate beta-Amyloid Accumulation by
Impairing Prodomain Chaperone Function
SO NEURON
LA English
DT Article
ID ALPHA-SECRETASE ACTIVITY; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE;
PROTEOLYTIC ACTIVITY; IN-VIVO; DISINTEGRIN; DOMAIN; BRAIN; APP;
PROLIFERATION
AB The generation of A beta, the main component of senile plaques in Alzheimer's disease (AD), is precluded by alpha-secretase cleavage within the A beta domain of the amyloid precursor protein (APP). We identified two rare mutations (Q170H and R181G) in the prodomain of the metalloprotease, ADAM10, that cosegregate with late-onset AD (LOAD). Here, we addressed the pathogenicity of these mutations in transgenic mice expressing human ADAM10 in brain. In Tg2576 AD mice, both mutations attenuated alpha-secretase activity of ADAM10 and shifted APP processing toward beta-secretase-mediated cleavage, while enhancing A beta plaque load and reactive gliosis. We also demonstrated ADAM10 expression potentiates adult hippocampal neurogenesis, which is reduced by the LOAD mutations. Mechanistically, both LOAD mutations impaired the molecular chaperone activity of ADAM10 prodomain. Collectively, these findings suggest that diminished alpha-secretase activity, owing to LOAD ADAM10 prodomain mutations, leads to AD-related pathology, strongly supporting ADAM10 as a promising therapeutic target for this devastating disease.
C1 [Suh, Jaehong; Choi, Se Hoon; Romano, Donna M.; Gannon, Moira A.; Lesinski, Andrea N.; Kim, Doo Yeon; Tanzi, Rudolph E.] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Boston, MA 02129 USA.
[Suh, Jaehong; Choi, Se Hoon; Romano, Donna M.; Gannon, Moira A.; Lesinski, Andrea N.; Kim, Doo Yeon; Tanzi, Rudolph E.] Harvard Univ, Sch Med, Boston, MA 02129 USA.
RP Tanzi, RE (reprint author), Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Boston, MA 02129 USA.
EM tanzi@helix.mgh.harvard.edu
FU Cure Alzheimer's Fund; NIA, NIMH; American Health Assistance Foundation
FX We thank Dr. Lin Wu for her scientific expertise and technical
assistance in generating ADAM10 transgenic mice. We also thank Dr. Jorg
Bartsch for providing ADAM10 prodomain antibody; Dr. Sam Sisodia for
providing MoPrP.Xhol plasmid; Dr. Matthew Frosch for providing Tg2576
mice; Dr. Basavaraj Hooli and Dr. Can Zhang for helpful discussions; and
William Wisdom for mouse tail genotyping. This study was supported by
the Cure Alzheimer's Fund, grants from the NIA, NIMH (R.E.T.), and the
American Health Assistance Foundation (J.S.).
NR 44
TC 51
Z9 52
U1 1
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD OCT 16
PY 2013
VL 80
IS 2
BP 385
EP 401
DI 10.1016/j.neuron.2013.08.035
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA 241VI
UT WOS:000326196400020
PM 24055016
ER
PT J
AU Shah, NR
Chokshi, DA
AF Shah, Nirav R.
Chokshi, Dave A.
TI Should Health Care Systems Become Insurers?
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID ORGANIZATIONS
C1 [Shah, Nirav R.] New York State Dept Hlth, Albany, NY USA.
[Chokshi, Dave A.] US Dept Vet Affairs, Washington, DC USA.
RP Chokshi, DA (reprint author), Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20006 USA.
EM dave.chokshi@alumni.duke.edu
OI Shah, Nirav/0000-0003-2044-7865; Chokshi, Dave/0000-0001-7467-4591
NR 6
TC 2
Z9 2
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 16
PY 2013
VL 310
IS 15
BP 1561
EP 1562
DI 10.1001/jama.2013.280015
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 234EP
UT WOS:000325624800015
PM 24129460
ER
PT J
AU Li, N
Lim, G
Chen, L
McCabe, MF
Kim, H
Zhang, SZ
Mao, JR
AF Li, Na
Lim, Grewo
Chen, Lucy
McCabe, Michael F.
Kim, Hyangin
Zhang, Shuzhuo
Mao, Jianren
TI Spinal expression of Hippo signaling components YAP and TAZ following
peripheral nerve injury in rats
SO BRAIN RESEARCH
LA English
DT Article
DE Neuropathic pain; Hippo signaling pathway; Spinal cord; Dorsal horn;
Proliferation; Dendrite; Synaptic plasticity; Structural plasticity
ID GENE-RELATED PEPTIDE; CORD DORSAL-HORN; NEUROPATHIC PAIN; SENSORY
NEURONS; ADULT-RAT; CENTRAL SENSITIZATION; CONSTRICTION INJURY;
DEPENDENT MECHANISM; NEGATIVE REGULATION; CELL-PROLIFERATION
AB Previous studies have shown that the morphology and number of cells in the spinal cord dorsal horn could change following peripheral nerve injury and that the Hippo signaling pathway plays an important role in cell growth, proliferation, apoptosis, and dendritic remolding. In the present study, we examined whether the expression of YAP and TAZ, two critical components regulated by Hippo signaling, in the spinal cord dorsal horn would be altered by chronic constriction sciatic nerve injury (CCI). We found that (1) YAP was mainly expressed on CGRP- and IB4-immunoreactive primary afferent nerve terminals without noticeable expression on glial cells, whereas TAZ was mainly expressed on spinal cord second order neurons as well as microglia; (2) upregulation of YAP and TAZ expression followed two distinct temporal patterns after CCI, such that the highest expression of YAP and TAZ was on day 14 and day 1 after CCI, respectively; (3) there were also unique topographic patterns of YAP and TAZ distribution in the spinal cord dorsal horn consistent with their distinctive association with primary afferents and second order neurons; (4) changes in the YAP expression were selectively induced by CCI but not CFA-induced hindpaw inflammation; and (5) the number of nuclear profiles of TAZ expression was significantly increased after CCI, indicating translocation of TAZ from the cytoplasma to nucleus. These findings indicate that peripheral nerve injury induced time-dependent and region-specific changes in the spinal YAP and TAZ expression. A role for Hippo signaling in synaptic and structural plasticity is discussed in relation to the cellular mechanism of neuropathic pain. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Li, Na; Lim, Grewo; Chen, Lucy; McCabe, Michael F.; Kim, Hyangin; Zhang, Shuzhuo; Mao, Jianren] Harvard Univ, MGH Ctr Translat Pain Res, Dept Anesthesia Crit Care & Pain Med, Sch Med,Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Li, Na] Chengdu Mil Command, Kunming Gen Hosp, Dept Anesthesiol, Kunming, Yunnan, Peoples R China.
[Zhang, Shuzhuo] Beijing Inst Pharmacol & Toxicol, Beijing, Peoples R China.
RP Mao, JR (reprint author), Harvard Univ, MGH Ctr Translat Pain Res, Dept Anesthesia Crit Care & Pain Med, Sch Med,Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM lina8346@yahoo.com; glim@partners.org; jmao@partners.org
FU NIH [DE18214, DE022901, DE18538]
FX This work was partially supported by NIH RO1 grants DE18214, DE022901
and DE18538. We thank Drs. Shuxing Wang and Zerong You for their
technique support.
NR 61
TC 3
Z9 3
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD OCT 16
PY 2013
VL 1535
BP 137
EP 147
DI 10.1016/j.brainres.2013.08.049
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 236WY
UT WOS:000325831400013
PM 23998984
ER
PT J
AU Hills, LB
Masri, A
Konno, K
Kakegawa, W
Lam, ATN
Lim-Melia, E
Chandy, N
Hill, RS
Partlow, JN
Al-Saffar, M
Nasir, R
Stoler, JM
Barkovich, AJ
Watanabe, M
Yuzaki, M
Mochida, GH
AF Hills, L. Benjamin
Masri, Amira
Konno, Kotaro
Kakegawa, Wataru
Lam, Anh-Thu N.
Lim-Melia, Elizabeth
Chandy, Nandini
Hill, R. Sean
Partlow, Jennifer N.
Al-Saffar, Muna
Nasir, Ramzi
Stoler, Joan M.
Barkovich, A. James
Watanabe, Masahiko
Yuzaki, Michisuke
Mochida, Ganeshwaran H.
TI Deletions in GRID2 lead to a recessive syndrome of cerebellar ataxia and
tonic upgaze in humans
SO NEUROLOGY
LA English
DT Article
ID DELTA-2 GLUTAMATE-RECEPTOR; COGNITIVE-AFFECTIVE SYNDROME; MOTOR
COORDINATION; SYNAPSE FORMATION; PURKINJE-CELLS; MUTANT MICE; HOT-SPOT;
GENE; MALFORMATIONS; SUBUNIT
AB Objective: To identify the genetic cause of a syndrome causing cerebellar ataxia and eye movement abnormalities.
Methods: We identified 2 families with cerebellar ataxia, eye movement abnormalities, and global developmental delay. We performed genetic analyses including single nucleotide polymorphism genotyping, linkage analysis, array comparative genomic hybridization, quantitative PCR, and Sanger sequencing. We obtained eye movement recordings of mutant mice deficient for the ortholog of the identified candidate gene, and performed immunohistochemistry using human and mouse brain specimens.
Results: All affected individuals had ataxia, eye movement abnormalities, most notably tonic upgaze, and delayed speech and cognitive development. Homozygosity mapping identified the disease locus on chromosome 4q. Within this region, a homozygous deletion of GRID2 exon 4 in the index family and compound heterozygous deletions involving GRID2 exon 2 in the second family were identified. Grid2-deficient mice showed larger spontaneous and random eye movements compared to wild-type mice. In developing mouse and human cerebella, GRID2 localized to the Purkinje cell dendritic spines. Brain MRI in 2 affected children showed progressive cerebellar atrophy, which was more severe than that of Grid2-deficient mice.
Conclusions: Biallelic deletions of GRID2 lead to a syndrome of cerebellar ataxia and tonic upgaze in humans. The phenotypic resemblance and similarity in protein expression pattern between humans and mice suggest a conserved role for GRID2 in the synapse organization between parallel fibers and Purkinje cells. However, the progressive and severe cerebellar atrophy seen in the affected individuals could indicate an evolutionarily unique role for GRID2 in the human cerebellum.
C1 [Hills, L. Benjamin; Lam, Anh-Thu N.; Hill, R. Sean; Partlow, Jennifer N.; Al-Saffar, Muna; Stoler, Joan M.; Mochida, Ganeshwaran H.] Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA.
[Nasir, Ramzi] Boston Childrens Hosp, Div Dev Med, Boston, MA USA.
[Partlow, Jennifer N.] Boston Childrens Hosp, Dept Med, Boston, MA USA.
[Partlow, Jennifer N.] Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA USA.
[Masri, Amira] Jordan Univ Hosp, Dept Pediat, Div Child Neurol, Amman, Jordan.
[Konno, Kotaro; Watanabe, Masahiko] Hokkaido Univ, Grad Sch Med, Dept Anat, Sapporo, Hokkaido, Japan.
[Kakegawa, Wataru; Yuzaki, Michisuke] Keio Univ, Sch Med, Dept Physiol, Tokyo 160, Japan.
[Lim-Melia, Elizabeth; Chandy, Nandini] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA.
[Al-Saffar, Muna] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Pediat, Al Ain, U Arab Emirates.
[Nasir, Ramzi; Stoler, Joan M.; Mochida, Ganeshwaran H.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Barkovich, A. James] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Mochida, Ganeshwaran H.] Massachusetts Gen Hosp, Dept Neurol, Pediat Neurol Unit, Boston, MA 02114 USA.
RP Mochida, GH (reprint author), Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA.
EM Ganesh.Mochida@childrens.harvard.edu
RI Yuzaki, Michisuke/K-5328-2013
OI Yuzaki, Michisuke/0000-0002-5750-3544
FU NINDS [R01NS035129]; Fogarty International Center [R21TW008223]; NHGRI
[U54 HG003067]; Simons Foundation; Dubai Harvard Foundation for Medical
Research
FX Supported by grants from NINDS (R01NS035129), the Fogarty International
Center (R21TW008223), NHGRI (U54 HG003067), the Simons Foundation, and
the Dubai Harvard Foundation for Medical Research.
NR 35
TC 26
Z9 27
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 15
PY 2013
VL 81
IS 16
BP 1378
EP 1386
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA AA0ET
UT WOS:000330769000006
PM 24078737
ER
PT J
AU De Luca, G
van't Hof, AWJ
Huber, K
Gibson, M
Bellandi, F
Arntz, HR
Maioli, M
Noc, M
Zorman, S
Zeymer, U
Gabriel, HM
Emre, A
Cutlip, D
Rakowski, T
Gyongyosi, M
Dudek, D
AF De Luca, Giuseppe
van't Hof, Arnoud W. J.
Huber, Kurt
Gibson, C. Michael
Bellandi, Francesco
Arntz, Hans-Richard
Maioli, Mauro
Noc, Marko
Zorman, Simona
Zeymer, Uwe
Gabriel, H. Mesquita
Emre, Ayse
Cutlip, Donald
Rakowski, Tomasz
Gyongyosi, Maryann
Dudek, Dariusz
CA Egypt Cooperation
TI Impact of Hypertension on Distal Embolization, Myocardial Perfusion, and
Mortality in Patients With ST Segment Elevation Myocardial Infarction
Undergoing Primary Angioplasty
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ARTERIAL-BLOOD PRESSURE; RANDOMIZED-TRIAL; THROMBOLYSIS; REPERFUSION;
THERAPY
AB Hypertension is a well-known risk factor for atherosclerosis. However, data on the impact of hypertension in patients with ST elevation myocardial infarction (STEMI) are inconsistent and mainly related to studies performed in the thrombolytic era, with very few data on patients undergoing primary angioplasty. The aim of the present study was to evaluate the impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with STEMI undergoing primary percutaneous coronary intervention. Our population is represented by 1,662 patients undergoing primary angioplasty for STEMI included in the Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty database. Myocardial perfusion was evaluated by myocardial blush grade and ST segment resolution. Follow-up data were collected within 1 year after primary angioplasty. Hypertension was observed in 700 patients (42.1%). Hypertension was associated with more advanced age (p <0.001), female gender (p <0.001), diabetes (p <0.001), hypercholesterolemia (p <0.001), previous revascularization (p <0.001), anterior myocardial infarction (p = 0.006), longer ischemia time (p = 0.03), more extensive coronary artery disease (p = 0.002), more often treated with abciximab (p <0.001), and less often smokers (p <0.001). Hypertension was associated with impaired postprocedural myocardial blush grade 2 to 3 (68.2% vs 74.2%, p = 0.019) and complete ST segment resolution (51.7% vs 61.1%, p = 0.001). By a mean follow-up of 206 +/- 158 days, 70 patients (4.3%) had died. Hypertension was associated with a greater mortality (6.2% vs 2.9%, hazard ratio 2.31, 95% confidence interval 1.42 to 3.73, p <0.001), confirmed after correction for baseline confounding factors (hazard ratio 1.82, 95% confidence interval 1.03 to 3.22, p <0.001). In conclusion, this study showed that among patients with STEMI undergoing primary angioplasty, hypertension is associated with impaired reperfusion and independently predicts 1-year mortality. (C) 2013 Elsevier Inc. All rights reserved.
C1 [De Luca, Giuseppe] Eastern Piedmont Univ, Maggiore della Carita Hosp, Div Cardiol, Novara, Italy.
[van't Hof, Arnoud W. J.] Hosp Weezenlanden, Div Cardiol, Zwolle, Netherlands.
[Huber, Kurt] Wilhelminenspital Stadt Wien, Dept Med Cardiol & Emergency Med 3, Vienna, Austria.
[Gibson, C. Michael] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Bellandi, Francesco; Maioli, Mauro] Prato Hosp, Div Cardiol, Prato, Italy.
[Arntz, Hans-Richard] Charite, Med Klin 2, Berlin, Germany.
[Noc, Marko; Zorman, Simona] Univ Med Ctr, Ctr Intens Internal Med, Ljubljana, Slovenia.
[Zeymer, Uwe] Herzzentrum Ludwigshafen, Div Cardiol, Ludwigshafen, Germany.
[Gabriel, H. Mesquita] Hosp Santa Maria, Div Cardiol, Lisbon, Portugal.
[Emre, Ayse] Siyami Ersek Thorac & Cardiovasc Surg Ctr, Istanbul, Turkey.
[Cutlip, Donald] Beth Israel Deaconess Med Ctr, Intervent Cardiol Sect, Boston, MA 02215 USA.
[Rakowski, Tomasz; Dudek, Dariusz] Jagiellonian Univ, Dept Cardiol 2, Inst Cardiol, Krakow, Poland.
[Dudek, Dariusz] Med Univ Vienna, Dept Cardiol, Vienna, Austria.
RP De Luca, G (reprint author), Eastern Piedmont Univ, Maggiore della Carita Hosp, Div Cardiol, Novara, Italy.
EM giuseppe.deluca@maggioreosp.novara.it
NR 20
TC 7
Z9 7
U1 0
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD OCT 15
PY 2013
VL 112
IS 8
BP 1083
EP 1086
DI 10.1016/j.amjcard.2013.05.053
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 236XV
UT WOS:000325833700005
PM 23910428
ER
PT J
AU Colilla, S
Crow, A
Petkun, W
Singer, DE
Simon, T
Liu, XC
AF Colilla, Susan
Crow, Ann
Petkun, William
Singer, Daniel E.
Simon, Teresa
Liu, Xianchen
TI Estimates of Current and Future Incidence and Prevalence of Atrial
Fibrillation in the US Adult Population
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID PROJECTIONS; RISK
AB Estimates and projections of diagnosed incidence and prevalence of atrial fibrillation (AF) in the United States have been highly inconsistent across published studies. Although it is generally acknowledged that AF incidence and prevalence are increasing due to growing numbers of older people in the U.S. population, estimates of the rate of expected growth have varied widely. Reasons for these variations include differences in study design, covered time period, birth cohort, and temporal effects, as well as improvements in AF diagnosis due to increased use of diagnostic tools and health care awareness. The objective of this study was to estimate and project the incidence and prevalence of diagnosed AF in the United States out to 2030. A large health insurance claims database for the years 2001 to 2008, representing a geographically diverse 5% of the U.S. population, was used in this study. The trend and growth rate in AF incidence and prevalence was projected by a dynamic age-period cohort simulation progression model that included all diagnosed AF cases in future prevalence projections regardless of follow-up treatment, as well as those cases expected to be chronic in nature. Results from the model showed that AF incidence will double, from 1.2 million cases in 2010 to 2.6 million cases in 2030. Given this increase in incidence, AF prevalence is projected to increase from 5.2 million in 2010 to 12.1 million cases in 2030. The effect of uncertainty in model parameters was explored in deterministic and probabilistic sensitivity analyses. Variability in future trends in AF incidence and recurrence rates has the greatest impact on the projected estimates of chronic AF prevalence. It can be concluded that both incidence and prevalence of AF are likely to rise from 2010 to 2030, but there exists a wide range of uncertainty around the magnitude of future trends. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Colilla, Susan] Bristol Myers Squibb Co, Global Hlth Econ & Outcomes Res, Princeton, NJ USA.
[Crow, Ann] Bristol Myers Squibb Co, Global Epidemiol Forecasting, Princeton, NJ USA.
[Petkun, William] Bristol Myers Squibb Co, Global Med Affairs, Princeton, NJ 08540 USA.
[Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
[Simon, Teresa] Bristol Myers Squibb Co, Global Pharmacovigilance & Epidemiol, New York, NY 10154 USA.
[Liu, Xianchen] Pfizer Inc, Global Hlth Econ & Outcomes Res, New York, NY USA.
RP Petkun, W (reprint author), Bristol Myers Squibb Co, Global Med Affairs, Princeton, NJ 08540 USA.
EM william.petkun@bms.com
FU Bristol-Myers Squibb; Pfizer Inc.
FX This study was supported by a grant from Bristol-Myers Squibb and Pfizer
Inc.
NR 10
TC 146
Z9 148
U1 0
U2 5
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD OCT 15
PY 2013
VL 112
IS 8
BP 1142
EP 1147
DI 10.1016/j.amjcard.2013.05.063
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 236XV
UT WOS:000325833700014
PM 23831166
ER
PT J
AU Hayes, JH
Barry, MJ
McMahon, PM
AF Hayes, Julia H.
Barry, Michael J.
McMahon, Pamela M.
TI Observation Versus Initial Treatment for Prostate Cancer RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Hayes, Julia H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hayes, Julia H.; McMahon, Pamela M.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Hayes, Julia H.; Barry, Michael J.; McMahon, Pamela M.] Harvard Univ, Sch Med, Boston, MA USA.
[Barry, Michael J.] Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Boston, MA 02114 USA.
RP Hayes, JH (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
FU NCI NIH HHS [R25 CA092203, L30 CA124353]
NR 1
TC 2
Z9 2
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 15
PY 2013
VL 159
IS 8
BP 574
EP 574
DI 10.7326/0003-4819-159-8-201310150-00016
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 249BH
UT WOS:000326751200025
PM 24126653
ER
PT J
AU Smucny, J
Tregellas, J
AF Smucny, Jason
Tregellas, Jason
TI Nicotinic modulation of intrinsic brain networks in Schizophrenia
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE Schizophrenia; Nicotinic; Salience network; Default network; Small-world
network
ID ANTERIOR CINGULATE CIRCUITS; RESTING-STATE NETWORKS; DEFAULT MODE
NETWORK; SMALL-WORLD NETWORKS; SUBUNIT GENE CHRNA7;
ACETYLCHOLINE-RECEPTOR; FUNCTIONAL CONNECTIVITY; ALLOSTERIC MODULATORS;
PARTIAL DUPLICATION; CIGARETTE-SMOKING
AB The nicotinic receptor is a promising drug target currently being investigated for the treatment of cognitive symptoms in schizophrenia. A key step in this process is the development of noninvasive functional neuroimaging biomarkers that can be used to determine if nicotinic agents are eliciting their targeted biological effect, ideally through modulation of a fundamental aspect of neuronal function. To that end, neuroimaging researchers are beginning to understand how nicotinic modulation affects "intrinsic" brain networks to elicit potentially therapeutic effects. An intrinsic network is a functionally and (often) structurally connected network of brain areas whose activity reflects a fundamental neurobiological organizational principle of the brain. This review summarizes findings of the effects of nicotinic drugs on three topics related to intrinsic brain network activity: (1) the default mode network, a group of brain areas for which activity is maximal at rest and reduced during cognitive tasks, (2) the salience network, which integrates incoming sensory data with prior internal representations to guide future actions and change predictive values, and (3) multi-scale complex network dynamics, which describe these brain's ability to efficiency integrate information while preserving local functional specialization. These early findings can be used to inform future neuroimaging studies that examine the network effects of nicotinic agents. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Smucny, Jason; Tregellas, Jason] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA.
[Smucny, Jason; Tregellas, Jason] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA.
[Smucny, Jason; Tregellas, Jason] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA.
RP Smucny, J (reprint author), Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO 80045 USA.
EM Jason.smucny@ucdenver.edu; Jason.tregellas@ucdenver.edu
RI Tregellas, Jason/J-3637-2015;
OI Smucny, Jason/0000-0001-5656-7987
FU NIMH NIH HHS [F31 MH102879]
NR 124
TC 7
Z9 7
U1 3
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD OCT 15
PY 2013
VL 86
IS 8
SI SI
BP 1163
EP 1172
DI 10.1016/j.bcp.2013.06.011
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 239FC
UT WOS:000326007000015
PM 23796751
ER
PT J
AU Fetterman, JL
Zelickson, BR
Johnson, LW
Moellering, DR
Westbrook, DG
Pompilius, M
Sammy, MJ
Johnson, M
Dunham-Snary, KJ
Cao, XM
Bradley, WE
Zhang, JJ
Wei, CC
Chacko, B
Schurr, TG
Kesterson, RA
Dell'Italia, LJ
Darley-Usmar, VM
Welch, DR
Ballinger, SW
AF Fetterman, Jessica L.
Zelickson, Blake R.
Johnson, Larry W.
Moellering, Douglas R.
Westbrook, David G.
Pompilius, Melissa
Sammy, Melissa J.
Johnson, Michelle
Dunham-Snary, Kimberly J.
Cao, Xuemei
Bradley, Wayne E.
Zhang, Jinju
Wei, Chih-Chang
Chacko, Balu
Schurr, Theodore G.
Kesterson, Robert A.
Dell'Italia, Louis J.
Darley-Usmar, Victor M.
Welch, Danny R.
Ballinger, Scott W.
TI Mitochondrial genetic background modulates bioenergetics and
susceptibility to acute cardiac volume overload
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE bioenergetics; disease susceptibility; mitochondria; mtDNA; oxidative
stress
ID NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; OXYGEN SPECIES PRODUCTION;
CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; SMOKE EXPOSURE;
ATHEROSCLEROSIS SUSCEPTIBILITY; C57BL/6J MICE; MOUSE; DNA; NUCLEAR
AB Dysfunctional bioenergetics has emerged as a key feature in many chronic pathologies such as diabetes and cardiovascular disease. This has led to the mitochondrial paradigm in which it has been proposed that mtDNA sequence variation contributes to disease susceptibility. In the present study we show a novel animal model of mtDNA polymorphisms, the MNX (mitochondrial nuclear exchange) mouse, in which the mtDNA from the C3H/HeN mouse has been inserted on to the C57/BL6 nuclear background and vice versa to test this concept. Our data show a major contribution of the C57/BL6 mtDNA to the susceptibility to the pathological stress of cardiac volume overload which is independent of the nuclear background. Mitochondria harbouring the C57/BL6J mtDNA generate more ROS (reactive oxygen species) and have a higher mitochondrial membrane potential relative to those with C3H/HeN mtDNA, independent of nuclear background. We propose this is the primary mechanism associated with increased bioenergetic dysfunction in response to volume overload. In summary, these studies support the 'mitochondrial paradigm' for the development of disease susceptibility, and show that the mtDNA modulates cellular bioenergetics, mitochondrial ROS generation and susceptibility to cardiac stress.
C1 [Fetterman, Jessica L.; Zelickson, Blake R.; Westbrook, David G.; Pompilius, Melissa; Sammy, Melissa J.; Johnson, Michelle; Dunham-Snary, Kimberly J.; Chacko, Balu; Darley-Usmar, Victor M.; Ballinger, Scott W.] Univ Alabama Birmingham, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA.
[Fetterman, Jessica L.; Zelickson, Blake R.; Moellering, Douglas R.; Sammy, Melissa J.; Dunham-Snary, Kimberly J.; Chacko, Balu; Dell'Italia, Louis J.; Darley-Usmar, Victor M.; Ballinger, Scott W.] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
[Johnson, Larry W.; Zhang, Jinju; Kesterson, Robert A.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
[Moellering, Douglas R.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Cao, Xuemei; Welch, Danny R.] Univ Kansas, Ctr Canc, Dept Canc Biol, Kansas City, KS 66160 USA.
[Bradley, Wayne E.; Wei, Chih-Chang; Dell'Italia, Louis J.] Univ Alabama Birmingham, Div Cardiol, Birmingham, AL 35294 USA.
[Schurr, Theodore G.] Univ Penn, Dept Anthropol, Philadelphia, PA 19104 USA.
[Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Welch, DR (reprint author), Univ Kansas, Ctr Canc, Dept Canc Biol, Kansas City, KS 66160 USA.
EM dwelch@kumc.edu; sballing@uab.edu
OI Sammy, Melissa/0000-0002-5460-0963
FU National Institutes for Health [RO1 94518, RO1 103859]; National
Foundation for Cancer Research; Susan G. Komen for the Cure [SAC111370];
U.S. Army Medical Research & Material Command [W81XWH-07-1-0540d];
University of Alabama at Birmingham Comprehensive Cancer Center
[CA013148]; National Institutes of Health [RO1 HL109785, P30 CA13148,
P30 AR048311, P30 DK074038, P30 DK05336, P60 DK079626]; a National
Institutes of Health predoctoral training programme in cardiovascular
pathophysiology [T32 HL007918]; American Heart Association
[09PRE2240046, 11PRE7650033]; Diabetes Research Center Bioanalytical
Redox Biology Core [P60 DK079626]
FX This work was funded by the National Institutes for Health [grant
numbers RO1 94518 and RO1 103859 (to S.W.B.)], the National Foundation
for Cancer Research (to D.R.W.), Susan G. Komen for the Cure [grant
number SAC111370 (to D.R.W.)], U.S. Army Medical Research & Material
Command [grant number W81XWH-07-1-0540d (to S.W.B.)] and a pilot grant
from the University of Alabama at Birmingham Comprehensive Cancer Center
[grant number CA013148 (to D.R.W. and S.W.B.)]. Additional support was
received from the National Institutes of Health [grant number RO1
HL109785 (to L.J.D.)), a National Institutes of Health predoctoral
training programme in cardiovascular pathophysiology [grant number T32
HL007918 (to J.L.F.)], American Heart Association predoctoral
fellowships [numbers 09PRE2240046 (to J.L.F.) and 11PRE7650033 (to
K.J.D.)). The University of Alabama at Birmingham Transgenic Mouse
Facility (RAK) is supported by the National Institutes of Health [grant
numbers P30 CA13148, P30 AR048311, P30 DK074038, P30 DK05336 and P60
DK079626] and by the National Institutes of Health-funded Diabetes
Research Center Bioanalytical Redox Biology Core [grant number P60
DK079626) located at the University of Alabama at Birmingham.
NR 66
TC 20
Z9 20
U1 2
U2 12
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD OCT 15
PY 2013
VL 455
BP 157
EP 167
DI 10.1042/BJ20130029
PN 2
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 243ZV
UT WOS:000326357800003
PM 23924350
ER
PT J
AU Blower, MD
Jambhekar, A
Schwarz, DS
Toombs, JA
AF Blower, Michael D.
Jambhekar, Ashwini
Schwarz, Dianne S.
Toombs, James A.
TI Combining Different mRNA Capture Methods to Analyze the Transcriptome:
Analysis of the Xenopus laevis Transcriptome
SO PLOS ONE
LA English
DT Article
ID MAJOR DEVELOPMENTAL TRANSITION; TRANSLATIONAL CONTROL; NONCODING RNAS;
REVEALS; LENGTH; EXPRESSION; TROPICALIS; LINCRNAS; GENOME;
POLYADENYLATION
AB mRNA sequencing (mRNA-seq) is a commonly used technique to survey gene expression from organisms with fully sequenced genomes. Successful mRNA-seq requires purification of mRNA away from the much more abundant ribosomal RNA, which is typically accomplished by oligo-dT selection. However, mRNAs with short poly-A tails are captured poorly by oligo-dT based methods. We demonstrate that combining mRNA capture via oligo-dT with mRNA capture by the 5' 7-methyl guanosine cap provides a more complete view of the transcriptome and can be used to assay changes in mRNA poly-A tail length on a genome-wide scale. We also show that using mRNA-seq reads from both capture methods as input for de novo assemblers provides a more complete reconstruction of the transcriptome than either method used alone. We apply these methods of mRNA capture and de novo assembly to the transcriptome of Xenopus laevis, a well-studied frog that currently lacks a finished sequenced genome, to discover transcript sequences for thousands of mRNAs that are currently absent from public databases. The methods we describe here will be broadly applicable to many organisms and will provide insight into the transcriptomes of organisms with sequenced and unsequenced genomes.
C1 [Blower, Michael D.; Jambhekar, Ashwini; Schwarz, Dianne S.; Toombs, James A.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Blower, Michael D.; Jambhekar, Ashwini; Schwarz, Dianne S.; Toombs, James A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
RP Blower, MD (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM blower@molbio.mgh.harvard.edu
NR 44
TC 4
Z9 4
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2013
VL 8
IS 10
AR e77700
DI 10.1371/journal.pone.0077700
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 237TP
UT WOS:000325894100096
PM 24143257
ER
PT J
AU McCarthy, AM
Bristol, M
Fredricks, T
Wilkins, L
Roelfsema, I
Liao, KJ
Shea, JA
Groeneveld, P
Domchek, SM
Armstrong, K
AF McCarthy, Anne Marie
Bristol, Mirar
Fredricks, Tracey
Wilkins, Lache
Roelfsema, Irene
Liao, Kaijun
Shea, Judy A.
Groeneveld, Peter
Domchek, Susan M.
Armstrong, Katrina
TI Are Physician Recommendations for BRCA1/2 Testing in Patients With
Breast Cancer Appropriate? A Population-Based Study
SO CANCER
LA English
DT Article
DE breast cancer; genetic testing; BRCA1; 2; physician recommendations;
cancer registry
ID MUTATION CARRIERS; WOMEN; RISK; DECISIONS; KNOWLEDGE; ATTITUDES;
FAMILIES; COVERAGE; SURGERY
AB BACKGROUNDTo the best of the authors' knowledge, few population-based studies to date have examined the use of BRCA1/2 testing or patterns of physician recommendations for genetic testing among women diagnosed with breast cancer. The objective of the current study was to evaluate the rates and predictors of physician recommendation for BRCA1/2 testing among patients with breast cancer.
METHODSWomen aged 18 years to 64 years who were diagnosed with invasive breast cancer in 2007 were identified from the Pennsylvania Cancer Registry and mailed a survey regarding their family history of cancer, physician treatment recommendations, and BRCA1/2 testing. Of the 4009 women who were sent surveys, 2258 responded (56%). Based on age at diagnosis and family history, women were categorized as being at high, moderate, or low risk of BRCA1/2 mutations.
RESULTSNearly 25% of the participants were classified as being at high risk of carrying a BRCA1/2 mutation based on their age at the time of breast cancer diagnosis and family history of breast and/or ovarian cancer. Physician recommendations for BRCA1/2 testing were found to be strongly associated with risk of carrying a mutation, with 53% of high-risk women reporting a testing recommendation compared with 9% of low-risk women. In addition, physician recommendations were strongly correlated with the use of testing in all risk groups. Among high-risk women, the lack of a recommendation for BRCA1/2 testing was more common among older, low-income, and employed women.
CONCLUSIONSAlthough BRCA1/2 testing recommendations appear to be appropriately correlated with mutation risk, a significant percentage of patients with breast cancer who meet criteria for BRCA1/2 testing may not receive a recommendation for such testing from their health care providers. Cancer 2013;119:3596-3603. (c) 2013 American Cancer Society.
C1 [McCarthy, Anne Marie; Bristol, Mirar; Fredricks, Tracey; Wilkins, Lache; Roelfsema, Irene; Liao, Kaijun; Shea, Judy A.; Groeneveld, Peter; Domchek, Susan M.; Armstrong, Katrina] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Groeneveld, Peter] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Domchek, Susan M.; Armstrong, Katrina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP McCarthy, AM (reprint author), Univ Penn, 423 Guardian Dr,Room 1009, Philadelphia, PA 19104 USA.
EM annemcc@mail.med.upenn.edu
FU National Institutes of Health grant from the National Cancer Institute
[5-R01-CA133004-3]
FX Supported by a National Institutes of Health grant from the National
Cancer Institute (5-R01-CA133004-3).
NR 25
TC 7
Z9 7
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3596
EP 3603
DI 10.1002/cncr.28268
PG 8
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700039
PM 23861169
ER
PT J
AU Skolarus, TA
Chan, S
Shelton, JB
Antonio, AL
Sales, AE
Malin, JL
Saigal, CS
AF Skolarus, Ted A.
Chan, Stephanie
Shelton, Jeremy B.
Antonio, Anna Liza
Sales, Anne E.
Malin, Jennifer L.
Saigal, Christopher S.
TI Quality of Prostate Cancer Care Among Rural Men in the Veterans Health
Administration
SO CANCER
LA English
DT Article
DE prostate cancer; quality; rural; integrated delivery system; access
ID RADIATION-THERAPY; ANDROGEN SUPPRESSION; ACCESS; ADENOCARCINOMA;
BARRIERS; TRIAL; RISK; TERM; VA
AB BACKGROUNDPatient travel distances, coupled with variation in facility-level resources, create barriers for prostate cancer care in the Veterans Health Administration integrated delivery system. For these reasons, the authors investigated the degree to which these barriers impact the quality of prostate cancer care.
METHODSThe Veterans Affairs Central Cancer Registry was used to identify all men who were diagnosed with prostate cancer in 2008. Patient residence was characterized using Rural Urban Commuting Area codes. The authors then examined whether rural residence, compared with urban residence, was associated with less access to cancer-related resources and worse quality of care for 5 prostate cancer quality measures.
RESULTSApproximately 25% of the 11,368 patients who were diagnosed with prostate cancer in 2008 lived in either a rural area or a large town. Rural patients tended to be white (62% urban vs 86% rural) and married (47% urban vs 63% rural), and they tended to have slightly higher incomes (all P<.01) but similar tumor grade (P=.23) and stage (P=.12) compared with urban patients. Rural patients were significantly less likely to be treated at facilities with comprehensive cancer resources, although they received a similar or better quality of care for 4 of the 5 prostate cancer quality measures. The time to prostate cancer treatment was similar (rural patients vs urban patients, 96.6 days vs 105.7 days).
CONCLUSIONSRural patients with prostate cancer had less access to comprehensive oncology resources, although they received a similar quality of care, compared with their urban counterparts in the Veterans Health Administration integrated delivery system. A better understanding of the degree to which facility factors contribute to the quality of cancer care may assist other organizations involved in rural health care delivery. Cancer 2013;119:3629-3635. (c) 2013 American Cancer Society.
C1 [Skolarus, Ted A.; Sales, Anne E.] Vet Affairs Ann Arbor Healthcare Syst, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA.
[Skolarus, Ted A.] Univ Michigan, Dow Div Hlth Serv Res, Dept Urol, Ann Arbor, MI 48109 USA.
[Chan, Stephanie] Frederick S Pardee RAND Grad Sch, Santa Monica, CA USA.
[Shelton, Jeremy B.; Antonio, Anna Liza; Malin, Jennifer L.; Saigal, Christopher S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Shelton, Jeremy B.; Saigal, Christopher S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA.
[Sales, Anne E.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
[Malin, Jennifer L.] Wellpoint Inc, Med Oncol, Indianapolis, IN USA.
RP Skolarus, TA (reprint author), Univ Michigan, Dept Urol, VA Ctr Clin Management Res, VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA.
EM tskolar@med.umich.edu
OI Sales, Anne/0000-0001-9360-3334
FU Veterans Health Administration Office of Analytics and Business
Intelligence; VA HSR&D Career Development Award - 2 [CDA 12-171]
FX This work was supported by the Veterans Health Administration Office of
Analytics and Business Intelligence "Supportive Care, End of Life Care,
and Crosscutting Quality Indicators for Patients with Cancer Within VA"
Project. Dr. Skolarus is supported by a VA HSR&D Career Development
Award - 2 (CDA 12-171).
NR 33
TC 7
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3629
EP 3635
DI 10.1002/cncr.28275
PG 7
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700043
PM 23913676
ER
PT J
AU Aggarwal, R
Halabi, S
Kelly, WK
George, D
Mahoney, JF
Millard, F
Stadler, WM
Morris, MJ
Kantoff, P
Monk, JP
Carducci, M
Small, EJ
AF Aggarwal, Rahul
Halabi, Susan
Kelly, William Kevin
George, Daniel
Mahoney, John F.
Millard, Frederick
Stadler, Walter M.
Morris, Michael J.
Kantoff, Philip
Monk, J. Paul
Carducci, Michael
Small, Eric J.
CA Alliance Clinical Trials Oncology
TI The Effect of Prior Androgen Synthesis Inhibition on Outcomes of
Subsequent Therapy With Docetaxel in Patients With Metastatic
Castrate-Resistant Prostate Cancer
SO CANCER
LA English
DT Article
DE prostatic neoplasms; chemotherapy; ketoconazole; steroid
17-alpha-hydroxylase; androgen antagonists
ID ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; KETOCONAZOLE; PREDNISONE; TRIAL;
MITOXANTRONE; ABIRATERONE; MEN; BIOSYNTHESIS; CHEMOTHERAPY
AB BACKGROUNDPreliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration-resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer and Leukemia Group B (CALGB) trial 90401 (Alliance), a phase 3 trial in patients with mCRPC who received docetaxel-based chemotherapy, offered the opportunity to evaluate effect of prior ketoconazole, an earlier generation ASI, on clinical outcomes after docetaxel.
METHODSIn CALGB trial 90401, 1050 men with chemotherapy-naive mCRPC were randomized to receive treatment with docetaxel and prednisone that included either bevacizumab or placebo. In total, 1005 men (96%) had data available regarding prior ketoconazole therapy. The observed effects of prior ketoconazole on overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) decline, and the objective response rate (ORR) were assessed using proportional hazards and Poisson regression methods adjusted for validated prognostic factors and treatment arm.
RESULTSBaseline characteristics between patients who did (N=277) and did not (N=728) receive prior ketoconazole therapy were similar. There were no statistically significant differences between patients who did and those who did not receive prior ketoconazole therapy with respect to OS (median OS, 21.1 months vs 22.3 months, respectively; stratified log-rank P=.635), PFS (median PFS, 8.1 months vs 8.6 months, respectively; stratified log-rank P=.342), the proportion achieving a decline 50% in PSA (61% vs 66%, respectively; relative risk, 1.09; adjusted P=.129), or ORR (39% vs 43%, respectively; relative risk, 1.11; adjusted P=.366).
CONCLUSIONSAs measured by OS, PFS, PSA, and the ORR, there was no evidence that prior treatment with ketoconazole had an impact on the clinical outcomes of patients with mCRPC who received subsequent docetaxel-based therapy. The current results highlight the need for prospective studies to assess for potential cross-resistance with novel ASIs and to define the optimal sequence of therapy in mCRPC. Cancer 2013;119:3636-3643. (c) 2013 American Cancer Society.
C1 [Aggarwal, Rahul] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Div Hematol Oncol, San Francisco, CA 94143 USA.
[Halabi, Susan] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA.
[Halabi, Susan] Duke Univ, Med Ctr, Alliance Stat & Data Ctr, Durham, NC USA.
[Kelly, William Kevin] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA.
[George, Daniel] Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC USA.
[Mahoney, John F.] Carolinas Med Ctr, Charlotte, NC 28203 USA.
[Millard, Frederick] Univ Calif San Diego, Div Hematol Oncol, San Diego, CA 92103 USA.
[Stadler, Walter M.] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA.
[Morris, Michael J.] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, New York, NY 10021 USA.
[Kantoff, Philip] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
[Monk, J. Paul] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA.
[Carducci, Michael] Johns Hopkins Univ, Dept Oncol & Urol, Baltimore, MD USA.
[Small, Eric J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med & Urol, San Francisco, CA 94143 USA.
RP Aggarwal, R (reprint author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 1600 Divisadero,3rd Floor, San Francisco, CA 94143 USA.
EM rahul.aggarwal@ucsf.edu
FU National Cancer Institute (NCI) [CA31946, CA60138, CA33601, CA13650,
CA7577, CA5808, CA11789, CA41287, CA77651, CA32291, CA77658, CA16116,
CA45418, CA04326, CA47577, CA29165]; NCI [CA114558, CA45389, CA35113,
CA114558-02, CA35279, CA45564, CA04457, CA35421, CA86726, CA08025,
CA59518, CA45808, CA21060, CA74811, CA47642, CA31983, CA16450, CA77298,
CA47559, CA37447, CA77406, CA77440, CA07968, CA16359]
FX The research for CALGB 90401 (Alliance) was supported in part by grants
from the National Cancer Institute (NCI) to the Alliance for Clinical
Trials in Oncology (Monica M. Bertagnolli, MD, Chair; grant CA31946) and
to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD;
grant CA33601).; Drs. Aggarwal and Small were supported by NCI grant
CA60138; Dr. Halabi was supported by NCI grant CA33601; Dr. Kelly was
supported by NCI grant CA13650; Dr. George was supported by NCI grant
CA7577; Dr. Mahoney was supported by NCI grant CA5808; Dr. Millard was
supported by NCI grant CA11789; Dr. Stadler was supported by NCI grant
CA41287; Dr. Morris was supported by NCI grant CA77651; Dr. Kantoff was
supported by NCI grant CA32291; Dr. Monk was supported by NCI grant
CA77658; and Dr. Carducci was supported by NCI grant CA16116.; The
following institutions participated in this study: Alliance Statistics
and Data Center, Duke University Medical Center, Durham, NC (Daniel J.
Sargent, PhD; supported by NCI grant CA33601); Christiana Care Health
Services, Inc. Community Clinical Oncology Program (CCOP), Wilmington,
Del (Stephen Grubbs, MD; supported by CA45418); Dana-Farber Cancer
Institute, Boston, Mass (Harold J. Burstein, MD, PhD; supported by
CA32291); Dartmouth Medical School-Norris Cotton Cancer Center, Lebanon,
NH (Konstantin Dragnev, MD; supported by CA04326); Duke University
Medical Center, Durham, NC (Jeffrey Crawford, MD; supported by CA47577);
Greenville CCOP, Greenville, SC (Jeffrey Giguere, MD; supported by
CA29165); Heartland Cancer Research CCOP, St. Louis, Mo (Alan P. Lyss,
MD; supported by CA114558 to Missouri Baptist Medical Center);
Hematology-Oncology Associates of Central New York CCOP, Syracuse, NY
(Jeffrey Kirshner, MD; supported by CA45389); Illinois Oncology Research
Association, Peoria, Ill (John W. Kugler, MD; supported by CA35113);
Kansas City CCOP, Kansas City, Mo (Rakesh Gaur, MD); Massachusetts
General Hospital, Boston, Mass (Jeffrey W. Clark, MD; supported by
CA32291); Memorial Sloan-Kettering Cancer Center, New York, NY (Clifford
A. Hudis, MD; supported by CA77651); Missouri Baptist Medical Center,
St. Louis, Mo (Alan P. Lyss, MD; supported by CA114558-02 [a grant only
to be used for studies that accrued patients after June 1, 2005; the
institution received no grant before 2005, and Missouri was an at-large
member]); Monter Cancer Center of North Shore-LIJ Health Systems, Lake
Success, NY (Daniel Budman, MD; supported by CA35279); Mount Sinai
Medical Center, Miami, Fla (Michael A. Schwartz, MD; supported by
CA45564); Mount Sinai School of Medicine, New York, NY (Lewis R.
Silverman, MD; supported by CA04457); Nevada Cancer Research Foundation
CCOP, Las Vegas, Nev (John A. Ellerton, MD; supported by CA35421); New
Hampshire Oncology-Hematology PA, Concord, NH (Douglas J. Weckstein,
MD); North Shore University Health System CCOP, Evanston, Ill (David L.
Grinblatt, MD); Northern Indiana Cancer Research Consortium CCOP, South
Bend, Ind (Rafat Ansari, MD; supported by CA86726); Rhode Island
Hospital, Providence, RI (William Sikov, MD; supported by CA08025);
Roswell Park Cancer Institute, Buffalo, NY (Ellis Levine, MD; supported
by CA59518); Sibley Memorial Hospital, Washington, DC (Frederick Barr,
MD); Southeast Cancer Control Consortium Inc. CCOP, Goldsboro, NC (James
N. Atkins, MD; supported by CA45808); State University of New York
Upstate Medical University, Syracuse, NY (Stephen L. Graziano, MD;
supported by CA21060); The Ohio State University Medical Center,
Columbus, Ohio (Clara D. Bloomfield, MD; supported by CA77658);
University of California at San Diego, San Diego, Calif (Barbara A.
Parker, MD; supported by CA11789); University of California at San
Francisco, San Francisco, Calif (Charles J. Ryan, MD; supported by
CA60138); University of Chicago, Chicago, Ill (Hedy L. Kindler, MD;
supported by CA41287); University of Illinois Minority-Based CCOP,
Chicago, Ill (David J. Peace, MD; supported by CA74811); University of
Iowa, Iowa City, Iowa (Daniel A. Vaena, MD; supported by CA47642);
University of Maryland Greenebaum Cancer Center, Baltimore, MD (Martin
Edelman, MD; supported by CA31983); University of Minnesota,
Minneapolis, Minn (Bruce A.; Peterson, MD; supported by CA16450);
University of Nebraska Medical Center, Omaha, Neb (Apar Ganti, MD;
supported by CA77298); University of North Carolina at Chapel Hill,
Chapel Hill, NC (Thomas C. Shea, MD; supported by CA47559); University
of Oklahoma, Oklahoma City, Okla (Shubham Pant, MD; supported by
CA37447); University of Vermont, Burlington, Vt (Steven M. Grunberg, MD;
supported by CA77406); Washington University School of Medicine, St.
Louis, Mo (Nancy Bartlett, MD; supported by CA77440); Weill Medical
College of Cornell University, New York, NY (John Leonard, MD; supported
by CA07968); Western Pennsylvania Cancer Institute, Pittsburgh, Pa, John
Lister, MD); and Yale University, New Haven, Conn (Lyndsay N. Harris,
MD; supported by CA16359).
NR 25
TC 8
Z9 9
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3636
EP 3643
DI 10.1002/cncr.28285
PG 8
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700044
PM 23913744
ER
PT J
AU Rauh-Hain, JA
Clemmer, JT
Bradford, LS
Clark, RM
Growdon, WB
Goodman, A
Boruta, DM
Schorge, JO
del Carmen, MG
AF Rauh-Hain, J. Alejandro
Clemmer, Joel T.
Bradford, Leslie S.
Clark, Rachel M.
Growdon, Whitfield B.
Goodman, Annekathryn
Boruta, David M., II
Schorge, John O.
del Carmen, Marcela G.
TI Racial Disparities in Cervical Cancer Survival Over Time
SO CANCER
LA English
DT Article
DE cervical cancer; African American; race; disparities; SEER
ID ETHNIC-DIFFERENCES; AFRICAN-AMERICAN; UTERINE CERVIX; SEER DATA; WOMEN;
STAGE; CARCINOMA; CARE; STATISTICS; RADIATION
AB BACKGROUNDThe purpose of this study is to examine changes over time in survival for African American (AA) and white women diagnosed with cervical cancer (CC).
METHODSSurveillance, Epidemiology, and End Results (SEER) Program data from 1985 to 2009 were used for this analysis. Racial differences in survival were evaluated between African American (AA) and white women. Kaplan-Meier and Cox proportional hazards survival methods were used to assess differences in survival by race at 5-year intervals.
RESULTSThe study sample included 23,368 women, including 3886 (16.6%) who were AA and 19,482 (83.4%) who were white. AA women were older (51.4 versus 48.9 years; P<.001) and had a higher rate of regional (38.3% versus 31.8%; P<.001) and distant metastasis (10.7% versus 8.7%; P<.001). AA less frequently received cancer-directed surgery (32.4% versus 46%; P<.001), and more frequently radiotherapy (36.3% versus 26.4%; P<.001). Overall, AA women had a hazard ratio (HR) of 1.41 (95% confidence interval=1.32-1.51) of cervical cancer (CC) mortality compared with whites. Adjusting for SEER registry, marital status, stage, age, treatment, grade, and histology, AA women had an HR of 1.13 (95% confidence interval=1.05-1.22) of CC-related mortality. After adjusting for the same variables, there was a significant difference in CC-specific mortality between 1985 to 1989 and 1990 to 1994, but not after 1995.
CONCLUSIONSAfter adjusting for race, SEER registry, marital status, stage, age, treatment, grade, and histology, there was a significant difference in CC-specific mortality between 1985 to 1989 and 1990 to 1994, but not after 1995. Cancer 2013;119:3644-3652. (c) 2013 American Cancer Society.
C1 [Rauh-Hain, J. Alejandro; Clemmer, Joel T.; Bradford, Leslie S.; Clark, Rachel M.; Growdon, Whitfield B.; Goodman, Annekathryn; Boruta, David M., II; Schorge, John O.; del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA USA.
RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9 E, Boston, MA 02114 USA.
EM mdelcarmen@partners.org
NR 31
TC 12
Z9 12
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3644
EP 3652
DI 10.1002/cncr.28261
PG 9
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700045
PM 23913530
ER
PT J
AU Evens, AM
Vanderplas, A
LaCasce, AS
Crosby, AL
Nademanee, AP
Kaminski, MS
Abel, GA
Millenson, M
Czuczman, MS
Rodriguez, MA
Niland, J
Zelenetz, AD
Gordon, LI
Friedberg, JW
AF Evens, Andrew M.
Vanderplas, Ann
LaCasce, Ann S.
Crosby, Allison L.
Nademanee, Auayporn P.
Kaminski, Mark S.
Abel, Gregory A.
Millenson, Michael
Czuczman, Myron S.
Rodriguez, Maria A.
Niland, Joyce
Zelenetz, Andrew D.
Gordon, Leo I.
Friedberg, Jonathan W.
TI Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory
After Prior Rituximab
SO CANCER
LA English
DT Article
DE follicular lymphoma; prognostication; autologous transplantation;
allogeneic transplantation; survival; rituximab; non-Hodgkin lymphoma;
stem cell transplantation
ID NON-HODGKINS-LYMPHOMA; HIGH-DOSE THERAPY; BONE-MARROW-TRANSPLANTATION;
TERM-FOLLOW-UP; PRETRANSPLANTATION TREATMENT; PROPENSITY-SCORE;
SURVIVAL; REMISSION; IMPROVES; OUTCOMES
AB BACKGROUNDStem cell transplant (SCT)-related outcomes and prognostication for relapsed/refractory follicular lymphoma (FL) are not well-defined in the post-rituximab era.
METHODSThrough the National Comprehensive Cancer Network (NCCN) lymphoma outcomes study, 184 patients with relapsed/refractory FL who underwent autologous SCT (autoSCT) or allogenic SCT (alloSCT) following disease relapse after prior rituximab-based therapy were examined.
RESULTSPatients who underwent autoSCT (N=136) were older compared with patients who underwent alloSCT (N=48) (54 versus 51 years, respectively, P=.01) and more frequently had grade 3 FL (35% versus 8%, respectively, P=.006). Patients who underwent alloSCT received more prior therapies (4 versus 3, respectively, P<.0001) and more often had resistant disease at SCT (19% versus 6%, respectively, P=.008). Cumulative 100-day nonrelapse mortality (NRM) for autoSCT and alloSCT were 1% and 6%, respectively (P<.0001), whereas 3-year NRM rates were 3% versus 24%, respectively (P<.0001). For autoSCT and alloSCT, cumulative rates of relapse, progression, and/or transformation were 32% versus 16%, respectively (P=.03), whereas 3-year overall survival rates were 87% versus 61% (P<.0001); there were no differences in failure-free survival. AlloSCT was associated with increased risk of death on multivariate analysis (hazard ratio=2.77, 95% confidence interval=1.46-5.26, P=.002). This finding persisted on propensity scoring/matching. Multivariate analysis for autoSCT patients identified age>60 years and>3 prior therapies as adverse factors. Furthermore, a survival model was created for the autoSCT cohort based on number of factors present (0, 1, 2); 3-year failure-free survival was 72%, 47%, and 20%, respectively (P=.0003), and 3-year overall survival was 96%, 82%, and 62%, respectively (P<.0001).
CONCLUSIONSAutoSCT remains an effective therapy for patients with FL. For alloSCT, continued strategies to reduce NRM are needed. Cancer 2013;119:3662-3671. (c) 2013 American Cancer Society.
C1 [Evens, Andrew M.] Tufts Univ, Sch Med, Div Hematol Oncol, Boston, MA 02111 USA.
[Vanderplas, Ann; Niland, Joyce] City Hope Natl Med Ctr, Dept Biostat, Duarte, CA 91010 USA.
[LaCasce, Ann S.; Crosby, Allison L.; Abel, Gregory A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Nademanee, Auayporn P.] City Hope Natl Med Ctr, Dept Stem Cell Transplant, Duarte, CA 91010 USA.
[Kaminski, Mark S.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA.
[Millenson, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Rodriguez, Maria A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Gordon, Leo I.] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA.
[Friedberg, Jonathan W.] Univ Rochester, Div Hematol Oncol, James P Wilmot Canc Ctr, Rochester, NY USA.
RP Evens, AM (reprint author), Tufts Univ, Sch Med, 800 Washington St, Boston, MA 02111 USA.
EM AEvens@tuftsmedicalcenter.org
FU National Comprehensive Cancer Network (NCCN); NCCN Data Outcomes;
Pfizer; GlaxoSmithKline; Amgen; NCCN; Genentech; Roche
FX Dr. Millenson has received support from a National Comprehensive Cancer
Network (NCCN) grant. Dr. Czuczman has received a grant from NCCN Data
Outcomes. Dr. Rodriguez has received grants for research funding from
Pfizer, GlaxoSmithKline, and Amgen. Dr. Niland has received support from
an NCCN contract with her institution for the Data Coordinating Center
for the support of responsibility for data analysis for this article.
Dr. Zelenetz has acted as a consultant for Genentech and Roche and has
received grants from both to support unrelated trials. Dr. Friedberg has
acted a member of the Trubion Data Safety Monitoring Committee, the
Bayer Data Safety Monitoring Committee, and the Sanofi Advisory Board.
NR 25
TC 22
Z9 22
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3662
EP 3671
DI 10.1002/cncr.28243
PG 10
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700047
PM 23921646
ER
PT J
AU Luke, JJ
Callahan, MK
Postow, MA
Romano, E
Ramaiya, N
Bluth, M
Giobbie-Hurder, A
Lawrence, DP
Ibrahim, N
Ott, PA
Flaherty, KT
Sullivan, RJ
Harding, JJ
D'Angelo, S
Dickson, M
Schwartz, GK
Chapman, PB
Wolchok, JD
Hodi, FS
Carvajal, RD
AF Luke, Jason J.
Callahan, Margaret K.
Postow, Michael A.
Romano, Emanuela
Ramaiya, Nikhil
Bluth, Mark
Giobbie-Hurder, Anita
Lawrence, Donald P.
Ibrahim, Nageatte
Ott, Patrick A.
Flaherty, Keith T.
Sullivan, Ryan J.
Harding, James J.
D'Angelo, Sandra
Dickson, Mark
Schwartz, Gary K.
Chapman, Paul B.
Wolchok, Jedd D.
Hodi, F. Stephen
Carvajal, Richard D.
TI Clinical Activity of Ipilimumab for Metastatic Uveal Melanoma
SO CANCER
LA English
DT Article
DE uveal melanoma; ipilimumab; cytotoxic T-lymphocyteassociated protein 4;
immunotherapy; absolute lymphocyte count
ID OCULAR MELANOMA; IV MELANOMA; STAGE-III; SURVIVAL; EXPERIENCE;
INTERLEUKIN-2; LYMPHOCYTE; EXPRESSION; TYROSINASE; MUTATIONS
AB BACKGROUNDUveal melanoma exhibits a high incidence of metastases; and, to date, there is no systemic therapy that clearly improves outcomes. The anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab is a standard of care for metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with metastatic uveal melanoma is poorly defined.
METHODSTo assess ipilimumab in this setting, the authors performed a multicenter, retrospective analysis of 4 hospitals in the United States and Europe. Clinical characteristics, toxicities, and radiographic disease burden, as determined by central, blinded radiology review, were evaluated.
RESULTSThirty-nine patients with uveal melanoma were identified, including 34 patients who received 3 mg/kg ipilimumab and 5 who received 10 mg/kg ipilimumab. Immune-related response criteria and modified World Health Organization criteria were used to assess the response rate (RR) and the combined response plus stable disease (SD) rate after 12 weeks, after 23 weeks, and overall (median follow-up, 50.4 weeks [12.6 months]). At week 12, the RR was 2.6%, and the response plus SD rate was 46.%; at week 23, the RR was 2.6%, and the response plus SD rate was 28.2%. There was 1 complete response and 1 late partial response (at 100 weeks after initial SD) for an immune-related RR of 5.1%. Immune-related adverse events were observed in 28 patients (71.8%) and included 7 (17.9%) grade 3 and 4 events. Immune-related adverse events were more frequent in patients who received 10 mg/kg ipilimumab than in those who received 3 mg/kg ipilimumab. The median overall survival from the first dose of ipilimumab was 9.6 months (95% confidence interval, 6.3-13.4 months; range, 1.6-41.6 months). Performance status, lactate dehydrogenase level, and an absolute lymphocyte count 1000 cells/L at week 7 were associated significantly with survival.
CONCLUSIONSIn this multicenter, retrospective analysis of 4 hospitals in the United States and Europe of patients with uveal melanoma, durable responses to ipilimumab and manageable toxicity were observed. Cancer 2013;119:3687-3695. (c) 2013 American Cancer Society.
C1 [Luke, Jason J.; Ibrahim, Nageatte; Ott, Patrick A.; Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Callahan, Margaret K.; Postow, Michael A.; Harding, James J.; D'Angelo, Sandra; Dickson, Mark; Schwartz, Gary K.; Chapman, Paul B.; Wolchok, Jedd D.; Carvajal, Richard D.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Romano, Emanuela] Univ Lausanne Hosp, Dept Oncol, Lausanne, Switzerland.
[Ramaiya, Nikhil] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.
[Bluth, Mark] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA.
[Giobbie-Hurder, Anita] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
[Lawrence, Donald P.; Flaherty, Keith T.; Sullivan, Ryan J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Carvajal, RD (reprint author), Mem Sloan Kettering Canc Ctr, Melanoma Sarcoma Serv, Dept Med, 300 East 66th St,BAIC 1071, New York, NY 10021 USA.
EM carvajar@mskcc.org
FU Bristol-Myers Squibb; GlaxcoSmithKline; Pfizer; MedImmune
FX Dr. Callahan has acted as a paid consultant to Bristol-Myers Squibb and
GlaxcoSmithKline and has received grant support from Bristol-Myers
Squibb. Dr. Dickson has acted as paid consultant to Pfizer. Dr. Harding
has acted as a paid consultant to MedImmune. Dr. Hodi has received
clinical trial support and reimbursement for travel expenses from
Bristol-Myers Squibb and has acted as a non-paid consultant to
Bristol-Myers Squibb. Dr. Postow has received grants from Bristol-Myers
Squibb and has received reimbursement for travel expenses from
Bristol-Myers Squibb for investigator meetings related to
immunotherapeutic agents, including ipilimumab. Dr. Wolchok has acted as
a paid consultant to Bristol-Myers Squibb and has received reimbursement
for travel/accommodations/meeting expenses and grant support from
Bristol-Myers Squibb.
NR 28
TC 51
Z9 51
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3687
EP 3695
DI 10.1002/cncr.28282
PG 9
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700050
PM 23913718
ER
PT J
AU Wang, LL
Suganuma, R
Ikegaki, N
Tang, X
Naranjo, A
McGrady, P
London, WB
Hogarty, MD
Gastier-Foster, JM
Look, AT
Park, JR
Maris, JM
Cohn, SL
Seeger, RC
Shimada, H
AF Wang, Larry L.
Suganuma, Rie
Ikegaki, Naohiko
Tang, Xao
Naranjo, Arlene
McGrady, Patrick
London, Wendy B.
Hogarty, Michael D.
Gastier-Foster, Julie M.
Look, A. Thomas
Park, Julie R.
Maris, John M.
Cohn, Susan L.
Seeger, Robert C.
Shimada, Hiroyuki
TI Neuroblastoma of Undifferentiated Subtype, Prognostic Significance of
Prominent Nucleolar Formation, and MYC/MYCN Protein Expression
SO CANCER
LA English
DT Article
DE neuroblastoma; undifferentiated subtype; MYCN amplification; MYC; MYCN
expression; prognostic factors
ID SCHWANNIAN STROMA-POOR; C-MYC PROTEIN; CHILDHOOD MEDULLOBLASTOMA;
PATHOLOGY CLASSIFICATION; N-MYC; TUMORS; AMPLIFICATION; PROGRESSION;
PHENOTYPE; COMMITTEE
AB BACKGROUNDThis study sought to investigate biological/clinicopathological characteristics of neuroblastoma, undifferentiated subtype (NBUD).
METHODSThis study examined 157 NBUD cases filed at the Children's Oncology Group Neuroblastoma Pathology Reference Laboratory, and survival rates of the patients were analyzed with known prognostic factors. Immunostainings for MYCN and MYC protein were performed on 68 tumors.
RESULTSNBUD cases had a poor prognosis (48.4%5.0% 3-year event-free survival [EFS]; 56.5%5.0% overall survival [OS]), and were often associated with high mitosis-karyorrhexis index (MKI, 65%), prominent nucleoli (PN, 83%), 18 months of age (75%), MYCN amplification (MYCN-A, 83%), diploid pattern (63%), and 1pLOH (loss of heterozygosity (72%). However, these prognostic indicators, except for MYCN status, had no significant impact on survival. Surprisingly, EFS for patients with MYCN-A tumors (53.4%+/- 5.6%) was significantly better (P=.0248) than for patients with MYCN-nonamplified (MYCN-NA) tumors (31.7%+/- 11.7%), with MYCN-NA and PN (+) tumors having the worst prognosis (9.3%+/- 8.8%, P=.0045). Immunohistochemically, MYCN expression was found in 42 of 48 MYCN-A tumors. In contrast, MYC expression was almost exclusively found in the MYCN-NA tumors (9 of 20) especially when they had PN (8 of 11). Those patients with only MYC-positive tumors had the worst EFS (N=8, 12.5%+/- 11.7%) compared with only MYCN-positive (N=39, 49.9%+/- 17.7%) and both negative tumors (N=15, 70.0%+/- 17.1%) (P=.0029). High MKI was often found in only MYCN-positive (30 of 38) but rarely in only MYC-positive (2 of 8) tumors.
CONCLUSIONSNBUD represents a unique subtype of neuroblastoma associated with a poor prognosis. In this subtype, MYC protein expression may be a new prognostic factor indicating more aggressive clinical behavior than MYCN amplification and subsequent MYCN protein expression. Cancer 2013;119:3718-3726. (c) 2013 American Cancer Society.
Neuroblastoma, undifferentiated subtype, which is the histologically defined entity composed of neuroblasts often having prominent nucleoli, is frequently associated with poor prognostic factors. In this subtype, MYC protein expression could indicate more aggressive clinical behavior than MYCN amplification and subsequent MYCN protein expression.
C1 [Wang, Larry L.; Suganuma, Rie; Shimada, Hiroyuki] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90027 USA.
[Wang, Larry L.; Suganuma, Rie; Seeger, Robert C.; Shimada, Hiroyuki] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Ikegaki, Naohiko; Tang, Xao] Univ Illinois, Coll Med, Dept Anat & Cell Biol, Chicago, IL USA.
[Naranjo, Arlene; McGrady, Patrick] Univ Florida, Childrens Oncol Grp Stat & Data Ctr, Dept Biostat, Gainesville, FL USA.
[London, Wendy B.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[London, Wendy B.] Boston Childrens Hosp, Childrens Oncol Grp Stat & Data Ctr, Boston, MA USA.
[London, Wendy B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hogarty, Michael D.] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.
[Gastier-Foster, Julie M.] Ohio Univ, Coll Med, Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH USA.
[Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Park, Julie R.] Univ Washington, Sch Med, Dept Pediat, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Park, Julie R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Philadelphia, PA 19104 USA.
[Cohn, Susan L.] Univ Chicago, Dept Pediat, Div Hematol Oncol, Chicago, IL 60637 USA.
[Seeger, Robert C.] Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA.
RP Shimada, H (reprint author), Childrens Hosp Los Angeles, 4650 Sunset Blvd,MS 43, Los Angeles, CA 90027 USA.
EM hshimada@chla.usc.edu
FU NCI/SAIC; Children's Oncology Group; SWOG; NIH/NCI-Children's Oncology
Group Statistics and Data Center; National Institutes of Health [U10
CA98413, U10 CA98543]
FX Dr. Hogarty has received salary support for Children's Oncology Group
(COG)-related activities, and travel to COG meetings has been
reimbursed. He also has grants submitted and/or awarded for research
from numerous granting agencies, received course instructor honorarium
from Acadia University, has intellectual property on ARID1 (no patent
filed, no monetary value anticipated), and is a committee member and is
reimbursed for travel and honorarium from the American Board of
Pediatrics. Dr. Gastier-Foster's institution has received, from
NCI/SAIC, a contract to Biospecimen Core Resource for specimen
processing, support from NCI/SAIC for travel to meetings for the study
or other purposes, grants from NCI/SAIC, Children's Oncology Group, and
SWOG, and travel/accommodations/meeting expenses from NCI, Children's
Oncology Group, SWOG, American Board of Medical Genetics (unrelated to
activities listed). Dr. London's institution has received grants from
NIH/NCI-Children's Oncology Group Statistics and Data Center. Dr.
Shimada has received National Institutes of Health grants U10 CA98413
and U10 CA98543. The other authors made no disclosure.
NR 33
TC 12
Z9 12
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2013
VL 119
IS 20
BP 3718
EP 3726
DI 10.1002/cncr.28251
PG 9
WC Oncology
SC Oncology
GA 230WJ
UT WOS:000325373700054
PM 23901000
ER
PT J
AU Dimitrov, SD
Lu, D
Naetar, N
Hu, YD
Pathania, S
Kanellopoulou, C
Livingston, DM
AF Dimitrov, Stoil D.
Lu, David
Naetar, Nana
Hu, Yiduo
Pathania, Shailja
Kanellopoulou, Chryssa
Livingston, David M.
TI Physiological modulation of endogenous BRCA1 p220 abundance suppresses
DNA damage during the cell cycle
SO GENES & DEVELOPMENT
LA English
DT Article
DE BRCA1; miR-545; DNA damage; cell cycle; G0/G1
ID SPORADIC BREAST-CANCER; HOMOLOGOUS RECOMBINATION; TUMOR SUPPRESSION;
GENE-EXPRESSION; OVARIAN-CANCER; MESSENGER-RNA; END RESECTION; NUCLEAR
PHOSPHOPROTEIN; CHECKPOINT ACTIVATION; PROMOTER METHYLATION
AB Endogenous BRCA1 p220 expression peaks in S and G2 when it is activated, and the protein participates in certain key DNA damage responses. In contrast, its expression is markedly reduced in G0/G1. While variations in transcription represent a significant part of p220 expression control, there is at least one other relevant process. We found that a microRNA, miR-545, that is expressed throughout the cell cycle down-modulates endogenous p220 mRNA and protein abundance directly in both G0/G1 and S/G2. When miR-545 function was inhibited by a specific antagomir, endogenous p220 expression increased in G0/G1, and aberrant p220-associated DNA damage responses and de novo DNA strand breaks accumulated. Analogous results were observed upon inhibition of miR-545 function in S/G2. Both sets of antagomir effects were mimicked by infecting cells with a p220 cDNA-encoding adenoviral vector. Thus, strand breaks were a product of p220 overexpression, and their prevention by miR-545 depends on its modulation of p220 expression. Breaks were also dependent on aberrant, overexpressed p220-driven recruitment of RAD51 to either spontaneously arising or mutagen-based DNA damage sites. Hence, when its level is not physiologically maintained, endogenous p220 aberrantly directs at least one DNA repair protein, RAD51, to damage sites, where their action contributes to the development of de novo DNA damage. Thus, like its loss, a surfeit of endogenous p220 function represents a threat to genome integrity.
C1 [Dimitrov, Stoil D.; Lu, David; Naetar, Nana; Hu, Yiduo; Pathania, Shailja; Kanellopoulou, Chryssa; Livingston, David M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Dimitrov, Stoil D.; Lu, David; Naetar, Nana; Hu, Yiduo; Pathania, Shailja; Kanellopoulou, Chryssa; Livingston, David M.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
RP Livingston, DM (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
EM david_livingston@dfci.harvard.edu
FU Breast Cancer SPORE grant; National Cancer Institute [5 P01CA80111];
Breast Cancer Research Foundation; Susan G. Komen Foundation for the
Cure [SAC110022]; National Institutes of Health Training grant
[5T32CA00938-30]
FX We thank Ronny Drapkin, Daniel Silver, Jean Feunteun, Todd Golub, and
members of the Livingston laboratory for insightful discussions and
suggestions. We are grateful to Serena Landini for technical advice and
help. We thank Asako Sakaue-Sawano and Atsushi Miyawaki (RIKEN) for the
mAG1-hGem-expressing and mKO2-hCdt1-expressing vectors, and Dipanjan
Chowdhury for graciously sharing results prior to publication. This work
was supported by funds from the Breast Cancer SPORE grant to
Dana-Farber/Harvard Cancer Center (to S.D.D. and D.M.L.) and grants from
the National Cancer Institute (5 P01CA80111), the Breast Cancer Research
Foundation, and the Susan G. Komen Foundation for the Cure (SAC110022)
(to D.M.L.). Generous support for this work was also provided by the
National Institutes of Health Training grant (5T32CA00938-30) (to
S.D.D.).
NR 89
TC 11
Z9 11
U1 0
U2 3
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD OCT 15
PY 2013
VL 27
IS 20
BP 2274
EP 2291
DI 10.1101/gad.225045.113
PG 18
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 238GP
UT WOS:000325932500009
PM 24142877
ER
PT J
AU Shahian, DM
Jacobs, JP
Edwards, FH
Brennan, JM
Dokholyan, RS
Prager, RL
Wright, CD
Peterson, ED
McDonald, DE
Grover, FL
AF Shahian, David M.
Jacobs, Jeffrey P.
Edwards, Fred H.
Brennan, J. Matthew
Dokholyan, Rachel S.
Prager, Richard L.
Wright, Cameron D.
Peterson, Eric D.
McDonald, Donna E.
Grover, Frederick L.
TI The Society of Thoracic Surgeons National Database
SO HEART
LA English
DT Article
ID ADULT CARDIAC-SURGERY; CONGENITAL HEART-SURGERY; BYPASS-GRAFTING
SURGERY; PERCUTANEOUS CORONARY INTERVENTION; RISK-ADJUSTMENT MODEL;
LONG-TERM SURVIVAL; STS DATABASE; LUNG-CANCER; REVASCULARIZATION
STRATEGIES; ADMINISTRATIVE DATABASES
AB Aims The Society of Thoracic Surgeons (STS) National Database collects detailed clinical information on patients undergoing adult cardiac, paediatric and congenital cardiac, and general thoracic surgical operations. These data are used to support risk-adjusted, nationally benchmarked performance assessment and feedback; voluntary public reporting; quality improvement initiatives; guideline development; appropriateness determination; shared decision making; research using cross-sectional and longitudinal registry linkages; comparative effectiveness studies; government collaborations including postmarket surveillance; regulatory compliance and reimbursement strategies.
Interventions All database participants receive feedback reports which they may voluntarily share with their hospitals or payers, or publicly report. STS analyses are regularly used as the basis for local, regional and national quality improvement efforts.
Population More than 90% of adult cardiac programmes in the USA participate, as do the majority of paediatric cardiac programmes, and general thoracic participation continues to increase. Since the inception of the Database in 1989, more than 5 million patient records have been submitted.
Baseline data Each of the three subspecialty databases includes several hundred variables that characterise patient demographics, diagnosis, medical history, clinical risk factors and urgency of presentation, operative details and postoperative course including adverse outcomes.
Data capture Data are entered by trained data abstractors and by the care team, using detailed data specifications for each element.
Data quality Quality and consistency checks assure accurate and complete data, missing data are rare, and audits are performed annually of selected participant sites.
Endpoints All major outcomes are reported including complications, status at discharge and mortality.
Data access Applications for STS Database participants to use aggregate national data for research are available at http://www.sts.org/quality-research-patient-safety/research/publications-and-research/access-data-sts-national-database.
C1 [Shahian, David M.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Shahian, David M.] Harvard Univ, Sch Med, Ctr Qual & Safety, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Jacobs, Jeffrey P.] Univ S Florida, All Childrens Hosp, Johns Hopkins Childrens Heart Surg, St Petersburg, FL 33701 USA.
[Jacobs, Jeffrey P.] All Childrens Hosp, Johns Hopkins Childrens Heart Surg, Tampa, FL USA.
[Jacobs, Jeffrey P.] All Childrens Hosp, Johns Hopkins Childrens Heart Surg, Orlando, FL USA.
[Jacobs, Jeffrey P.] Florida Hosp Children, St Petersburg, FL USA.
[Jacobs, Jeffrey P.] Florida Hosp Children, Tampa, FL USA.
[Jacobs, Jeffrey P.] Florida Hosp Children, Orlando, FL USA.
[Edwards, Fred H.] Univ Florida Coll Med Jacksonville, Shands Jacksonville, Jacksonville, FL USA.
[Brennan, J. Matthew; Dokholyan, Rachel S.; Peterson, Eric D.] Duke Univ Med Ctr, DCRI, Durham, NC USA.
[Prager, Richard L.] Univ Michigan Hlth Syst, Dept Cardiac Surg, Ann Arbor, MI USA.
[Wright, Cameron D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Surg, Boston, MA USA.
[McDonald, Donna E.] Soc Thorac Surg, Chicago, IL USA.
[Grover, Frederick L.] Univ Colorado Denver, Sch Med, Dept Surg, Aurora, CO USA.
RP Shahian, DM (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St, Boston, MA 02114 USA.
EM dshahian@partners.org
NR 69
TC 43
Z9 45
U1 0
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD OCT 15
PY 2013
VL 99
IS 20
BP 1494
EP 1501
DI 10.1136/heartjnl-2012-303456
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 221FV
UT WOS:000324644200006
PM 23335498
ER
PT J
AU Brandauer, J
Vienberg, SG
Andersen, MA
Ringholm, S
Risis, S
Larsen, PS
Kristensen, JM
Frosig, C
Leick, L
Fentz, J
Jorgensen, S
Kiens, B
Wojtaszewski, JFP
Richter, EA
Zierath, JR
Goodyear, LJ
Pilegaard, H
Treebak, JT
AF Brandauer, Josef
Vienberg, Sara G.
Andersen, Marianne A.
Ringholm, Stine
Risis, Steve
Larsen, Per S.
Kristensen, Jonas M.
Frosig, Christian
Leick, Lotte
Fentz, Joachim
Jorgensen, Sebastian
Kiens, Bente
Wojtaszewski, Jorgen F. P.
Richter, Erik A.
Zierath, Juleen R.
Goodyear, Laurie J.
Pilegaard, Henriette
Treebak, Jonas T.
TI AMP-activated protein kinase regulates nicotinamide phosphoribosyl
transferase expression in skeletal muscle
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID CALORIE RESTRICTION; SACCHAROMYCES-CEREVISIAE; GLUCOSE-HOMEOSTASIS;
INSULIN SENSITIVITY; LIFE-SPAN; SIRT1; PGC-1-ALPHA; METABOLISM;
EXERCISE; METFORMIN
AB Deacetylases such as sirtuins (SIRTs) convert NAD to nicotinamide (NAM). Nicotinamide phosphoribosyl transferase (Nampt) is the rate-limiting enzyme in the NAD salvage pathway responsible for converting NAM to NAD to maintain cellular redox state. Activation of AMP-activated protein kinase (AMPK) increases SIRT activity by elevating NAD levels. As NAM directly inhibits SIRTs, increased Nampt activation or expression could be a metabolic stress response. Evidence suggests that AMPK regulates Nampt mRNA content, but whether repeated AMPK activation is necessary for increasing Nampt protein levels is unknown. To this end, we assessed whether exercise training- or 5-amino-1--d-ribofuranosyl-imidazole-4-carboxamide (AICAR)-mediated increases in skeletal muscle Nampt abundance are AMPK dependent. One-legged knee-extensor exercise training in humans increased Nampt protein by 16% (P < 0.05) in the trained, but not the untrained leg. Moreover, increases in Nampt mRNA following acute exercise or AICAR treatment (P < 0.05 for both) were maintained in mouse skeletal muscle lacking a functional AMPK 2 subunit. Nampt protein was reduced in skeletal muscle of sedentary AMPK 2 kinase dead (KD), but 6.5 weeks of endurance exercise training increased skeletal muscle Nampt protein to a similar extent in both wild-type (WT) (24%) and AMPK 2 KD (18%) mice. In contrast, 4 weeks of daily AICAR treatment increased Nampt protein in skeletal muscle in WT mice (27%), but this effect did not occur in AMPK 2 KD mice. In conclusion, functional 2-containing AMPK heterotrimers are required for elevation of skeletal muscle Nampt protein, but not mRNA induction. These findings suggest AMPK plays a post-translational role in the regulation of skeletal muscle Nampt protein abundance, and further indicate that the regulation of cellular energy charge and nutrient sensing is mechanistically related.
C1 [Brandauer, Josef; Vienberg, Sara G.; Andersen, Marianne A.; Risis, Steve; Larsen, Per S.; Zierath, Juleen R.; Treebak, Jonas T.] Univ Copenhagen, Novo Nordisk Fdn, Ctr Basic Metab Res, Sect Integrat Physiol, DK-2200 Copenhagen, Denmark.
[Brandauer, Josef] Gettysburg Coll, Dept Hlth Sci, Gettysburg, PA 17325 USA.
[Brandauer, Josef; Goodyear, Laurie J.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Metab Sect, Boston, MA 02115 USA.
[Ringholm, Stine; Leick, Lotte; Pilegaard, Henriette] Univ Copenhagen, August Krogh Ctr, Dept Biol, DK-2200 Copenhagen, Denmark.
[Kristensen, Jonas M.; Frosig, Christian; Fentz, Joachim; Jorgensen, Sebastian; Kiens, Bente; Wojtaszewski, Jorgen F. P.; Richter, Erik A.] Univ Copenhagen, August Krogh Ctr, Dept Nutr Exercise & Sports, Sect Mol Physiol, DK-2200 Copenhagen, Denmark.
[Zierath, Juleen R.] Karolinska Inst, Dept Mol Med, Sect Integrat Physiol, Stockholm, Sweden.
[Zierath, Juleen R.] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.
RP Treebak, JT (reprint author), Univ Copenhagen, NNF Ctr Basic Metab Res, Blegdamsvej 3B,6-6-28, DK-2200 Copenhagen, Denmark.
EM jttreebak@sund.ku.dk
RI Pilegaard, Henriette/M-2315-2014; Wojtaszewski, Jorgen /P-6583-2014;
Frosig, Christian/A-3750-2015; Fentz, Joachim/B-1973-2015; Treebak,
Jonas/B-4521-2017;
OI Pilegaard, Henriette/0000-0002-1071-0327; Wojtaszewski, Jorgen
/0000-0001-9785-6830; Frosig, Christian/0000-0001-9302-9328; Fentz,
Joachim/0000-0002-9334-1298; Treebak, Jonas/0000-0003-1488-7012;
Agerholm Andersen, Marianne/0000-0001-8687-1031; Zierath,
Juleen/0000-0001-6891-7497
FU Novo Nordisk Foundation Center for Basic Metabolic Research; Novo
Nordisk Foundation; Danish Agency for Science, Technology and
Innovation; Gettysburg College; Danish National Research Foundation
[504-14, 02-512-555]; Research and Technological Development Projects
[QLG1-CT-2001-01488]; European Commission; Media and Grants Secretariat
of the Danish Ministry of Culture; Danish Diabetes Association; Danish
Medical Research Council; Lundbeck Foundation; European Commission FP6
Integrated Project Exgenesis [LSHM-CT-2004-005272]; Danish Natural
Science Research Council
FX Support for this project was provided by the Novo Nordisk Foundation
Center for Basic Metabolic Research and the Novo Nordisk Foundation to
Jonas T. Treebak. Jonas T. Treebak was supported by a postdoctoral
fellowship from The Danish Agency for Science, Technology and
Innovation. Josef Brandauer was supported by a Research and Professional
Development Grant by Gettysburg College. J. F. P. Wojtaszewski was
supported by a Hallas Moller fellowship from the Novo Nordisk
Foundation.; The human training study was supported by grants from the
Danish National Research Foundation (no. 504-14), a Research and
Technological Development Projects (QLG1-CT-2001-01488) grant funded by
the European Commission, by the Media and Grants Secretariat of the
Danish Ministry of Culture, by the Danish Diabetes Association, by the
Novo Nordisk Foundation, and by the Danish Medical Research Council.;
Experiments in PGC-1 alpha KO mice were supported by the Lundbeck
Foundation, the Novo Nordisk Foundation and a grant from the European
Commission FP6 Integrated Project Exgenesis (Ref. LSHM-CT-2004-005272).
Support was also provided by the Danish National Research Foundation
(grant no. 02-512-555) to the Centre of Inflammation and Metabolism.;
Studies in AMPK alpha 2 KO mice were funded by the Danish National
Research Foundation (#504-14), the Danish Diabetes Association, the
Danish Medical Research Council, the Danish Natural Science Research
Council, the Novo Nordisk Foundation and by an integrated project
(contract LSHM-CT-2004-005272) funded by the European Commission.
NR 53
TC 22
Z9 22
U1 1
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD OCT 15
PY 2013
VL 591
IS 20
BP 5207
EP 5220
DI 10.1113/jphysiol.2013.259515
PG 14
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 238VX
UT WOS:000325980700027
PM 23918774
ER
PT J
AU Wills, LP
Beeson, GC
Trager, RE
Lindsey, CC
Beeson, CC
Peterson, YK
Schnellmann, RG
AF Wills, Lauren P.
Beeson, Gyda C.
Trager, Richard E.
Lindsey, Christopher C.
Beeson, Craig C.
Peterson, Yuri K.
Schnellmann, Rick G.
TI High-throughput respirometric assay identifies predictive toxicophore of
mitochondrial injury
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Mitochondria; Toxicophore; Renal proximal tubule cells; LOPAC;
ChemBridge; Seahorse Biosciences Extracellular Flux
ID OXYGEN-SENSITIVE PROBES; IN-VITRO; PERMEABILITY TRANSITION; TOXICITY;
CELLS; DRUGS; MECHANISMS; APOPTOSIS; CULTURE; TARGETS
AB Many environmental chemicals and drugs negatively affect human health through deleterious effects on mitochondrial function. Currently there is no chemical library of mitochondrial toxicants, and no reliable methods for predicting mitochondrial toxicity. We hypothesized that discrete toxicophores defined by distinct chemical entities can identify previously unidentified mitochondrial toxicants. We used a respirometric assay to screen 1760 compounds (5 mu M) from the LOPAC and ChemBridge DIVERSet libraries. Thirty-one of the assayed compounds decreased uncoupled respiration, a stress test for mitochondrial dysfunction, prior to a decrease in cell viability and reduced the oxygen consumption rate in isolated mitochondria. The mitochondrial toxicants were grouped by chemical similarity and two clusters containing four compounds each were identified. Cheminformatic analysis of one of the clusters identified previously uncharacterized mitochondrial toxicants from the ChemBridge DIVERSet This approach will enable the identification of mitochondrial toxicants and advance the prediction of mitochondrial toxicity for both drug discovery and risk assessment. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Beeson, Gyda C.; Trager, Richard E.; Lindsey, Christopher C.; Peterson, Yuri K.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
[Wills, Lauren P.; Beeson, Craig C.] MitoHealth Inc, Charleston, SC 29403 USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU NCRR NIH HHS [S10 RR027122]; NIEHS NIH HHS [R43 ES019378, R44 ES019378];
NIGMS NIH HHS [R01 GM084147, R43 GM097770]
NR 44
TC 5
Z9 5
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD OCT 15
PY 2013
VL 272
IS 2
BP 490
EP 502
DI 10.1016/j.taap.2013.06.014
PG 13
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 237XS
UT WOS:000325905500025
PM 23811330
ER
PT J
AU Chavarro, JE
Kenfield, SA
Stampfer, MJ
Loda, M
Campos, H
Sesso, HD
Ma, J
AF Chavarro, Jorge E.
Kenfield, Stacey A.
Stampfer, Meir J.
Loda, Massimo
Campos, Hannia
Sesso, Howard D.
Ma, Jing
TI Blood Levels of Saturated and Monounsaturated Fatty Acids as Markers of
De Novo Lipogenesis and Risk of Prostate Cancer
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE biomarkers; epidemiology; fatty acids; nutrition; prostate cancer
ID C-REACTIVE PROTEIN; BODY-MASS INDEX; ADIPOSE-TISSUE; WHOLE-BLOOD;
PLASMA; SYNTHASE; INHIBITION; APOPTOSIS; CELLS; EXPRESSION
AB De novo lipogenesis has been implicated in prostate carcinogenesis, and blood levels of specific saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs) could reflect activity of this pathway. We used gas chromatography to measure blood SFA and MUFA levels in prediagnostic samples from 476 incident prostate cancer cases (19821995) in the Physicians Health Study and an equal number of controls matched on age and smoking status. Five tagging polymorphisms in the fatty acid synthase (FASN) gene (rs1127678, rs6502051, rs4246444, rs12949488, and rs8066956) were related to blood SFA and MUFA levels. Conditional logistic regression was used to estimate the rate ratios, with 95 confidence intervals, of prostate cancer across quintiles of blood fatty acid levels. The polymorphisms rs6502051 and rs4246444 were associated with lower levels of 14:1n-5, 16:1n-7, and 18:1n-9. Blood levels of 16:1n-7 were associated with higher prostate cancer incidence, with rate ratios for men in increasing quintiles of 1.00, 1.40, 1.35, 1.44, and 1.97 (95 confidence interval: 1.273.06; P-trend 0.003). Furthermore, 16:1n-7 levels were positively related to incidence of high-grade (Gleason score 7) tumors (rate ratio(Q5Q1) 3.92; 95 confidence interval: 1.728.94) but not low-grade tumors (rate ratio(Q5Q1) 1.51; 95 confidence interval: 0.872.62) (P-heterogeneity 0.02). Higher activity of enzymes involved in de novo lipogenesis, as reflected in blood levels of 16:1n-7, could be involved in the development of high-grade prostate cancer.
C1 [Chavarro, Jorge E.; Stampfer, Meir J.; Campos, Hannia] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Chavarro, Jorge E.; Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Chavarro, Jorge E.; Stampfer, Meir J.; Ma, Jing] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med,Dept Med, Boston, MA 02115 USA.
[Kenfield, Stacey A.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA.
[Loda, Massimo] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol,Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Loda, Massimo] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Sesso, Howard D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med,Dept Med, Boston, MA 02115 USA.
RP Chavarro, JE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM jchavarr@hsph.harvard.edu
FU US Department of Defense [W81XWH-11-1-0529]; National Institutes of
Health [CA42182, CA58684, CA90598, CA141298, CA97193, CA34944, CA40360,
CA131945, P50CA90381, 1U54CA155626-01, P30DK046200, HL26490, HL34595]
FX This work was supported by grant W81XWH-11-1-0529 from the US Department
of Defense and grants CA42182, CA58684, CA90598, CA141298, CA97193,
CA34944, CA40360, CA131945, P50CA90381, 1U54CA155626-01, P30DK046200,
HL26490, and HL34595 from the National Institutes of Health.
NR 39
TC 9
Z9 9
U1 0
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD OCT 15
PY 2013
VL 178
IS 8
BP 1246
EP 1255
DI 10.1093/aje/kwt136
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 235YK
UT WOS:000325759000010
PM 23989197
ER
PT J
AU Reginato, E
Mroz, P
Chung, H
Kawakubo, M
Wolf, P
Hamblin, MR
AF Reginato, E.
Mroz, P.
Chung, H.
Kawakubo, M.
Wolf, P.
Hamblin, M. R.
TI Photodynamic therapy plus regulatory T-cell depletion produces immunity
against a mouse tumour that expresses a self-antigen
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE photodynamic therapy; regulatory T cells; TGF beta; CT26 tumour;
anti-tumour immunity
ID LOW-DOSE CYCLOPHOSPHAMIDE; GROWTH-FACTOR-BETA; TGF-BETA; ANTITUMOR
IMMUNITY; MURINE TUMOR; HUMAN CANCER; INDUCTION; IMMUNOTHERAPY;
AUTOIMMUNITY; LYMPHOCYTES
AB Background: Photodynamic therapy (PDT) can lead to development of antigen-specific immune response and PDT-mediated immunity can be potentiated by T regulatory cell (Treg) depletion. We investigated whether the combination of PDT with cyclophosphamide (CY) could foster immunity against wild-type tumours expressing self-antigen (gp70).
Methods: Mice with CT26 tumours were treated with PDT alone or in combination with low-dose CY. T regulatory cell numbers and transforming growth factor-beta (TGF-beta) levels were measured at several time points after treatment. Mice cured by PDT+CY were rechallenged with CT26 and monitored for long-term survival.
Results: Photodynamic therapy+CY led to complete tumour regression and long-term survival in 90% of treated mice while the absolute numbers of Treg decreased after PDT+CY and the TGF-beta levels were reduced to a level comparable to naive mice. Sixty-five percent of the mice treated with PDT+CY that survived over 90 days tumour free rejected the rechallenge with the same tumour when a second dose of CY was administered before rechallenge but not without.
Conclusion: Administration of CY before PDT led to depletion of Treg and potentiated PDT-mediated immunity, leading to long-term survival and development of memory immunity that was only uncovered by second Treg depletion.
C1 [Reginato, E.; Mroz, P.; Chung, H.; Kawakubo, M.; Hamblin, M. R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Reginato, E.; Wolf, P.] Med Univ Graz, Dept Dermatol, A-8036 Graz, Austria.
[Mroz, P.; Chung, H.; Hamblin, M. R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
[Mroz, P.] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA.
[Hamblin, M. R.] Harvard Mit Div Hlth Sci & Technol, Boston, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM Hamblin@helix.mgh.harvard.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU US NIH [AI050875]; Medical University of Graz, Graz, Austria
FX Research in the Hamblin laboratory is supported by US NIH grant
AI050875. ER was supported by the PhD program of the Medical University
of Graz, Graz, Austria.
NR 47
TC 17
Z9 18
U1 2
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 15
PY 2013
VL 109
IS 8
BP 2167
EP 2174
DI 10.1038/bjc.2013.580
PG 8
WC Oncology
SC Oncology
GA 236KN
UT WOS:000325795000017
PM 24064977
ER
PT J
AU Jorgenson, TC
Zhong, WX
Oberley, TD
AF Jorgenson, Tonia C.
Zhong, Weixiong
Oberley, Terry D.
TI Redox Imbalance and Biochemical Changes in Cancer
SO CANCER RESEARCH
LA English
DT Article
ID MOLECULAR-MECHANISMS; S-GLUTATHIONYLATION; OXIDATIVE STRESS;
THIOREDOXIN; ACTIVATION; CELLS; NRF2; SUMOYLATION; METHYLATION; LEUKEMIA
AB For this article, we explore a hypothesis involving the possible role of reduction/oxidation (redox) state in cancer. We hypothesize that many modifications in cellular macromolecules, observed in cancer progression, may be caused by redox imbalance. Recent biochemical data suggest that human prostate cancer cell lines show a redox imbalance (oxidizing) compared with benign primary prostate epithelial cells; the degree of oxidation varied with aggressive behavior of each cell line. Our recent data suggest that human breast cancer tissues show a redox imbalance (reducing) compared with benign adjacent breast tissues. Accumulating data summarized in this article suggest that redox imbalance may regulate gene expression and alter protein stability by posttranslational modifications, in turn modulating existing cellular programs. Despite significant improvements in cancer therapeutics, resistance occurs, and redox imbalance may play a role in this process. Studies show that some cancer therapeutic agents increase generation of reactive oxygen/nitrogen species and antioxidant enzymes, which may alter total antioxidant capacity, cause cellular adaptation, and result in reduced effectiveness of treatment modalities. Approaches involving modulations of intra-and extracellular redox states, in combination with other therapies, may lead to new treatment options, especially for patients who are resistant to standard treatments. Cancer Res; 73(20); 6118-23. (C) 2013 AACR.
C1 [Jorgenson, Tonia C.; Zhong, Weixiong; Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Inst Med Res, Dept Pathol & Lab Med, Madison, WI 53705 USA.
[Zhong, Weixiong; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA.
RP Jorgenson, TC (reprint author), Univ Wisconsin, Wisconsin Inst Med Res, 1111 Highland Ave, Madison, WI 53705 USA.
EM tjorgenson@wisc.edu
FU Department of Pathology and Laboratory Medicine, University of
Wisconsin; NCI UW Carbone Comprehensive Cancer Center (NIH) [P30
CA014520]; NIH [RO1CA139844, RO1CA139843, RO1CA073599]
FX This work was supported in part by funds from the Department of
Pathology and Laboratory Medicine, University of Wisconsin, NCI UW
Carbone Comprehensive Cancer Center (NIH grant P30 CA014520), NIH grants
RO1CA139844, RO1CA139843, RO1CA073599 (TDO-CoI), and resources and
facilities at the William S. Middleton Memorial Veterans Hospital
(Madison, WI). Tonia C. Jorgenson is supported in part by
PF-13-286-01-TBE from the American Cancer Society.
NR 30
TC 26
Z9 27
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2013
VL 73
IS 20
BP 6118
EP 6123
DI 10.1158/0008-5472.CAN-13-1117
PG 6
WC Oncology
SC Oncology
GA 236KV
UT WOS:000325796100004
PM 23878188
ER
PT J
AU Kaelin, W
Livingston, D
Loda, M
Vousden, K
Mihich, E
AF Kaelin, William
Livingston, David
Loda, Massimo
Vousden, Karen
Mihich, Enrico
TI Twenty-fifth Annual Pezcoller Symposium: Metabolism and Tumorigenesis
SO CANCER RESEARCH
LA English
DT Editorial Material
ID DIFFERENTIATION; PROMOTE; GROWTH; CELLS
AB Choking cancer via inhibition of metabolic enzymes essential for tumor but dispensable in normal tissues was discussed as was the altered metabolism in cancer cells related to: tumor suppressor protein (pVHL) function, the histone acetylation dependence upon glucose, the epigenomic reprogramming of acetyl CoA synthesis, the plasticity of aging mechanisms, and the metabolism orchestration in macrophage polarization. The p53 and p73 pathways role in metabolic adaptation, the effects on growth of AMP-dependent kinase, the growth regulation by the mTOR pathways, and the bioenergetics requirements of cancer cells were also discussed. A novel computational model of personalized metabolic changes in cancer was outlined with applications in patients with breast cancer. Imaging metabolic characteristics of tumors by MRI and C-13-nuclear magnetic resonance was described. The cancer metabolism regulation related to O-linked beta-N-acetylglucosame was described. DNA hypermethylation and impaired hematopoietic differentiation in AML after isocitrate dehydrogenase 1/2 mutation and 2-hydroxyglutarate increases were outlined. Cancer Res; 73(20); 6124-7. (C) 2013 AACR.
C1 [Kaelin, William; Livingston, David; Loda, Massimo; Mihich, Enrico] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Loda, Massimo] Harvard Univ, Sch Med, Boston, MA USA.
[Vousden, Karen] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.
RP Mihich, E (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM enrico_mihich@dfci.harvard.edu
NR 14
TC 0
Z9 0
U1 1
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2013
VL 73
IS 20
BP 6124
EP 6127
DI 10.1158/0008-5472.CAN-13-2445
PG 4
WC Oncology
SC Oncology
GA 236KV
UT WOS:000325796100005
PM 24097824
ER
PT J
AU Pfaffle, HN
Wang, M
Gheorghiu, L
Ferraiolo, N
Greninger, P
Borgmann, K
Settleman, J
Benes, CH
Sequist, LV
Zou, L
Willers, H
AF Pfaeffle, Heike N.
Wang, Meng
Gheorghiu, Liliana
Ferraiolo, Natalie
Greninger, Patricia
Borgmann, Kerstin
Settleman, Jeffrey
Benes, Cyril H.
Sequist, Lecia V.
Zou, Lee
Willers, Henning
TI EGFR-Activating Mutations Correlate with a Fanconi Anemia-like Cellular
Phenotype That Includes PARP Inhibitor Sensitivity
SO CANCER RESEARCH
LA English
DT Article
ID CROSS-LINK REPAIR; GROWTH-FACTOR RECEPTOR; HOMOLOGOUS RECOMBINATION
REPAIR; DOUBLE-STRAND BREAKS; DNA-REPAIR; LUNG-CANCER; POLY(ADP-RIBOSE)
POLYMERASE; IONIZING-RADIATION; TUMOR-CELLS; NSCLC CELLS
AB In patients with lung cancer whose tumors harbor activating mutations in the EGF receptor (EGFR), increased responses to platinum-based chemotherapies are seen compared with wild-type cancers. However, the mechanisms underlying this association have remained elusive. Here, we describe a cellular phenotype of cross-linker sensitivity in a subset of EGFR-mutant lung cancer cell lines that is reminiscent of the defects seen in cells impaired in the Fanconi anemia pathway, including a pronounced G(2)-M cell-cycle arrest and chromosomal radial formation. We identified a defect downstream of FANCD2 at the level of recruitment of FAN1 nuclease and DNA interstrand cross-link (ICL) unhooking. The effect of EGFR mutation was epistatic with FANCD2. Consistent with the known role of FANCD2 in promoting RAD51 foci formation and homologous recombination repair (HRR), EGFR-mutant cells also exhibited an impaired RAD51 foci response to ICLs, but not to DNA double-strand breaks. EGFR kinase inhibition affected RAD51 foci formation neither in EGFR-mutant nor wild-type cells. In contrast, EGFR depletion or overexpression of mutant EGFR in wild-type cells suppressed RAD51 foci, suggesting an EGFR kinase-independent regulation of DNA repair. Interestingly, EGFR-mutant cells treated with the PARP inhibitor olaparib also displayed decreased FAN1 foci induction, coupled with a putative block in a late HRR step. As a result, EGFR-mutant lung cancer cells exhibited olaparib sensitivity in vitro and in vivo. Our findings provide insight into the mechanisms of cisplatin and PARP inhibitor sensitivity of EGFR-mutant cells, yielding potential therapeutic opportunities for further treatment individualization in this genetically defined subset of lung cancer. Cancer Res; 73(20); 6254-63. (C) 2013 AACR.
C1 [Pfaeffle, Heike N.; Wang, Meng; Gheorghiu, Liliana; Ferraiolo, Natalie; Willers, Henning] Harvard Univ, Lab Cellular & Mol Radiat Oncol, Dept Radiat Oncol, Sch Med,Massachusetts Gen Hosp, Charlestown, MA USA.
[Sequist, Lecia V.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Greninger, Patricia; Settleman, Jeffrey; Benes, Cyril H.; Zou, Lee] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Res, Charlestown, MA USA.
[Settleman, Jeffrey] Genentech Inc, Res Oncol, San Francisco, CA 94080 USA.
[Pfaeffle, Heike N.] Univ Munich, Dept Pharmaceut Biol, Munich, Germany.
[Borgmann, Kerstin] Univ Hamburg, Ctr Oncol, Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany.
RP Willers, H (reprint author), Massachusetts Gen Hosp, Cox 3,55 Fruit St, Boston, MA 02114 USA.
EM hwillers@partners.org
FU Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer, NCI [P50
CA090578]; Department of Defense [W81XWH-06-1-0309]; UK Wellcome Trust
[086357]; Massachusetts General Hospital, Proton Therapy Research and
Treatment Center [C06 CA059267]
FX This work was supported by the Dana-Farber/Harvard Cancer Center SPORE
in Lung Cancer, NCI P50 CA090578 (J. Settleman, L. Zou, and H. Willers),
Department of Defense W81XWH-06-1-0309 (H. Willers), the UK Wellcome
Trust 086357 (C.H. Benes and J. Settleman), and the Federal Share of
program income earned by Massachusetts General Hospital on C06 CA059267,
Proton Therapy Research and Treatment Center (L. Zou, L.V. Sequist, and
H. Willers).
NR 49
TC 11
Z9 11
U1 2
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2013
VL 73
IS 20
BP 6254
EP 6263
DI 10.1158/0008-5472.CAN-13-0044
PG 10
WC Oncology
SC Oncology
GA 236KV
UT WOS:000325796100017
PM 23966292
ER
PT J
AU Abazeed, ME
Adams, DJ
Hurov, KE
Tamayo, P
Creighton, CJ
Sonkin, D
Giacomelli, AO
Du, C
Fries, DF
Wong, KK
Mesirov, JP
Loeffler, JS
Schreiber, SL
Hammerman, PS
Meyerson, M
AF Abazeed, Mohamed E.
Adams, Drew J.
Hurov, Kristen E.
Tamayo, Pablo
Creighton, Chad J.
Sonkin, Dmitriy
Giacomelli, Andrew O.
Du, Charles
Fries, Daniel F.
Wong, Kwok-Kin
Mesirov, Jill P.
Loeffler, Jay S.
Schreiber, Stuart L.
Hammerman, Peter S.
Meyerson, Matthew
TI Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer
SO CANCER RESEARCH
LA English
DT Article
ID ANTIOXIDANT RESPONSE ELEMENTS; GENE-EXPRESSION; RADIATION SENSITIVITY;
CONNECTIVITY MAP; NRF2; CARCINOMA; KINASE; P53; RESISTANCE; INHIBITORS
AB Radiotherapy is one of the mainstays of anticancer treatment, but the relationship between the radiosensitivity of cancer cells and their genomic characteristics is still not well defined. Here, we report the development of a high-throughput platform for measuring radiation survival in vitro and its validation in comparison with conventional clonogenic radiation survival analysis. We combined results from this high-throughput assay with genomic parameters in cell lines from squamous cell lung carcinoma, which is standardly treated by radiotherapy, to identify parameters that predict radiation sensitivity. We showed that activation of NFE2L2, a frequent event in lung squamous cancers, confers radiation resistance. An expression-based, in silico screen nominated inhibitors of phosphoinositide 3-kinase (PI3K) as NFE2L2 antagonists. We showed that the selective PI3K inhibitor, NVP-BKM120, both decreased NRF2 protein levels and sensitized NFE2L2 or KEAP1-mutant cells to radiation. We then combined results from this high-throughput assay with single-sample gene set enrichment analysis of gene expression data. The resulting analysis identified pathways implicated in cell survival, genotoxic stress, detoxification, and innate and adaptive immunity as key correlates of radiation sensitivity. The integrative and high-throughput methods shown here for large-scale profiling of radiation survival and genomic features of solid-tumor-derived cell lines should facilitate tumor radiogenomics and the discovery of genotype-selective radiation sensitizers and protective agents. Cancer Res; 73(20); 6289-98. (C) 2013 AACR.
C1 [Abazeed, Mohamed E.] Harvard Univ, Harvard Radiat Oncol Program, Boston, MA 02115 USA.
[Giacomelli, Andrew O.] Harvard Univ, Div Med Sci, Boston, MA 02115 USA.
[Loeffler, Jay S.] Harvard Univ, Sch Med, Dept Radiat Therapy, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Fries, Daniel F.; Wong, Kwok-Kin; Hammerman, Peter S.; Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Wong, Kwok-Kin] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA.
[Meyerson, Matthew] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Adams, Drew J.; Schreiber, Stuart L.] Chem Biol Program, Cambridge, MA USA.
[Schreiber, Stuart L.] Howard Hughes Med Inst, Cambridge, MA USA.
[Adams, Drew J.; Tamayo, Pablo; Mesirov, Jill P.; Schreiber, Stuart L.; Hammerman, Peter S.; Meyerson, Matthew] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Hurov, Kristen E.; Sonkin, Dmitriy] Novartis Inst Biomed Res, Cambridge, MA USA.
[Schreiber, Stuart L.] Dept Chem & Chem Biol, Cambridge, MA USA.
[Du, Charles; Schreiber, Stuart L.] Harvard Univ, Cambridge, MA 02138 USA.
[Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Meyerson, M (reprint author), Dana Farber Canc Inst, Dana Bldg,Room 1540,44 Binney St,1523A, Boston, MA 02215 USA.
EM phammerman@partners.org; matthew_meyerson@dfci.harvard.edu
OI Sonkin, Dmitriy/0000-0002-1649-0652; wong, kwok kin/0000-0001-6323-235X
FU NIH [5T32CA009382-30, RC2 CA138399-01]; Harvard Radiation Oncology
Program; NCI [RO1 CA109038]; Stephen D. and Alice Cutler Investigator
Fund; National Institute of General Medical Sciences [GM38627]; [K08
CA163677]
FX M.E. Abazeed was supported by NIH training grant 5T32CA009382-30 and by
funding from the Harvard Radiation Oncology Program. M. Meyerson was
supported by NCI RO1 CA109038. P.S. Hammerman was supported by the
Stephen D. and Alice Cutler Investigator Fund and by K08 CA163677. The
experiments described in Supplementary Fig. S3 were supported in part by
NIH RC2 CA138399-01 (S.L. Schreiber). National Institute of General
Medical Sciences provided partial support (GM38627; S.L. Schreiber).
NR 50
TC 27
Z9 28
U1 1
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2013
VL 73
IS 20
BP 6289
EP 6298
DI 10.1158/0008-5472.CAN-13-1616
PG 10
WC Oncology
SC Oncology
GA 236KV
UT WOS:000325796100020
PM 23980093
ER
PT J
AU Hyder, JA
Barbara, DW
AF Hyder, Joseph A.
Barbara, David W.
TI Letter by Hyder and Barbara Regarding Article, "Perioperative
Dexmedetomidine Improves Outcomes of Cardiac Surgery"
SO CIRCULATION
LA English
DT Letter
C1 [Hyder, Joseph A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA.
[Barbara, David W.] Mayo Clin, Coll Med, Dept Anesthesiol, Rochester, MN USA.
RP Hyder, JA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA.
NR 4
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD OCT 15
PY 2013
VL 128
IS 16
BP E336
EP E336
DI 10.1161/CIRCULATIONAHA.113.003733
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 235AP
UT WOS:000325686800005
PM 24126328
ER
PT J
AU Potash, J
Anderson, KC
AF Potash, Jesse
Anderson, Kenneth C.
TI Announcing the AACR Cancer Progress Report 2013
SO CLINICAL CANCER RESEARCH
LA English
DT Editorial Material
C1 [Potash, Jesse; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Potash, J (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
EM kenneth_anderson@dfci.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2013
VL 19
IS 20
BP 5545
EP 5545
DI 10.1158/1078-0432.CCR-13-2431
PG 1
WC Oncology
SC Oncology
GA 236LH
UT WOS:000325797600001
PM 24130218
ER
PT J
AU Metzger, O
Winer, EP
Krop, I
AF Metzger-Filho, Otto
Winer, Eric P.
Krop, Ian
TI Pertuzumab: Optimizing HER2 Blockade
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; METASTATIC BREAST-CANCER; TRASTUZUMAB; DOMAIN;
ACTIVATION; ERBB3/HER3; DOCETAXEL; MECHANISM; SURVIVAL; THERAPY
AB Pertuzumab has been approved by the U.S. Food and Drug Administration for use in combination with trastuzumab and docetaxel for the first-line treatment of patients with advanced HER2-positive (HER2(+)) breast cancer. Pertuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2 and inhibits heterodimerization of HER2 with other HER family members, including EGF receptor (EGFR), HER3, and HER4. The HER2-HER3 heterodimer is a robust activator of phosphoinositide 3-kinase (PI3K) pathway signaling and functions as the most transforming and mitogenic of the receptor complexes formed by the HER family of proteins; thus, blockade of HER2-HER3 likely represents the most relevant action of pertuzumab. In the seminal phase III study, patients with HER2(+) metastatic breast cancer were randomized to receive trastuzumab and docetaxel, with or without pertuzumab: Addition of pertuzumab significantly prolonged progression-free survival with an increase of 6.1 months (12.4 vs. 18.5 months, respectively). In a subsequent analysis with 30 months of median follow-up, pertuzumab conferred a 34% reduction in the risk of mortality. Here, we review the mechanism of action of pertuzumab, the rationale for combining it with trastuzumab/pertuzumab, clinical data, and future directions for this work. (C) 2013 AACR.
C1 [Metzger-Filho, Otto; Winer, Eric P.; Krop, Ian] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Metzger, O (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Yawkey 1238, Boston, MA 02115 USA.
EM otto_metzger@dfci.harvard.edu
FU Susan G. Komen for the Cure; ACT NOW Fund
FX This work was supported in part by Susan G. Komen for the Cure (to E. P.
Winer, I. Krop) and the ACT NOW Fund (to E. P. Winer).
NR 21
TC 15
Z9 16
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2013
VL 19
IS 20
BP 5552
EP 5556
DI 10.1158/1078-0432.CCR-13-0518
PG 5
WC Oncology
SC Oncology
GA 236LH
UT WOS:000325797600004
PM 23942091
ER
PT J
AU de Haart, SJ
van de Donk, NWCJ
Minnema, MC
Huang, JH
Aarts-Riemens, T
Bovenschen, N
Yuan, HP
Groen, RWJ
McMillin, DW
Jakubikova, J
Lokhorst, HM
Martens, AC
Mitsiades, CS
Mutis, T
AF de Haart, Sanne J.
van de Donk, Niels W. C. J.
Minnema, Monique C.
Huang, Julie H.
Aarts-Riemens, Tineke
Bovenschen, Niels
Yuan, Huipin
Groen, Richard W. J.
McMillin, Douglas W.
Jakubikova, Jana
Lokhorst, Henk M.
Martens, Anton C.
Mitsiades, Constantine S.
Mutis, Tuna
TI Accessory Cells of the Microenvironment Protect Multiple Myeloma from
T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MINOR HISTOCOMPATIBILITY ANTIGEN; BONE-MARROW MICROENVIRONMENT;
DRUG-RESISTANCE; ADOPTIVE IMMUNOTHERAPY; TUMOR MICROENVIRONMENT;
DOWN-REGULATION; DEATH; DISEASE; CONTRIBUTOR; INTEGRINS
AB Purpose: Cellular immunotherapy frequently fails to induce sustained remissions in patients with multiple myeloma, indicating the ability of multiple myeloma cells to evade cellular immunity. Toward a better understanding and effective therapeutic modulation of multiple myeloma immune evasion mechanisms, we here investigated the role of the tumor microenvironment in rendering multiple myeloma cells resistant to the cytotoxic machinery of T cells.
Experimental Design: Using a compartment-specific, bioluminescence imaging-based assay system, we measured the lysis of luciferase-transduced multiple myeloma cells by CD4(+) or CD8(+) CTLs in the presence versus absence of adherent accessory cells of the bone marrow microenvironment. We simultaneously determined the level of CTL activation by measuring the granzyme B release in culture supernatants.
Results: Bone marrow stromal cells from patients with multiple myeloma and healthy individuals, as well as vascular endothelial cells, significantly inhibited the lysis of multiple myeloma cells in a cell-cell contact-dependent manner and without substantial T-cell suppression, thus showing the induction of a cell adhesion-mediated immune resistance (CAM-IR) against CTL lysis. Further analyses revealed that adhesion to accessory cells downregulated Fas and upregulated the caspase-3 inhibitor survivin in multiple myeloma cells. Reconstitution of Fas expression with bortezomib enhanced the CTL-mediated lysis of multiple myeloma cells. Repressing survivin with the small-molecule YM155 synergized with CTLs and abrogated CAM-IR in vitro and in vivo.
Conclusion: These results reveal the cell adhesion-mediated induction of apoptosis resistance as a novel immune escape mechanism and provide a rationale to improve the efficacy of cellular therapies by pharmacologic modulation of CAM-IR. (C) 2013 AACR.
C1 [de Haart, Sanne J.; Huang, Julie H.; Aarts-Riemens, Tineke; Mutis, Tuna] Univ Med Ctr Utrecht, Dept Clin Chem & Hematol, NL-3584 CX Utrecht, Netherlands.
[van de Donk, Niels W. C. J.; Minnema, Monique C.; Lokhorst, Henk M.] Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands.
[Bovenschen, Niels] Univ Med Ctr Utrecht, Dept Pathol, NL-3584 CX Utrecht, Netherlands.
[Groen, Richard W. J.; Martens, Anton C.] Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands.
[Martens, Anton C.] Univ Med Ctr Utrecht, Dept Immunol, NL-3584 CX Utrecht, Netherlands.
[Yuan, Huipin] Xpand Biotechnol BV, Bilthoven, Netherlands.
[van de Donk, Niels W. C. J.; Groen, Richard W. J.; McMillin, Douglas W.; Jakubikova, Jana; Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
RP Mutis, T (reprint author), Univ Med Ctr Utrecht, Dept Clin Chem & Hematol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
EM tmutis@umcutrecht.nl
OI Groen, Richard/0000-0002-5010-4604
FU Dutch Cancer Society; NIH
FX This work was supported by the Dutch Cancer Society (to N.W.C.J. van de
Donk) and the NIH (to C. S. Mitsiades).
NR 41
TC 16
Z9 16
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2013
VL 19
IS 20
BP 5591
EP 5601
DI 10.1158/1078-0432.CCR-12-3676
PG 11
WC Oncology
SC Oncology
GA 236LH
UT WOS:000325797600009
PM 24004671
ER
PT J
AU Warren, RS
Atreya, CE
Niedzwiecki, D
Weinberg, VK
Donner, DB
Mayer, RJ
Goldberg, RM
Compton, CC
Zuraek, MB
Ye, C
Saltz, LB
Bertagnolli, MM
AF Warren, Robert S.
Atreya, Chloe E.
Niedzwiecki, Donna
Weinberg, Vivian K.
Donner, David B.
Mayer, Robert J.
Goldberg, Richard M.
Compton, Carolyn C.
Zuraek, Marlene B.
Ye, Cynthia
Saltz, Leonard B.
Bertagnolli, Monica M.
TI Association of TP53 Mutational Status and Gender with Survival after
Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ZINC-BINDING DOMAIN; LONG-TERM SURVIVAL; COLORECTAL-CANCER;
MICROSATELLITE INSTABILITY; POOR SURVIVAL; P53 MUTATIONS; BREAST-CANCER;
TUMOR SITE; FLUOROURACIL; LEUCOVORIN
AB Purpose: The TP53 tumor suppressor is frequently mutated in colon cancer, but the influence of such mutations on survival remains controversial. We investigated whether mutations in the DNA-binding domain of TP53 are associated with survival in stage III colon cancer.
Experimental Design: The impact of TP53 genotype was prospectively evaluated in Cancer and Leukemia Group B 89803, a trial that randomized stage III colon cancer patients to receive adjuvant 5-fluorouracil/leucovorin (5FU/LV) or 5FU/LV with irinotecan (IFL).
Results: TP53 mutations were identified in 274 of 607 cases. The presence of any TP53 mutation did not predict disease-free survival (DFS) or overall survival with either adjuvant regimen when men and women were considered together or as separate groups. However, outcome differences among women became apparent when tumor TP53 genotype was stratified as wild-type versus zinc-or non-zinc-binding mutations in the TP53 DNA-binding domain. DFS at 5 years was 0.59, 0.52, and 0.78 for women with TP53 wild-type tumors, and tumors with zinc-or non-zinc-binding mutations, respectively. Survival at 5 years for these same women was 0.72, 0.59, and 0.90, respectively. No differences in survival by TP53 genotype were observed in men.
Conclusions: The presence of any TP53 mutation within the DNA-binding domain did not predict survival in stage III colon cancer. However, TP53 genotype was predictive of survival in women following adjuvant therapy. Future colon cancer therapeutic trials, with inclusion of correlative molecular markers, should be designed to permit evaluation of survival and/or response to treatment in women separately from men. (C) 2013 AACR.
C1 [Warren, Robert S.; Atreya, Chloe E.; Weinberg, Vivian K.; Donner, David B.; Zuraek, Marlene B.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA.
[Niedzwiecki, Donna; Ye, Cynthia] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Alliance Stat & Data Ctr, Durham, NC USA.
[Mayer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bertagnolli, Monica M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Goldberg, Richard M.] Ohio State Univ, Columbus, OH 43210 USA.
[Compton, Carolyn C.] NCI, Bethesda, MD 20892 USA.
[Saltz, Leonard B.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RP Warren, RS (reprint author), Univ Calif San Francisco, Dept Surg, Helen Diller Family Comprehens Canc Ctr, 1600 Divisadero St, San Francisco, CA 94115 USA.
EM robert.warren@ucsfmedctr.org
RI Goldberg , Richard/M-1311-2013;
OI Saltz, Leonard/0000-0001-8353-4670
FU NIH [RO184018]; American Cancer Society [11-183-01-TBG]; American
Society of Clinical Oncology; Edmund Wattis Littlefield Foundation;
Cancer and Leukemia Group B Foundation; Conquer Cancer Foundation of the
American Society of Clinical Oncology
FX This work is supported by NIH, The American Cancer Society, The American
Society of Clinical Oncology, the Edmund Wattis Littlefield Foundation,
and the Cancer and Leukemia Group B Foundation. R.S. Warren was
supported by a grant from the NIH (RO184018) and by the Edmund Wattis
Littlefield Foundation. C.E. Atreya is supported by Postdoctoral
Fellowship 11-183-01-TBG from the American Cancer Society and Young
Investigator Awards from the Conquer Cancer Foundation of the American
Society of Clinical Oncology and the Alliance for Clinical Trials in
Oncology.
NR 39
TC 10
Z9 10
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2013
VL 19
IS 20
BP 5777
EP 5787
DI 10.1158/1078-0432.CCR-13-0351
PG 11
WC Oncology
SC Oncology
GA 236LH
UT WOS:000325797600026
PM 23983256
ER
PT J
AU Akbareian, SE
Nagy, N
Steiger, CE
Mably, JD
Miller, SA
Hotta, R
Molnar, D
Goldstein, AM
AF Akbareian, Sophia E.
Nagy, Nandor
Steiger, Casey E.
Mably, John D.
Miller, Sarah A.
Hotta, Ryo
Molnar, David
Goldstein, Allan M.
TI Enteric neural crest-derived cells promote their migration by modifying
their microenvironment through tenascin-C production
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Enteric nervous system; Extracellular matrix; Neural crest cells;
Tenascin-C; Hirschsprung disease
ID PRESUMPTIVE AGANGLIONIC BOWEL; TYROSINE KINASE RET; NERVOUS-SYSTEM;
CHORIOALLANTOIC MEMBRANE; EXTRACELLULAR-MATRIX; NEURITE OUTGROWTH;
MESSENGER-RNA; CHICK-EMBRYO; GUT; EXPRESSION
AB The enteric nervous system (ENS) is derived from vagal and sacral neural crest cells that migrate, proliferate, and differentiate into enteric neurons and glia within the gut wall. The mechanisms regulating enteric neural crest-derived cell (ENCC) migration are poorly characterized despite the importance of this process in gut formation and function. Characterization of genes involved in ENCC migration is essential to understand ENS development and could provide targets for treatment of human ENS disorders. We identified the extracellular matrix glycoprotein tenascin-C (TNC) as an important regulator of ENCC development. We find TNC dynamically expressed during avian gut development. It is absent from the cecal region just prior to ENCC arrival, but becomes strongly expressed around ENCCs as they enter the ceca and hindgut In aganglionic hindguts, 'INC expression is strong throughout the outer mesenchyme, but is absent from the submucosal region, supporting the presence of both ENCC-dependent and independent expression within the gut wall. Using rat-chick coelomic grafts, neural tube cultures, and gut explants, we show that ENCCs produce TNC and that this ECM protein promotes their migration. Interestingly, only vagal neural crest-derived ENCCs express TNC, whereas sacral neural crest-derived cells do not. These results demonstrate that vagal crest-derived ENCCs actively modify their microenvironment through TNC expression and thereby help to regulate their own migration. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Akbareian, Sophia E.; Steiger, Casey E.; Miller, Sarah A.; Hotta, Ryo; Goldstein, Allan M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Surg, Boston, MA 02114 USA.
[Nagy, Nandor; Molnar, David] Semmelweis Univ, Fac Med, Dept Human Morphol & Dev Biol, H-1094 Budapest, Hungary.
[Mably, John D.] Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Pediat, Boston, MA 02114 USA.
[Mably, John D.] Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Genet, Boston, MA 02114 USA.
RP Goldstein, AM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Surg, Warren 1153, Boston, MA 02114 USA.
EM agoldstein@partners.org
FU NIH-NIDDK [R01 DK080914]; Bolyai Fellowship [Tamop-4.2.2/B-10/1
-2010-2013]; Uehara Memorial Foundation
FX AMG is supported by NIH-NIDDK R01 DK080914. NN is supported by a Bolyai
Fellowship and Tamop-4.2.2/B-10/1 -2010-2013. RH is supported by a grant
from the Uehara Memorial Foundation. Antibodies for TNC, Fibronectin,
Laminin, N-cadherin, and 8F3 were obtained from the Developmental
Studies Hybridoma Bank, developed under the auspices of the NICHD and
maintained by The University of Iowa.
NR 57
TC 15
Z9 15
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0012-1606
EI 1095-564X
J9 DEV BIOL
JI Dev. Biol.
PD OCT 15
PY 2013
VL 382
IS 2
BP 446
EP 456
DI 10.1016/j.ydbio.2013.08.006
PG 11
WC Developmental Biology
SC Developmental Biology
GA 234UW
UT WOS:000325670800007
PM 23958436
ER
PT J
AU Bailey, JNC
Sobrin, L
Pericak-Vance, MA
Haines, JL
Hammond, CJ
Wiggs, JL
AF Bailey, Jessica N. Cooke
Sobrin, Lucia
Pericak-Vance, Margaret A.
Haines, Jonathan L.
Hammond, Christopher J.
Wiggs, Janey L.
TI Advances in the genomics of common eye diseases
SO HUMAN MOLECULAR GENETICS
LA English
DT Review
ID AGE-RELATED MACULOPATHY; OPEN-ANGLE GLAUCOMA; COMPLEMENT FACTOR-H;
PROLIFERATIVE DIABETIC-RETINOPATHY; CENTRAL CORNEAL THICKNESS;
HIGH-GRADE MYOPIA; BEAVER DAM EYE; OXIDASE-LIKE 1; MACULAR DEGENERATION;
WIDE ASSOCIATION
AB Genome-wide association studies (GWAS) and other genomic technologies have accelerated the discovery of genes and genomic regions contributing to common human ocular disorders with complex inheritance. Age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and myopia account for the majority of visual impairment worldwide. Over 19 genes and/or genomic regions have been associated with AMD. Current investigations are assessing the clinical utility of risk score panels and therapies targeting disease-specific pathways. DR is the leading cause of blindness in the United States and globally is a major cause of vision loss. Genomic investigations have identified molecular pathways associated with DR in animal models which could suggest novel therapeutic targets. Three types of glaucoma, primary-open-angle glaucoma (POAG), angle-closure glaucoma and exfoliation syndrome (XFS) glaucoma, are common age-related conditions. Five genomic regions have been associated with POAG, three with angle-closure glaucoma and one with XFS. Myopia causes substantial ocular morbidity throughout the world. Recent large GWAS have identified 20 associated loci for this condition. In this report, we present a comprehensive overview of the genes and genomic regions contributing to disease susceptibility for these common blinding ocular disorders and discuss the next steps toward translation to effective gene-based screening tests and novel therapies targeting the molecular events contributing to disease.
C1 [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
[Sobrin, Lucia; Wiggs, Janey L.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Hussman Inst Human Genom, Miami, FL 33136 USA.
[Hammond, Christopher J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
RP Wiggs, JL (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM janey_wiggs@meei.harvard.edu
OI Hammond, Christopher/0000-0002-3227-2620
FU NIH/NEI [EY022302, EY012118, EY021453, EY022305, EY020928]
FX The authors acknowledge funding support from NIH/NEI grants EY022302
(L.S.), EY012118 (M.A.P.-V.), EY021453 (J.L.H.), EY022305 (J.L.W.),
EY020928 (J.L.W.).
NR 93
TC 23
Z9 23
U1 1
U2 29
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2013
VL 22
SI 1
BP R59
EP R65
DI 10.1093/hmg/ddt396
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 230LH
UT WOS:000325340500010
ER
PT J
AU Pore, D
Parameswaran, N
Matsui, K
Stone, MB
Saotome, I
McClatchey, AI
Veatch, SL
Gupta, N
AF Pore, Debasis
Parameswaran, Neetha
Matsui, Ken
Stone, Matthew B.
Saotome, Ichiko
McClatchey, Andrea I.
Veatch, Sarah L.
Gupta, Neetu
TI Ezrin Tunes the Magnitude of Humoral Immunity
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CELL ANTIGEN RECEPTOR; LIPID RAFTS REVEALS; ACTIVATED B-CELLS; MHC
CLASS-II; ERM PROTEINS; LYMPHOCYTE-ACTIVATION; FATE DECISION;
ORGANIZATION; EXPRESSION; MICE
AB Ezrin is a member of the ezrin-radixin-moesin family of membrane-actin cytoskeleton cross-linkers that participate in a variety of cellular processes. In B cells, phosphorylation of ezrin at different sites regulates multiple processes, such as lipid raft coalescence, BCR diffusion, microclustering, and endosomal JNK activation. In this study, we generated mice with conditional deletion of ezrin in the B cell lineage to investigate the physiological significance of ezrin's function in Ag receptor-mediated B cell activation and humoral immunity. B cell development, as well as the proportion and numbers of major B cell subsets in peripheral lymphoid organs, was unaffected by the loss of ezrin. Using superresolution imaging methods, we show that, in the absence of ezrin, BCRs respond to Ag binding by accumulating into larger and more stable signaling microclusters. Loss of ezrin led to delayed BCR capping and accelerated lipid raft coalescence. Although proximal signaling proteins showed stronger activation in the absence of ezrin, components of the distal BCR signaling pathways displayed distinct effects. Ezrin deficiency resulted in increased B cell proliferation and differentiation into Ab-secreting cells ex vivo and stronger T cell-independent and -dependent responses to Ag in vivo. Overall, our data demonstrate that ezrin regulates amplification of BCR signals and tunes the strength of B cell activation and humoral immunity.
C1 [Pore, Debasis; Parameswaran, Neetha; Matsui, Ken; Gupta, Neetu] Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA.
[Stone, Matthew B.; Veatch, Sarah L.] Univ Michigan, Dept Biophys, Ann Arbor, MI 48109 USA.
[Saotome, Ichiko; McClatchey, Andrea I.] Massachusetts Gen Hosp, Ctr Canc, Dept Pathol, Charlestown, MA 02129 USA.
[Saotome, Ichiko; McClatchey, Andrea I.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Gupta, N (reprint author), Cleveland Clin, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave,NE40, Cleveland, OH 44195 USA.
EM guptan@ccf.org
RI Veatch, Sarah/G-9512-2016
OI Veatch, Sarah/0000-0002-9317-2308
FU National Institute of Allergy and Infectious Diseases [AI081743];
National Institute of Diabetes and Digestive and Kidney Diseases
[DK068242]; Cancer Research Institute; National Institute of General
Medical Sciences [GM087810]
FX This work was supported by Grant AI081743 from the National Institute of
Allergy and Infectious Diseases, Grant DK068242 from the National
Institute of Diabetes and Digestive and Kidney Diseases, an Investigator
Award from the Cancer Research Institute (to N.G.), and Grant GM087810
from the National Institute of General Medical Sciences (to S.L.V.).
NR 54
TC 8
Z9 8
U1 0
U2 8
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2013
VL 191
IS 8
BP 4048
EP 4058
DI 10.4049/jimmunol.1301315
PG 11
WC Immunology
SC Immunology
GA 232IT
UT WOS:000325487700011
PM 24043890
ER
PT J
AU Chen, HW
King, K
Tu, J
Sanchez, M
Luster, AD
Shresta, S
AF Chen, Hui-Wen
King, Kevin
Tu, Jui
Sanchez, Marisa
Luster, Andrew D.
Shresta, Sujan
TI The Roles of IRF-3 and IRF-7 in Innate Antiviral Immunity against Dengue
Virus
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INTERFERON RESPONSE; INFECTION; MICE; REPLICATION; TRAFFICKING;
MACROPHAGES; RESISTANCE; SURVIVAL; CXCR3
AB We investigated the roles of IFN regulatory factor (IRF)-3 and IRF-7 in innate antiviral immunity against dengue virus (DENV). Double-deficient Irf-3(-/-)7(-/-) mice infected with the DENV2 strain S221 possessed 1,000-150,000 fold higher levels of viral RNA than wild-type and single-deficient mice 24 h postinfection (hpi); however, they remained resistant to lethal infection. IFN-alpha/beta was induced similarly in wild-type and Irf-3(-/-) mice post-DENV infection, whereas in the Irf-7(-/-) and Irf-3(-/-)7(-/-) mice, significantly low levels of IFN-alpha/beta expression was observed within 24 hpi. IFN-stimulated gene induction was also delayed in Irf-3(-/-)7(-/-) mice relative to wild-type and single-deficient mice. In particular, Cxcl10 and Ifn alpha 2 were rapidly induced independently of both IRF-3 and IRF-7 in the Irf-3(-/-)7(-/-) mice with DENV infection. Higher levels of serum IFN-gamma, IL-6, CXCL10, IL-8, IL-12 p70, and TNF were also observed in Irf-3(-/-)7(-/-) mice 24 hpi, at which time point viral titers peaked and started to be cleared. Ab-mediated blockade experiments revealed that IFN-gamma, CXCL10, and CXCR3 function to restrict DENV replication in Irf-3(-/-)7(-/-) mice. Additionally, the IFN-stimulated genes Cxcl10, Ifit1, Ifit3, and Mx2 can be induced via an IRF-3- and IRF-7-independent pathway that does not involve IFN-gamma signaling for protection against DENV. Collectively, these results demonstrate that IRF-3 and IRF-7 are redundant, albeit IRF-7 plays a more important role than IRF-3 in inducing the initial IFN-alpha/beta response; only the combined actions of IRF-3 and IRF-7 are necessary for efficient control of early DENV infection; and the late, IRF-3- and IRF-7-independent pathway contributes to anti-DENV immunity.
C1 [Chen, Hui-Wen; King, Kevin; Tu, Jui; Sanchez, Marisa; Shresta, Sujan] Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
[Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol, Boston, MA 02115 USA.
RP Shresta, S (reprint author), Jolla Inst Allergy & Immunol, Div Vaccine Discovery, 9420 Athena Circle, La Jolla, CA 92037 USA.
EM sujan@liai.org
OI CHEN, HUI-WEN/0000-0002-0595-3420
FU National Institutes of Health from the Southeast Regional Center of
Excellence for Emerging Infections and Biodefense [U01 AI082185, U54
AI057157]; National Institute of Allergy and Infectious Diseases
[HHSN272200900042C]
FX This work was supported by National Institutes of Health Grants U01
AI082185 and U54 AI057157 from the Southeast Regional Center of
Excellence for Emerging Infections and Biodefense and National Institute
of Allergy and Infectious Diseases Contract HHSN272200900042C.
NR 25
TC 27
Z9 30
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2013
VL 191
IS 8
BP 4194
EP 4201
DI 10.4049/jimmunol.1300799
PG 8
WC Immunology
SC Immunology
GA 232IT
UT WOS:000325487700026
PM 24043884
ER
PT J
AU Yeung, MY
McGrath, MM
Nakayama, M
Shimizu, T
Boenisch, O
Magee, CN
Abdoli, R
Akiba, H
Ueno, T
Turka, LA
Najafian, N
AF Yeung, Melissa Y.
McGrath, Martina M.
Nakayama, Masafumi
Shimizu, Tetsunosuke
Boenisch, Olaf
Magee, Ciara N.
Abdoli, Rozita
Akiba, Hisaya
Ueno, Takuya
Turka, Laurence A.
Najafian, Nader
TI Interruption of Dendritic Cell-Mediated TIM-4 Signaling Induces
Regulatory T Cells and Promotes Skin Allograft Survival
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID IN-VIVO; APOPTOTIC CELLS; TGF-BETA; PHOSPHATIDYLSERINE RECEPTOR;
TOLERANCE; ANTIGEN; DIFFERENTIATION; IMMUNOGLOBULIN; AUTOIMMUNITY;
HOMEOSTASIS
AB Dendritic cells (DCs) are the central architects of the immune response, inducing inflammatory or tolerogenic immunity, dependent on their activation status. As such, DCs are highly attractive therapeutic targets and may hold the potential to control detrimental immune responses. TIM-4, expressed on APCs, has complex functions in vivo, acting both as a costimulatory molecule and a phosphatidylserine receptor. The effect of TIM-4 costimulation on T cell activation remains unclear. In this study, we demonstrate that Ab blockade of DC-expressed TIM-4 leads to increased induction of induced regulatory T cells (iTregs) from naive CD4(+) T cells, both in vitro and in vivo. iTreg induction occurs through suppression of IL-4/STAT6/Gata3-induced Th2 differentiation. In addition, blockade of TIM-4 on previously activated DCs still leads to increased iTreg induction. iTregs induced under TIM-4 blockade have equivalent potency to control and, upon adoptive transfer, significantly prolong skin allograft survival in vivo. In RAG(-/-) recipients of skin allografts adoptively transferred with CD4(+) T cells, we show that TIM-4 blockade in vivo is associated with a 3-fold prolongation in allograft survival. Furthermore, in this mouse model of skin transplantation, increased induction of allospecific iTregs and a reduction in T effector responses were observed, with decreased Th1 and Th2 responses. This enhanced allograft survival and protolerogenic skewing of the alloresponse is critically dependent on conversion of naive CD4(+) to Tregs in vivo. Collectively, these studies identify blockade of DC-expressed TIM-4 as a novel strategy that holds the capacity to induce regulatory immunity in vivo.
C1 [Yeung, Melissa Y.; McGrath, Martina M.; Shimizu, Tetsunosuke; Boenisch, Olaf; Magee, Ciara N.; Abdoli, Rozita; Ueno, Takuya; Najafian, Nader] Harvard Univ, Sch Med, Transplantat Res Ctr, Brigham & Womens Hosp,Renal Div, Boston, MA 02115 USA.
[Nakayama, Masafumi] Tohoku Univ, Dept Immunobiol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan.
[Akiba, Hisaya] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1338421, Japan.
[Turka, Laurence A.] Harvard Univ, Sch Med, Transplantat Biol Res Ctr, Dept Surg,Massachusetts Gen Hosp, Boston, MA 02129 USA.
[Najafian, Nader] Cleveland Clin Florida, Dept Nephrol, Weston, FL 33331 USA.
RP Najafian, N (reprint author), Harvard Univ, Sch Med, Transplantat Res Ctr, Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA.
EM nnajafian@rics.bwh.harvard.edu
FU National Kidney Foundation; American Heart Association; National
Institutes of Health [R01AI037691-17A1, R56AI089777-01A1, R56
AI101150-0141]
FX This work was supported by a postdoctoral fellowship from the National
Kidney Foundation (to M.Y.Y.), a fellow-to-faculty transition grant from
the American Heart Association (to M.Y.Y.), and National Institutes of
Health Grants R01AI037691-17A1 (to L.A.T.) and R56AI089777-01A1 and R56
AI101150-0141 (to N.N.).
NR 44
TC 12
Z9 14
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2013
VL 191
IS 8
BP 4447
EP 4455
DI 10.4049/jimmunol.1300992
PG 9
WC Immunology
SC Immunology
GA 232IT
UT WOS:000325487700052
PM 24038092
ER
PT J
AU Yancy, CW
Jessup, M
Bozkurt, B
Butler, J
Casey, DE
Drazner, MH
Fonarow, GC
Geraci, SA
Horwich, T
Januzzi, JL
Johnson, MR
Kasper, EK
Levy, WC
Masoudi, FA
McBride, PE
McMurray, JJV
Mitchell, JE
Peterson, PN
Riegel, B
Sam, F
Stevenson, LW
Tang, WHW
Tsai, EJ
Wilkoff, BL
Anderson, JL
Jacobs, AK
Halperin, JL
Albert, NM
Bozkurt, B
Brindis, RG
Creager, MA
Curtis, LH
DeMets, D
Guyton, RA
Hochman, JS
Kovacs, RJ
Kushner, FG
Ohman, EM
Pressler, SJ
Sellke, FW
Shen, WK
Stevenson, WG
Yancy, CW
AF Yancy, Clyde W.
Jessup, Mariell
Bozkurt, Biykem
Butler, Javed
Casey, Donald E., Jr.
Drazner, Mark H.
Fonarow, Gregg C.
Geraci, Stephen A.
Horwich, Tamara
Januzzi, James L.
Johnson, Maryl R.
Kasper, Edward K.
Levy, Wayne C.
Masoudi, Frederick A.
McBride, Patrick E.
McMurray, John J. V.
Mitchell, Judith E.
Peterson, Pamela N.
Riegel, Barbara
Sam, Flora
Stevenson, Lynne W.
Tang, W. H. Wilson
Tsai, Emily J.
Wilkoff, Bruce L.
Anderson, Jeffrey L.
Jacobs, Alice K.
Halperin, Jonathan L.
Albert, Nancy M.
Bozkurt, Biykem
Brindis, Ralph G.
Creager, Mark A.
Curtis, Lesley H.
DeMets, David
Guyton, Robert A.
Hochman, Judith S.
Kovacs, Richard J.
Kushner, Frederick G.
Ohman, E. Magnus
Pressler, Susan J.
Sellke, Frank W.
Shen, Win-Kuang
Stevenson, William G.
Yancy, Clyde W.
TI 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive
Summary
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE ACCF/AHA Practice Guidelines; cardio-renal physiology/pathophysiology;
congestive heart failure; CV surgery: transplantation, ventricular
assistance, cardiomyopathy; epidemiology; health policy and outcome
research; heart failure; other heart failure
ID LEFT-VENTRICULAR DYSFUNCTION; BRAIN NATRIURETIC PEPTIDE; ASSOCIATION
TASK-FORCE; RANDOMIZED CONTROLLED-TRIAL; CARDIAC-RESYNCHRONIZATION
THERAPY; CONVERTING-ENZYME-INHIBITORS; MECHANICAL CIRCULATORY SUPPORT;
ACUTE MYOCARDIAL-INFARCTION; POSITIVE AIRWAY PRESSURE;
PLACEBO-CONTROLLED TRIAL
C1 [Yancy, Clyde W.] Northwestern Univ, Div Cardiol, Evanston, IL 60208 USA.
[Jessup, Mariell] Univ Penn, Philadelphia, PA 19104 USA.
[Butler, Javed] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
[Casey, Donald E., Jr.] Clin Integrated Phys Network, NYU Langone Med Ctr, New York, NY USA.
[Drazner, Mark H.] Univ Texas, Southwestern Med Ctr, Dallas, TX USA.
[Fonarow, Gregg C.; Horwich, Tamara] Univ Calif Los Angeles, Cardiomyopathy Ctr, Los Angeles, CA USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
[Geraci, Stephen A.] E Tennessee State Univ, Quillen Coll Med, Johnson City, TN 37614 USA.
[Januzzi, James L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Januzzi, James L.] Massachusetts Gen Hosp, Cardiac Intens Care Unit, Boston, MA 02114 USA.
[Johnson, Maryl R.] Univ Wisconsin, Madison, WI 53706 USA.
[Kasper, Edward K.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Levy, Wayne C.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Masoudi, Frederick A.] Univ Colorado, Div Cardiol, Denver, CO 80202 USA.
[McBride, Patrick E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[McMurray, John J. V.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8QQ, Lanark, Scotland.
[Mitchell, Judith E.] Suny Downstate Med Ctr, Heart Failure Ctr, Brooklyn, NY USA.
[Peterson, Pamela N.] Univ Colorado, Denver Hlth Med Ctr, Div Cardiol, Boulder, CO 80309 USA.
[Riegel, Barbara] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Sam, Flora] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Div Cardiol,Cardiomyopathy Program, Boston, MA 02215 USA.
[Stevenson, Lynne W.] Brigham & Womens Hosp, Cardiovasc Div, Cardiomyopathy & Heart Failure Program, Boston, MA 02115 USA.
[Tang, W. H. Wilson] Cleveland Clin Fdn, Cleveland, OH USA.
[Tsai, Emily J.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
[Wilkoff, Bruce L.] Cleveland Clin, Cleveland, OH USA.
RP Yancy, CW (reprint author), Northwestern Univ, Div Cardiol, Evanston, IL 60208 USA.
NR 380
TC 82
Z9 85
U1 1
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 15
PY 2013
VL 62
IS 16
BP 1495
EP 1539
DI 10.1016/j.jacc.2013.05.020
PG 45
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 231NZ
UT WOS:000325425100022
ER
PT J
AU Yarchoan, M
Louneva, N
Xie, SX
Swenson, FJ
Hu, W
Soares, H
Trojanowski, JQ
Lee, VMY
Kling, MA
Shaw, LM
Chen-Plotkin, A
Wolk, DA
Arnold, SE
AF Yarchoan, Mark
Louneva, Natalia
Xie, Sharon X.
Swenson, Frank J.
Hu, William
Soares, Holly
Trojanowski, John Q.
Lee, Virginia M. -Y.
Kling, Mitchel A.
Shaw, Leslie M.
Chen-Plotkin, Alice
Wolk, David A.
Arnold, Steven E.
TI Association of plasma C-reactive protein levels with the diagnosis of
Alzheimer's disease
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Alzheimer disease; Mild cognitive impairment; C-reactive protein;
Inflammation; Biological markers; Apolipoprotein E
ID COGNITIVE FUNCTION; INFLAMMATION; RISK; DEMENTIA; MARKER; HEALTH; CRP
AB C-reactive protein (CRP) participates in the systemic response to inflammation. Previous studies report inconsistent findings regarding the relationship between plasma CRP and Alzheimer's disease (AD). We measured plasma CRP in 203 subjects with AD, 58 subjects with mild cognitive impairment (MCI) and 117 normal aging subjects and administered annual Mini-Mental State Examinations (MMSE) during a 3-year follow-up period to investigate CRP's relationship with diagnosis and progression of cognitive decline. Adjusted for age, sex, and education, subjects with AD had significantly lower levels of plasma CRP than subjects with MCI and normal aging. However, there was no significant association between plasma CRP at baseline and subsequent cognitive decline as assessed by longitudinal changes in MMSE score. Our results support previous reports of reduced levels of plasma CRP in AD and indicate its potential utility as a biomarker for the diagnosis of AD. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Yarchoan, Mark] Univ Penn, Dept Internal Med, Philadelphia, PA 19104 USA.
[Louneva, Natalia; Arnold, Steven E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Swenson, Frank J.] Pfizer Diagnost, PharmaTX Precis Med, Groton, CT USA.
[Hu, William] Emory Univ, Emory Alzheimers Dis Res Ctr, Atlanta, GA 30322 USA.
[Soares, Holly] Pfizer Global Res & Dev, Groton, CT USA.
[Trojanowski, John Q.; Lee, Virginia M. -Y.] Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.
[Kling, Mitchel A.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA.
[Shaw, Leslie M.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Chen-Plotkin, Alice; Wolk, David A.; Arnold, Steven E.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
RP Arnold, SE (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM steven.arnold@uphs.upenn.edu
OI Kling, Mitchel/0000-0002-2232-1409
FU National Institutes of Health [AG10124]; Penn-Pfizer Research Alliance
at the University of Pennsylvania; Marian S. Ware Alzheimer's Program;
Allen H. and Selma W. Berkman Charitable Trust
FX This study has been supported by the National Institutes of Health
(grant no. AG10124), the Penn-Pfizer Research Alliance at the University
of Pennsylvania, the Marian S. Ware Alzheimer's Program, and the Allen
H. and Selma W. Berkman Charitable Trust. We thank Xiaoyan Han, M.S.,
for her help with the statistical programming of the mixed-effects model
analysis.
NR 16
TC 12
Z9 12
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD OCT 15
PY 2013
VL 333
IS 1-2
BP 9
EP 12
DI 10.1016/j.jns.2013.05.028
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 235SN
UT WOS:000325741100003
PM 23978419
ER
PT J
AU Johnson, N
Johnson, SF
Yao, W
Li, YC
Choi, YE
Bernhardy, AJ
Wang, YF
Capelletti, M
Sarosiek, KA
Moreau, LA
Chowdhury, D
Wickramanayake, A
Harrell, MI
Liu, JF
D'Andrea, AD
Miron, A
Swisher, EM
Shapiro, GI
AF Johnson, Neil
Johnson, Shawn F.
Yao, Wei
Li, Yu-Chen
Choi, Young-Eun
Bernhardy, Andrea J.
Wang, Yifan
Capelletti, Marzia
Sarosiek, Kristopher A.
Moreau, Lisa A.
Chowdhury, Dipanjan
Wickramanayake, Anneka
Harrell, Maria I.
Liu, Joyce F.
D'Andrea, Alan D.
Miron, Alexander
Swisher, Elizabeth M.
Shapiro, Geoffrey I.
TI Stabilization of mutant BRCA1 protein confers PARP inhibitor and
platinum resistance
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE homologous recombination; cancer therapy
ID POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; OVARIAN
CARCINOMAS; TUMOR SUPPRESSION; BREAST CANCERS; 53BP1; CELLS; MUTATIONS;
REPAIR; CHEMOTHERAPY
AB Breast Cancer Type 1 Susceptibility Protein (BRCA1)-deficient cells have compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. Despite initial responses, the development of resistance limits clinical efficacy. Mutations in the BRCA C-terminal (BRCT) domain of BRCA1 frequently create protein products unable to fold that are subject to protease-mediated degradation. Here, we show HSP90-mediated stabilization of a BRCT domain mutant BRCA1 protein under PARP inhibitor selection pressure. The stabilized mutant BRCA1 protein interacted with PALB2-BRCA2-RAD51, was essential for RAD51 focus formation, and conferred PARP inhibitor as well as cisplatin resistance. Treatment of resistant cells with the HSP90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin reduced mutant BRCA1 protein levels and restored their sensitivity to PARP inhibition. Resistant cells also acquired a TP53BP1 mutation that facilitated DNA end resection in the absence of a BRCA1 protein capable of binding CtIP. Finally, concomitant increased mutant BRCA1 and decreased 53BP1 protein expression occur in clinical samples of BRCA1-mutated recurrent ovarian carcinomas that have developed resistance to platinum. These results provide evidence for a two-event mechanism by which BRCA1-mutant tumors acquire anticancer therapy resistance.
C1 [Johnson, Neil; Johnson, Shawn F.; Yao, Wei; Li, Yu-Chen; Capelletti, Marzia; Sarosiek, Kristopher A.; Liu, Joyce F.; Shapiro, Geoffrey I.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Choi, Young-Eun; Moreau, Lisa A.; Chowdhury, Dipanjan; D'Andrea, Alan D.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Miron, Alexander] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Miron, Alexander] Harvard Univ, Sch Med, Boston, MA USA.
[Johnson, Neil; Liu, Joyce F.; Shapiro, Geoffrey I.] Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
[Johnson, Neil; Moreau, Lisa A.; Liu, Joyce F.; D'Andrea, Alan D.; Shapiro, Geoffrey I.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Bernhardy, Andrea J.; Wang, Yifan] Fox Chase Canc Ctr, Dev Therapeut Program, Philadelphia, PA 19111 USA.
[Moreau, Lisa A.; D'Andrea, Alan D.] Childrens Hosp, Dept Pediat, Boston, MA 02115 USA.
[Wickramanayake, Anneka; Harrell, Maria I.; Swisher, Elizabeth M.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
[Wickramanayake, Anneka; Harrell, Maria I.; Swisher, Elizabeth M.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
RP Johnson, N (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM neil.johnson@fccc.edu; geoffrey_shapiro@dfci.harvard.edu
FU Clovis; AstraZeneca; US National Institutes of Health [R01 CA090687, P50
CA089393, P50 CA090578, P50 CA83636, P30 CA006927, R01 CA142698]; Susan
G. Komen Investigator Initiated Research Grant [12223953]; Susan G.
Komen Career Catalyst Award [CCR12226280]; Wendy Feuer Ovarian Cancer
Research Fund; American Cancer Society [RSG-12-079-01]
FX Rucaparib and olaparib were supplied by Clovis and AstraZeneca,
respectively. This work was supported by US National Institutes of
Health Grants R01 CA090687 (to G. I. S.), P50 CA089393
[Dana-Farber/Harvard Cancer Center (DF/HCC) Specialized Program of
Research Excellence (SPORE) in Breast Cancer (to G. I. S.)], P50
CA090578 [DF/HCC SPORE in Lung Cancer (to G. I. S.)], P50 CA83636
[Pacific Ovarian Cancer Research Consortium SPORE in Ovarian Cancer (to
E. M. S.)], P30 CA006927 [Fox Chase Cancer Center Developmental New
Investigator Funds (to N.J.)], and R01 CA142698 (to D. C.); Susan G.
Komen Investigator Initiated Research Grant 12223953 (to G. I. S.);
Susan G. Komen Career Catalyst Award CCR12226280 (to N.J.); the Wendy
Feuer Ovarian Cancer Research Fund (to E. M. S.); and American Cancer
Society Research Scholar Grant RSG-12-079-01 (to D. C.).
NR 24
TC 36
Z9 36
U1 3
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 15
PY 2013
VL 110
IS 42
BP 17041
EP 17046
DI 10.1073/pnas.1305170110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 234HT
UT WOS:000325634200073
PM 24085845
ER
PT J
AU Chen, CH
Fiecas, M
Gutierrez, ED
Panizzon, MS
Eyler, LT
Vuoksimaa, E
Thompson, WK
Fennema-Notestine, C
Hagler, DJ
Jernigan, TL
Neale, MC
Franz, CE
Lyons, MJ
Fischl, B
Tsuang, MT
Dale, AM
Kremen, WS
AF Chen, Chi-Hua
Fiecas, Mark
Gutierrez, E. D.
Panizzon, Matthew S.
Eyler, Lisa T.
Vuoksimaa, Eero
Thompson, Wesley K.
Fennema-Notestine, Christine
Hagler, Donald J., Jr.
Jernigan, Terry L.
Neale, Michael C.
Franz, Carol E.
Lyons, Michael J.
Fischl, Bruce
Tsuang, Ming T.
Dale, Anders M.
Kremen, William S.
TI Genetic topography of brain morphology
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE genetics; MRI; regionalization
ID SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; CORTICAL SURFACE;
COORDINATE SYSTEM; AREA IDENTITY; NEOCORTEX; REGIONALIZATION;
SPECIFICATION; THICKNESS; PAX6
AB Animal data show that cortical development is initially patterned by genetic gradients largely along three orthogonal axes. We previously reported differences in genetic influences on cortical surface area along an anterior-posterior axis using neuroimaging data of adult human twins. Here, we demonstrate differences in genetic influences on cortical thickness along a dorsal-ventral axis in the same cohort. The phenomenon of orthogonal gradations in cortical organization evident in different structural and functional properties may originate from genetic gradients. Another emerging theme of cortical patterning is that patterns of genetic influences recapitulate the spatial topography of the cortex within hemispheres. The genetic patterning of both cortical thickness and surface area corresponds to cortical functional specializations. Intriguingly, in contrast to broad similarities in genetic patterning, two sets of analyses distinguish cortical thickness and surface area genetically. First, genetic contributions to cortical thickness and surface area are largely distinct; there is very little genetic correlation (i.e., shared genetic influences) between them. Second, organizing principles among genetically defined regions differ between thickness and surface area. Examining the structure of the genetic similarity matrix among clusters revealed that, whereas surface area clusters showed great genetic proximity with clusters from the same lobe, thickness clusters appear to have close genetic relatedness with clusters that have similar maturational timing. The discrepancies are in line with evidence that the two traits follow different mechanisms in neurodevelopment. Our findings highlight the complexity of genetic influences on cortical morphology and provide a glimpse into emerging principles of genetic organization of the cortex.
C1 [Chen, Chi-Hua; Fiecas, Mark; Panizzon, Matthew S.; Eyler, Lisa T.; Vuoksimaa, Eero; Thompson, Wesley K.; Fennema-Notestine, Christine; Jernigan, Terry L.; Franz, Carol E.; Tsuang, Ming T.; Kremen, William S.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Gutierrez, E. D.; Jernigan, Terry L.] Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA.
[Fennema-Notestine, Christine; Hagler, Donald J., Jr.; Dale, Anders M.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA.
[Dale, Anders M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Chen, Chi-Hua; Fiecas, Mark; Panizzon, Matthew S.; Vuoksimaa, Eero; Franz, Carol E.; Tsuang, Ming T.; Kremen, William S.] Univ Calif San Diego, Ctr Behav Genom, La Jolla, CA 92093 USA.
[Tsuang, Ming T.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
[Kremen, William S.] Vet Affairs San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, La Jolla, CA 92161 USA.
[Eyler, Lisa T.] Vet Affairs San Diego Healthcare Syst, Vet Integrated Serv Network 22, Mental Illness Res Educ & Clin Ctr, La Jolla, CA 92161 USA.
[Lyons, Michael J.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23220 USA.
[Neale, Michael C.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA 23220 USA.
[Fischl, Bruce] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Fischl, Bruce] Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Lyons, Michael J.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Vuoksimaa, Eero] Univ Helsinki, Dept Publ Hlth, FI-00014 Helsinki, Finland.
[Fischl, Bruce] MIT Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
RP Chen, CH (reprint author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
EM chc101@ucsd.edu
OI Lyons, Michael/0000-0001-6516-9219; Fennema-Notestine,
Christine/0000-0002-6527-6361
FU National Institute on Aging [AG022381, AG018386, AG018384, AG022982,
AG031224]; National Institute on Drug Abuse [DA029475]; National
Institute of Neurological Disorders and Stroke [NS056883]; Academy of
Finland [257075]; US Department of Veterans Affairs
FX This work was funded by National Institute on Aging Grants AG022381,
AG018386, AG018384, AG022982, and AG031224; National Institute on Drug
Abuse Grant DA029475; National Institute of Neurological Disorders and
Stroke Grant NS056883; and Academy of Finland Grant 257075 (to E. V.).
The US Department of Veterans Affairs has provided financial support for
the development and maintenance of the Vietnam Era Twin (VET) Registry.
NR 51
TC 50
Z9 50
U1 2
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 15
PY 2013
VL 110
IS 42
BP 17089
EP 17094
DI 10.1073/pnas.1308091110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 234HT
UT WOS:000325634200081
PM 24082094
ER
PT J
AU Satpute, AB
Wager, TD
Cohen-Adad, J
Bianciardi, M
Choi, JK
Buhle, JT
Wald, LL
Barrett, LF
AF Satpute, Ajay B.
Wager, Tor D.
Cohen-Adad, Julien
Bianciardi, Marta
Choi, Ji-Kyung
Buhle, Jason T.
Wald, Lawrence L.
Barrett, Lisa Feldman
TI Identification of discrete functional subregions of the human
periaqueductal gray
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE brain stem; neuroimaging; emotion; high-resolution
ID HUMAN BRAIN; PEPTIDERGIC ORGANIZATION; EMOTION; PAIN; STATE; FMRI;
METAANALYSIS; CIRCUITS; TESLA; FIELD
AB The midbrain periaqueductal gray (PAG) region is organized into distinct subregions that coordinate survival-related responses during threat and stress [Bandler R, Keay KA, Floyd N, Price J (2000) Brain Res 53 (1):95-104]. To examine PAG function in humans, researchers have relied primarily on functional MRI (fMRI), but technological and methodological limitations have prevented researchers from localizing responses to different PAG subregions. We used high-field strength (7-T) fMRI techniques to image the PAG at high resolution (0.75 mm isotropic), which was critical for dissociating the PAG from the greater signal variability in the aqueduct. Activation while participants were exposed to emotionally aversive images segregated into subregions of the PAG along both dorsal/ventral and rostral/caudal axes. In the rostral PAG, activity was localized to lateral and dorsomedial subregions. In caudal PAG, activity was localized to the ventrolateral region. This shifting pattern of activity from dorsal to ventral PAG along the rostrocaudal axis mirrors structural and functional neurobiological observations in nonhuman animals. Activity in lateral and ventrolateral subregions also grouped with distinct emotional experiences (e. g., anger and sadness) in a factor analysis, suggesting that each subregion participates in distinct functional circuitry. This study establishes the use of high-field strength fMRI as a promising technique for revealing the functional architecture of the PAG. The techniques developed here also may be extended to investigate the functional roles of other brainstem nuclei.
C1 [Satpute, Ajay B.; Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
[Wager, Tor D.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA.
[Cohen-Adad, Julien] Ecole Polytech, Dept Elect Engn, Montreal, PQ H3T 1J4, Canada.
[Bianciardi, Marta; Choi, Ji-Kyung; Wald, Lawrence L.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Barrett, Lisa Feldman] Massachusetts Gen Hosp, Dept Psychiat, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Buhle, Jason T.] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
RP Satpute, AB (reprint author), Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
EM a.satpute@neu.edu
RI Wald, Lawrence/D-4151-2009;
OI Satpute, Ajay/0000-0003-0227-0816
FU National Institute of Biomedical Imaging and Bioengineering, National
Institutes of Health (NIH); NIH Shared Instrumentation Grant Program
[S10RR023043, S10RR019307, S10RR023401]; NIH [DP1OD003312]; Army
Research Institute [W5J9CQ-11-C-0046]; National Institute of Mental
Health [2R01MH076136, R21MH082308]
FX We thank Jochen Weber for assistance with figures. This research was
carried out in part at the Athinoula A. Martinos Center for Biomedical
Imaging at the Massachusetts General Hospital using resources provided
by the Center for Functional Neuroimaging Technologies, P41EB015896, a
P41 Regional Resource supported by the National Institute of Biomedical
Imaging and Bioengineering, National Institutes of Health (NIH). This
work involved the use of instrumentation supported by the NIH Shared
Instrumentation Grant Program Grants S10RR023043, S10RR019307, and
S10RR023401. This work also was funded by NIH Director's Pioneer Award
DP1OD003312 (to L. F. B.), Army Research Institute Contract
W5J9CQ-11-C-0046 (to L. F. B.), and by National Institute of Mental
Health Grants 2R01MH076136 and R21MH082308 (both to T. D. W.). The
views, opinion, and/or findings contained in this article are solely
those of the authors and should not be construed as an official
Department of the Army or Department of Defense position, policy, or
decision.
NR 44
TC 30
Z9 30
U1 2
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 15
PY 2013
VL 110
IS 42
BP 17101
EP 17106
DI 10.1073/pnas.1306095110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 234HT
UT WOS:000325634200083
PM 24082116
ER
PT J
AU Brecher, SM
Novak-Weekley, SM
Nagy, E
AF Brecher, Stephen M.
Novak-Weekley, Susan M.
Nagy, Elisabeth
TI Laboratory Diagnosis of Clostridium difficile Infections: There Is Light
at the End of the Colon
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Clostridium difficile; laboratory design of C. difficile; Brecher
guidelines
ID REAL-TIME PCR; ILLUMIGENE C.-DIFFICILE; ENZYME-IMMUNOASSAY;
GLUTAMATE-DEHYDROGENASE; CLINICAL MICROBIOLOGY; CYTOTOXICITY ASSAY;
EUROPEAN-SOCIETY; 2-STEP ALGORITHM; TOXIN; TESTS
AB Single molecular or multistep assays (glutamate dehydrogenase, toxin A/B, +/- molecular) are recommended for the diagnosis of CDI in patients with clinically significant diarrhea. Rapid and accurate tests can improve resource allocations and improve patient care. Enzyme immunoassay (EIA) for toxins A/B is too insensitive for use as a stand-alone assay. This guideline will examine the use of molecular tests and multitest algorithms for the diagnosis of Clostridium difficile infection (CDI). These new tests, alone or in a multistep algorithm consisting of >1 assay, are more expensive than the older EIA assays; however, rapid and accurate testing can save money overall by initiating appropriate treatment and infection control protocols sooner and by possibly reducing length of hospital stay. We recommend testing only unformed stool in patients with clinically significant diarrhea by a molecular method or by a 2- to 3-step algorithm.
C1 [Brecher, Stephen M.] VA Boston Healthcare Syst, Pathol & Lab Med, West Roxbury, MA 02132 USA.
[Brecher, Stephen M.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA.
[Nagy, Elisabeth] Univ Szeged, Inst Clin Microbiol, Szeged, Hungary.
RP Brecher, SM (reprint author), VA Boston Healthcare Syst, Pathol & Lab Med, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM stephen.brecher@va.gov
NR 55
TC 34
Z9 35
U1 0
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2013
VL 57
IS 8
BP 1175
EP 1181
DI 10.1093/cid/cit424
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 228EJ
UT WOS:000325168100021
PM 23788237
ER
PT J
AU Pallin, DJ
Camargo, CA
AF Pallin, Daniel J.
Camargo, Carlos A., Jr.
TI Use of Cephalexin Plus Trimethoprim/Sulfamethoxazole vs Cephalexin Alone
for Treatment of Uncomplicated Cellulitis Reply
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Pallin, Daniel J.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
[Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
RP Pallin, DJ (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St,Neville House 304-D, Boston, MA 02115 USA.
EM dpallin@partners.org
RI Pallin, Daniel/H-6382-2013
OI Pallin, Daniel/0000-0002-8517-9702
NR 3
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2013
VL 57
IS 8
BP 1217
EP 1218
DI 10.1093/cid/cit450
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 228EJ
UT WOS:000325168100032
PM 23821732
ER
PT J
AU Buikema, JW
Mady, AS
Mittal, NV
Atmanli, A
Caron, L
Doevendans, PA
Sluijter, JPG
Domian, IJ
AF Buikema, Jan Willem
Mady, Ahmed S.
Mittal, Nikhil V.
Atmanli, Ayhan
Caron, Leslie
Doevendans, Pieter A.
Sluijter, Joost P. G.
Domian, Ibrahim J.
TI Wnt/beta-catenin signaling directs the regional expansion of first and
second heart field-derived ventricular cardiomyocytes
SO DEVELOPMENT
LA English
DT Article
DE Cardiac development; Cardiomyocyte differentiation; Cardiomyocyte
proliferation; First heart field; Gsk3 inhibitor; Wnt/beta-catenin;
Mouse
ID EMBRYONIC STEM-CELLS; SMALL-MOLECULE INHIBITORS; CARDIAC PROGENITOR
CELLS; BETA-CATENIN; CARDIOVASCULAR PROGENITORS; MAMMALIAN HEART;
SELF-RENEWAL; PATHWAY; DIFFERENTIATION; MOUSE
AB In mammals, cardiac development proceeds from the formation of the linear heart tube, through complex looping and septation, all the while increasing in mass to provide the oxygen delivery demands of embryonic growth. The developing heart must orchestrate regional differences in cardiomyocyte proliferation to control cardiac morphogenesis. During ventricular wall formation, the compact myocardium proliferates more vigorously than the trabecular myocardium, but the mechanisms controlling such regional differences among cardiomyocyte populations are not understood. Control of definitive cardiomyocyte proliferation is of great importance for application to regenerative cell-based therapies. We have used murine and human pluripotent stem cell systems to demonstrate that, during in vitro cellular differentiation, early ventricular cardiac myocytes display a robust proliferative response to beta-cateninmediated signaling and conversely accelerate differentiation in response to inhibition of this pathway. Using gain-and loss-of-function murine genetic models, we show that beta-catenin controls ventricular myocyte proliferation during development and the perinatal period. We further demonstrate that the differential activation of the Wnt/beta-catenin signaling pathway accounts for the observed differences in the proliferation rates of the compact versus the trabecular myocardium during normal cardiac development. Collectively, these results provide a mechanistic explanation for the differences in localized proliferation rates of cardiac myocytes and point to a practical method for the generation of the large numbers of stem cell-derived cardiac myocytes necessary for clinical applications.
C1 [Buikema, Jan Willem; Mady, Ahmed S.; Mittal, Nikhil V.; Atmanli, Ayhan; Domian, Ibrahim J.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Buikema, Jan Willem; Mady, Ahmed S.; Mittal, Nikhil V.; Domian, Ibrahim J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Buikema, Jan Willem; Doevendans, Pieter A.; Sluijter, Joost P. G.] Univ Med Ctr Utrecht, Dept Cardiol, NL-3584 CX Utrecht, Netherlands.
[Caron, Leslie] Genea FSHD, Sydney, NSW 2000, Australia.
[Domian, Ibrahim J.] Harvard Univ, Stem Cell Inst, Cambridge, MA 02138 USA.
RP Domian, IJ (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charles River Plaza CPZN 3200,185 Cambridge St, Boston, MA 02114 USA.
EM idomian@partners.org
FU National Institutes of Health/National Heart, Lung, and Blood Institute
(NIH/NHLBI) [U01HL10040801, 1K08 HL091209]; Dutch Ministry of Economic
Affairs, Agriculture and Innovation; Dutch Heart Foundation
FX This work was supported by grants from the National Institutes of
Health/National Heart, Lung, and Blood Institute (NIH/NHLBI)
[U01HL10040801 and NIH/NHLBI 1K08 HL091209]; by project P1.04 SMARTCARE
of the BioMedical Materials institute, co- funded by the Dutch Ministry
of Economic Affairs, Agriculture and Innovation; and by the Dutch Heart
Foundation. Deposited in PMC for release after 12 months.
NR 74
TC 13
Z9 14
U1 3
U2 14
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0950-1991
J9 DEVELOPMENT
JI Development
PD OCT 15
PY 2013
VL 140
IS 20
BP 4165
EP +
DI 10.1242/dev.099325
PG 22
WC Developmental Biology
SC Developmental Biology
GA 227ZC
UT WOS:000325153200006
PM 24026118
ER
PT J
AU Henrich, TJ
Gandhi, RT
AF Henrich, Timothy J.
Gandhi, Rajesh T.
TI Early Treatment and HIV-1 Reservoirs: A Stitch in Time?
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; antiretroviral therapy; HIV reservoirs; HIV persistence;
gut-associated-lymphoid-tissue
ID T-CELL SUBSETS; ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; INFECTION;
MEMORY; QUANTIFICATION; ESTABLISHMENT; PERSISTENCE; DEPLETION; DRIVEN
C1 [Henrich, Timothy J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Henrich, Timothy J.; Gandhi, Rajesh T.] Harvard Univ, Sch Med, Boston, MA USA.
[Gandhi, Rajesh T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Gandhi, RT (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA.
EM rgandhi@partners.org
FU National Institutes of Health (NIH) [R01 AI066992-04A1, NIH
G08LM008830-01, NIH U01 AI 694722]; National Institutes of Health (NIH),
Harvard University Center for AIDS Research [NIH 2P30 AI060354-06]; NIH
[1K23AI098480-01]; Foundation for AIDS Research (amfAR)
[108466-52-RGRL]; Harvard University Center for AIDS Research [NIH P30
AI060354]
FX This work was supported by the National Institutes of Health (NIH) (R01
AI066992-04A1 to R.T.G.) and NIH G08LM008830-01 (to R.T.G.) and by
grants to the AIDS Clinical Trials Group (NIH U01 AI 694722) and the
Harvard University Center for AIDS Research (NIH 2P30 AI060354-06) (to
R.T.G.). T.J.H. is supported by the NIH (1K23AI098480-01), the
Foundation for AIDS Research (amfAR) (108466-52-RGRL), and the Harvard
University Center for AIDS Research (NIH P30 AI060354).
NR 33
TC 5
Z9 6
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2013
VL 208
IS 8
BP 1189
EP 1193
DI 10.1093/infdis/jit307
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 223TJ
UT WOS:000324832800001
PM 23852126
ER
PT J
AU Yukl, SA
Shergill, AK
Ho, T
Killian, M
Girling, V
Epling, L
Li, PL
Wong, LK
Crouch, P
Deeks, SG
Havlir, DV
McQuaid, K
Sinclair, E
Wong, JK
AF Yukl, Steven A.
Shergill, Amandeep K.
Ho, Terence
Killian, Maudi
Girling, Valerie
Epling, Lorrie
Li, Peilin
Wong, Lisa K.
Crouch, Pierre
Deeks, Steven G.
Havlir, Diane V.
McQuaid, Kenneth
Sinclair, Elizabeth
Wong, Joseph K.
TI The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and
Blood of HIV-Positive Patients on ART: Implications for Viral
Persistence
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; HIV-1; ART; persistence; reservoir; CD4(+) T cell; gut; intestine;
ileum; rectum
ID ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; VIRUS TYPE-1 RNA;
LYMPHOID-TISSUE; IN-VIVO; PERIPHERAL-BLOOD; CENTRAL MEMORY; INFECTION;
PLASMA; RESERVOIR
AB Even with optimal antiretroviral therapy, human immunodeficiency virus (HIV) persists in plasma, blood cells, and tissues. To develop new therapies, it is essential to know what cell types harbor residual HIV. We measured levels of HIV DNA, RNA, and RNA/DNA ratios in sorted subsets of CD4(+) T cells (CCR7(+), transitional memory, and effector memory) and non-CD4(+) T leukocytes from blood, ileum, and rectum of 8 ART-suppressed HIV-positive subjects. Levels of HIV DNA/million cells in CCR7(+) and effector memory cells were higher in the ileum than blood. When normalized by cell frequencies, most HIV DNA and RNA in the blood were found in CCR7(+) cells, whereas in both gut sites, most HIV DNA and RNA were found in effector memory cells. HIV DNA and RNA were observed in non-CD4(+) T leukocytes at low levels, particularly in gut tissues. Compared to the blood, the ileum had higher levels of HIV DNA and RNA in both CD4(+) T cells and non-CD4(+) T leukocytes, whereas the rectum had higher HIV DNA levels in both cell types but lower RNA levels in CD4(+) T cells. Future studies should determine whether different mechanisms allow HIV to persist in these distinct reservoirs, and the degree to which different therapies can affect each reservoir.
C1 [Yukl, Steven A.; Shergill, Amandeep K.; Li, Peilin; Crouch, Pierre; McQuaid, Kenneth; Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA.
[Yukl, Steven A.; Shergill, Amandeep K.; Ho, Terence; Killian, Maudi; Girling, Valerie; Epling, Lorrie; Li, Peilin; Crouch, Pierre; Deeks, Steven G.; Havlir, Diane V.; McQuaid, Kenneth; Sinclair, Elizabeth; Wong, Joseph K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ho, Terence; Killian, Maudi; Girling, Valerie; Epling, Lorrie; Deeks, Steven G.; Havlir, Diane V.; Sinclair, Elizabeth] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA.
[Wong, Lisa K.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
RP Yukl, SA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111W3, San Francisco, CA 94121 USA.
EM steven.yukl@ucsf.edu
FU US Department of Veterans Affairs [1 IK2 CX000520-01, I01 BX000192];
UCSF-Gladstone Center for AIDS Research (CFAR) [P30-AI027763]; National
Institute of Allergy and Infectious Diseases at the National Institutes
of Health [R56AI091573, K24 AI069994, U19AI096109]
FX This work was supported by the US Department of Veterans Affairs (1 IK2
CX000520-01 [to S. Y.], I01 BX000192 [to J. W.]); the UCSF-Gladstone
Center for AIDS Research (CFAR) (P30-AI027763 [to S. Y.]); and the
National Institute of Allergy and Infectious Diseases at the National
Institutes of Health (R56AI091573 [J. W., S. Y., A. S., D. H.], K24
AI069994 [to S. D.], U19AI096109 [to S. D., J. W.]).
NR 43
TC 42
Z9 42
U1 1
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2013
VL 208
IS 8
BP 1212
EP 1220
DI 10.1093/infdis/jit308
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 223TJ
UT WOS:000324832800004
PM 23852128
ER
PT J
AU Koehler, RN
Alter, G
Tovanabutra, S
Saathoff, E
Arroyo, MA
Walsh, AM
Sanders-Buell, EE
Maboko, L
Hoelscher, M
Robb, ML
Michael, NL
McCutchan, FE
Kim, JH
Kijak, GH
AF Koehler, Rebecca N.
Alter, Galit
Tovanabutra, Sodsai
Saathoff, Elmar
Arroyo, Miguel A.
Walsh, Anne M.
Sanders-Buell, Eric E.
Maboko, Leonard
Hoelscher, Michael
Robb, Merlin L.
Michael, Nelson L.
McCutchan, Francine E.
Kim, Jerome H.
Kijak, Gustavo H.
TI Natural Killer Cell-Mediated Innate Sieve Effect on HIV-1: The Impact of
KIR/HLA Polymorphism on HIV-1 Subtype-Specific Acquisition in East
Africa
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; innate immunity; KIR; HLA; sieve effect; subtypes; East Africa
ID HLA; DIVERSITY; INDIVIDUALS; TANZANIA; COMPLEX; MBEYA
AB Here we explore the association between killer cell immunoglobulin-like receptor (KIR)/HLA and human immunodeficiency virus type 1 (HIV-1) acquisition with different viral subtypes circulating in East Africa. In the prospective Cohort Development (CODE) cohort (Mbeya, Tanzania), carriers of KIR3DS1 and its putative ligand (HLA-A or HLA-B Bw4-80Ile alleles) showed increased HIV-1 acquisition risk (odds ratio [OR] = 3.46; 95% confidence interval [CI], 1.12-10.63; P =. 04) and a trend for enrichment for subtype A and A-containing recombinants (78% vs 46%; OR = 4.05; 95% CI,.91-28.30; P = .09) at the expense of subtype C (11% vs 43%; OR = 0.17; 95% CI,.01-.97; P = .08). In vitro, only natural killer cells from KIR3DS1(+)/HLA-Bw4-80Ile (+) healthy donors showed a 2-fold increased capacity to inhibit replication of subtype C vs subtype A viruses (P = .01). These findings suggest the presence of an innate sieve effect and may inform HIV-1 vaccine development.
C1 [Koehler, Rebecca N.; Tovanabutra, Sodsai; Arroyo, Miguel A.; Walsh, Anne M.; Sanders-Buell, Eric E.; Robb, Merlin L.; Michael, Nelson L.; McCutchan, Francine E.; Kim, Jerome H.; Kijak, Gustavo H.] US Mil HIV Res Program, Rockville, MD USA.
[Koehler, Rebecca N.; Tovanabutra, Sodsai; Walsh, Anne M.; Sanders-Buell, Eric E.; Robb, Merlin L.; McCutchan, Francine E.; Kijak, Gustavo H.] Henry M Jackson Fdn, Rockville, MD USA.
[Alter, Galit] Harvard Univ, Ragon Inst, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Alter, Galit] MIT, Boston, MA USA.
[Saathoff, Elmar; Hoelscher, Michael] Univ Munich, Dept Infect Dis & Trop Med, D-81377 Munich, Germany.
[Arroyo, Miguel A.; Michael, Nelson L.; Kim, Jerome H.] Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD USA.
[Maboko, Leonard; Hoelscher, Michael] NIMR Mbeya Med Res Programme, Mbeya, Tanzania.
RP Kijak, GH (reprint author), Walter Reed Army Inst Res, US Mil HIV Res Program, Henry M Jackson Fdn, 503 Robert Grant Ave,Rm 2N27, Silver Spring, MD 20910 USA.
EM gkijak@hivresearch.org
RI Hoelscher, Michael/D-3436-2012;
OI Arroyo, Miguel/0000-0001-7416-8867
FU Henry M. Jackson Foundation for the Advancement of Military Medicine; US
Department of Defense (DOD); National Institute for Allergy and
Infectious Diseases (NIAID); National Institutes of Health (NIH) [Y01
AI2642-12]; DOD; NIAID/NIH
FX This work was supported through a cooperative agreement between the
Henry M. Jackson Foundation for the Advancement of Military Medicine and
the US Department of Defense (DOD), by the National Institute for
Allergy and Infectious Diseases (NIAID), and National Institutes of
Health (NIH; grant Y01 AI2642-12). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript. The US Military HIV Research Program is
jointly planned and funded by the DOD and NIAID/NIH by an interagency
agreement. This manuscript was approved for publication by the Walter
Reed Army Institute of Research. The views and opinions expressed herein
are those of the authors and do not necessarily reflect those of the US
Army or DOD or the NIH.
NR 15
TC 4
Z9 4
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2013
VL 208
IS 8
BP 1250
EP 1254
DI 10.1093/infdis/jit349
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 223TJ
UT WOS:000324832800008
PM 23922366
ER
PT J
AU Je, Y
Jeon, JY
Giovannucci, EL
Meyerhardt, JA
AF Je, Youjin
Jeon, Justin Y.
Giovannucci, Edward L.
Meyerhardt, Jeffrey A.
TI Association between physical activity and mortality in colorectal
cancer: A meta-analysis of prospective cohort studies
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE physical activity; exercise; colon; rectum; cancer; mortality
ID III COLON-CANCER; BODY-MASS INDEX; INSULIN SENSITIVITY; STAGE-II;
SURVIVAL; IMPACT; INTERVENTION; RECURRENCE; DIAGNOSIS; LEVEL
AB Several prospective cohort studies have examined the association between prediagnosis and/or postdiagnosis physical activity (PA) on colorectal cancer outcomes and reported conflicting results. To quantitatively assess this association, we have conducted a meta-analysis of prospective studies. Databases and reference lists of relevant studies were searched using MEDLINE and EMBASE up to January 2013. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. For this meta-analysis, a total of seven prospective cohort studies were included. The analysis included 5,299 patients for prediagnosis PA and 6,348 patients for postdiagnosis PA, followed up over a period ranging from 3.8 to 11.9 years. The analyses showed that patients who participated in any amount of PA before diagnosis had a RR of 0.75 (95% CI: 0.65-0.87, p < 0.001) for colorectal cancer-specific mortality compared to patients who did not participate in any PA. Those who participated in high PA before diagnosis (vs. low PA) had a RR of 0.70 (95% CI: 0.56-0.87, p = 0.002). Similarly, patients who participated in any PA after diagnosis had a RR of 0.74 (95% CI: 0.58-0.95, p = 0.02) for colorectal cancer-specific mortality compared to patients who did not participate in any PA. Those who participated in high PA after diagnosis (vs. low PA) had a RR of 0.65 (95% CI: 0.47-0.92, p = 0.01). Similar inverse associations of prediagnosis or postdiagnosis PA were found for all-cause mortality. In conclusion, both prediagnosis and postdiagnosis PA were associated with reduced colorectal cancer-specific mortality and all-cause mortality.
What's new? Everyone knows exercise is good for you, and it's been shown that physical activity reduces the risk of developing colorectal cancer. A new study investigated what impact exercise has on colorectal cancer outcomes. The authors included a large sample size from seven prospective cohort studies and compared levels of physical activity before and after diagnosis with mortality from all causes after diagnosis with colorectal cancer. They found that physical activity, undertaken either before or after diagnosis, reduces colon cancer mortality.
C1 [Je, Youjin] Kyung Hee Univ, Dept Food & Nutr, Seoul, South Korea.
[Jeon, Justin Y.] Yonsei Univ, Dept Sport & Leisure Studies, Seoul 120749, South Korea.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Meyerhardt, Jeffrey A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Jeon, JY (reprint author), Yonsei Univ, Dept Sport & Leisure Studies, 50 Yonsei Ro, Seoul 120749, South Korea.
EM jjeon@yonsei.ac.kr
FU National Research Foundation of Korea (NRF) [2011-0004892]
FX Grant sponsor: National Research Foundation of Korea (NRF); Grant
number: 2011-0004892
NR 27
TC 50
Z9 50
U1 2
U2 49
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 15
PY 2013
VL 133
IS 8
BP 1905
EP 1913
DI 10.1002/ijc.28208
PG 9
WC Oncology
SC Oncology
GA 198FW
UT WOS:000322908600017
PM 23580314
ER
PT J
AU Setsompop, K
Kimmlingen, R
Eberlein, E
Witzel, T
Cohen-Adad, J
McNab, JA
Keil, B
Tisdall, MD
Hoecht, P
Dietz, P
Cauley, SF
Tountcheva, V
Matschl, V
Lenz, VH
Heberlein, K
Potthast, A
Thein, H
Van Horn, J
Toga, A
Schmitt, F
Lehne, D
Rosen, BR
Wedeen, V
Wald, LL
AF Setsompop, K.
Kimmlingen, R.
Eberlein, E.
Witzel, T.
Cohen-Adad, J.
McNab, J. A.
Keil, B.
Tisdall, M. D.
Hoecht, P.
Dietz, P.
Cauley, S. F.
Tountcheva, V.
Matschl, V.
Lenz, V. H.
Heberlein, K.
Potthast, A.
Thein, H.
Van Horn, J.
Toga, A.
Schmitt, F.
Lehne, D.
Rosen, B. R.
Wedeen, V.
Wald, L. L.
TI Pushing the limits of in vivo diffusion MRI for the Human Connectome
Project
SO NEUROIMAGE
LA English
DT Article
DE MRI; Structural connectivity; Diffusion imaging; Gradient hardware;
HARDI; DSI
ID FIBER ORIENTATION DISTRIBUTIONS; Q-BALL RECONSTRUCTION; TO-NOISE RATIO;
HUMAN BRAIN; 7 TESLA; SPHERICAL DECONVOLUTION; B-1(+) INHOMOGENEITY;
MAGNETIC-FIELDS; RF EXCITATION; 8 CHANNELS
AB Perhaps more than any other "-omics" endeavor, the accuracy and level of detail obtained from mapping the major connection pathways in the living human brain with diffusion MRI depend on the capabilities of the imaging technology used. The current tools are remarkable; allowing the formation of an "image" of the water diffusion probability distribution in regions of complex crossing fibers at each of half a million voxels in the brain. Nonetheless our ability to map the connection pathways is limited by the image sensitivity and resolution, and also the contrast and resolution in encoding of the diffusion probability distribution.
The goal of our Human Connectome Project (HCP) is to address these limiting factors by re-engineering the scanner from the ground up to optimize the high b-value, high angular resolution diffusion imaging needed for sensitive and accurate mapping of the brain's structural connections. Our efforts were directed based on the relative contributions of each scanner component. The gradient subsection was a major focus since gradient amplitude is central to determining the diffusion contrast, the amount of T-2 signal loss, and the blurring of the water PDF over the course of the diffusion time. By implementing a novel 4-port drive geometry and optimizing size and linearity for the brain, we demonstrate a whole-body sized scanner with G(max) = 300 mT/m on each axis capable of the sustained duty cycle needed for diffusion imaging. The system is capable of slewing the gradient at a rate of 200 T/m/s as needed for the EPI image encoding. In order to enhance the efficiency of the diffusion sequence we implemented a FOV shifting approach to Simultaneous MultiSlice (SMS) EPI capable of unaliasing 3 slices excited simultaneously with a modest g-factor penalty allowing us to diffusion encode whole brain volumes with low TR and TE. Finally we combine the multi-slice approach with a compressive sampling reconstruction to sufficiently undersample q-space to achieve a DSI scan in less than 5 mm. To augment this accelerated imaging approach we developed a 64-channel, tight-fitting brain array coil and show its performance benefit compared to a commercial 32-channel coil at all locations in the brain for these accelerated acquisitions.
The technical challenges of developing the over-all system are discussed as well as results from SNR comparisons, ODF metrics and fiber tracking comparisons. The ultra-high gradients yielded substantial and immediate gains in the sensitivity through reduction of TE and improved signal detection and increased efficiency of the DSI or HARDI acquisition, accuracy and resolution of diffusion tractography, as defined by identification of known structure and fiber crossing. Published by Elsevier Inc.
C1 [Setsompop, K.; Witzel, T.; Cohen-Adad, J.; McNab, J. A.; Keil, B.; Tisdall, M. D.; Cauley, S. F.; Tountcheva, V.; Rosen, B. R.; Wedeen, V.; Wald, L. L.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,AA Martinos Ctr Biomed Ima, Boston, MA 02115 USA.
[Kimmlingen, R.; Eberlein, E.; Hoecht, P.; Dietz, P.; Matschl, V.; Lenz, V. H.; Potthast, A.; Thein, H.; Schmitt, F.; Lehne, D.] Siemens Healthcare, Erlangen, Germany.
[Heberlein, K.] Siemens Healthcare, Boston, MA USA.
[Van Horn, J.; Toga, A.] Univ Calif Los Angeles, Dept Neurol, Lab Neuro Imaging, Los Angeles, CA 90024 USA.
RP Wald, LL (reprint author), MGH AA Martinos Imaging Ctr, Bldg 149 13th St Rm 2301, Charlestown, MA 02129 USA.
EM wald@nmr.mgh.harvard.edu
RI Setsompop, Kawin/P-1464-2014; Wald, Lawrence/D-4151-2009; Keil,
Boris/P-1411-2014; Cauley, Stephen/P-1386-2014; Witzel,
Thomas/P-1402-2014
OI Setsompop, Kawin/0000-0003-0455-7634;
FU National Institutes of Health [P41EB015896]; NIH Blueprint Initiative
for Neuroscience Research grant [U01MH093765]; NIH NIBIB grant
[K99/R00EB012107]
FX This work acknowledges funding from the National Institutes of Health,
NIH Blueprint Initiative for Neuroscience Research grant U01MH093765,
National Institutes of Health grant P41EB015896, and NIH NIBIB grant
K99/R00EB012107.
NR 77
TC 86
Z9 87
U1 3
U2 50
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD OCT 15
PY 2013
VL 80
BP 220
EP 233
DI 10.1016/j.neuroimage.2013.05.078
PG 14
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 191MB
UT WOS:000322416000017
PM 23707579
ER
PT J
AU McNab, JA
Edlow, BL
Witzel, T
Huang, SY
Bhat, H
Heberlein, K
Feiweier, T
Liu, KC
Keil, B
Cohen-Adad, J
Tisdall, MD
Folkerth, RD
Kinney, HC
Wald, LL
AF McNab, Jennifer A.
Edlow, Brian L.
Witzel, Thomas
Huang, Susie Y.
Bhat, Himanshu
Heberlein, Keith
Feiweier, Thorsten
Liu, Kecheng
Keil, Boris
Cohen-Adad, Julien
Tisdall, M. Dylan
Folkerth, Rebecca D.
Kinney, Hannah C.
Wald, Lawrence L.
TI The Human Connectome Project and beyond: Initial applications of 300
mT/m gradients
SO NEUROIMAGE
LA English
DT Article
DE Human connectome; Diffusion MRI; Tractography; Traumatic coma;
Consciousness; Axon diameter; Corpus callosum; In vivo; Postmortem
ID AMYOTROPHIC-LATERAL-SCLEROSIS; THALAMIC INTRALAMINAR NUCLEI; AXON
DIAMETER DISTRIBUTION; ASCENDING AROUSAL SYSTEM; PLACEBO-CONTROLLED
TRIAL; TRAUMATIC BRAIN-INJURY; CORPUS-CALLOSUM; DIFFUSION MRI;
HEAD-INJURY; RETICULAR-FORMATION
AB The engineering of a 3 T human MRI scanner equipped with 300 mT/m gradients - the strongest gradients ever built for an in vivo human MRI scanner - was a major component of the NIH Blueprint Human Connectome Project (HCP). This effort was motivated by the HCP's goal of mapping, as completely as possible, the macroscopic structural connections of the in vivo healthy, adult human brain using diffusion tractography. Yet, the 300 mT/m gradient system is well suited to many additional types of diffusion measurements. Here, we present three initial applications of the 300 mT/m gradients that fall outside the immediate scope of the HCP. These include: 1) diffusion tractography to study the anatomy of consciousness and the mechanisms of brain recovery following traumatic coma; 2) q-space measurements of axon diameter distributions in the in vivo human brain and 3) postmortem diffusion tractography as an adjunct to standard histopathological analysis. We show that the improved sensitivity and diffusion-resolution provided by the gradients are rapidly enabling human applications of techniques that were previously possible only for in vitro and animal models on small-bore scanners, thereby creating novel opportunities to map the microstructure of the human brain in health and disease. (C) 2013 Elsevier Inc. All rights reserved.
C1 [McNab, Jennifer A.] Stanford Univ, RM Lucas Ctr Imaging, Dept Radiol, Stanford, CA 94305 USA.
[Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Edlow, Brian L.; Witzel, Thomas; Huang, Susie Y.; Keil, Boris; Tisdall, M. Dylan; Wald, Lawrence L.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Bhat, Himanshu; Heberlein, Keith; Liu, Kecheng] Siemens Med Solut USA Inc, Alpharetta, GA USA.
[Feiweier, Thorsten] Siemens AG, Healthcare Sect, Erlangen, Germany.
[Cohen-Adad, Julien] Ecole Polytech, Dept Elect Engn, Montreal, PQ H3C 3A7, Canada.
[Folkerth, Rebecca D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Folkerth, Rebecca D.; Kinney, Hannah C.] Harvard Univ, Sch Med, Dept Pathol, Childrens Hosp Boston, Boston, MA 02115 USA.
RP McNab, JA (reprint author), Stanford Univ, RM Lucas Ctr Imaging, Dept Radiol, Stanford, CA 94305 USA.
EM mcnabj@stanford.edu
RI Keil, Boris/P-1411-2014; Witzel, Thomas/P-1402-2014; Wald,
Lawrence/D-4151-2009
FU CIHR Fellowship; NIH Blueprint for Neuroscience Research Grant
[U01MH093765]; NIH [NCRR P41RR14075, NIBIB RO1 EB006847, NINDS
R25NS065743]; Center for Integration of Medicine and Innovative
Technology (Boston, MA)
FX This work was funded by: a CIHR Fellowship and an NIH Blueprint for
Neuroscience Research Grant: U01MH093765, as well as NIH funding from
NCRR P41RR14075, NIBIB RO1 EB006847 and NINDS R25NS065743 and the Center
for Integration of Medicine and Innovative Technology (Boston, MA). We
are grateful to the patient who volunteered for this study and whose
recovery from traumatic coma continues to inspire this work. Thank you
to Louis Vinke for assistance with processing postmortem brain
specimens. Thank you to Emi Takahashi and Guangping Dai for assistance
with acquisition of brainstem-diencephalon postmortem data acquired on
the small-bore scanner.
NR 78
TC 61
Z9 62
U1 4
U2 47
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD OCT 15
PY 2013
VL 80
BP 234
EP 245
DI 10.1016/j.neuroimage.2013.05.074
PG 12
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 191MB
UT WOS:000322416000018
PM 23711537
ER
PT J
AU Hyle, EP
Sax, PE
Walensky, RP
AF Hyle, Emily P.
Sax, Paul E.
Walensky, Rochelle P.
TI Potential Savings by Reduced CD4 Monitoring in Stable Patients With HIV
Receiving Antiretroviral Therapy
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Hyle, Emily P.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Sax, Paul E.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
RP Hyle, EP (reprint author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM ehyle@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X
FU NIAID NIH HHS [R37 AI042006, R37 AI42006, T32 AI007433]; PHS HHS [T32
A1007433]
NR 5
TC 17
Z9 17
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 14
PY 2013
VL 173
IS 18
BP 1746
EP 1748
DI 10.1001/jamainternmed.2013.9329
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268TO
UT WOS:000328193600019
PM 23978894
ER
PT J
AU Seabury, SA
Chandra, A
Jena, AB
AF Seabury, Seth A.
Chandra, Amitabh
Jena, Anupam B.
TI Trends in the Earnings of Male and Female Health Care Professionals in
the United States, 1987 to 2010
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID PHYSICIANS
C1 [Seabury, Seth A.] Univ So Calif, Dept Emergency Med, Los Angeles, CA USA.
[Seabury, Seth A.] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA.
[Chandra, Amitabh] Harvard Univ, Harvard Kennedy Sch Govt, Cambridge, MA 02138 USA.
[Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM jena@hcp.med.harvard.edu
FU NIA NIH HHS [P01 AG19783-02]
NR 6
TC 22
Z9 22
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 14
PY 2013
VL 173
IS 18
BP 1748
EP 1750
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268TO
UT WOS:000328193600021
PM 23999898
ER
PT J
AU Caverly, TJ
Prochazka, AV
Stickrath, C
AF Caverly, Tanner J.
Prochazka, Allan V.
Stickrath, Chad
TI Do Physicians Have an Obligation to Disclose the Uncertainty About Harms
or Just the Harms? Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; CT SCANS; CHILDHOOD; RISK
C1 [Caverly, Tanner J.; Prochazka, Allan V.; Stickrath, Chad] Univ Colorado, Div Gen Internal Med, Dept Med, Aurora, CO 80042 USA.
[Caverly, Tanner J.; Prochazka, Allan V.; Stickrath, Chad] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Caverly, TJ (reprint author), Univ Colorado, Univ Phys Inc, Div Gen Internal Med, Dept Med,Sch Med, 13199 E Montview Blvd,3rd Floor,Ste 300, Aurora, CO 80042 USA.
EM Tanner.Caverly@gmail.com
FU PHS HHS [T32HP1006]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 14
PY 2013
VL 173
IS 18
BP 1752
EP 1752
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268TO
UT WOS:000328193600024
PM 24126773
ER
PT J
AU Singh, H
Sittig, DF
AF Singh, Hardeep
Sittig, Dean F.
TI Toward Electronic Medical Record Alerts That Consume Less Physician Time
Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Singh, Hardeep] Baylor Coll Med, Dept Med, Houston VA Hlth Serv Res & Dev HSR&D, Ctr Excellence,Michael E DeBakey Vet Affairs Med, Houston, TX 77030 USA.
[Singh, Hardeep] Sect Hlth Serv Res, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA.
RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD OCT 14
PY 2013
VL 173
IS 18
BP 1756
EP 1756
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268TO
UT WOS:000328193600031
PM 24126782
ER
PT J
AU Rochet, N
Kahn, RS
Niemierko, A
Delaney, TF
Russell, AH
AF Rochet, Nathalie
Kahn, Rachel S.
Niemierko, Andrzej
Delaney, Thomas F.
Russell, Anthony H.
TI Consolidation whole abdomen irradiation following adjuvant
carboplatin-paclitaxel based chemotherapy for advanced uterine
epithelial cancer: feasibility, toxicity and outcomes
SO RADIATION ONCOLOGY
LA English
DT Article
DE Whole abdomen irradiation; Advanced endometrial cancer; Chemotherapy;
Radiotherapy
ID GYNECOLOGIC-ONCOLOGY-GROUP; ABDOMINOPELVIC RADIATION-THERAPY; IV
ENDOMETRIAL CARCINOMA; ADVANCED OVARIAN-CANCER; ABDOMINAL IRRADIATION;
STAGE-III; HIGH-RISK; WEEKLY CISPLATIN; PHASE-I; RADIOTHERAPY
AB Background: To evaluate feasibility and preliminary outcomes associated with sequential whole abdomen irradiation (WAI) as consolidative treatment following comprehensive surgery and systemic chemotherapy for advanced endometrial cancer.
Methods: We conducted a retrospective analysis of patients treated at our institution from 2000 to 2011. Inclusion criteria were stage III-IV endometrial cancer patients with histological proof of one or more sites of extra-uterine abdomen-confined disease, treated with WAI as part of multimodal therapy. Endpoints were feasibility, acute toxicity, late effects, recurrence-free survival (RFS) and overall survival (OS). Twenty patients were identified. Chemotherapy consisted of 3 to 6 cycles of a platinum-paclitaxel regimen in 18 patients. WAI was delivered using conventional technique to a median total dose of 27.5 Gy.
Results: No grade 4 toxicities occurred during chemotherapy or radiotherapy. No radiation dose reduction was necessary. Three patients developed small bowel obstruction, all in the context of recurrent intraperitoneal disease. Kaplan-Meier estimates and 95% confidence intervals for RFS and OS at one year were 63% (38-80%) and 83% (56-94%) and at 3 years 57% (33-76%) and 62% (34-81%), respectively. On univariate Cox analysis, stage IVB and serous papillary (SP) histology were found to be statistically significantly (at the p = 0.05 level) associated with worse RFS and OS. The peritoneal cavity was the most frequent site of initial failure.
Conclusions: Consolidative WAI following chemotherapy is feasible and can be performed without interruption with manageable acute and late toxicity. Patients with endometrioid adenocarcinoma, especially stage FIGO III, had favorable outcomes possibly meriting prospective evaluation of the addition of WAI following chemotherapy in selected patients. Patients with SP do poorly and do not routinely benefit from this approach.
C1 [Rochet, Nathalie; Niemierko, Andrzej; Delaney, Thomas F.; Russell, Anthony H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Rochet, Nathalie] Heidelberg Univ, Dept Radiat Oncol, D-69120 Heidelberg, Germany.
[Kahn, Rachel S.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Rochet, Nathalie] CHU Vaudois, Univ Lausanne Hosp, Dept Radiat Oncol, CH-1011 Lausanne, Switzerland.
RP Rochet, N (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,COX3, Boston, MA 02114 USA.
EM Nathalie.Rochet@chuv.ch
FU German Society of Radiation Oncology (DEGRO)
FX Actual or potential conflicts of interest do not exist. All authors
declare that there are no conflicts of interest. NR is financially
supported by a scholarship from the German Society of Radiation Oncology
(DEGRO) for this project. This study has been presented as a poster
during ASTRO's 2012 Annual Meeting in Boston (Abstract #2617).
NR 25
TC 1
Z9 1
U1 2
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-717X
J9 RADIAT ONCOL
JI Radiat. Oncol.
PD OCT 14
PY 2013
VL 8
AR 236
DI 10.1186/1748-717X-8-236
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 262JT
UT WOS:000327731700001
PM 24125168
ER
PT J
AU Timmerman, LA
Holton, T
Yuneva, M
Louie, RJ
Padro, M
Daemen, A
Hu, M
Chan, DA
Ethier, SP
van 't Veer, LJ
Polyak, K
McCormick, F
Gray, JW
AF Timmerman, Luika A.
Holton, Thomas
Yuneva, Mariia
Louie, Raymond J.
Padro, Merce
Daemen, Anneleen
Hu, Min
Chan, Denise A.
Ethier, Stephen P.
van 't Veer, Laura J.
Polyak, Kornelia
McCormick, Frank
Gray, Joe W.
TI Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common
Triple-Negative Breast Tumor Therapeutic Target
SO CANCER CELL
LA English
DT Article
ID CANCER CELL-LINES; X(C)(-) CYSTINE/GLUTAMATE ANTIPORTER; AEROBIC
GLYCOLYSIS; L-ASPARAGINASE; DNA-DAMAGE; IN-VITRO; GROWTH; METABOLISM;
CYSTINE; GLUTATHIONE
AB A handful of tumor-derived cell lines form the mainstay of cancer therapeutic development, yielding drugs with an impact typically measured as months to disease progression. To develop more effective breast cancer therapeutics and more readily understand their clinical impact, we constructed a functional metabolic portrait of 46 independently derived breast cell lines. Our analysis of glutamine uptake and dependence identified a subset of triple-negative samples that are glutamine auxotrophs. Ambient glutamine indirectly supports environmental cystine acquisition via the xCT antiporter, which is expressed on one-third of triple-negative tumors in vivo. xCT inhibition with the clinically approved anti-inflammatory sulfasalazine decreases tumor growth, revealing a therapeutic target in breast tumors of poorest prognosis and a lead compound for rapid, effective drug development.
C1 [Timmerman, Luika A.; Louie, Raymond J.; Padro, Merce; Daemen, Anneleen; Chan, Denise A.; van 't Veer, Laura J.; McCormick, Frank] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA.
[Daemen, Anneleen; van 't Veer, Laura J.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94115 USA.
[Louie, Raymond J.; Padro, Merce; Chan, Denise A.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94115 USA.
[Holton, Thomas] San Francisco State Univ, Sch Engn, San Francisco, CA 94115 USA.
[Hu, Min] Novartis Inst BioMed Res China, Pudong New Area, Shanghai 201203, Peoples R China.
[Yuneva, Mariia] MRC Natl Inst Med Res, Div Physiol & Metab, London NW7 1AA, England.
[Ethier, Stephen P.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Polyak, Kornelia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Gray, Joe W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.
RP Timmerman, LA (reprint author), Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA.
EM timmerma@cc.ucsf.edu
FU National Institutes of Health, National Cancer Institute; Bay Area
Breast Cancer SPORE [P50 CA 58207]; Prospect Creek Foundation; Durra
Family Fund; Mount Zion Health Fund; Supporting Foundation of the Jewish
Community Federation; [U54 CA 112970]
FX We thank the UCSF/Gladstone Genome Core for microarray dataset
generation; T. Cowan, Stanford Biochemical Genetics Laboratory for HPLC
amino acid analysis; R. Higashi, CREAM, University of Louisville, for
mass spectrometry; the UCSF Preclinical Therapeutics Core for
xenografts; and D. Albertson, T. Tlsty, J. Korkola, and W. Kin law for
valuable manuscript critiques. Support was provided by the National
Institutes of Health, National Cancer Institute, Bay Area Breast Cancer
SPORE (P50 CA 58207), grant U54 CA 112970, the Prospect Creek
Foundation, the Durra Family Fund, the Mount Zion Health Fund, and a
Supporting Foundation of the Jewish Community Federation.
NR 59
TC 78
Z9 79
U1 2
U2 22
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD OCT 14
PY 2013
VL 24
IS 4
BP 450
EP 465
DI 10.1016/j.ccr.2013.08.020
PG 16
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 241WD
UT WOS:000326198500008
PM 24094812
ER
PT J
AU Turner, EH
AF Turner, Erick H.
TI How to access and process FDA drug approval packages for use in research
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID CLINICAL-TRIALS; PUBLICATION; INFORMATION; DOCUMENTS; REVIEWS
C1 [Turner, Erick H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA.
[Turner, Erick H.] Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA.
RP Turner, EH (reprint author), Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA.
EM turnere@ohsu.edu
RI Turner, Erick/A-4848-2008
OI Turner, Erick/0000-0002-3522-3357
NR 25
TC 15
Z9 15
U1 2
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD OCT 14
PY 2013
VL 347
AR f5992
DI 10.1136/bmj.f5992
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 238VR
UT WOS:000325980100001
PM 24126858
ER
PT J
AU Tikkanen, AU
Opotowsky, AR
Bhatt, AB
Landzberg, MJ
Rhodes, J
AF Tikkanen, Ana Ubeda
Opotowsky, Alexander R.
Bhatt, Ami B.
Landzberg, Michael J.
Rhodes, Jonathan
TI Physical activity is associated with improved aerobic exercise capacity
over time in adults with congenital heart disease
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Congenital heart disease; Adults; Exercise capacity and physical
activity
ID QUALITY-OF-LIFE; SOCIETAL DATABASE COMMITTEE; ALL-CAUSE MORTALITY;
CARDIAC REHABILITATION; CONSENSUS DEFINITIONS; FONTAN OPERATION; TRIAL;
LONG; HOSPITALIZATIONS; EXPERIENCE
AB Background: Impaired exercise capacity is common in adults with congenital heart disease (ACHD). This impairment is progressive and is associatedwith increasedmorbidity andmortality. We studied the influence of the frequency of at least moderately strenuous physical activity (PhysAct) on changes in exercise capacity of ACHD patients over time.
Methods: We studied ACHD patients >= 21 years old who had repeated maximal (RER >= 1.09) cardiopulmonary exercise tests within 6 to 24 months. On the basis of data extracted from each patient's clinical records, PhysAct frequency was classified as (1) Low: minimal PhysAct, (2) Occasional: moderate PhysAct <2 times/week, or (3) Frequent: moderate PhysAct >= 2 times/week.
Results: PhysAct frequency could be classified for 146 patients. Those who participated in frequent exercise tended to have improved pVO(2) (Delta pVO(2) = + 1.63 +/- 2.67 ml/kg/min) compared to those who had low or occasional activity frequency (Delta pVO(2) = + 0.06 +/- 2.13 ml/kg/min, p = 0.003) over a median follow-up of 13.2 months. This differencewas independent of baseline clinical characteristics, time between tests, medication changes, orweight change. Thosewho engaged in frequent PhysActweremore likely to have an increase of pVO(2) of = 1SD between tests as compared with sedentary patients (multivariable OR = 7.4, 95% CI 1.5-35.7). Aerobic exercise capacity also increased for patients who increased activity frequency from baseline to follow-up; 27.3% of those who increased their frequency of moderately strenuous physical activity had a clinically significant (at least+ 1SD) increase in pVO2 compared to only 11% of thosewhomaintained or decreased activity frequency.
Conclusions: ACHD patients who engage in frequent physical activity tend to have improved exercise capacity over time. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Tikkanen, Ana Ubeda; Opotowsky, Alexander R.; Landzberg, Michael J.; Rhodes, Jonathan] Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
[Opotowsky, Alexander R.; Landzberg, Michael J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Bhatt, Ami B.] Massachusetts Gen Hosp, Ctr Heart, Boston, MA 02114 USA.
RP Tikkanen, AU (reprint author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
EM anaubedatikkanen@yahoo.es
FU Fundacion Alfonso Martin Escudero; National Institutes of Health
[5-T32-HL07604-25]; Dunlevie Fund
FX This work was supported by Fundacion Alfonso Martin Escudero (AUT),
National Institutes of Health 5-T32-HL07604-25 (ARO) and the Dunlevie
Fund (ARO/MJL).
NR 35
TC 10
Z9 10
U1 0
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 12
PY 2013
VL 168
IS 5
BP 4685
EP 4691
DI 10.1016/j.ijcard.2013.07.177
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 242EI
UT WOS:000326219800022
ER
PT J
AU Ferreira, E
Porter, RM
Wehling, N
O'Sullivan, RP
Liu, FJ
Boskey, A
Estok, DM
Harris, MB
Vrahas, MS
Evans, CH
Wells, JW
AF Ferreira, Elisabeth
Porter, Ryan M.
Wehling, Nathalie
O'Sullivan, Regina P.
Liu, Fangjun
Boskey, Adele
Estok, Daniel M.
Harris, Mitchell B.
Vrahas, Mark S.
Evans, Christopher H.
Wells, James W.
TI Inflammatory Cytokines Induce a Unique Mineralizing Phenotype in
Mesenchymal Stem Cells Derived from Human Bone Marrow
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; NONSPECIFIC ALKALINE-PHOSPHATASE; INORGANIC
PYROPHOSPHATE; OSTEOBLASTS; DIFFERENTIATION; CALCIFICATION; CARTILAGE;
MODEL; INTERLEUKIN-1-BETA; EXPRESSION
AB Bone marrow contains mesenchymal stem cells (MSCs) that can differentiate along multiple mesenchymal lineages. In this capacity they are thought to be important in the intrinsic turnover and repair of connective tissues while also serving as a basis for tissue engineering and regenerative medicine. However, little is known of the biological responses of human MSCs to inflammatory conditions. When cultured with IL-1 beta, marrow-derived MSCs from 8 of 10 human subjects deposited copious hydroxyapatite, in which authenticity was confirmed by Fourier transform infrared spectroscopy. Transmission electron microscopy revealed the production of fine needles of hydroxyapatite in conjunction with matrix vesicles. Alkaline phosphatase activity did not increase in response to inflammatory mediators, but PPi production fell, reflecting lower ectonucleotide pyrophosphatase activity in cells and matrix vesicles. Because PPi is the major physiological inhibitor of mineralization, its decline generated permissive conditions for hydroxyapatite formation. This is in contrast to MSCs treated with dexamethasone, where PPi levels did not fall and mineralization was fuelled by a large and rapid increase in alkaline phosphatase activity. Bone sialoprotein was the only osteoblast marker strongly induced by IL-1 beta; thus these cells do not become osteoblasts despite depositing abundant mineral. RT-PCR did not detect transcripts indicative of alternative mesenchymal lineages, including chondrocytes, myoblasts, adipocytes, ligament, tendon, or vascular smooth muscle cells. IL-1 beta phosphorylated multiple MAPKs and activated nuclear factor-kappa B (NF-kappa B). Certain inhibitors of MAPK and PI3K, but not NF-kappa B, prevented mineralization. The findings are of importance to soft tissue mineralization, tissue engineering, and regenerative medicine.
C1 [Ferreira, Elisabeth; Porter, Ryan M.; O'Sullivan, Regina P.; Liu, Fangjun; Evans, Christopher H.; Wells, James W.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, Boston, MA 02215 USA.
[Ferreira, Elisabeth; Porter, Ryan M.; Vrahas, Mark S.; Evans, Christopher H.; Wells, James W.] AO Fdn, Collaborat Res Ctr, CH-7270 Davos, Switzerland.
[Wehling, Nathalie] Asklepios Stadtklin, Dept Surg, D-83646 Bad Tolz, Germany.
[Boskey, Adele] Hosp Special Surg, New York, NY 10021 USA.
[Estok, Daniel M.; Harris, Mitchell B.] Brigham & Womens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA.
[Vrahas, Mark S.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Evans, CH (reprint author), Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, RN-115,330 Brookline Ave, Boston, MA 02215 USA.
EM cevans@bidmc.harvard.edu
RI Wells, James/C-7480-2011;
OI Wells, James/0000-0002-9618-6940; Boskey, Adele/0000-0002-6181-2219
FU National Institutes of Health [AR050243]; AO Foundation [S-10-72F];
GENDEF
FX This work was supported, in whole or in part, by National Institutes of
Health Grant AR050243 (NIAMS). This work was also supported by AO
Foundation Grants S-10-72F and GENDEF.
NR 36
TC 22
Z9 23
U1 2
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 11
PY 2013
VL 288
IS 41
BP 29494
EP 29505
DI 10.1074/jbc.M113.471268
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 302OT
UT WOS:000330615300026
PM 23970554
ER
PT J
AU Kang, HS
Lee, S
Lee, SA
Park, JK
AF Kang, Hong Suk
Lee, Seungwoo
Lee, Sol-Ah
Park, Jung-Ki
TI Multi-Level Micro/Nanotexturing by Three-Dimensionally Controlled
Photofluidization and its Use in Plasmonic Applications
SO ADVANCED MATERIALS
LA English
DT Article
DE micro; nanotexturing; azobenzene; photofluidization; holography;
plasmonics
ID SURFACE-RELIEF GRATINGS; AZOBENZENE MATERIALS; POLYMER-FILMS;
LITHOGRAPHY; ARRAYS; ILLUMINATION
C1 [Kang, Hong Suk; Park, Jung-Ki] Korea Adv Inst Sci & Technol, Grad Sch EEWS, Taejon 305701, South Korea.
[Lee, Seungwoo] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Lee, Seungwoo] Harvard Univ, Wyss Inst Biol Inspired Engn, Harvard Med Sch, Boston, MA 02215 USA.
[Lee, Seungwoo; Lee, Sol-Ah; Park, Jung-Ki] Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Taejon 305701, South Korea.
RP Lee, S (reprint author), Harvard Univ, Dana Farber Canc Inst, Boston, MA 02215 USA.
EM seungwoo.lee@wyss.harvard.edu; jungpark@kaist.ac.kr
RI Park, Jung-Ki/C-1966-2011; Lee, Seungwoo/E-9350-2012
FU Basic Science Research Program through the National Research Foundation
of Korea (NRF); Ministry of Education, Science and Technology
[NRF-2012R1A1A2042558]; WCU program (EEWS) at KAIST
[R-31-2008-000-1005-0]
FX H. S. K and S. L. equally contributed to this work. This research was
supported by Basic Science Research Program through the National
Research Foundation of Korea (NRF) funded by the Ministry of Education,
Science and Technology (code# NRF-2012R1A1A2042558), and WCU program
(EEWS) at KAIST (code# R-31-2008-000-1005-0).
NR 34
TC 17
Z9 17
U1 4
U2 43
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD OCT 11
PY 2013
VL 25
IS 38
BP 5490
EP 5497
DI 10.1002/adma.201301715
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA 262RY
UT WOS:000327756500011
PM 23857634
ER
PT J
AU Grecco, LAC
Duarte, NDC
de Mendonca, ME
Pasini, H
Lima, VLCD
Franco, RC
de Oliveira, LVF
de Carvalho, PDC
Correa, JCF
Collange, NZ
Sampaio, LMM
Galli, M
Fregni, F
Oliveira, CS
AF Collange Grecco, Luanda Andre
Carvalho Duarte, Natalia de Almeida
de Mendonca, Mariana Emerenciano
Pasini, Hugo
Costa de Carvalho Lima, Vania Lucia
Franco, Renata Calhes
Franco de Oliveira, Luis Vicente
Camilo de Carvalho, Paulo de Tarso
Ferrari Correa, Joao Carlos
Collange, Nelci Zanon
Malosa Sampaio, Luciana Maria
Galli, Manuela
Fregni, Felipe
Oliveira, Claudia Santos
TI Effect of transcranial direct current stimulation combined with gait and
mobility training on functionality in children with cerebral palsy:
study protocol for a double-blind randomized controlled clinical trial
SO BMC PEDIATRICS
LA English
DT Article
DE Cerebral palsy; Child; Physiotherapy; Cerebral cortex; Electrical
stimulation
ID BODY-WEIGHT SUPPORT; GROSS MOTOR FUNCTION; 6-MINUTE WALK TEST; MAGNETIC
STIMULATION; OVERGROUND WALKING; PHYSICAL-ACTIVITY; AEROBIC EXERCISE;
REHABILITATION; SYSTEM; WII
AB Background: The project proposes three innovative intervention techniques (treadmill training, mobility training with virtual reality and transcranial direct current stimulation that can be safely administered to children with cerebral palsy. The combination of transcranial stimulation and physical therapy resources will provide the training of a specific task with multiple rhythmic repetitions of the phases of the gait cycle, providing rich sensory stimuli with a modified excitability threshold of the primary motor cortex to enhance local synaptic efficacy and potentiate motor learning.
Methods/design: A prospective, double-blind, randomized, controlled, analytical, clinical trial will be carried out. Eligible participants will be children with cerebral palsy classified on levels I, II and III of the Gross Motor Function Classification System between four and ten years of age. The participants will be randomly allocated to four groups: 1) gait training on a treadmill with placebo transcranial stimulation; 2) gait training on a treadmill with active transcranial stimulation; 3) mobility training with virtual reality and placebo transcranial stimulation; 4) mobility training with virtual reality and active transcranial stimulation. Transcranial direct current stimulation will be applied with the anodal electrode positioned in the region of the dominant hemisphere over C3, corresponding to the primary motor cortex, and the cathode positioned in the supraorbital region contralateral to the anode. A 1 mA current will be applied for 20 minutes. Treadmill training and mobility training with virtual reality will be performed in 30-minute sessions five times a week for two weeks (total of 10 sessions). Evaluations will be performed on four occasions: one week prior to the intervention; one week following the intervention; one month after the end of the intervention; and 3 months after the end of the intervention. The evaluations will involve three-dimensional gait analysis, analysis of cortex excitability (motor threshold and motor evoked potential), Six-Minute Walk Test, Timed Up-and-Go Test, Pediatric Evaluation Disability Inventory, Gross Motor Function Measure, Berg Balance Scale, stabilometry, maximum respiratory pressure and an effort test.
Discussion: This paper offers a detailed description of a prospective, double-blind, randomized, controlled, analytical, clinical trial aimed at demonstrating the effect combining transcranial stimulation with treadmill and mobility training on functionality and primary cortex excitability in children with Cerebral Palsy classified on Gross Motor Function Classification System levels I, II and III. The results will be published and will contribute to evidence regarding the use of treadmill training on this population.
C1 [Collange Grecco, Luanda Andre; Carvalho Duarte, Natalia de Almeida; Pasini, Hugo; Franco, Renata Calhes; Franco de Oliveira, Luis Vicente; Camilo de Carvalho, Paulo de Tarso; Ferrari Correa, Joao Carlos; Malosa Sampaio, Luciana Maria; Oliveira, Claudia Santos] Univ Nove Julho UNINOVE, Masters & Doctoral Programs Rehabil Sci, Sao Paulo, Brazil.
[de Mendonca, Mariana Emerenciano] Univ Sao Paulo, Inst Psychol, Doctoral Program, Sao Paulo, Brazil.
[Costa de Carvalho Lima, Vania Lucia] Univ Fed Sao Paulo, Masters & Doctoral Programs Commun Disordes Speec, Sao Paulo, Brazil.
[Collange, Nelci Zanon] Univ Sao Paulo, Sao Paulo, Brazil.
[Collange, Nelci Zanon] Fed Pediat Neurosurg Ctr CENEPE, Sao Paulo, Brazil.
[Galli, Manuela] Politecn Milan, Dipartimento Bioingn, I-20133 Milan, Italy.
[Fregni, Felipe] Spaulding Rehabil Hosp, Lab Neuromodulat, Boston, MA USA.
[Fregni, Felipe] Spaulding Rehabil Hosp, Ctr Clin Res Learning, Dept Phys Med & Rehabil, Boston, MA USA.
[Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Grecco, LAC (reprint author), Univ Nove Julho UNINOVE, Masters & Doctoral Programs Rehabil Sci, Sao Paulo, Brazil.
EM luandacollange@hotmail.com
RI Oliveira, Luis/K-8838-2013; Oliveira, Claudia/H-2328-2013; Sampaio,
Luciana Maria/H-9429-2016; Grecco , Luanda/N-5075-2015; Duarte,
Natalia/K-5260-2016; Moura, Renata/R-5974-2016; de Carvalho, Paulo de
Tarso/G-5333-2011
OI Oliveira, Luis/0000-0002-3852-9415; Sampaio, Luciana
Maria/0000-0002-0110-7710; Duarte, Natalia/0000-0003-1486-1330; Moura,
Renata/0000-0002-4727-2375; de Carvalho, Paulo de
Tarso/0000-0001-9624-4103
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
FX This protocol study received funding from the Conselho Nacional de
Desenvolvimento Cientifico e Tecnologico (CNPq).
NR 82
TC 10
Z9 11
U1 1
U2 27
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD OCT 11
PY 2013
VL 13
AR 168
DI 10.1186/1471-2431-13-168
PG 11
WC Pediatrics
SC Pediatrics
GA 258YJ
UT WOS:000327494300001
PM 24112817
ER
PT J
AU Shuvaev, VV
Han, JY
Tliba, S
Arguiri, E
Christofidou-Solomidou, M
Ramirez, SH
Dykstra, H
Persidsky, Y
Atochin, DN
Huang, PL
Muzykantov, VR
AF Shuvaev, Vladimir V.
Han, Jingyan
Tliba, Samira
Arguiri, Evguenia
Christofidou-Solomidou, Melpo
Ramirez, Servio H.
Dykstra, Holly
Persidsky, Yuri
Atochin, Dmitriy N.
Huang, Paul L.
Muzykantov, Vladimir R.
TI Anti-Inflammatory Effect of Targeted Delivery of SOD to Endothelium:
Mechanism, Synergism with NO Donors and Protective Effects In Vitro and
In Vivo
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; ALLEVIATES OXIDATIVE STRESS;
CELL-ADHESION MOLECULE-1; OXIDASE-DERIVED ROS; SUPEROXIDE-DISMUTASE;
NITRIC-OXIDE; INDUCED APOPTOSIS; CATALASE; ACTIVATION
AB Pro-inflammatory activation of vascular endothelium is implicated in pathogenesis of severe conditions including stroke, infarction and sepsis. We have recently reported that superoxide dismutase (SOD) conjugated with antibodies (Ab/SOD) that provide targeted delivery into endothelial endosomes mitigates inflammatory endothelial activation by cytokines and agonists of Toll-like receptors (TLR). The goal of this study was to appraise potential utility and define the mechanism of this effect. Ab/SOD, but not non-targeted SOD injected in mice alleviated endotoxin-induced leukocyte adhesion in the cerebral vasculature and protected brain from ischemia-reperfusion injury. Transfection of endothelial cells with SOD, but not catalase inhibited NF kappa B signaling and expression of Vascular Cell Adhesion Molecule-1 induced by both cytokines and TLR agonists. These results affirmed that Ab/SOD-quenched superoxide anion produced by endothelial cells in response to proinflammatory agents mediates NF kappa B activation. Furthermore, Ab/SOD potentiates anti-inflammatory effect of NO donors in endothelial cells in vitro, as well as in the endotoxin-challenged mice. These results demonstrate the central role of intracellular superoxide as a mediator of pro-inflammatory activation of endothelium and support the notion of utility of targeted interception of this signaling pathway for management of acute vascular inflammation.
C1 [Shuvaev, Vladimir V.; Han, Jingyan; Tliba, Samira; Muzykantov, Vladimir R.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA.
[Shuvaev, Vladimir V.; Han, Jingyan; Tliba, Samira; Muzykantov, Vladimir R.] Univ Penn, Inst Translat Med & Therapeut, Ctr Translat Targeted Therapeut & Nanomed, Philadelphia, PA 19104 USA.
[Arguiri, Evguenia; Christofidou-Solomidou, Melpo] Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA.
[Ramirez, Servio H.; Dykstra, Holly; Persidsky, Yuri] Temple Univ, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19122 USA.
[Atochin, Dmitriy N.; Huang, Paul L.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Atochin, Dmitriy N.; Huang, Paul L.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Atochin, Dmitriy N.; Huang, Paul L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Muzykantov, VR (reprint author), Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
RI Ramirez, Servio/F-8277-2014; Shuvaev, Vladimir/O-1719-2014; Atochin,
Dmitriy/Q-3150-2016
FU National Institutes of Health [RO1 HL073940]
FX This work was supported by the National Institutes of Health [Grant RO1
HL073940] (to V.R.M.). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 58
TC 12
Z9 13
U1 2
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 11
PY 2013
VL 8
IS 10
AR e77002
DI 10.1371/journal.pone.0077002
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 236SL
UT WOS:000325819400093
PM 24146950
ER
PT J
AU Yousuf, MA
Zhou, XH
Mukherjee, S
Chintakuntlawar, AV
Lee, JY
Ramke, M
Chodosh, J
Rajaiya, J
AF Yousuf, Mohammad A.
Zhou, Xiaohong
Mukherjee, Santanu
Chintakuntlawar, Ashish V.
Lee, Jeong Yoon
Ramke, Mirja
Chodosh, James
Rajaiya, Jaya
TI Caveolin-1 Associated Adenovirus Entry into Human Corneal Cells
SO PLOS ONE
LA English
DT Article
ID MOUTH-DISEASE VIRUS; MEDIATED ENDOCYTOSIS; LIPID RAFTS; CD46-UTILIZING
ADENOVIRUSES; MEMBRANE CHOLESTEROL; ALPHA(V) INTEGRINS; TYPE-19
INFECTION; GENE FAMILY; EARLY STEPS; HOST-CELLS
AB The cellular entry of viruses represents a critical area of study, not only for viral tropism, but also because viral entry dictates the nature of the immune response elicited upon infection. Epidemic keratoconjunctivitis (EKC), caused by viruses within human adenovirus species D (HAdV-D), is a severe, ocular surface infection associated with corneal inflammation. Clathrin-mediated endocytosis has previously been shown to play a critical role in entry of other HAdV species into many host cell types. However, HAdV-D endocytosis into corneal cells has not been extensively studied. Herein, we show an essential role for cholesterol rich, lipid raft microdomains and caveolin-1, in the entry of HAdV-D37 into primary human corneal fibroblasts. Cholesterol depletion using methyl-beta-cyclodextrin (M beta CD) profoundly reduced viral infection. When replenished with soluble cholesterol, the effect of M beta CD was reversed, allowing productive viral infection. HAdV-D37 DNA was identified in caveolin-1 rich endosomal fractions after infection. Src kinase activity was also increased in caveolin-1 rich endosomal fractions after infection, and Src phosphorylation and CXCL1 induction were both decreased in caveolin-1-/-mice corneas compared to wild type mice. siRNA knock down of caveolin-1 in corneal cells reduced chemokine induction upon viral infection, and caveolin-1-/-mouse corneas showed reduced cellular entry of HAdV-D37. As a control, HAdV-C2, a non-corneal pathogen, appeared to utilize the caveolar pathway for entry into A549 cells, but failed to infect corneal cells entirely, indicating virus and cell specific tropism. Immuno-electron microscopy confirmed the presence of caveolin-1 in HAdV-D37-containing vesicles during the earliest stages of viral entry. Collectively, these experiments indicate for the first time that HAdV-D37 uses a lipid raft mediated caveolin-1 associated pathway for entry into corneal cells, and connects the processes of viral entry with downstream proinflammatory cell signaling.
C1 [Yousuf, Mohammad A.; Zhou, Xiaohong; Mukherjee, Santanu; Chintakuntlawar, Ashish V.; Lee, Jeong Yoon; Ramke, Mirja; Chodosh, James; Rajaiya, Jaya] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
RP Rajaiya, J (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
EM jaya_rajaiya@meei.harvard.edu
FU national Institutes of Health (NIH) [EY013124, EY021558, EY014104];
Research to Prevent Blindness Senior Scientific Investigator Award; Falk
Foundation; Massachusetts Lions Eye Research Fund
FX This work was supported by national Institutes of Health (NIH) grants
EY013124, EY021558, and EY014104, a Research to Prevent Blindness Senior
Scientific Investigator Award (JC), the Falk Foundation, and the
Massachusetts Lions Eye Research Fund. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 99
TC 10
Z9 11
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 11
PY 2013
VL 8
IS 10
AR UNSP e77462
DI 10.1371/journal.pone.0077462
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 236SL
UT WOS:000325819400119
PM 24147000
ER
PT J
AU Dickerson, BC
Wolk, DA
AF Dickerson, Bradford C.
Wolk, David A.
CA Alzheimers Dis Neuroimaging Initia
TI Biomarker-based prediction of progression in MCI: comparison of AD
signature and hippocampal volume with spinal fluid amyloid-beta and tau
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE Alzheimer's disease; MRI; biomarkers; mild cognitive impairment; CSF
biomarkers
ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; CSF BIOMARKERS;
CEREBROSPINAL-FLUID; CORTICAL SIGNATURE; PROSPECTIVE COHORT; MRI;
DEMENTIA; ASSOCIATION; DIAGNOSIS
AB Objective: New diagnostic criteria for mild cognitive impairment (MCI) due to Alzheimers disease (AD) have been developed using biomarkers aiming to establish whether the clinical syndrome is likely due to underlying AD. We investigated the utility of magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers in predicting progression from amnesic MCI to dementia, testing the hypotheses that (1) markers of amyloid and neurodegeneration provide distinct and complementary prognostic information over different time intervals, and that (2) evidence of neurodegeneration in amyloid-negative MCI individuals would be useful prognostically. Methods: Data were obtained from the ADNI-1 (Alzheimers Disease Neuroimaging Initiative Phase 1) database on all individuals with a baseline diagnosis of MCI, baseline MRI and CSF data, and at least one follow-up visit. MRI data were processed using a published set of a priori regions of interest to derive a measure known as the AD signature, as well as hippocampal volume. The CSF biomarkers amyloid-beta, total tau, and phospho tau were also examined. We performed logistic regression analyses to identify the best baseline biomarker predictors of progression to dementia over 1 or 3 years, and Cox regression models to test the utility of these markers for predicting time-to-dementia. Results: For prediction of dementia in MCI, the AD signature cortical thickness biomarker performed better than hippocampal volume. Although CSF tau measures were better than CSF amyloid-beta at predicting dementia within 1 year, the AD signature was better than all CSF measures at prediction over this relatively short-term interval. CSF amyloid-beta was superior to tau and AD signature at predicting dementia over 3 years. When CSF amyloid-beta was dichotomized using previously published cutoff values and treated as a categorical variable, a multivariate stepwise Cox regression model indicated that both the AD signature MRI marker and the categorical CSF amyloid-beta marker were useful in predicting time-to-event diagnosis of AD dementia. Conclusion: In amnesic MCI, short-term (1 year) prognosis of progression to dementia relates strongly to baseline markers of neurodegeneration, with the AD signature MRI biomarker of cortical thickness performing the best among MRI and CSF markers studied here. Longer-term (3 year) prognosis in these individuals was better predicted by a marker indicative of brain amyloid. Prediction of time-to-event in a survival model was predicted by the combination of these biomarkers. These results provide further support for emerging models of the temporal relationship of pathophysiologic events in AD and demonstrate the utility of these biomarkers at the prodromal stage of the illness.
C1 [Dickerson, Bradford C.] Massachusetts Gen Hosp, Frontotemporal Dementia Unit, Boston, MA 02129 USA.
[Dickerson, Bradford C.] Harvard Univ, Sch Med, Boston, MA 02129 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02129 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
[Wolk, David A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Wolk, David A.] Univ Penn, Alzheimers Dis Core Ctr, Philadelphia, PA 19104 USA.
[Wolk, David A.] Univ Penn, Penn Memory Ctr, Philadelphia, PA 19104 USA.
RP Dickerson, BC (reprint author), Massachusetts Gen Hosp, Frontotemporal Dementia Unit, 149 13th St,Suite 2691, Boston, MA 02129 USA.
EM bradd@nmr.mgh.harvard.edu
FU Alzheimer's Disease Neuroimaging Initiative (ADNI; National Institutes
of Health) [U01 AG024904]; National Institute on Aging; National
Institute of Biomedical Imaging and Bioengineering; Alzheimer's
Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.;
Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan
Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd;
Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen
Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson
Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck Co.,
Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier;
Synarc Inc.; Takeda Pharmaceutical Company; Canadian Institutes of
Health Research; NIH [P30 AG010129, K01 AG030514]; Dana Foundation; NIA
[P50-AG005134, P30AG010124]; Alzheimer's Association
FX Data collection and sharing for this project was funded by the
Alzheimers Disease Neuroimaging Initiative (ADNI; National Institutes of
Health Grant U01 AG024904). ADNI is funded by the National Institute on
Aging, the National Institute of Biomedical Imaging and Bioengineering,
and through generous contributions from the following: Alzheimers
Association; Alzheimers Drug Discovery Foundation; BioClinica, Inc.;
Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan
Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd
and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics,
N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &
Development, LLC.; Johnson & Johnson Pharmaceutical Research &
Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale
Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals
Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and
Takeda Pharmaceutical Company. The Canadian Institutes of Health
Research is providing funds to support ADNI clinical sites in Canada.
Private sector contributions are facilitated by the Foundation for the
National Institutes of Health (www.fnih.org). The grantee organization
is the Northern California Institute for Research and Education, and the
study is coordinated by the Alzheimers Disease Cooperative Study at the
University of California, San Diego. ADNI data are disseminated by the
Laboratory for Neuro Imaging at the University of California, Los
Angeles. This research was also supported by NIH grants P30 AG010129 and
K01 AG030514. This research was also supported by NIH grants P30
AG010129, K01 AG030514, and the Dana Foundation. This analysis was also
supported by grants from the NIA P50-AG005134, P30AG010124, and the
Alzheimers Association. We thank Michael Brickhouse for his assistance
in data management and analysis.
NR 31
TC 31
Z9 33
U1 2
U2 26
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD OCT 11
PY 2013
VL 5
AR UNSP 55
DI 10.3389/fnagi.2013.00055
PG 9
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 232WY
UT WOS:000325526400001
PM 24130528
ER
PT J
AU Bauer, DE
Kamran, SC
Lessard, S
Xu, J
Fujiwara, Y
Lin, C
Shao, Z
Canver, MC
Smith, EC
Pinello, L
Sabo, PJ
Vierstra, J
Voit, RA
Yuan, GC
Porteus, MH
Stamatoyannopoulos, JA
Lettre, G
Orkin, SH
AF Bauer, Daniel E.
Kamran, Sophia C.
Lessard, Samuel
Xu, Jian
Fujiwara, Yuko
Lin, Carrie
Shao, Zhen
Canver, Matthew C.
Smith, Elenoe C.
Pinello, Luca
Sabo, Peter J.
Vierstra, Jeff
Voit, Richard A.
Yuan, Guo-Cheng
Porteus, Matthew H.
Stamatoyannopoulos, John A.
Lettre, Guillaume
Orkin, Stuart H.
TI An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines
Fetal Hemoglobin Level
SO SCIENCE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SICKLE-CELL-DISEASE; HAPLOTYPE FUSION PCR;
LYMPHOID DEVELOPMENT; COMMON DISEASE; GLOBIN; DNA; DISSECTION;
EXPRESSION; DYNAMICS
AB Genome-wide association studies (GWASs) have ascertained numerous trait-associated common genetic variants, frequently localized to regulatory DNA. We found that common genetic variation at BCL11A associated with fetal hemoglobin (HbF) level lies in noncoding sequences decorated by an erythroid enhancer chromatin signature. Fine-mapping uncovers a motif-disrupting common variant associated with reduced transcription factor (TF) binding, modestly diminished BCL11A expression, and elevated HbF. The surrounding sequences function in vivo as a developmental stage-specific, lineage-restricted enhancer. Genome engineering reveals the enhancer is required in erythroid but not B-lymphoid cells for BCL11A expression. These findings illustrate how GWASs may expose functional variants of modest impact within causal elements essential for appropriate gene expression. We propose the GWAS-marked BCL11A enhancer represents an attractive target for therapeutic genome engineering for the beta-hemoglobinopathies.
C1 [Bauer, Daniel E.; Xu, Jian; Fujiwara, Yuko; Lin, Carrie; Shao, Zhen; Smith, Elenoe C.; Orkin, Stuart H.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Bauer, Daniel E.; Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Bauer, Daniel E.; Kamran, Sophia C.; Xu, Jian; Canver, Matthew C.; Orkin, Stuart H.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Kamran, Sophia C.; Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA.
[Lessard, Samuel; Lettre, Guillaume] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Lessard, Samuel; Lettre, Guillaume] Univ Montreal, Montreal, PQ H1T 1C8, Canada.
[Pinello, Luca; Yuan, Guo-Cheng] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Sabo, Peter J.; Vierstra, Jeff; Stamatoyannopoulos, John A.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Sabo, Peter J.; Vierstra, Jeff; Stamatoyannopoulos, John A.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Voit, Richard A.; Porteus, Matthew H.] Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA.
[Yuan, Guo-Cheng] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Orkin, SH (reprint author), Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
EM stuart_orkin@dfci.harvard.edu
OI Kamran, Sophia/0000-0001-9283-6515
FU Doris Duke Charitable Foundation [2009089]; Canadian Institute of Health
Research [123382]; Amon Carter Foundation; Hyundai Hope on Wheels; NIH
[U54HG004594, U54HG007010, R01HL032259, P01HL032262, P30DK049216];
Lucille Packard Foundation; National Institute of Diabetes and Digestive
and Kidney Diseases Career Development [K08DK093705]
FX We thank A. Woo, A. Cantor, M. Kowalczyk, S. Burns, J. Wright, J. Snow,
J. Trowbridge, and members of the Orkin laboratory-particularly C. Peng,
P. Das, G. Guo, M. Kerenyi, and E. Baena-for discussions. C. Guo and F.
Alt provided the pre-B cell line; A. He and W. Pu provided the pWHERE
lacZ reporter construct; C. Currie and M. Nguyen provided technical
assistance; D. Bates and T. Kutyavin provided expertise with sequence
analysis; R. Sandstrom provided help with data management; G. Losyev and
J. Daley provided aid with flow cytometry; and J. Desimini provided
graphical assistance. L. Yan at EpigenDx (Hopkinton, Massachusetts)
conducted the custom pyrosequencing reactions. This work was funded by
grants from the Doris Duke Charitable Foundation (2009089) and Canadian
Institute of Health Research (123382) to G. L.; Amon Carter Foundation,
Hyundai Hope on Wheels, NIH, Lucille Packard Foundation to M. H. P.; NIH
grants U54HG004594 and U54HG007010 to J. A. S.; and NIH R01HL032259,
P01HL032262, and P30DK049216 (Center of Excellence in Molecular
Hematology) to S. H. O. D. E. B. is supported by National Institute of
Diabetes and Digestive and Kidney Diseases Career Development Award
K08DK093705. D. E. B., J. X., and S. H. O. are inventors on a patent
application related to this work, filed by Boston Children's Hospital.
The CSSCD samples with DNA and associated phenotype information are
available from the National Heart, Lung, and Blood Institute to
researchers that have appropriate institutional review board approval to
use the materials.
NR 37
TC 161
Z9 163
U1 9
U2 50
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD OCT 11
PY 2013
VL 342
IS 6155
BP 253
EP 257
DI 10.1126/science.1242088
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232EV
UT WOS:000325475200047
PM 24115442
ER
PT J
AU Haddad, RI
AF Haddad, Robert I.
TI How to Incorporate New Tyrosine Kinase Inhibitors in the Treatment of
Patients With Medullary Thyroid Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID CABOZANTINIB; TRIAL
C1 [Haddad, Robert I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Haddad, Robert I.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Haddad, RI (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
NR 9
TC 3
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 10
PY 2013
VL 31
IS 29
BP 3618
EP 3620
DI 10.1200/JCO.2013.51.5098
PG 3
WC Oncology
SC Oncology
GA 301NT
UT WOS:000330539700004
PM 24002516
ER
PT J
AU Elisei, R
Schlumberger, MJ
Muller, SP
Schoffski, P
Brose, MS
Shah, MH
Licitra, L
Jarzab, B
Medvedev, V
Kreissl, MC
Niederle, B
Cohen, EEW
Wirth, LJ
Ali, H
Hessel, C
Yaron, Y
Ball, D
Nelkin, B
Sherman, SI
AF Elisei, Rossella
Schlumberger, Martin J.
Mueller, Stefan P.
Schoffski, Patrick
Brose, Marcia S.
Shah, Manisha H.
Licitra, Lisa
Jarzab, Barbara
Medvedev, Viktor
Kreissl, Michael C.
Niederle, Bruno
Cohen, Ezra E. W.
Wirth, Lori J.
Ali, Haythem
Hessel, Colin
Yaron, Yifah
Ball, Douglas
Nelkin, Barry
Sherman, Steven I.
TI Cabozantinib in Progressive Medullary Thyroid Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CARCINOEMBRYONIC ANTIGEN LEVELS; ENDOTHELIAL GROWTH-FACTOR; RET
PROTOONCOGENE; PHASE-II; SOMATIC MUTATIONS; SERUM CALCITONIN; KINASE
INHIBITOR; DOUBLING-TIMES; FOLLOW-UP; CARCINOMA
AB Purpose
Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.
Patients and Methods
We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2: 1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). Additional outcome measures included tumor response rate, overall survival, and safety.
Results
The estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001). Prolonged PFS with cabozantinib was observed across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic). Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status. Kaplan-Meier estimates of patients alive and progression-free at 1 year are 47.3% for cabozantinib and 7.2% for placebo. Common cabozantinib-associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients. Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.
Conclusion
Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.
C1 [Elisei, Rossella] Univ Pisa, I-56124 Pisa, Italy.
[Licitra, Lisa] Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, I-20133 Milan, Italy.
[Schlumberger, Martin J.] Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
[Mueller, Stefan P.] Univ Klinikum Essen, Essen, Germany.
[Kreissl, Michael C.] Univ Klinikum Wurzburg, Wurzburg, Germany.
[Schoffski, Patrick] Katholieke Univ Leuven Hosp, Louvain, Belgium.
[Brose, Marcia S.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Shah, Manisha H.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Jarzab, Barbara] Inst Marii Sklodowskiej Curie Oddzial Gliwicach, Ctr Onkol, Gliwice, Poland.
[Medvedev, Viktor] Russian Acad Med Sci, Med Radiol Res Ctr, Obninsk, Russia.
[Niederle, Bruno] Med Univ Wien, Vienna, Austria.
[Cohen, Ezra E. W.] Univ Chicago, Chicago, IL 60637 USA.
[Wirth, Lori J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ali, Haythem] Henry Ford Hlth Syst, Detroit, MI USA.
[Hessel, Colin; Yaron, Yifah] Exelixis, San Francisco, CA USA.
[Ball, Douglas; Nelkin, Barry] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Sherman, Steven I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP Elisei, R (reprint author), Univ Pisa, Dept Endocrinol, Via Paradisa 2, I-56124 Pisa, Italy.
EM rossella.elisei@med.unipi.it
RI Licitra, Lisa/C-6271-2017;
OI Licitra, Lisa/0000-0003-0623-4118; Sherman, Steven/0000-0002-3079-5153;
Niederle, Bruno/0000-0001-8107-4068
FU Exelixis; Eisai; Bayer; Douglas Ball
FX Rossella Elisei, Exelixis; Martin J. Schlumberger, Exelixis; Marcia S.
Brose, Exelixis; Manisha H. Shah, Exelixis, Eisai, Bayer; Viktor
Medvedev, Exelixis; Douglas Ball, Exelixis
NR 37
TC 234
Z9 243
U1 1
U2 26
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 10
PY 2013
VL 31
IS 29
BP 3639
EP +
DI 10.1200/JCO.2012.48.4659
PG 9
WC Oncology
SC Oncology
GA 301NT
UT WOS:000330539700008
PM 24002501
ER
PT J
AU San-Miguel, JF
Richardson, PG
Gunther, A
Sezer, O
Siegel, D
Blade, J
LeBlanc, R
Sutherland, H
Sopala, M
Mishra, KK
Mu, S
Bourquelot, PM
Mateos, MV
Anderson, KC
AF San-Miguel, Jesus F.
Richardson, Paul G.
Guenther, Andreas
Sezer, Orhan
Siegel, David
Blade, Joan
LeBlanc, Richard
Sutherland, Heather
Sopala, Monika
Mishra, Kaushal K.
Mu, Song
Bourquelot, Priscille M.
Victoria Mateos, Maria
Anderson, Kenneth C.
TI Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed
and Refractory Multiple Myeloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID LENALIDOMIDE PLUS DEXAMETHASONE; INHIBITOR PANOBINOSTAT; DEACETYLASE
INHIBITORS; WORKING GROUP; SINGLE-AGENT; COMBINATION; PREDNISONE;
PROTEASOME; MELPHALAN; CRITERIA
AB Purpose
Despite advancements, prognosis for patients with relapsed/refractory multiple myeloma (MM) is poor, and novel therapies are needed. Panobinostat is a potent deacetylase inhibitor that elicits synergistic effects on MM cells in combination with bortezomib. This phase Ib study sought to determine the maximum-tolerated dose (MTD) of panobinostat plus bortezomib in patients with relapsed or relapsed and refractory MM.
Patients and Methods
In the dose-escalation phase (n = 47), panobinostat was administered orally thrice weekly every week in combination with bortezomib (21-day cycles). After MTD determination, patients were evaluated in an expansion phase (n = 15) that incorporated a 1-week treatment holiday of panobinostat, with dexamethasone added in cycle 2. Additional assessments included safety, pharmacokinetics, and efficacy per International Myeloma Working Group criteria.
Results
The MTD was established at panobinostat 20 mg plus bortezomib 1.3 mg/m(2). Grade 3 or 4 adverse events (AEs) included thrombocytopenia (85.1%), neutropenia (63.8%), and asthenia (29.8%) in the escalation phase, and thrombocytopenia (66.7%), neutropenia (46.7%), and fatigue (20.0%) in the expansion phase. At MTD in the escalation phase, eight patients (47.1%) discontinued therapy as a result of AEs, whereas five patients (33.3%) discontinued treatment in the expansion phase. Expansion phase patients demonstrated greater median treatment duration. Overall response rate (ORR) was 73.3% in the expansion phase and 52.9% at the escalation phase MTD. Among bortezomib-refractory patients, the ORR was 26.3%, and 42.1% of patients had minimal response.
Conclusion
The MTD of panobinostat plus bortezomib was determined and demonstrated activity in patients with relapsed or relapsed/refractory MM, including bortezomib-refractory patients. A phase II/III clinical trial program (Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma [PANORAMA]) has been initiated.
C1 [San-Miguel, Jesus F.; Victoria Mateos, Maria] Univ Salamanca, Spanish Natl Res Council, Inst Bil Mol Barcelona, Inst Invest Biomed Salamanca,Hosp Univ Salamanca, E-37008 Salamanca, Spain.
[Blade, Joan] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.
[Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Siegel, David] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Mishra, Kaushal K.; Mu, Song] Novartis Pharmaceut, E Hanover, NJ USA.
[Guenther, Andreas] Univ Kiel, Kiel, Germany.
[Sezer, Orhan] Charite, D-13353 Berlin, Germany.
[LeBlanc, Richard] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada.
[Sutherland, Heather] Vancouver Gen Hosp, Vancouver, BC, Canada.
[Sopala, Monika; Bourquelot, Priscille M.] Novartis Pharma AG, Basel, Switzerland.
RP San-Miguel, JF (reprint author), Hosp Univ Salamanca, Paseo San Vicente 58-182, Salamanca 37007, Spain.
EM sanmigiz@usal.es
OI Sopala, Monika/0000-0001-9587-7953; SAN MIGUEL,
JESUS/0000-0002-9183-4857
FU Novartis; Janssen-Ortho
FX Andreas Gunther, Novartis; Orhan Sezer, Janssen-Ortho, Novartis; Joan
Blade, Janssen-Ortho
NR 35
TC 72
Z9 73
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 10
PY 2013
VL 31
IS 29
BP 3696
EP +
DI 10.1200/JCO.2012.46.7068
PG 15
WC Oncology
SC Oncology
GA 301NT
UT WOS:000330539700018
PM 24019544
ER
PT J
AU Di Saverio, S
Coccolini, F
Galati, M
Smerieri, N
Biffl, WL
Ansaloni, L
Tugnoli, G
Velmahos, GC
Sartelli, M
Bendinelli, C
Fraga, GP
Kelly, MD
Moore, FA
Mandala, V
Mandala, S
Masetti, M
Jovine, E
Pinna, AD
Peitzman, AB
Leppaniemi, A
Sugarbaker, PH
Van Goor, H
Moore, EE
Jeekel, J
Catena, F
AF Di Saverio, Salomone
Coccolini, Federico
Galati, Marica
Smerieri, Nazareno
Biffl, Walter L.
Ansaloni, Luca
Tugnoli, Gregorio
Velmahos, George C.
Sartelli, Massimo
Bendinelli, Cino
Fraga, Gustavo Pereira
Kelly, Michael D.
Moore, Frederick A.
Mandala, Vincenzo
Mandala, Stefano
Masetti, Michele
Jovine, Elio
Pinna, Antonio D.
Peitzman, Andrew B.
Leppaniemi, Ari
Sugarbaker, Paul H.
Van Goor, Harry
Moore, Ernest E.
Jeekel, Johannes
Catena, Fausto
TI Bologna guidelines for diagnosis and management of adhesive small bowel
obstruction (ASBO): 2013 update of the evidence-based guidelines from
the world society of emergency surgery ASBO working group
SO WORLD JOURNAL OF EMERGENCY SURGERY
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; UNSUCCESSFUL CONSERVATIVE TREATMENT;
POSTOPERATIVE ABDOMINAL ADHESIONS; SOLUBLE CONTRAST-MEDIUM; LAPAROSCOPIC
ADHESIOLYSIS; BIORESORBABLE MEMBRANE; INTESTINAL-OBSTRUCTION;
CLINICAL-TRIAL; ANIMAL-MODEL; HELICAL CT
AB Background: In 2013 Guidelines on diagnosis and management of ASBO have been revised and updated by the WSES Working Group on ASBO to develop current evidence-based algorithms and focus indications and safety of conservative treatment, timing of surgery and indications for laparoscopy.
Recommendations: In absence of signs of strangulation and history of persistent vomiting or combined CT-scan signs (free fluid, mesenteric edema, small-bowel feces sign, devascularization) patients with partial ASBO can be managed safely with NOM and tube decompression should be attempted. These patients are good candidates for Water-Soluble-Contrast-Medium (WSCM) with both diagnostic and therapeutic purposes. The radiologic appearance of WSCM in the colon within 24 hours from administration predicts resolution. WSCM maybe administered either orally or via NGT both immediately at admission or after failed conservative treatment for 48 hours. The use of WSCM is safe and reduces need for surgery, time to resolution and hospital stay.
NOM, in absence of signs of strangulation or peritonitis, can be prolonged up to 72 hours. After 72 hours of NOM without resolution, surgery is recommended.
Patients treated non-operatively have shorter hospital stay, but higher recurrence rate and shorter time to readmission, although the risk of new surgically treated episodes of ASBO is unchanged. Risk factors for recurrences are age <40 years and matted adhesions. WSCM does not decrease recurrence rates or recurrences needing surgery.
Open surgery is often used for strangulating ASBO as well as after failed conservative management. In selected patients and with appropriate skills, laparoscopic approach is advisable using open access technique. Access in left upper quadrant or left flank is the safest and only completely obstructing adhesions should be identified and lysed with cold scissors. Laparoscopic adhesiolysis should be attempted preferably if first episode of SBO and/or anticipated single band. A low threshold for open conversion should be maintained.
Peritoneal adhesions should be prevented. Hyaluronic acid-carboxycellulose membrane and icodextrin decrease incidence of adhesions. Icodextrin may reduce the risk of re-obstruction. HA cannot reduce need of surgery. Adhesions quantification and scoring maybe useful for achieving standardized assessment of adhesions severity and for further research in diagnosis and treatment of ASBO.
C1 [Di Saverio, Salomone; Galati, Marica; Smerieri, Nazareno; Tugnoli, Gregorio; Masetti, Michele; Jovine, Elio] Maggiore Hosp Trauma Ctr, Emergency & Trauma Surg Unit, Dept Emergency, Bologna, Italy.
[Di Saverio, Salomone; Galati, Marica; Smerieri, Nazareno; Tugnoli, Gregorio; Masetti, Michele; Jovine, Elio] Maggiore Hosp Trauma Ctr, Emergency & Trauma Surg Unit, Dept Surg, Bologna, Italy.
[Pinna, Antonio D.; Catena, Fausto] S Orsola Malpighi Univ Hosp, Dept Gen & Multivisceral Transplant Surg, Emergency Surg Unit, Bologna, Italy.
[Kelly, Michael D.] NHS Trust, Frenchay Hosp, Dept Surg, Upper GI Unit, Bristol, Avon, England.
[Biffl, Walter L.; Moore, Ernest E.] Univ Colorado Hlth Sci Denver, Denver Hlth Med Ctr, Denver Hlth, Dept Surg, Denver, CO 80204 USA.
[Coccolini, Federico; Ansaloni, Luca] Osped Riuniti Bergamo, I-24100 Bergamo, Italy.
[Mandala, Vincenzo; Mandala, Stefano] Associated Hosp Villa Sofia Cervello, Dept Gen & Emergency Surg, Palermo, Italy.
[Velmahos, George C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA.
[Sartelli, Massimo] Macerata Hosp, Dept Surg, I-62100 Macerata, Italy.
[Sugarbaker, Paul H.] Washington Hosp Ctr, Washington Canc Inst, Washington, DC 20010 USA.
[Van Goor, Harry] Radboud Univ Nijmegen, Med Ctr, Dept Surg, NL-6525 ED Nijmegen, Netherlands.
[Moore, Frederick A.] Univ Florida, Dept Surg, Gainesville, FL 32610 USA.
[Jeekel, Johannes] Erasmus MC, Dept Surg, Rotterdam, Netherlands.
[Bendinelli, Cino] John Hunter Hosp, Dept Surg, Newcastle, NSW 2310, Australia.
[Bendinelli, Cino] Univ Newcastle, Locke Bag Hunter Reg Maile Ctr 1, Newcastle, NSW 2310, Australia.
[Catena, Fausto] Maggiore Hosp Parma, Dept Emergency & Trauma Surg, Parma, Italy.
[Leppaniemi, Ari] Univ Helsinki, Meilahti Hosp, Dept Abdominal Surg, FIN-00029 Helsinki, Hus, Finland.
[Peitzman, Andrew B.] Univ Pittsburgh Phys, Div Gen Surg, Pittsburgh, PA 15213 USA.
[Fraga, Gustavo Pereira] Univ Estadual Campinas, Div Trauma Surg, Campinas, SP, Brazil.
RP Catena, F (reprint author), S Orsola Malpighi Univ Hosp, Dept Gen & Multivisceral Transplant Surg, Emergency Surg Unit, Bologna, Italy.
EM faustocatena@gmail.com
RI Goor, H./H-8035-2014;
OI Ansaloni, Luca/0000-0001-6427-0307; Di Saverio,
Salomone/0000-0001-5685-5022
NR 102
TC 30
Z9 31
U1 3
U2 22
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-7922
J9 WORLD J EMERG SURG
JI World J. Emerg. Surg.
PD OCT 10
PY 2013
VL 8
AR 42
DI 10.1186/1749-7922-8-42
PG 14
WC Emergency Medicine; Surgery
SC Emergency Medicine; Surgery
GA 262FY
UT WOS:000327720900001
PM 24112637
ER
PT J
AU Kulkarni-Datar, K
Orsulic, S
Foster, R
Rueda, BR
AF Kulkarni-Datar, Kashmira
Orsulic, Sandra
Foster, Rosemary
Rueda, Bo R.
TI Ovarian tumor initiating cell populations persist following paclitaxel
and carboplatin chemotherapy treatment in vivo
SO CANCER LETTERS
LA English
DT Article
DE Ovarian cancer tumor initiating cells; Sca-1 cells; CD133 cells
ID CANCER STEM-CELLS; GYNECOLOGIC-ONCOLOGY-GROUP; CISPLATIN TREATMENT;
PROSTATE-CANCER; CARCINOMA; SURVIVAL; CD133; CHEMORESISTANCE;
RESISTANCE; EXPRESSION
AB Development of recurrent platinum resistant disease following chemotherapy presents a challenge in managing ovarian cancer. Using tumors derived from genetically defined mouse ovarian cancer cells, we investigated the stem cell properties of residual cells post-chemotherapy. Utilizing CD133 and Sca-1 as markers of candidate tumor initiating cells (TIC), we determined that the relative levels of CD133(+) and sca-1(+) cells were unaltered following chemotherapy. CD133(+) and Sca-1(+) cells exhibited increased stem cell-related gene expression, were enriched in G(0)/G(1)-early S phase and exhibited increased tumor initiating capacity, giving rise to heterogeneous tumors. Our findings suggest that residual TICs may contribute to recurrent disease. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Kulkarni-Datar, Kashmira; Foster, Rosemary; Rueda, Bo R.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Vincent Obstet & Gynecol, Boston, MA 02114 USA.
[Kulkarni-Datar, Kashmira; Foster, Rosemary; Rueda, Bo R.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Orsulic, Sandra] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
RP Rueda, BR (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Vincent Obstet & Gynecol, Boston, MA 02114 USA.
EM brueda@partners.org
FU Advanced Medical Research Foundation; Vincent Memorial Research Funds
FX This research was funded in part by grants from the Advanced Medical
Research Foundation (BRR) and the Vincent Memorial Research Funds (BRR).
NR 63
TC 7
Z9 7
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD OCT 10
PY 2013
VL 339
IS 2
BP 237
EP 246
DI 10.1016/j.canlet.2013.06.014
PG 10
WC Oncology
SC Oncology
GA 229YO
UT WOS:000325304000010
PM 23791886
ER
PT J
AU Andrews, JR
Lawn, SD
Dowdy, DW
Walensky, RP
AF Andrews, Jason R.
Lawn, Stephen D.
Dowdy, David W.
Walensky, Rochelle P.
TI Challenges in Evaluating the Cost-effectiveness of New Diagnostic Tests
for HIV-Associated Tuberculosis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE tuberculosis; HIV; diagnostics; cost-effectiveness; health policy
ID NEGATIVE PULMONARY TUBERCULOSIS; ANTIRETROVIRAL THERAPY; SOUTH-AFRICA;
HEALTH IMPACT; CARE; POINT; LIPOARABINOMANNAN; CULTURE; ADULTS; URINE
AB With an emerging array of rapid diagnostic tests for tuberculosis, cost-effectiveness analyses are needed to inform scale-up in various populations and settings. Human immunodeficiency virus (HIV)-associated tuberculosis poses unique challenges in estimating and interpreting the cost-effectiveness of novel diagnostic tools. First, gains in sensitivity and specificity do not directly correlate with impact on clinical outcomes. Second, the cost-effectiveness of implementing tuberculosis diagnostics in HIV-infected populations is heavily influenced by downstream costs of HIV care. As a result, tuberculosis diagnostics may appear less cost-effective in this population than among HIV-uninfected individuals, raising important ethical and policy questions about the design and interpretation of cost-effectiveness analyses in this setting. Third, conventional cost-effectiveness benchmarks may be inadequate for making decisions about whether to adopt new diagnostics. If we are to appropriately deploy novel diagnostics for tuberculosis to people living with HIV in resource-constrained settings, these challenges in measuring cost-effectiveness must be more widely recognized and addressed.
C1 [Andrews, Jason R.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Andrews, Jason R.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Dept Med, Boston, MA 02114 USA.
[Lawn, Stephen D.] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7700 Rondebosch, South Africa.
[Lawn, Stephen D.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1E 7HT, England.
[Dowdy, David W.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Dowdy, David W.] Johns Hopkins Univ, Ctr TB Res, Baltimore, MD USA.
RP Andrews, JR (reprint author), Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 9th Floor,50 Staniford St, Boston, MA 02114 USA.
EM jandrews6@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X; Andrews,
Jason/0000-0002-5967-251X
FU National Institute of Allergy and Infectious Diseases [R01 AI093269, R01
AI058736, T32AI007433]; Harvard Global Health Institute; Wellcome Trust,
London, UK
FX This work was supported by the National Institute of Allergy and
Infectious Diseases (grant numbers R01 AI093269, R01 AI058736, and
T32AI007433) and the Harvard Global Health Institute. S. D. L. is funded
by the Wellcome Trust, London, UK.
NR 46
TC 7
Z9 7
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 10
PY 2013
VL 57
IS 7
BP 1021
EP 1026
DI 10.1093/cid/cit412
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 239LX
UT WOS:000326027400015
PM 23788239
ER
PT J
AU Goodson, JM
Tavares, M
Wang, XS
Niederman, R
Cugini, M
Hasturk, H
Barake, R
Alsmadi, O
Al-Mutawa, S
Ariga, J
Soparkar, P
Behbehani, J
Behbehani, K
AF Goodson, J. Max
Tavares, Mary
Wang, Xiaoshan
Niederman, Richard
Cugini, Maryann
Hasturk, Hatice
Barake, Roula
Alsmadi, Osama
Al-Mutawa, Sabiha
Ariga, Jitendra
Soparkar, Pramod
Behbehani, Jawad
Behbehani, Kazem
TI Obesity and Dental Decay: Inference on the Role of Dietary Sugar
SO PLOS ONE
LA English
DT Article
ID NUTRITIONAL-STATUS; KUWAITI CHILDREN; US CHILDREN; CARIES; ASSOCIATION;
SCHOOLCHILDREN; ADOLESCENTS; OVERWEIGHT; RATES
AB Objective: To evaluate the relationship of children's obesity and dental decay.
Methods: We measured parameters related to obesity and dental decay in 8,275 4th and 5th grade Kuwaiti children (average age=11.36 years) in a cross-sectional study. First to determine body weight, height, age for computation of BMI. Second, to determine numbers of teeth, numbers of fillings and numbers of untreated decayed teeth to determine extent and severity of dental disease. From these measurements, we computed measures of dental decay in children from four body weight categories; obese, overweight, normal healthy weight and underweight children.
Results: The percentage of children with decayed or filled teeth varied inversely with the body weight category. The percentage of decayed or filled teeth decreased from 15.61% (n=193) in underweight children, to 13.03% (n=4,094) in normal healthy weight children, to 9.73% (n=1,786) in overweight children to 7.87% (n=2,202) in obese children. Differences between all groups were statistically significant. Male children in this population had more dental decay than female children but the reduction of tooth decay as a function of BMI was greater in male children.
Conclusions: The finding of an inverse obesity-dental decay relationship contradicts the obesity-sugar and the obesity-dental decay relationship hypotheses. Sugar is well recognized as necessary and sufficient for dental decay. Sugar is also hypothesized to be a leading co-factor in obesity. If the later hypothesis is true, one would expect dental decay to increase with obesity. This was not found. The reasons for this inverse relationship are not currently clear.
C1 [Goodson, J. Max; Tavares, Mary; Wang, Xiaoshan; Niederman, Richard; Cugini, Maryann; Hasturk, Hatice; Soparkar, Pramod] Forsyth Inst, Cambridge, MA USA.
[Barake, Roula] Dasman Diabet Inst, Nutr Serv, Kuwait, Kuwait.
[Alsmadi, Osama; Behbehani, Kazem] Dasman Diabet Inst, Kuwait, Kuwait.
[Al-Mutawa, Sabiha] Minist Hlth, Kuwait, Kuwait.
[Ariga, Jitendra] Minist Hlth, Sch Oral Hlth Program, Kuwait, Kuwait.
[Behbehani, Jawad] Kuwait Univ, Fac Dent, Kuwait, Kuwait.
RP Goodson, JM (reprint author), Forsyth Inst, Cambridge, MA USA.
EM mgoodson@forsyth.org
RI Wang, Xiaoshan/D-6292-2014
OI Wang, Xiaoshan/0000-0002-6760-5456
FU Dasman Institute, Kuwait
FX This work was funded by the Dasman Institute, Kuwait. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 20
TC 6
Z9 6
U1 2
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2013
VL 8
IS 10
AR e74461
DI 10.1371/journal.pone.0074461
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 236QM
UT WOS:000325814200001
PM 24130667
ER
PT J
AU Elmariah, SB
Lerner, EA
AF Elmariah, Sarina B.
Lerner, Ethan A.
TI The Missing Link between Itch and Inflammation in Atopic Dermatitis
SO CELL
LA English
DT Editorial Material
ID THYMIC STROMAL LYMPHOPOIETIN; SKIN; MICE
AB Atopic dermatitis is a common skin disease with high morbidity and is associated with severe itch and chronic skin inflammation. In this issue of Cell, Wilson et al. demonstrate that epithelial cells communicate directly with cutaneous sensory neurons via a cytokine to induce itch.
C1 [Elmariah, Sarina B.; Lerner, Ethan A.] Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.
[Elmariah, Sarina B.; Lerner, Ethan A.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Elmariah, SB (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.
EM sbelmariah@partners.org
FU NIAMS NIH HHS [R01AR057744, R01 AR057744]
NR 11
TC 7
Z9 7
U1 0
U2 25
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD OCT 10
PY 2013
VL 155
IS 2
BP 267
EP 269
DI 10.1016/j.cell.2013.09.038
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 235LH
UT WOS:000325719800002
PM 24120126
ER
PT J
AU Israelsen, WJ
Dayton, TL
Davidson, SM
Fiske, BP
Hosios, AM
Bellinger, G
Li, J
Yu, YM
Sasaki, M
Horner, JW
Burga, LN
Xie, JX
Jurczak, MJ
DePinho, RA
Clish, CB
Jacks, T
Kibbey, RG
Wulf, GM
Di Vizio, D
Mills, GB
Cantley, LC
Vander Heiden, MG
AF Israelsen, William J.
Dayton, Talya L.
Davidson, Shawn M.
Fiske, Brian P.
Hosios, Aaron M.
Bellinger, Gary
Li, Jie
Yu, Yimin
Sasaki, Mika
Horner, James W.
Burga, Laura N.
Xie, Jianxin
Jurczak, Michael J.
DePinho, Ronald A.
Clish, Clary B.
Jacks, Tyler
Kibbey, Richard G.
Wulf, Gerburg M.
Di Vizio, Dolores
Mills, Gordon B.
Cantley, Lewis C.
Vander Heiden, Matthew G.
TI PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for
Pyruvate Kinase in Tumor Cells
SO CELL
LA English
DT Article
ID GENE-TRANSCRIPTION; HNRNP PROTEINS; M2 ISOFORM; CANCER; GROWTH;
METABOLISM; PROMOTES; ACTIVATION; MICE; PHOSPHORYLATION
AB The pyruvate kinase M2 isoform (PKM2) is expressed in cancer and plays a role in regulating anabolic metabolism. To determine whether PKM2 is required for tumor formation or growth, we generated mice with a conditional allele that abolishes PKM2 expression without disrupting PKM1 expression. PKM2 deletion accelerated mammary tumor formation in a Brca1-loss-driven model of breast cancer. PKM2 null tumors displayed heterogeneous PKM1 expression, with PKM1 found in nonproliferating tumor cells and no detectable pyruvate kinase expression in proliferating cells. This suggests that PKM2 is not necessary for tumor cell proliferation and implies that the inactive state of PKM2 is associated with the proliferating cell population within tumors, whereas nonproliferating tumor cells require active pyruvate kinase. Consistent with these findings, variable PKM2 expression and heterozygous PKM2 mutations are found in human tumors. These data suggest that regulation of PKM2 activity supports the different metabolic requirements of proliferating and nonproliferating tumor cells.
C1 [Israelsen, William J.; Dayton, Talya L.; Davidson, Shawn M.; Fiske, Brian P.; Hosios, Aaron M.; Bellinger, Gary; Yu, Yimin; Jacks, Tyler; Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Li, Jie; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
[Sasaki, Mika; Burga, Laura N.; Wulf, Gerburg M.; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Dept Med, Boston, MA 02115 USA.
[Horner, James W.; DePinho, Ronald A.; Vander Heiden, Matthew G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Xie, Jianxin] Cell Signaling Technol, Danvers, MA 01923 USA.
[Jurczak, Michael J.; Kibbey, Richard G.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Clish, Clary B.] Broad Inst, Cambridge, MA 02142 USA.
[Kibbey, Richard G.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA.
[Di Vizio, Dolores] Cedars Sinai Med Ctr, Div Canc Biol & Therapeut, Los Angeles, CA 90048 USA.
[Di Vizio, Dolores] Boston Childrens Hosp, Urol Dis Res Ctr, Boston, MA 02115 USA.
[Di Vizio, Dolores] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Vander Heiden, MG (reprint author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM mvh@mit.edu
RI Cantley, Lewis/D-1800-2014
OI Cantley, Lewis/0000-0002-1298-7653
FU NIH [R01CA168653, 5P01CA117969, P30CA147882, 5P30CA14051, 5K08CA136983,
DK059635, R01DK092606, R00CA131472, R01GM056203]; ADA grant
[7-12-BS-09]; Belfer Foundation; Smith Family Foundation; Burroughs
Wellcome Fund; Damon Runyon Cancer Research Foundation; Stern family
FX We thank Chu-Xia Deng for sharing the BRCA1 mouse model; Luigi
Terracciano and Luigi Tornillo for providing the multitissue TMA; and
Cynthia Clower, Sarah-Maria Fendt, Andrea J. Howell, Vivian M. Liu,
Sophia Lunt, Katherine R. Mattaini, Benjamin A. Olenchock, and Kerry
Pierce for technical assistance. Eric L. Bell provided advice and
reagents. Denise G. Crowley, Michael Brown, and Kathleen S. Cormier
assisted with histology. This work was supported, in part, by NIH grants
R01CA168653, 5P01CA117969, P30CA147882, 5P30CA14051, 5K08CA136983,
DK059635, R01DK092606, R00CA131472, and R01GM056203 and ADA grant
7-12-BS-09. R.A.D. and J.W.H. acknowledge support from the Belfer
Foundation. M.G.V.H. acknowledges additional support from the Smith
Family Foundation, the Burroughs Wellcome Fund, the Damon Runyon Cancer
Research Foundation, and the Stern family. C.B.C. is a shareholder in
Agios Pharmaceuticals. M.G.V.H. is a shareholder and Scientific Advisory
Board member at Agios Pharmaceuticals. L.C.C. owns equity in and
receives compensation from Agios Pharmaceuticals and serves on the Board
of Directors and Scientific Advisory Board.
NR 43
TC 109
Z9 113
U1 4
U2 58
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD OCT 10
PY 2013
VL 155
IS 2
BP 397
EP 409
DI 10.1016/j.cell.2013.09.025
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 235LH
UT WOS:000325719800016
PM 24120138
ER
PT J
AU Brennan, CW
Verhaak, RGW
McKenna, A
Campos, B
Noushmehr, H
Salama, SR
Zheng, SY
Chakravarty, D
Sanborn, JZ
Berman, SH
Beroukhim, R
Bernard, B
Wu, CJ
Genovese, G
Shmulevich, I
Barnholtz-Sloan, J
Zou, LH
Vegesna, R
Shukla, SA
Ciriello, G
Yung, WK
Zhang, W
Sougnez, C
Mikkelsen, T
Aldape, K
Bigner, DD
Van Meir, EG
Prados, M
Sloan, A
Black, KL
Eschbacher, J
Finocchiaro, G
Friedman, W
Andrews, DW
Guha, A
Iacocca, M
O'Neill, BP
Foltz, G
Myers, J
Weisenberger, DJ
Penny, R
Kucherlapati, R
Perou, CM
Hayes, DN
Gibbs, R
Marra, M
Mills, GB
Lander, E
Spellman, P
Wilson, R
Sander, C
Weinstein, J
Meyerson, M
Gabriel, S
Laird, PW
Haussler, D
Getz, G
Chin, L
AF Brennan, Cameron W.
Verhaak, Roel G. W.
McKenna, Aaron
Campos, Benito
Noushmehr, Houtan
Salama, Sofie R.
Zheng, Siyuan
Chakravarty, Debyani
Sanborn, J. Zachary
Berman, Samuel H.
Beroukhim, Rameen
Bernard, Brady
Wu, Chang-Jiun
Genovese, Giannicola
Shmulevich, Ilya
Barnholtz-Sloan, Jill
Zou, Lihua
Vegesna, Rahulsimham
Shukla, Sachet A.
Ciriello, Giovanni
Yung, W. K.
Zhang, Wei
Sougnez, Carrie
Mikkelsen, Tom
Aldape, Kenneth
Bigner, Darell D.
Van Meir, Erwin G.
Prados, Michael
Sloan, Andrew
Black, Keith L.
Eschbacher, Jennifer
Finocchiaro, Gaetano
Friedman, William
Andrews, David W.
Guha, Abhijit
Iacocca, Mary
O'Neill, Brian P.
Foltz, Greg
Myers, Jerome
Weisenberger, Daniel J.
Penny, Robert
Kucherlapati, Raju
Perou, Charles M.
Hayes, D. Neil
Gibbs, Richard
Marra, Marco
Mills, Gordon B.
Lander, Eric
Spellman, Paul
Wilson, Richard
Sander, Chris
Weinstein, John
Meyerson, Matthew
Gabriel, Stacey
Laird, Peter W.
Haussler, David
Getz, Gad
Chin, Lynda
CA TCGA Res Network
TI The Somatic Genomic Landscape of Glioblastoma
SO CELL
LA English
DT Article
ID COPY-NUMBER ALTERATION; DRIVER MUTATIONS; HUMAN CANCERS; GRADE GLIOMA;
TUMORS; EGFR; EXPRESSION; MELANOMA; PATHWAYS; SURVIVAL
AB We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer.
C1 [Brennan, Cameron W.; Chakravarty, Debyani; Berman, Samuel H.] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
[Brennan, Cameron W.] Weill Cornell Med Ctr, Dept Neurol Surg, Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA.
[Verhaak, Roel G. W.; Zheng, Siyuan; Vegesna, Rahulsimham; Weinstein, John] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
[McKenna, Aaron; Beroukhim, Rameen; Zou, Lihua; Sougnez, Carrie; Lander, Eric; Meyerson, Matthew; Gabriel, Stacey; Getz, Gad; Chin, Lynda] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA 02142 USA.
[Campos, Benito; Beroukhim, Rameen; Shukla, Sachet A.; Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Campos, Benito] Univ Heidelberg Hosp, Dept Neurosurg, Div Expt Neurosurg, D-69120 Heidelberg, Germany.
[Noushmehr, Houtan; Weisenberger, Daniel J.; Laird, Peter W.] Univ So Calif, Keck Sch Med, Univ Southern Calif Epigenome Ctr, Los Angeles, CA 90033 USA.
[Noushmehr, Houtan] Univ Sao Paulo, Fac Med Ribeirao Preto, Ctr Integrat Syst Biol, Dept Genet, BR-14049900 Sao Paulo, Brazil.
[Salama, Sofie R.; Sanborn, J. Zachary; Haussler, David] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.
[Salama, Sofie R.; Sanborn, J. Zachary; Haussler, David] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA.
[Bernard, Brady; Shmulevich, Ilya] Inst Syst Biol, Seattle, WA 98109 USA.
[Verhaak, Roel G. W.; Wu, Chang-Jiun; Genovese, Giannicola; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
[Barnholtz-Sloan, Jill] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
[Ciriello, Giovanni; Sander, Chris] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10065 USA.
[Yung, W. K.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.
[Zhang, Wei; Aldape, Kenneth] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
[Mikkelsen, Tom] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA.
[Mikkelsen, Tom] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
[Bigner, Darell D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Van Meir, Erwin G.] Emory Univ, Winship Canc Inst, Dept Neurosurg, Atlanta, GA 30322 USA.
[Van Meir, Erwin G.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
[Van Meir, Erwin G.] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
[Prados, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.
[Sloan, Andrew] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Neurosurg, Cleveland, OH 44106 USA.
[Black, Keith L.] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA.
[Eschbacher, Jennifer] St Josephs Hosp, Dept Pathol, Phoenix, AZ 85013 USA.
[Finocchiaro, Gaetano] Ist Neurol Besta, Dept Neurooncol, I-20133 Milan, Italy.
[Friedman, William] Univ Florida, Dept Neurosurg, Gainesville, FL 32610 USA.
[Andrews, David W.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA.
[Guha, Abhijit] Toronto Western Hosp, Dept Neurosurg, Toronto, ON M5T 2S8, Canada.
[Iacocca, Mary] Helen F Graham Canc Ctr, Christiana Care, Dept Pathol, Newark, DE 19713 USA.
[O'Neill, Brian P.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
[O'Neill, Brian P.] Mayo Clin, Ctr Canc, Rochester, MN 55905 USA.
[Foltz, Greg] Swedish Neurosci Inst, Ivy Brain Tumor Ctr, Seattle, WA 98122 USA.
[Myers, Jerome] Penrose St Francis Hlth Serv, Dept Pathol, Colorado Springs, CO 80907 USA.
[Penny, Robert] Int Genom Consortium, Phoenix, AZ 85004 USA.
[Kucherlapati, Raju] Brigham & Womens Hosp, Boston, MA 02215 USA.
[Kucherlapati, Raju] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Perou, Charles M.; Hayes, D. Neil] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Gibbs, Richard] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Marra, Marco] BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4S6, Canada.
[Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
[Spellman, Paul] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
[Wilson, Richard] Washington Univ, Genome Inst, St Louis, MO 63110 USA.
[Haussler, David] Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA.
RP Brennan, CW (reprint author), Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
EM cbrennan@mskcc.org; lchin@mdanderson.org
RI Schumacher, Steven/E-9821-2013; Noushmehr, Houtan/C-9692-2013; Tang,
Macy/B-9798-2014; Laird, Peter/G-8683-2012; Jacobsen,
Anders/K-1081-2013; Lee, Semin/S-2629-2016; Marra, Marco/B-5987-2008;
Miller, Ryan/B-9365-2008;
OI Schumacher, Steven/0000-0002-6819-5647; Noushmehr,
Houtan/0000-0003-4051-8114; Jacobsen, Anders/0000-0001-6847-4980; Lee,
Semin/0000-0002-9015-6046; Miller, Ryan/0000-0002-0096-8762; Van Meir,
Erwin G./0000-0003-2444-7707; Chakravarty, Debyani/0000-0001-8629-5732;
Brennan, Cameron/0000-0003-4064-8891; Lash, Alex/0000-0003-3787-1590;
Pot, David/0000-0002-1480-9826; Fuller, Gregory/0000-0001-9447-2647;
Perou, Charles/0000-0001-9827-2247; Gehlenborg, Nils/0000-0003-0327-8297
FU USA National Institutes of Health [U24CA143883, U24CA143858, U24C
A143840, U24CA143799, U24CA143835, U24CA143845, U24CA143882, U24
CA143867, U24CA143866]; [U24CA143848]; [U24CA144025]; [U24CA143843];
[U54HG003067]; [U54HG003079]; [U54HG003273]; [U24CA126543]; [U24CA12
6544]; [U24CA126546]; [U24CA126551]; [U24CA126554]; [U24CA126561];
[U24CA 126563]; [U24CA143731]
FX The TCGA research network contributed collectively to this study.
Biospecimens were provided by the Tissue Source Sites and processed by
the Biospecimen Core Resource. Data generation and analyses were
performed by the Genome Sequencing Centers, Cancer Genome
Characterization Centers, and Genome Data Analysis Centers. All data
were released through the Data Coordinating Center. Project activities
were coordinated by NCI and NHGRI Project Teams. This work was supported
by the following grants from the USA National Institutes of Health:
U24CA143883, U24CA143858, U24C A143840, U24CA143799, U24CA143835,
U24CA143845, U24CA143882, U24 CA143867, U24CA143866, U24CA143848,
U24CA144025, U24CA143843, U54HG003067, U54HG003079, U54HG003273,
U24CA126543, U24CA12 6544, U24CA126546, U24CA126551, U24CA126554,
U24CA126561, U24CA 126563, and U24CA143731.
NR 50
TC 710
Z9 725
U1 31
U2 161
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD OCT 10
PY 2013
VL 155
IS 2
BP 462
EP 477
DI 10.1016/j.cell.2013.09.034
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 235LH
UT WOS:000325719800021
PM 24120142
ER
PT J
AU Avivar-Valderas, A
Bobrovnikova-Marjon, E
Diehl, JA
Bardeesy, N
Debnath, J
Aguirre-Ghiso, JA
AF Avivar-Valderas, A.
Bobrovnikova-Marjon, E.
Diehl, J. Alan
Bardeesy, N.
Debnath, J.
Aguirre-Ghiso, J. A.
TI Regulation of autophagy during ECM detachment is linked to a selective
inhibition of mTORC1 by PERK
SO ONCOGENE
LA English
DT Article
DE anoikis; breast cancer; unfolded protein response
ID ACTIVATED PROTEIN-KINASE; EXTRACELLULAR-MATRIX DETACHMENT;
ENDOPLASMIC-RETICULUM KINASE; ANOIKIS RESISTANCE; UPSTREAM KINASE;
CELL-GROWTH; STRESS; PHOSPHORYLATION; SUPPRESSION; SURVIVAL
AB Adhesion to the extracellular matrix (ECM) is critical for epithelial tissue homeostasis and function. ECM detachment induces metabolic stress and programmed cell death via anoikis. ECM-detached mammary epithelial cells are able to rapidly activate autophagy allowing for survival and an opportunity for re-attachment. However, the mechanisms controlling detachment-induced autophagy remain unclear. Here we uncover that the kinase PERK rapidly promotes autophagy in ECM-detached cells by activating AMP-activated protein kinase (AMPK), resulting in downstream inhibition of mTORC1-p70(S6K) signaling. LKB1 and TSC2, but not TSC1, are required for PERK-mediated inhibition of mammalian target of rapamycinin MCF10A cells and mouse embryo fibroblast cells. Importantly, this pathway shows fast kinetics, is transcription-independent and is exclusively activated during ECM detachment, but not by canonical endoplasmic reticulum stressors. Moreover, enforced PERK or AMPK activation upregulates autophagy and causes luminal filling during acinar morphogenesis by perpetuating a population of surviving autophagic luminal cells that resist anoikis. Hence, we identify a novel pathway in which suspension-activated PERK promotes the activation of LKB1, AMPK and TSC2, leading to the rapid induction of detachment-induced autophagy. We propose that increased autophagy, secondary to persistent PERK and LKB1-AMPK signaling, can robustly protect cells from anoikis and promote luminal filling during early carcinoma progression.
C1 [Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Med, New York, NY 10029 USA.
[Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Otolaryngol, New York, NY 10029 USA.
[Bobrovnikova-Marjon, E.; Diehl, J. Alan] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA.
[Bobrovnikova-Marjon, E.; Diehl, J. Alan] Univ Penn, Sch Med, Abramson Canc Res Inst, Philadelphia, PA 19104 USA.
[Bardeesy, N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
[Debnath, J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.
[Debnath, J.] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
RP Aguirre-Ghiso, JA (reprint author), Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM julio.aguirre-ghiso@mssm.edu
OI Aguirre-Ghiso, Julio/0000-0002-6694-6507
FU NIH-NCI shared resources [5R24CA095823-04]; NSF Major Research
Instrumentation grant [DBI-9724504]; NIH [1 S10RR0 9145-01, RO1
CA126792, CA126792-S1, P01 CA104838]; Samuel Waxman Cancer Research
Foundation Tumor Dormancy Program; NIH/National Cancer Institute
[CA109182, CA163131]; NIEHS [ES017146]; NYSTEM; Leukemia and Lymphoma
Scholar
FX Confocal laser scanning microscopy was performed at the MSSM-Microscopy
Shared Resources Facility, supported with funding from NIH-NCI shared
resources grant (5R24CA095823-04), NSF Major Research Instrumentation
grant (DBI-9724504) and NIH shared instrumentation grant (1 S10RR0
9145-01). This work is supported by grants from the Samuel Waxman Cancer
Research Foundation Tumor Dormancy Program, NIH/National Cancer
Institute (CA109182, CA163131), NIEHS (ES017146) and NYSTEM to J. A.
A-G, NIH RO1 CA126792, CA126792-S1 (ARRA) to JD, and P01 CA104838 and a
Leukemia and Lymphoma Scholar award to JAD.
NR 39
TC 38
Z9 38
U1 2
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT 10
PY 2013
VL 32
IS 41
BP 4932
EP 4940
DI 10.1038/onc.2012.512
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 235KQ
UT WOS:000325717800009
PM 23160380
ER
PT J
AU Ghoshal, G
Chi, LP
Barabasi, AL
AF Ghoshal, Gourab
Chi, Liping
Barabasi, Albert-Laszlo
TI Uncovering the role of elementary processes in network evolution
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWING RANDOM NETWORKS; COMPLEX NETWORKS; DEGREE DISTRIBUTIONS;
EVOLVING NETWORKS; ROBUSTNESS; INTERNET; GRAPHS; WEB
AB The growth and evolution of networks has elicited considerable interest from the scientific community and a number of mechanistic models have been proposed to explain their observed degree distributions. Various microscopic processes have been incorporated in these models, among them, node and edge addition, vertex fitness and the deletion of nodes and edges. The existing models, however, focus on specific combinations of these processes and parameterize them in a way that makes it difficult to elucidate the role of the individual elementary mechanisms. We therefore formulated and solved a model that incorporates the minimal processes governing network evolution. Some contribute to growth such as the formation of connections between existing pair of vertices, while others capture deletion; the removal of a node with its corresponding edges, or the removal of an edge between a pair of vertices. We distinguish between these elementary mechanisms, identifying their specific role on network evolution.
C1 [Ghoshal, Gourab; Chi, Liping; Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Dept Phys Biol & Comp Sci, Boston, MA 02115 USA.
[Ghoshal, Gourab; Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Ghoshal, Gourab; Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
[Chi, Liping] Cent China Normal Univ, Inst Particle Phys, Complex Sci Res Ctr, Wuhan 430079, Peoples R China.
RP Ghoshal, G (reprint author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.
EM gghoshal@fas.harvard.edu
FU Network Science Collaborative Technology Alliance; US Army Research
Laboratory [W911NF-09-2-0053]; Defense Advanced Research Projects Agency
[11645021]; Defense Threat Reduction Agency [WMD BRBAA07-J-2-0035]
FX We thank C. Song for valuable discussions. This work was supported by
the Network Science Collaborative Technology Alliance sponsored by the
US Army Research Laboratory under Agreement Number W911NF-09-2-0053; the
Defense Advanced Research Projects Agency under Agreement Number
11645021; the Defense Threat Reduction Agency award WMD
BRBAA07-J-2-0035; and the generous support of Lockheed Martin.
NR 51
TC 8
Z9 10
U1 0
U2 33
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 10
PY 2013
VL 3
AR 2920
DI 10.1038/srep02920
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232DH
UT WOS:000325469500007
PM 24108146
ER
PT J
AU Hormoz, S
AF Hormoz, Sahand
TI Amino acid composition of proteins reduces deleterious impact of
mutations
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENETIC-CODE; ESCHERICHIA-COLI; SEQUENCES; EVOLUTION; MODELS;
THERMODYNAMICS; POTENTIALS; STABILITY; DESIGN
AB The evolutionary origin of amino acid occurrence frequencies in proteins (composition) is not yet fully understood. We suggest that protein composition works alongside the genetic code to minimize impact of mutations on protein structure. First, we propose a novel method for estimating thermodynamic stability of proteins whose sequence is constrained to a fixed composition. Second, we quantify the average deleterious impact of substituting one amino acid with another. Natural proteome compositions are special in at least two ways: 1) Natural compositions do not generate more stable proteins than the average random composition, however, they result in proteins that are less susceptible to damage from mutations. 2) Natural proteome compositions that result in more stable proteins (i.e. those of thermophiles) are also tuned to have a higher tolerance for mutations. This is consistent with the observation that environmental factors selecting for more stable proteins also enhance the deleterious impact of mutations.
C1 [Hormoz, Sahand] Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA.
[Hormoz, Sahand] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Hormoz, Sahand] Harvard Univ, Kavli Inst Bionano Sci & Technol, Cambridge, MA 02138 USA.
[Hormoz, Sahand] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
RP Hormoz, S (reprint author), Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Kohn Hall, Santa Barbara, CA 93106 USA.
EM hormoz@kitp.ucsb.edu
FU National Science Foundation [NSF PHY11-25915]
FX The author is thankful to Michael P. Brenner for stimulating discussions
and critical reading of the manuscript, and Eugene Shakhnovich for
helpful suggestions. This research was supported in part by the National
Science Foundation under Grant No. NSF PHY11-25915.
NR 46
TC 13
Z9 13
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 10
PY 2013
VL 3
AR 2919
DI 10.1038/srep02919
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232DH
UT WOS:000325469500006
PM 24108121
ER
PT J
AU Katz, IT
Bassett, IV
Wright, AA
AF Katz, Ingrid T.
Bassett, Ingrid V.
Wright, Alexi A.
TI PEPFAR in Transition - Implications for HIV Care in South Africa
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
AB With the U.S. government halving the budget for the President's Emergency Plan for AIDS Relief in South Africa by 2017, the country is transitioning to full ownership of its HIV program. Will the move jeopardize the health of 1.7 million South Africans being treated for HIV? This summer marked the 10th anniversary of the creation of the President's Emergency Plan for AIDS Relief (PEPFAR), widely considered the most ambitious and successful global public health program since smallpox eradication. Over the past decade, PEPFAR has funded HIV-AIDS treatment for more than 5 million people in resource-limited settings in sub-Saharan Africa. Now, the U.S. government has reached a turning point in its emergency response and has decided to reduce funding to many of these countries, including South Africa, recipient of the most PEPFAR dollars. In August 2012, the U.S. government announced it would cut South Africa's PEPFAR budget ...
C1 [Katz, Ingrid T.] Massachusetts Gen Hosp, Div Womens Hlth, Brigham & Womens Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Katz, Ingrid T.; Bassett, Ingrid V.; Wright, Alexi A.] Harvard Univ, Sch Med, Boston, MA USA.
[Bassett, Ingrid V.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Bassett, Ingrid V.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Bassett, Ingrid V.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
[Wright, Alexi A.] Dana Farber Canc Ctr, Boston, MA USA.
RP Katz, IT (reprint author), Massachusetts Gen Hosp, Div Womens Hlth, Brigham & Womens Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
FU NIMH NIH HHS [K23 MH097667, R01 MH090326]
NR 5
TC 18
Z9 18
U1 0
U2 22
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 10
PY 2013
VL 369
IS 15
BP 1385
EP 1387
DI 10.1056/NEJMp1310982
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 231QE
UT WOS:000325431500002
PM 24106930
ER
PT J
AU Ruschitzka, F
Abraham, WT
Singh, JP
Bax, JJ
Borer, JS
Brugada, J
Dickstein, K
Ford, I
Gorcsan, J
Gras, D
Krum, H
Sogaard, P
Holzmeister, J
AF Ruschitzka, Frank
Abraham, William T.
Singh, Jagmeet P.
Bax, Jeroen J.
Borer, Jeffrey S.
Brugada, Josep
Dickstein, Kenneth
Ford, Ian
Gorcsan, John
Gras, Daniel
Krum, Henry
Sogaard, Peter
Holzmeister, Johannes
CA EchoCRT Study Grp
TI Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS
Complex
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID LEFT-VENTRICULAR DYSSYNCHRONY; LONG-TERM SURVIVAL; MECHANICAL
DYSSYNCHRONY; RADIAL STRAIN; TRIAL; ECHOCARDIOGRAPHY; DEFIBRILLATOR;
PREVALENCE; ASYNCHRONY; REDUCTION
AB BackgroundCardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.
MethodsWe conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony. All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off. The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.
ResultsOn March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board. At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months. The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15). There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).
ConclusionsIn patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality. (Funded by Biotronik and GE Healthcare; EchoCRT ClinicalTrials.gov number, NCT00683696.)
In a randomized trial, patients with heart failure and a QRS duration of less than 130 msec were assigned to cardiac-resynchronization therapy (CRT) or no CRT. There were no significant differences in rates of death from any cause or hospitalization for heart failure. Despite recent advances, heart failure remains a common cause of death and morbidity. According to current guidelines, cardiac-resynchronization therapy (CRT) is indicated for patients receiving stable medical therapy recommended by current guidelines who have moderate-to-severe heart failure, a left ventricular ejection fraction of 35% or less, and a QRS duration of 120 msec or more as assessed electrocardiographically.(1) However, many patients with heart failure have a QRS duration of less than 120 msec,(2) and it is currently not recommended that they receive CRT. Up to 50% of these patients show echocardiographic evidence of ventricular dyssynchrony(3),(4) and hence might benefit ...
C1 [Ruschitzka, Frank; Holzmeister, Johannes] Univ Zurich Hosp, Clin Cardiol, CH-8091 Zurich, Switzerland.
[Abraham, William T.] Ohio State Univ, Med Ctr, Div Cardiovascular Med, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
[Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, Boston, MA USA.
[Bax, Jeroen J.] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands.
[Borer, Jeffrey S.] State Univ New York Downstate Coll Med, Div Cardiovasc Med, New York, NY USA.
[Borer, Jeffrey S.] State Univ New York Downstate Coll Med, Howard Gilman & Ron Inst, New York, NY USA.
[Borer, Jeffrey S.] State Univ New York Downstate Coll Med, Jean Schiavone Inst, New York, NY USA.
[Brugada, Josep] Univ Barcelona, Dept Cardiol, Thorax Inst, Hosp Clin, Barcelona, Spain.
[Dickstein, Kenneth] Univ Bergen, Stavanger Univ Hosp, Stavanger, Norway.
[Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland.
[Gorcsan, John] Univ Pittsburgh, Pittsburgh, PA USA.
[Gras, Daniel] Nouvelles Clin Nantaises, Nantes, France.
[Krum, Henry] Monash Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, Australia.
[Sogaard, Peter] Aalborg Univ, Aalborg, Denmark.
RP Holzmeister, J (reprint author), Univ Zurich Hosp, Clin Cardiol, Raemistr 100, CH-8091 Zurich, Switzerland.
EM johannes.holzmeister@usz.ch; johannes.holzmeister@usz.ch
RI Ponikowski, Piotr/O-6454-2015;
OI Ponikowski, Piotr/0000-0002-3391-7064; BRUGADA,
JOSEP/0000-0002-5662-8302; Ng, G. Andre/0000-0001-5965-0671
FU Biotronik; GE Healthcare
FX Supported by Biotronik and GE Healthcare.
NR 32
TC 201
Z9 207
U1 5
U2 33
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 10
PY 2013
VL 369
IS 15
BP 1395
EP 1405
DI 10.1056/NEJMoa1306687
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 231QE
UT WOS:000325431500007
PM 23998714
ER
PT J
AU Heller, HM
Wu, CC
Pierce, VM
Kradin, RL
AF Heller, Howard M.
Wu, Carol C.
Pierce, Virginia M.
Kradin, Richard L.
TI Case 31-2013: A 29-Year-Old Man with Abdominal Pain, Fever, and Weight
Loss
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GASTROINTESTINAL HISTOPLASMOSIS; AIDS;
DIAGNOSIS
AB A 29-year-old man was seen in an outpatient clinic because of abdominal pain, fever, and weight loss. Testing for HIV antibodies was positive, and the CD4 T-lymphocyte count was 10 per cubic millimeter. Chest imaging revealed tiny nodules in both lungs. Presentation of CaseDr. Nosheen Reza (Medicine): A 29-year-old man was seen in an outpatient clinic affiliated with this hospital because of abdominal pain, fever, and weight loss. The patient was reportedly well until unintentional weight loss occurred approximately 6 weeks before presentation. Three weeks before presentation, upper abdominal pain developed that the patient rated at 8 on a scale of 0 to 10, with 10 indicating the most severe pain. The pain radiated to his throat, increased after eating and drinking, and did not diminish with ibuprofen. At the outpatient clinic, the patient reported nausea, occasional vomiting, decreased food ...
C1 [Heller, Howard M.] MIT, Dept Med, Cambridge, MA 02139 USA.
[Heller, Howard M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Wu, Carol C.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Pierce, Virginia M.; Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Heller, Howard M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Wu, Carol C.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Pierce, Virginia M.; Kradin, Richard L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Heller, HM (reprint author), MIT, Dept Med, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
NR 14
TC 2
Z9 2
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 10
PY 2013
VL 369
IS 15
BP 1453
EP 1461
DI 10.1056/NEJMcpc1304165
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 231QE
UT WOS:000325431500014
PM 24106939
ER
PT J
AU Haghani, M
Shabani, M
Moazzami, K
AF Haghani, M.
Shabani, M.
Moazzami, K.
TI MATERNAL MOBILE PHONE EXPOSURE ADVERSELY AFFECTS THE
ELECTROPHYSIOLOGICAL PROPERTIES OF PURKINJE NEURONS IN RAT OFFSPRING
SO NEUROSCIENCE
LA English
DT Article
DE mobile phone exposure; pregnancy; neural excitability; Purkinje cells;
offspring
ID FREQUENCY ELECTROMAGNETIC-FIELDS; WI-FI SIGNAL; CELLULAR PHONES;
PYRAMIDAL NEURONS; 900 MHZ; RECEPTOR ACTIVATION; MEMORY TASK; HUMAN
SLEEP; IN-UTERO; RADIATION
AB Electromagnetic field (EMF) radiations emitted from mobile phones may cause structural damage to neurons. With the increased usage of mobile phones worldwide, concerns about their possible effects on the nervous system are rising. In the present study, we aimed to elucidate the possible effects of prenatal EMF exposure on the cerebellum of offspring Wistar rats. Rats in the EMF group were exposed to 900-MHz pulse-EMF irradiation for 6 h per day during all gestation period. Ten offspring per each group were evaluated for behavioral and electrophysiological evaluations. Cerebellum-related behavioral dysfunctions were analyzed using motor learning and cerebellum-dependent functional tasks (Accelerated Rotarod, Hanging and Open field tests). Whole-cell patch clamp recordings were used for electrophysiological evaluations. The results of the present study failed to show any behavioral abnormalities in rats exposed to chronic EMF radiation. However, whole-cell patch clamp recordings revealed decreased neuronal excitability of Purkinje cells in rats exposed to EMF. The most prominent changes included afterhyperpolarization amplitude, spike frequency, half width and first spike latency. In conclusion, the results of the present study show that prenatal EMF exposure results in altered electrophysiological properties of Purkinje neurons. However, these changes may not be severe enough to alter the cerebellum-dependent functional tasks. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Haghani, M.] Shiraz Univ Med Sci, Dept Physiol, Shiraz, Iran.
[Shabani, M.] Kerman Univ Med Sci, Kerman Neurosci Res Ctr, Kerman 7619813159, Iran.
[Moazzami, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02129 USA.
RP Shabani, M (reprint author), Kerman Univ Med Sci, Kerman Neurosci Res Ctr, Dept Neurosci, Kerman 7619813159, Iran.
EM haghani55@yahoo.com; shabani@kmu.ac.ir; kasra.moazzami@gmail.com
NR 39
TC 14
Z9 15
U1 1
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD OCT 10
PY 2013
VL 250
BP 588
EP 598
DI 10.1016/j.neuroscience.2013.07.049
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 223YC
UT WOS:000324847400053
PM 23906636
ER
PT J
AU Holsen, LM
Lancaster, K
Klibanski, A
Whitfield-Gabrieli, S
Cherkerzian, S
Buka, S
Goldstein, JM
AF Holsen, L. M.
Lancaster, K.
Klibanski, A.
Whitfield-Gabrieli, S.
Cherkerzian, S.
Buka, S.
Goldstein, J. M.
TI HPA-AXIS HORMONE MODULATION OF STRESS RESPONSE CIRCUITRY ACTIVITY IN
WOMEN WITH REMITTED MAJOR DEPRESSION
SO NEUROSCIENCE
LA English
DT Article
DE depression; stress; HPA-axis; sex differences; fMRI
ID PITUITARY-ADRENAL AXIS; URINARY FREE CORTISOL; PSYCHOLOGICAL STRESS;
PSYCHOSOCIAL STRESS; GLUCOSE-METABOLISM; NEURAL RESPONSE; MOOD
DISORDERS; NERVOUS-SYSTEM; ACTIVATION; AMYGDALA
AB Decades of clinical and basic research indicate significant links between altered hypothalamic pituitary adrenal (HPA)-axis hormone dynamics and major depressive disorder (MDD). Recent neuroimaging studies of MDD highlight abnormalities in stress response circuitry regions which play a role in the regulation of the HPA-axes. However, there is a dearth of research examining these systems in parallel, especially as related to potential trait characteristics. The current study addresses this gap by investigating neural responses to a mild visual stress challenge with real-time assessment of adrenal hormones in women with MDD in remission and controls. Fifteen women with recurrent MDD in remission (rMDD) and 15 healthy control women were scanned on a 3T Siemens MR scanner while viewing neutral and negative (stress-evoking) stimuli. Blood samples were obtained before, during, and after scanning for the measurement of HPA-axis hormone levels. Compared to controls, rMDD women demonstrated higher anxiety ratings, increased cortisol levels, and hyperactivation in the amygdala and hippocampus, p < 0.05, family-wise error (FWE)-corrected in response to the stress challenge. Among rMDD women, amygdala activation was negatively related to cortisol changes and positively associated with the duration of remission. Findings presented here provide evidence for differential effects of altered HPA-axis hormone dynamics on hyperactivity in stress response circuitry regions elicited by a well-validated stress paradigm in women with recurrent MDD in remission. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Holsen, L. M.; Lancaster, K.; Cherkerzian, S.; Goldstein, J. M.] Brigham & Womens Hosp, Dept Med, Div Womens Hlth, Boston, MA 02120 USA.
[Holsen, L. M.; Goldstein, J. M.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02120 USA.
[Holsen, L. M.; Klibanski, A.; Goldstein, J. M.] Harvard Univ, Sch Med, Boston, MA USA.
[Klibanski, A.] Massachusetts Gen Hosp, Dept Med, Neuroendocrine Unit, Boston, MA 02114 USA.
[Whitfield-Gabrieli, S.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Whitfield-Gabrieli, S.; Goldstein, J. M.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Charlestown, MA USA.
[Whitfield-Gabrieli, S.; Goldstein, J. M.] MIT, Charlestown, MA USA.
[Buka, S.] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA.
RP Goldstein, JM (reprint author), Brigham & Womens Hosp, OBC, 3rd Floor,1620 Tremont St, Boston, MA 02120 USA.
EM jill_goldstein@hms.harvard.edu
RI Buka, Stephen/H-7335-2014
OI Buka, Stephen/0000-0002-8578-9308
FU National Institutes of Health Office for Research on Women's Health and
Mental Health (ORWH-NIMH) [P50 MH082679]; NIMH [K01 MH091222]; Harvard
Catalyst \ The Harvard Clinical and Translational Science Center (NIH)
[UL1 RR025758]
FX This work was supported by the National Institutes of Health Office for
Research on Women's Health and Mental Health (ORWH-NIMH) P50 MH082679
(Goldstein, P.I.). L.M.H. was also funded by NIMH K01 MH091222. The
research was conducted with support from Harvard Catalyst vertical bar
The Harvard Clinical and Translational Science Center (NIH #UL1
RR025758). We thank Jenn Watch, M.Ed. and Anne Remington for help with
project management, Harlyn Aizley, M.Ed. for clinical interviewing, and
Jo-Ann Donatelli, Ph.D. for her contributions to diagnostic review with
Dr. Goldstein. The authors also thank Stuart Tobet, Ph.D. and Robert
Handa, Ph.D. for their collaborative work with the Goldstein Lab (on P50
MH082679) regarding the impact of hormones on stress response circuitry
and mood and anxiety.
NR 61
TC 21
Z9 23
U1 7
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD OCT 10
PY 2013
VL 250
BP 733
EP 742
DI 10.1016/j.neuroscience.2013.07.042
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 223YC
UT WOS:000324847400064
PM 23891965
ER
PT J
AU Daniels, KM
Zavin, A
Allsup, K
Joseph, J
Arena, R
Lazzari, AA
Schulze, PC
Lecker, SH
Brown, J
Forman, DE
AF Daniels, Karla M.
Zavin, Alexandra
Allsup, Kelly
Joseph, Jacob
Arena, Ross
Lazzari, Antonio A.
Schulze, P. Christian
Lecker, Stewart H.
Brown, Jonathan
Forman, Daniel E.
TI Serum adiponectin in non-cachectic heart failure patients
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Adiponectin; Heart failure; Dual-energy X-ray absorptiometry
ID MORTALITY
C1 [Daniels, Karla M.; Joseph, Jacob; Brown, Jonathan; Forman, Daniel E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Zavin, Alexandra; Allsup, Kelly; Joseph, Jacob; Lazzari, Antonio A.; Forman, Daniel E.] VA Boston Healthcare Syst, Boston, MA USA.
[Arena, Ross] Univ New Mexico, Albuquerque, NM 87131 USA.
[Lazzari, Antonio A.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Schulze, P. Christian] Columbia Univ, Med Ctr, New York, NY 10027 USA.
[Lecker, Stewart H.] Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Lecker, Stewart H.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Forman, DE (reprint author), Brigham & Womens Hosp, Boston, MA 02115 USA.
EM deforman@partners.org
RI Arena, Ross/A-3141-2008
OI Arena, Ross/0000-0002-6675-1996
FU NHLBI NIH HHS [R01 HL114813]
NR 8
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 9
PY 2013
VL 168
IS 4
BP 4363
EP 4364
DI 10.1016/j.ijcard.2013.05.059
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 242EG
UT WOS:000326219600224
PM 23739548
ER
PT J
AU Hawn, MT
Graham, LA
Richman, JS
Itani, KMF
Henderson, WG
Maddox, TM
AF Hawn, Mary T.
Graham, Laura A.
Richman, Joshua S.
Itani, Kamal M. F.
Henderson, William G.
Maddox, Thomas M.
TI Risk of Major Adverse Cardiac Events Following Noncardiac Surgery in
Patients With Coronary Stents
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID DRUG-ELUTING STENTS; RANDOMIZED CLINICAL-TRIALS; LATE THROMBOSIS;
BARE-METAL; ANTIPLATELET THERAPY; INTERVENTION; IMPLANTATION;
DISCONTINUATION; MANAGEMENT; REGISTRY
AB IMPORTANCE Guidelines recommend delaying noncardiac surgery in patients after coronary stent procedures for 1 year after drug-eluting stents (DES) and for 6 weeks after bare metal stents (BMS). The evidence underlying these recommendations is limited and conflicting.
OBJECTIVE To determine risk factors for adverse cardiac events in patients undergoing noncardiac surgery following coronary stent implantation.
DESIGN, SETTING, AND PARTICIPANTS A national, retrospective cohort study of 41 989 Veterans Affairs (VA) and non-VA operations occurring in the 24 months after a coronary stent implantation between 2000 and 2010. Nonlinear generalized additive models examined the association between timing of surgery and stent type with major adverse cardiac events (MACE) adjusting for patient, surgery, and cardiac risk factors. A nested case-control study assessed the association between perioperative antiplatelet cessation and MACE.
MAIN OUTCOMES AND MEASURES A composite 30-day MACE rate of all-cause mortality, myocardial infarction, and cardiac revascularization.
RESULTS Within 24 months of 124 844 coronary stent implantations (47.6% DES, 52.4% BMS), 28 029 patients (22.5%; 95% CI, 22.2%-22.7%) underwent noncardiac operations resulting in 1980 MACE (4.7%; 95% CI, 4.5%-4.9%). Time between stent and surgery was associated with MACE (<6 weeks, 11.6%; 6 weeks to <6 months, 6.4%; 6-12 months, 4.2%; >12-24 months, 3.5%; P<.001). MACE rate by stent type was 5.1% for BMS and 4.3% for DES (P<.001). After adjustment, the 3 factors most strongly associated with MACE were nonelective surgical admission (adjusted odds ratio [AOR], 4.77; 95% CI, 4.07-5.59), history of myocardial infarction in the 6 months preceding surgery (AOR, 2.63; 95% CI, 2.32-2.98), and revised cardiac risk index greater than 2 (AOR, 2.13; 95% CI, 1.85-2.44). Of the 12 variables in the model, timing of surgery ranked fifth in explanatory importance measured by partial effects analysis. Stent type ranked last, and DES was not significantly associated with MACE (AOR, 0.91; 95% CI, 0.83-1.01). After both BMS and DES placement, the risk of MACE was stable at 6 months. A case-control analysis of 284 matched pairs found no association between antiplatelet cessation and MACE (OR, 0.86; 95% CI, 0.57-1.29).
CONCLUSIONS AND RELEVANCE Among patients undergoing noncardiac surgery within 2 years of coronary stent placement, MACE were associated with emergency surgery and advanced cardiac disease but not stent type or timing of surgery beyond 6 months after stent implantation. Guideline emphasis on stent type and surgical timing for both DES and BMS should be reevaluated.
C1 [Hawn, Mary T.; Graham, Laura A.; Richman, Joshua S.] Birmingham Vet Adm Hosp, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Hawn, Mary T.; Richman, Joshua S.] Univ Alabama Birmingham, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA.
[Itani, Kamal M. F.] Boston Univ, Dept Surg, VA Boston Hlth Care Syst, Boston, MA 02215 USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
[Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA.
[Henderson, William G.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
[Maddox, Thomas M.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Maddox, Thomas M.] Univ Colorado, Denver, CO 80202 USA.
RP Hawn, MT (reprint author), Univ Alabama Birmingham, Dept Surg, Sect Gastrointestinal Surg, 1922 7th Ave S,KB 428, Birmingham, AL 35294 USA.
EM mhawn@uab.edu
FU VA Health Services Research & Development grant [IIR 09-347]; VA Career
Development Awards
FX This study is supported by a VA Health Services Research & Development
grant (No. IIR 09-347). In addition, Drs Maddox and Richman are
supported by VA Career Development Awards.
NR 28
TC 92
Z9 93
U1 3
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 9
PY 2013
VL 310
IS 14
BP 1462
EP 1472
DI 10.1001/jama.2013.278787
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 230PK
UT WOS:000325354100022
PM 24101118
ER
PT J
AU Bekelman, JE
Epstein, AJ
Emanuel, EJ
AF Bekelman, Justin E.
Epstein, Andrew J.
Emanuel, Ezekiel J.
TI Single- vs Multiple-Fraction Radiotherapy for Bone Metastases From
Prostate Cancer
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Bekelman, Justin E.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
RP Bekelman, JE (reprint author), Univ Penn, Perelman Sch Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM bekelman@uphs.upenn.edu
FU NCI NIH HHS [K07 CA163616, K07-CA163616]
NR 6
TC 24
Z9 24
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 9
PY 2013
VL 310
IS 14
BP 1501
EP 1502
DI 10.1001/jama.2013.277081
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 230PK
UT WOS:000325354100027
PM 24104375
ER
PT J
AU Froberg, JE
Yang, L
Lee, JT
AF Froberg, John E.
Yang, Lin
Lee, Jeannie T.
TI Guided by RNAs: X-Inactivation as a Model for lncRNA Function
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE long non-coding RNA; X-inactivation; polycomb complexes
ID LONG NONCODING RNAS; ES CELL-DIFFERENTIATION; BREAST-CANCER CELLS;
POLYCOMB GROUP GENE; XIST RNA; ANTISENSE TRANSCRIPTION; CHROMOSOME
INACTIVATION; CHROMATIN-STRUCTURE; TSIX TRANSCRIPTION; ANGELMAN SYNDROME
AB The recent revolution in sequencing technology has helped to reveal a large transcriptome of long non-coding RNAs (lncRNAs). A major challenge in the years to come is to determine what biological functions, if any, they serve. Although the purpose of these transcripts is largely unknown at present, existing examples suggest that lncRNAs play roles in a wide variety of biological processes. Exemplary cases are lncRNAs within the X-inactivation center. Indeed, lncRNAs dominate control of random X-chromosome inactivation (XCI). The RNA-based regulatory mechanisms of XCI include recruitment of chromatin modifiers, formation of RNA-based subnuclear compartments, and regulation of transcription by antisense transcription. XCI and lncRNAs now also appear to be very relevant in the development and progression of cancer. This perspective focuses on new insights into lncRNA-dependent regulation of XCI, which we believe serve as paradigms for understanding lncRNA function more generally. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Lee, Jeannie T.] Howard Hughes Med Inst, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
RP Lee, JT (reprint author), Howard Hughes Med Inst, Boston, MA 02114 USA.
EM lee@molbio.mgh.harvard.edu
FU NIGMS NIH HHS [R01 GM090278, R37 GM058839]
NR 100
TC 44
Z9 47
U1 3
U2 55
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD OCT 9
PY 2013
VL 425
IS 19
BP 3698
EP 3706
DI 10.1016/j.jmb.2013.06.031
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 226MP
UT WOS:000325040800010
PM 23816838
ER
PT J
AU Atassi, N
Yerramilli-Rao, P
Szymonifka, J
Yu, H
Kearney, M
Grasso, D
Deng, J
Levine-Weinberg, M
Shapiro, J
Lee, A
Joseph, L
Macklin, EA
Cudkowicz, ME
AF Atassi, Nazem
Yerramilli-Rao, Padmaja
Szymonifka, Jackie
Yu, Hong
Kearney, Marianne
Grasso, Daniela
Deng, Jing
Levine-Weinberg, Mark
Shapiro, Jordan
Lee, Alexandra
Joseph, Lucia
Macklin, Eric A.
Cudkowicz, Merit E.
TI Analysis of start-up, retention, and adherence in ALS clinical trials
SO NEUROLOGY
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; COOPERATIVE-ONCOLOGY-GROUP; PREVENTION
TRIALS; RECRUITMENT; DISEASE; COSTS; CHALLENGES; DEMENTIA; MG/DAY;
IMPACT
AB Objective: To investigate predictors of trial start-up times, high attrition, and poor protocol adherence in amyotrophic lateral sclerosis (ALS) trials.
Methods: Retrospective analysis of start-up times, retention, and protocol adherence was performed on 5 clinical studies conducted by the Northeast ALS Consortium and 50 ALS clinical trials identified by PubMed search. Predictors of start-up times were estimated by accelerated failure time models with random effects. Predictors of retention and protocol deviations were estimated by mixed-model logistic regression.
Results: Median times for contract execution and institutional review board (IRB) approval were 105 days and 125 days, respectively. Contract execution was faster at sites with more ongoing trials (p = 0.005), and more full-time (p = 0.006) and experienced (p < 0.001) coordinators. IRB approval was faster at sites with more ongoing trials (p = 0.010) and larger ALS clinics (p = 0.038). Site activation after IRB approval was faster at sites with more full-time (p = 0.038) and experienced (p < 0.001) coordinators. Twenty-two percent of surviving participants withdrew before completing the trial. Better participant functional score at baseline was an independent predictor of trial completion (odds ratio 1.29, p = 0.002) and fewer protocol deviations (odds ratio 0.86, p = 0.030).
Conclusion: Delays in IRB review contribute the most to prolonged trial start-up times, and these timelines are faster in sites with more experienced staff. Strategies to improve protocol adherence and participants' retention may include enrolling people at early disease stages.
C1 [Atassi, Nazem; Yerramilli-Rao, Padmaja; Yu, Hong; Kearney, Marianne; Grasso, Daniela; Deng, Jing; Levine-Weinberg, Mark; Shapiro, Jordan; Lee, Alexandra; Joseph, Lucia; Cudkowicz, Merit E.] Massachusetts Gen Hosp, Neurol Clin Res Inst, Dept Neurol, Boston, MA 02114 USA.
[Szymonifka, Jackie; Macklin, Eric A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Atassi, Nazem; Yerramilli-Rao, Padmaja; Macklin, Eric A.; Cudkowicz, Merit E.] Harvard Univ, Sch Med, Boston, MA USA.
RP Atassi, N (reprint author), Massachusetts Gen Hosp, Neurol Clin Res Inst, Dept Neurol, Boston, MA 02114 USA.
EM na.tassi@partners.org
FU Muscular Dystrophy Association (MDA); American Academy of Neurology
(AAN); MGH ALS Research Fund; National Institute of Neurological
Disorders and Stroke [U01-NS049640, U01-NS049640-04S1]
FX Supported by institutional funding. This work was conducted with support
from the Muscular Dystrophy Association (MDA) Clinical Research Training
Grant, research fellowship from the American Academy of Neurology (AAN),
the MGH ALS Research Fund, and the National Institute of Neurological
Disorders and Stroke U01-NS049640 and U01-NS049640-04S1.
NR 27
TC 3
Z9 3
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 8
PY 2013
VL 81
IS 15
BP 1350
EP 1355
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA AA0EQ
UT WOS:000330768600015
PM 24005339
ER
PT J
AU Skalnikova, HK
Navarro, R
Marsala, S
Hrabakova, R
Vodicka, P
Gadher, SJ
Kovarova, H
Marsala, M
AF Skalnikova, Helena Kupcova
Navarro, Roman
Marsala, Silvia
Hrabakova, Rita
Vodicka, Petr
Gadher, Suresh Jivan
Kovarova, Hana
Marsala, Martin
TI Signaling proteins in spinal parenchyma and dorsal root ganglion in rat
with spinal injury-induced spasticity
SO JOURNAL OF PROTEOMICS
LA English
DT Article
DE Spinal cord trauma; Spasticity; Hyper-reflexia; Proteomic profiling;
Dorsal root ganglia; Spinal gray matter
ID COLONY-STIMULATING FACTOR; CORD-INJURY; NEUROPATHIC PAIN; MECHANICAL
ALLODYNIA; MULTIPLE-SCLEROSIS; PROTEOMIC ANALYSIS; DOWN-REGULATION;
NERVOUS-SYSTEM; KINASE; EXPRESSION
AB Development of progressive muscle spasticity resulting from spinal traumatic injury can be mediated by loss of local segmental inhibition and/or by an increased sensory afferent drive with resulting exacerbated a-motoneuron activity. To identify potential contributions of neuroactive substances in the development of such spasticity state, we employed a well-defined spinal injury-evoked spasticity rat model. Signaling molecules were analyzed in the spinal parenchyma below the level of spinal injury and in the corresponding dorsal root ganglion cells using Kinex (TM) antibody microarrays. The results uncovered the involvement of angiogenesis and neurodegeneration pathways together with direct cross-talk mediated by several hub proteins with SH-2 domains. At 2 and 5 weeks after transection, up-regulation of several proteins including CaMKIV, RON alpha and PKC delta as well as MAPK3/ERK1 phosphorylation was observed in the spinal ventral horns. Our results indicate that these signaling molecules and their neuronal effector systems cannot only play an important role in the initiation but also in the maintenance of spasticity states after spinal trauma. The exclusivity of specific protein changes observed in lumbar spinal parenchyma but not in dorsal root ganglia indicates that new treatment strategies should primarily target specific spinal segments to prevent or attenuate spasticity states.
Biological significance
Development of progressive muscle spasticity and rigidity represents a serious complication associated with spinal ischemic or traumatic injury. Signaling proteins, including their phosphorylation status, were analyzed in the spinal parenchyma below the level of spinal injury and in the corresponding dorsal root ganglion cells in a rat model of spinal injury using Kinex (TM) antibody microarrays. The results uncovered direct protein interaction mediated cross-talk between angiogenesis and neurodegeneration pathways, which may significantly contribute to the healing process in the damaged region. Importantly, we identified several target proteins exclusively observed in the spinal lumbar ventral horns, where such proteins may not only play an important role in the initiation but also in the maintenance of spasticity states after spinal trauma. Hence, potential new treatment strategies such as gene silencing or drug treatment should primarily target spinal parenchymal sites at and around the injury epicenter and most likely employ intrathecal or targeted spinal segment-specific vector or drug delivery. We believe that this work will stimulate future translational research, ultimately leading to the improvement of quality of life of patients with spinal traumatic injury. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Skalnikova, Helena Kupcova; Hrabakova, Rita; Kovarova, Hana] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Lab Biochem & Mol Biol Germ Cells, Vvi, Libechov, Czech Republic.
[Navarro, Roman; Marsala, Silvia; Marsala, Martin] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA.
[Vodicka, Petr] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Lab Cell Regenerat & Plast, Vvi, Libechov, Czech Republic.
[Vodicka, Petr] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Gadher, Suresh Jivan] Life Technol, Frederick, MD USA.
[Marsala, Martin] Slovak Acad Sci, Inst Neurobiol, Kosice 04001, Slovakia.
RP Kovarova, H (reprint author), Acad Sci Czech Republic, Inst Anim Physiol & Genet, Lab Biochem & Mol Biol Germ Cells, Vvi, Libechov, Czech Republic.
EM kovarova@iapg.cas.cz
RI Hrabakova, Rita/G-7136-2014; Kupcova Skalnikova, Helena/G-7138-2014;
Kovarova, Hana/G-7135-2014; Vodicka, Petr/C-3845-2009
OI Vodicka, Petr/0000-0002-6605-9158
FU MEYS [ME10044]; NIH [NS051644]; TACR [TA01011466]; Institutional
Research Concept [RV067985904]; Operational Program Research and
Development for Innovations [CZ.1.05/2.1.00/03.0124]
FX This work was supported in part by MEYS (ME10044; H.K.), NIH (NS051644;
M.M.), TACR (TA01011466; HK), and Institutional Research Concept
RV067985904 (IAPG, AS CR, v.v.i). Infrastructural part of this project
was supported from the Operational Program Research and Development for
Innovations (CZ.1.05/2.1.00/03.0124).
NR 73
TC 7
Z9 7
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1874-3919
EI 1876-7737
J9 J PROTEOMICS
JI J. Proteomics
PD OCT 8
PY 2013
VL 91
BP 41
EP 57
DI 10.1016/j.jprot.2013.06.028
PG 17
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 264UH
UT WOS:000327906000004
ER
PT J
AU Leyton, PA
Beppu, H
Pappas, A
Martyn, TM
Derwall, M
Baron, DM
Galdos, R
Bloch, DB
Bloch, KD
AF Leyton, Patricio A.
Beppu, Hideyuki
Pappas, Alexandra
Martyn, Trejeeve M.
Derwall, Matthias
Baron, David M.
Galdos, Rita
Bloch, Donald B.
Bloch, Kenneth D.
TI Deletion of the Sequence Encoding the Tail Domain of the Bone
Morphogenetic Protein type 2 Receptor Reveals a Bone Morphogenetic
Protein 7-Specific Gain of Function
SO PLOS ONE
LA English
DT Article
ID PRIMARY PULMONARY-HYPERTENSION; II RECEPTOR; ARTERIAL-HYPERTENSION;
INCREASED SUSCEPTIBILITY; SIGNAL-TRANSDUCTION; MICE; BMPR2; MUTATIONS;
GENERATION; CLONING
AB The bone morphogenetic protein (BMP) type II receptor (BMPR2) has a long cytoplasmic tail domain whose function is incompletely elucidated. Mutations in the tail domain of BMPR2 are found in familial cases of pulmonary arterial hypertension. To investigate the role of the tail domain of BMPR2 in BMP signaling, we generated a mouse carrying a Bmpr2 allele encoding a non-sense mediated decay-resistant mutant receptor lacking the tail domain of Bmpr2. We found that homozygous mutant mice died during gastrulation, whereas heterozygous mice grew normally without developing pulmonary arterial hypertension. Using pulmonary artery smooth muscle cells (PaSMC) from heterozygous mice, we determined that the mutant receptor was expressed and retained its ability to transduce BMP signaling. Heterozygous PaSMCs exhibited a BMP7-specific gain of function, which was transduced via the mutant receptor. Using siRNA knockdown and cells from conditional knockout mice to selectively deplete BMP receptors, we observed that the tail domain of Bmpr2 inhibits Alk2-mediated BMP7 signaling. These findings suggest that the tail domain of Bmpr2 is essential for normal embryogenesis and inhibits Alk2-mediated BMP7 signaling in PaSMCs.
C1 [Leyton, Patricio A.; Beppu, Hideyuki; Pappas, Alexandra; Martyn, Trejeeve M.; Derwall, Matthias; Baron, David M.; Bloch, Donald B.; Bloch, Kenneth D.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, Boston, MA 02114 USA.
[Leyton, Patricio A.; Beppu, Hideyuki; Pappas, Alexandra; Martyn, Trejeeve M.; Derwall, Matthias; Baron, David M.; Galdos, Rita; Bloch, Donald B.; Bloch, Kenneth D.] Harvard Univ, Sch Med, Boston, MA USA.
[Beppu, Hideyuki] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Clin Lab & Mol Pathol, Toyama 930, Japan.
[Derwall, Matthias] Rhein Westfal TH Aachen, Uniklin Aachen, Dept Anesthesiol, Aachen, North Rhine Wes, Germany.
[Baron, David M.] Med Univ Vienna, Dept Anesthesia Gen Intens Care & Pain Management, Vienna, Austria.
[Galdos, Rita; Bloch, Donald B.] Massachusetts Gen Hosp, Dept Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
[Bloch, Kenneth D.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Cardiovasc Res Ctr, Boston, MA 02114 USA.
RP Leyton, PA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, Boston, MA 02114 USA.
EM pleyton@partners.org
FU National Institutes of Health Heart, Lung and Blood Institute
[HL074352]; Deutsche Forschungsgemeinschaft [DE-1685-1/1]
FX Funding came from National Institutes of Health Heart, Lung and Blood
Institute HL074352, http://www.nhlbi.nih.gov, DE-1685-1/1, Deutsche
Forschungsgemeinschaft, http://www.dfg.de/en/. The funders had no role
in study design, data collection and analysis, decisio to publish, or
preparation of the manuscript.
NR 33
TC 8
Z9 8
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2013
VL 8
IS 10
AR e76947
DI 10.1371/journal.pone.0076947
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 233FK
UT WOS:000325552200087
PM 24116187
ER
PT J
AU Martin, ME
Bhatnagar, S
George, MD
Paster, BJ
Canfield, DR
Eisen, JA
Solnick, JV
AF Martin, Miriam E.
Bhatnagar, Srijak
George, Michael D.
Paster, Bruce J.
Canfield, Don R.
Eisen, Jonathan A.
Solnick, Jay V.
TI The Impact of Helicobacter pylori Infection on the Gastric Microbiota of
the Rhesus Macaque
SO PLOS ONE
LA English
DT Article
ID 16S RIBOSOMAL-RNA; BACTERIAL MICROBIOTA; MAXIMUM-LIKELIHOOD; SPIRAL
BACTERIA; GUT MICROBIOTA; MONKEYS; HEILMANNII; DIVERSITY; HEALTH;
IDENTIFICATION
AB Helicobacter pylori colonization is highly prevalent among humans and causes significant gastric disease in a subset of those infected. When present, this bacterium dominates the gastric microbiota of humans and induces antimicrobial responses in the host. Since the microbial context of H. pylori colonization influences the disease outcome in a mouse model, we sought to assess the impact of H. pylori challenge upon the pre-existing gastric microbial community members in the rhesus macaque model. Deep sequencing of the bacterial 16S rRNA gene identified a community profile of 221 phylotypes that was distinct from that of the rhesus macaque distal gut and mouth, although there were taxa in common. High proportions of both H. pylori and H. suis were observed in the post-challenge libraries, but at a given time, only one Helicobacter species was dominant. However, the relative abundance of non-Helicobacter taxa was not significantly different before and after challenge with H. pylori. These results suggest that while different gastric species may show competitive exclusion in the gastric niche, the rhesus gastric microbial community is largely stable despite immune and physiological changes due to H. pylori infection.
C1 [Martin, Miriam E.; Solnick, Jay V.] Univ Calif Davis, Dept Med, Davis, CA 95616 USA.
[Martin, Miriam E.; Bhatnagar, Srijak; George, Michael D.; Eisen, Jonathan A.; Solnick, Jay V.] Univ Calif Davis, Dept Microbiol & Immunol, Davis, CA 95616 USA.
[Bhatnagar, Srijak; Eisen, Jonathan A.] Univ Calif Davis, Dept Ecol & Evolut, Davis, CA 95616 USA.
[Bhatnagar, Srijak] Univ Calif Davis, Microbiol Grad Grp, Davis, CA 95616 USA.
[Canfield, Don R.; Solnick, Jay V.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.
[Paster, Bruce J.] Forsyth Inst, Cambridge, MA USA.
RP Solnick, JV (reprint author), Univ Calif Davis, Dept Med, Davis, CA 95616 USA.
EM jvsolnick@ucdavis.edu
OI Bhatnagar, Srijak/0000-0003-0240-2655; Eisen, Jonathan
A./0000-0002-0159-2197; Solnick, Jay/0000-0002-7435-8393
FU National Institutes of Health [R21 AI080788, R21 DE020025]
FX Funding was provided by grants from the National Institutes of Health to
JVS (R21 AI080788) and to MDG (R21 DE020025). http://www.nih.gov/. The
sponsors of this research had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 54
TC 12
Z9 13
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2013
VL 8
IS 10
AR e76375
DI 10.1371/journal.pone.0076375
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 233FK
UT WOS:000325552200052
PM 24116104
ER
PT J
AU Shioda, T
Rosenthal, NF
Coser, KR
Suto, M
Phatak, M
Medvedovic, M
Carey, VJ
Isselbacher, KJ
AF Shioda, Toshi
Rosenthal, Noel F.
Coser, Kathryn R.
Suto, Mizuki
Phatak, Mukta
Medvedovic, Mario
Carey, Vincent J.
Isselbacher, Kurt J.
TI Expressomal approach for comprehensive analysis and visualization of
ligand sensitivities of xenoestrogen responsive genes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID ENDOCRINE-DISRUPTING CHEMICALS; BREAST-CANCER CELLS;
ESTROGEN-RECEPTOR-ALPHA; PUBLIC-HEALTH; EXPOSURE; PHYTOESTROGENS;
PRINCIPLES; STATEMENT; SOCIETY; DISEASE
AB Although biological effects of endocrine disrupting chemicals (EDCs) are often observed at unexpectedly low doses with occasional nonmonotonic dose-response characteristics, transcriptome-wide profiles of sensitivities or dose-dependent behaviors of the EDC responsive genes have remained unexplored. Here, we describe expressome analysis for the comprehensive examination of dose-dependent gene responses and its applications to characterize estrogen responsive genes in MCF-7 cells. Transcriptomes of MCF-7 cells exposed to varying concentrations of representative natural and xenobiotic estrogens for 48 h were determined by microarray and used for computational calculation of interpolated approximations of estimated transcriptomes for 300 doses uniformly distributed in log space for each chemical. The entire collection of these estimated transcriptomes, designated as the expressome, has provided unique opportunities to profile chemical-specific distributions of ligand sensitivities for large numbers of estrogen responsive genes, revealing that at low concentrations estrogens generally tended to suppress rather than to activate transcription. Gene ontology analysis demonstrated distinct functional enrichment between high-and low-sensitivity estrogen responsive genes, supporting the notion that a single EDC chemical can cause qualitatively distinct biological responses at different doses. Expressomal heatmap visualization of dose-dependent induction of Bisphenol A inducible genes showed a weak gene activation peak at a very low concentration range (ca. 0.1 nM) in addition to the main, strong gene activation peak at and above 100 nM. Thus, expressome analysis is a powerful approach to understanding the EDC dose-dependent dynamic changes in gene expression at the transcriptomal level, providing important information on the overall profiles of ligand sensitivities and nonmonotonic responses.
C1 [Shioda, Toshi; Rosenthal, Noel F.; Coser, Kathryn R.; Suto, Mizuki; Isselbacher, Kurt J.] Massachusetts Gen Hosp, Mol Profiling Lab, Ctr Canc Res, Charlestown, MA 02129 USA.
[Shioda, Toshi; Carey, Vincent J.; Isselbacher, Kurt J.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Phatak, Mukta; Medvedovic, Mario] Univ Cincinnati, Coll Med, Lab Stat Genom & Syst Biol, Dept Environm Hlth, Cincinnati, OH 45267 USA.
[Carey, Vincent J.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
RP Shioda, T (reprint author), Massachusetts Gen Hosp, Mol Profiling Lab, Ctr Canc Res, Charlestown, MA 02129 USA.
EM tshioda@partners.org; kisselbacher@partners.org
FU Susan G. Komen for Cure Grants [FAS0703860, KG090515]; NIH
[U41-HG004059, R01-HL086601]
FX This study was supported by Susan G. Komen for Cure Grants FAS0703860
and KG090515 (to T.S.) and NIH Grants U41-HG004059 and R01-HL086601 (to
V.J.C.).
NR 29
TC 8
Z9 8
U1 0
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 8
PY 2013
VL 110
IS 41
BP 16508
EP 16513
DI 10.1073/pnas.1315929110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231ED
UT WOS:000325395600056
PM 24062438
ER
PT J
AU Raitt, MH
AF Raitt, Merritt H.
TI Inappropriate Implantable Defibrillator Shocks
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE beta-blockers; carvedilol; defibrillator; heart failure; inappropriate
therapy
ID CARDIAC-RESYNCHRONIZATION THERAPY; HEART-FAILURE;
CARDIOVERTER-DEFIBRILLATORS; BETA-BLOCKERS; CARVEDILOL; METOPROLOL;
METAANALYSIS; PREVENTION; OUTCOMES; TRIAL
C1 [Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Cardiol, Portland, OR 97201 USA.
[Raitt, Merritt H.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA.
RP Raitt, MH (reprint author), Portland VA Med Ctr, P-3 CARD,3710 SW US Vet Rd, Portland, OR 97239 USA.
EM merritt.raitt@va.gov
NR 14
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 8
PY 2013
VL 62
IS 15
BP 1351
EP 1352
DI 10.1016/j.jacc.2013.05.055
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 225ZY
UT WOS:000325005000008
PM 23770170
ER
PT J
AU Zhang, JH
Palevsky, PM
Chertow, GM
Hartigan, J
O'Connor, TZ
Guarino, P
Zhou, BQ
AF Zhang, Jane H.
Palevsky, Paul M.
Chertow, Glenn M.
Hartigan, John
O'Connor, Theresa Z.
Guarino, Peter
Zhou, Bingqing
TI Piecewise Analysis of Patient Survival after Onset of AKI
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; MORTALITY; EPIDEMIOLOGY;
INTENSITY; OUTCOMES; THERAPY; SUPPORT; TRIAL; POINT
AB Background and objectivesAKI affects approximately 2%-7% of hospitalized patients and >35% of critically ill patients. Survival after AKI may be described as having an acute phase (including an initial hyperacute component) followed by a convalescent phase, which may itself have early and late components.Design, setting, participants, & measurementsData from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) study was used to model mortality risk among patients with dialysis-requiring AKI. This study assumed that the mortality hazard can be described by a piecewise log-linear function with change points. Using an average likelihood method, the authors tested for the number of change points in a piecewise log-linear hazard model. The maximum likelihood approach to locate the change point(s) was then adopted, and associated parameters and standard errors were estimated.ResultsThere were 1124 ATN participants with follow-up to 1 year. The mortality hazard of AKI decreased over time with inflections in the rate of decrease at days 4, 42, and 148, with the sharpest change at day 42. The daily rate of decline in the log of the hazard for death was 0.220 over the first 4 days, 0.046 between day 4 and day 42, 0.017 between day 42 and day 148, and 0.003 between day 148 and day 365.ConclusionsThere appear to be two major phases of mortality risk after AKI: an early phase extending over the first 6 weeks and a late phase from 6 weeks to 1 year. Within the first 42 days, this can be further divided into hyperacute (days 1-4) and acute (days 4-42) phases. After 42 days, there appear to be early (days 42-148) and late (after day 148) convalescent phases. These findings may help to inform the design of AKI clinical trials and assist critical care physicians in prognostic stratification.
C1 [Zhang, Jane H.; O'Connor, Theresa Z.; Guarino, Peter; Zhou, Bingqing] Vet Affairs Connecticut Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, West Haven, CT 06516 USA.
[Palevsky, Paul M.] Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
[Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Hartigan, John] Yale Univ, Dept Stat, New Haven, CT USA.
[Zhou, Bingqing] Yale Univ, Sch Publ Hlth, Div Biostat, New Haven, CT USA.
RP Zhang, JH (reprint author), Vet Affairs Connecticut Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, 950 Campbell Ave, West Haven, CT 06516 USA.
EM Jane.Zhang@va.gov
OI Palevsky, Paul/0000-0002-7334-5400
FU Department of Veterans Affairs Office of Research and Development;
National Institute of Diabetes and Digestive and Kidney Diseases
[Y1-DK-3508-01]
FX This study was supported by the Cooperative Studies Program of the
Department of Veterans Affairs Office of Research and Development and by
the National Institute of Diabetes and Digestive and Kidney Diseases
(interagency agreement Y1-DK-3508-01).
NR 19
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD OCT 7
PY 2013
VL 8
IS 10
BP 1679
EP 1684
DI 10.2215/CJN.07250712
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 229MA
UT WOS:000325268200008
PM 23813558
ER
PT J
AU Kim, J
Lee, S
Jeong, Y
Kim, JK
Jung, YM
Merenda, F
Salathe, RP
Shin, JS
Oh, K
AF Kim, Jongki
Lee, Sungrae
Jeong, Yoonseob
Kim, Jun-Ki
Jung, Yongmin
Merenda, Fabrice
Salathe, Rene-Paul
Shin, Jeon-Soo
Oh, Kyunghwan
TI Crossed fiber optic Bessel beams for curvilinear optofluidic transport
of dielectric particles
SO OPTICS EXPRESS
LA English
DT Article
ID WAVE-GUIDES; LIGHT-BEAM; TWEEZERS; TRAP; GENERATION; MICROMANIPULATION;
MANIPULATION; PROPAGATION; AIR
AB Due to its unique non-diffracting and self-reconstructing nature, Bessel beams have been successfully adopted to trap multiple particles along the beam's axial direction. However, prior bulk-optic based Bessel beams have a fundamental form-factor limitation for in situ, in-vitro, and in-vivo applications. Here we present a novel implementation of Fourier optics along a single strand of hybrid optical fiber in a monolithic manner that can generate pseudo Bessel beam arrays in two-dimensional space. We successfully demonstrate unique optofluidic transport of the trapped dielectric particles along a curvilinear optical route by multiplexing the fiber optic pseudo Bessel beams. The proposed technique can form a new building block to realize reconfigurable optofluidic transportation of particulates that can break the limitations of both prior bulk-optic Bessel beam generation techniques and conventional microfluidic channels. (C) 2013 Optical Society of America
C1 [Kim, Jongki; Lee, Sungrae; Jeong, Yoonseob; Oh, Kyunghwan] Yonsei Univ, Dept Phys, Coll Sci, Seoul 120749, South Korea.
[Kim, Jun-Ki] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Jung, Yongmin] Univ Southampton Highfield, Optoelect Res Ctr, Southampton SO17 1BJ, Hants, England.
[Merenda, Fabrice; Salathe, Rene-Paul] Ecole Polytech Fed Lausanne, Adv Photon Lab, CH-1015 Lausanne, Switzerland.
[Shin, Jeon-Soo] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Dept Microbiol, Seoul 120752, South Korea.
RP Oh, K (reprint author), Yonsei Univ, Dept Phys, Coll Sci, Seoul 120749, South Korea.
EM koh@yonsei.ac.kr
FU Brain Korea 21Project; NRF of Korea; Korea government (MEST)
[2011-00181613, 2012M3A7B4049800]; Seoul RBD Program [PA110081]
FX This work was supported in part by the Brain Korea 21Project, in part by
the NRF of Korea and a grant funded by the Korea government (MEST)
(2011-00181613, 2012M3A7B4049800), in part by the Seoul R&BD Program
(PA110081)
NR 35
TC 3
Z9 3
U1 0
U2 16
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD OCT 7
PY 2013
VL 21
IS 20
BP 23021
EP 23029
DI 10.1364/OE.21.023021
PG 9
WC Optics
SC Optics
GA 233EU
UT WOS:000325549800002
PM 24104217
ER
PT J
AU Sung, YJ
Gupta, R
AF Sung, Yongjin
Gupta, Rajiv
TI X-ray phase tomography of a moving object
SO OPTICS EXPRESS
LA English
DT Article
ID OPTICAL DIFFRACTION TOMOGRAPHY; DARK-FIELD; MICROTOMOGRAPHY;
INTERFEROMETRY; REGULARIZATION; SCATTERING; RETRIEVAL
AB We propose an algorithm for tomographic reconstruction of the refractive index map of an object translated across a fan-shaped X-ray beam. We adopt a forward image model valid under the non-paraxial condition, and use a unique mapping of the acquired projection images to reduce the computational cost. Even though the imaging setup affords only a limited angular coverage, our algorithm provides accurate refractive index values by employing the positivity and piecewise-smoothness constraints. (C) 2013 Optical Society of America
C1 [Sung, Yongjin] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Sung, Yongjin; Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Sung, Yongjin; Gupta, Rajiv] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Sung, YJ (reprint author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
EM yongjin.sung@gmail.com
FU Department of Homeland Security's Science and Technology Directorate
[HSHQDC-11-C-0083]; National Research Foundation of Singapore through
the Singapore-MIT Alliance for Research and Technology Centre; DARPA
AXiS [N66001-11-4204, 1300217190]
FX This work was supported by the Department of Homeland Security's Science
and Technology Directorate through contract HSHQDC-11-C-0083, the
National Research Foundation of Singapore through the Singapore-MIT
Alliance for Research and Technology Centre, and the DARPA AXiS program
(Grant No. N66001-11-4204, P.R. No. 1300217190). The authors thank Prof.
George Barbastathis and Dr. Niyom Lue for useful discussion.
NR 39
TC 0
Z9 0
U1 2
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD OCT 7
PY 2013
VL 21
IS 20
BP 23671
EP 23678
DI 10.1364/OE.21.023671
PG 8
WC Optics
SC Optics
GA 233EU
UT WOS:000325549800064
PM 24104279
ER
PT J
AU Landry, G
Seco, J
Gaudreault, M
Verhaegen, F
AF Landry, Guillaume
Seco, Joao
Gaudreault, Mathieu
Verhaegen, Frank
TI Deriving effective atomic numbers from DECT based on a parameterization
of the ratio of high and low linear attenuation coefficients
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID ENERGY COMPUTED-TOMOGRAPHY; X-RAY CT; DENSITY; SCANNER; TISSUES;
RECONSTRUCTION; SIMULATION; RADIATION; MODELS; SINGLE
AB Dual energy computed tomography (DECT) can provide simultaneous estimation of relative electron density rho(e) and effective atomic number Z(eff). The ability to obtain these quantities (rho(e), Z(eff)) has been shown to benefit selected radiotherapy applications where tissue characterization is required. The conventional analysis method (spectral method) relies on knowledge of the CT scanner photon spectra which may be difficult to obtain accurately. Furthermore an approximate empirical attenuation correction of the photon spectrum through the patient is necessary. We present an alternative approach based on a parameterization of the measured ratio of low and high kVp linear attenuation coefficients for deriving Z(eff) which does not require the estimation of the CT scanner spectra. In a first approach, the tissue substitute method (TSM), the Rutherford parameterization of the linear attenuation coefficients was employed to derive a relation between Z(eff) and the ratio of the linear attenuation coefficients measured at the low and high kVp of the CT scanner. A phantom containing 16 tissue mimicking inserts was scanned with a dual source DECT scanner at 80 and 140 kVp. The data from the 16 inserts phantom was used to obtain model parameters for the relation between Z(eff) and mu vertical bar(80kVp)(140kVp). The accuracy of the method was evaluated with a second phantom containing 4 tissue mimicking inserts. The TSM was compared to a more complex approach, the reference tissue method (RTM), which requires the derivation of stoichiometric fit parameters. These were derived from the 16 inserts phantom scans and used to calculate CT numbers at 80 and 140 kVp for a set of tabulated reference human tissues. Model parameters for the parameterization of mu vertical bar(80kVp)(140 kVp) were estimated for this reference tissue dataset and compared to the results of the TSM. Residuals on Z(eff) for the reference tissue dataset for both TSM and RTM were compared to those obtained from the spectral method. The tissue substitutes were well fitted by the TSM with R-2 = 0.9930. Residuals on Z(eff) for the phantoms were similar between the TSM and spectral methods for Z(eff) < 8 while they were improved by the TSM for higher Z(eff). The RTM fitted the reference tissue dataset well with R-2 = 0.9999. Comparing the Z(eff) extracted from TSM and the more complex RTM to the known values from the reference tissue dataset yielded errors of up to 0.3 and 0.15 units of Z(eff) respectively. The parameterization approach yielded standard deviations which were up to 0.3 units of Z(eff) higher than those observed with the spectral method for Z(eff) around 7.5. Procedures for the DECT estimation of Z(eff) removing the need for estimates of the CT scanner spectra have been presented. Both the TSM and the more complex RTM performed better than the spectral method. The RTM yielded the best results for the reference human tissue dataset reducing errors from up to 0.3 to 0.15 units of Z(eff) compared to the simpler TSM. Both TSM and RTM are simpler to implement than the spectral method which requires estimates of the CT scanner spectra.
C1 [Landry, Guillaume; Gaudreault, Mathieu; Verhaegen, Frank] MUMC, Dept Radiat Oncol MAASTRO, GROW Sch Oncol & Dev Biol, NL-6201 BN Maastricht, Netherlands.
[Seco, Joao] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Seco, Joao] Harvard Univ, Sch Med, Boston, MA USA.
[Gaudreault, Mathieu] CHU Quebec, Dept Radiooncol, Quebec City, PQ, Canada.
[Gaudreault, Mathieu] CHU Quebec, Ctr Rech, Quebec City, PQ, Canada.
[Gaudreault, Mathieu] Univ Laval, Dept Phys Genie Phys & Opt, Quebec City, PQ, Canada.
[Gaudreault, Mathieu] Univ Laval, Ctr Rech Cancerol, Quebec City, PQ, Canada.
[Verhaegen, Frank] McGill Univ, Dept Oncol, Med Phys Unit, Montreal, PQ, Canada.
RP Landry, G (reprint author), MUMC, Dept Radiat Oncol MAASTRO, GROW Sch Oncol & Dev Biol, NL-6201 BN Maastricht, Netherlands.
EM frank.verhaegen@maastro.nl
FU O'Brien Foundation
FX Dr Joachim E Wildberger is acknowledged for providing access to the DECT
scanner. We thank Dr Bernhard Schmidt from Siemens Medical for providing
information on the operation of the DECT scanner. Frank P Eschbach and
Jasper P Jansen are acknowledged for adapting scripts to analyze the
Gammex 467 phantom measurements. We acknowledge Gammex RMI and Vladimir
Varchena of CIRS for divulging phantom compositions. GL would like to
acknowledge the O'Brien Foundation for funding. Patrick V Granton is
acknowledged for commenting on the paper.
NR 23
TC 17
Z9 19
U1 1
U2 13
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 7
PY 2013
VL 58
IS 19
BP 6851
EP 6866
DI 10.1088/0031-9155/58/19/6851
PG 16
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 220HN
UT WOS:000324573600015
PM 24025623
ER
PT J
AU van de Water, S
Kraan, AC
Breedveld, S
Schillemans, W
Teguh, DN
Kooy, HM
Madden, TM
Heijmen, BJM
Hoogeman, MS
AF van de Water, S.
Kraan, A. C.
Breedveld, S.
Schillemans, W.
Teguh, D. N.
Kooy, H. M.
Madden, T. M.
Heijmen, B. J. M.
Hoogeman, M. S.
TI Improved efficiency of multi-criteria IMPT treatment planning using
iterative resampling of randomly placed pencil beams
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID MODULATED PROTON THERAPY; ROBOTIC RADIOSURGERY; OPTIMIZATION;
UNCERTAINTIES; RADIOTHERAPY; CANCER; PLANS
AB This study investigates whether 'pencil beam resampling', i.e. iterative selection and weight optimization of randomly placed pencil beams (PBs), reduces optimization time and improves plan quality for multi-criteria optimization in intensity-modulated proton therapy, compared with traditional modes in which PBs are distributed over a regular grid. Resampling consisted of repeatedly performing: (1) random selection of candidate PBs from a very fine grid, (2) inverse multi-criteria optimization, and (3) exclusion of low-weight PBs. The newly selected candidate PBs were added to the PBs in the existing solution, causing the solution to improve with each iteration. Resampling and traditional regular grid planning were implemented into our in-house developed multi-criteria treatment planning system 'Erasmus iCycle'. The system optimizes objectives successively according to their priorities as defined in the so-called 'wish-list'. For five head-and-neck cancer patients and two PB widths (3 and 6 mm sigma at 230 MeV), treatment plans were generated using: (1) resampling, (2) anisotropic regular grids and (3) isotropic regular grids, while using varying sample sizes (resampling) or grid spacings (regular grid). We assessed differences in optimization time (for comparable plan quality) and in plan quality parameters (for comparable optimization time). Resampling reduced optimization time by a factor of 2.8 and 5.6 on average (7.8 and 17.0 at maximum) compared with the use of anisotropic and isotropic grids, respectively. Doses to organs-at-risk were generally reduced when using resampling, with median dose reductions ranging from 0.0 to 3.0Gy (maximum: 14.3Gy, relative: 0%-42%) compared with anisotropic grids and from -0.3 to 2.6 Gy (maximum: 11.4 Gy, relative: -4%-19%) compared with isotropic grids. Resampling was especially effective when using thin PBs (3 mm sigma). Resampling plans contained on average fewer PBs, energy layers and protons than anisotropic grid plans and more energy layers and protons than isotropic grid plans. In conclusion, resampling resulted in improved plan quality and in considerable optimization time reduction compared with traditional regular grid planning.
C1 [van de Water, S.; Kraan, A. C.; Breedveld, S.; Schillemans, W.; Teguh, D. N.; Heijmen, B. J. M.; Hoogeman, M. S.] Erasmus MC Daniel den Hoed Canc Ctr, Dept Radiat Oncol, NL-3075 EA Rotterdam, Netherlands.
[Kooy, H. M.; Madden, T. M.] Massachusetts Gen Hosp, Dept Radiat Oncol, FH Burr Proton Therapy Ctr, Boston, MA 02114 USA.
[Kooy, H. M.; Madden, T. M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP van de Water, S (reprint author), Erasmus MC Daniel den Hoed Canc Ctr, Dept Radiat Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.
EM s.vandewater@erasmusmc.nl
NR 18
TC 7
Z9 7
U1 0
U2 5
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 7
PY 2013
VL 58
IS 19
BP 6969
EP 6983
DI 10.1088/0031-9155/58/19/6969
PG 15
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 220HN
UT WOS:000324573600022
PM 24029721
ER
PT J
AU Cervantes, TM
Bassett, EK
Tseng, A
Kimura, A
Roscioli, N
Randolph, MA
Vacanti, JP
Hadlock, TA
Gupta, R
Pomerantseva, I
Sundback, CA
AF Cervantes, Thomas M.
Bassett, Erik K.
Tseng, Alan
Kimura, Anya
Roscioli, Nick
Randolph, Mark A.
Vacanti, Joseph P.
Hadlock, Theresa A.
Gupta, Rajiv
Pomerantseva, Irina
Sundback, Cathryn A.
TI Design of composite scaffolds and three-dimensional shape analysis for
tissue-engineered ear
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE tissue engineering; ear reconstruction; three-dimensional shape
analysis; bending moment
ID AURICULAR RECONSTRUCTION; IN-VITRO; CARTILAGE; MODEL; AURICLE
AB Engineered cartilage is a promising option for auricular reconstruction. We have previously demonstrated that a titanium wire framework within a composite collagen ear-shaped scaffold helped to maintain the gross dimensions of the engineered ear after implantation, resisting the deformation forces encountered during neocartilage maturation and wound healing. The ear geometry was redesigned to achieve a more accurate aesthetic result when implanted subcutaneously in a nude rat model. A non-invasive method was developed to assess size and shape changes of the engineered ear in three dimensions. Computer models of the titanium framework were obtained from CT scans before and after implantation. Several parameters were measured including the overall length, width and depth, the minimum intrahelical distance and overall curvature values for each beam section within the framework. Local curvature values were measured to gain understanding of the bending forces experienced by the framework structure in situ. Length and width changed by less than 2%, whereas the depth decreased by approximately 8% and the minimum intrahelical distance changed by approximately 12%. Overall curvature changes identified regions most susceptible to deformation. Eighty-nine per cent of local curvature measurements experienced a bending moment less than 50 mu N-m owing to deformation forces during implantation. These quantitative shape analysis results have identified opportunities to improve shape fidelity of engineered ear constructs.
C1 [Cervantes, Thomas M.; Bassett, Erik K.; Tseng, Alan; Kimura, Anya; Vacanti, Joseph P.; Pomerantseva, Irina; Sundback, Cathryn A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Randolph, Mark A.] Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02114 USA.
[Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Roscioli, Nick] Kensey Nash Corp, Exton, PA USA.
[Randolph, Mark A.; Vacanti, Joseph P.; Hadlock, Theresa A.; Pomerantseva, Irina; Sundback, Cathryn A.] Harvard Univ, Sch Med, Boston, MA USA.
[Hadlock, Theresa A.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Vacanti, JP (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
EM jvacanti@partners.org
FU Armed Forces Institute of Regenerative Medicine award [W81XWH-08-2-0034]
FX This research was sponsored in part by the Armed Forces Institute of
Regenerative Medicine award number W81XWH-08-2-0034. The U.S. Army
Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick
MD 21702-5014 is the awarding and administering acquisition office.
NR 26
TC 5
Z9 7
U1 1
U2 9
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742-5689
EI 1742-5662
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD OCT 6
PY 2013
VL 10
IS 87
AR 20130413
DI 10.1098/rsif.2013.0413
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 298BG
UT WOS:000330298300006
PM 23904585
ER
PT J
AU Lee, DY
Wauquier, F
Eid, AA
Roman, LJ
Ghosh-Choudhury, G
Khazim, K
Block, K
Gorin, Y
AF Lee, Doug-Yoon
Wauquier, Fabien
Eid, Assaad A.
Roman, Linda J.
Ghosh-Choudhury, Goutam
Khazim, Khaled
Block, Karen
Gorin, Yves
TI Nox4 NADPH Oxidase Mediates Peroxynitrite-dependent Uncoupling of
Endothelial Nitric-oxide Synthase and Fibronectin Expression in Response
to Angiotensin II ROLE OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Angiotensin II; Extracellular Matrix Proteins; Kidney; Nitric-oxide
Synthase; Nox; Oxidative Stress
ID RAT MESANGIAL CELLS; EXPERIMENTAL DIABETIC-NEPHROPATHY; NAD(P)H OXIDASE;
MOLECULAR-MECHANISMS; GLOMERULAR INJURY; RECEPTOR BLOCKADE;
VASCULAR-DISEASE; REDOX CONTROL; UP-REGULATION; SUPEROXIDE
AB Activation of glomerular mesangial cells (MCs) by angiotensin II (Ang II) leads to extracellular matrix accumulation. Here, we demonstrate that, in MCs, Ang II induces endothelial nitric-oxide synthase (eNOS) uncoupling with enhanced generation of reactive oxygen species (ROS) and decreased production of NO. Ang II promotes a rapid increase in 3-nitrotyrosine formation, and uric acid attenuates Ang II-induced decrease in NO bioavailability, demonstrating that peroxynitrite mediates the effects of Ang II on eNOS dysfunction. Ang II rapidly up-regulates Nox4 protein. Inhibition of Nox4 abolishes the increase in ROS and peroxynitrite generation as well as eNOS uncoupling triggered by Ang II, indicating that Nox4 is upstream of eNOS. This pathway contributes to Ang II-mediated fibronectin accumulation in MCs. Ang II also elicits an increase in mitochondrial abundance of Nox4 protein, and the oxidase contributes to ROS production in mitochondria. Overexpression of mitochondrial manganese superoxide dismutase prevents the stimulatory effects of Ang II on mitochondrial ROS production, loss of NO availability, and MC fibronectin accumulation, whereas manganese superoxide dismutase depletion increases mitochondrial ROS, NO deficiency, and fibronectin synthesis basally and in cells exposed to Ang II. This work provides the first evidence that uncoupled eNOS is responsible for Ang II-induced MC fibronectin accumulation and identifies Nox4 and mitochondrial ROS as mediators of eNOS dysfunction. These data shed light on molecular processes underlying the oxidative signaling cascade engaged by Ang II and identify potential targets for intervention to prevent renal fibrosis.
C1 [Lee, Doug-Yoon; Wauquier, Fabien; Eid, Assaad A.; Ghosh-Choudhury, Goutam; Khazim, Khaled; Block, Karen; Gorin, Yves] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Roman, Linda J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Goutam] Vet Adm Res & Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Goutam; Block, Karen] South Texas Vet Hlth Care Syst, Audie Leon Murphy Mem Hosp Div, San Antonio, TX 78229 USA.
RP Gorin, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol MC 7882, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM gorin@uthscsa.edu
FU National Institutes of Health [RO1 DK 079996, RO1 CA 131272, RO1 DK
50190]; Juvenile Diabetes Research Foundation Multiproject Grant;
Juvenile Diabetes Research Foundation Advanced Research Fellowship
Grant; Veterans Administration Merit Awards; Veterans Administration
Senior Research Career Scientist Award
FX This work was supported, in whole or in part, by National Institutes of
Health Grants RO1 DK 079996 (to Y. G.), RO1 CA 131272 (to K. B.), and
RO1 DK 50190 (to G. G. C.). This work was also supported in part by a
Juvenile Diabetes Research Foundation Multiproject Grant (to Y. G. and
K. B.), a Juvenile Diabetes Research Foundation Advanced Research
Fellowship Grant (to A. A. E.), and Veterans Administration Merit Awards
(to K. B. and G. G. C.).; Recipient of Veterans Administration Senior
Research Career Scientist Award.
NR 78
TC 44
Z9 45
U1 4
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 4
PY 2013
VL 288
IS 40
BP 28668
EP 28686
DI 10.1074/jbc.M113.470971
PG 19
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 298BL
UT WOS:000330298800022
PM 23940049
ER
PT J
AU Armata, IA
Balaj, L
Kuster, JK
Zhang, X
Tsai, SL
Armatas, AA
Multhaupt-Buell, TJ
Soberman, R
Breakefield, XO
Ichinose, H
Sharma, N
AF Armata, Ioanna A.
Balaj, Leonora
Kuster, John K.
Zhang, Xuan
Tsai, Shelun
Armatas, Andreas A.
Multhaupt-Buell, Trisha J.
Soberman, Roy
Breakefield, Xandra O.
Ichinose, Hiroshi
Sharma, Nutan
TI Dopa-Responsive Dystonia: Functional Analysis of Single Nucleotide
Substitutions within the 5 ' Untranslated GCH1 Region
SO PLOS ONE
LA English
DT Article
ID GTP CYCLOHYDROLASE-I; HEREDITARY PROGRESSIVE DYSTONIA; MARKED DIURNAL
FLUCTUATION; TRANSLATION INITIATION; GENE-EXPRESSION; MUTATION;
TETRAHYDROBIOPTERIN; METABOLISM; MECHANISMS; DISORDERS
AB Background: Mutations in the GCH1 gene are associated with childhood onset, dopa-responsive dystonia (DRD). Correct diagnosis of DRD is crucial, given the potential for complete recovery once treated with L-dopa. The majority of DRD associated mutations lie within the coding region of the GCH1 gene, but three additional single nucleotide sequence substitutions have been reported within the 5' untranslated (5'UTR) region of the mRNA. The biologic significance of these 5' UTR GCH1 sequence substitutions has not been analyzed.
Methodology/Principal Findings: Luciferase reporter assays, quantitative real time PCR and RNA decay assays, combined with bioinformatics, revealed a pathogenic 5' UTR GCH1 substitution. The +142C>T single nucleotide 5' UTR substitution that segregates with affected status in DRD patients, substantially attenuates translation without altering RNA expression levels or stability. The +142C>T substitution disrupts translation most likely by creating an upstream initiation start codon (uAUG) and an upstream open reading frame (uORF).
Conclusions/Significance: This is the first GCH1 regulatory substitution reported to act at a post-transcriptional level, increasing the list of genetic diseases caused by abnormal translation and reaffirming the importance of investigating potential regulatory substitutions in genetic diseases.
C1 [Armata, Ioanna A.; Balaj, Leonora; Kuster, John K.; Zhang, Xuan; Tsai, Shelun; Multhaupt-Buell, Trisha J.; Breakefield, Xandra O.; Sharma, Nutan] Massachusetts Gen Hosp, Dept Neurogenet, Boston, MA 02114 USA.
[Armata, Ioanna A.; Balaj, Leonora; Kuster, John K.; Zhang, Xuan; Tsai, Shelun; Multhaupt-Buell, Trisha J.; Breakefield, Xandra O.; Sharma, Nutan] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
[Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Armatas, Andreas A.] Univ Patras, Dept Biol, Rion, Greece.
[Soberman, Roy] Massachusetts Gen Hosp, Dept Med, Renal Unit, Boston, MA 02114 USA.
[Ichinose, Hiroshi] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 227, Japan.
RP Armata, IA (reprint author), Massachusetts Gen Hosp, Dept Neurogenet, Boston, MA 02114 USA.
EM ionarm999@gmail.com
RI Ichinose, Hiroshi/D-8986-2015
OI Ichinose, Hiroshi/0000-0001-6008-6860
FU NIH/NINDS [5P50NS037409]
FX This work was supported by NIH/NINDS 5P50NS037409 (XOB and NS). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 33
TC 0
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 4
PY 2013
VL 8
IS 10
AR e76975
DI 10.1371/journal.pone.0076975
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232JF
UT WOS:000325489100159
PM 24124602
ER
PT J
AU Ballandras-Colas, A
Naraharisetty, H
Li, X
Serrao, E
Engelman, A
AF Ballandras-Colas, Allison
Naraharisetty, Hema
Li, Xiang
Serrao, Erik
Engelman, Alan
TI Biochemical Characterization of Novel Retroviral Integrase Proteins
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 DNA INTEGRATION; DERMAL
SARCOMA-VIRUS; STRAND TRANSFER; NUCLEOTIDE-SEQUENCE; TARGET SITES;
MECHANISM; CONSTRUCTION; REPLICATION; INHIBITION
AB Integrase is an essential retroviral enzyme, catalyzing the stable integration of reverse transcribed DNA into cellular DNA. Several aspects of the integration mechanism, including the length of host DNA sequence duplication flanking the integrated provirus, which can be from 4 to 6 bp, and the nucleotide preferences at the site of integration, are thought to cluster among the different retroviral genera. To date only the spumavirus prototype foamy virus integrase has provided diffractable crystals of integrase-DNA complexes, revealing unprecedented details on the molecular mechanisms of DNA integration. Here, we characterize five previously unstudied integrase proteins, including those derived from the alpharetrovirus lymphoproliferative disease virus (LPDV), betaretroviruses Jaagsiekte sheep retrovirus (JSRV), and mouse mammary tumor virus (MMTV), epsilonretrovirus walleye dermal sarcoma virus (WDSV), and gammaretrovirus reticuloendotheliosis virus strain A (Rev-A) to identify potential novel structural biology candidates. Integrase expressed in bacterial cells was analyzed for solubility, stability during purification, and, once purified, 3' processing and DNA strand transfer activities in vitro. We show that while we were unable to extract or purify accountable amounts of WDSV, JRSV, or LPDV integrase, purified MMTV and Rev-A integrase each preferentially support the concerted integration of two viral DNA ends into target DNA. The sequencing of concerted Rev-A integration products indicates high fidelity cleavage of target DNA strands separated by 5 bp during integration, which contrasts with the 4 bp duplication generated by a separate gammaretrovirus, the Moloney murine leukemia virus (MLV). By comparing Rev-A in vitro integration sites to those generated by MLV in cells, we concordantly conclude that the spacing of target DNA cleavage is more evolutionarily flexible than are the target DNA base contacts made by integrase during integration. Given their desirable concerted DNA integration profiles, Rev-A and MMTV integrase proteins have been earmarked for structural biology studies.
C1 [Engelman, Alan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Engelman, A (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.
EM alan_engelman@dfci.harvard.edu
FU US National Institutes of Health [R01 AI070042, T32 AI007245]
FX This work was supported by US National Institutes of Health grants R01
AI070042 and T32 AI007245. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 37
TC 9
Z9 10
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 4
PY 2013
VL 8
IS 10
AR e76638
DI 10.1371/journal.pone.0076638
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232JF
UT WOS:000325489100138
PM 24124581
ER
PT J
AU Kloverpris, HN
Jackson, A
Handley, A
Hayes, P
Gilmour, J
Riddell, L
Chen, FB
Atkins, M
Boffito, M
Walker, BD
Ackland, J
Sullivan, M
Goulder, P
AF Kloverpris, Henrik N.
Jackson, Akil
Handley, Amanda
Hayes, Peter
Gilmour, Jill
Riddell, Lynn
Chen, Fabian
Atkins, Mark
Boffito, Marta
Walker, Bruce D.
Ackland, Jim
Sullivan, Mark
Goulder, Philip
TI Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous
Cells after Vaccination of HIV Infected Individuals
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY VIRUS SIVMAC239; T-CELLS; CLINICAL-TRIALS; DENDRITIC
CELLS; CANDIDATE VACCINE; HEALTHY-ADULTS; PHASE-1 SAFETY; DNA VACCINE;
RESPONSES; IMMUNITY
AB Background: HIV Gag-specific CD4+ and CD8+ T-cell responses are important for HIV immune control. Pulsing overlapping Gag peptides on autologous lymphocytes (OPAL) has proven immunogenic and effective in reducing viral loads in multiple pigtail macaque studies, warranting clinical evaluation.
Methodology: We performed a phase I, single centre, placebo-controlled, double-blinded and dose-escalating study to evaluate the safety and preliminary immunogenicity of a novel therapeutic vaccine approach 'OPAL-HIV-Gag(c)'. This vaccine is comprised of 120 15mer peptides, overlapping by 11 amino acids, spanning the HIV Gag C clade sequence proteome, pulsed on white blood cells enriched from whole blood using a closed system, followed by intravenous reinfusion. Patients with undetectable HIV viral loads (<50 copies/ml plasma) on HAART received four administrations at week 0, 4, 8 and 12, and were followed up for 12 weeks post-treatment. Twenty-three people were enrolled in four groups: 12 mg (n = 6), 24 mg (n = 7), 48 mg (n = 2) or matching placebo (n = 8) with 18 immunologically evaluable. T-cell immunogenicity was assessed by IFN gamma ELIspot and intracellular cytokine staining (ICS).
Results: The OPAL-HIV-Gag(c) peptides were antigenic in vitro in 17/17 subjects. After vaccination with OPAL-HIV-Gag(c), 1/6 subjects at 12 mg and 1/6 subjects at 24 mg dose groups had a 2- and 3-fold increase in ELIspot magnitudes from baseline, respectively, of Gag-specific CD8+ T-cells at week 14, compared to 0/6 subjects in the placebo group. No Gag-specific CD4+ T-cell responses or overall change in Rev, Nef, Tat and CMV specific responses were detected. Marked, transient and self-limiting lymphopenia was observed immediately post-vaccination (4 hours) in OPAL-HIV-Gag(c) but not in placebo recipients, with median fall from 1.72 to 0.67 million lymphocytes/mL for active groups (P<0.001), compared to post-placebo from 1.70 to 1.56 lymphocytes/ml (P = 0.16).
Conclusion/Significance: Despite strong immunogenicity observed in several Macaca nemestrina studies using this approach, OPAL-HIV-Gag(c) was not significantly immunogenic in humans and improved methods of generating high-frequency Gag-specific T-cell responses are required.
C1 [Kloverpris, Henrik N.; Goulder, Philip] Univ Oxford, Dept Paediat, Oxford, England.
[Jackson, Akil; Boffito, Marta] Chelsea & Westminster Hosp, St Stephens AIDS Trust St Stephens Ctr, London, England.
[Handley, Amanda; Sullivan, Mark] Med Dev, Melbourne, Vic, Australia.
[Hayes, Peter; Gilmour, Jill; Atkins, Mark] Univ London Imperial Coll Sci Technol & Med, IAVI Human Immunol Lab, London, England.
[Riddell, Lynn] Northhamptonshire Healthcare Natl Hlth Serv Trust, Northhampton Gen Hosp, Dept Genitourinary Med, Cliftonville, Northhampton, England.
[Chen, Fabian] Royal Berkshire Hosp, Dept Sexual Hlth, Reading RG1 5AN, Berks, England.
[Kloverpris, Henrik N.] Univ Kwazulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Inst TB & HIV K RITH, Durban, KwaZulu Natal, South Africa.
[Kloverpris, Henrik N.] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Copenhagen, Denmark.
[Walker, Bruce D.; Goulder, Philip] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA.
[Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Ackland, Jim] Global Biosolut, Craigeburn, Vic, Australia.
RP Kloverpris, HN (reprint author), Univ Oxford, Dept Paediat, Oxford, England.
EM henrik.kloverpris@k-rith.org
FU Phillip T; Susan M Ragon Foundation
FX The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. The funding for
this project was provided by the Phillip T and Susan M Ragon Foundation.
Medicines Development was a study Sponsor, as defined in the US Code of
Federal Regulations, Title 21, Chapter I, Subchapter D, Subpart D, Part
312.50.
NR 44
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 4
PY 2013
VL 8
IS 10
AR e74389
DI 10.1371/journal.pone.0074389
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232JF
UT WOS:000325489100008
PM 24124451
ER
PT J
AU Lin, G
Field, JJ
Yu, JC
Ken, R
Neuberg, D
Nathan, DG
Linden, J
AF Lin, Gene
Field, Joshua J.
Yu, Jennifer C.
Ken, Ruey
Neuberg, Donna
Nathan, David G.
Linden, Joel
TI NF-kappa B Is Activated in CD4(+) iNKT Cells by Sickle Cell Disease and
Mediates Rapid Induction of Adenosine A(2A) Receptors
SO PLOS ONE
LA English
DT Article
ID KILLER T-CELLS; ISCHEMIA-REPERFUSION INJURY; IFN-GAMMA PRODUCTION; NKT
CELLS; INVARIANT NKT; VASCULAR INFLAMMATION; MURINE; MICE;
VASOOCCLUSION; LOCALIZATION
AB Reperfusion injury following tissue ischemia occurs as a consequence of vaso-occlusion that is initiated by activation of invariant natural killer T (iNKT) cells. Sickle cell disease (SDC) results in widely disseminated microvascular ischemia and reperfusion injury as a result of vaso-occlusion by rigid and adhesive sickle red blood cells. In mice, iNKT cell activation requires NF-kappa B signaling and can be inhibited by the activation of anti-inflammatory adenosine A(2A) receptors (A(2A)Rs). Human iNKT cells are divided into subsets of CD4+ and CD4- cells. In this study we found that human CD4+ iNKT cells, but not CD4- cells undergo rapid NF-kappa B activation (phosphorylation of NF-kappa B on p65) and induction of A(2A)Rs (detected with a monoclonal antibody 7F6-G5-A2) during SCD painful vaso-occlusive crises. These findings indicate that SCD primarily activates the CD4+ subset of iNKT cells. Activation of NF-kappa B and induction of A(2A)Rs is concordant, i.e. only CD4+ iNKT cells with activated NF-kappa B expressed high levels of A(2A)Rs. iNKT cells that are not activated during pVOC express low levels of A(2A)R immunoreactivity. These finding suggest that A(2A)R transcription may be induced in CD4+ iNKT cells as a result of NFkB activation in SCD. In order to test this hypothesis further we examined cultured human iNKT cells. In cultured cells, blockade of NF-kappa B with Bay 11-7082 or IKK inhibitor VII prevented rapid induction of A(2A)R mRNA and protein upon iNKT activation. In conclusion, NF-kappa B-mediated induction of A(2A)Rs in iNKT cells may serve as a counter-regulatory mechanism to limit the extent and duration of inflammatory immune responses. As activated iNKT cells express high levels of A(2A)Rs following their activation, they may become highly sensitive to inhibition by A(2A)R agonists.
C1 [Lin, Gene; Yu, Jennifer C.; Ken, Ruey; Linden, Joel] La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA USA.
[Field, Joshua J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Neuberg, Donna; Nathan, David G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Linden, J (reprint author), La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA USA.
EM jlinden@liai.org
RI Linden, Joel/J-9259-2014
OI Linden, Joel/0000-0002-0689-1647
FU National Institutes of Health [RC2 HL101367, R34 HL108757, R01HL095704]
FX Supported by grants RC2 HL101367, R34 HL108757 and R01HL095704 from the
National Institutes of Health. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 43
TC 13
Z9 13
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 4
PY 2013
VL 8
IS 10
AR e74664
DI 10.1371/journal.pone.0074664
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232JF
UT WOS:000325489100010
PM 24124453
ER
PT J
AU Wang, HY
Meyer, CA
Fei, T
Wang, G
Zhang, F
Liu, XS
AF Wang, Haiyun
Meyer, Clifford A.
Fei, Teng
Wang, Gang
Zhang, Fan
Liu, X. Shirley
TI A systematic approach identifies FOXA1 as a key factor in the loss of
epithelial traits during the epithelial-to-mesenchymal transition in
lung cancer
SO BMC GENOMICS
LA English
DT Article
DE The epithelial-to-mesenchymal transition; Lung cancer; ChIP-Seq; FOXA1
ID TUMOR-METASTASIS; E-CADHERIN; TRANSCRIPTION FACTORS; CELLS; GENE;
DIFFERENTIATION; REGULATOR; RECEPTOR; POLARITY; GENOME
AB Background: The epithelial-to-mesenchymal transition is an important mechanism in cancer metastasis. Although transcription factors including SNAIL, SLUG, and TWIST1 regulate the epithelial-to-mesenchymal transition, other unknown transcription factors could also be involved. Identification of the full complement of transcription factors is essential for a more complete understanding of gene regulation in this process. Chromatin immunoprecipitation-sequencing (ChIP-Seq) technologies have been used to detect genome-wide binding of transcription factors; here, we developed a systematic approach to integrate existing ChIP-Seq and transcriptome data. We scanned multiple transcription factors to investigate their functional impact on the epithelial-to-mesenchymal transition in the human A549 lung adenocarcinoma cell line.
Results: Among the transcription factors tested, impact scores identified the forkhead box protein A1 (FOXA1) as the most significant transcription factor in the epithelial-to-mesenchymal transition. FOXA1 physically associates with the promoters of its predicted target genes. Several critical epithelial-to-mesenchymal transition effectors involved in cellular adhesion and cellular communication were identified in the regulatory network of FOXA1, including FOXA2, FGA, FGB, FGG, and FGL1. The implication of FOXA1 in the epithelial-to-mesenchymal transition via its regulatory network indicates that FOXA1 may play an important role in the initiation of lung cancer metastasis.
Conclusions: We identified FOXA1 as a potentially important transcription factor and negative regulator in the initial stages of lung cancer metastasis. FOXA1 may modulate the epithelial-to-mesenchymal transition via its transcriptional regulatory network. Further, this study demonstrates how ChIP-Seq and expression data could be integrated to delineate the impact of transcription factors on a specific biological process.
C1 [Wang, Haiyun] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
[Wang, Haiyun; Meyer, Clifford A.; Fei, Teng; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Wang, Haiyun; Meyer, Clifford A.; Fei, Teng; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
[Wang, Haiyun] Tongji Univ, Adv Inst Translat Med, Shanghai 200092, Peoples R China.
[Fei, Teng] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02215 USA.
[Fei, Teng] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Wang, Gang; Zhang, Fan] Tongji Univ, Sch Life Sci & Technol, Shanghai Pulm Hosp, Clin Translat Res Ctr, Shanghai 200092, Peoples R China.
RP Wang, HY (reprint author), Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
EM wanghaiyun@tongji.edu.cn; fzhang@tongji.edu.cn
RI Fei, Teng/G-5324-2015
OI Fei, Teng/0000-0001-5707-0673
FU National Natural Science Foundation of China [31100912, 31329003];
National Institutes of Health [HG4069]
FX This work was supported by National Natural Science Foundation of China
(31100912); National Natural Science Foundation of China (31329003); and
National Institutes of Health (HG4069).
NR 33
TC 9
Z9 10
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD OCT 4
PY 2013
VL 14
AR 680
DI 10.1186/1471-2164-14-680
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 241NQ
UT WOS:000326174300002
PM 24093963
ER
PT J
AU Widge, A
AF Widge, Alik
TI NextGen Speaks
SO SCIENCE
LA English
DT Letter
C1 [Widge, Alik] Massachusetts Gen Hosp, Dept Psychiat, Div Neurotherapeut, Charlestown, MA 02129 USA.
[Widge, Alik] MIT, Picower Inst Learning & Memory, Cambridge, MA 02139 USA.
RP Widge, A (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Div Neurotherapeut, Charlestown, MA 02129 USA.
EM awidge@mit.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD OCT 4
PY 2013
VL 342
IS 6154
BP 37
EP 37
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 227PP
UT WOS:000325126100020
ER
PT J
AU Khurana, E
Fu, Y
Colonna, V
Mu, XJ
Kang, HM
Lappalainen, T
Sboner, A
Lochovsky, L
Chen, JM
Harmanci, A
Das, J
Abyzov, A
Balasubramanian, S
Beal, K
Chakravarty, D
Challis, D
Chen, Y
Clarke, D
Clarke, L
Cunningham, F
Evani, US
Flicek, P
Fragoza, R
Garrison, E
Gibbs, R
Guemues, ZH
Herrero, J
Kitabayashi, N
Kong, Y
Lage, K
Liluashvili, V
Lipkin, SM
MacArthur, DG
Marth, G
Muzny, D
Pers, TH
Ritchie, GRS
Rosenfeld, JA
Sisu, C
Wei, XM
Wilson, M
Xue, YL
Yu, FL
Dermitzakis, ET
Yu, HY
Rubin, MA
Tyler-Smith, C
Gerstein, M
AF Khurana, Ekta
Fu, Yao
Colonna, Vincenza
Mu, Xinmeng Jasmine
Kang, Hyun Min
Lappalainen, Tuuli
Sboner, Andrea
Lochovsky, Lucas
Chen, Jieming
Harmanci, Arif
Das, Jishnu
Abyzov, Alexej
Balasubramanian, Suganthi
Beal, Kathryn
Chakravarty, Dimple
Challis, Daniel
Chen, Yuan
Clarke, Declan
Clarke, Laura
Cunningham, Fiona
Evani, Uday S.
Flicek, Paul
Fragoza, Robert
Garrison, Erik
Gibbs, Richard
Guemues, Zeynep H.
Herrero, Javier
Kitabayashi, Naoki
Kong, Yong
Lage, Kasper
Liluashvili, Vaja
Lipkin, Steven M.
MacArthur, Daniel G.
Marth, Gabor
Muzny, Donna
Pers, Tune H.
Ritchie, Graham R. S.
Rosenfeld, Jeffrey A.
Sisu, Cristina
Wei, Xiaomu
Wilson, Michael
Xue, Yali
Yu, Fuli
Dermitzakis, Emmanouil T.
Yu, Haiyuan
Rubin, Mark A.
Tyler-Smith, Chris
Gerstein, Mark
CA 1000 Genomes Project Consortium
TI Integrative Annotation of Variants from 1092 Humans: Application to
Cancer Genomics
SO SCIENCE
LA English
DT Article
ID TERT PROMOTER MUTATIONS; NATURAL-SELECTION; PROSTATE-CANCER; POSITIVE
SELECTION; GENETIC-VARIATION; HUMAN-EVOLUTION; COPY NUMBER; ELEMENTS;
NETWORK; DISEASE
AB Interpreting variants, especially noncoding ones, in the increasing number of personal genomes is challenging. We used patterns of polymorphisms in functionally annotated regions in 1092 humans to identify deleterious variants; then we experimentally validated candidates. We analyzed both coding and noncoding regions, with the former corroborating the latter. We found regions particularly sensitive to mutations ("ultrasensitive") and variants that are disruptive because of mechanistic effects on transcription-factor binding (that is, "motif-breakers"). We also found variants in regions with higher network centrality tend to be deleterious. Insertions and deletions followed a similar pattern to single-nucleotide variants, with some notable exceptions (e. g., certain deletions and enhancers). On the basis of these patterns, we developed a computational tool (FunSeq), whose application to similar to 90 cancer genomes reveals nearly a hundred candidate noncoding drivers.
C1 [Khurana, Ekta; Fu, Yao; Mu, Xinmeng Jasmine; Lochovsky, Lucas; Chen, Jieming; Harmanci, Arif; Abyzov, Alexej; Balasubramanian, Suganthi; Sisu, Cristina; Wilson, Michael; Gerstein, Mark] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA.
[Khurana, Ekta; Harmanci, Arif; Abyzov, Alexej; Balasubramanian, Suganthi; Kong, Yong; Sisu, Cristina; Gerstein, Mark] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.
[Colonna, Vincenza; Chen, Yuan; Xue, Yali; Tyler-Smith, Chris] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
[Colonna, Vincenza] CNR, Inst Genet & Biophys, I-80131 Naples, Italy.
[Kang, Hyun Min] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Lappalainen, Tuuli; Dermitzakis, Emmanouil T.] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland.
[Lappalainen, Tuuli; Dermitzakis, Emmanouil T.] Univ Geneva, iGE3, CH-1211 Geneva, Switzerland.
[Lappalainen, Tuuli; Dermitzakis, Emmanouil T.] Swiss Inst Bioinformat, CH-1211 Geneva, Switzerland.
[Sboner, Andrea; Chakravarty, Dimple; Kitabayashi, Naoki; Rubin, Mark A.] Weill Cornell Med Coll, Inst Precis Med, New York, NY 10065 USA.
[Sboner, Andrea; Chakravarty, Dimple; Kitabayashi, Naoki; Rubin, Mark A.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
New York Presbyterian Hosp, New York, NY 10065 USA.
[Sboner, Andrea; Guemues, Zeynep H.; Liluashvili, Vaja] Weill Cornell Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY 10021 USA.
[Chen, Jieming] Yale Univ, Integrated Grad Program Phys & Engn Biol, New Haven, CT 06520 USA.
[Das, Jishnu; Yu, Haiyuan] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA.
[Das, Jishnu; Fragoza, Robert; Wei, Xiaomu; Yu, Haiyuan] Cornell Univ, Inst Cell & Mol Biol, Ithaca, NY 14853 USA.
[Beal, Kathryn; Clarke, Laura; Cunningham, Fiona; Flicek, Paul; Herrero, Javier; Ritchie, Graham R. S.] European Bioinformat Inst, European Mol Biol Lab, Cambridge CB10 1SD, England.
[Challis, Daniel; Evani, Uday S.; Gibbs, Richard; Muzny, Donna; Yu, Fuli] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Clarke, Declan] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
[Fragoza, Robert] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.
[Garrison, Erik; Marth, Gabor] Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA.
[Guemues, Zeynep H.; Liluashvili, Vaja] Weill Cornell Med ical Coll, Dept Physiol & Biophys, New York, NY 10065 USA.
[Kong, Yong] Yale Univ, Keck Biotechnol Resource Lab, New Haven, CT 06511 USA.
[Lage, Kasper] Massachusetts Gen Hosp, MassGeneral Hosp Children, Pediat Surg Res Labs, Boston, MA 02114 USA.
[Lage, Kasper; MacArthur, Daniel G.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Lage, Kasper] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Lage, Kasper; Pers, Tune H.] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark.
[Lage, Kasper] Univ Copenhagen, Ctr Prot Res, Copenhagen, Denmark.
[Lipkin, Steven M.; Wei, Xiaomu] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.
[MacArthur, Daniel G.] Broad Inst Harvard & Massachusetts Inst Technol M, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Pers, Tune H.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Pers, Tune H.] Childrens Hosp, Ctr Basic & Translat Obes Res, Boston, MA 02115 USA.
[Pers, Tune H.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Rosenfeld, Jeffrey A.] Rutgers New Jersey Med Sch, Dept Med, Newark, NJ 07101 USA.
[Rosenfeld, Jeffrey A.] Rutgers State Univ, IST High Performance & Res Comp, Newark, NJ 07101 USA.
[Rosenfeld, Jeffrey A.] Amer Museum Nat Hist, Sackler Inst Comparat Genom, New York, NY 10024 USA.
[Wilson, Michael] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.
[Gerstein, Mark] Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA.
RP Tyler-Smith, C (reprint author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.
EM cts@sanger.ac.uk; mark.gerstein@yale.edu
RI Abyzov, Alexej/M-4284-2013; Sboner, Andrea/C-6487-2008; Altshuler,
David/A-4476-2009; Ye, Kai/B-3640-2012; Chakravarty, Dimple/N-3325-2014;
Das, Jishnu/C-6924-2015; Browning, Brian/A-1178-2010; Li,
Yingrui/K-1064-2015; Angius, Andrea/P-9549-2015; Mu,
Xinmeng/P-2562-2016; Colonna, Vincenza/H-2021-2014;
OI Sboner, Andrea/0000-0001-6915-3070; Altshuler,
David/0000-0002-7250-4107; Chakravarty, Dimple/0000-0002-8588-8461; Das,
Jishnu/0000-0002-5747-064X; Browning, Brian/0000-0001-6454-6633; Angius,
Andrea/0000-0003-2596-6461; Mu, Xinmeng/0000-0002-8079-0828; Streeter,
Ian/0000-0003-4024-3552; Angius, Andrea/0000-0001-9372-1162; Kulesha,
Eugene/0000-0002-4285-6232; Colonna, Vincenza/0000-0002-3966-0474; Kim,
Kicheol/0000-0003-3667-9900; Walter, Klaudia/0000-0003-4448-0301;
Herrero, Javier/0000-0001-7313-717X; Rubin, Mark/0000-0002-8321-9950;
Clarke, Laura/0000-0002-5989-6898; Cooper, David N./0000-0002-8943-8484;
Flicek, Paul/0000-0002-3897-7955; McLaren, William/0000-0001-6218-1116;
Keane, Thomas/0000-0001-7532-6898; Ritchie, Graham/0000-0002-6456-9736;
Radhakrishnan, Rajesh/0000-0001-7170-699X; Sisu,
Cristina/0000-0001-9371-0797; Abyzov, Alexej/0000-0001-5405-6729;
Leinonen, Rasko/0000-0002-2639-7187; Rodriguez-Flores, Juan
L/0000-0002-0394-8062; Lappalainen, Tuuli/0000-0002-7746-8109; Chen,
Jieming/0000-0003-3767-9486; Sebat, Jonathan/0000-0002-9087-526X; Kong,
Yong/0000-0002-2881-5274; Fuchsberger, Christian/0000-0002-5918-8947
FU Danish Council for Independent Research Medical Sciences; European
Molecular Biology Laboratory; Wellcome Trust [WT085532, WT095908];
Wellcome-Trust Sanger Institute [098051]; National Cancer Institute
(NCI) [R01CA152057]; Early Detection Research Network NCI [U01
CA111275]; Prostate Cancer Foundation [HG005718, HG007000]; National
Human Genome Research Institute [R01HG4719, U01HG6513]; National
Institute of General Medical Sciences [GM104424]
FX We thank G. Boysen and C. O'Reilly for help with SNV experimental
validation, K. Yip for target-gene identification, and Z. Liu for Web
site design. T. H. P. is supported by the Danish Council for Independent
Research Medical Sciences (FSS). Funding at the European Bioinformatics
Institute is provided by European Molecular Biology Laboratory and the
Wellcome Trust (WT085532 and WT095908). C.T.-S. acknowledges grant
098051 from the Wellcome-Trust Sanger Institute. Funding for the
Institute for Precision Medicine (Weill Cornell Medical College/New York
Presbyterian) is provided by National Cancer Institute (NCI) grant
R01CA152057 (A. S., M. G., and M. A. R.) and Early Detection Research
Network NCI U01 CA111275 (M. A. R.). M. A. R. also thanks the Prostate
Cancer Foundation. M. G. also acknowledges grants HG005718 and HG007000.
G. M. acknowledges National Human Genome Research Institute grants
R01HG4719 and U01HG6513. H.Y. and S. M. L. are supported by NCI grant
CA167824, National Institute of General Medical Sciences grant GM104424,
and a Clinical and Translational Science Center Pilot Award and Cornell
Seed Grant for intercampus collaborations. H. M. K., T. L., A. S., L.
L., J.C., A. H., and J.D. contributed equally.
NR 48
TC 140
Z9 146
U1 7
U2 66
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD OCT 4
PY 2013
VL 342
IS 6154
BP 84
EP +
AR 1235587
DI 10.1126/science.1235587
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 227PP
UT WOS:000325126100049
PM 24092746
ER
PT J
AU Wang, DS
Song, CM
Barabasi, AL
AF Wang, Dashun
Song, Chaoming
Barabasi, Albert-Laszlo
TI Quantifying Long-Term Scientific Impact
SO SCIENCE
LA English
DT Article
ID CITATION; NETWORKS; JOURNALS; SCIENCE; INDEX
AB The lack of predictability of citation-based measures frequently used to gauge impact, from impact factors to short-term citations, raises a fundamental question: Is there long-term predictability in citation patterns? Here, we derive a mechanistic model for the citation dynamics of individual papers, allowing us to collapse the citation histories of papers from different journals and disciplines into a single curve, indicating that all papers tend to follow the same universal temporal pattern. The observed patterns not only help us uncover basic mechanisms that govern scientific impact but also offer reliable measures of influence that may have potential policy implications.
C1 [Wang, Dashun; Song, Chaoming; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Biol, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA.
[Wang, Dashun; Song, Chaoming; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Comp Sci, Boston, MA 02115 USA.
[Wang, Dashun] IBM Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA.
[Song, Chaoming] Univ Miami, Dept Phys, Coral Gables, FL 33124 USA.
[Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo] Cent European Univ, Ctr Network Sci, Budapest, Hungary.
RP Barabasi, AL (reprint author), Northeastern Univ, Dept Biol, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA.
EM alb@neu.edu
FU Lockheed Martin Corporation [SRA 11.18.11]; Network Science
Collaborative Technology Alliance; U.S. Army Research Laboratory
[W911NF-09-2-0053]; Defense Advanced Research Projects Agency
[11645021]; Future and Emerging Technologies Project [317 532]; European
Commission
FX The authors thank P. Azoulay, C. Hidalgo, J. Loscalzo, D. Pedreschi, B.
Uzzi, M. Vidal, and members of Center for Complex Network Research for
insightful discussions and the anonymous referee for suggesting the
lognormal model, which led to the analytical prediction of the citation
threshold for preferential attachment. The PR data set is available upon
request through American Physical Society. Supported by Lockheed Martin
Corporation (SRA 11.18.11), the Network Science Collaborative Technology
Alliance is sponsored by the U.S. Army Research Laboratory under
agreement W911NF-09-2-0053, Defense Advanced Research Projects Agency
under agreement 11645021, and the Future and Emerging Technologies
Project 317 532 "Multiplex" financed by the European Commission.
NR 30
TC 115
Z9 119
U1 16
U2 154
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD OCT 4
PY 2013
VL 342
IS 6154
BP 127
EP 132
DI 10.1126/science.1237825
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 227PP
UT WOS:000325126100061
PM 24092745
ER
PT J
AU Liu, XH
Ide, JL
Norton, I
Marchionni, MA
Ebling, MC
Wang, LY
Davis, E
Sauvageot, CM
Kesari, S
Kellersberger, KA
Easterling, ML
Santagata, S
Stuart, DD
Alberta, J
Agar, JN
Stiles, CD
Agar, NYR
AF Liu, Xiaohui
Ide, Jennifer L.
Norton, Isaiah
Marchionni, Mark A.
Ebling, Maritza C.
Wang, Lan Y.
Davis, Erin
Sauvageot, Claire M.
Kesari, Santosh
Kellersberger, Katherine A.
Easterling, Michael L.
Santagata, Sandro
Stuart, Darrin D.
Alberta, John
Agar, Jeffrey N.
Stiles, Charles D.
Agar, Nathalie Y. R.
TI Molecular imaging of drug transit through the blood-brain barrier with
MALDI mass spectrometry imaging
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; TISSUE-SECTIONS; ERLOTINIB; PATHWAY; CELL;
AUTORADIOGRAPHY; INHIBITOR; DISCOVERY; CANCER; OPTIMIZATION
AB Drug transit through the blood-brain barrier (BBB) is essential for therapeutic responses in malignant glioma. Conventional methods for assessment of BBB penetrance require synthesis of isotopically labeled drug derivatives. Here, we report a new methodology using matrix assisted laser desorption ionization mass spectrometry imaging (MALDI MSI) to visualize drug penetration in brain tissue without molecular labeling. In studies summarized here, we first validate heme as a simple and robust MALDI MSI marker for the lumen of blood vessels in the brain. We go on to provide three examples of how MALDI MSI can provide chemical and biological insights into BBB penetrance and metabolism of small molecule signal transduction inhibitors in the brain - insights that would be difficult or impossible to extract by use of radiolabeled compounds.
C1 [Liu, Xiaohui; Ide, Jennifer L.; Norton, Isaiah; Ebling, Maritza C.; Agar, Nathalie Y. R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
[Marchionni, Mark A.; Wang, Lan Y.; Davis, Erin; Sauvageot, Claire M.; Alberta, John; Stiles, Charles D.; Agar, Nathalie Y. R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Kesari, Santosh] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Kellersberger, Katherine A.; Easterling, Michael L.] Bruker Daltonics Inc, Billerica, MA USA.
[Santagata, Sandro] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Stuart, Darrin D.] Novartis Inst BioMed Res, Emeryville, CA USA.
[Agar, Jeffrey N.] Brandeis Univ, Waltham, MA USA.
[Agar, Nathalie Y. R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
RP Agar, NYR (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
EM Charles_Stiles@dfci.harvard.edu; Nathalie_Agar@dfci.harvard.edu
RI Kesari, Santosh/E-8461-2013
FU US National Institute of Health (NIH) [1DP2OD007383-01]; NIH-NCI [P01
CA142536]; Pediatric Low Grade Astrocytoma Program at Dana-Farber Cancer
Institute; Brain Science Foundation; Daniel E. Ponton fund for the
Neurosciences at BWH; Dana-Farber/Novartis Program in Drug Discovery;
Amyotrophic Lateral Sclerosis Association [1856]
FX This work was funded in part by US National Institute of Health (NIH)
Director's New Innovator Award (1DP2OD007383-01 to N.Y.R.A.), and the
NIH-NCI (P01 CA142536 to C. D. S. and N.Y.R.A.). The work received
support from the Pediatric Low Grade Astrocytoma Program at Dana-Farber
Cancer Institute, the Brain Science Foundation and the Daniel E. Ponton
fund for the Neurosciences at BWH and the Dana-Farber/Novartis Program
in Drug Discovery. J.N.A. received support from the Amyotrophic Lateral
Sclerosis Association grant number 1856. We thank Daniel Feldman for his
assistance with the tandem MS experiments.
NR 38
TC 36
Z9 37
U1 4
U2 38
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 4
PY 2013
VL 3
AR 2859
DI 10.1038/srep02859
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 228UH
UT WOS:000325216000006
PM 24091529
ER
PT J
AU Brumbaugh, J
Hochedlinger, K
AF Brumbaugh, Justin
Hochedlinger, Konrad
TI Removing Reprogramming Roadblocks: Mbd3 Depletion Allows Deterministic
iPSC Generation
SO CELL STEM CELL
LA English
DT Editorial Material
ID PLURIPOTENT STEM-CELLS; SOMATIC-CELLS
AB Transcription factor-induced pluripotency is extremely inefficient and assumed to be stochastic. In a recent Nature publication, Rais et al. show that depletion of the methyl-binding protein 3 yields reprogramming efficiencies of up to 100% within days, suggesting that elimination of a single gene suffices to render reprogramming a deterministic process.
C1 [Brumbaugh, Justin; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Brumbaugh, Justin; Hochedlinger, Konrad] Ctr Regenerat Med, Boston, MA 02114 USA.
[Brumbaugh, Justin; Hochedlinger, Konrad] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Hochedlinger, Konrad] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
[Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Hochedlinger, Konrad] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Hochedlinger, K (reprint author), Massachusetts Gen Hosp, Ctr Canc, 185 Cambridge St, Boston, MA 02114 USA.
EM khochedlinger@helix.mgh.harvard.edu
NR 9
TC 5
Z9 6
U1 0
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD OCT 3
PY 2013
VL 13
IS 4
BP 379
EP 381
DI 10.1016/j.stem.2013.09.012
PG 3
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VT
UT WOS:000329571100005
PM 24094318
ER
PT J
AU Doulatov, S
Vo, LT
Chou, SS
Kim, PG
Arora, N
Li, H
Hadland, BK
Bernstein, ID
Collins, JJ
Zon, LI
Daley, GQ
AF Doulatov, Sergei
Vo, Linda T.
Chou, Stephanie S.
Kim, Peter G.
Arora, Natasha
Li, Hu
Hadland, Brandon K.
Bernstein, Irwin D.
Collins, James J.
Zon, Leonard I.
Daley, George Q.
TI Induction of Multipotential Hematopoietic Progenitors from Human
Pluripotent Stem Cells via Respecification of Lineage-Restricted
Precursors
SO CELL STEM CELL
LA English
DT Article
ID RED-BLOOD-CELLS; IN-VIVO; DIFFERENTIATION CULTURES; REPOPULATING
ABILITY; AORTIC ENDOTHELIUM; GENERATION; EXPRESSION; MACROPHAGES;
TRANSFUSION; ENGRAFTMENT
AB Human pluripotent stem cells (hPSCs) represent a promising source of patient-specific cells for disease modeling, drug screens, and cellular therapies. However, the inability to derive engraftable human hematopoietic stem and progenitor cells (HSPCs) has limited their characterization to in vitro assays. We report a strategy to respecify lineage-restricted CD34(+)CD45(+) myeloid precursors derived from hPSCs into multilineage progenitors that can be expanded in vitro and engrafted in vivo. HOXA9, ERG, and RORA conferred self-renewal and multilineage potential in vitro and maintained primitive CD34(+)CD38(-) cells. Screening cells via transplantation revealed that two additional factors, SOX4 and MYB, conferred engraftment. Progenitors specified with all five factors gave rise to reproducible short-term engraftment with myeloid and erythroid lineages. Erythroid precursors underwent hemoglobin switching in vivo, silencing embryonic and activating adult globin expression. Our combinatorial screening approach establishes a strategy for obtaining transcription-factor-mediated engraftment of blood progenitors from human pluripotent cells.
C1 [Doulatov, Sergei; Vo, Linda T.; Chou, Stephanie S.; Kim, Peter G.; Arora, Natasha; Daley, George Q.] Childrens Hosp, Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol,Manton Ctr Orphan Dis Re, Boston, MA 02115 USA.
[Doulatov, Sergei; Vo, Linda T.; Chou, Stephanie S.; Kim, Peter G.; Arora, Natasha; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Doulatov, Sergei; Vo, Linda T.; Chou, Stephanie S.; Kim, Peter G.; Arora, Natasha; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Doulatov, Sergei; Vo, Linda T.; Chou, Stephanie S.; Kim, Peter G.; Arora, Natasha; Zon, Leonard I.; Daley, George Q.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Li, Hu; Collins, James J.] Boston Univ, Howard Hughes Med Inst, Dept Biomed Engn, Boston, MA 02215 USA.
[Li, Hu; Collins, James J.] Boston Univ, Ctr BioDynam, Boston, MA 02215 USA.
[Li, Hu; Collins, James J.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
[Hadland, Brandon K.; Bernstein, Irwin D.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
[Hadland, Brandon K.; Bernstein, Irwin D.] Univ Washington, Dept Pediat, Seattle, WA 98105 USA.
[Zon, Leonard I.] Childrens Hosp, Howard Hughes Med Inst, Div Pediat Hematol Oncol, Stem Cell Program, Boston, MA 02115 USA.
[Zon, Leonard I.; Daley, George Q.] Broad Inst, Cambridge, MA 02141 USA.
RP Daley, GQ (reprint author), Childrens Hosp, Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol,Manton Ctr Orphan Dis Re, Boston, MA 02115 USA.
EM george.daley@childrens.harvard.edu
FU US National Institute of Diabetes and Digestive and Kidney Diseases
[R24-DK092760]; National Heart, Lung, Blood Institute Progenitor Cell
Biology Consortium [UO1-HL100001]; Alex's Lemonade Stand; Doris Duke
Medical Foundation; Helen Hay Whitney Foundation; NSF
FX The authors would like to thank Thorsten Schlaeger and the BCH ESC core,
Ronald Mathieu from the flow cytometry core, and Norman Gerry from the
Coriell Genotyping and Microarray Center for assistance. Andrea Ditadi
and Gordon Keller provided reagents and advice. Band3 antibody was a
gift from the Narla Mohandas lab. This work is supported by grants from
the US National Institute of Diabetes and Digestive and Kidney Diseases
(R24-DK092760) and the National Heart, Lung, Blood Institute Progenitor
Cell Biology Consortium (UO1-HL100001); Alex's Lemonade Stand; and the
Doris Duke Medical Foundation. G. Q. D. is an associate member of the
Broad Institute and an investigator of the Howard Hughes Medical
Institute and the Manton Center for Orphan Disease Research. S. D. is
supported by a fellowship from the Helen Hay Whitney Foundation. L. T.
V. is supported by the NSF Graduate Research Fellowship.
NR 47
TC 72
Z9 72
U1 4
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD OCT 3
PY 2013
VL 13
IS 4
BP 459
EP 470
DI 10.1016/j.stem.2013.09.002
PG 12
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VT
UT WOS:000329571100014
PM 24094326
ER
PT J
AU Liu, JC
Guan, X
Ryan, JA
Rivera, AG
Mock, C
Agarwal, V
Letai, A
Lerou, PH
Lahav, G
AF Liu, Julia C.
Guan, Xiao
Ryan, Jeremy A.
Rivera, Ana G.
Mock, Caroline
Agarwal, Vishesh
Letai, Anthony
Lerou, Paul H.
Lahav, Galit
TI High Mitochondrial Priming Sensitizes hESCs to DNA-Damage-Induced
Apoptosis
SO CELL STEM CELL
LA English
DT Article
ID EMBRYONIC STEM-CELLS; BCL-2 FAMILY; SELF-RENEWAL; IN-VIVO; P53;
DIFFERENTIATION; PUMA; ACTIVATION; EXPRESSION; RADIATION
AB Human embryonic stem cells (hESCs) are highly sensitive to DNA damage and have low survival ability relative to differentiated cells. We investigated the source of this difference by comparing damage response pathways in hESCs and differentiated cells. We found that hESCs undergo more rapid p53-dependent apoptosis after DNA damage than differentiated cells do. However, p53 localization and function are similar between hESCs and differentiated cells, suggesting that p53 alone cannot explain the difference in sensitivity. Instead, we show that mitochondrial readiness for apoptosis, known as mitochondrial priming, differs between hESCs and differentiated cells. Specifically, the balance between proapoptotic and antiapoptotic proteins is shifted closer to the apoptotic threshold in hESCs than in differentiated cells. Altering this balance in differentiated cells increases their sensitivity and results in cell death, suggesting that manipulation of mitochondrial priming could potentially alter the sensitivity of other stem cells, including cancer stem cells.
C1 [Liu, Julia C.; Rivera, Ana G.; Mock, Caroline; Lahav, Galit] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Letai, Anthony] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Guan, Xiao; Agarwal, Vishesh; Lerou, Paul H.] Brigham & Womens Hosp, Dept Pediat Newborn Med, Boston, MA 02115 USA.
[Guan, Xiao; Agarwal, Vishesh; Lerou, Paul H.] Brigham & Womens Hosp, Div Genet, Dept Med, Boston, MA 02115 USA.
[Ryan, Jeremy A.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Lerou, Paul H.] Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA.
[Lerou, Paul H.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Lerou, PH (reprint author), Brigham & Womens Hosp, Dept Pediat Newborn Med, 75 Francis St, Boston, MA 02115 USA.
EM plerou@partners.org; galit@hms.harvard.edu
OI Mock, Charles/0000-0002-0564-568X
FU Molecular Biophysics Training Grant [NIH/NIGMS T32008313]; National
Science Foundation; Harvard College Program for Research in Science and
Engineering; FAS Center for Systems Biology; Charles H. Hood Foundation;
NIH/NICHD [HD061981]
FX We thank R. Agami for the p53shRNA construct; G. Daley for the CHB8 cell
line; D. Melton for the HUES9 cell line; Y. Xu for the HUES9
p53-/- cell line; A. Baccei, B. Gorman, and K. Karhohs for
assistance with IF imaging and analysis; J. Moore and J.
Stewart-Ornstein for assistance with flow cytometry and analysis; J.
Reyes for assistance with illustration; and E. Batchelor and all members
of our laboratory for comments and discussions. J. C. L. was supported
by the Molecular Biophysics Training Grant (NIH/NIGMS T32008313) and the
National Science Foundation Graduate Research Fellowship. A. G. R. was
supported by the Harvard College Program for Research in Science and
Engineering and the FAS Center for Systems Biology. P. H. L. was
supported by the Charles H. Hood Foundation and NIH/NICHD HD061981.
NR 33
TC 41
Z9 43
U1 2
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD OCT 3
PY 2013
VL 13
IS 4
BP 483
EP 491
DI 10.1016/j.stem.2013.07.018
PG 9
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VT
UT WOS:000329571100016
PM 23954752
ER
PT J
AU Guo, GJ
Luc, S
Marco, E
Lin, TW
Peng, C
Kerenyi, MA
Beyaz, S
Kim, W
Xu, J
Das, PP
Neff, T
Zou, KY
Yuan, GC
Orkin, SH
AF Guo, Guoji
Luc, Sidinh
Marco, Eugenio
Lin, Ta-Wei
Peng, Cong
Kerenyi, Marc A.
Beyaz, Semir
Kim, Woojin
Xu, Jian
Das, Partha Pratim
Neff, Tobias
Zou, Keyong
Yuan, Guo-Cheng
Orkin, Stuart H.
TI Mapping Cellular Hierarchy by Single-Cell Analysis of the Cell Surface
Repertoire
SO CELL STEM CELL
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; GENE-EXPRESSION ANALYSIS; ACUTE
MYELOID-LEUKEMIA; MOUSE BONE-MARROW; MESSENGER-RNA-SEQ; TRANSCRIPTION
FACTOR; PROGENITOR CELLS; IDENTIFICATION; GATA-1; LINEAGES
AB Stem cell differentiation pathways are most often studied at the population level, whereas critical decisions are executed at the level of single cells. We have established a highly multiplexed, quantitative PCR assay to profile in an unbiased manner a panel of all commonly used cell surface markers (280 genes) from individual cells. With this method, we analyzed over 1,500 single cells throughout the mouse hematopoietic system and illustrate its utility for revealing important biological insights. The comprehensive single cell data set permits mapping of the mouse hematopoietic stem cell differentiation hierarchy by computational lineage progression analysis. Further profiling of 180 intracellular regulators enabled construction of a genetic network to assign the earliest differentiation event during hematopoietic lineage specification. Analysis of acute myeloid leukemia elicited by MLL-AF9 uncovered a distinct cellular hierarchy containing two independent self-renewing lineages with different clonal activities. The strategy has broad applicability in other cellular systems.
C1 [Guo, Guoji; Luc, Sidinh; Peng, Cong; Kerenyi, Marc A.; Beyaz, Semir; Kim, Woojin; Xu, Jian; Das, Partha Pratim; Orkin, Stuart H.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Guo, Guoji; Luc, Sidinh; Peng, Cong; Kerenyi, Marc A.; Beyaz, Semir; Kim, Woojin; Xu, Jian; Das, Partha Pratim; Orkin, Stuart H.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA.
[Marco, Eugenio; Yuan, Guo-Cheng] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Lin, Ta-Wei] Childrens Hosp, Mol Genet Core Facil, Boston, MA 02115 USA.
[Neff, Tobias] Univ Colorado, Pediat Hematol Oncol BMT, Aurora, CO 80045 USA.
[Zou, Keyong] Boston Open Labs, Cambridge, MA 02138 USA.
RP Orkin, SH (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
EM stuart_orkin@dfci.harvard.edu
OI Neff, Tobias/0000-0002-0188-8393; Beyaz, Semir/0000-0003-4730-4012
FU National Institutes of Health; Harvard Stem Cell Institute
FX We thank H. Skaletsky from Whitehead Institute for extensive help on the
multiplexed primer design; Y. Fujiwara, E. Baena, O. Yilmaz, M. Nguyen,
X. Han, V. Bragt, D. Linn, and J. Buchman for help with different parts
of the sample preparations; and H. Huang, Z. Li, D. Scadden, H. Xie, and
H. Hock for insightful discussions on the project. This work was
supported by funding from the National Institutes of Health and the
Harvard Stem Cell Institute (S. H. O). S. H. O. is an investigator of
the Howard Hughes Medical Institute.
NR 41
TC 86
Z9 87
U1 0
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD OCT 3
PY 2013
VL 13
IS 4
BP 492
EP 505
DI 10.1016/j.stem.2013.07.017
PG 14
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VT
UT WOS:000329571100017
PM 24035353
ER
PT J
AU Lassus, J
Gayat, E
Mueller, C
Peacock, WF
Spinar, J
Harjola, VP
van Kimmenade, R
Pathak, A
Mueller, T
diSomma, S
Metra, M
Pascual-Figal, D
Laribi, S
Logeart, D
Nouira, S
Sato, N
Potocki, M
Parenica, J
Collet, C
Cohen-Solal, A
Januzzi, JL
Mebazaa, A
AF Lassus, Johan
Gayat, Etienne
Mueller, Christian
Peacock, W. Frank
Spinar, Jindrich
Harjola, Veli-Pekka
van Kimmenade, Roland
Pathak, Atul
Mueller, Thomas
diSomma, Salvatore
Metra, Marco
Pascual-Figal, Domingo
Laribi, Said
Logeart, Damien
Nouira, Semir
Sato, Naoki
Potocki, Michael
Parenica, Jiri
Collet, Corinne
Cohen-Solal, Alain
Januzzi, James L., Jr.
Mebazaa, Alexandre
CA GREAT-Network
TI Incremental value of biomarkers to clinical variables for mortality
prediction in acutely decompensated heart failure: The Multinational
Observational Cohort on Acute Heart Failure (MOCA) study
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE ADHF; Mortality; Risk prediction; Biomarkers; Reclassification
ID IN-HOSPITAL MORTALITY; NATRIURETIC PEPTIDE; RISK STRATIFICATION;
RENAL-FUNCTION; ROC CURVE; NT-PROBNP; DIAGNOSIS; RECLASSIFICATION;
GUIDELINES; PROGNOSIS
AB Aim: This study aims to evaluate the incremental value of plasma biomarkers to traditional clinical variables for risk stratification of 30-day and one-year mortality in acutely decompensated heart failure (ADHF).
Methods and results: Through an international collaborative network, individual patient data on 5306 patients hospitalized for ADHF were collected. The all-cause mortality rate was 11.7% at 30 days and 32.9% at one year. The clinical prediction model (age, gender, blood pressure on admission, estimated glomerular filtration rate <60mL/min/1.73 m(2), sodium and hemoglobin levels, and heart rate) had a c-statistic of 0.74 for 30-day mortality and 0.73 for one-year mortality. Several biomarkers measured at presentation improved risk stratification when added to the clinical model. At 30 days, the net reclassification improvement (NRI) was 28.7% for mid-regional adrenomedullin (MR-proADM; p<0.001) and 25.5% for soluble (s) ST2 (p<.001). At one year, sST2 (NRI 10.3%), MR-proADM (NRI 9.1%), amino-terminal pro-B-type natriuretic peptide (NT-proBNP; NRI 9.1%), mid-regional proatrial natriuretic peptide (MR-proANP; NRI 7.4%), B-type natriuretic peptide (NRI 5.5%) and C-reactive protein (CRP; NRI 5.3%) reclassified patients with ADHF (p<0.05 for all). CRP also markedly improved risk stratification of patients with ADHF as a dual biomarker combination with MR-proADM (NRI 36.8% [p<0.001] for death at 30 days) or with sST2 (NRI 20.3%; [p<0.001] for one-year mortality).
Conclusion: In this study, biomarkers provided incremental value for risk stratification of ADHF patients. Biomarkers such as sST2, MR-proADM, natriuretic peptides and CRP, reflecting different pathophysiologic pathways, add prognostic value to clinical risk factors for predicting both short-term and one-year mortality in ADHF. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Lassus, Johan; Harjola, Veli-Pekka] Univ Helsinki, Cent Hosp, Div Emergency Care, FIN-00014 Helsinki, Finland.
[Lassus, Johan; Harjola, Veli-Pekka] Univ Helsinki, Cent Hosp, Dept Med, FIN-00014 Helsinki, Finland.
[Lassus, Johan; Laribi, Said; Logeart, Damien; Collet, Corinne; Cohen-Solal, Alain; Mebazaa, Alexandre] Lariboisiere Univ Hosp, INSERM UMR 942, Paris, France.
[Gayat, Etienne; Mebazaa, Alexandre] Lariboisiere Univ Hosp, AP HP, Dept Anesthesiol & Crit Care Med, Mobile Care Unit, Paris, France.
[Gayat, Etienne] St Louis Univ Hosp, INSERM UMR 717, Paris, France.
[Mueller, Christian; Potocki, Michael] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland.
[Peacock, W. Frank] Baylor Coll Med, Houston, TX 77030 USA.
[Spinar, Jindrich; Parenica, Jiri] Univ Hosp Brno, Dept Internal Med & Cardiol, Brno, Czech Republic.
[Spinar, Jindrich; Parenica, Jiri] Masaryk Univ, Fac Med, Brno, Czech Republic.
[van Kimmenade, Roland] Univ Med Ctr Utrecht, Dept Cardiol, Utrecht, Netherlands.
[Pathak, Atul] Toulouse Univ Hosp, Dept Cardiol, Toulouse, France.
[Mueller, Thomas] Konventhosp Barmherzige Brueder, Dept Lab Med, Linz, Austria.
[diSomma, Salvatore] Univ Roma La Sapienza, St Andrea Hosp, Emergency Dept, I-00185 Rome, Italy.
[Metra, Marco] Univ Brescia, Dept Expt & Appl Med, Brescia, Italy.
[Pascual-Figal, Domingo] Virgen Arrixaca Hosp, Serv Cardiol, Murcia, Spain.
[Pascual-Figal, Domingo] Univ Murcia, Dept Med, Murcia, Spain.
[Pascual-Figal, Domingo] Univ Murcia, Fac Med, Murcia, Spain.
[Laribi, Said] Lariboisiere Univ Hosp, AP HP, Dept Emergency Med, Paris, France.
[Logeart, Damien; Cohen-Solal, Alain] Lariboisiere Univ Hosp, AP HP, Dept Cardiol, Paris, France.
[Nouira, Semir] Fattouma Bourguiba Univ Hosp, Emergency Dept, Monastir, Tunisia.
[Nouira, Semir] Fattouma Bourguiba Univ Hosp, Res Unit UR06SP21, Monastir, Tunisia.
[Sato, Naoki] Nippon Med Sch, Musashi Kosugi Hosp, Tokyo 113, Japan.
[Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Mebazaa, A (reprint author), Hop Lariboisiere, Dept Anesthesie Reanimat, 2 Rue Ambroise Pare, F-75475 Paris 10, France.
EM Alexandre.Mebazaaa@lrb.aphp.fr
RI Laribi, Said/D-5229-2014; Harjola, Veli-Pekka/G-9229-2015; Kimmenade,
R.R.J./L-4432-2015; Laribi, said/S-3693-2016;
OI Metra, Marco/0000-0001-6691-8568; Nouira, Semir/0000-0002-0137-5491;
Samuel, Jane-Lise/0000-0002-7346-2404; Pascual Figal, Domingo
A./0000-0002-4993-9540
FU Roche Diagnostics; Siemens Diagnostics; Critical Diagnostics;
Thermo-Fisher Diagnostics; Abbott; Alere; Baxter; Brahms; Novartis;
Medicine's Company; Lily
FX JL speaker's honoraria from Abbott, consultant fees from Roche
Diagnostics; JLJ grants from Roche Diagnostics, Siemens Diagnostics,
Critical Diagnostics, Thermo-Fisher Diagnostics, consultant fees from
Roche Diagnostics, Critical Diagnostics; V-PH consultant fees from Roche
Diagnostics; WFP research grants from Abbott, Alere, Baxter, Brahms,
Novartis, The Medicine's Company; consultant fees from Abbott, Alere,
Lily, The Medicine's Company, speaker's honoraria from Abbott, Alere;
ownership interest in Comprehensive Research Associates LLC, Vital
Sensors, Emergencies in Medicine LLC, DP-F grants from Roche
Diagnostics; CM research support and speaker's honoraria from BRAHMS,
Alere, Abbott, and Critical Diagnostics; TM speaker's honoraria Abbott
Diagnostics, B. R. A. H. M. S AG, and Roche Diagnostics, SdS consultant
fees for Alere and Thermo-Fisher Diagnostics; AM speaker's honoraria
from Alere, BRAHMS, Edwards, Orion, Bayer.
NR 31
TC 56
Z9 58
U1 0
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 3
PY 2013
VL 168
IS 3
BP 2186
EP 2194
DI 10.1016/j.ijcard.2013.01.228
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 241RF
UT WOS:000326184400077
PM 23538053
ER
PT J
AU Ezekowitz, JA
Bakal, JA
Westerhout, CM
Giugliano, RP
White, H
Keltai, M
Prabhakaran, D
Tricoci, P
de Werf, FV
Califf, RM
Newby, LK
Armstrong, PW
AF Ezekowitz, Justin A.
Bakal, Jeffrey A.
Westerhout, Cynthia M.
Giugliano, Robert P.
White, Harvey
Keltai, Matyas
Prabhakaran, Dorairaj
Tricoci, Pierluigi
de Werf, Frans Van
Califf, Robert M.
Newby, L. Kristin
Armstrong, Paul W.
TI The relationship between meteorological conditions and index acute
coronary events in a global clinical trial
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Acute coronary syndromes; Climate; Temperature
ID ACUTE MYOCARDIAL-INFARCTION; DAILY WEATHER CONDITIONS; TEMPERATURE;
MORTALITY; ISCHEMIA; REGISTRY; PROJECT; DEATH; HEAT; RISK
AB Background: Considerable uncertainty exists concerning the interaction between climate and human health. We explored this issue by evaluating the relationship between meteorological events and acute coronary syndrome (ACS) events.
Methods: 9406 patients in 29 countries at 440 Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) clinical trial sites were linked to a weather station by location. Temperature, barometric pressure, precipitation, wind speed and combined temperature and relative humidity were normalized by location for the 37 days prior to the index ACS event that precipitated study enrollment. A meteorological event was defined as a change in any weather metric that was expected to occur in less than 10% of the exposure intervals: four separate 48-hour intervals within the seven days prior to an ACS event (T1, day of event and-1 day; T2, -2 to -3 days; T3, -4 to -5 days; and T4, -6 to -7 days). Results are reported as ratio of observed to expected events for the meteorological parameter.
Results: There were 10% more drops in temperature observed in T4 (95% CI: 3-17%), and more increases in temperature observed during T1 (4%; 95% CI-2-9%). An excess number of wind speed increases (9%; 95% CI 2-16%) and relative humidity increases (6%; 95% CI 0.1-14%) occurred during T4. Additionally, female patients in this cohort presented less often than male patients following drops in average temperature.
Conclusions: Using a new method for integrating meteorological data into a clinical trial dataset, we identified associations between changes in weather conditions and the likelihood of an ACS event. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Ezekowitz, Justin A.] Univ Alberta, Dept Med, Div Cardiol, Edmonton, AB, Canada.
[Ezekowitz, Justin A.] Mazankowski Alberta Heart Inst, Edmonton, AB, Canada.
[Bakal, Jeffrey A.; Westerhout, Cynthia M.; Armstrong, Paul W.] Univ Alberta, Edmonton, AB, Canada.
[Giugliano, Robert P.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA.
[White, Harvey] Auckland City Hosp, Auckland, New Zealand.
[Keltai, Matyas] Semmelweis Univ, Hungarian Inst Cardiol, H-1085 Budapest, Hungary.
[Prabhakaran, Dorairaj] Ctr Chron Dis Control, New Delhi, India.
[Tricoci, Pierluigi; Califf, Robert M.; Newby, L. Kristin] Duke Clin Res Inst, Durham, NC USA.
RP Ezekowitz, JA (reprint author), 2C2 Walter Mackenzie Hlth Sci Cntr,8440-112 St, Edmonton, AB T6G 2B7, Canada.
EM jae2@ualberta.ca
RI Ezekowitz, Justin/C-4579-2013;
OI Ezekowitz, Justin/0000-0002-2724-4086; Van de Werf,
Frans/0000-0001-9479-7767; Prabhakaran, Dorairaj/0000-0002-3172-834X
FU Schering Plough
FX Funding: Schering Plough provided the funding for the EARLY ACS trial,
however they had no role associated with this current study.
NR 21
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 3
PY 2013
VL 168
IS 3
BP 2315
EP 2321
DI 10.1016/j.ijcard.2013.01.061
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 241RF
UT WOS:000326184400096
PM 23416014
ER
PT J
AU Castro, ML
Barbosa, MM
Barbosa, JAA
de Almeida, FR
Esteves, WAD
Tan, TC
Nunes, MCP
AF Castro, Marildes L.
Barbosa, Marcia M.
Barbosa, Jose Augusto A.
de Almeida, Fernanda Rodrigues
Esteves, William Antonio de Magalhaes
Tan, Timothy C.
Nunes, Maria Carmo P.
TI Value of right ventricular strain in predicting functional capacity in
patients with mitral stenosis
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Mitral stenosis; Right ventricular function; Right ventricular strain;
Functional capacity
ID HEART-DISEASE; ECHOCARDIOGRAPHY
C1 [Castro, Marildes L.; de Almeida, Fernanda Rodrigues; Esteves, William Antonio de Magalhaes; Nunes, Maria Carmo P.] Univ Fed Minas Gerais, Sch Med, Postgrad Program Infect Dis & Trop Med, Belo Horizonte, MG, Brazil.
[Barbosa, Marcia M.; Barbosa, Jose Augusto A.] Hosp Socor, Ecoctr, Belo Horizonte, MG, Brazil.
[Tan, Timothy C.; Nunes, Maria Carmo P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Ultrasound Lab, Boston, MA USA.
RP Nunes, MCP (reprint author), Univ Fed Minas Gerais, Dept Clin Med, Av Prof Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil.
EM mcarmo@waymail.com.br
NR 16
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 3
PY 2013
VL 168
IS 3
BP 2927
EP 2930
DI 10.1016/j.ijcard.2013.03.181
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 241RF
UT WOS:000326184400210
PM 23651817
ER
PT J
AU Chen, C
Xu, JM
Huang, F
AF Chen, Chan
Xu, Junmei
Huang, Feng
TI Recent players in the field of acute myocardial infarction biomarkers:
Circulating cell-free DNA or microRNAs?
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Acute myocardial infarction; Biomarkers; Cell-free DNA; Circulating
microRNAs
ID PROGNOSTIC MARKER; CHEST-PAIN
C1 [Chen, Chan; Xu, Junmei] Cent S Univ, Dept Anesthesiol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
[Chen, Chan; Xu, Junmei] Cent S Univ, Anesthesiol Res Inst, Changsha 410011, Hunan, Peoples R China.
[Chen, Chan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Huang, Feng] Cent S Univ, Dept Cardiol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
RP Xu, JM (reprint author), Cent S Univ, Dept Anesthesiol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
EM doctorjmxu@gmail.com
NR 16
TC 4
Z9 4
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 3
PY 2013
VL 168
IS 3
BP 2956
EP 2957
DI 10.1016/j.ijcard.2013.03.118
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 241RF
UT WOS:000326184400224
PM 23602868
ER
PT J
AU Abtahian, F
Yonetsu, T
Vergallo, R
Jia, HB
Kato, K
Tian, JW
Hu, SN
McNulty, I
Jang, IK
AF Abtahian, Farhad
Yonetsu, Taishi
Vergallo, Rocco
Jia, Haibo
Kato, Koji
Tian, Jinwei
Hu, Sining
McNulty, Iris
Jang, Ik-Kyung
TI Ticagrelor immediately prior to stenting is associated with smaller
residual thrombus in patients with acute coronary syndrome
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Percutaneous coronary intervention; Platelet; P2Y12; Optical coherence
tomography
ID MYOCARDIAL-INFARCTION; INTERVENTION; CLOPIDOGREL; IMPACT; TRIAL
C1 [Abtahian, Farhad; Yonetsu, Taishi; Vergallo, Rocco; Jia, Haibo; Kato, Koji; Tian, Jinwei; Hu, Sining; McNulty, Iris; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Jia, Haibo; Tian, Jinwei; Hu, Sining] Harbin Med Univ, Dept Cardiol, Affiliated Hosp 2, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin, Peoples R China.
RP Jang, IK (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 800, Boston, MA 02114 USA.
EM ijang@partners.org
NR 10
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 3
PY 2013
VL 168
IS 3
BP 3099
EP 3101
DI 10.1016/j.ijcard.2013.04.076
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 241RF
UT WOS:000326184400299
PM 23642594
ER
PT J
AU Poultney, CS
Goldberg, AP
Drapeau, E
Kou, Y
Harony-Nicolas, H
Kajiwara, Y
De Rubeis, S
Durand, S
Stevens, C
Rehnstrom, K
Palotie, A
Daly, MJ
Ma'ayan, A
Fromer, M
Buxbaum, JD
AF Poultney, Christopher S.
Goldberg, Arthur P.
Drapeau, Elodie
Kou, Yan
Harony-Nicolas, Hala
Kajiwara, Yuji
De Rubeis, Silvia
Durand, Simon
Stevens, Christine
Rehnstroem, Karola
Palotie, Aarno
Daly, Mark J.
Ma'ayan, Avi
Fromer, Menachem
Buxbaum, Joseph D.
TI Identification of Small Exonic CNV from Whole-Exome Sequence Data and
Application to Autism Spectrum Disorder
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COPY-NUMBER VARIATION; DE-NOVO MUTATIONS; HUMAN GENOME; GENE; TOOL;
REVEALS; DISCOVERY; NETWORK; 17P13.1; MAP
AB Copy number variation (CNV) is an important determinant of human diversity and plays important roles in susceptibility to disease. Most studies of CNV carried out to date have made use of chromosome microarray and have had a lower size limit for detection of about 30 kilobases (kb). With the emergence of whole-exome sequencing studies, we asked whether such data could be used to reliably call rare exonic CNV in the size range of 1-30 kilobases (kb), making use of the eXome Hidden Markov Model (XHMM) program. By using both transmission information and validation by molecular methods, we confirmed that small CNV encompassing as few as three exons can be reliably called from whole-exome data. We applied this approach to an autism case-control sample (n = 811, mean per-target read depth = 161) and observed a significant increase in the burden of rare (MAF <= 1%) 1-30 kb CNV, 1-30 kb deletions, and 1-10 kb deletions in ASD. CNV in the 1-30 kb range frequently hit just a single gene, and we were therefore able to carry out enrichment and pathway analyses, where we observed enrichment for disruption of genes in cytoskeletal and autophagy pathways in ASD. In summary, our results showed that XHMM provided an effective means to assess small exonic CNV from whole-exome data, indicated that rare 1-30 kb exonic deletions could contribute to risk in up to 7% of individuals with ASD, and implicated a candidate pathway in developmental delay syndromes.
C1 [Poultney, Christopher S.; Goldberg, Arthur P.; Drapeau, Elodie; Kou, Yan; Harony-Nicolas, Hala; Kajiwara, Yuji; De Rubeis, Silvia; Durand, Simon; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA.
[Poultney, Christopher S.; Goldberg, Arthur P.; Drapeau, Elodie; Harony-Nicolas, Hala; Kajiwara, Yuji; De Rubeis, Silvia; Durand, Simon; Fromer, Menachem; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Goldberg, Arthur P.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA.
[Kou, Yan; Ma'ayan, Avi] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
[Kou, Yan; Ma'ayan, Avi] Icahn Sch Med Mt Sinai, Syst Biol Ctr New York, New York, NY 10029 USA.
[Stevens, Christine; Palotie, Aarno; Daly, Mark J.] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Rehnstroem, Karola; Palotie, Aarno] Univ Helsinki, Inst Mol Med Finland FIMM, FIN-00290 Helsinki, Finland.
[Rehnstroem, Karola] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
[Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Fromer, Menachem; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Neurosci, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Fromer, Menachem; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA.
RP Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA.
EM joseph.buxbaum@mssm.edu
RI De Rubeis, Silvia/E-9852-2013;
OI De Rubeis, Silvia/0000-0001-9383-6883; Buxbaum,
Joseph/0000-0001-8898-8313
FU National Institute of Mental Health, National Institutes of Health
[MH089025, MH097849, MH100233]; Seaver Foundation
FX This work was supported by the National Institute of Mental Health,
National Institutes of Health (grants MH089025, MH097849, and MH100233
to J.D.B.) and the Seaver Foundation. C.S.P. is a Seaver Fellow and
A.P.G. is a Seaver Fellow.
NR 47
TC 54
Z9 56
U1 0
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT 3
PY 2013
VL 93
IS 4
BP 607
EP 619
DI 10.1016/j.ajhg.2013.09.001
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 243GT
UT WOS:000326305600003
PM 24094742
ER
PT J
AU Austin-Tse, C
Halbritter, J
Zariwala, MA
Gilberti, RM
Gee, HY
Hellman, N
Pathak, N
Liu, Y
Panizzi, JR
Patel-King, RS
Tritschler, D
Bower, R
O'Toole, E
Porath, JD
Hurd, TW
Chaki, M
Diaz, KA
Kohl, S
Lovric, S
Hwang, DY
Braun, DA
Schueler, M
Airik, R
Otto, EA
Leigh, MW
Noone, PG
Carson, JL
Davis, SD
Pittman, JE
Ferkol, TW
Atkinson, JJ
Olivier, KN
Sagel, SD
Dell, SD
Rosenfeld, M
Milla, CE
Loges, NT
Omran, H
Porter, ME
King, SM
Knowles, MR
Drummond, IA
Hildebrandt, F
AF Austin-Tse, Christina
Halbritter, Jan
Zariwala, Maimoona A.
Gilberti, Renee M.
Gee, Heon Yung
Hellman, Nathan
Pathak, Narendra
Liu, Yan
Panizzi, Jennifer R.
Patel-King, Ramila S.
Tritschler, Douglas
Bower, Raqual
O'Toole, Eileen
Porath, Jonathan D.
Hurd, Toby W.
Chaki, Moumita
Diaz, Katrina A.
Kohl, Stefan
Lovric, Svjetlana
Hwang, Daw-Yang
Braun, Daniela A.
Schueler, Markus
Airik, Rannar
Otto, Edgar A.
Leigh, Margaret W.
Noone, Peadar G.
Carson, Johnny L.
Davis, Stephanie D.
Pittman, Jessica E.
Ferkol, Thomas W.
Atkinson, Jeffry J.
Olivier, Kenneth N.
Sagel, Scott D.
Dell, Sharon D.
Rosenfeld, Margaret
Milla, Carlos E.
Loges, Niki T.
Omran, Heymut
Porter, Mary E.
King, Stephen M.
Knowles, Michael R.
Drummond, Iain A.
Hildebrandt, Friedhelm
TI Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies
C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID DYNEIN REGULATORY COMPLEX; OUTER ARM DYNEIN; CHLAMYDOMONAS-REINHARDTII;
PROTEOMIC ANALYSIS; MOTILE CILIA; SCHMIDTEA-MEDITERRANEA;
KARTAGENER-SYNDROME; FLAGELLAR MOTILITY; SEQUENCE-ANALYSIS; DISEASE
GENES
AB Primary ciliary dyskinesia (PCD) is caused when defects of motile cilia lead to chronic airway infections, male infertility, and situs abnormalities. Multiple causative PCD mutations account for only 65% of cases, suggesting that many genes essential for cilia function remain to be discovered. By using zebrafish morpholino knockdown of PCD candidate genes as an in vivo screening platform, we identified c21orf59, ccdc65, and c15orf26 as critical for cilia motility. c21orf59 and c15orf26 knockdown in zebrafish and planaria blocked outer dynein arm assembly, and ccdc65 knockdown altered cilia beat pattern. Biochemical analysis in Chlamydomonas revealed that the C21orf59 ortholog FBB18 is a flagellar matrix protein that accumulates specifically when cilia motility is impaired. The Chlamydomonas ida6 mutant identifies CCDC65/FAP250 as an essential component of the nexin-dynein regulatory complex. Analysis of 295 individuals with PCD identified recessive truncating mutations of C21orf59 in four families and CCDC65 in two families. Similar to findings in zebrafish and planaria, mutations in C21orf59 caused loss of both outer and inner dynein arm components. Our results characterize two genes associated with PCD-causing mutations and elucidate two distinct mechanisms critical for motile cilia function: dynein arm assembly for C21orf59 and assembly of the nexin-dynein regulatory complex for CCDC65.
C1 [Austin-Tse, Christina; Hellman, Nathan; Pathak, Narendra; Liu, Yan; Panizzi, Jennifer R.; Drummond, Iain A.] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA.
[Austin-Tse, Christina; Drummond, Iain A.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Nephrol,Dept Genet, Boston, MA 02115 USA.
[Halbritter, Jan; Gee, Heon Yung; Porath, Jonathan D.; Kohl, Stefan; Lovric, Svjetlana; Hwang, Daw-Yang; Braun, Daniela A.; Schueler, Markus; Airik, Rannar; Hildebrandt, Friedhelm] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA.
[Zariwala, Maimoona A.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
[Gilberti, Renee M.; Patel-King, Ramila S.; King, Stephen M.] Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA.
[Tritschler, Douglas; Bower, Raqual; Porter, Mary E.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
[O'Toole, Eileen] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder Lab Electron Microscopy Cells 3D, Boulder, CO 80309 USA.
[Hurd, Toby W.; Chaki, Moumita; Diaz, Katrina A.; Otto, Edgar A.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.
[Leigh, Margaret W.; Noone, Peadar G.; Carson, Johnny L.; Davis, Stephanie D.; Pittman, Jessica E.] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA.
[Ferkol, Thomas W.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
[Atkinson, Jeffry J.] Washington Univ, Sch Med, Div Pulm & Crit Care, St Louis, MO 63110 USA.
[Olivier, Kenneth N.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
[Sagel, Scott D.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA.
[Dell, Sharon D.] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada.
[Rosenfeld, Margaret] Childrens Hosp, Seattle, WA 98105 USA.
[Rosenfeld, Margaret] Univ Washington, Seattle, WA 98105 USA.
[Milla, Carlos E.] Stanford Univ, Dept Pediat, Stanford, CA 94304 USA.
[Loges, Niki T.; Omran, Heymut] Univ Childrens Hosp Muenster, Dept Gen Pediat, D-48149 Munster, Germany.
[Knowles, Michael R.] Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.
[Hildebrandt, Friedhelm] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Drummond, IA (reprint author), Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA.
EM idrummond@partners.org; friedhelm.hildebrandt@childrens.harvard.edu
OI Austin-Tse, Christina/0000-0001-6492-6716; Otto,
Edgar/0000-0002-2387-9973
FU National Institutes of Health; Howard Hughes Medical Institute; Deutsche
Forschungsgemeinschaft; IZKF Muenster; European Community
FX We are grateful to all PCD subjects and family members for their
participation and thank the US PCD Foundation and to the investigators
and the coordinators of the "Genetic Disorders of Mucociliary Clearance
Consortium." We are also grateful to the funding agencies that supported
this work; these include the National Institutes of Health, the Howard
Hughes Medical Institute, the Deutsche Forschungsgemeinschaft, the IZKF
Muenster, and the European Community's Seventh Framework Programme.
Detailed acknowledgements can be found in the Supplemental Data.
NR 71
TC 47
Z9 54
U1 0
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT 3
PY 2013
VL 93
IS 4
BP 672
EP 686
DI 10.1016/j.ajhg.2013.08.015
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 243GT
UT WOS:000326305600009
PM 24094744
ER
PT J
AU Richardson, PG
Schlossman, RL
Alsina, M
Weber, DM
Coutre, SE
Gasparetto, C
Mukhopadhyay, S
Ondovik, MS
Khan, M
Paley, CS
Lonial, S
AF Richardson, Paul G.
Schlossman, Robert L.
Alsina, Melissa
Weber, Donna M.
Coutre, Steven E.
Gasparetto, Cristina
Mukhopadhyay, Sutapa
Ondovik, Michael S.
Khan, Mahmudul
Paley, Carole S.
Lonial, Sagar
TI PANORAMA 2: panobinostat in combination with bortezomib and
dexamethasone in patients with relapsed and bortezomib-refractory
myeloma
SO BLOOD
LA English
DT Article
ID LENALIDOMIDE PLUS DEXAMETHASONE; DIAGNOSED MULTIPLE-MYELOMA; WORKING
GROUP; THERAPY; MULTICENTER; CRITERIA; PHASE-2; LBH589
AB Panobinostat is an oral pan-deacetylase inhibitor that synergizes with bortezomib to inhibit both the aggresome and proteasome pathways in preclinical studies. PANORAMA 2 is a phase 2 trial of panobinostat in combination with bortezomib and dexamethasone to treat patients with relapsed and bortezomib-refractory multiple myeloma (with >= 2 prior lines of therapy, including an immunomodulatory drug, and patients who had progressed on or within 60 days of the last bortezomib-based therapy). Fifty-five heavily pretreated patients were enrolled (median, 4 prior regimens, including a median of 2 prior bortezomib-containing regimens). The overall response rate was 34.5% (1 near-complete response and 18 partial responses). An additional 10 patients achieved minimal response, for a clinical benefit rate of 52.7%. Median exposure and progression-free survival were 4.6 and 5.4 months, respectively. In patients who achieved a response, median time to response was 1.4 months, and median duration of response was 6.0 months. Common grade 3/4 adverse events, regardless of study drug relationship, included thrombocytopenia (63.6%), fatigue (20.0%), and diarrhea (20.0%). Only 1 patient had grade 3 peripheral neuropathy. Panobinostat, when combined with bortezomib and dexamethasone, can recapture responses in heavily pretreated, bortezomib-refractory multiple myeloma patients.
C1 [Richardson, Paul G.; Schlossman, Robert L.] Harvard Univ, Dana Farber Canc Inst, Sch Med, Boston, MA 02215 USA.
[Alsina, Melissa] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Weber, Donna M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Coutre, Steven E.] Stanford Canc Ctr, Palo Alto, CA USA.
[Coutre, Steven E.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Gasparetto, Cristina] Duke Univ, Med Ctr, Durham, NC USA.
[Mukhopadhyay, Sutapa; Ondovik, Michael S.; Khan, Mahmudul; Paley, Carole S.] Novartis Pharmaceut, E Hanover, NJ USA.
[Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
RP Richardson, PG (reprint author), Harvard Univ, Dana Farber Canc Inst, 450 Brookline Ave,Mailstop Dana 1B02, Boston, MA 02215 USA.
EM paul_richardson@dfci.harvard.edu
FU Novartis Pharmaceuticals Corporation; Novartis
FX This study was supported in part by research funding for clinical
studies and medical editorial assistance from Novartis Pharmaceuticals
Corporation and Novartis research funding (D.M.W.).
NR 25
TC 105
Z9 106
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD OCT 3
PY 2013
VL 122
IS 14
BP 2331
EP 2337
DI 10.1182/blood-2013-01-481325
PG 7
WC Hematology
SC Hematology
GA 240ER
UT WOS:000326078200016
PM 23950178
ER
PT J
AU Vlachos, A
Farrar, JE
Atsidaftos, E
Muir, E
Narla, A
Markello, TC
Singh, SA
Landowski, M
Gazda, HT
Blanc, L
Liu, JM
Ellis, SR
Arceci, RJ
Ebert, BL
Bodine, DM
Lipton, JM
AF Vlachos, Adrianna
Farrar, Jason E.
Atsidaftos, Eva
Muir, Ellen
Narla, Anupama
Markello, Thomas C.
Singh, Sharon A.
Landowski, Michael
Gazda, Hanna T.
Blanc, Lionel
Liu, Johnson M.
Ellis, Steven R.
Arceci, Robert J.
Ebert, Benjamin L.
Bodine, David M.
Lipton, Jeffrey M.
TI Diminutive somatic deletions in the 5q region lead to a phenotype
atypical of classical 5q-syndrome
SO BLOOD
LA English
DT Article
ID DIAMOND-BLACKFAN ANEMIA; PROTEIN GENE DELETIONS; IDENTIFICATION;
LENALIDOMIDE
AB Classical 5q- syndrome is an acquired macrocytic anemia of the elderly. Similar to Diamond Blackfan anemia (DBA), an inherited red cell aplasia, the bone marrow is characterized by a paucity of erythroid precursors. RPS14 deletions in combination with other deletions in the region have been implicated as causative of the 5q- syndrome phenotype. We asked whether smaller, less easily detectable deletions could account for a syndrome with a modified phenotype. We employed single-nucleotide polymorphism array genotyping to identify small deletions in patients diagnosed with DBA and other anemias lacking molecular diagnoses. Diminutive mosaic deletions involving RPS14 were identified in a 5-year-old patient with nonclassical DBA and in a 17-year-old patient with myelodysplastic syndrome. Patients with nonclassical DBA and other hypoproliferative anemias may have somatically acquired 5q deletions with RPS14 haploinsufficiency not identified by fluorescence in situ hybridization or cytogenetic testing, thus refining the spectrum of disorders with 5q- deletions.
C1 [Vlachos, Adrianna; Singh, Sharon A.; Blanc, Lionel; Liu, Johnson M.; Lipton, Jeffrey M.] Steven & Alexandra Cohen Childrens Med Ctr New Yo, New Hyde Pk, NY 11040 USA.
[Vlachos, Adrianna; Atsidaftos, Eva; Muir, Ellen; Singh, Sharon A.; Blanc, Lionel; Liu, Johnson M.; Lipton, Jeffrey M.] Feinstein Inst Med Res, Manhasset, NY USA.
[Farrar, Jason E.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
[Narla, Anupama; Ebert, Benjamin L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Narla, Anupama; Gazda, Hanna T.; Ebert, Benjamin L.] Harvard Univ, Sch Med, Boston, MA USA.
[Narla, Anupama; Ebert, Benjamin L.] Brigham & Womens Hosp, Dept Hematol, Boston, MA 02115 USA.
[Markello, Thomas C.] NHGRI, Off Clin Director, NIH, Bethesda, MD 20892 USA.
[Landowski, Michael; Gazda, Hanna T.] Childrens Hosp Boston, Div Genet, Manton Ctr Orphan Dis Res, Boston, MA USA.
[Landowski, Michael; Gazda, Hanna T.] Childrens Hosp Boston, Program Genom, Manton Ctr Orphan Dis Res, Boston, MA USA.
[Ellis, Steven R.] Univ Louisville, Louisville, KY 40292 USA.
[Arceci, Robert J.] Johns Hopkins Univ, Baltimore, MD USA.
[Bodine, David M.] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA.
RP Vlachos, A (reprint author), Steven & Alexandra Cohen Childrens Med Ctr New Yo, 269-01 76th Ave, New Hyde Pk, NY 11040 USA.
EM avlachos@nshs.edu
OI Farrar, Jason/0000-0003-2148-5839; Blanc, Lionel/0000-0002-0185-6260
FU Diamond Blackfan Anemia Foundation; Pediatric Cancer Foundation;
Arkansas Biosciences Institute; Feinstein Institute for Medical Research
General Clinical Research Center [M01 RR018535]; Centers for Disease
Control-sponsored Diamond Blackfan Anemia Surveillance and Awareness
Program; National Institutes of Health [R01-HL079571, R01-HL107558,
R109-MOHLKE, K02-HL111156, K08-HL092224]; National Human Genome Research
Institute Intramural funds; St. Baldrick's Foundation Scholar Career
Development Award; St. Baldrick's Consortium on Pediatric
Myelodysplastic Syndrome
FX This work was supported in part by grants from the Diamond Blackfan
Anemia Foundation (H. T. G., D. M. B., A. V., E. M.), the Pediatric
Cancer Foundation (J.M. Lipton), the Arkansas Biosciences Institute
(J.E.F.), The Feinstein Institute for Medical Research General Clinical
Research Center (M01 RR018535; A. V., J.M. Lipton), the Centers for
Disease Control-sponsored Diamond Blackfan Anemia Surveillance and
Awareness Program (A. V., E. M.), and the National Institutes of Health
(R01-HL079571 [A. V., E. A., J.M. Lipton], R01-HL107558 [H. T. G.],
R109-MOHLKE [A. V., E. A., J.M. Lipton], K02-HL111156 [H. T. G.],
K08-HL092224 [J.E.F.], and National Human Genome Research Institute
Intramural funds [D. M. B.]), St. Baldrick's Foundation Scholar Career
Development Award (S. A. S.), and St. Baldrick's Consortium on Pediatric
Myelodysplastic Syndrome (J.M. Liu).
NR 16
TC 6
Z9 6
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD OCT 3
PY 2013
VL 122
IS 14
BP 2487
EP 2490
DI 10.1182/blood-2013-06-509935
PG 4
WC Hematology
SC Hematology
GA 240ER
UT WOS:000326078200032
PM 23943650
ER
PT J
AU Levy, O
Zhao, WA
Mortensen, LJ
LeBlanc, S
Tsang, K
Fu, MY
Phillips, JA
Sagar, V
Anandakumaran, P
Ngai, J
Cui, CH
Eimon, P
Angel, M
Lin, CP
Yanik, MF
Karp, JM
AF Levy, Oren
Zhao, Weian
Mortensen, Luke J.
LeBlanc, Sarah
Tsang, Kyle
Fu, Moyu
Phillips, Joseph A.
Sagar, Vinay
Anandakumaran, Priya
Ngai, Jessica
Cui, Cheryl H.
Eimon, Peter
Angel, Matthew
Lin, Charles P.
Yanik, Mehmet Fatih
Karp, Jeffrey M.
TI mRNA-engineered mesenchymal stem cells for targeted delivery of
interleukin-10 to sites of inflammation
SO BLOOD
LA English
DT Article
ID VERSUS-HOST-DISEASE; BONE-MARROW; STROMAL CELLS; IN-VIVO;
MYOCARDIAL-INFARCTION; THERAPEUTIC-EFFICACY; ADHESION MOLECULE-1; MICE;
ENGRAFTMENT; TRANSPLANTATION
AB Mesenchymal stem cells (MSCs) are promising candidates for cell-based therapy to treat several diseases and are compelling to consider as vehicles for delivery of biological agents. However, MSCs appear to act through a seemingly limited "hit-and-run" mode to quickly exert their therapeutic impact, mediated by several mechanisms, including a potent immunomodulatory secretome. Furthermore, MSC immunomodulatory properties are highly variable and the secretome composition following infusion is uncertain. To determine whether a transiently controlled antiinflammatory MSC secretome could be achieved at target sites of inflammation, we harnessed mRNA transfection to generate MSCs that simultaneously express functional rolling machinery (P-selectin glycoprotein ligand-1 [PSGL-1] and Sialyl-Lewis(x) [SLeX]) to rapidly target inflamed tissues and that express the potent immunosuppressive cytokine interleukin-10 (IL-10), which is not inherently produced by MSCs. Indeed, triple-transfectedPSGL-1/SLeX/IL-10 MSCs transiently increased levels of IL-10 in the inflamed ear and showed a superior antiinflammatory effect in vivo, significantly reducing local inflammation following systemic administration. This was dependent on rapid localization of MSCs to the inflamed site. Overall, this study demonstrates that despite the rapid clearance of MSCs in vivo, engineered MSCs can be harnessed via a "hit-and-run" action for the targeted delivery of potent immunomodulatory factors to treat distant sites of inflammation.
C1 [Levy, Oren; Zhao, Weian; LeBlanc, Sarah; Tsang, Kyle; Fu, Moyu; Sagar, Vinay; Anandakumaran, Priya; Ngai, Jessica; Cui, Cheryl H.; Karp, Jeffrey M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Biomed Engn,Dept Med,Ctr Regenerat Therapeut, Cambridge, MA 02139 USA.
[Levy, Oren; Zhao, Weian; LeBlanc, Sarah; Tsang, Kyle; Fu, Moyu; Sagar, Vinay; Anandakumaran, Priya; Ngai, Jessica; Cui, Cheryl H.; Karp, Jeffrey M.] Harvard Stem Cell Inst, Cambridge, MA USA.
[Levy, Oren; Zhao, Weian; LeBlanc, Sarah; Tsang, Kyle; Fu, Moyu; Sagar, Vinay; Anandakumaran, Priya; Ngai, Jessica; Cui, Cheryl H.; Karp, Jeffrey M.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA USA.
[Mortensen, Luke J.; Phillips, Joseph A.; Lin, Charles P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Mortensen, Luke J.; Phillips, Joseph A.; Lin, Charles P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Cambridge, MA 02139 USA.
[Eimon, Peter; Angel, Matthew; Yanik, Mehmet Fatih] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Yanik, Mehmet Fatih] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
RP Karp, JM (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02139 USA.
EM yanik@mit.edu; jeffkarp.bwh@gmail.com
FU NIH, Heart, Lung and Blood Institute [HL095722]; American Heart
Association [0970178N]; Prostate Cancer Foundation
FX This work was supported by NIH, Heart, Lung and Blood Institute grant
HL095722 to J.M.K, and by the American Heart Association grant 0970178N
to J.M.K. This work was also supported by a Prostate Cancer Foundation
Challenge Award to J.M.K.
NR 51
TC 49
Z9 50
U1 1
U2 22
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD OCT 3
PY 2013
VL 122
IS 14
BP E23
EP E32
DI 10.1182/blood-2013-04-495119
PG 10
WC Hematology
SC Hematology
GA 240ER
UT WOS:000326078200002
PM 23980067
ER
PT J
AU Scirica, BM
Bhatt, DL
Braunwald, E
Steg, PG
Davidson, J
Hirshberg, B
Ohman, P
Frederich, R
Wiviott, SD
Hoffman, EB
Cavender, MA
Udell, JA
Desai, NR
Mosenzon, O
McGuire, DK
Ray, KK
Leiter, LA
Raz, I
Braunwald, E
Bhatt, DL
Scirica, BM
Udell, JA
Cavender, MA
Desai, N
Abrahamsen, T
Grossman, M
Morin, S
Im, K
Hoffman, E
Gabovitch, D
Pricken, A
Mosenzon, O
Buskila, A
Ohman, P
Hirshberg, B
Stahre, C
Price, D
Billing-Clason, S
Sabel, K
Monyak, J
Sjostrand, M
Wei, C
Lu, J
Miller, E
Raichlen, J
Fitt, S
Frederich, R
Iqbal, N
Donovan, M
Davidson, JA
Steg, PG
Aguilar-Salinas, C
Alvarsson, M
Amerena, J
Ardissino, D
Averkov, O
Avogaro, A
Barnett, A
Bretzel, R
Chiang, CE
Codoceo, V
Corbalan, R
Dalby, A
Darius, H
Deerochanawong, C
Dellborg, M
Eliaschewitz, F
Garcia-Castillo, A
Gomis, R
Henry, P
Hoekstra, J
Jermendy, G
Kastelein, J
Keech, A
Kiss, R
Krempf, M
Laakso, M
Leiter, L
Leitersdorf, E
Lewis, B
Litwak, L
Lopez-Sendon, J
Ma, R
McGuire, D
Medina, F
Moses, R
Nicolau, JC
Opolski, G
Ophuis, TO
Paolasso, E
Ray, KK
Ruda, M
Kumar, KMP
Shestakova, M
Sheu, WHH
Smahelova, A
Bhupathiraju, BSR
Spinar, J
Sritata, P
Strojeck, K
Villena-Chavez, JE
Jia, WP
Huo, Y
Wiviott, SD
Lowe, C
Awtry, E
Berger, C
Desai, AS
Gelfand, E
Leeman, D
Link, M
Ruberg, F
Vita, J
Rost, N
Silverman, S
Greenberger, NJ
Lerch, MM
Gersh, B
Nesto, R
Del Prato, S
Tuomilehto, J
Kelsey, S
Alvarisqueta, A
Cuadrado, J
Rista, L
Hermida, S
Baccaro, C
Luquez, C
Lagrutta, M
Maffei, L
Bartolacci, I
Montana, O
Cutuli, H
Berli, M
Lorenzatti, A
Frechtel, G
La Greca, R
Fretes, O
Diaz, M
Papini, NR
Farias, E
Issa, C
Elbert, A
Lehman, R
Arya, M
Singh, B
Colquhoun, D
Jayasinghe, R
de Looze, F
Blombery, P
Ward, G
Szto, G
Abhayaratna, W
Borges, J
Russo, L
Felicio, J
Santos, F
Guimaraes, F
Castro, ML
Rossi, P
Armaganijan, D
Leaes, P
Bandeira, F
Franken, M
Rassi, N
Rea, R
Zanella, M
Amodeo, C
Cesar, L
Betti, R
Chacra, A
Schmid, H
Bell, A
Syan, G
Zadra, R
Conter, H
Dumas, R
Borts, D
Dattani, I
Poirier, P
Cha, J
Dzongowski, P
Labonte, R
St Pierre, B
Gaudet, D
Kouz, S
Lamy, A
Tishler, S
Chehayeb, R
Bedard, J
Hramiak, I
Teitelbaum, I
Fortin, C
Woo, V
Conway, J
Mehta, P
Robinson, S
Sussex, B
Chiasson, J
Muirhead, N
Bose, S
Ouellet, A
Yale, J
Bhargava, R
Lau, D
Tobe, S
Perron, P
Sigalas, J
Bilodeau, L
Tytus, R
Achyuthan, G
Pearce, M
Steele, A
Bailey, G
Ma, P
St-Maurice, F
Rupka, D
Houlden, R
Bailey, A
Rewa, G
Sohal, P
Ting, R
Prieto, J
Rodriguez, M
Godoy, G
Larenas, G
Pincetti, C
Cobos, L
Saavedra, V
Varleta, P
Lucero, F
Kuzmanic, O
Acevedo, M
Aguirre, M
Florenzano, F
Ma, J
Bao, Y
Jiang, M
Xu, W
Shi, Y
Zheng, M
Li, Y
Dong, Y
Zhao, W
Sun, M
Lei, M
Wang, J
Pistek, Z
Rihacek, I
Kucera, D
Brada, M
Naplava, R
Karasova, J
Vlasicova, H
Skopecek, J
Spinarova, L
Raclavska, L
Sarbochova, R
Okenka, L
Racicka, E
Urbancova, K
Oznerova, M
Lorenc, Z
Wasserburger, B
Zahumensky, E
Grunfeldova, H
Hradec, J
Lukac, M
Svacina, S
Podzimek, J
Hemzsky, L
Mikulkova, I
Pavlickova, J
Brychta, T
Chochola, J
Couffinhal, T
Elbaz, M
Petit, C
Faller, B
Marechaud, R
Moulin, P
Fendri, S
Nazeyrollas, P
Wendisch, U
Busch, K
Klausmann, G
Duengen, H
Appel, K
Toursarkissian, N
Jung, T
Ott, P
Schenkenberger, I
Kuesters, D
Landers, B
Nischik, R
Fischer, H
Tschoepe, D
Paschen, B
Krause, K
Derwahl, K
Wenzl-Bauer, V
Hamann, A
Strotmann, H
Milek, K
Mueller, S
Chu, D
Tan, K
Kung, K
Chu, D
Tsang, C
Chu, D
Tomlinson, B
Kung, K
Koranyi, L
Kerenyi, Z
Benczur, B
Illyes, L
Hidvegi, T
Somogyi, A
Valco, J
Ferenczi, S
Rapi, J
Voros, P
Winkler, G
Sydo, T
Hetey, M
Simon, K
Penzes, J
Kempler, P
Bako, B
Lengyel, Z
Witmann, I
Dudas, M
Vandorfi, G
Takacs, J
Matoltsy, A
Ladanyi, E
Gyimesi, A
Sadikot, S
Parikh, K
Jain, S
Yajnik, C
Sosale, A
Shamanna, P
Srikanta, S
Shah, S
Srinivas, A
Banker, D
Shah, P
Sharda, A
Makkar, B
Desai, N
Rais, N
Mardikar, H
Mishra, A
Bhupati, S
Menon, J
Sathe, S
Gupta, R
Sharma, V
Darawsha, M
Herskovits, T
Hamoud, S
Nikolsky, E
Adawi, F
Zimlichman, R
Tsalihin, D
Wainstein, J
Klainman, E
Mosseri, M
Yerushalmi, Y
Karnieli, E
Knobler, H
Zimlichman, R
Benchetrit, S
Tsur, A
Yagil, Y
Atar, S
Beberashvili, I
Fuchs, S
Stern, N
Pollak, A
Chajek-Shaul, T
Rozenman, Y
Biton, A
Bramucci, E
Fiscella, A
Grassia, V
Piatti, P
De Cosmo, S
Di Lorenzo, L
Merlini, P
Mannucci, E
Frontoni, S
Trevisan, R
Zenari, L
Lambiase, C
Salvioni, A
Silvestri, O
Ambrosio, G
Di Bartolo, P
Fattore, L
Presbitero, P
Calabrese, M
Evola, R
Gamba, MA
Ibarra, MOD
Munoz, EC
Sanchez, DR
Herrera, CH
Rios, JP
Llamas, EB
Esperon, GL
Cantu, EG
Fragoso, JN
Gonzalez, JG
Martinez, GR
Padilla, FP
Mier, GM
Marmolejo, DH
Ruiz, JG
Portilla, NC
Rosas, EL
Machado, GM
Ramos, JC
Briones, IR
van Hessen, MWJ
Strikwerda, S
The, SHK
Kooy, A
Ronner, E
Nierop, PR
Remmen, JJ
Groenemeijer, BE
Hamer, BJB
Basart, DCG
van Lennep, HWOR
Nieuwdorp, M
van Dijk, MPM
Kentgens, S
van Kempen, WW
Hoogendijk, J
Spiering, W
Voors-Pette, C
Kose, V
de Waard, DEP
Gonkel, F
Kaasjager, HAH
Lingan, GMR
Agous, I
Kruik, HJ
Imholz, BPM
Pieterse, M
Manrique, H
Villena, J
Leon, L
Kundert, K
Minchola, J
Pinto, M
Heredia, J
Rodriguez, A
Guerreros, C
Berrospi, P
Zubiate, C
Allemant, A
Arbanil, H
Ponciano, W
Calderon, J
Lisson, R
Segura, L
Sidorowicz-Bialynicka, A
Sciborski, R
Fares, I
Mader, P
Skierkowska, J
Stasinska, T
Pomiecko, W
Skorski, M
Krzyzagorska, E
Polaszewska-Muszynska, M
Sowinski, D
Strojek, K
Rosinska-Migda, J
Romanczuk, P
Golebiowski, G
Kubica, J
Mazurek, T
Wojnowski, L
Pasternak, D
Stachlewski, P
Trzepla, E
Bogdanowicz, G
Uzunow, A
Potakowska, I
Miszczyszyn, Z
Waszyrowski, T
Smolenskaya, O
Lukyanov, Y
Vorokhobina, N
Khalimov, Y
Orlikova, O
Rebrov, A
Kukharchuk, V
Boldueva, S
Arkhipov, M
Zhelninova, T
Pavlysh, E
Antsiferov, M
Panov, A
Pavlova, M
Shustov, S
Demchenko, E
Galyavich, A
Malakhina, E
Semenova, O
Kobalava, Z
Kotova, S
Gavrisheva, I
Oschepkova, E
Karpov, Y
Sidorenko, B
Kislyak, O
Ametov, A
Dreval, A
Grineva, E
Mkrtumyan, A
Tyurina, T
Sazonova, O
Bonnici, F
Ranjith, N
Burgess, L
Nortje, H
Distiller, L
Mitha, I
Moore, R
Conradie, M
Horak, A
Pillay, S
Wellmann, H
Berg, E
Pillai, P
Padayachee, T
Corbett, C
Makan, H
Wing, J
Vawda, Z
Ebrahim, I
Dalby, A
Mitha, E
Bhorat, A
Fernandez, JC
Munoz, C
Cortada, JB
Conde, AC
Calvo, C
Extremera, BG
Delgado, E
Masmiquel, L
Puig, JG
Parreno, LD
Mauricio, D
Redon, J
Brito, M
Lopez, C
de la Morera, JS
Linderfalk, C
Larnefeldt, H
Olsson, A
Lonneborg, L
Ekelund, M
Samad, B
Borgencrantz, B
Nilsson, J
Berglund, O
Svensson, M
Mooe, T
Curiac, D
Albin, J
Angesjo, E
Lannemyr, O
Chiang, C
Sheu, W
Chen, J
Tien, K
Ueng, K
Lai, W
Yin, W
Hung, Y
Shyu, K
Hou, J
Lam, H
Laothavorn, P
Kuanprasert, S
Khovidhunkit, W
Benjasuratwong, Y
Chotinaiwattarakul, C
Mamanasiri, S
Suraamornkul, S
Pratipanawatr, T
Nitiyanant, W
Heller, S
Ray, K
Pieters, R
Strang, C
Bodalia, B
Middleton, A
Hall, T
Chapman, G
Calvert, J
Reed, R
Tam, D
Butcher, G
Jones, N
Takhar, A
Turner, W
McNally, D
Corey, O
Chapman, J
Mohr, S
Edwards, S
Bhatt, D
Davidson, J
Ocampo, A
Kandath, D
Aude, Y
Ervin, W
Savin, V
Anderson, R
Littlefield, R
Oberoi, M
Platt, GE
Yazdani, S
Mangoo-Karim, R
Walder, J
Gogia, H
Chandrashekhar, Y
Boccalandro, F
Rogers, W
Bilazarian, S
Zieve, F
Siage, Y
O'Connor, T
Mudaliar, S
Nikas, A
Giusti, R
Glover, R
Chilka, S
French, W
Roth, E
Singh, N
Christofferson, R
Stich, M
Dagogo-Jack, S
Allison, J
Zengotita, GA
Ison, R
Iteld, B
Sulistio, M
Gonzalez, E
Gorman, T
Hage-Korban, E
Reddy, R
Byars, W
Antonishen, M
Benjamin, S
First, B
Rosado, J
Bruschetta, H
Mehta, P
Poling, T
Rosendorff, C
Kerstein, HJ
Saba, F
Willis, J
Adams, K
Vazquez, EC
Ellison, H
Kahn, B
Kereiakes, D
Powell, S
Raskin, P
Smith, K
Varma, S
Whittier, F
Casanova, R
Isserman, S
Kaye, W
McGuinn, W
Bartkowiak, A
Dworkin, L
Labrador, CA
Podlecki, D
Popovtzer, M
Aronoff, S
Ballantyne, C
Ortiz, EG
Mora, A
Pitts, T
Reinhardt, S
Soucie, G
Wainwright, W
Henson, B
Sklaver, N
Arakaki, R
Brown, J
Chalavarya, G
Chochinov, R
Dixon, T
Kutner, M
Perlman, R
Raisinghani, A
Salacata, A
Awasty, V
Elinoff, V
George, W
LaRochelle-Gryseels, A
Mercado, A
Miller, G
Qureshi, M
Steljes, A
Wefald, F
Wilson, J
Chinn, J
Chuang, RB
Comulada-Rivera, A
Hartman, I
Narayan, P
Pacheco, T
Weiss, R
Beavins, J
Creevy, J
Hamroff, G
Hodson, R
Kosinski, E
Krichmar, P
Patel, R
Schneider, R
Shapiro, J
Sharp, D
Speer, J
Stegemoller, R
Waxman, F
Chang, FY
Braun, E
Eder, F
Minor, S
Albert, M
Carr, KW
Diaczok, B
Gastman, I
Gupta, V
Longshaw, K
Gonzalez-Campoy, JM
Raikhel, M
Thomas, J
Wood, K
Diab, I
Furda, J
Gelernt, M
Halter, M
House, B
Kaster, S
Raad, G
Stamatin, R
Barker, B
Blonder, R
Bloomberg, RJ
Calderon, RB
Carrol, A
Comerota, A
Feinglos, M
Henderson, D
Kastelic, R
Stonesifer, LD
Talano, J
Lee, PV
Brosseau, J
Clark, W
Cohen, E
Fialkow, J
Horton, K
Kozman, H
McGill, J
Mihills, C
Poonawala, R
Shore, K
Tejada, L
Torres, R
Wright, W
Calatayud, G
Chandna, H
Drozdiak, R
Fink, R
Gill, R
Glandt, M
Gottlieb, DW
Hack, T
Kay, J
Mansouri, V
McKnight, T
Mostel, E
Schmidt, L
Seide, H
Sonel, E
Taylor, R
Velasquez, M
Bretton, E
Feldman, R
Hartman, A
Hershon, K
Leach, CR
Martin, E
Mohiuddin, F
Naygandhi, Y
Riske, T
Schima, S
Uzoaga, ER
Ward, H
Weinstock, R
Williams, T
Altschuller, A
Aoki, T
Blumenthal, S
Cash, A
Eisner, G
Gutmann, J
Hagan, M
Kabour, A
Markus, T
McKenzie, W
Moursi, M
Mystkowski, P
Ovalle, F
Perkins, R
Popeil, L
Saniuk, R
Sierra, Y
Alvarado, O
Anderson, J
Bajaj, M
Blank, R
Chu, A
Levinsky, L
Levy, P
Osborne, J
Pavon, H
Sanderlin, D
Schaer, G
Zarich, S
Atassi, K
Bayron, C
Casagrande, M
Das, D
Gimness, M
Handel, F
Kinstrey, T
Leu, S
Osei, K
Nouel, JS
Soltani, Z
Sussman, H
Chiu, K
Duda, R
Farnsworth, K
Lano, M
Lee, F
Levin, P
Pratt, S
Richwine, R
Ruiz-Rivera, L
Turner, J
Wood, J
Zigrang, WD
Baquerizo, HR
Colon, CB
Demattia, J
Desai, V
Fitz-Patrick, D
Goral, S
Odhav, A
Prentiss, A
Ruff, C
Wu, W
Wyne, K
Abbott, LG
Applegate, R
Cabral, J
Kotha, P
Ortega, P
Simmons, D
AF Scirica, Benjamin M.
Bhatt, Deepak L.
Braunwald, Eugene
Steg, P. Gabriel
Davidson, Jaime
Hirshberg, Boaz
Ohman, Peter
Frederich, Robert
Wiviott, Stephen D.
Hoffman, Elaine B.
Cavender, Matthew A.
Udell, Jacob A.
Desai, Nihar R.
Mosenzon, Ofri
McGuire, Darren K.
Ray, Kausik K.
Leiter, Lawrence A.
Raz, Itamar
Braunwald, Eugene
Bhatt, Deepak L.
Scirica, Benjamin M.
Udell, Jacob A.
Cavender, Matthew A.
Desai, Nihar
Abrahamsen, Timothy
Grossman, Michelle
Morin, Suzanne
Im, Kyungah
Hoffman, Elaine
Gabovitch, Daniel
Pricken, Alexandra
Mosenzon, Ofri
Buskila, Alona
Ohman, Peter
Hirshberg, Boaz
Stahre, Christina
Price, Deborah
Billing-Clason, Solveig
Sabel, Karin
Monyak, John
Sjostrand, Mikalea
Wei, Cheryl
Lu, Jane
Miller, Elinor
Raichlen, Joel
Fitt, Sandy
Frederich, Robert
Iqbal, Nayyar
Donovan, Mark
Davidson, Jaime A.
Steg, Ph. Gabriel
Aguilar-Salinas, Carlos
Alvarsson, Michael
Amerena, John
Ardissino, Diego
Averkov, Oleg
Avogaro, Angelo
Barnett, Anthony
Bretzel, Reinhard
Chiang, Chern-En
Codoceo, Verner
Corbalan, Ramon
Dalby, Anthony
Darius, Harald
Deerochanawong, Chaicharn
Dellborg, Mikael
Eliaschewitz, Freddy
Garcia-Castillo, Armando
Gomis, Ramon
Henry, Patrick
Hoekstra, Joost
Jermendy, Gyorgy
Kastelein, John
Keech, Anthony
Kiss, Robert
Krempf, Michel
Laakso, Markku
Leiter, Lawrence
Leitersdorf, Eran
Lewis, Basil
Litwak, Leon
Lopez-Sendon, Jose
Ma, Ronald
McGuire, Darren
Medina, Felix
Moses, Robert
Nicolau, Jose C.
Opolski, Grzegorz
Ophuis, Ton Oude
Paolasso, Ernesto
Ray, Kausik K.
Ruda, Mikhail
Kumar, K. M. Prasanna
Shestakova, Marina
Sheu, Wayne H-H
Smahelova, Alena
Bhupathiraju, B. Soma Raju
Spinar, Jindrich
Sritata, Piyamitr
Strojeck, Krysztof
Villena-Chavez, Jaime E.
Jia, Weiping
Huo, Young
Wiviott, Stephen D.
Lowe, Cheryl
Awtry, Eric
Berger, Clifford
Desai, Akshay S.
Gelfand, Eli
Leeman, David
Link, Mark
Ruberg, Frederick
Vita, Joseph
Rost, Natalia
Silverman, Scott
Greenberger, Norton J.
Lerch, Markus M.
Gersh, Bernard
Nesto, Richard
Del Prato, Stefano
Tuomilehto, Jaakko
Kelsey, Sheryl
Alvarisqueta, A.
Cuadrado, J.
Rista, L.
Hermida, S.
Baccaro, C.
Luquez, C.
Lagrutta, M.
Maffei, L.
Bartolacci, I.
Montana, O.
Cutuli, H.
Berli, M.
Lorenzatti, A.
Frechtel, G.
La Greca, R.
Fretes, O.
Diaz, M.
Rodriguez Papini, N.
Farias, E.
Issa, C.
Elbert, A.
Lehman, R.
Arya, M.
Singh, B.
Colquhoun, D.
Jayasinghe, R.
de Looze, F.
Blombery, P.
Ward, G.
Szto, G.
Abhayaratna, W.
Borges, J.
Russo, L.
Felicio, J.
Santos, F.
Guimaraes Filho, F.
Lazaretti Castro, M.
Rossi, P.
Armaganijan, D.
Leaes, P.
Bandeira, F.
Franken, M.
Rassi, N.
Rea, R.
Zanella, M.
Amodeo, C.
Cesar, L.
Betti, R.
Chacra, A.
Schmid, H.
Bell, A.
Syan, G.
Zadra, R.
Conter, H.
Dumas, R.
Borts, D.
Dattani, I.
Poirier, P.
Cha, J.
Dzongowski, P.
Labonte, R.
St Pierre, B.
Gaudet, D.
Kouz, S.
Lamy, A.
Tishler, S.
Chehayeb, R.
Bedard, J.
Hramiak, I.
Teitelbaum, I.
Fortin, C.
Woo, V.
Conway, J.
Mehta, P.
Robinson, S.
Sussex, B.
Chiasson, J.
Muirhead, N.
Bose, S.
Ouellet, A.
Yale, J.
Bhargava, R.
Lau, D.
Tobe, S.
Perron, P.
Sigalas, J.
Bilodeau, L.
Tytus, R.
Achyuthan, G.
Pearce, M.
Steele, A.
Bailey, G.
Ma, P.
St-Maurice, F.
Rupka, D.
Houlden, R.
Bailey, A.
Rewa, G.
Sohal, P.
Ting, R.
Prieto, J.
Rodriguez, M.
Godoy, G.
Larenas, G.
Pincetti, C.
Cobos, L.
Saavedra, V.
Varleta, P.
Lucero, F.
Kuzmanic, O.
Acevedo, M.
Aguirre, M.
Florenzano, F.
Ma, J.
Bao, Y.
Jiang, M.
Xu, W.
Shi, Y.
Zheng, M.
Li, Y.
Dong, Y.
Zhao, W.
Sun, M.
Lei, M.
Wang, J.
Pistek, Z.
Rihacek, I.
Kucera, D.
Brada, M.
Naplava, R.
Karasova, J.
Vlasicova, H.
Skopecek, J.
Spinarova, L.
Raclavska, L.
Sarbochova, R.
Okenka, L.
Racicka, E.
Urbancova, K.
Oznerova, M.
Lorenc, Z.
Wasserburger, B.
Zahumensky, E.
Gruenfeldova, H.
Hradec, J.
Lukac, M.
Svacina, S.
Podzimek, J.
Hemzsky, L.
Mikulkova, I.
Pavlickova, J.
Brychta, T.
Chochola, J.
Couffinhal, T.
Elbaz, M.
Petit, C.
Faller, B.
Marechaud, R.
Moulin, P.
Fendri, S.
Nazeyrollas, P.
Wendisch, U.
Busch, K.
Klausmann, G.
Duengen, H.
Appel, K.
Toursarkissian, N.
Jung, T.
Ott, P.
Schenkenberger, I.
Kuesters, D.
Landers, B.
Nischik, R.
Fischer, H.
Tschoepe, D.
Paschen, B.
Krause, K.
Derwahl, K.
Wenzl-Bauer, V.
Hamann, A.
Strotmann, H.
Milek, K.
Mueller, S.
Chu, D.
Tan, K.
Kung, K.
Chu, D.
Tsang, C.
Chu, D.
Tomlinson, B.
Kung, K.
Koranyi, L.
Kerenyi, Z.
Benczur, B.
Illyes, L.
Hidvegi, T.
Somogyi, A.
Valco, J.
Ferenczi, S.
Rapi, J.
Voeroes, P.
Winkler, G.
Sydo, T.
Hetey, M.
Simon, K.
Penzes, J.
Kempler, P.
Bako, B.
Lengyel, Z.
Witmann, I.
Dudas, M.
Vandorfi, G.
Takacs, J.
Matoltsy, A.
Ladanyi, E.
Gyimesi, A.
Sadikot, S.
Parikh, K.
Jain, S.
Yajnik, C.
Sosale, A.
Shamanna, P.
Srikanta, S.
Shah, S.
Srinivas, A.
Banker, D.
Shah, P.
Sharda, A.
Makkar, B.
Desai, N.
Rais, N.
Mardikar, H.
Mishra, A.
Bhupati, S.
Menon, J.
Sathe, S.
Gupta, R.
Sharma, V.
Darawsha, M.
Herskovits, T.
Hamoud, S.
Nikolsky, E.
Adawi, F.
Zimlichman, R.
Tsalihin, D.
Wainstein, J.
Klainman, E.
Mosseri, M.
Yerushalmi, Y.
Karnieli, E.
Knobler, H.
Zimlichman, R.
Benchetrit, S.
Tsur, A.
Yagil, Y.
Atar, S.
Beberashvili, I.
Fuchs, S.
Stern, N.
Pollak, A.
Chajek-Shaul, T.
Rozenman, Y.
Biton, A.
Bramucci, E.
Fiscella, A.
Grassia, V.
Piatti, P.
De Cosmo, S.
Di Lorenzo, L.
Merlini, P.
Mannucci, E.
Frontoni, S.
Trevisan, R.
Zenari, L.
Lambiase, C.
Salvioni, A.
Silvestri, O.
Ambrosio, G.
Di Bartolo, P.
Fattore, L.
Presbitero, P.
Calabrese, M.
Evola, R.
Alcocer Gamba, M.
de los Rios Ibarra, M. Odin
Cardona Munoz, E.
Reyes Sanchez, D.
Hernandez Herrera, C.
Perez Rios, J.
Bayram Llamas, E.
Llamas Esperon, G.
Garcia Cantu, E.
Nunez Fragoso, J.
Gonzalez Gonzalez, J.
Rivera Martinez, G.
Padilla Padilla, F.
Melendez Mier, G.
Herrera Marmolejo, D.
Garza Ruiz, J.
Caracas Portilla, N.
Lopez Rosas, E.
Mendez Machado, G.
Chevaile Ramos, J.
Rodriguez Briones, I.
van Hessen, M. W. J.
Strikwerda, S.
The, S. H. K.
Kooy, A.
Ronner, E.
Nierop, P. R.
Remmen, J. J.
Groenemeijer, B. E.
Hamer, B. J. B.
Basart, D. C. G.
van Lennep, H. W. O. Roeters
Nieuwdorp, M.
van Dijk, M. P. M.
Kentgens, S.
van Kempen, W. W.
Hoogendijk, J.
Spiering, W.
Voors-Pette, C.
Kose, V.
de Waard, D. E. P.
Gonkel, F.
Kaasjager, H. A. H.
Lingan, G. M. Rojas
Agous, I.
Kruik, H. J.
Imholz, B. P. M.
Pieterse, M.
Manrique, H.
Villena, J.
Leon, L.
Kundert, K.
Minchola, J.
Pinto, M.
Heredia, J.
Rodriguez, A.
Guerreros, C.
Berrospi, P.
Zubiate, C.
Allemant, A.
Arbanil, H.
Ponciano, W.
Calderon, J.
Lisson, R.
Segura, L.
Sidorowicz-Bialynicka, A.
Sciborski, R.
Fares, I.
Mader, P.
Skierkowska, J.
Stasinska, T.
Pomiecko, W.
Skorski, M.
Krzyzagorska, E.
Polaszewska-Muszynska, M.
Sowinski, D.
Strojek, K.
Rosinska-Migda, J.
Romanczuk, P.
Golebiowski, G.
Kubica, J.
Mazurek, T.
Wojnowski, L.
Pasternak, D.
Stachlewski, P.
Trzepla, E.
Bogdanowicz, G.
Uzunow, A.
Potakowska, I.
Miszczyszyn, Z.
Waszyrowski, T.
Smolenskaya, O.
Lukyanov, Y.
Vorokhobina, N.
Khalimov, Y.
Orlikova, O.
Rebrov, A.
Kukharchuk, V.
Boldueva, S.
Arkhipov, M.
Zhelninova, T.
Pavlysh, E.
Antsiferov, M.
Panov, A.
Pavlova, M.
Shustov, S.
Demchenko, E.
Galyavich, A.
Malakhina, E.
Semenova, O.
Kobalava, Z.
Kotova, S.
Gavrisheva, I.
Oschepkova, E.
Karpov, Y.
Sidorenko, B.
Kislyak, O.
Ametov, A.
Dreval, A.
Grineva, E.
Mkrtumyan, A.
Tyurina, T.
Sazonova, O.
Bonnici, F.
Ranjith, N.
Burgess, L.
Nortje, H.
Distiller, L.
Mitha, I.
Moore, R.
Conradie, M.
Horak, A.
Pillay, S.
Wellmann, H.
Berg, E.
Pillai, P.
Padayachee, T.
Corbett, C.
Makan, H.
Wing, J.
Vawda, Z.
Ebrahim, I.
Dalby, A.
Mitha, E.
Bhorat, A.
Cruz Fernandez, J.
Munoz, C.
Bruguera Cortada, J.
Castro Conde, A.
Calvo, C.
Gil Extremera, B.
Delgado, E.
Masmiquel, L.
Garcia Puig, J.
de Teresa Parreno, L.
Mauricio, D.
Redon, J.
Brito, M.
Lopez, C.
Segura de la Morera, J.
Linderfalk, C.
Larnefeldt, H.
Olsson, A.
Lonneborg, L.
Ekelund, M.
Samad, B.
Borgencrantz, B.
Nilsson, J.
Berglund, O.
Svensson, M.
Mooe, T.
Curiac, D.
Albin, J.
Angesjo, E.
Lannemyr, O.
Chiang, C.
Sheu, W.
Chen, J.
Tien, K.
Ueng, K.
Lai, W.
Yin, W.
Hung, Y.
Shyu, K.
Hou, J.
Lam, H.
Laothavorn, P.
Kuanprasert, S.
Khovidhunkit, W.
Benjasuratwong, Y.
Chotinaiwattarakul, C.
Mamanasiri, S.
Suraamornkul, S.
Pratipanawatr, T.
Nitiyanant, W.
Heller, S.
Ray, K.
Pieters, R.
Strang, C.
Bodalia, B.
Middleton, A.
Hall, T.
Chapman, G.
Calvert, J.
Reed, R.
Tam, D.
Butcher, G.
Jones, N.
Takhar, A.
Turner, W.
McNally, D.
Corey, O.
Chapman, J.
Mohr, S.
Edwards, S.
Bhatt, D.
Davidson, J.
Ocampo, A.
Kandath, D.
Aude, Y.
Ervin, W.
Savin, V.
Anderson, R.
Littlefield, R.
Oberoi, M.
Platt, George E.
Yazdani, S.
Mangoo-Karim, R.
Walder, J.
Gogia, H.
Chandrashekhar, Y.
Boccalandro, F.
Rogers, W., Jr.
Bilazarian, S.
Zieve, F.
Siage, Y.
O'Connor, T.
Mudaliar, S.
Nikas, A.
Giusti, R.
Glover, R.
Chilka, S.
French, W.
Roth, E.
Singh, N.
Christofferson, R.
Stich, M.
Dagogo-Jack, S.
Allison, J., III
Zengotita, G. Arroyo
Ison, R.
Iteld, B.
Sulistio, M.
Gonzalez, E.
Gorman, T.
Hage-Korban, E.
Reddy, R.
Byars, W.
Antonishen, M.
Benjamin, S.
First, B.
Rosado, J.
Bruschetta, H.
Mehta, P.
Poling, T.
Rosendorff, C.
Kerstein, Howard J.
Saba, F.
Willis, J.
Adams, K.
Vazquez, E. Camilo
Ellison, H.
Kahn, B.
Kereiakes, D.
Powell, S.
Raskin, P.
Smith, K.
Varma, S.
Whittier, F.
Casanova, R.
Isserman, S.
Kaye, W.
McGuinn, W., II
Bartkowiak, A., Jr.
Dworkin, L.
Labrador, Carlos A.
Podlecki, D.
Popovtzer, M.
Aronoff, S.
Ballantyne, C.
Gonzalez-Ortiz, Elena
Mora, A., III
Pitts, T.
Reinhardt, S.
Soucie, G.
Wainwright, W.
Henson, B.
Sklaver, N.
Arakaki, R.
Brown, J.
Chalavarya, G.
Chochinov, R.
Dixon, T.
Kutner, M.
Perlman, R.
Raisinghani, A.
Salacata, A.
Awasty, V.
Elinoff, V.
George, W.
LaRochelle-Gryseels, A.
Mercado, A.
Miller, G.
Qureshi, M.
Steljes, A.
Wefald, F.
Wilson, J.
Chinn, J.
Chuang, Rita B.
Comulada-Rivera, A.
Hartman, I.
Narayan, P.
Pacheco, T.
Weiss, R.
Beavins, J.
Creevy, J.
Hamroff, G.
Hodson, R.
Kosinski, E.
Krichmar, P.
Patel, R.
Schneider, R.
Shapiro, J.
Sharp, D.
Speer, J.
Stegemoller, R.
Waxman, F.
Chang, F. Young
Braun, E.
Eder, F.
Minor, S.
Albert, M.
Carr, Kenneth W.
Diaczok, B.
Gastman, I.
Gupta, V.
Longshaw, K.
Gonzalez-Campoy, J. M.
Raikhel, M.
Thomas, J.
Wood, K.
Diab, I.
Furda, J.
Gelernt, M.
Halter, M.
House, B.
Kaster, S.
Raad, G.
Stamatin, R.
Barker, B.
Blonder, R.
Bloomberg, Robert J.
Calderon, R. Burgos
Carrol, A.
Comerota, A.
Feinglos, M.
Henderson, D.
Kastelic, R.
Stonesifer, Larry D.
Talano, J.
Lee, P. Ver
Brosseau, J.
Clark, W.
Cohen, E.
Fialkow, J.
Horton, K.
Kozman, H.
McGill, J.
Mihills, C.
Poonawala, R.
Shore, K.
Tejada, L.
Torres, R.
Wright, W.
Calatayud, G.
Chandna, H.
Drozdiak, R.
Fink, R.
Gill, R.
Glandt, M.
Gottlieb, Daniel W.
Hack, T.
Kay, J.
Mansouri, V.
McKnight, T.
Mostel, E.
Schmidt, L.
Seide, H.
Sonel, E.
Taylor, R.
Velasquez, M.
Bretton, E.
Feldman, R.
Hartman, A.
Hershon, K.
Leach, Charles R.
Martin, E.
Mohiuddin, F.
Naygandhi, Y.
Riske, T.
Schima, S.
Uzoaga, E. R.
Ward, H.
Weinstock, R.
Williams, T.
Altschuller, A.
Aoki, T.
Blumenthal, S.
Cash, A.
Eisner, Gilbert
Gutmann, J.
Hagan, M.
Kabour, A.
Markus, T.
McKenzie, W.
Moursi, M.
Mystkowski, P.
Ovalle, F.
Perkins, R.
Popeil, L.
Saniuk, R.
Sierra, Y.
Alvarado, O.
Anderson, J.
Bajaj, M.
Blank, R.
Chu, A.
Levinsky, L.
Levy, P.
Osborne, J.
Pavon, H.
Sanderlin, D.
Schaer, G.
Zarich, S.
Atassi, K.
Bayron, C.
Casagrande, M.
Das, D.
Gimness, M.
Handel, F.
Kinstrey, T.
Leu, S.
Osei, K.
Nouel, J. Soba
Soltani, Z.
Sussman, H.
Chiu, K.
Duda, R., Jr.
Farnsworth, K.
Lano, M.
Lee, F.
Levin, P.
Pratt, S.
Richwine, R.
Ruiz-Rivera, L.
Turner, J.
Wood, J.
Zigrang, William D.
Baquerizo, Hernan R.
Colon, Carlos Benitez
Demattia, J.
Desai, V.
Fitz-Patrick, D.
Goral, S.
Odhav, A.
Prentiss, A.
Ruff, C.
Wu, W.
Wyne, K.
Abbott, Lisa G.
Applegate, R.
Cabral, J.
Kotha, P.
Ortega, P.
Simmons, D.
CA Savor-Timi Steering Comm Investig
TI Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mellitus
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; INCRETIN-BASED THERAPIES; BLOOD-GLUCOSE
CONTROL; VASCULAR OUTCOMES; CLINICAL-TRIAL; HEART-FAILURE; ALL-CAUSE;
METAANALYSIS; EVENTS; DEATH
AB BackgroundThe cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.
MethodsWe randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke.
ResultsA primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the on-treatment analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively).
ConclusionsDPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes.
C1 [Bhatt, Deepak L.] VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA.
[Scirica, Benjamin M.; Bhatt, Deepak L.; Braunwald, Eugene; Wiviott, Stephen D.; Hoffman, Elaine B.; Cavender, Matthew A.; Udell, Jacob A.; Desai, Nihar R.] Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div, Boston, MA 02115 USA.
[Scirica, Benjamin M.; Bhatt, Deepak L.; Braunwald, Eugene; Wiviott, Stephen D.; Hoffman, Elaine B.; Cavender, Matthew A.; Udell, Jacob A.; Desai, Nihar R.] Harvard Univ, Sch Med, Boston, MA USA.
[Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA 02132 USA.
[Steg, P. Gabriel] Univ Paris Diderot, Paris, France.
[Steg, P. Gabriel] Hop Bichat Claude Bernard, AP HP, Dept Hosp Univ FIRE, F-75877 Paris, France.
[Davidson, Jaime] Univ Texas SW Med Ctr Dallas, Div Endocrinol, Dept Internal Med, Dallas, TX 75390 USA.
[McGuire, Darren K.] Univ Texas SW Med Ctr Dallas, Div Cardiovasc Med, Dept Internal Med, Dallas, TX 75390 USA.
[Hirshberg, Boaz; Ohman, Peter] AstraZeneca Res & Dev, Wilmington, DE USA.
[Frederich, Robert] Bristol Myers Squibb, Princeton, NJ USA.
[Mosenzon, Ofri; Raz, Itamar] Hadassah Univ Hosp, Diabet Unit, Dept Internal Med, Jerusalem, Israel.
[Ray, Kausik K.] St Georges Univ London, Cardiovasc Sci Res Ctr, London, England.
[Leiter, Lawrence A.] Univ Toronto, Div Endocrinol & Metab, Keenan Res Ctr, Li Ka Shing Knowledge Inst,St Michaels Hosp, Toronto, ON, Canada.
[Alvarisqueta, A.] Ctr Invest Med, Mar Del Plata, Buenos Aires, Argentina.
[Cuadrado, J.] Framingham, La Plata, Buenos Aires, Argentina.
[Rista, L.] CEDyN Ctr Diabet & Nutr, Rosario, Santa Fe, Argentina.
[Hermida, S.] CIAD Consultorio Integral Atenc Diabet, Moron, Buenos Aires, Argentina.
[Baccaro, C.] CIMeL, Lanus, Buenos Aires, Argentina.
[Luquez, C.] Ctr Med Luquez Fdn Luquez, Cordoba, Argentina.
[Lagrutta, M.] Inst Invest Clin Rosario, Rosario, Santa Fe, Argentina.
[Maffei, L.] Consultorios Asociados Endocrionol, Buenos Aires, DF, Argentina.
[Bartolacci, I.] Inst Invest Clin Cordoba, Cordoba, Argentina.
[Montana, O.] DIM Clin Privada, Ramos Mejia, Buenos Aires, Argentina.
[Cutuli, H.] Ctr Urol Ballester SRL, Villa Ballester, Buenos Aires, Argentina.
[Berli, M.] CEDIR Ctr Diagnost & Rehabil, San Martin, Santa Fe, Argentina.
[Lorenzatti, A.] Fdn Rusculleda, Cordoba, Argentina.
[Frechtel, G.] Hosp Sirio Libanes, Buenos Aires, DF, Argentina.
[La Greca, R.] Hosp Churruca Visca, Buenos Aires, DF, Argentina.
[Fretes, O.] St Deniss Med Grp, Buenos Aires, DF, Argentina.
[Diaz, M.] MD Invest, Buenos Aires, DF, Argentina.
[Rodriguez Papini, N.] INSARES, Mendoza, Argentina.
[Farias, E.] Inst Cardiol Juana F Cabral, Corrientes, Argentina.
[Issa, C.] Sanat Guemes, Buenos Aires, DF, Argentina.
[Elbert, A.] CEREHA Ctr Enfermedades Renales & Hipertens, Sarandi, Buenos Aires, Argentina.
[Lehman, R.] Adelaide Med Res, Ashford, SA, Australia.
[Amerena, John] Geelong Hosp, Geelong, Vic, Australia.
[Arya, M.] Australian Clin Res Network, Maroubra, NSW, Australia.
[Singh, B.] Launceston Gen Hosp, Launceston, Tas, Australia.
[Colquhoun, D.] Core Res Grp, Milton, Qld, Australia.
[Jayasinghe, R.] Gold Coast Hosp, Southport, Qld, Australia.
[de Looze, F.] AusTrials, Auchenflower, Qld, Australia.
[Blombery, P.] Ave Cardiovasc Ctr, Windsor, NSW, Australia.
[de Looze, F.] AusTrials, Sherwood, Qld, Australia.
[Ward, G.] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia.
[Szto, G.] Peninsula Heart Ctr, Frankston, Vic, Australia.
[Abhayaratna, W.] Canberra Hosp, Clin Trials Unit, Woden, ACT, Australia.
[Borges, J.] Ctr Pesquisa Clin Brasil, Brasilia, DF, Brazil.
[Russo, L.] CCBR BRASIL Ctr Pesquisas & Anal Clin, Rio De Janeiro, Brazil.
[Eliaschewitz, Freddy] CPClin Ctr Pesquisas Clin, Sao Paulo, Brazil.
[Felicio, J.] Hosp Univ Joao Barros Barreto, Belem, Para, Brazil.
[Santos, F.] Loema Inst Pesquisa Clin, Campinas, SP, Brazil.
[Guimaraes Filho, F.] Inst Coracao Marilia, Marilia, SP, Brazil.
[Lazaretti Castro, M.] IMA Brasil Inst Med Avancada, Sao Paulo, Brazil.
[Rossi, P.] Nucl Pesquisa Clin, Curitiba, Parana, Brazil.
[Armaganijan, D.] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil.
[Leaes, P.] Irm Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
[Bandeira, F.] Ctr Pesquisas Med Basica & Clin, Recife, PE, Brazil.
[Franken, M.; Cesar, L.; Betti, R.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
[Rassi, N.] Hosp Geral Goiania Dr Alberto Rassi, Goiania, Go, Brazil.
[Rea, R.] UFPR, Hosp Clin, Serv Endocrinol, Curitiba, Parana, Brazil.
[Zanella, M.] Hosp Rim & Hipertensao, Sao Paulo, Brazil.
[Amodeo, C.] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil.
[Chacra, A.] Univ Fed Sao Paulo, Ctr Pesquisa Clin Diabet, Sao Paulo, Brazil.
[Schmid, H.] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
[Bell, A.] Keele Med Pl, Toronto, ON, Canada.
[Syan, G.] GS Cardiac Lab Med Profess Corp, Sudbury, ON, Canada.
[Zadra, R.] Newmarket Cardiol Grp, Newmarket, ON, Canada.
[Conter, H.] MSHJ Res Associates Inc, Halifax, NS, Canada.
[Dumas, R.] Ctr Rech Clin Laval, Laval, PQ, Canada.
[Borts, D.] Brampton Res Associates, Brampton, ON, Canada.
[Dattani, I.] Prairie Clin Res Grp, Saskatoon, SK, Canada.
[Poirier, P.] Inst Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.
[Dzongowski, P.] Milestone Res, London, ON, Canada.
[Labonte, R.] Dr R Labonte Profess Med Corp, Sudbury, ON, Canada.
[St Pierre, B.] Ctr Rech Godin & St Pierre, Sherbrooke, PQ, Canada.
[Gaudet, D.] Ctr Sante & Serv Sociaux Chicoutimi, ECOGENE Clin Trial Ctr 21, Chicoutimi, PQ, Canada.
[Kouz, S.] CSSSNL CHRDL, St Charles Borromee, PQ, Canada.
[Lamy, A.] Hamilton Hlth Sci, Hamilton, ON, Canada.
[Tishler, S.] Mississauga Clin Res Ctr Inc, Mississauga, ON, Canada.
[Chehayeb, R.] Viacar Rech Clin Inc, Greenfield Pk, PQ, Canada.
[Bedard, J.] Rech Clin London, Sherbrooke, PQ, Canada.
[Hramiak, I.] St Josephs Hlth Care London, London, ON, Canada.
[Teitelbaum, I.] JJ DIG Res Ltd, Toronto, ON, Canada.
[Fortin, C.] Neufort Inc, St Lambert, PQ, Canada.
[Woo, V.] Hlth Sci Ctr, Diabet Res Grp, Winnipeg, MB, Canada.
[Conway, J.] Diabet Clin, Smiths Falls, ON, Canada.
[Mehta, P.] Laxmi Ctr, Winnipeg, MB, Canada.
[Robinson, S.] Victoria Heart Inst Fdn, Victoria, BC, Canada.
[Sussex, B.] Hlth Sci Ctr, St John, NF, Canada.
[Chiasson, J.] CRCHUM, Montreal, PQ, Canada.
[Muirhead, N.] London Hlth Sci Ctr, London, ON, Canada.
[Bose, S.] Dr S Bose Med Prof Corp, Saskatoon, SK, Canada.
[Ouellet, A.] ViaCar Rech Clin, Longueuil, PQ, Canada.
[Yale, J.] MUHC Royal Victoria, Montreal, PQ, Canada.
[Bhargava, R.] Heart Care Res, Oshawa, ON, Canada.
[Lau, D.] Univ Calgary, Clin Trials Unit, Calgary, AB, Canada.
[Tobe, S.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
[Perron, P.] Ctr Hosp Univ Sherbrooke, Sherbrooke, PQ, Canada.
[Sigalas, J.] Rouge Valley Metab Res Associates, Scarborough, ON, Canada.
[Bilodeau, L.] LEnjeu Med Ctr, Montreal, PQ, Canada.
[Tytus, R.] Hamilton Med Res Grp, Hamilton, ON, Canada.
[Achyuthan, G.] Regina Med Ctr, Regina, SK, Canada.
[Pearce, M.] St Mary Gen Hosp, Kitchener, ON, Canada.
[Steele, A.] Comed Res Res Network Inc, Courtice, ON, Canada.
[Bailey, G.] Bailey Clin, Red Deer, AB, Canada.
[Ma, P.] Heart Hlth Res, Calgary, AB, Canada.
[St-Maurice, F.] ViaCar Rech Clin Inc, Brossard, PQ, Canada.
[Rupka, D.] Fraser Clin Trials Inc, New Westminster, BC, Canada.
[Houlden, R.] Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada.
[Bailey, A.] BioQuest Res, Spruce Grove, AB, Canada.
[Rewa, G.] Toronto East Cardiol Res Associates, Toronto, ON, Canada.
[Sohal, P.] Surrey Med & Travel Clin, Surrey, BC, Canada.
[Ting, R.] Corp Med Ctr, Scarborough, ON, Canada.
[Prieto, J.] Univ Chile, Hosp Clin, Santiago, Chile.
[Rodriguez, M.] Hosp Dr Sotero del Rio, Santiago, Chile.
[Godoy, G.] Serv Med Godoy Ltda, Santiago, Chile.
[Larenas, G.] Ctr Med Stockins & Larenas, Temuco, Chile.
[Pincetti, C.] Ctr Invest Clin Sur, Temuco, Chile.
[Cobos, L.] CARDIOCOB, Santiago, Chile.
[Saavedra, V.] CECIM, Santiago, Chile.
[Varleta, P.] Hosp DIPRECA, Santiago, Chile.
[Lucero, F.] Hosp San Borja Arriaran, Santiago, Chile.
[Kuzmanic, O.] Hosp Mil, Santiago, Chile.
[Acevedo, M.] Ctr Invest Clin UC, Santiago, Chile.
[Aguirre, M.] ADICH, Santiago, Chile.
[Florenzano, F.] Psicomedica, Santiago, Chile.
[Ma, J.] Nanjing First Hosp, Nanjing, Jiangsu, Peoples R China.
[Bao, Y.] Shanghai 6th Peoples Hosp, Shanghai, Peoples R China.
[Jiang, M.] Beijing Univ, Affiliated Hosp 1, Beijing 100871, Peoples R China.
[Xu, W.] Suchow Univ, Affiliated Hosp 2, Suzhou, Peoples R China.
[Shi, Y.] Shanghai Changzheng Hosp, Shanghai, Peoples R China.
[Zheng, M.] Tianjin Med Univ, Affiliated Hosp 2, Tianjin, Peoples R China.
[Li, Y.; Dong, Y.] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.
[Zhao, W.] Beijing Union Med Coll Hosp, Beijing, Peoples R China.
[Sun, M.] Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China.
[Lei, M.] Ctr South Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China.
[Li, Y.] Shanghai Huashan Hosp, Shanghai, Peoples R China.
[Wang, J.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China.
[Pistek, Z.] Interni & Diabetol Ambulance, Uherske Hradiste, Czech Republic.
[Rihacek, I.] Ctr Zdravi Sro, Brno, Czech Republic.
[Kucera, D.] Kardiol & Angiol Ambulance, Ostrava, Czech Republic.
[Brada, M.] Privatni Diabetol Ambulance, Breclav, Czech Republic.
[Naplava, R.] Lunacor Sro, Ctr Choroby Srdce & Cev, Kromeriz, Czech Republic.
[Spinar, Jindrich] Fak Nemocnice Brno, Interni Kardiol Klin 1, Brno, Czech Republic.
[Karasova, J.] Interni & Diabetol Ordinace, Cheb, Czech Republic.
[Vlasicova, H.] Diabetol Ambulance, Zlin, Czech Republic.
[Skopecek, J.] Interni & Diabetol Ambulance, Horovice, Czech Republic.
[Spinarova, L.] Fak Nemocnice U Sv Anny, Interni Kardioangiol Klin 1, Brno, Czech Republic.
[Smahelova, Alena] Fak Nemocnice Hradec Kralove, Klin Gerontol & Metabol, Hradec Kralove, Czech Republic.
[Raclavska, L.] Spol Sro, Medictr Beroun, Beroun, Czech Republic.
[Sarbochova, R.] Nemocnice Slany, Interni Oddeleni, Slany, Czech Republic.
[Okenka, L.] Diabetol Ambulance, Hodonin, Czech Republic.
[Racicka, E.] Poliklin Mittal Steel, Interni & Diabetol Ordinace, Ostrava, Czech Republic.
[Urbancova, K.] Diabetol & Interni Ambulance, Ostrava, Czech Republic.
[Oznerova, M.] Soukroma Diabetol & Interni Ambulance, Ostrava, Czech Republic.
[Lorenc, Z.] Kardiol Ordinace, Plzen, Czech Republic.
[Wasserburger, B.] DIKa Ctr Sro, Havirov, Czech Republic.
[Zahumensky, E.] Interni & Diabetol Ordinace, Zlin, Czech Republic.
[Gruenfeldova, H.] Mestska Nemocnice Caslav, Interni Oddileni, Caslav, Czech Republic.
[Hradec, J.] Interni & Diabetol Ordinace, Chrudim, Czech Republic.
[Lukac, M.] Nefromed Sro, Prague, Czech Republic.
[Svacina, S.] Vseobecna Fak Nemocnice, Interni Klin 3, Lekarska Fak UK VFN 1, Prague, Czech Republic.
[Podzimek, J.] Diabetol & Interni Ordinace, Jablonec Nisou, Czech Republic.
[Hemzsky, L.] Preloucska Poliklin As, Ordinace Diabetol, Prelouc, Czech Republic.
[Mikulkova, I.] Nemocnice Blansko, Interni & Diabetol Ambulance, Blansko, Czech Republic.
[Pavlickova, J.] Diabetol Ambulance, Pardubice, Czech Republic.
[Brychta, T.] Diabetol & Interni Ambulance, Olomouc, Czech Republic.
[Chochola, J.] Nemocnice Milosrdnych Sester Sv Karla Boromejskeh, Interni Oddileni, Prague, Czech Republic.
[Henry, Patrick] Hop Lariboisiere, F-75475 Paris, France.
[Couffinhal, T.] Hop Haut Leveque, Pessac, France.
[Krempf, Michel] Hop Nord Laennec, CHU Nantes, Nantes, France.
[Elbaz, M.] CHU Rangueil, F-31054 Toulouse, France.
[Petit, C.] Ctr Hosp, Corbeil Essonnes, France.
[Faller, B.] Hop Civils Colmar, Colmar, France.
[Marechaud, R.] CHRU Miletrie, Poitiers, France.
[Moulin, P.] Hop Louis Pradel, Bron, France.
[Fendri, S.] CHU Amiens, Hop Sud, Amiens, France.
[Nazeyrollas, P.] CHR Robert Debre, Reims, France.
[Klausmann, G.] Studienzentrum Haematol Onkol Diabetol, Aschaffenburg, Germany.
[Duengen, H.] Campus Virchow Klinikum, Charite Berlin Med Klin Schwerpunkt Kardiol Campu, Berlin, Germany.
[Appel, K.] Ambulantes Herzzentrum Kassel, Kassel, Germany.
[Ott, P.] Teleportalklinik, Dippoldiswalde, Germany.
[Schenkenberger, I.] Klin Forsch Berlin, Berlin, Germany.
[Nischik, R.] Medamed GmbH, Leipzig, Germany.
[Fischer, H.] Facharztzentrum Dresden Neustadt GbR, Zentrum Klin Prufungen, Dresden, Germany.
[Tschoepe, D.] Herz & Diabet Zentrum NRW Forsch Leitung Diabet Z, Bad Oeynhausen, Germany.
[Derwahl, K.] Inst Klin Forsch, Berlin, Germany.
[Derwahl, K.] Entwicklung Berlin GmbHam St Hedwig Krankenhaus E, Berlin, Germany.
[Hamann, A.] Diabet Klin Bad Nauheim GmbH, Bad Nauheim, Germany.
[Strotmann, H.] Med Consult GmbH, Rotenburg, Germany.
[Ma, Ronald; Tomlinson, B.] Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
[Chu, D.] Chai Wan Hlth Ctr, Hong Kong, Hong Kong, Peoples R China.
[Tan, K.] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
[Kung, K.] Lek Yuen Gen Outpatient Clin, Hong Kong, Hong Kong, Peoples R China.
[Chu, D.] Violet Peel Gen Outpatient Clin, Hong Kong, Hong Kong, Peoples R China.
[Tsang, C.] Alice Ho Miu Ling Nethersole Hosp, Hong Kong, Hong Kong, Peoples R China.
[Chu, D.] Sai Wan Ho Hlth Ctr, Hong Kong, Hong Kong, Peoples R China.
[Kung, K.] Fanling Family Med Ctr, Shatin, Hong Kong, Peoples R China.
[Koranyi, L.] DRC Gyogyszervizsgalo Kozpont, Balatonfured, Hungary.
[Kerenyi, Z.] Csepeli Egeszsegugyi Szolgalat Szakorvosi Rendelo, Budapest, Hungary.
[Benczur, B.] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz, Szolnok, Hungary.
[Illyes, L.] Kardiol Szakrendeles Miskolc, H-3530 Miskolc, Hungary.
[Hidvegi, T.] Petz Aladar Megyei Korhaz, Gyor, Hungary.
[Somogyi, A.] Semmelweis Egyet II Belgyogyaszati Klin, Budapest, Hungary.
[Valco, J.] Cegledi Toldy Ferenc Korhaz, Cegled, Hungary.
[Jermendy, Gyorgy] Bajcsy Zsilinszky Korhaz Med Dept, Budapest, Hungary.
[Ferenczi, S.] Petz Aladar Megyei Korhaz Immunnephrol, Gyor, Hungary.
[Rapi, J.] Bugat Pal Korhaz Belgyogyaszat, Gyongyos, Hungary.
[Voeroes, P.] Fovarosi Onk Szent Istvan Korhaz, Budapest, Hungary.
[Winkler, G.] Szent Janos Korhaz II Belgyogyaszati Osztaly, Budapest, Hungary.
[Sydo, T.] Jeruzsalemhegy Egeszseghaz, Veszprem, Hungary.
[Hetey, M.] Markhot Ferenc Korhaz Egeszsegugyi Szolgaltato No, Eger, Hungary.
[Simon, K.] Siofok Varosi Korhaz Rendeloint, Siofok, Hungary.
[Penzes, J.] Konszenzus Plusz Kft, Csongrad, Hungary.
[Kempler, P.] Semmelweis Egyet I Belgyogyaszati Klin, Budapest, Hungary.
[Bako, B.] Borsod Abauj Zemplen Megyei Korhaz, Miskolc, Hungary.
[Lengyel, Z.] Szent Margit Korhaz Belgyogyaszat Nephrol, Budapest, Hungary.
[Witmann, I.] PTE AOK II Belgyogyaszati Klin, Pecs, Hungary.
[Dudas, M.] Pandy Kalman Megyei Korhaz, Gyula, Hungary.
[Vandorfi, G.] Veszprem Megyei Csolnoky Ferenc Korhaz, Veszprem, Hungary.
[Takacs, J.] Jahn Ferenc Del Pesti Korhaz, Budapest, Hungary.
[Matoltsy, A.] Kanizsai Dorottya Korhaz Begyogyaszat Kardiol, Nagykanizsa, Hungary.
[Kiss, Robert] Allami Egeszsegugyi Kozpont Kardiol Osztaly, Budapest, Hungary.
[Ladanyi, E.] FMC Miskolci Nefrol Kozpont, Miskolc, Hungary.
[Gyimesi, A.] Rethy Pal Korhaz II Belgyogyaszati Osztaly, Bekescsaba, Hungary.
[Parikh, K.] Care Inst Med Sci, Ahmadabad, Gujarat, India.
[Jain, S.] Totall Diabet Hormone Inst, Indore, Madhya Pradesh, India.
[Yajnik, C.] KEM Hosp, Pune, Maharashtra, India.
[Sosale, A.] DIACON Hosp & Res Ctr, Bangalore, Karnataka, India.
[Shamanna, P.] Bangalore Clinisearch, Bangalore, Karnataka, India.
[Srikanta, S.] Jnana Sanjeevini Med Ctr, Bangalore, Karnataka, India.
[Shah, S.] Diabet Act Ctr, Bombay, Maharashtra, India.
[Srinivas, A.] Vikram Hosp Private Ltd, Mysore, Karnataka, India.
[Kumar, K. M. Prasanna] Bangalore Diabet Hosp Bengaluru, Bangalore, Karnataka, India.
[Banker, D.] Bankers Heart Inst, Vadodara, India.
[Shah, P.] Gujarat Endocrine Ctr, Ahmadabad, Gujarat, India.
[Sharda, A.] Endocrinol & Diabet Ctr, Bangalore, Karnataka, India.
[Makkar, B.] Diabet & Obes Ctr, New Delhi, India.
[Desai, N.] Namana Med Ctr, Bangalore, Karnataka, India.
[Rais, N.] Chowpatty Med Ctr, Bombay, Maharashtra, India.
[Mardikar, H.] Spandan Heart Inst, Nagpur, Maharashtra, India.
[Mishra, A.] Fortis Flt Lt Rajan Dhall Hosp, New Delhi, India.
[Bhupati, S.] CARE Hosp, Hyderabad, Andhra Pradesh, India.
[Menon, J.] Mar Augustine Golden Jubilee Hosp, Mookkannur, Kerala, India.
[Sathe, S.] Dr Shireesh Sathe Clin, Pune, Maharashtra, India.
[Gupta, R.] Fortis Escorts Hosp, Jaipur, Rajasthan, India.
[Sharma, V.] NHIAI Heart Fdn, New Delhi, India.
[Darawsha, M.] Diabet & Lipid Dept Linn MC, Haifa, Israel.
[Herskovits, T.] Western Galillee Hosp Diabet Inst, Nahariyya, Israel.
[Hamoud, S.] Rambam Med Ctr Internal Med Haifa, Haifa, Israel.
[Nikolsky, E.] Rambam Hlth Care Campus Dept Cardiol, Haifa, Israel.
[Raz, Itamar] Hadassah Ein Karem MC Diabet Unit, Jerusalem, Israel.
[Adawi, F.] Ziv Med Ctr, Endocrinol Unit, Safed, Israel.
[Zimlichman, R.] Tel Aviv Community Ctr, Tel Aviv, Israel.
[Tsalihin, D.] Ben Yair Community Clin Beer Sheva, Beer Sheva, Israel.
[Wainstein, J.] Wolfson Med Ctr, Diabet Unit, Holon, Israel.
[Klainman, E.] Gefen Cardiac Hlth Ctr, Giv'atayim, Israel.
[Mosseri, M.] Meir Med Ctr, Div Cardiol, Kefar Sava, Israel.
[Yerushalmi, Y.] Clalit Tel Aviv Diabet Clin, Tel Aviv, Israel.
[Karnieli, E.] Rambam Med Ctr, Inst Endocrinol, Haifa, Israel.
[Knobler, H.] Kaplan Med Ctr Metabol Unit, Rehovot, Israel.
[Zimlichman, R.] Wolfson Med Ctr Med & Hypertens, Holon, Israel.
[Benchetrit, S.] Meir MC Blood Pressure & Nephrol, Kefar Sava, Israel.
[Tsur, A.] Clalit Hlth Serv Diabet Clin, Jerusalem, Israel.
[Yagil, Y.] Barzilai Med Ctr Nephrol, Ashqelon, Israel.
[Lewis, Basil] Lady Davis Carmel Med Ctr, Haifa, Israel.
[Atar, S.] Western Galilee Hosp Cardiol, Nahriya, Israel.
[Beberashvili, I.] Assaf Harofeh Med Ctr Nephrol, Beer Yaagov, Israel.
[Fuchs, S.] Beilinson Med Ctr, Dept Internal Med, Petah Tiqwa, Israel.
[Stern, N.] Sourasky Med Ctr, Metabol Unit, Tel Aviv, Israel.
[Pollak, A.] Hadassah Med Org, Inst Heart, Jerusalem, Israel.
[Chajek-Shaul, T.] Hadassah Hosp Mt Scopus Internal Med, Jerusalem, Israel.
[Rozenman, Y.] Wolfson Med Ctr Heart Inst, Holon, Israel.
[Biton, A.] Clalit Clin Dimona, Dimona, Israel.
[Ardissino, Diego] AOU, Parma, Italy.
[Bramucci, E.] OP San Matteo, Pavia, Italy.
[Fiscella, A.] AO Cannizzaro, Catania, Italy.
[Grassia, V.] POS Maria delle Grazie, Pozzuoli, Italy.
[Piatti, P.] Ist Ricovero & Cura Carattere Sci, Milan, Italy.
[Piatti, P.] Univ Osped San Raffaele, Milan, Italy.
[De Cosmo, S.] Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy.
[Di Lorenzo, L.] Osped San Rocco, Sessa Aurunca, Italy.
[Merlini, P.] Osped Niguarda Ca Granda, Milan, Italy.
[Mannucci, E.] AOU Careggi, Florence, Italy.
[Frontoni, S.] Osped Fatebenefratelli, Rome, Italy.
[Trevisan, R.] Osped Riuniti Bergamo, I-24100 Bergamo, Italy.
[Zenari, L.] Osped Sacro Cuore Don Calabria, Negrar, Italy.
[Avogaro, Angelo] AO Padova, Padua, Italy.
[Lambiase, C.] Osped Amico Gaetano Fucito, Mercato San Severino, Italy.
[Salvioni, A.] Osped Cardiol Monzino, Milan, Italy.
[Silvestri, O.] AO Cardarelli, Naples, Italy.
[Ambrosio, G.] Osped Santa Maria Terni, Terni, Italy.
[Di Bartolo, P.] AUSL Ravenna, Ravenna, Italy.
[Fattore, L.] PO San Giuseppe, S Maria Capua Vetere, Italy.
[Presbitero, P.] Ist Clin Humanitas, Rozzano, Italy.
[Calabrese, M.] AUSL 4, Prato, Italy.
[Evola, R.] Osped San Vincenzo USL 5, Taormina, Italy.
[Alcocer Gamba, M.] Inst Corazon Queretaro, Queretaro, Mexico.
[de los Rios Ibarra, M. Odin] Ctr Desarrollo Med & Asistencia Med Especializada, Culiacan, Mexico.
[Cardona Munoz, E.] ICLE SC, Guadalajara, Jalisco, Mexico.
[Reyes Sanchez, D.] Cardioprevent SC, Durango, Mexico.
[Hernandez Herrera, C.] Ctr Desarrollo Med & Asistencia Med Especializada, Monclova, Mexico.
[Perez Rios, J.] Oaxaca Site Management Org, Oaxaca De Juarez, Mexico.
[Bayram Llamas, E.] Fdn Cardiovasc Aguascalientes AC, Aguascalientes, Mexico.
[Llamas Esperon, G.] Hosp Cardiol Aguascalientes, Aguascalientes, Mexico.
[Garcia Cantu, E.] Cardiolink Clin Trials SC, Monterrey, Mexico.
Hosp Gen Durango, Durango, Mexico.
[Gonzalez Gonzalez, J.] Hosp Univ Dr Jose Eleuterio Gonzalez, Monterrey, Mexico.
[Rivera Martinez, G.] Hosp Gen Tijuana, Tijuana, Mexico.
[Padilla Padilla, F.] Consultorios Tarascos, Guadalajara, Jalisco, Mexico.
[Melendez Mier, G.] Ctr Invest Med Mexico MENTRIALS SA de CV, Mexico City, DF, Mexico.
[Herrera Marmolejo, D.] Torre Med Prov, Guadalajara, Jalisco, Mexico.
[Garza Ruiz, J.] Internal Med Clin Trials, Monterrey, Mexico.
[Caracas Portilla, N.] Hosp Angeles Lindavista, Mexico City, DF, Mexico.
[Lopez Rosas, E.] Ctr Especialidades Med Estado Veracruz CEMEV, Xalapa, Veracruz, Mexico.
[Aguilar-Salinas, Carlos] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
[Mendez Machado, G.] Med Este, Xalapa, Veracruz, Mexico.
[Chevaile Ramos, J.] Hosp Cent Dr Ignacio Morones Prieto, San Luis Potosi, Mexico.
[Rodriguez Briones, I.] Cardioarritmias & Invest SC, San Luis Potosi, Mexico.
[van Hessen, M. W. J.] Groene Hart Ziekenhuis Locatie Bleuland, Gouda, Netherlands.
[Strikwerda, S.] Amphia Ziekenhuis Locatie Molengracht, Breda, Netherlands.
Bethesda Ziekenhuis, Hoogeveen, Netherlands.
[Kooy, A.] Bethesda Diabet Res Ctr, Hoogeveen, Netherlands.
[Ronner, E.] Reinier de Graaf Gasthuis, Delft, Netherlands.
[Nierop, P. R.] St Franciscus Gasthuis, Rotterdam, Netherlands.
[Remmen, J. J.] Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands.
[Groenemeijer, B. E.] Gelre Ziekenhuizen Loc Lukas Ziekenhuis, Apeldoorn, Netherlands.
[Hamer, B. J. B.] Meander Med Ctr, Amersfoort, Netherlands.
[Basart, D. C. G.] Vasc Onderzoeksctr Hoorn BV, Hoorn, Netherlands.
[van Lennep, H. W. O. Roeters] Admiraal Ruyterziekenhuis, Goes, Netherlands.
[Nieuwdorp, M.] AMC, Amsterdam, Netherlands.
[van Dijk, M. P. M.] Julius Ctr UMCU, Utrecht, Netherlands.
[Kentgens, S.] Andromed Eindhoven, Eindhoven, Netherlands.
[van Kempen, W. W.] Andromed Rotterdam, Rotterdam, Netherlands.
[Hoogendijk, J.] Andromed Oost, Velp, Netherlands.
[Spiering, W.] UMCU, Utrecht, Netherlands.
[Voors-Pette, C.] Andromed Noord, Groningen, Netherlands.
[Kose, V.] Andromed Breda, Breda, Netherlands.
[de Waard, D. E. P.] Antonius Ziekenhuis, Sneek, Netherlands.
[Gonkel, F.] Saxenburgh Grp Ropcke Zweers Ziekenhuis, Hardenberg, Netherlands.
[Kaasjager, H. A. H.] Rijnstate Ziekenhuis, Arnhem, Netherlands.
[Lingan, G. M. Rojas] Andromed Zoetermeer, Eindhoven, Netherlands.
[Agous, I.] Andromed Leiden, Leiderdorp, Netherlands.
[Kruik, H. J.] Ziekenhuis Grp Twente Lokatie Almelo, Almelo, Netherlands.
[Imholz, B. P. M.] Tweesteden Ziekenhuis, Waalwijk, Netherlands.
[Pieterse, M.] Stichting Cardiol Amsterdam, Amsterdam, Netherlands.
[Manrique, H.] Ctr Expertos Diabet Obesidad & Nutr, Lima, Peru.
[Medina, Felix] Clin Med Cayetano Heredia, Lima, Peru.
[Villena, J.] Hosp Nacl Cayetano Heredia, Lima, Peru.
[Leon, L.; Heredia, J.] Clin Anglo Am, Lima, Peru.
[Kundert, K.] Ctr Invest Ricardo Palma, Lima, Peru.
[Minchola, J.] Clin San Gabriel, Lima, Peru.
[Pinto, M.] Clin Oftalmolaser, Lima, Peru.
[Rodriguez, A.] Hosp Nacl Alberto Sabogal Sologuren, Callao, Peru.
[Guerreros, C.] Clin Int, Lima, Peru.
[Berrospi, P.] Clin El Golf, Lima, Peru.
[Zubiate, C.] METABOLICARE, Lima, Peru.
[Allemant, A.] Hosp Nacl Hipolito Unanue, Lima, Peru.
[Arbanil, H.] Hosp Nacl Dos de Mayo, Lima, Peru.
[Ponciano, W.] Clin San Borja, Lima, Peru.
[Calderon, J.] Clin Novocardio, Lima, Peru.
[Lisson, R.] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru.
[Segura, L.] Inst Med Miraflores, Lima, Peru.
[Sidorowicz-Bialynicka, A.] Synexus SCM, Wroclaw, Poland.
[Sciborski, R.] Zespol Opieki Zdrowotnej Olawie SPZOZ, Olawa, Poland.
[Fares, I.] NZOZ Medicus, Naklo Nad Notecia, Poland.
[Mader, P.] NZOZ Praktyka Dentystyczno Internistyczna, Kamieniec Zabkowicki, Poland.
[Skierkowska, J.] NZOZ JUDYTA, Skierniewice, Poland.
[Stasinska, T.] NZOZ Regionalna Poradnia Diabetol, Wroclaw, Poland.
[Pomiecko, W.] Samodzielny Niepubl ZOZ Mazur Med, Mragowo, Poland.
[Skorski, M.] SPZOZ Lecznej Szpital Powiatowy, Leczna, Poland.
[Krzyzagorska, E.] Praktyka Lekarska Ewa Krzyzagorska, Poznan, Poland.
[Polaszewska-Muszynska, M.] Bydgoskie Ctr Diabetol & Endokrynol SPZOZ, Bydgoszcz, Poland.
[Sowinski, D.] Wroclawiu SP ZOZ, Wojewodzki Zespol Specjalistycznej Opieki Zdrowot, Wroclaw, Poland.
[Strojek, K.] Wojewodzka Przychodnia Chorych Cukrzyce, Zabrze, Poland.
[Rosinska-Migda, J.] NZOZ Mig Med, Wabrzezno, Poland.
[Romanczuk, P.] NZOZ Gdanska Poradnia Cukrzycowa, Gdansk, Poland.
[Golebiowski, G.] Szpital Specjalisty Sw Wojciecha Adalberta SP ZOZ, Gdansk, Poland.
[Kubica, J.] NZOZ MEDICUS Jacek Kubica, Bydgoszcz, Poland.
[Mazurek, T.] I Katedra & Klin Kardiol Akad Med, Warsaw, Poland.
[Wojnowski, L.] Lecznice Citomed, Torun, Poland.
[Pasternak, D.] NZOZ Ctr Zdrowia & Profilaktyki Dabie, Krakow, Poland.
[Stachlewski, P.] NZOZ Eskulap, Koluszki, Poland.
[Trzepla, E.] Ctr Med Warszawskiego Uniwersytetu Med, Warsaw, Poland.
[Bogdanowicz, G.] PS ZOZ Wojewodzkie Ctr Med, Opole, Poland.
[Uzunow, A.] Przychodnia Med Rodzinnej Nowy Fordon, Bydgoszcz, Poland.
[Potakowska, I.] Zespol Poradni Zdrowie NZOZ, Sieradz, Poland.
[Miszczyszyn, Z.] Prywatny Specjalisty Gabinet Lekarski, Przemysl, Poland.
[Waszyrowski, T.] Wojewodzka Stacja Ratownictwa Med Lodzi SPZOZ, Lodz, Poland.
[Smolenskaya, O.] Hosp 14 Ural State Med Acad Ekat, Ekaterinburg, Russia.
[Lukyanov, Y.] State Med Univ Na Pavlov, St Petersburg, Russia.
[Vorokhobina, N.] Chair Endocrinol Med Postgrad Acad, St Petersburg, Russia.
[Khalimov, Y.] Endocrinol NII Med Postgrad Acad, St Petersburg, Russia.
[Orlikova, O.] Res Inst Cardiol Saratov, Saratov, Russia.
[Rebrov, A.] SGMU Na Razumovsky Saratov, Saratov, Russia.
[Kukharchuk, V.] Atherosclerosis Problems Dept Cardiocomplex, Moscow, Russia.
[Boldueva, S.] Cardiol Clin Mechnikov Med Acad, St Petersburg, Russia.
[Arkhipov, M.] MO Novaya Ural State Med Acad Ekat, Ekaterinburg, Russia.
[Zhelninova, T.] Out Patient Dep Almazov Fed Ctr, St Petersburg, Russia.
[Pavlysh, E.] Out Patient Dept 25, St Petersburg, Russia.
[Antsiferov, M.] Moscow Endocrinol Dispensary, Moscow, Russia.
[Panov, A.] Cardiol Dep Almazov Fed Ctr, St Petersburg, Russia.
[Pavlova, M.] MMA Na Sechenov IM, Moscow, Russia.
[Shustov, S.] Mil Med Acad Na Kirov, St Petersburg, Russia.
[Demchenko, E.] Rehabil Lab Almazov Fed Ctr, St Petersburg, Russia.
[Galyavich, A.] KGMU Kazan, Kazan, Russia.
[Malakhina, E.] Ctr New Med Technol Novosibirsk, Novosibirsk, Russia.
[Semenova, O.] Alexandrovskaya City Hosp, St Petersburg, Russia.
[Kobalava, Z.] City Clin Hosp 64, Moscow, Russia.
[Shestakova, Marina] Inst Diabet Sci Ctr Endocri, Moscow, Russia.
[Kotova, S.] Chair Endocrinol Mechnikov Med Acad, St Petersburg, Russia.
[Gavrisheva, I.] OOO AVA Peter, St Petersburg, Russia.
[Oschepkova, E.] Arterial Hypertens Dept Cardiocomplex, Moscow, Russia.
[Karpov, Y.] Angiol Dept Cardiocomplex, Moscow, Russia.
[Sidorenko, B.] Cent Clin Hosp, Moscow, Russia.
[Kislyak, O.] City Clin Hosp 79, Moscow, Russia.
[Ametov, A.] Chair Endocrinol RMAPO, Moscow, Russia.
[Dreval, A.] Moscow Res Clin Inst Na Vladimirsky, Moscow, Russia.
[Grineva, E.] Endocrinol Inst Almazov Fed Ctr, St Petersburg, Russia.
[Mkrtumyan, A.] MGMSU, Moscow, Russia.
[Tyurina, T.] Leningrad Reg Cardiol Dispensary, St Petersburg, Russia.
[Sazonova, O.] Novosibirsk State Med Univ, Novosibirsk, Russia.
[Ranjith, N.] Dr Nash Ranjith Res Ctr, Durban, South Africa.
[Burgess, L.] TREAD Res Tygerberg Hosp, Parow, South Africa.
[Nortje, H.] Unit B1 N1 City Mews, Cape Town, South Africa.
[Distiller, L.] Ctr Diabet & Endocrinol, Johannesburg, South Africa.
[Mitha, I.] Worthwhile Clin Trials Lakeview Hosp, Benoni, South Africa.
[Moore, R.] 14 Medigate Med Ctr, Umhlanga Rocks, South Africa.
[Conradie, M.] Tygerberg Hosp, Endocrine Unit, Parow, South Africa.
[Horak, A.] Vincent Pallotti Hosp, Pinelands, South Africa.
[Pillay, S.] Dr SR Pillay Practice, Ottawa, Verulam, South Africa.
[Wellmann, H.] Helderberg Diabat & Med Ctr, Cape Town, South Africa.
[Berg, E.] Dr EC Van den Berg Practice Zuid Afrikaans Hosp, Pretoria, South Africa.
[Pillai, P.] Drs Chetty & Pillai Med Ctr, Phoenix, South Africa.
[Padayachee, T.] Aliwal Shoal Med Ctr, Umkomaas, South Africa.
[Corbett, C.] Panorama Mediclin, Cape Town, South Africa.
[Makan, H.] Seva Sadan, Lenasia, South Africa.
[Wing, J.] Charlotte Maxeke Johannesburg Acad Hosp, Johannesburg, South Africa.
[Vawda, Z.] Dr ZFA Vawdas Practice, Durban, South Africa.
[Ebrahim, I.] Unitas Hosp, Centurion, South Africa.
[Dalby, A.] Milpark Hosp, Johannesburg, South Africa.
[Mitha, E.] Newgate Ctr, Johannesburg, South Africa.
[Bhorat, A.] Soweto Clin Trial Ctr, Soweto, South Africa.
[Cruz Fernandez, J.] Hosp Univ Virgen Macarena, Seville, Spain.
[Munoz, C.] Hosp Gen Jerez de la Frontera, Jerez De La Frontera Cad, Spain.
[Bruguera Cortada, J.] Hosp del Mar, Barcelona, Spain.
[Castro Conde, A.] Hosp Cantoblanco La Paz, Madrid, Spain.
[Calvo, C.] Hosp Univ Santiago, Santiago De Compostela, Spain.
[Gil Extremera, B.] Hosp Clin San Cecilio, Granada, Spain.
[Delgado, E.] Hosp Univ Cent Asturias, Oviedo, Spain.
[Masmiquel, L.] Hosp Son Llatzer, Palma de Mallorca, Spain.
[Garcia Puig, J.] Hosp Univ La Paz, Madrid, Spain.
[de Teresa Parreno, L.] Clin Mediterranea Neurociencias, Alicante, Spain.
[Mauricio, D.] Hosp Arnau Vilanova, Lerida, Spain.
[Redon, J.] Hosp Clin Univ Valencia, Valencia, Spain.
[Brito, M.] Hosp Univ Puerta Hierro Majadahonda, Majadahonda Madrid, Spain.
[Lopez, C.] Ctr Salud El Cristo, Oviedo, Spain.
[Segura de la Morera, J.] Hosp Univ Doce de Octubre, Madrid, Spain.
[Linderfalk, C.] Redeby Eksjo, Eksjo, Sweden.
[Larnefeldt, H.] Rattvikshalsan, Rattvik, Sweden.
[Olsson, A.] Sthlm Heart Ctr, Stockholm, Sweden.
[Lonneborg, L.; Albin, J.] Sorakers Vardcent, Soraker, Sweden.
[Ekelund, M.] Hbg Lasarett, Helsingborg, Sweden.
[Samad, B.] Danderyd, Stockholm, Sweden.
[Borgencrantz, B.] Capio Lakargrp AB Orebro, Orebro, Sweden.
[Nilsson, J.] Skanes Univ Sjukhus Malmo, Malmo, Sweden.
[Berglund, O.] Alidhem Umea, Umea, Sweden.
[Svensson, M.] SU SS Gbg, Gothenburg, Sweden.
[Mooe, T.] Ostersunds Sjukhus, Ostersund, Sweden.
[Alvarsson, Michael] KS Solna, Stockholm, Sweden.
[Curiac, D.] Me3and Gbg, Stockholm, Sweden.
[Angesjo, E.] Bramhults VC, Bramhult, Sweden.
[Lannemyr, O.] Lanssjukhuset Ryhov, Jonkoping, Sweden.
[Dellborg, Mikael] SU Ostra Gbg, Gothenburg, Sweden.
[Chiang, C.] Taipei Vet Gen Hosp, Taipei, Taiwan.
[Sheu, W.] Taichung Vet Gen Hosp, Taichung, Taiwan.
[Chen, J.] Chang Gung Med Fdn Kaohsiung Branch, Kaohsiung, Taiwan.
[Tien, K.] Chi Mei Med Ctr, Tainan, Taiwan.
[Ueng, K.] Chung Shan Med Univ Hosp, Taichung 40201, Taiwan.
[Lai, W.] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan.
[Yin, W.] Cheng Hsin Gen Hosp, Taipei, Taiwan.
[Hung, Y.] Tri Serv Gen Hosp, Taipei, Taiwan.
[Shyu, K.] Shin Kong Wu Ho Su Mem Hosp, Taipei, Taiwan.
[Hou, J.] Mackay Mem Hosp, Taipei, Taiwan.
[Lam, H.] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan.
[Laothavorn, P.; Benjasuratwong, Y.] Phramongkutklao Hosp, Bangkok, Thailand.
[Sritata, Piyamitr] Ramathibodi Hosp, Bangkok, Thailand.
[Kuanprasert, S.] MaharajNakornChiangMai Hosp, Chiangmai, Thailand.
[Deerochanawong, Chaicharn] Rajavithi Hosp, Bangkok, Thailand.
[Khovidhunkit, W.] King Chulalongkorn Mem Hosp, Bangkok, Thailand.
[Chotinaiwattarakul, C.; Nitiyanant, W.] Siriraj Hosp, Bangkok, Thailand.
[Mamanasiri, S.] Ratchaburi Hosp, Ratchaburi, Thailand.
[Suraamornkul, S.] Vajira Hosp, Bangkok, Thailand.
[Pratipanawatr, T.] Srinagarind Hosp, Khon Kaen, Thailand.
[Pieters, R.] Estuary View Med Ctr, Whitstable, England.
[Strang, C.] Mortimer Surg, Mortimer Reading, England.
[Bodalia, B.] Gables Med Ctr, Coventry, W Midlands, England.
[Middleton, A.] Fowey River Practice, Fowey, England.
[Hall, T.] Knowle House Surg, Plymouth, Devon, England.
[Chapman, G.] Sunbury Hlth Ctr, Sunbury On Thames, England.
[Calvert, J.] Waterloo Med Ctr, Blackpool, England.
[Reed, R.] Westongrove Res Ctr Aston Clinton Surg, Aston Clinton Aylesbur, England.
[Tam, D.] Circle Practice, Kenton, England.
[Butcher, G.] Ecclesfield Grp Practice, Sheffield, S Yorkshire, England.
[Jones, N.] St Chads Surg, Bath, Avon, England.
[Takhar, A.] Wansford & Kings Cliffe Practice, Wansford Peterborough, England.
[Turner, W.] Burbage Surg, Burbage Leicester, England.
[McNally, D.] Ormeau Hlth Ctr, Belfast, Antrim, North Ireland.
[Corey, O.] Ave Surg, Warminister, England.
[Chapman, J.] Widcombe Surg, Bath, Avon, England.
[Mohr, S.] Porch Surg, Bath, Avon, England.
[Edwards, S.] Elm Tree Surg, Swindon, Wilts, England.
[Ocampo, A.] Future Care Solut LLC, Miami, FL USA.
[Kandath, D.] Saratoga Clin Res LLC, Saratoga Springs, NY USA.
[Aude, Y.] Valley Heart Consultants, Mcallen, TX USA.
[Ervin, W.] InterMed PA, Portland, ME USA.
[Savin, V.] Kansas City VA Med Ctr, Kansas City, MO USA.
[Anderson, R.] VA Nebraska Western Iowa Healthcare Syst, Omaha, NE USA.
[Littlefield, R.] Palmetto Res Ctr LLC, Spartanburg, SC USA.
[Oberoi, M.] Cent Jersey Med Res Ctr, Elizabeth, NJ USA.
[Yazdani, S.] Virginia Cardiovasc Associates, Manassas, VA USA.
[Mangoo-Karim, R.] Gamma Clin Res Inst, Mission, TX USA.
[Walder, J.] Black Hills Cardiovasc Res, Rapid City, SD USA.
[Gogia, H.] Cardiol Consultants Orange Cty Med Grp Inc, Anaheim, CA USA.
[Chandrashekhar, Y.] VA Med Ctr, Minneapolis, MN USA.
[Boccalandro, F.] Permian Res Fdn, Odessa, TX USA.
[Rogers, W., Jr.] Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA.
[Bilazarian, S.] Pentucket Med Associates, Haverhill, MA USA.
[Zieve, F.] McGuire VA Med Ctr, Richmond, VA USA.
[Siage, Y.] Deaconess Clin Inc, Evansville, IN USA.
[O'Connor, T.] Am Hlth Network Indiana LLC, Greenfield, IN USA.
[Mudaliar, S.] VA San Diego Healthcare Syst, San Diego, CA USA.
[Nikas, A.] Hlth Texas Res Inst, San Antonio, TX USA.
[Giusti, R.] Clin Res Cent Florida, Winter Haven, FL USA.
[Glover, R.] Heartland Res Associates LLC, Newton, KS USA.
[Chilka, S.] Midland Clin Res Ctr, Midland, TX USA.
[French, W.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst Harbor, Torrance, CA 90509 USA.
[Roth, E.] Sterling Res Grp Ltd, Cincinnati, OH USA.
[Singh, N.] Atlanta Heart Specialists LLC, Cumming, GA USA.
[Christofferson, R.] North Ohio Res Ltd, Elyria, OH USA.
[Stich, M.] Westside Ctr Clin Res, Jacksonville, FL USA.
[Dagogo-Jack, S.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA.
[Allison, J., III] Three Rivers Med Associates, Columbia, SC USA.
[Zengotita, G. Arroyo] Jardines Loiza, Georgina Arroyo Zengotita Med Familia, Loiza, PR USA.
[Ison, R.] Community Hlth Care Inc, Canal Fulton, OH USA.
[Iteld, B.] Louisiana Heart Ctr, Slidell, LA USA.
[Sulistio, M.; Raskin, P.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Gonzalez, E.] Eastside Clin Res Associates Inc, Los Angeles, CA USA.
[Gorman, T.] Great Lakes Med Res, Westfield, NY USA.
[Hage-Korban, E.] Kore CV Res, Jackson, TN USA.
[Reddy, R.] T&R Clin PA, Ft Worth, TX USA.
[Byars, W.] Mt View Clin Res, Greer, SC USA.
[Antonishen, M.] Northern Michigan Reg Hosp, Petoskey, MI USA.
[Benjamin, S.] Universal Res Grp, Tacoma, WA USA.
[First, B.] Ritchken & First MDs, San Diego, CA USA.
[Rosado, J.] Florida Heart & Vasc Ctr, Leesburg, FL USA.
[Bruschetta, H.] Humberto Rafael Bruschetta, Kingsville, TX USA.
[Mehta, P.; Poling, T.] Heartland Res Associates LLC, Wichita, KS USA.
[Rosendorff, C.] James J Peters VA Med Ctr, Bronx, NY USA.
[Saba, F.] Profess Hlth Care Pinellas Inc, St Petersburg, FL USA.
[Willis, J.] San Gabriel Clin Res, Georgetown, TX USA.
[Adams, K.] Baptist Heart Specialists, Jacksonville, FL USA.
[Vazquez, E. Camilo] Cent Res Clin Puerto Rico, Aguas Buenas, PR USA.
[Ellison, H.] Rockdale Med Res Associates, Conyers, GA USA.
[Kahn, B.] Overlea Personal Phys, Baltimore, MD USA.
[Kereiakes, D.] Christ Hosp, Carl & Edyth Lindner Ctr Res & Educ, Cincinnati, OH 45219 USA.
[Powell, S.] PMG Res Bristol, Bristol, TN USA.
[Smith, K.] Burke Primary Care, Morganton, NC USA.
[Varma, S.] Boice Willis Clin PA, Rocky Mount, NC USA.
[Whittier, F.] Clin Res Ltd, Canton, OH USA.
[Casanova, R.] South East Med Ctr, Oakland Pk, FL USA.
[Isserman, S.] Clin Trials Am Inc, Hickory, NC USA.
[Kaye, W.] Metab Res Inst Inc, W Palm Beach, FL USA.
[McGuinn, W., II] North Ohio Res Ltd, Sandusky, OH USA.
[Bartkowiak, A., Jr.] Blair Med Associates PA, Altoona, PA USA.
[Dworkin, L.] Rhode Isl Hosp, Providence, RI USA.
[Podlecki, D.] Longmont Med Res Network, Longmont, CO USA.
[Popovtzer, M.] Southern Arizona VA Healthcare Syst, Tucson, AZ USA.
[Aronoff, S.] Res Inst Dallas PA, Dallas, TX USA.
[Ballantyne, C.] Baylor Coll Med, Houston, TX 77030 USA.
[Mora, A., III] Southwest Clin, San Antonio, TX USA.
[Pitts, T.] Diverse Clin Res Ctr Chicago LLC, Chicago, IL USA.
[Reinhardt, S.] Cent Bucks Cardiol, Doylestown, PA USA.
[Soucie, G.] Blackfoot Med Ctr, Blackfoot, ID USA.
[Wainwright, W.] Baptist Heart Specialists, Jacksonville Beach, FL USA.
[Henson, B.] Essentia Inst Rural Hlth, Duluth, MN USA.
[Sklaver, N.] Med Specialists Associated, Dallas, TX USA.
[Arakaki, R.] Univ Hawaii, Diabet & Endocrinol, Honolulu, HI 96822 USA.
[Brown, J.] Internal Med Associates Grand Isl PC, Grand Isl, NE USA.
[Chalavarya, G.] Florida Cardiol Grp, Hudson, FL USA.
[Dixon, T.] Northport Vet Affairs Med Ctr, Northport, NY USA.
[Kutner, M.] Suncoast Res Grp LLC, Miami, FL USA.
[Perlman, R.] Associated Cardiovasc Consultants, Voorhess, NJ USA.
[Raisinghani, A.] Univ Calif San Diego, Med Ctr, 225 Dickinson St, San Diego, CA 92103 USA.
[Salacata, A.] Endeavor Med Res, Alpena, MI USA.
[Awasty, V.] Harrison Community Res Ctr, Cadiz, OH USA.
[Elinoff, V.] Reg Clin Res Inc, Endwell, NY USA.
[George, W.] Cadillac Clin Res LLC, Cadillac, MI USA.
[LaRochelle-Gryseels, A.] Sharon Reg Phys Serv, Hermitage, PA USA.
[Mercado, A.] Stewart Med Grp, Alhambra, CA USA.
[Miller, G.] Clin Res Works, Bristol, CT USA.
[Qureshi, M.] Michigan Heart PC, Ypsilanti, MI USA.
[Steljes, A.] Steljes Cardiol PC, Henderson, NV USA.
[Wefald, F.] Clin Trials Am Inc, Smithfield, NC USA.
[Wilson, J.] PMG Res Winston Salem, Winston Salem, NC USA.
[Chinn, J.] VA Southern Nevada Hlth Care Syst, N Las Vegas, NV USA.
[Chuang, Rita B.] Clin Res Advantage Inc, Henderson, NV USA.
[Comulada-Rivera, A.] Inst Endocrinol Diabet & Metab, Bayamon, PR USA.
[Hartman, I.] Discovery Clin Trials, Arlington, TX USA.
[Narayan, P.] Clin Res Inst Northern Virginia, Burke, VA USA.
[Pacheco, T.] North Ohio Res Ltd, Lorain, OH USA.
[Weiss, R.] Cent Maine Med Ctr, Lewiston, ME USA.
[Beavins, J.] Am Hlth Network Indiana LLC, Franklin, IN USA.
[Creevy, J.] Intercoastal Med Grp, Sarasota, FL USA.
[Hamroff, G.] NYU Hudson Valley Cardiol, Cortlandt Manor, NY USA.
[Hodson, R.] Oregon Clin Gateway, Providence Heart Clin, Portland, OR USA.
[Kosinski, E.] Connecticut Clin Res LLC, Bridgeport, CT USA.
[Krichmar, P.] Res Phys Network Alliance, Pembroke Pines, FL USA.
[Patel, R.] Lycoming Internal Med Inc, Jersey Shore, PA USA.
[Schneider, R.] Holy Cross Med Grp, Coral Springs, FL USA.
[Shapiro, J.] Philadelphia Hlth Associates Adult Med PC, Philadelphia, PA USA.
[Sharp, D.] Clin Res Advantage Inc Internal Med Phys PC, Omaha, NE USA.
[Speer, J.] Clin Res Advantage Colorado Springs Hlth Partners, Colorado Springs, CO USA.
[Stegemoller, R.] Am Hlth Network Indiana LLC, Avon, IN USA.
[Waxman, F.] GSA Med Res, Deerfield Beach, FL USA.
[Chang, F. Young] Pasco Cardiol Ctr, Hudson, FL USA.
[Braun, E.] Midtown Med Ctr, Tampa, FL USA.
[Eder, F.] United Med Associates, Binghamton, NY USA.
[Minor, S.] Austin Heart PLLC, San Marcos, TX USA.
[Albert, M.] Acadia Clin Res LLC, Bangor, ME USA.
[Diaczok, B.] St Joseph Mercy Oakland, Pontiac, MI USA.
[Gastman, I.] Waterford Med Associates PC, Waterford, MI USA.
[Gupta, V.] Borgess Res Inst Borgess Cardiovasc Res, Kalamazoo, MI USA.
[Longshaw, K.] Texas Hlth Phys Grp, Dallas, TX USA.
[Gonzalez-Campoy, J. M.] MNCOME Fdn, Eagan, MN USA.
[Raikhel, M.] Torrance Clin Res, Lomita, CA USA.
[Thomas, J.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Wood, K.] Belleville Family Med Associates Ltd, Belleville, IL USA.
[Diab, I.] Paramount Med Res & Consulting LLC, Middleburg Hts, OH USA.
[Furda, J.] Minneapolis Heart Inst, Baxter, MN USA.
[Gelernt, M.] Cardiovasc Associates Delaware Valley PA, Elmer, NJ USA.
[Halter, M.] Ilumina Clin Associates, Tyrone, PA USA.
[House, B.] Am Hlth Network Indiana LLC, Fishers, IN USA.
[Kaster, S.] Wenatchee Valley Med Ctr, Wenatchee, WA USA.
[Raad, G.] PMG Res Charlotte, Charlotte, NC USA.
[Stamatin, R.] Remedica LLC, Rochester, MI USA.
[Barker, B.] Delaware Smith Clin, Delaware, OH USA.
[Blonder, R.] Colorado Hlth Med Grp, Colorado Springs, CO USA.
[Calderon, R. Burgos] RCMI Clin Res Ctr, Rio Piedras, PR USA.
[Carrol, A.] Ctr Thyroid Dis & Endocrinol, Beachwood, OH USA.
[Comerota, A.] Jobst Vasc Ctr, Toledo, OH USA.
[Feinglos, M.] Duke Univ, Med Ctr, Durham, NC USA.
[Henderson, D.] Cardiol Res Associates, Daytona Beach, FL USA.
[Kastelic, R.] Ilumina Clin Associates, Johnstown, PA USA.
[Talano, J.] Southwest Florida Res LLC, Naples, FL USA.
[Lee, P. Ver] EMMC Northeast Cardiol Associates, Bangor, ME USA.
[Brosseau, J.] Altru Hlth Syst, Grand Forks, ND USA.
[Clark, W.] Oregon Hlth & Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA.
[Cohen, E.] Metab Res Inst, Boynton Beach, FL USA.
[Fialkow, J.] Cardiovasc Res Ctr South Florida, Miami, FL USA.
[Horton, K.] IMED Healthcare Associated PLLC, San Antonio, TX USA.
[Kozman, H.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
[McGill, J.] Washington Univ, St Louis, MO USA.
[Mihills, C.] Southlake Clin Trials, Southlake, TX USA.
[Poonawala, R.] Family Practice Ctr South, Austin, TX USA.
[Shore, K.] Med Clin North Texas, Plano, TX USA.
[Tejada, L.] St Lukes Hosp & Hlth Network, Bethlehem, PA USA.
[Torres, R.] Caribbean Clin Trials Corp, San Juan, PR USA.
[Wright, W.] Esse Hlth Cardiol Consultants, St Louis, MO USA.
[Calatayud, G.] Del Rosario Med Ctr Inc, Huntington Pk, CA USA.
[Chandna, H.] Victoria Heart & Vasc Ctr, Victoria, TX USA.
[Drozdiak, R.] Ilumina Clin Associates, Clymer, PA USA.
[Fink, R.] Diabet & Endocrine Associates, La Mesa, CA USA.
[Gill, R.] Virginia Commonwealth Univ, Richmond, VA USA.
[Glandt, M.] Bronx Lebanon Hosp Ctr, Bronx, NY 10456 USA.
[Hack, T.] Primary Care Cardiol Res Inc, Ayer, MA USA.
[Kay, J.] Clin Res Advantage Inc, Ridge Family Practice, Council Bluffs, IA USA.
[Mansouri, V.] St Thomas Res Inst, Nashville, TN USA.
[McKnight, T.] Prairie Fields Family Med PC, Fremont, NE USA.
[Mostel, E.] Palm Beach Gardens Res Ctr LLC, Palm Beach Gardens, FL USA.
[Schmidt, L.] Genova Clin Res, Tucson, AZ USA.
[Seide, H.] Daytona Heart Grp, Daytona Beach, FL USA.
[Sonel, E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Taylor, R.] North Mem Heart & Vasc Inst, Robbinsdale, MN USA.
[Velasquez, M.] George Washington Univ, Med Faculty Associates, Washington, DC USA.
[Bretton, E.] Albuquerque Clin Trials Inc, Albuquerque, NM USA.
[Feldman, R.] MediQuest Res Grp Inc, Munroe Reg Med Ctr, Ocala, FL USA.
[Hartman, A.] Virginia Res Ctr LLC, Midlothian, VA USA.
[Hershon, K.] North Shore Diabet & Endocrine Associates, New Hyde Pk, NY USA.
[Martin, E.] Martin Diagnost Clin, Tomball, TX USA.
[Mohiuddin, F.] Apollo Med Res LTD, Niles, IL USA.
[Naygandhi, Y.] Northwest Med Care PA, Houston, TX USA.
[Riske, T.] Hayden Lake Family Phys, Hayden Lake, ID USA.
[Schima, S.] Creighton Univ, Cardiac Ctr, Omaha, NE 68178 USA.
[Uzoaga, E. R.] Oxford Clin Res LLC, Houston, TX USA.
[Ward, H.] Clin Res Works LLC, Southington, CT USA.
[Weinstock, R.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
[Williams, T.] Texas Hlth Phys Grp, Irving, TX USA.
[Altschuller, A.] Hawthorn Med Associates, N Dartmouth, MA USA.
[Aoki, T.] Aoki Diabet Res Inst, Sacramento, CA USA.
[Blumenthal, S.] Zablocki VAMC, Milwaukee, WI USA.
[Cash, A.] Ilumina Clin Associates, Indiana, PA USA.
[Gutmann, J.] Deaconess Clin Inc, Evansville, IN USA.
[Hagan, M.] Montana Hlth Res Inst Inc, Billings, MT USA.
[Kabour, A.] Cardiovasc Res Ctr LLC, Toledo, OH USA.
[Markus, T.] Dayton Heart Ctr, Dayton, OH USA.
[McKenzie, W.] M&O Clin Res LLC, Ft Lauderdale, FL USA.
[Moursi, M.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA.
[Mystkowski, P.] Hope Heart Inst, Bellevue, WA USA.
[Ovalle, F.] Univ Alabama Birmingham, Birmingham, AL USA.
[Perkins, R.] Texas Hlth Phys Grp, Grapevine, TX USA.
[Popeil, L.] Magnolia Res Grp Inc, Ocala, FL USA.
[Saniuk, R.] Bellevue Family Practice PC, Clin Res Advantage Inc, Bellevue, NE USA.
[Sierra, Y.] Med Interna, Toa Baja, PR USA.
[Alvarado, O.] Med Grp Texas, Ft Worth, TX USA.
[Anderson, J.] Integris Cardiovasc Phys LLC, Oklahoma City, OK USA.
[Bajaj, M.] Baylor Coll Med, Houston, TX 77030 USA.
[Blank, R.] Presbyterian Novant Heart & Wellness, Southern Peidmont Primary Care, Monroe, NC USA.
[Chu, A.] Amarillo Heart Clin Res Inst Inc, Amarillo, TX USA.
[Levinsky, L.] CPL Associates LLC, Buffalo, NY USA.
[Levy, P.] Phoenix Endocrinol Clin Ltd, Phoenix, AZ USA.
[Osborne, J.] State Heart Cardiol, Grapevine, TX USA.
[Pavon, H.] Internal Med Kidney & Hypertens Ctr, Norfolk, VA USA.
[Sanderlin, D.] Lone Star Clin Res, Houston, TX USA.
[Schaer, G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Zarich, S.] Bridgeport Hosp, Bridgeport, CT USA.
[Atassi, K.] Northwest Indiana Cardiovasc Phys PC, Valparaiso, IN USA.
[Bayron, C.] Intervent Cardiac Consultants PLC, Trinity, FL USA.
[Casagrande, M.] West Houston Area Clin Trial Consultants LLC, Houston, TX USA.
[Das, D.] St Vincent Heart Clin Arkansas, Little Rock, AR USA.
[Gimness, M.] Clin Res Cent Florida, Plant City, FL USA.
[Handel, F.] Schuster Cardiol Associates Inc, Kettering, OH USA.
[Kinstrey, T.] Family Med Clin, Shreveport, LA USA.
[Leu, S.] Baptist Heart Specialists, Jacksonville, FL USA.
[Osei, K.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Nouel, J. Soba] Jose M Soba Med Gen, Juncos, PR USA.
[Soltani, Z.] LSU Hlth Sci Ctr, Dept Internal Med, Sect Nephrol & Hypertens, Kenner, LA USA.
[Sussman, H.] Icon Clin Trials, Pembroke Pines, FL USA.
[Chiu, K.] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.
[Duda, R., Jr.] Oklahoma Heart Inst, Tulsa, OK USA.
[Farnsworth, K.] Northern Indiana Res Alliance, Ft Wayne, IN USA.
[Lano, M.] Ridgeview Res, Chaska, MN USA.
[Lee, F.] Guthrie Clin Ltd, Sayre, PA USA.
[Lee, F.] Robert Packer Hosp, Sayre, PA USA.
[Levin, P.] MODEL Clin Res, Baltimore, MD USA.
[Pratt, S.] West Coast Res LLC, San Ramon, CA USA.
[Richwine, R.] Hlth Phys Grp, Ft Worth, TX USA.
[Ruiz-Rivera, L.] Endocrine Lipid Diabet Res Inst, Ponce, PR USA.
[Turner, J.] Cardiac Wellness Consultants SC, Chicago, IL USA.
[Wood, J.] Texas Hlth Phys Grp, Richardson, TX USA.
[Colon, Carlos Benitez] Dr Carlos Benitez Colon Med Interna, San Juan, PR USA.
[Demattia, J.] JVC Family Med, Houston, TX USA.
[Desai, V.] Charles River Med Associates, Natick, MA USA.
[Fitz-Patrick, D.] East West Med Res Inst, Honolulu, HI USA.
[Goral, S.] Univ Penn, Philadelphia, PA 19104 USA.
[Odhav, A.] West Houston Area Clin Trial Consultants LLC, Houston, TX USA.
[Prentiss, A.] Prentiss Family Med, Colleyville, TX USA.
[Ruff, C.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Wu, W.] Cent Cardiovasc Res Fdn, San Antonio, TX USA.
[Wyne, K.] Methodist Hosp, Res Inst, 6535 Fannin, Houston, TX 77030 USA.
[Applegate, R.] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA.
[Cabral, J.] Cleveland Clin Florida, Weston, FL USA.
[Kotha, P.] Purushotham & Akther Kotha MD Inc, La Mesa, CA USA.
[Ortega, P.] Cent Florida Primary Care, Winter Pk, FL USA.
[Simmons, D.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA.
RP Bhatt, DL (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA.
EM dlbhattmd@post.harvard.edu
RI Ma, Ronald/C-2788-2009; Delgado, Elias/B-2634-2013; Kubica,
Jacek/D-6906-2014; Arkhipov, Mikhail/Q-2316-2015; Lerch, Markus
M./E-2206-2016; Colquhoun, David/F-9078-2013; Mauricio,
Didac/B-7951-2009; De Cosmo, Salvatore/J-7420-2016; Del Prato,
Stefano/K-3405-2016; Muirhead, Norman/G-3337-2011; Miller,
Elzbieta/S-9249-2016; Kobalava, Zhanna/S-3842-2016; Svacina,
Stepan/C-1962-2017; Gutmann, Jochen/A-5103-2009;
OI Ma, Ronald/0000-0002-1227-803X; Delgado, Elias/0000-0001-6114-9712;
Lerch, Markus M./0000-0002-9643-8263; Mauricio,
Didac/0000-0002-2868-0250; De Cosmo, Salvatore/0000-0001-8787-8286; Del
Prato, Stefano/0000-0002-5388-0270; Svacina, Stepan/0000-0002-0894-4116;
Ametov, A.S./0000-0002-7936-7619; Oschepkova, Elena/0000-0003-4534-9890;
Gutmann, Jochen/0000-0002-1394-9202; Mazurek, Tomasz/0000-0002-3693-8741
FU AstraZeneca; Bristol-Myers Squibb
FX Funded by AstraZeneca and Bristol-Myers Squibb
NR 35
TC 866
Z9 904
U1 41
U2 184
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 3
PY 2013
VL 369
IS 14
BP 1317
EP 1326
DI 10.1056/NEJMoa1307684
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 227KI
UT WOS:000325111200009
PM 23992601
ER
PT J
AU Kapoor, R
Johnson, RA
AF Kapoor, Roger
Johnson, Richard A.
TI Porphyria Cutanea Tarda and Hypertrichosis
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
AB A 54-year-old woman with hepatitis C infection presented with excess hair on her face, which she had had since the age of 25 years, and new erosions on her hands. Several ulcerations, milia, and thickened skin were noted on the dorsal aspect of her hands. A 54-year-old woman who had had hepatitis C infection for 12 years presented with excess hair on her face, which she had had since the age of 25 years, and new erosions on her hands. On physical examination, several ulcerations, milia, and thickened skin were noted on the dorsal aspect of both hands (Panel A). Excess hair growth (hypertrichosis) was noted in the temporal and malar facial areas (Panel B). Laboratory studies revealed an elevated level of 24-hour urinary porphyrin of 707 g (851 nmol; normal, <30 g [36 nmol]). Porphyria cutanea tarda refers to a group of anomalies in ...
C1 [Kapoor, Roger] Beloit Hlth Syst, Beloit, WI USA.
[Johnson, Richard A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Kapoor, R (reprint author), Beloit Hlth Syst, Beloit, WI USA.
EM rogerkapoor@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 3
PY 2013
VL 369
IS 14
BP 1356
EP 1356
DI 10.1056/NEJMicm1010902
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 227KI
UT WOS:000325111200013
PM 24088095
ER
PT J
AU Greene, MF
AF Greene, Michael F.
TI Delivering Twins
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID RETROSPECTIVE COHORT; PERINATAL DEATH; BIRTHS; RISK
AB The rate of twin births in the United States has risen 76% from 1980 through 2009-2011. The rate of rise was particularly steep from the early 1990s through the early 2000s and seems to have reached a plateau of approximately 33.2 twin births per 1000 deliveries in the period from 2009 through 2011.(1) The incidence of naturally occurring twin pregnancy rises with increasing maternal age, and the age of women having babies in the United States has risen steadily from 20% of all births among women 30 years of age or older in 1980 to more than 35% for the ...
C1 Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
RP Greene, MF (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
NR 12
TC 1
Z9 1
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 3
PY 2013
VL 369
IS 14
BP 1365
EP 1366
DI 10.1056/NEJMe1310744
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 227KI
UT WOS:000325111200015
PM 24088097
ER
PT J
AU Korboe, AA
Carney, J
AF Korboe, Akosua A.
Carney, Julia
TI Mental Health and the Global Agenda
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Korboe, Akosua A.] Univ Rochester Sch Med & Dent, Rochester, NY USA.
[Carney, Julia] Massachusetts Gen Hosp, Boston, MA USA.
RP Korboe, AA (reprint author), Univ Rochester Sch Med & Dent, Rochester, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 3
PY 2013
VL 369
IS 14
BP 1380
EP 1380
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 227KI
UT WOS:000325111200030
PM 24088112
ER
PT J
AU Ortega, F
Counter, SA
Buchanan, LH
Parra, AMC
Collaguaso, MA
Jacobs, AB
AF Ortega, Fernando
Counter, S. Allen
Buchanan, Leo H.
Coronel Parra, Angelica Maria
Angela Collaguaso, Maria
Jacobs, Anthony B.
TI TRACKING BLOOD LEAD AND ZINC PROTOPORPHYRIN LEVELS IN ANDEAN ADULTS
WORKING IN A LEAD CONTAMINATED ENVIRONMENT
SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES
LA English
DT Article
ID BREAST-MILK; COMET ASSAY; DNA-DAMAGE; EXPOSURE; WORKERS; CHILDREN;
PERFORMANCE
AB The purpose of this study was to investigate current blood lead (PbB) and zinc protoporphyrin (ZPP) levels in adults presently living in environmentally Pb-contaminated Andean communities, and to compare the findings with the PbB and ZPP levels of Pb-exposed adult cohorts from the same study area tested between 1996 and 2007. Blood samples from 39 adults were measured for PbB and ZPP concentrations. The current mean PbB level (22.7 g/dl) was significantly lower than the mean (37.9 g/dl) of the initial 1996 cohort. PbB levels for the 1997, 1998, 2003, and 2006 cohorts were also significantly lower than the levels for the 1996 group. Elevated ZPP/heme ratios of 103.3, 128.4, and 134.2 mol/mol were not significantly different for the 2006, 2007, and 2012 groups, indicating chronic Pb exposure. While ZPP levels of Andean Ecuadorian Pb-glazing workers have remained elevated, PbB levels declined. Lead exposure of the workers needs to be continually monitored.
C1 [Ortega, Fernando] Colegio Ciencias Salud, Escuela Med, Escuela Salud Publ,Inst Arts & Sci GAIAS, Colegio Artes Liberales & Galapagos, Quito, Ecuador.
[Ortega, Fernando] Univ San Francisco Quito, Quito, Ecuador.
[Counter, S. Allen] Harvard Univ, Sch Med, Biol Labs, Dept Neurol, Cambridge, MA 02138 USA.
[Counter, S. Allen] Massachusetts Gen Hosp, Dept Neurophysiol, Boston, MA 02114 USA.
[Buchanan, Leo H.] Univ Massachusetts, Sch Med, Eunice Kennedy Shriver Ctr, Dept Pediat, Waltham, MA USA.
[Buchanan, Leo H.] Harvard Univ, Hlth Serv, Dept Otolaryngol, Cambridge, MA 02138 USA.
[Coronel Parra, Angelica Maria; Angela Collaguaso, Maria] Subctr Salud, Pujili, Cotopaxi, Ecuador.
[Jacobs, Anthony B.] Harvard Biol Labs, Cambridge, MA USA.
RP Counter, SA (reprint author), Harvard Univ, Sch Med, Biol Labs, Dept Neurol, 16 Divin Ave, Cambridge, MA 02138 USA.
EM allen_counter@harvard.edu
FU National Institutes of Health (NIH) [P30 HD04147]
FX LHB is supported in part by National Institutes of Health (NIH) grant
P30 HD04147.
NR 37
TC 7
Z9 7
U1 1
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1528-7394
EI 1087-2620
J9 J TOXICOL ENV HEAL A
JI J. Toxicol. Env. Health Part A
PD OCT 2
PY 2013
VL 76
IS 19
BP 1111
EP 1120
DI 10.1080/15287394.2013.840708
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA 256FE
UT WOS:000327294300003
PM 24274152
ER
PT J
AU Samur, MK
Shah, PK
Wang, XJ
Minvielle, S
Magrangeas, F
Avet-Loiseau, H
Munshi, NC
Li, C
AF Samur, Mehmet K.
Shah, Parantu K.
Wang, Xujun
Minvielle, Stephane
Magrangeas, Florence
Avet-Loiseau, Herve
Munshi, Nikhil C.
Li, Cheng
TI The shaping and functional consequences of the dosage effect landscape
in multiple myeloma
SO BMC GENOMICS
LA English
DT Article
DE Copy number alteration; Dosage effect; Multiple myeloma; Hyperdiploid;
Integrative genomics
ID GENE-EXPRESSION; COPY-NUMBER; INTEGRATIVE ANALYSIS; ANALYSIS REVEALS;
CANCER; ANEUPLOIDY; SURVIVAL; LEUKEMIA; IDENTIFICATION; TUMORIGENESIS
AB Background: Multiple myeloma (MM) is a malignant proliferation of plasma B cells. Based on recurrent aneuploidy such as copy number alterations (CNAs), myeloma is divided into two subtypes with different CNA patterns and patient survival outcomes. How aneuploidy events arise, and whether they contribute to cancer cell evolution are actively studied. The large amount of transcriptomic changes resultant of CNAs (dosage effect) pose big challenges for identifying functional consequences of CNAs in myeloma in terms of specific driver genes and pathways. In this study, we hypothesize that gene-wise dosage effect varies as a result from complex regulatory networks that translate the impact of CNAs to gene expression, and studying this variation can provide insights into functional effects of CNAs.
Results: We propose gene-wise dosage effect score and genome-wide karyotype plot as tools to measure and visualize concordant copy number and expression changes across cancer samples. We find that dosage effect in myeloma is widespread yet variable, and it is correlated with gene expression level and CNA frequencies in different chromosomes. Our analysis suggests that despite the enrichment of differentially expressed genes between hyperdiploid MM and non-hyperdiploid MM in the trisomy chromosomes, the chromosomal proportion of dosage sensitive genes is higher in the non-trisomy chromosomes. Dosage-sensitive genes are enriched by genes with protein translation and localization functions, and dosage resistant genes are enriched by apoptosis genes. These results point to future studies on differential dosage sensitivity and resistance of pro-and anti-proliferation pathways and their variation across patients as therapeutic targets and prognosis markers.
Conclusions: Our findings support the hypothesis that recurrent CNAs in myeloma are selected by their functional consequences. The novel dosage effect score defined in this work will facilitate integration of copy number and expression data for identifying driver genes in cancer genomics studies. The accompanying R code is available at http://www.canevolve.org/dosageEffect/.
C1 [Samur, Mehmet K.; Shah, Parantu K.; Li, Cheng] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Samur, Mehmet K.; Shah, Parantu K.; Li, Cheng] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
[Samur, Mehmet K.] Akdeniz Univ, Dept Biostat & Med Informat, TR-07058 Antalya, Turkey.
[Wang, Xujun] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China.
[Minvielle, Stephane; Magrangeas, Florence; Avet-Loiseau, Herve] Univ Nantes, INSERM, CNRS 6299, UMR892, Nantes, France.
[Minvielle, Stephane; Magrangeas, Florence; Avet-Loiseau, Herve] CHU Nantes, Unite Mixte Genom Canc, F-44035 Nantes 01, France.
[Munshi, Nikhil C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02215 USA.
RP Munshi, NC (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
EM Nikhil_Munshi@dfci.harvard.edu; lch3000@gmail.com
RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015
FU NIH [R01 GM077122]; National Basic Research Program of China (973
Program) [2010CB944904]; Claudia Adams Barr Program in Innovative Basic
Cancer Research; Multiple Myeloma Career Development award; National
Institutes of Health [RO1-124929, PO1-155258, P50-100007, PO1-78378];
Dept. of Veterans Affairs Merit Review Awards; French National Research
Agency [R08079NS]
FX Grant support are from NIH R01 GM077122 (C Li), National Basic Research
Program of China (973 Program; No. 2010CB944904) (X Wang), and Claudia
Adams Barr Program in Innovative Basic Cancer Research and the Multiple
Myeloma Career Development award (PK Shah). This work is also supported
in part by grants from the National Institutes of Health Grants
RO1-124929, PO1-155258, P50-100007 and PO1-78378 to NC Munshi and C Li
and from the Dept. of Veterans Affairs Merit Review Awards to NC Munshi.
S Minvielle and F Magrangeas were supported by French National Research
Agency, Grant R08079NS.
NR 43
TC 6
Z9 6
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD OCT 2
PY 2013
VL 14
AR 672
DI 10.1186/1471-2164-14-672
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 241NJ
UT WOS:000326173600001
PM 24088394
ER
PT J
AU Zhang, JM
Fang, SNC
Mittleman, MA
Christiani, DC
Cavallari, JM
AF Zhang, Jinming
Fang, Shona C.
Mittleman, Murray A.
Christiani, David C.
Cavallari, Jennifer M.
TI Secondhand tobacco smoke exposure and heart rate variability and
inflammation among non-smoking construction workers: a repeated measures
study
SO ENVIRONMENTAL HEALTH
LA English
DT Article
DE Secondhand smoke; Tobacco; Autonomic nervous system; Heart rate
variability; Inflammatory marker
ID PARTICULATE AIR-POLLUTION; SUDDEN CARDIAC DEATH; CARDIOVASCULAR-DISEASE;
CIGARETTE-SMOKING; PASSIVE SMOKING; NEVER-SMOKERS; UNITED-STATES;
POPULATION; PARTICLES; COHORT
AB Background: Although it has been well recognized that exposure to secondhand tobacco smoke (SHS) is associated with cardiovascular mortality, the mechanisms and time course by which SHS exposure may lead to cardiovascular effects are still being explored.
Methods: Non-smoking workers were recruited from a local union and monitored inside a union hall while exposed to SHS over approximately 6 hours. Participants were fitted with a continuous electrocardiographic monitor upon enrollment which was removed at the end of a 24-hr monitoring period. A repeated measures study design was used where resting ECGs and blood samples were taken from individuals before SHS exposure (baseline), immediately following SHS exposure (post) and the morning following SHS exposure (next-morning). Inflammatory markers, including high sensitivity C-reactive protein (CRP) and white blood cell count (WBC) were analyzed. Heart rate variability (HRV) was analyzed from the ECG recordings in time (SDNN, rMSSD) and frequency (LF, HF) domain parameters over 5-minute periods. SHS exposure was quantified using a personal fine particulate matter (PM2.5) monitor.
Linear mixed effects regression models were used to examine within-person changes in inflammatory and HRV parameters across the 3 time periods. Exposure-response relationships with PM2.5 were examined using mixed effects models. All models were adjusted for age, BMI and circadian variation.
Results: A total of 32 male non-smokers were monitored between June 2010 and June 2012. The mean PM2.5 from SHS exposure was 132 mu g/m(3). Immediately following SHS exposure, a 100 mu g/m(3) increase in PM2.5 was associated with declines in HRV (7.8% [ standard error (SE) = 3%] SDNN, 8.0% (SE = 3.9%) rMSSD, 17.2% (SE = 6.3%) LF, 29.0% (SE = 10.1%) HF) and increases in WBC count 0.42 (SE = 0.14) k/mu l. Eighteen hours following SHS exposure, a 100 mu g/m(3) increase in PM2.5 was associated with 24.2% higher CRP levels.
Conclusions: Our study suggest that short-term SHS exposure is associated with significantly lower HRV and higher levels of inflammatory markers. Exposure-associated declines in HRV were observed immediately following exposure while higher levels of CRP were not observed until 18 hours following exposure. Cardiovascular autonomic and inflammation responses may contribute to the pathophysiologic pathways that link SHS exposure with adverse cardiovascular outcomes.
C1 [Zhang, Jinming; Fang, Shona C.; Christiani, David C.; Cavallari, Jennifer M.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Cavallari, Jennifer M.] Univ Connecticut Hlth Ctr, Div Occupat & Environm Med, Farmington, CT USA.
[Mittleman, Murray A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Christiani, David C.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
[Mittleman, Murray A.; Christiani, David C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Cardiovasc Epidemiol Res Unit, Sch Med, Boston, MA 02215 USA.
[Fang, Shona C.] New England Res Inst Inc, Watertown, MA USA.
RP Cavallari, JM (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
EM CAVALLARI@uchc.edu
FU Flight Attendants Medical Research Institute Young Clinical Scientist
Award; NIEHS [ES009860, ES00002, T32 ES 07069]
FX The study is supported by the Flight Attendants Medical Research
Institute Young Clinical Scientist Award and NIEHS ES009860, ES00002,
T32 ES 07069. The authors would like to thank Angela Fan, Cali Chang, Li
Su, Mike Wang, Rachel Grashow, Rihong Zai and the International
Brotherhood of Boilermakers, Local 29, Quincy MA, USA.
NR 38
TC 5
Z9 5
U1 1
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD OCT 2
PY 2013
VL 12
AR 83
DI 10.1186/1476-069X-12-83
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA 242YX
UT WOS:000326284000001
PM 24083379
ER
PT J
AU Desikan, RS
Thompson, WK
Holland, D
Hess, CP
Brewer, JB
Zetterberg, H
Blennow, K
Andreassen, OA
McEvoy, LK
Hyman, BT
Dale, AM
AF Desikan, Rahul S.
Thompson, Wesley K.
Holland, Dominic
Hess, Christopher P.
Brewer, James B.
Zetterberg, Henrik
Blennow, Kaj
Andreassen, Ole A.
McEvoy, Linda K.
Hyman, Bradley T.
Dale, Anders M.
CA Alzheimer's Dis Neuroimaging Initi
TI Heart fatty acid binding protein and A beta-associated Alzheimer's
neurodegeneration
SO MOLECULAR NEURODEGENERATION
LA English
DT Article
DE Alzheimer's disease; Fatty acids; Lipids; Amyloid; Tau; Brain atrophy
ID CEREBROSPINAL-FLUID; CHOLESTEROL LEVEL; CEREBRAL-CORTEX; MOUSE MODEL;
STATIN USE; DISEASE; PLASMA; DEMENTIA; BRAIN; OVEREXPRESSION
AB Background: Epidemiological and molecular findings suggest a relationship between Alzheimer's disease (AD) and dyslipidemia, although the nature of this association is not well understood.
Results: Using linear mixed effects models, we investigated the relationship between CSF levels of heart fatty acid binding protein (HFABP), a lipid binding protein involved with fatty acid metabolism and lipid transport, amyloid beta (A beta), phospho-tau, and longitudinal MRI-based measures of brain atrophy among 295 non-demented and demented older individuals. Across all participants, we found a significant association of CSF HFABP with longitudinal atrophy of the entorhinal cortex and other AD-vulnerable neuroanatomic regions. However, we found that the relationship between CSF HABP and brain atrophy was significant only among those with low CSF A beta(1-42) and occurred irrespective of phospho-tau(181p) status.
Conclusions: Our findings indicate that A beta associated volume loss occurs in the presence of elevated HFABP irrespective of phospho-tau. This implicates a potentially important role for fatty acid binding proteins in Alzheimer's disease neurodegeneration.
C1 [Desikan, Rahul S.; Brewer, James B.; McEvoy, Linda K.; Dale, Anders M.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92037 USA.
[Thompson, Wesley K.; Andreassen, Ole A.; Dale, Anders M.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92037 USA.
[Holland, Dominic; Brewer, James B.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92037 USA.
[Hess, Christopher P.] Univ Calif San Diego, Neuroradiol Sect, Dept Radiol & Biomed Imaging, San Francisco, CA 92093 USA.
[Zetterberg, Henrik; Blennow, Kaj] Goteburg Univ, Sahlgrenska Acad, Clin Neurochem Lab, S-40530 Molndal, Sweden.
[Zetterberg, Henrik] UCL Inst Neurol, London WC1N 3BG, England.
[Andreassen, Ole A.] Univ Oslo, Inst Clin Med, Oslo, Norway.
[Andreassen, Ole A.] Oslo Univ Hosp, Div Mental Hlth & Addict, Oslo, Norway.
[Hyman, Bradley T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Desikan, RS (reprint author), Univ Calif San Diego, Dept Radiol, 8950 Villa La Jolla Dr,Suite C101, La Jolla, CA 92037 USA.
EM rdesikan@ucsd.edu
FU National Institutes of Health [R01AG031224, K01AG029218, K02 NS067427,
T32 EB005970]; Research Council of Norway [183782/V50]; South East
Norway Health Authority [2010-074]; Alzheimer's Disease Neuroimaging
Initiative (ADNI) (National Institutes of Health) [U01 AG024904];
National Institute on Aging; National Institute of Biomedical Imaging
and Bioengineering; Alzheimer's Association; Alzheimer's Drug Discovery
Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb
Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company;
F. Hoffmann-La Roche Ltd; Genentech, Inc.; GE Healthcare; Innogenetics,
N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &
Development, LLC.; Johnson & Johnson Pharmaceutical Research &
Development LLC.; Medpace, Inc.; Merck Co., Inc.; Meso Scale
Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals
Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; Takeda
Pharmaceutical Company; Canadian Institutes of Health Research; Northern
California Institute for Research and Education; NIH [P30 AG010129, K01
AG030514]
FX This research was supported by grants from the National Institutes of
Health (R01AG031224; K01AG029218; K02 NS067427; T32 EB005970), the
Research Council of Norway (183782/V50) and the South East Norway Health
Authority (2010-074). Data collection and sharing for this project was
funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI)
(National Institutes of Health Grant U01 AG024904). ADNI is funded by
the National Institute on Aging, the National Institute of Biomedical
Imaging and Bioengineering, and through generous contributions from the
following:; Alzheimer's Association; Alzheimer's Drug Discovery
Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb
Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company;
F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE
Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer
Immunotherapy Research & Development, LLC.; Johnson & Johnson
Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co.,
Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier;
Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes
of Health Research is providing funds to support ADNI clinical sites in
Canada. Private sector contributions are facilitated by the Foundation
for the National Institutes of Health (www.fnih.org). The grantee
organization is the Northern California Institute for Research and
Education, and the study is coordinated by the Alzheimer's Disease
Cooperative Study at the University of California, San Diego. ADNI data
are disseminated by the Laboratory for Neuro Imaging at the University
of California, Los Angeles. This research was also supported by NIH
grants P30 AG010129 and K01 AG030514.
NR 39
TC 10
Z9 10
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD OCT 2
PY 2013
VL 8
AR 39
DI 10.1186/1750-1326-8-39
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 237JK
UT WOS:000325865500001
PM 24088526
ER
PT J
AU Walton, E
Geisler, D
Hass, J
Liu, JY
Turner, J
Yendiki, A
Smolka, MN
Ho, BC
Manoach, DS
Gollub, RL
Roessner, V
Calhoun, VD
Ehrlich, S
AF Walton, Esther
Geisler, Daniel
Hass, Johanna
Liu, Jingyu
Turner, Jessica
Yendiki, Anastasia
Smolka, Michael N.
Ho, Beng-Choon
Manoach, Dara S.
Gollub, Randy L.
Roessner, Veit
Calhoun, Vince D.
Ehrlich, Stefan
TI The Impact of Genome-Wide Supported Schizophrenia Risk Variants in the
Neurogranin Gene on Brain Structure and Function
SO PLOS ONE
LA English
DT Article
ID DORSOLATERAL PREFRONTAL CORTEX; WORKING-MEMORY PERFORMANCE; LONG-TERM
POTENTIATION; ENCODING NEUROGRANIN; CEREBRAL-CORTEX; FLIP-FLOP;
ASSOCIATION; DYSFUNCTION; FMRI; METAANALYSIS
AB The neural mechanisms underlying genetic risk for schizophrenia, a highly heritable psychiatric condition, are still under investigation. New schizophrenia risk genes discovered through genome-wide association studies (GWAS), such as neurogranin (NRGN), can be used to identify these mechanisms. In this study we examined the association of two common NRGN risk single nucleotide polymorphisms (SNPs) with functional and structural brain-based intermediate phenotypes for schizophrenia. We obtained structural, functional MRI and genotype data of 92 schizophrenia patients and 114 healthy volunteers from the multisite Mind Clinical Imaging Consortium study. Two schizophrenia-associated NRGN SNPs (rs12807809 and rs12541) were tested for association with working memory-elicited dorsolateral prefrontal cortex (DLPFC) activity and surface-wide cortical thickness. NRGN rs12541 risk allele homozygotes (TT) displayed increased working memory-related activity in several brain regions, including the left DLPFC, left insula, left somatosensory cortex and the cingulate cortex, when compared to non-risk allele carriers. NRGN rs12807809 non-risk allele (C) carriers showed reduced cortical gray matter thickness compared to risk allele homozygotes (TT) in an area comprising the right pericalcarine gyrus, the right cuneus, and the right lingual gyrus. Our study highlights the effects of schizophrenia risk variants in the NRGN gene on functional and structural brain-based intermediate phenotypes for schizophrenia. These results support recent GWAS findings and further implicate NRGN in the pathophysiology of schizophrenia by suggesting that genetic NRGN risk variants contribute to subtle changes in neural functioning and anatomy that can be quantified with neuroimaging methods.
C1 [Walton, Esther; Geisler, Daniel; Hass, Johanna; Roessner, Veit; Ehrlich, Stefan] Tech Univ Dresden, Dept Child & Adolescent Psychiat, Univ Hosp Carl Gustav Carus, Dresden, Germany.
[Liu, Jingyu; Turner, Jessica; Calhoun, Vince D.] MIND Res Network, Albuquerque, NM USA.
[Liu, Jingyu; Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA.
[Yendiki, Anastasia; Manoach, Dara S.; Gollub, Randy L.; Ehrlich, Stefan] Massachusetts Gen Hosp, MGH MIT HMS Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Smolka, Michael N.] Tech Univ Dresden, Dept Psychiat & Psychotherapy, Dresden, Germany.
[Smolka, Michael N.] Tech Univ Dresden, Neuroimaging Ctr, Dept Psychol, Dresden, Germany.
[Ho, Beng-Choon] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA.
[Manoach, Dara S.; Gollub, Randy L.; Ehrlich, Stefan] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Ehrlich, S (reprint author), Tech Univ Dresden, Dept Child & Adolescent Psychiat, Univ Hosp Carl Gustav Carus, Dresden, Germany.
EM transden.lab@uniklinikum-dresden.de
RI Ho, Beng-Choon/D-6959-2011; Smolka, Michael/B-4865-2011; Turner,
Jessica/H-7282-2015;
OI Ho, Beng-Choon/0000-0003-3976-1555; Smolka, Michael/0000-0001-5398-5569;
Turner, Jessica/0000-0003-0076-8434; Ehrlich,
Stefan/0000-0003-2132-4445; Gollub, Randy L./0000-0002-9434-4044;
Walton, Esther/0000-0002-0935-2200; Liu, Jingyu/0000-0002-1724-7523
FU National Institutes of Health (NIH/NCRR) [P41RR14075]; Department of
Energy [DE-FG02-99ER62764]; Mind Research Network, Morphometry BIRN
[1U24, RR021382A]; Function BIRN [U24RR021992]; NIH.NCRR [MO1
RR025758-01]; NIMH [1RC1MH089257, 2 R01MH067720]; NIH/NIBIB [K99/R00];
Deutsche Forschungsgemeinschaft; NARSAD Young Investigator Grant;
Friedrich-Ebert Stiftung; [EB008129]
FX This work was supported by the National Institutes of Health (NIH/NCRR
P41RR14075), Department of Energy (DE-FG02-99ER62764), Mind Research
Network, Morphometry BIRN (1U24, RR021382A), Function BIRN
(U24RR021992-01, NIH.NCRR MO1 RR025758-01, NIMH 1RC1MH089257 to VDC), 2
R01MH067720 (DSM), NIH/NIBIB K99/R00 Pathway to Independence award
EB008129 (AY), the Deutsche Forschungsgemeinschaft (research fellowship
to SE), the NARSAD Young Investigator Grant (to SE) and the
Friedrich-Ebert Stiftung (stipend to EW). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 70
TC 9
Z9 9
U1 1
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 2
PY 2013
VL 8
IS 10
AR e76815
DI 10.1371/journal.pone.0076815
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231RG
UT WOS:000325434500086
PM 24098564
ER
PT J
AU Day, ML
Delgutte, B
AF Day, Mitchell L.
Delgutte, Bertrand
TI Decoding Sound Source Location and Separation Using Neural Population
Activity Patterns
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID INTERAURAL TIME DIFFERENCES; INFERIOR COLLICULUS; LOCALIZATION ACUITY;
CORTICAL-NEURONS; CUES; CAT; SENSITIVITY; AZIMUTH; MODEL; CODE
AB The strategies by which the central nervous system decodes the properties of sensory stimuli, such as sound source location, from the responses of a population of neurons are a matter of debate. We show, using the average firing rates of neurons in the inferior colliculus (IC) of awake rabbits, that prevailing decoding models of sound localization (summed population activity and the population vector) fail to localize sources accurately due to heterogeneity in azimuth tuning across the population. In contrast, a maximum-likelihood decoder operating on the pattern of activity across the population of neurons in one IC accurately localized sound sources in the contralateral hemifield, consistent with lesion studies, and did so with a precision consistent with rabbit psychophysical performance. The pattern decoder also predicts behavior in response to incongruent localization cues consistent with the long-standing "duplex" theory of sound localization. We further show that the pattern decoder accurately distinguishes two concurrent, spatially separated sources from a single source, consistent with human behavior. Decoder detection of small amounts of source separation directly in front is due to neural sensitivity to the interaural decorrelation of sound, at both low and high frequencies. The distinct patterns of IC activity between single and separated sound sources thereby provide a neural correlate for the ability to segregate and localize sources in everyday, multisource environments.
C1 [Day, Mitchell L.; Delgutte, Bertrand] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
[Day, Mitchell L.; Delgutte, Bertrand] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Delgutte, Bertrand] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
RP Day, ML (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, 243 Charles St, Boston, MA 02114 USA.
EM day@meei.harvard.edu
OI Day, Mitchell/0000-0002-2754-234X; , /0000-0003-1349-9608
FU National Institute on Deafness and Other Communication Disorders [R01
DC002258, P30 DC005209]
FX This work was supported by National Institute on Deafness and Other
Communication Disorders grants R01 DC002258 and P30 DC005209. We thank
Ross Williamson, Ken Hancock, and Dan Polley for a critical reading of
an earlier version of this manuscript.
NR 41
TC 14
Z9 14
U1 0
U2 14
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 2
PY 2013
VL 33
IS 40
BP 15837
EP 15847
DI 10.1523/JNEUROSCI.2034-13.2013
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 229RA
UT WOS:000325283600018
PM 24089491
ER
PT J
AU Lai, PS
Thompson, BT
AF Lai, Peggy S.
Thompson, B. Taylor
TI Why Activated Protein C Was Not Successful in Severe Sepsis and Septic
Shock: Are We Still Tilting at Windmills?
SO CURRENT INFECTIOUS DISEASE REPORTS
LA English
DT Article
DE Sepsis; Septic shock; Systemic inflammatory response syndrome;
Drotrecogin alfa activated; Protein C
ID RANDOMIZED CONTROLLED-TRIAL; PROPENSITY-MATCHED ANALYSIS;
PULMONARY-ARTERY CATHETERS; INTENSIVE-CARE UNITS; CLINICAL
EFFECTIVENESS; OUTCOMES; PROGRAM; ADULTS; METAANALYSIS; MANAGEMENT
AB Drotrecogin alpha activated (DAA), trade name Xigris, is a recombinant human protein C that has been the subject of controversy since 2001, when it became the first biologic agent approved for the treatment of severe sepsis and septic shock. The PROWESS trial showed a 6.1 % absolute reduction in 28-day mortality, although these findings were not replicated in later trials, ultimately leading to the withdrawal of DAA in 2011. Observational trials, however, have consistently shown a mortality benefit with the use of DAA, leading to the following questions: Did DAA truly fail and, if so, why? While these questions may never be definitively answered on the basis of available evidence, several factors may explain the conflicting results. In clinical practice, DAA may have been preferentially given to subjects more likely to survive. Contemporary treatments, including early antibiotic administration and volume resuscitation, may have mitigated the inflammatory processes leading to disordered coagulation and microvascular thrombosis and, thus, reduced or abolished the therapeutic opportunity for DAA. Later randomized clinical trials of DAA focused on the clinical phenotype of refractory shock, largely due to a strong efficacy signal in this subset from PROWESS; however, this clinical phenotype may not be tightly linked, at least after contemporary early resuscitation strategies, to the mechanistic phenotype of dysregulated coagulation that may have been a better target for DAA. Future trials of biologic therapies in severe sepsis and septic shock should use a combination of clinical phenotype and biomarkers to identify responsive populations that may benefit from such therapies.
C1 [Lai, Peggy S.; Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA.
RP Thompson, BT (reprint author), Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Bulfinch Suite 148,55 Fruit St, Boston, MA 02114 USA.
EM tthompson1@partners.org
OI Lai, Peggy/0000-0001-9501-8606
FU NHLBI
FX Taylor Thompson has been a board member for Astra Zeneca; has been a
consultant for Sirius Genetics, Immunetrics, and Lilly; and has received
grant funding from NHLBI.
NR 40
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3847
EI 1534-3146
J9 CURR INFECT DIS REP
JI Curr. Infect. Dis. Rep.
PD OCT
PY 2013
VL 15
IS 5
BP 407
EP 412
DI 10.1007/s11908-013-0358-9
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA AK2YT
UT WOS:000338287200009
PM 23925482
ER
PT J
AU Jeon, HJ
Hong, JP
Fava, M
Mischoulon, D
Nyer, M
Inamori, A
Sohn, JH
Seong, S
Cho, MJ
AF Jeon, Hong Jin
Hong, Jin-Pyo
Fava, Maurizio
Mischoulon, David
Nyer, Maren
Inamori, Aya
Sohn, Jee Hoon
Seong, Sujeong
Cho, Maeng Je
TI Childhood parental death and lifetime suicide attempt of the
opposite-gender offspring in a nationwide community sample of Korea
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Meeting Abstract
C1 [Jeon, Hong Jin] Sungkyunkwan Univ, Depress Ctr, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Hong, Jin-Pyo] Univ Ulsan, Dept Psychiat, Asan Med Ctr, Coll Med, Seoul, South Korea.
[Fava, Maurizio; Mischoulon, David; Nyer, Maren; Inamori, Aya] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA.
[Sohn, Jee Hoon; Seong, Sujeong; Cho, Maeng Je] Seoul Natl Univ, Coll Med, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD OCT
PY 2013
VL 25
SU 1
MA PS02-133
BP S180
EP S180
PG 1
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA AJ5UB
UT WOS:000337753100409
ER
PT J
AU Sano, M
Egelko, S
Donohue, M
Paparello, S
Sun, CK
Aisen, P
Ferris, S
Kaye, J
Hayes, T
Mundt, J
AF Sano, Mary
Egelko, Susan
Donohue, Michael
Paparello, Silvia
Sun, Chung-Kai
Aisen, Paul
Ferris, Steven
Kaye, Jeffrey
Hayes, Tamara
Mundt, James
TI Satisfaction of elderly research participants with home-based clinical
trial participation
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Meeting Abstract
C1 [Sano, Mary; Egelko, Susan] Mt Sinai Sch Med, New York, NY USA.
[Sano, Mary; Egelko, Susan] James J Peters VAMC, New York, NY USA.
[Donohue, Michael; Paparello, Silvia; Sun, Chung-Kai; Aisen, Paul] Univ Calif San Diego, San Diego, CA 92103 USA.
[Ferris, Steven] NYU Langone Med Ctr ADC, New York, NY USA.
[Kaye, Jeffrey; Hayes, Tamara] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Mundt, James] Ctr Psychol Res Training & Consultat, Little Rock, AR USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD OCT
PY 2013
VL 25
SU 1
MA PS01-106
BP S109
EP S110
PG 2
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA AJ5UB
UT WOS:000337753100247
ER
PT J
AU Shea, PL
Spaeder, MC
Sayal, P
Jacobs, BR
Stockwell, DC
AF Shea, Paul L.
Spaeder, Michael C.
Sayal, Puneet
Jacobs, Brian R.
Stockwell, David C.
TI Hypoglycemia Adverse Events in PICUs and Cardiac ICUs: Differentiating
Preventable and Nonpreventable Events
SO PEDIATRIC CRITICAL CARE MEDICINE
LA English
DT Article
DE adverse events; hypoglycemia; insulin; patient safety; pediatrics; PICU;
trigger
ID CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; MEDICATION-RELATED HARM;
FOCUSED TRIGGER TOOL; INSULIN THERAPY; NEONATAL HYPOGLYCEMIA; GLUCOSE
VARIABILITY; INCREASED MORTALITY; DRUG EVENTS; CHILDREN
AB Objectives: To describe the use of an adverse event detection system to identify, characterize, and categorize preventable versus nonpreventable hypoglycemia AEs in PICUs and cardiac ICUs.
Design: Retrospective observational study.
Setting: PICU and cardiac ICU of a tertiary pediatric hospital.
Subjects: All hypoglycemia triggers generated over a 3-year period.
Interventions: All hypoglycemia triggers generated via an electronic health record-driven surveillance system were investigated to determine if they represented a true adverse event and if that event was preventable or nonpreventable. Clinical and demographic variables were analyzed to identify characteristics of patients who developed a preventable or nonpreventable hypoglycemia adverse event.
Measurements and Main Results: There were 197 hypoglycemia adverse events in 90 patients. Thirty percent of the adverse events in the PICU and 36% of the adverse events in the cardiac ICU were characterized as preventable. Of the adverse events, 118 (59.9%) necessitated an intravenous dextrose bolus. No adverse events were associated with reporting of symptoms of hypoglycemia including apnea, altered mental status, or seizures. Events were more likely to be preventable (p < 0.001) if the patient was receiving only parenteral sources of nutrition (intravenous fluids or total parenteral nutrition). Controlling for weekends and holidays, adverse events associated with sole parenteral nutrition source had an increased odds ratio of 9.5 (95% confidence interval: 2.8-31.9) of being preventable. Stratifying by ICU, cardiac ICU events occurring on a weekend or holiday were more likely to be preventable (p = 0.001). Stratifying by unit and controlling for parenteral nutrition source, adverse events in the cardiac ICU occurring on weekends or holidays had an increased odds ratio of 11.6 (95% confidence interval: 2.7-50.2) of being preventable.
Conclusions: Preventable hypoglycemia adverse events are associated with patients receiving sole parenteral sources of nutrition in both the PICU and cardiac ICU. In the cardiac ICU, there is an association between weekend and holiday time periods and the development of preventable hypoglycemia adverse events.
C1 [Shea, Paul L.] St Christophers Hosp Children, Dept Pediat, Sect Crit Care, Philadelphia, PA 19133 USA.
[Shea, Paul L.] Drexel Univ, Coll Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Spaeder, Michael C.; Jacobs, Brian R.; Stockwell, David C.] Childrens Natl Med Ctr, Dept Crit Care Med, Washington, DC 20010 USA.
[Spaeder, Michael C.; Jacobs, Brian R.; Stockwell, David C.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA.
[Sayal, Puneet] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
Childrens Natl Med Ctr, Washington, DC 20010 USA.
RP Shea, PL (reprint author), St Christophers Hosp Children, Dept Pediat, Sect Crit Care, Philadelphia, PA 19133 USA.
EM paul.shea@tenethealth.com
FU Cerner Corporation, Kansas City, MO; Cerner Corporation
FX Dr. Stockwell received a research grant from the Cerner Corporation,
Kansas City, MO. Drs. Stockwell, Shea, Spaeder, Sayal, Jacobs, and
Stockwell received funding from the Cerner Corporation.
NR 37
TC 1
Z9 1
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1529-7535
EI 1947-3893
J9 PEDIATR CRIT CARE ME
JI Pediatr. Crit. Care Med.
PD OCT
PY 2013
VL 14
IS 8
BP 741
EP 746
DI 10.1097/PCC.0b013e3182975f0f
PG 6
WC Critical Care Medicine; Pediatrics
SC General & Internal Medicine; Pediatrics
GA AI0EF
UT WOS:000336518300007
PM 23863820
ER
PT J
AU Rajagopal, J
Mou, HM
AF Rajagopal, Jayaraj
Mou, Hongmei
TI IPS CELLS FOR CF AIRWAYS DISEASE
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
ID GFP-CFTR; DEGRADATION; MATURATION; EPITHELIUM
C1 [Rajagopal, Jayaraj; Mou, Hongmei] Massachusetts Gen Hosp, Ctr Regenerat Pulmonol, Boston, MA 02114 USA.
NR 9
TC 0
Z9 0
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 106
EP 107
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200006
ER
PT J
AU Vinarsky, V
Chu, K
Lam, A
Wain, J
Kim, JK
Yun, SH
Tearney, G
Rajagopal, J
AF Vinarsky, Vladimir
Chu, Kengueh
Lam, Adam
Wain, John
Kim, Jun Ki
Yun, Seok-Hyun
Tearney, Guillermo
Rajagopal, Jayaraj
TI HUMANIZED MICE FOR CF AIRWAYS RESEARCH
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
ID EPITHELIUM
C1 [Vinarsky, Vladimir; Rajagopal, Jayaraj] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Vinarsky, Vladimir; Lam, Adam; Wain, John] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Chu, Kengueh; Kim, Jun Ki; Yun, Seok-Hyun; Tearney, Guillermo] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Rajagopal, Jayaraj] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
NR 8
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 107
EP 109
PG 3
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200007
ER
PT J
AU Madan, J
Hibberd, PL
AF Madan, Juliette
Hibberd, Patricia L.
TI THE GASTROINTESTINAL AND RESPIRATORY MICROBIOME IN CF: POTENTIAL
INTERACTIONS
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
ID CYSTIC-FIBROSIS; GUT MICROBIOTA; RESPONSES; INFANTS; DISEASE
C1 [Madan, Juliette] Dartmouth Hitchcock Med Ctr, Div Neonatol, Lebanon, NH 03766 USA.
[Hibberd, Patricia L.] Massachusetts Gen Hosp, Dept Pediat, Div Global Hlth, Boston, MA 02114 USA.
NR 19
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 127
EP 128
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200020
ER
PT J
AU Moskowitz, SM
AF Moskowitz, Samuel M.
TI COLISTIN RESISTANCE: AN EMERGING THREAT TO A LAST LINE THERAPY
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
ID CYSTIC-FIBROSIS PATIENTS; PSEUDOMONAS-AERUGINOSA; POLYMYXIN RESISTANCE;
PEPTIDES; SYSTEM
C1 [Moskowitz, Samuel M.] Massachusetts Gen Hosp, Cyst Fibrosis Ctr, Boston, MA 02114 USA.
[Moskowitz, Samuel M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Moskowitz, Samuel M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 180
EP 181
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200061
ER
PT J
AU Nippins, M
AF Nippins, Matthew
TI AIRWAY CLEARANCE AND PHYSICAL ACTIVITY: THE PERFECT HARMONY
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
ID CYSTIC-FIBROSIS; EXERCISE
C1 [Nippins, Matthew] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 4
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 202
EP 203
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200077
ER
PT J
AU Birket, S
Chu, KK
Li, Y
Houser, GH
Mazur, M
Schuster, BS
Hanes, J
Tearney, GJ
Rowe, SM
AF Birket, S.
Chu, K. K.
Li, Y.
Houser, G. H.
Mazur, M.
Schuster, B. S.
Hanes, J.
Tearney, G. J.
Rowe, S. M.
TI THE RELATIONSHIP BETWEEN PERICILIARY LIQUID HYDRATION AND MUCUS
TRANSPORT IS AFFECTED BY BICARBONATE TRANSPORT
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
C1 [Birket, S.; Li, Y.; Houser, G. H.; Mazur, M.; Rowe, S. M.] Univ Alabama Birmingham, Birmingham, AL USA.
[Chu, K. K.; Tearney, G. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Schuster, B. S.; Hanes, J.] Johns Hopkins, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 235
EP 236
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200165
ER
PT J
AU Wilsterman, E
Chu, KK
Li, Y
Diephuis, B
Birket, S
Schuster, BS
Hanes, J
Rowe, SM
Tearney, GJ
AF Wilsterman, E.
Chu, K. K.
Li, Y.
Diephuis, B.
Birket, S.
Schuster, B. S.
Hanes, J.
Rowe, S. M.
Tearney, G. J.
TI RHEOLOGICAL VALIDATION OF PARTICLETRACKING MICRO-OPTICAL COHERENCE
TOMOGRAPHY
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
C1 [Wilsterman, E.; Chu, K. K.; Diephuis, B.; Tearney, G. J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Li, Y.; Birket, S.; Rowe, S. M.] Univ Alabama Birmingham, Birmingham, AL USA.
[Schuster, B. S.; Hanes, J.] Johns Hopkins Univ, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 301
EP 302
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200347
ER
PT J
AU Nick, JA
Chmiel, J
Forssen, A
Hamblett, NM
Moskowitz, SM
Saiman, L
Nichols, D
AF Nick, J. A.
Chmiel, J.
Forssen, A.
Hamblett, N. M.
Moskowitz, S. M.
Saiman, L.
Nichols, D.
TI AZITHROMYCIN APPEARS TO INHIBIT INHALED TOBRAMYCIN BUT NOT AZTREONAM
WHEN TARGETING P-AERUGINOSA, IN THE CF AIRWAY
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
C1 [Nick, J. A.; Forssen, A.; Nichols, D.] Natl Jewish Hlth, Denver, CO USA.
[Chmiel, J.] Case Med Ctr, Cleveland, OH USA.
[Hamblett, N. M.] Seattle Childrens Res Inst, TDN Coordinating Ctr, Seattle, WA USA.
[Moskowitz, S. M.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Saiman, L.] Columbia Univ, Med Ctr, New York, NY USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 305
EP 305
PG 1
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200357
ER
PT J
AU Madan, J
Li, J
Koestler, D
Moulton, L
Hibberd, P
Filkins, LM
Morrison, H
Guill, MF
O'Toole, GA
AF Madan, J.
Li, J.
Koestler, D.
Moulton, L.
Hibberd, P.
Filkins, L. M.
Morrison, H.
Guill, M. F.
O'Toole, G. A.
TI THE DEVELOPING GUT AND RESPIRATORY TRACT MICROBIOME IN INFANTS WITH CF
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
C1 [Madan, J.; Moulton, L.; Guill, M. F.] Dartmouth Hitchcock Med Ctr, Dept Pediat, Lebanon, NH 03766 USA.
[Li, J.; Koestler, D.] Geisel Sch Med Dartmouth, Translat Genom Reserach Inst, Hanover, NH USA.
[Filkins, L. M.; O'Toole, G. A.] Dartmouth Hitchcock Med Ctr, Dept Microbiol & Immunol, Lebanon, NH 03766 USA.
[Morrison, H.] Marine Biol Lab, Josephine Bay Paul Ctr, Woods Hole, MA 02543 USA.
[Hibberd, P.] Massachusetts Gen Hosp, Dept Pediat, Div Global Hlth, Boston, MA 02114 USA.
RI Koestler, Devin /D-7902-2015
OI Koestler, Devin /0000-0002-0598-0146
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 308
EP 309
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200366
ER
PT J
AU Gutu, A
Xavier, DE
Sgambati, N
Strasbourger, P
Gales, AC
Moskowitz, SM
AF Gutu, A.
Xavier, D. E.
Sgambati, N.
Strasbourger, P.
Gales, A. C.
Moskowitz, S. M.
TI ENHANCED POLYMYXIN RESISTANCE OF PSEUDOMONAS AERUGINOSA ASSOCIATED WITH
MUTATIONS IN A PHOSPHATE TRANSPORT SYSTEM
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
C1 [Gutu, A.; Sgambati, N.; Moskowitz, S. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Xavier, D. E.; Gales, A. C.] Univ Fed Sao Paulo, Div Infect Dis, Lab Alerta, Sao Paulo, Brazil.
[Strasbourger, P.] Univ Washington, Seattle, WA 98195 USA.
[Moskowitz, S. M.] Harvard Univ, Sch Med, Boston, MA USA.
RI Gales, Ana/C-8280-2013
OI Gales, Ana/0000-0003-0913-768X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 309
EP 309
PG 1
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200368
ER
PT J
AU Havasi, V
Clines, GA
Stalvey, MS
AF Havasi, V
Clines, G. A.
Stalvey, M. S.
TI REDUCED BONE DENSITY IN G551D-CFTR MICE: A NOVEL MODEL TO STUDY EFFECTS
OF CFTR ON BONE METABOLISM
SO PEDIATRIC PULMONOLOGY
LA English
DT Meeting Abstract
C1 [Havasi, V; Clines, G. A.; Stalvey, M. S.] Univ Alabama Birmingham, Birmingham, AL USA.
[Clines, G. A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2013
VL 48
SU 36
BP 419
EP 420
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA AF0FB
UT WOS:000334387200658
ER
PT J
AU Tennis, P
Johannes, C
Camargo, CA
Sturmer, T
Lanes, S
Brown, J
Andrews, E
Davis, K
Schatz, M
AF Tennis, Patricia
Johannes, Catherine
Camargo, C. A., Jr.
Stuermer, Til
Lanes, Stephan
Brown, Jeff
Andrews, Elizabeth
Davis, Kourtney
Schatz, Michael
TI Feasibility of Ruling out Small Treatment-Associated Increase in Asthma
Mortality Risk
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Tennis, Patricia; Johannes, Catherine; Andrews, Elizabeth] RTI Hlth Solut, Res Triangle Pk, NC USA.
[Camargo, C. A., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Stuermer, Til] Univ N Carolina, Chapel Hill, NC USA.
[Lanes, Stephan] United BioSource Corp, Lexington, MA USA.
[Brown, Jeff] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Davis, Kourtney] GlaxoSmithKline R&D, Res Triangle Pk, NC USA.
[Schatz, Michael] So Calif Permanente Med Grp, San Diego, CA 92120 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2013
VL 22
SU 1
SI SI
MA 64
BP 34
EP 35
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AF7EJ
UT WOS:000334876100065
ER
PT J
AU Bateman, BT
Bykov, K
Schneeweiss, S
Gagne, J
Polinski, JM
Franklin, JM
Fischer, MA
Choudhry, NK
Rassen, JA
AF Bateman, Brian T.
Bykov, Katsiaryna
Schneeweiss, Sebastian
Gagne, Joshua
Polinski, Jennifer M.
Franklin, Jessica M.
Fischer, Michael A.
Choudhry, Niteesh K.
Rassen, Jeremy A.
TI Type of Stress Ulcer Prophylaxis and the Risk of Nosocomial Pneumonia in
Cardiac Surgical Patients
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Bateman, Brian T.; Bykov, Katsiaryna; Schneeweiss, Sebastian; Gagne, Joshua; Polinski, Jennifer M.; Franklin, Jessica M.; Fischer, Michael A.; Choudhry, Niteesh K.; Rassen, Jeremy A.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
[Bateman, Brian T.; Bykov, Katsiaryna; Schneeweiss, Sebastian; Gagne, Joshua; Polinski, Jennifer M.; Franklin, Jessica M.; Fischer, Michael A.; Choudhry, Niteesh K.; Rassen, Jeremy A.] Harvard Univ, Sch Med, Boston, MA USA.
[Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RI Schneeweiss, Sebastian/C-2125-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2013
VL 22
SU 1
SI SI
MA 66
BP 35
EP 36
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AF7EJ
UT WOS:000334876100067
ER
PT J
AU Soriano, LC
Bateman, BT
Rodriguez, LAG
Hernandez-Diaz, S
AF Cea Soriano, Lucia
Bateman, Brian T.
Garcia Rodriguez, Luis A.
Hernandez-Diaz, Sonia
TI Hypertension and Patterns of Prescription of Antihypertensive
Medications during Pregnancy Using THIN Database
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Cea Soriano, Lucia; Garcia Rodriguez, Luis A.] Spanish Ctr Pharmacoepidemiol Res CEIFE, Madrid, Spain.
[Cea Soriano, Lucia; Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Bateman, Brian T.] Harvard Univ, Div Pharmacoepidemiol & Pharmacoecon, Dept Anesthesia Crit Care & Pain Med,Sch Med, Brigham & Womens Hosp,Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2013
VL 22
SU 1
SI SI
MA 301
BP 145
EP 146
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AF7EJ
UT WOS:000334876100280
ER
PT J
AU Bateman, BT
Huybrechts, KF
Hernandez-Diaz, S
Liu, J
Avorn, J
AF Bateman, Brian T.
Huybrechts, Krista F.
Hernandez-Diaz, Sonia
Liu, Jun
Avorn, Jerry
TI Methylergonovine Maleate and the Risk of Myocardial Ischemia and
Infarction
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Bateman, Brian T.; Huybrechts, Krista F.; Liu, Jun; Avorn, Jerry] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
[Bateman, Brian T.; Huybrechts, Krista F.; Liu, Jun; Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA USA.
[Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2013
VL 22
SU 1
SI SI
MA 399
BP 195
EP 195
PG 1
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AF7EJ
UT WOS:000334876100376
ER
PT J
AU Yenikomshian, MA
LaCasce, AS
Skarin, AT
Trahey, A
Guignard, A
Haguinet, FF
Karner, PE
Duh, MS
AF Yenikomshian, Mihran A.
LaCasce, Ann S.
Skarin, Arthur T.
Trahey, Alex
Guignard, Adrienne
Haguinet, Francois F.
Karner, Paul E.
Duh, Mei S.
TI The Epidemiology of Herpes Zoster (HZ) and Its Complications in Medicare
Cancer Patients
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Yenikomshian, Mihran A.; Trahey, Alex; Karner, Paul E.; Duh, Mei S.] Anal Grp, Boston, MA USA.
[LaCasce, Ann S.; Skarin, Arthur T.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Guignard, Adrienne; Haguinet, Francois F.] GlaxoSmithKline Biol, Wavre, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2013
VL 22
SU 1
SI SI
MA 551
BP 271
EP 271
PG 1
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AF7EJ
UT WOS:000334876101119
ER
PT J
AU Johannes, CB
McQuay, LJ
Tennis, P
Camargo, CA
Schatz, M
Midkiff, KD
Lanes, S
DiSantostefano, R
Davis, KJ
AF Johannes, Catherine B.
McQuay, Lisa J.
Tennis, Patricia
Camargo, Carlos A., Jr.
Schatz, Michael
Midkiff, Kirk D.
Lanes, Stephan
DiSantostefano, Rachael
Davis, Kourtney J.
TI Characteristics of Initiators of Asthma Maintenance Medications in 10
Health Care Populations
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Johannes, Catherine B.] RTI Hlth Solut, Epidemiol, Waltham, MA USA.
[McQuay, Lisa J.; Tennis, Patricia; Midkiff, Kirk D.] RTI Hlth Solut, Epidemiol, Res Triangle Pk, NC USA.
[Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Schatz, Michael] So Calif Permanente Med Grp, San Diego, CA 92120 USA.
[Lanes, Stephan] United BioSource Corp, Lexington, MA USA.
[DiSantostefano, Rachael; Davis, Kourtney J.] GlaxoSmithKline R&D, Res Triangle Pk, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2013
VL 22
SU 1
SI SI
MA 555
BP 273
EP 274
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AF7EJ
UT WOS:000334876101123
ER
PT J
AU Linsky, A
Simon, SR
Bokhour, B
AF Linsky, Amy
Simon, Steven R.
Bokhour, Barbara
TI Clinical Provider Perceptions of Intentional Medication Discontinuation
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Linsky, Amy; Simon, Steven R.] VA Boston Healthcare Syst, Gen Internal Med, Boston, MA USA.
[Linsky, Amy; Simon, Steven R.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Linsky, Amy; Simon, Steven R.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Linsky, Amy; Simon, Steven R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bokhour, Barbara] ENRM Vet Affairs Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Bokhour, Barbara] Boston Univ, Sch Publ Hlth, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2013
VL 22
SU 1
SI SI
MA 911
BP 456
EP 457
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AF7EJ
UT WOS:000334876102029
ER
PT J
AU Linsky, A
Volk, L
Maniam, N
Simon, SR
AF Linsky, Amy
Volk, Lynn
Maniam, Nivethietha
Simon, Steven R.
TI Effect of Computerized Clinical Decision Support on Appropriate
Laboratory Monitoring of Medications
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Linsky, Amy; Simon, Steven R.] VA Boston Healthcare Syst, Gen Internal Med, Boston, MA USA.
[Linsky, Amy; Simon, Steven R.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Linsky, Amy; Simon, Steven R.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Linsky, Amy; Simon, Steven R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Volk, Lynn; Maniam, Nivethietha] Partners Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD OCT
PY 2013
VL 22
SU 1
SI SI
MA 960
BP 480
EP 481
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AF7EJ
UT WOS:000334876102072
ER
PT J
AU Munoz, JL
Bliss, SA
Greco, SJ
Ramkissoon, SH
Ligon, KL
Rameshwar, P
AF Munoz, Jessian L.
Bliss, Sarah A.
Greco, Steven J.
Ramkissoon, Shakti H.
Ligon, Keith L.
Rameshwar, Pranela
TI Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived
Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID BREAST-CANCER; GLIOMA; CHEMORESISTANCE; ACTIVATION; EXPRESSION;
MICRORNAS; ABCB1
AB Glioblastoma multiforme (GBM), the most common and lethal tumor of the adult brain, generally shows chemo-and radioresistance. MicroRNAs (miRs) regulate physiological processes, such as resistance of GBM cells to temozolomide (TMZ). Although miRs are attractive targets for cancer therapeutics, the effectiveness of this approach requires targeted delivery. Mesenchymal stem cells (MSCs) can migrate to the sites of cancers, including GBM. We report on an increase in miR-9 in TMZ-resistant GBM cells. miR-9 was involved in the expression of the drug efflux transporter, P-glycoprotein. To block miR-9, methods were developed with Cy5-tagged anti-miR-9. Dye-transfer studies indicated intracellular communication between GBM cells and MSCs. This occurred by gap junctional intercellular communication and the release of microvesicles. In both cases, anti-miR-9 was transferred from MSCs to GBM cells. However, the major form of transfer occurred with the microvesicles. The delivery of anti-miR-9 to the resistant GBM cells reversed the expression of the multidrug transporter and sensitized the GBM cells to TMZ, as shown by increased cell death and caspase activity. The data showed a potential role for MSCs in the functional delivery of synthetic anti-miR-9 to reverse the chemoresistance of GBM cells.
C1 [Munoz, Jessian L.; Bliss, Sarah A.] Rutgers State Univ, Sch Biomed Sci, Newark, NJ 07102 USA.
[Munoz, Jessian L.; Bliss, Sarah A.; Greco, Steven J.; Rameshwar, Pranela] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA.
[Ramkissoon, Shakti H.; Ligon, Keith L.] Boston Childrens Hosp, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA.
[Ramkissoon, Shakti H.; Ligon, Keith L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Rameshwar, P (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Rutgers Biomed Hlth Sci, 185 South Orange Ave,MSB E-585, Newark, NJ 07103 USA.
EM rameshwa@njms.rutgers.edu
NR 27
TC 70
Z9 74
U1 6
U2 24
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD OCT
PY 2013
VL 2
AR e126
DI 10.1038/mtna.2013.60
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AC4CQ
UT WOS:000332468600002
PM 24084846
ER
PT J
AU Roetker, NS
Page, CD
Yonker, JA
Chang, V
Roan, CL
Herd, P
Hauser, TS
Hauser, RM
Atwood, CS
AF Roetker, Nicholas S.
Page, C. David
Yonker, James A.
Chang, Vicky
Roan, Carol L.
Herd, Pamela
Hauser, Taissa S.
Hauser, Robert M.
Atwood, Craig S.
TI Assessment of Genetic and Nongenetic Interactions for the Prediction of
Depressive Symptomatology: An Analysis of the Wisconsin Longitudinal
Study Using Machine Learning Algorithms
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID NATIONAL COMORBIDITY SURVEY; SEROTONIN TRANSPORTER GENE; GENOME-WIDE
ASSOCIATION; STRESSFUL LIFE EVENTS; HORMONE-RECEPTOR GENE; MAJOR
DEPRESSION; ADULT DEPRESSION; ENVIRONMENT INTERACTIONS; CHILDHOOD
MALTREATMENT; TREATMENT RESPONSE
AB Objectives. We examined depression within a multidimensional framework consisting of genetic, environmental, and sociobehavioral factors and, using machine learning algorithms, explored interactions among these factors that might better explain the etiology of depressive symptoms.
Methods. We measured current depressive symptoms using the Center for Epidemiologic Studies Depression Scale (n = 6378 participants in the Wisconsin Longitudinal Study). Genetic factors were 78 single nucleotide polymorphisms (SNPs); environmental factors-13 stressful life events (SLEs), plus a composite proportion of SLEs index; and sociobehavioral factors-18 personality, intelligence, and other health or behavioral measures. We performed traditional SNP associations via logistic regression likelihood ratio testing and explored interactions with support vector machines and Bayesian networks.
Results. After correction for multiple testing, we found no significant single genotypic associations with depressive symptoms. Machine learning algorithms showed no evidence of interactions. Naive Bayes produced the best models in both subsets and included only environmental and sociobehavioral factors.
Conclusions. We found no single or interactive associations with genetic factors and depressive symptoms. Various environmental and sociobehavioral factors were more predictive of depressive symptoms, yet their impacts were independent of one another. A genome-wide analysis of genetic alterations using machine learning methodologies will provide a framework for identifying genetic-environmental-sociobehavioral interactions in depressive symptoms.
C1 [Roetker, Nicholas S.; Yonker, James A.; Chang, Vicky; Roan, Carol L.; Herd, Pamela; Hauser, Taissa S.; Hauser, Robert M.] Univ Wisconsin Madison, Dept Sociol, Madison, WI 53715 USA.
[Herd, Pamela] Univ Wisconsin Madison, La Follete Sch Publ Affairs, Madison, WI USA.
[Page, C. David] Univ Wisconsin Madison, Dept Biostat & Med Informat, Madison, WI USA.
[Atwood, Craig S.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Atwood, Craig S.] Univ Wisconsin Madison Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA.
RP Atwood, CS (reprint author), Univ Wisconsin Madison Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp GRECC 11G, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM csa@medicine.wisc.edu
RI Yonker, James/J-6561-2014
OI Yonker, James/0000-0002-9483-8511
FU National Institute on Aging [AG-9775, AG-21079, AG-033285]; Vilas Estate
Trust; National Science Foundation; Spencer Foundation; Graduate School
of the University of Wisconsin-Madison
FX This research used data from the Wisconsin Longitudinal Study (WLS) of
the University of Wisconsin-Madison. Since 1991, the WLS has been
supported principally by the National Institute on Aging (AG-9775,
AG-21079, and AG-033285), with additional support from the Vilas Estate
Trust, the National Science Foundation, the Spencer Foundation, and the
Graduate School of the University of Wisconsin-Madison. A public use
file of data from the Wisconsin Longitudinal Study is available from the
WLS, University of Wisconsin-Madison, 1180 Observatory Drive, Madison,
WI 53706, and at http://www.ssc.wisc.edu/wlsresearch/data. This material
is the result of work supported with resources at the William S.
Middleton Memorial Veterans Hospital, Madison, WI.
NR 82
TC 1
Z9 1
U1 2
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD OCT
PY 2013
VL 103
SU 1
BP 136
EP 144
DI 10.2105/AJPH.2012.301141
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA4NC
UT WOS:000331071600021
ER
PT J
AU Shea, S
Kothari, D
Teresi, JA
Kong, J
Eimicke, JP
Lantigua, RA
Palmas, W
Weinstock, RS
AF Shea, Steven
Kothari, Dhruva
Teresi, Jeanne A.
Kong, Jian
Eimicke, Joseph P.
Lantigua, Rafael A.
Palmas, Walter
Weinstock, Ruth S.
TI Social Impact Analysis of the Effects of a Telemedicine Intervention to
Improve Diabetes Outcomes in an Ethnically Diverse, Medically
Underserved Population: Findings From the IDEATel Study
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID COLUMBIA-UNIVERSITY INFORMATICS; RANDOMIZED CONTROLLED-TRIALS;
BLOOD-PRESSURE; CARE; EDUCATION; MODEL; CHOLESTEROL; MANAGEMENT;
MELLITUS; PROJECT
AB Objectives. We examined the social impact of the telemedicine intervention effects in lower-and higher-socioeconomic status (SES) participants in the Informatics for Diabetes Education and Telemedicine (IDEATel) study.
Methods. We conducted a randomized controlled trial comparing telemedicine case management with usual care, with blinded outcome evaluation, in 1665 Medicare recipients with diabetes, aged 55 years or older, residing in federally designated medically underserved areas of New York State. The primary trial endpoints were hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol, and systolic blood pressure levels.
Results. HbA1c was higher in lower-income participants at the baseline examination. However, we found no evidence that the intervention increased disparities. A significant moderator effect was seen for HbA1c (P = .004) and systolic blood pressure (P = .023), with the lowest-income group showing greater intervention effects.
Conclusions. Lower-SES participants in the IDEATel study benefited at least as much as higher-SES participants from telemedicine nurse case management for diabetes. Tailoring the intensity of the intervention based on clinical need may have led to greater improvements among those not at goal for diabetes control, a group that also had lower income, thereby avoiding the potential for an innovative intervention to widen socioeconomic disparities.
C1 [Shea, Steven; Lantigua, Rafael A.; Palmas, Walter] Columbia Univ, Dept Med, New York, NY USA.
[Kothari, Dhruva] Columbia Univ Coll Phys & Surg, New York, NY USA.
[Teresi, Jeanne A.; Kong, Jian; Eimicke, Joseph P.] Hebrew Home Riverdale, Div Res, Bronx, NY USA.
[Teresi, Jeanne A.] Columbia Univ, Morris W Stroud III Ctr Studies Qual Life, New York, NY USA.
[Weinstock, Ruth S.] SUNY Upstate Med Univ, Joslin Diabet Ctr, Syracuse, NY 13210 USA.
[Weinstock, Ruth S.] SUNY Upstate Med Univ, Div Endocrinol Diabet & Metab, Syracuse, NY 13210 USA.
RP Shea, S (reprint author), Div Gen Med, 630 W 168th St, New York, NY 10032 USA.
EM ss35@columbia.edu
FU Centers for Medicare and Medicaid Services [95-C-90998]; National
Institute on Minority Health and Health Disparities [P60-MD000206]
FX This project was supported by the Centers for Medicare and Medicaid
Services (cooperative agreement 95-C-90998) and by the National
Institute on Minority Health and Health Disparities (grant
P60-MD000206).
NR 25
TC 6
Z9 6
U1 0
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD OCT
PY 2013
VL 103
IS 10
BP 1888
EP 1894
DI 10.2105/AJPH.2012.300909
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA3PK
UT WOS:000331004600045
PM 23488491
ER
PT J
AU Blosnich, JR
Brown, GR
Shipherd, JC
Kauth, M
Piegari, RI
Bossarte, RM
AF Blosnich, John R.
Brown, George R.
Shipherd, Jillian C.
Kauth, Michael
Piegari, Rebecca I.
Bossarte, Robert M.
TI Prevalence of Gender Identity Disorder and Suicide Risk Among
Transgender Veterans Utilizing Veterans Health Administration Care
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID CROSS-SEX HORMONES; TRANSSEXUALISM; IDEATION; BEHAVIORS; MORTALITY
AB Objectives. We estimated the prevalence and incidence of gender identity disorder (GID) diagnoses among veterans in the Veterans Health Administration (VHA) health care system and examined suicide risk among veterans with a GID diagnosis.
Methods. We examined VHA electronic medical records from 2000 through 2011 for 2 official ICD-9 diagnosis codes that indicate transgender status. We generated annual period prevalence estimates and calculated incidence using the prevalence of GID at 2000 as the baseline year. We cross-referenced GID cases with available data (2009-2011) of suicide-related events among all VHA users to examine suicide risk.
Results. GID prevalence in the VHA is higher (22.9/100 000 persons) than are previous estimates of GID in the general US population (4.3/100 000 persons). The rate of suicide-related events among GID-diagnosed VHA veterans was more than 20 times higher than were rates for the general VHA population.
Conclusions. The prevalence of GID diagnosis nearly doubled over 10 years among VHA veterans. Research is needed to examine suicide risk among transgender veterans and how their VHA utilization may be enhanced by new VA initiatives on transgender care.
C1 [Blosnich, John R.] Univ Rochester, Dept Psychiat, Rochester, NY USA.
[Brown, George R.] VA Off Hlth Equ 10A6, Washington, DC USA.
[Shipherd, Jillian C.] VA Boston Healthcare Syst, Boston, MA USA.
[Kauth, Michael] Michael E DeBakey VA Med Ctr, Educ & Clin Ctr, VA South Cent Mental Illness Res, Houston, TX USA.
[Piegari, Rebecca I.; Bossarte, Robert M.] Ctr Excellence Suicide Prevent, Dept Vet Affairs VISN 2, Canandaigua, NY 14424 USA.
RP Blosnich, JR (reprint author), Ctr Excellence Suicide Prevent, Dept Vet Affairs VISN 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA.
EM john_blosnich@urmc.rochester.edu
FU Department of Veterans Affairs VISN-2 Center of Excellence for Suicide
Prevention; National Institute of Mental Health [5T32MH02006112]
FX This work was partially supported by the Department of Veterans Affairs
VISN-2 Center of Excellence for Suicide Prevention and by a postdoctoral
fellowship in an Institutional National Research Service Award from the
National Institute of Mental Health (award 5T32MH02006112 to J.R.B.).
NR 47
TC 43
Z9 43
U1 0
U2 16
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD OCT
PY 2013
VL 103
IS 10
BP E27
EP E32
DI 10.2105/AJPH.2013.301507
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA3PK
UT WOS:000331004600013
PM 23947310
ER
PT J
AU Hirsch, JA
Donovan, WD
Nicola, GN
Barr, RM
Schaefer, PW
Silva, E
AF Hirsch, J. A.
Donovan, W. D.
Nicola, G. N.
Barr, R. M.
Schaefer, P. W.
Silva, E., III
TI Alphabet Soup: Our Government "In-Action"
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Editorial Material
ID RUC
C1 [Hirsch, J. A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurovasc Program, Boston, MA 02114 USA.
[Donovan, W. D.] Norwich Diagnost Imaging Associates, Norwich, CT USA.
[Nicola, G. N.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Barr, R. M.] Mecklenburg Radiol Associates, Charlotte, NC USA.
[Schaefer, P. W.] Massachusetts Gen Hosp, Neuroradiol Div, Boston, MA 02114 USA.
[Silva, E., III] Univ Texas San Antonio, South Texas Radiol Grp, San Antonio, TX USA.
RP Hirsch, JA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroendovasc Program, Boston, MA 02114 USA.
EM Hirsch@snisonline.org
OI Barr, Robert/0000-0002-9214-9448
NR 13
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD OCT
PY 2013
VL 34
IS 10
BP 1887
EP 1889
DI 10.3174/ajnr.A3672
PG 3
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 301NQ
UT WOS:000330539400008
PM 23811971
ER
PT J
AU Barakos, J
Sperling, R
Salloway, S
Jack, C
Gass, A
Fiebach, JB
Tampieri, D
Melancon, D
Miaux, Y
Rippon, G
Black, R
Lu, Y
Brashear, HR
Arrighi, HM
Morris, KA
Grundman, M
AF Barakos, J.
Sperling, R.
Salloway, S.
Jack, C.
Gass, A.
Fiebach, J. B.
Tampieri, D.
Melancon, D.
Miaux, Y.
Rippon, G.
Black, R.
Lu, Y.
Brashear, H. R.
Arrighi, H. M.
Morris, K. A.
Grundman, M.
TI MR Imaging Features of Amyloid-Related Imaging Abnormalities
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID ANGIOPATHY-RELATED INFLAMMATION; ALZHEIMERS-DISEASE; BRAIN; BETA;
BAPINEUZUMAB; TRIALS
AB BACKGROUND AND PURPOSE: AD is one of the few leading causes of death without a disease-modifying drug; however, hopeful agents are in various phases of development. MR imaging abnormalities, collectively referred to as amyloid-related imaging abnormalities, have been reported for several agents that target cerebral A beta burden. ARIA includes ARIA-E, parenchymal or sulcal hyperintensities on FLAIR indicative of parenchymal edema or sulcal effusions, and ARIA-H, hypointense regions on gradient recalled-echo/T2* indicative of hemosiderin deposition. This report describes imaging characteristics of ARIA-E and ARIA-H identified during studies of bapineuzumab, a humanized monoclonal antibody against A beta.
MATERIALS AND METHODS: Two neuroradiologists with knowledge of imaging changes reflective of ARIA reviewed MR imaging scans from 210 bapineuzumab-treated patients derived from 3 phase 2 studies. Each central reader interpreted the studies independently, and discrepancies were resolved by consensus. The inter-reader kappa was 0.76, with 94% agreement between neuroradiologists regarding the presence or absence of ARIA-E in individual patients.
RESULTS: Thirty-six patients were identified with incident ARIA-E (17.1%, 36/210) and 26 with incident ARIA-H (12.4%, 26/210); of those with incident ARIA-H, 24 had incident microhemorrhages and 2 had incident large superficial hemosiderin deposits.
CONCLUSIONS: In 49% of cases of ARIA-E, there was the associated appearance of ARIA-H. In treated patients without ARIA-E, the risk for incident blood products was 4%. This association between ARIA-E and ARIA-H may suggest a common pathophysiologic mechanism. Familiarity with ARIA should permit radiologists and clinicians to recognize and communicate ARIA findings more reliably for optimal patient management.
C1 [Barakos, J.] Calif Pacific Med Ctr, San Francisco, CA 94115 USA.
[Barakos, J.; Miaux, Y.] Synarc, Newark, CA USA.
[Sperling, R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Brigham & Womens Hosp, Boston, MA USA.
[Salloway, S.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Jack, C.] Mayo Clin, Rochester, MN USA.
[Gass, A.] Heidelberg Univ, Univ Hosp Mannheim, Mannheim, Germany.
[Fiebach, J. B.] Charite, Ctr Stroke Res, Berlin, Germany.
[Tampieri, D.; Melancon, D.] NeuroRx Res, Montreal, PQ, Canada.
[Rippon, G.; Black, R.] Pfizer Inc, Collegeville, PA USA.
[Brashear, H. R.; Arrighi, H. M.; Morris, K. A.; Grundman, M.] Janssen Alzheimer Immunotherapy Res & Dev LLC, San Francisco, CA USA.
[Grundman, M.] Global Partners Inc, Cambridge, MA USA.
RP Barakos, J (reprint author), Calif Pacific Med Ctr, 2333 Buchanan St, San Francisco, CA 94115 USA.
EM barakosmd@gmail.com
RI Jack, Clifford/F-2508-2010;
OI Jack, Clifford/0000-0001-7916-622X; Fiebach, Jochen
B./0000-0002-7936-6958
FU Janssen Alzheimer Immunotherapy Research & Development, LLC; Pfizer
Inc.; Pfizer Inc; Janssen Alzheimer Immunotherapy Research &
Development, LLC.
FX This work was supported by Janssen Alzheimer Immunotherapy Research &
Development, LLC, and Pfizer Inc. Michael Grundman was a paid consultant
to Janssen Alzheimer Immunotherapy Research & Development, LLC, in the
development of this article. Editorial support was provided by Lisette
T. Arnaud, PhD, at Phase Five Communications Inc and was funded by
Pfizer Inc and Janssen Alzheimer Immunotherapy Research & Development,
LLC.
NR 21
TC 10
Z9 10
U1 1
U2 5
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD OCT
PY 2013
VL 34
IS 10
BP 1958
EP 1965
DI 10.3174/ajnr.A3500
PG 8
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 301NQ
UT WOS:000330539400020
PM 23578674
ER
PT J
AU Leslie-Mazwi, TM
Heddier, M
Nordmeyer, H
Stauder, M
Velasco, A
Mosimann, PJ
Chapot, R
AF Leslie-Mazwi, T. M.
Heddier, M.
Nordmeyer, H.
Stauder, M.
Velasco, A.
Mosimann, P. J.
Chapot, R.
TI Stent Retriever Use for Retrieval of Displaced Microcoils: A Consecutive
Case Series
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID GUGLIELMI DETACHABLE COILS; ANEURYSMS
AB Coil displacement during endovascular coiling procedures may require coil retrieval in the context of flow limitation or thromboembolic risk. No standard recommended method of coil retrieval exists. We present a consecutive series of 14 patients with displaced coil during aneurysm coiling in whom the complication was effectively managed with the use of a stent retriever system. Two illustrative cases from the 14 are described, and technical notes are detailed regarding use of the technique. The use of stent retrievers presents a simple, safe, and effective choice for removal of prolapsed coils during aneurysm coiling.
C1 [Leslie-Mazwi, T. M.; Heddier, M.; Nordmeyer, H.; Stauder, M.; Velasco, A.; Mosimann, P. J.; Chapot, R.] Alfried Krupp Hosp, Dept Intervent Neuroradiol, Essen, Germany.
[Leslie-Mazwi, T. M.] Massachusetts Gen Hosp, Dept Intervent Neuroradiol Endovasc Neurosurg, Boston, MA 02114 USA.
[Mosimann, P. J.] CHU Vaudois, Dept Radiol & Neuroradiol, CH-1011 Lausanne, Switzerland.
Univ Lausanne, Lausanne, Switzerland.
RP Chapot, R (reprint author), Dept Intracranial Endovasc Therapy, Alfried Krupp Str 21, D-45131 Essen, Germany.
EM rene.chapot@krupp-krankenhaus.de
NR 15
TC 11
Z9 11
U1 0
U2 0
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD OCT
PY 2013
VL 34
IS 10
BP 1996
EP 1999
DI 10.3174/ajnr.A3552
PG 4
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 301NQ
UT WOS:000330539400027
PM 23764724
ER
PT J
AU Elmi, A
Hedgire, SS
Covarrubias, D
Abtahi, SM
Hahn, PF
Harisinghani, M
AF Elmi, A.
Hedgire, S. S.
Covarrubias, D.
Abtahi, S. M.
Hahn, P. F.
Harisinghani, M.
TI Apparent diffusion coefficient as a non-invasive predictor of treatment
response and recurrence in locally advanced rectal cancer
SO CLINICAL RADIOLOGY
LA English
DT Article
ID WEIGHTED MRI; RADIOTHERAPY; CHEMORADIATION; MANAGEMENT; THERAPY; VALUES
AB AIM: To evaluate the role of pretreatment apparent diffusion coefficient (ADC) as a predictor of treatment response and local recurrence in patients with locally advanced rectal cancer who underwent neoadjuvant therapy.
MATERIALS AND METHODS: Forty-nine patients who underwent preoperative diffusion-weighted magnetic resonance imaging (MRI) followed by neoadjuvant chemoradiation and surgery were enrolled in the study. The mean tumour ADC was measured independently from multiple, non-overlapping regions of interest (ROIs) to cover the entire tumour area on a single section by two radiologists and patients were followed postoperatively for a median of 16.4 months. Diagnostic accuracy of ADC for predicting treatment response and recurrence was evaluated using the area under the receiver-operating characteristic (ROC) curve, sensitivity, specificity, and predictive values. Univariate and multivariate analyses including clinical tumour (cT) staging, carcinoembryonic antigen (CEA) level, lymph-node involvement, tumour grade, surgical margin, vascular involvement, and ADC were performed with respect to recurrence. Interobserver agreement of ADC values was assessed.
RESULTS: Twenty patients showed response to neoadjuvant therapy and recurrence was noted in 17 patients. Low pretreatment ADC, MRI findings of cT4 staging, and node involvement were significantly related to poor treatment response. Sensitivity and specificity of ADC = 0.833 x 10(-3) mm(2)/s for prediction of treatment response was 75 and 48% for reader 1 and 65 and 52% for reader 2, respectively. Univariate and multivariate analyses identified pretreatment tumour ADC as the only predictive factor for recurrence. Sensitivity and specificity of ADC = 0.833 x 10(-3) mm(2)/s for prediction of recurrence was 86 and 77% for reader 1 and 80 and 69% for reader 2, respectively. Interobserver agreement for measuring ADC was good with a kappa value of 0.70.
CONCLUSION: Pretreatment rectal tumour ADC values may be an early biomarker for predicting treatment response and local recurrence in patients who underwent neoadjuvant chemoradiation. (C) 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Elmi, A.; Hedgire, S. S.; Covarrubias, D.; Abtahi, S. M.; Hahn, P. F.; Harisinghani, M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Boston, MA USA.
RP Elmi, A (reprint author), Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, 55 Fruit St,White 270, Boston, MA 02114 USA.
EM aelmi@partners.org
NR 26
TC 19
Z9 19
U1 0
U2 9
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0009-9260
EI 1365-229X
J9 CLIN RADIOL
JI Clin. Radiol.
PD OCT
PY 2013
VL 68
IS 10
BP E524
EP E531
DI 10.1016/j.crad.2013.05.094
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AA5UV
UT WOS:000331166000002
PM 23830776
ER
PT J
AU Ioannou, GN
Scott, JD
Yang, Y
Green, P
Beste, LA
AF Ioannou, George N.
Scott, John D.
Yang, Yin
Green, Pamela
Beste, Lauren A.
TI Antiviral Treatment for Hepatitis C Virus in HIV/HCV Co-infected
Patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Ioannou, George N.; Yang, Yin; Green, Pamela; Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Ioannou, George N.; Scott, John D.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 37
BP 225A
EP 225A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201037
ER
PT J
AU Patel, SJ
Luther, J
King, KR
Bohr, S
Scichilone, J
Garber, J
Peng, LF
Chung, RT
Yarmush, ML
AF Patel, Suraj J.
Luther, Jay
King, Kevin R.
Bohr, Stefan
Scichilone, John
Garber, John
Peng, Lee F.
Chung, Raymond T.
Yarmush, Martin L.
TI Hepatic Gap Junction Inhibition Limits Liver Injury and Inflammation in
Non-alcoholic Steatohepatitis (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Patel, Suraj J.; Luther, Jay; King, Kevin R.; Bohr, Stefan; Scichilone, John; Garber, John; Peng, Lee F.; Chung, Raymond T.; Yarmush, Martin L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Patel, Suraj J.; Bohr, Stefan; Scichilone, John; Yarmush, Martin L.] Shriners Burns Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 50
BP 232A
EP 232A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201050
ER
PT J
AU Hammond, SP
Ho, VT
Ukomadu, C
Baden, LR
Marty, FM
AF Hammond, Sarah P.
Ho, Vincent T.
Ukomadu, Chinweike
Baden, Lindsey R.
Marty, Francisco M.
TI Hepatitis B Virus (HBV) Reverse Seroconversion after Allogeneic
Hematopoietic Stem Cell Transplantation the Impact of Post-Transplant
Vaccination
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Hammond, Sarah P.; Baden, Lindsey R.; Marty, Francisco M.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Hammond, Sarah P.; Ho, Vincent T.; Baden, Lindsey R.; Marty, Francisco M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ukomadu, Chinweike] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 192
BP 303A
EP 304A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201192
ER
PT J
AU Zhu, CL
Hong, J
Zhao, L
Chusri, P
Jilg, N
Fusco, DN
Schaefer, EA
Brisac, C
Chevaliez, S
Wambua, D
Peng, LF
Lin, WY
Chung, RT
AF Zhu, Chuanlong
Hong, Jian
Zhao, Lei
Chusri, Pattranuch
Jilg, Nikolaus
Fusco, Dahlene N.
Schaefer, Esperance A.
Brisac, Cynthia
Chevaliez, Stephane
Wambua, Daniel
Peng, Lee F.
Lin, Wenyu
Chung, Raymond T.
TI EFTUD2 regulates hepatitis C virus replication through the RIG-I/MDA5
pathway
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Zhu, Chuanlong; Hong, Jian; Zhao, Lei; Chusri, Pattranuch; Jilg, Nikolaus; Fusco, Dahlene N.; Schaefer, Esperance A.; Brisac, Cynthia; Chevaliez, Stephane; Wambua, Daniel; Peng, Lee F.; Lin, Wenyu; Chung, Raymond T.] Harvard Univ, Gastrointestinal Unit, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 197
BP 306A
EP 306A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201197
ER
PT J
AU Curry, MP
Forns, X
Chung, RT
Terrault, N
Brown, RS
Fenkel, JM
Gordon, FD
O'Leary, JG
Kuo, A
Schiano, TD
Everson, GT
Schiff, ER
Befeler, A
McHutchison, JG
Symonds, WT
Denning, JM
McNair, L
Arterburn, S
Moonka, D
Gane, EJ
Afdhal, NH
AF Curry, Michael P.
Forns, Xavier
Chung, Raymond T.
Terrault, Norah
Brown, Robert S.
Fenkel, Jonathan M.
Gordon, Fredric D.
O'Leary, Jacqueline G.
Kuo, Alexander
Schiano, Thomas D.
Everson, Gregory T.
Schiff, Eugene R.
Befeler, Alex
McHutchison, John G.
Symonds, William T.
Denning, Jill M.
McNair, Lindsay
Arterburn, Sarah
Moonka, Dilip
Gane, Edward J.
Afdhal, Nezam H.
TI Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV
Infection after Liver Transplantation
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Curry, Michael P.; Afdhal, Nezam H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Forns, Xavier] Hosp Clin Barcelona, Liver Unit, Barcelona, Spain.
[Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Brown, Robert S.] Columbia Univ, New York, NY USA.
[Fenkel, Jonathan M.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA.
[Gordon, Fredric D.] Lahey Clin Fdn, Burlington, MA USA.
[O'Leary, Jacqueline G.] Baylor Univ, Med Ctr, Dallas, TX USA.
[Kuo, Alexander] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Schiano, Thomas D.] Mt Sinai Sch Med, New York, NY USA.
[Everson, Gregory T.] Univ Colorado, Denver, CO 80202 USA.
[Schiff, Eugene R.] Univ Miami, Miami, FL USA.
[Befeler, Alex] St Louis Univ, St Louis, MO 63103 USA.
[McHutchison, John G.; Symonds, William T.; Denning, Jill M.; McNair, Lindsay; Arterburn, Sarah] Gilead Sci Inc, Foster City, CA 94404 USA.
[Moonka, Dilip] Henry Ford Hlth Syst, Detroit, MI USA.
[Gane, Edward J.] Auckland City Hosp, Auckland, New Zealand.
NR 0
TC 32
Z9 32
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 213
BP 314A
EP 315A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201213
ER
PT J
AU Hong, J
Yuan, YF
Wang, JP
Liao, Y
Zou, RH
Zhu, CL
Li, BK
Liang, Y
Huang, PZ
Lin, WY
Dai, JL
Chung, RT
AF Hong, Jian
Yuan, Yunfei
Wang, Jianping
Liao, Yadi
Zou, Ruhai
Zhu, Chuanlong
Li, Binkui
Liang, Yi
Huang, Pinzhu
Lin, Wenyu
Dai, Jia Le
Chung, Raymond T.
TI SYK(L) and its splicing variant SYK(S) exert opposing roles in
hepatocellular carcinoma
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Hong, Jian; Yuan, Yunfei; Liao, Yadi; Zou, Ruhai; Li, Binkui; Liang, Yi; Huang, Pinzhu] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
[Hong, Jian; Zhu, Chuanlong; Lin, Wenyu; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
[Wang, Jianping] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Surg, Guangzhou 510275, Guangdong, Peoples R China.
[Dai, Jia Le] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 234
BP 324A
EP 325A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201234
ER
PT J
AU Harwood, NM
Golden-Mason, L
Rosen, HR
Mengshol, JA
AF Harwood, Noah M.
Golden-Mason, Lucy
Rosen, Hugo R.
Mengshol, John A.
TI Macrophage Immunoregulatory Galectin-9 Production is increased by
Contact with Hepatitis C Virus-infected Hepatocytes and Differentiation
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Harwood, Noah M.; Golden-Mason, Lucy; Rosen, Hugo R.; Mengshol, John A.] Univ Colorado SOM, Denver VA Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 235
BP 325A
EP 325A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201235
ER
PT J
AU Lin, WY
Zhu, CL
Hong, J
Zhao, L
Xu, QK
Chusri, P
Jilg, N
Fusco, DN
Schaefer, EA
Brisac, C
Peng, LF
Chung, RT
AF Lin, Wenyu
Zhu, Chuanlong
Hong, Jian
Zhao, Lei
Xu, Qikai
Chusri, Pattranuch
Jilg, Nikolaus
Fusco, Dahlene N.
Schaefer, Esperance A.
Brisac, Cynthia
Peng, Lee F.
Chung, Raymond T.
TI The anti-HCV gene SART1 regulates IFN stimulated genes through
nonclassical mechanisms
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Lin, Wenyu; Zhu, Chuanlong; Hong, Jian; Zhao, Lei; Chusri, Pattranuch; Jilg, Nikolaus; Fusco, Dahlene N.; Schaefer, Esperance A.; Brisac, Cynthia; Peng, Lee F.; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
[Xu, Qikai] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Genet, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 240
BP 327A
EP 328A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201240
ER
PT J
AU Koch, DG
Battenhouse, H
Durkalski, V
Lee, WM
Liou, IW
Fix, OK
Ganger, D
Fontana, RJ
Schilsky, ML
McGuire, BM
Chung, RT
Reddy, R
Stravitz, RT
Han, SHB
AF Koch, David G.
Battenhouse, Holly
Durkalski, Valerie
Lee, William M.
Liou, Iris W.
Fix, Oren K.
Ganger, Daniel
Fontana, Robert J.
Schilsky, Michael L.
McGuire, Brendan M.
Chung, Raymond T.
Reddy, Rajender
Stravitz, R. Todd
Han, Steven-Huy B.
TI The Natural History of Severe Acute Liver Injury (ALI)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Koch, David G.] Med Univ S Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA.
[Battenhouse, Holly; Durkalski, Valerie] Med Univ S Carolina, Charleston, SC 29425 USA.
[Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA.
[Liou, Iris W.] Univ Washington, Seattle, WA 98195 USA.
[Fix, Oren K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ganger, Daniel] Northwestern Univ, Sch Med, Chicago, IL USA.
[Fontana, Robert J.] Univ Michigan, Med Ctr, New Haven, CT USA.
[Schilsky, Michael L.] Yale Univ, Sch Med, New Haven, CT USA.
[McGuire, Brendan M.] Univ Alabama Birmingham, Birmingham, AL USA.
[Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Reddy, Rajender] Univ Penn, Philadelphia, PA 19104 USA.
[Stravitz, R. Todd] Virginia Commonwealth Univ, Richmond, VA USA.
[Han, Steven-Huy B.] Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 307
BP 358A
EP 359A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201307
ER
PT J
AU Alvarez, NN
Machaidze, Z
Schuetz, C
Ndishabandi, D
Alessandrini, A
Sachs, D
Buhler, LH
Markmann, J
Yeh, H
AF Alvarez, Nalu Navarro
Machaidze, Zurab
Schuetz, Christian
Ndishabandi, Dorothy
Alessandrini, Alessandro
Sachs, David
Buhler, Leo H.
Markmann, James
Yeh, Heidi
TI Neutrophilia and High IL-6 Levels are Associated with Impaired Survival
and Liver Regeneration
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Alvarez, Nalu Navarro; Machaidze, Zurab; Schuetz, Christian; Ndishabandi, Dorothy; Alessandrini, Alessandro; Sachs, David; Markmann, James; Yeh, Heidi] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Alvarez, Nalu Navarro; Machaidze, Zurab; Sachs, David] Massachusetts Gen Hosp, TBRC, Boston, MA 02114 USA.
[Buhler, Leo H.] Univ Geneva, Geneva, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 311
BP 361A
EP 361A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201311
ER
PT J
AU Izamis, ML
Keravnou, C
Christofides, D
Averkiou, MA
AF Izamis, Maria-Louisa
Keravnou, Christina
Christofides, Damianos
Averkiou, Michalakis A.
TI Quantification of liver perfusion is a sensitive approach to
non-invasive evaluation of donor liver viability
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Izamis, Maria-Louisa; Keravnou, Christina; Christofides, Damianos; Averkiou, Michalakis A.] Univ Cyprus, Nicosia, Cyprus.
[Izamis, Maria-Louisa] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Averkiou, Michalakis A.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 332
BP 371A
EP 371A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252201332
ER
PT J
AU Chaturantabut, S
Cutting, CC
Goessling, W
North, TE
AF Chaturantabut, Saireudee
Cutting, Claire C.
Goessling, Wolfram
North, Trista E.
TI The novel membrane estrogen receptor GPER positively regulates liver
growth during development
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Chaturantabut, Saireudee] Harvard Univ, MCB, Cambridge, MA 02138 USA.
[Cutting, Claire C.; Goessling, Wolfram] Brigham & Womens Hosp, Boston, MA 02115 USA.
[North, Trista E.] PaBeth Israel Deaconess Med Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 538
BP 465A
EP 465A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202142
ER
PT J
AU Mellinger, J
Pencina, KM
Massaro, JM
Hoffmann, U
Seshadri, S
Fox, CS
O'Donnell, CJ
Speliotes, EK
AF Mellinger, Jessica
Pencina, Karol M.
Massaro, Joseph M.
Hoffmann, Udo
Seshadri, Sudha
Fox, Caroline S.
O'Donnell, Christopher J.
Speliotes, Elizabeth K.
TI Nonalcoholic Fatty Liver Disease Associates with Cardiovascular Disease
Outcomes: The Framingham Heart Study
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Mellinger, Jessica; Speliotes, Elizabeth K.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Pencina, Karol M.] Boston Univ, Stat & Consulting Unit, Boston, MA 02215 USA.
[Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Hoffmann, Udo] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hoffmann, Udo] Harvard Univ, Sch Med, Boston, MA USA.
[Seshadri, Sudha] Boston Univ, Boston, MA 02215 USA.
[Seshadri, Sudha; Fox, Caroline S.; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Fox, Caroline S.; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Framingham, MA USA.
[Speliotes, Elizabeth K.] Univ Michigan Hosp, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 579
BP 484A
EP 485A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202183
ER
PT J
AU Bril, F
Lomonaco, R
Orsak, B
Chang, Z
Ortiz-Lopez, C
Hecht, J
Tio, F
Cusi, K
AF Bril, Fernando
Lomonaco, Romina
Orsak, Beverly
Chang, Zhi
Ortiz-Lopez, Carolina
Hecht, Joan
Tio, Fermin
Cusi, Kenneth
TI Role of plasma FGF21 as a biomarker for nonalcoholic fatty liver disease
(NAFLD) and steatohepatitis (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bril, Fernando; Lomonaco, Romina; Cusi, Kenneth] Univ Florida, Gainesville, FL USA.
[Orsak, Beverly; Chang, Zhi; Ortiz-Lopez, Carolina; Hecht, Joan; Tio, Fermin; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Hecht, Joan; Tio, Fermin] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 3
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 585
BP 487A
EP 487A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202189
ER
PT J
AU Bril, F
Lomonaco, R
Orsak, B
Hecht, J
Ortiz-Lopez, C
Hardies, J
Tio, F
Cusi, K
AF Bril, Fernando
Lomonaco, Romina
Orsak, Beverly
Hecht, Joan
Ortiz-Lopez, Carolina
Hardies, Jean
Tio, Fermin
Cusi, Kenneth
TI Predictors of response after extended pioglitazone treatment in patients
with prediabetes or T2DM and nonalcoholic steatohepatitis (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bril, Fernando; Lomonaco, Romina; Hardies, Jean; Cusi, Kenneth] Univ Florida, Gainesville, FL USA.
[Orsak, Beverly; Hecht, Joan; Ortiz-Lopez, Carolina; Tio, Fermin; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Hecht, Joan; Tio, Fermin] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 639
BP 513A
EP 514A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202243
ER
PT J
AU Khalili, M
Sanyal, AJ
Cloonan, YK
Ghany, MG
Kim, WR
Chung, RT
Terrault, N
Brunt, EM
Lau, D
Lisker-Melman, M
Lok, AS
AF Khalili, Mandana
Sanyal, Arun J.
Cloonan, Yona K.
Ghany, Marc G.
Kim, W. Ray
Chung, Raymond T.
Terrault, Norah
Brunt, Elizabeth M.
Lau, Daryl
Lisker-Melman, Mauricio
Lok, Anna S.
TI Factors associated with diabetes and prediabetes in HBV-infected
patients residing in North America: Results from the Adult Cohort Study
of the NIDDK-Sponsored Hepatitis B Research Network (HBRN)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Khalili, Mandana; Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Sanyal, Arun J.] Virginia Commonwealth Univ, Richmond, VA USA.
[Cloonan, Yona K.] Univ Pittsburgh, Pittsburgh, PA USA.
[Ghany, Marc G.] NIH, Bethesda, MD 20892 USA.
[Kim, W. Ray] Mayo Clin, Bethesda, MD USA.
[Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Brunt, Elizabeth M.; Lisker-Melman, Mauricio] Washington Univ, St Louis, MO USA.
[Lau, Daryl] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Lok, Anna S.] Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 638
BP 513A
EP 513A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202242
ER
PT J
AU Bril, F
Lomonaco, R
Orsak, B
Subbarayan, S
Kadiyala, S
Ortiz-Lopez, C
Webb, A
Cusi, K
AF Bril, Fernando
Lomonaco, Romina
Orsak, Beverly
Subbarayan, Sreevidya
Kadiyala, Sushma
Ortiz-Lopez, Carolina
Webb, Amy
Cusi, Kenneth
TI Is there a link between hypothyroidism and nonalcoholic fatty liver
disease?
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bril, Fernando; Lomonaco, Romina; Subbarayan, Sreevidya; Kadiyala, Sushma; Cusi, Kenneth] Univ Florida, Gainesville, FL USA.
[Orsak, Beverly; Ortiz-Lopez, Carolina; Webb, Amy; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Webb, Amy] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 656
BP 521A
EP 522A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202260
ER
PT J
AU Bril, F
Lomonaco, R
Orsak, B
Ortiz-Lopez, C
Biernacki, D
Klaczak, A
Chang, Z
Hardies, J
Cusi, K
AF Bril, Fernando
Lomonaco, Romina
Orsak, Beverly
Ortiz-Lopez, Carolina
Biernacki, Diane
Klaczak, Ashley
Chang, Zhi
Hardies, Jean
Cusi, Kenneth
TI Vitamin D deficiency and development of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bril, Fernando; Lomonaco, Romina; Biernacki, Diane; Klaczak, Ashley; Cusi, Kenneth] Univ Florida, Gainesville, FL USA.
[Orsak, Beverly; Ortiz-Lopez, Carolina; Chang, Zhi; Hardies, Jean; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Biernacki, Diane] Malcom Randall Vet Adm Med Ctr, Gainesville, FL USA.
[Hardies, Jean] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 657
BP 522A
EP 522A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202261
ER
PT J
AU Bettermann, K
Mehta, AK
Lederer, E
Ernst, C
Kessler, SM
Chen, XT
Hoshida, Y
Bardeesy, N
Fuchs, BC
Tanabe, KK
Muller, H
Svendova, V
Schimek, MG
Mach, M
Speicher, MR
Mahajan, V
Stumptner, C
Thueringer, A
Stojakovic, T
Longerich, T
Schirmacher, P
Magin, TM
Strnad, P
Fuchs, CD
Trauner, M
Spilka, R
Kiemer, AK
Teufel, A
Maass, T
Moriggl, R
Campbell, JS
Thorgeirsson, SS
Stauffer, J
Karin, M
Llovet, JM
Zatloukal, K
Lackner, C
Hayback, J
AF Bettermann, Kira
Mehta, Anita Kuldeep
Lederer, Eva
Ernst, Christina
Kessler, Sonja M.
Chen, Xintong
Hoshida, Yujin
Bardeesy, Nabeel
Fuchs, Bryan C.
Tanabe, Kenneth K.
Mueller, Heimo
Svendova, Vendula
Schimek, Michael G.
Mach, Monika
Speicher, Michael R.
Mahajan, Vineet
Stumptner, Cornelia
Thueringer, Andrea
Stojakovic, Tatjana
Longerich, Thomas
Schirmacher, Peter
Magin, Thomas M.
Strnad, Pavel
Fuchs, Claudia D.
Trauner, Michael
Spilka, Rita
Kiemer, Alexandra K.
Teufel, Andreas
Maass, Thorsten
Moriggl, Richard
Campbell, Jean S.
Thorgeirsson, Snorri S.
Stauffer, Jim
Karin, Michael
Llovet, Josep M.
Zatloukal, Kurt
Lackner, Carolin
Haybaeck, Johannes
TI Steatohepatitits-associated Hepatocellular Carcinoma: Evidence of a
Keratinopathy
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Bettermann, Kira; Mehta, Anita Kuldeep; Lederer, Eva; Ernst, Christina; Kessler, Sonja M.; Mueller, Heimo; Mahajan, Vineet; Stumptner, Cornelia; Thueringer, Andrea; Zatloukal, Kurt; Lackner, Carolin; Haybaeck, Johannes] Med Univ Graz, Inst Pathol, Graz, Austria.
[Kessler, Sonja M.; Kiemer, Alexandra K.] Univ Saarland, Dept Pharm, Saarbrucken, Germany.
[Chen, Xintong; Hoshida, Yujin; Llovet, Josep M.] Icahn Sch Med Mt Sinai, Div Liver Dis, Tisch Canc Inst, Liver Canc Program, New York, NY USA.
[Bardeesy, Nabeel; Fuchs, Bryan C.; Tanabe, Kenneth K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc Res, Boston, MA USA.
[Svendova, Vendula; Schimek, Michael G.] Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria.
[Mach, Monika; Speicher, Michael R.] Med Univ Graz, Inst Human Genet, Graz, Austria.
[Stojakovic, Tatjana] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria.
[Longerich, Thomas; Schirmacher, Peter] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany.
[Magin, Thomas M.] Univ Leipzig, Translat Ctr Regenerat Med Leipzig, D-04109 Leipzig, Germany.
[Strnad, Pavel] Univ Hosp RWTH Aachen, Dept Internal Med 3, Aachen, Germany.
[Fuchs, Claudia D.; Trauner, Michael] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Vienna, Austria.
[Spilka, Rita] Gen Hosp Zams, Pathol Lab, Zams, Austria.
[Teufel, Andreas; Maass, Thorsten] Univ Clin Regensburg, Clin & Polyclin Internal Med 1, Regensburg, Germany.
[Moriggl, Richard] Ludwig Boltzmann Inst Canc Res LBI CR, Vienna, Austria.
[Campbell, Jean S.] Univ Washington, Dept Med Pathol, Seattle, WA 98195 USA.
[Thorgeirsson, Snorri S.] NCI, Lab Expt Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
Univ Cologne, Inst Genet, Cologne, Germany.
[Stauffer, Jim] NCI, Mouse Canc Genet Program, Genet Modifiers Tumorigenesis Sect, Ctr Canc Res, Frederick, MD 21701 USA.
[Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Llovet, Josep M.] Hosp Clin Barcelona, Inst Invest Biomed, CIBERehd,Liver Unit, Hepatocellular Carcinoma Translat Res Lab,Barcelo, Barcelona, Spain.
RI Kiemer, Alexandra/I-9300-2012
OI Kiemer, Alexandra/0000-0002-7224-9900
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 702
BP 543A
EP 543A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202306
ER
PT J
AU Luther, J
Scichilone, J
Garber, J
Khalili, H
Peng, LF
Chevaliez, S
Chung, RT
Patel, SJ
AF Luther, Jay
Scichilone, John
Garber, John
Khalili, Hamed
Peng, Lee F.
Chevaliez, Stephane
Chung, Raymond T.
Patel, Suraj J.
TI Crosstalk between the liver and intestine contributes to NASH
pathogenesis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Luther, Jay; Garber, John; Khalili, Hamed; Peng, Lee F.; Chevaliez, Stephane; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Scichilone, John; Patel, Suraj J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Scichilone, John; Patel, Suraj J.] Shriners Hosp Crippled Children, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 732
BP 556A
EP 556A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202336
ER
PT J
AU Schippers, M
Post, E
Cetintas, A
Reker-Smit, C
Malo, MS
Hodin, RA
Millan, JL
Beljaars, L
Poelstra, K
AF Schippers, Marlies
Post, Eduard
Cetintas, Aysegul
Reker-Smit, Catharina
Malo, Madhu S.
Hodin, Richard A.
Millan, Jose L.
Beljaars, Leonie
Poelstra, Klaas
TI Intrahepatic alkaline phosphatase attenuates LPS-mediated effects during
liver fibrosis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Schippers, Marlies; Post, Eduard; Cetintas, Aysegul; Reker-Smit, Catharina; Beljaars, Leonie; Poelstra, Klaas] Univ Groningen, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands.
[Malo, Madhu S.; Hodin, Richard A.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Millan, Jose L.] Sanford Childrens Hlth Res Ctr, Sanford Burnham Med Res Inst, La Jolla, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 783
BP 579A
EP 579A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252202387
ER
PT J
AU Chang, MF
Dominitz, JA
Ioannou, GN
Forsberg, CW
Boyko, EJ
Sporleder, JL
Smith, NL
AF Chang, Michael F.
Dominitz, Jason A.
Ioannou, George N.
Forsberg, Christopher W.
Boyko, Edward J.
Sporleder, Jennifer L.
Smith, Nicholas L.
TI Elevated prevalence of hepatitis B chronic infection and exposure in
users of United States Veterans Medical Centers
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Chang, Michael F.] OHSU PVAMC, Portland, OR USA.
[Chang, Michael F.] Portland VA Med Ctr, Northwest Hepatitis Resource Ctr C, Portland, OR USA.
[Dominitz, Jason A.; Ioannou, George N.] VA Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.
[Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Sporleder, Jennifer L.] VA Puget Sound Hlth Care Syst, Northwest Hepatitis Resource Ctr C, Seattle, WA USA.
[Forsberg, Christopher W.; Sporleder, Jennifer L.; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Boyko, Edward J.; Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 876
BP 623A
EP 624A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252203044
ER
PT J
AU Hammond, SP
Ho, VT
Ukomadu, C
Baden, LR
Marty, FM
AF Hammond, Sarah P.
Ho, Vincent T.
Ukomadu, Chinweike
Baden, Lindsey R.
Marty, Francisco M.
TI Resolution of Hepatitis B Virus (HBV) Infection is Common after
Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant
(HSCT) Recipients who Develop Reverse Seroconversion
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Hammond, Sarah P.; Baden, Lindsey R.; Marty, Francisco M.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Hammond, Sarah P.; Ho, Vincent T.; Baden, Lindsey R.; Marty, Francisco M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ukomadu, Chinweike] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 882
BP 626A
EP 627A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252203050
ER
PT J
AU Wu, Y
Johnson, KB
Lopez, J
Zheng, H
Roccaro, G
Muiru, A
Ufere, N
Kattan, O
Chung, RT
AF Wu, Ying
Johnson, Kara B.
Lopez, Joanna
Zheng, Hui
Roccaro, Giorgio
Muiru, Anthony
Ufere, Nneka
Kattan, Omar
Chung, Raymond T.
TI Poor Adherence to AASLD Guidelines for Chronic Hepatitis B Management in
a Large Academic Medical Center
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Wu, Ying; Johnson, Kara B.; Lopez, Joanna; Zheng, Hui; Roccaro, Giorgio; Muiru, Anthony; Ufere, Nneka; Kattan, Omar; Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Johnson, Kara B.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 902
BP 636A
EP 636A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252203070
ER
PT J
AU Mangia, A
Kugelmas, M
Everson, GT
Hinestrosa, F
Ma, J
McNally, J
Brainard, DM
Symonds, WT
McHutchison, JG
Gane, EJ
Shafran, SD
Chung, RT
Lawitz, E
AF Mangia, Alessandra
Kugelmas, Marcelo
Everson, Gregory T.
Hinestrosa, Federico
Ma, Julie
McNally, John
Brainard, Diana M.
Symonds, William T.
McHutchison, John G.
Gane, Edward J.
Shafran, Stephen D.
Chung, Raymond T.
Lawitz, Eric
TI Virologic Response Rates to Sofosbuvir-Containing Regimens Are Similar
in Patients With and Without Traditional Negative Predictive Factors: A
Retrospective Analysis of Phase 3 Data
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Mangia, Alessandra] IRCCS Osped Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy.
[Kugelmas, Marcelo] South Denver Gastroenterol, Englewood, CA USA.
[Everson, Gregory T.] Univ Colorado, Aurora, CO USA.
[Hinestrosa, Federico] Orlando Immunol Ctr, Orlando, FL USA.
[Ma, Julie; McNally, John; Brainard, Diana M.; Symonds, William T.; McHutchison, John G.] Gilead Sci Inc, Foster City, CA 94404 USA.
[Gane, Edward J.] Auckland City Hosp, Auckland, New Zealand.
[Shafran, Stephen D.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada.
[Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lawitz, Eric] Texas Liver Inst, San Antonio, TX USA.
NR 0
TC 6
Z9 6
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1115
BP 752A
EP 753A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252203281
ER
PT J
AU Vagefi, PA
Dodge, JL
Feng, S
Roberts, JP
AF Vagefi, Parsia A.
Dodge, Jennifer L.
Feng, Sandy
Roberts, John P.
TI Regional Importer or Exporter? Multiple Listings as Insight into the
Geographic Inequity Facing Liver Transplant Candidates
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Vagefi, Parsia A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Dodge, Jennifer L.; Feng, Sandy; Roberts, John P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1136
BP 764A
EP 764A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252203302
ER
PT J
AU Kohn, R
Kratz, JR
Markmann, J
Vagefi, PA
AF Kohn, Rachel
Kratz, Johannes R.
Markmann, James
Vagefi, Parsia A.
TI The "exported" liver transplant candidate: A reflection of geographic
inequity in liver allocation
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Kohn, Rachel; Kratz, Johannes R.; Markmann, James; Vagefi, Parsia A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1157
BP 774A
EP 775A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252203323
ER
PT J
AU Basu, P
Shah, NJ
Rahman, MA
Siriki, R
Farhat, S
AF Basu, Patrick
Shah, Niraj J.
Rahman, Md A.
Siriki, Ravi
Farhat, Sakina
TI Restless Leg Syndrome (RLS) is associated with Hepatic Encephalopathy
(HE) in decompensated cirrhosis. A clinical pilot study
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Basu, Patrick; Farhat, Sakina] Columbia Univ, Sch Phys & Surg, Forest Hills, NY USA.
[Basu, Patrick; Rahman, Md A.; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1355
BP 867A
EP 867A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204138
ER
PT J
AU Tartaglione, E
Derleth, M
Yu, L
Ioannou, GN
AF Tartaglione, Erica
Derleth, Mark
Yu, Lei
Ioannou, George N.
TI Can computerized brain training games be used to identify early
cognitive impairment in cirrhosis?
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Tartaglione, Erica; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Derleth, Mark; Yu, Lei; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1391
BP 884A
EP 884A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204174
ER
PT J
AU King, LY
Johnson, KB
Zheng, H
Wei, L
Gudewicz, T
Tokunbo, A
Ufere, N
Tanabe, K
Fuchs, BC
Chung, RT
AF King, Lindsay Y.
Johnson, Kara B.
Zheng, Hui
Wei, Lan
Gudewicz, Thomas
Tokunbo, Ajayi
Ufere, Nneka
Tanabe, Kenneth
Fuchs, Bryan C.
Chung, Raymond T.
TI A Polymorphism in the EGF Gene Independently Predicts Hepatic Outcomes
in HCV-Related Cirrhosis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [King, Lindsay Y.; Johnson, Kara B.; Ufere, Nneka; Chung, Raymond T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Johnson, Kara B.] Harvard Univ, Sch Med, Boston, MA USA.
[Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Wei, Lan; Gudewicz, Thomas; Tanabe, Kenneth; Fuchs, Bryan C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tokunbo, Ajayi] Salem Hosp, Salem, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1430
BP 902A
EP 902A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204213
ER
PT J
AU Schaefer, EA
Meixiong, J
Motola, D
Deik, A
Fusco, DN
Lin, C
Jilg, N
Chevaliez, S
Brisac, C
Chusri, P
Lin, WY
Clish, CB
Musunuru, K
Cowan, CA
Chung, RT
Peng, LF
AF Schaefer, Esperance A.
Meixiong, James
Motola, Daniel
Deik, Amy
Fusco, Dahlene N.
Lin, Carol
Jilg, Nikolaus
Chevaliez, Stephane
Brisac, Cynthia
Chusri, Pattranuch
Lin, Wenyu
Clish, Clary B.
Musunuru, Kiran
Cowan, Chad A.
Chung, Raymond T.
Peng, Lee F.
TI Loss of apolipoprotein B100 decreases viral infectivity and depletes
cholesterol from HCV virions
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Schaefer, Esperance A.; Motola, Daniel; Fusco, Dahlene N.; Jilg, Nikolaus; Chevaliez, Stephane; Brisac, Cynthia; Chusri, Pattranuch; Lin, Wenyu; Chung, Raymond T.; Peng, Lee F.] Massachusetts Gen Hosp, Med GI Unit, Boston, MA 02114 USA.
[Deik, Amy; Clish, Clary B.] Broad Inst, Boston, MA USA.
[Musunuru, Kiran; Cowan, Chad A.] Harvard Stem Cell Inst, Boston, MA USA.
[Meixiong, James; Lin, Carol] Harvard Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1487
BP 929A
EP 929A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204270
ER
PT J
AU Chevaliez, S
Brisac, C
Schaefer, EA
Wambua, D
Jilg, N
Luther, J
Chusri, P
Zablocki, L
Lin, WY
Peng, LF
Fusco, DN
Chung, RT
AF Chevaliez, Stephane
Brisac, Cynthia
Schaefer, Esperance A.
Wambua, Daniel
Jilg, Nikolaus
Luther, Jay
Chusri, Pattranuch
Zablocki, Laurent
Lin, Wenyu
Peng, Lee F.
Fusco, Dahlene N.
Chung, Raymond T.
TI Role of the PDIP1 protein in the IFN response during hepatitis C virus
infection: impact of PPAR nuclear receptors
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Chevaliez, Stephane; Brisac, Cynthia; Schaefer, Esperance A.; Wambua, Daniel; Jilg, Nikolaus; Luther, Jay; Chusri, Pattranuch; Zablocki, Laurent; Lin, Wenyu; Peng, Lee F.; Fusco, Dahlene N.; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Chevaliez, Stephane] Univ Hosp Henri Mondor, Creteil, France.
[Chevaliez, Stephane] Univ Hosp Henri Mondor, INSERM U955, Creteil, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1490
BP 930A
EP 930A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204273
ER
PT J
AU Peng, LF
Meixiong, J
Deik, A
Schaefer, EA
Jilg, N
Chusri, P
Brisac, C
Chevaliez, S
Zhu, CL
Luther, J
Wambua, D
Fusco, DN
Lin, WY
Clish, CB
Chung, RT
AF Peng, Lee F.
Meixiong, James
Deik, Amy
Schaefer, Esperance A.
Jilg, Nikolaus
Chusri, Pattranuch
Brisac, Cynthia
Chevaliez, Stephane
Zhu, Chuanlong
Luther, Jay
Wambua, Daniel
Fusco, Dahlene N.
Lin, Wenyu
Clish, Clary B.
Chung, Raymond T.
TI HMG-CoA Reductase Inhibition Alters the Lipidome and Infectious
Properties of HCV Virus Particles
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Peng, Lee F.; Meixiong, James; Schaefer, Esperance A.; Jilg, Nikolaus; Chusri, Pattranuch; Brisac, Cynthia; Chevaliez, Stephane; Zhu, Chuanlong; Luther, Jay; Wambua, Daniel; Fusco, Dahlene N.; Lin, Wenyu; Chung, Raymond T.] Massachusetts Gen Hosp, GI Unit, Boston, MA 02114 USA.
[Deik, Amy; Clish, Clary B.] Broad Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1503
BP 936A
EP 936A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204286
ER
PT J
AU Zator, ZA
Somsouk, M
Zheng, H
King, LY
Lin, WY
Hunt, PW
Deeks, SG
Chung, RT
AF Zator, Zachary A.
Somsouk, Ma
Zheng, Hui
King, Lindsay Y.
Lin, Wenyu
Hunt, Peter W.
Deeks, Steven G.
Chung, Raymond T.
TI HIV infection is associated with elevated markers of hepatocyte
apoptosis: a possible mechanism for accelerated HCV liver disease
progression
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Zator, Zachary A.; Zheng, Hui] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Somsouk, Ma] UCSF, San Francisco, CA USA.
[King, Lindsay Y.; Lin, Wenyu; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Hunt, Peter W.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1529
BP 948A
EP 948A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204312
ER
PT J
AU Jilg, N
Hatoum, IJ
Greenawalt, DM
Lin, WY
Kaplan, LM
Chung, RT
AF Jilg, Nikolaus
Hatoum, Ida J.
Greenawalt, Danielle M.
Lin, Wenyu
Kaplan, Lee M.
Chung, Raymond T.
TI IL28B genotype is not associated with differential gene expression in a
large cohort of patients without known HCV infection
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Jilg, Nikolaus; Hatoum, Ida J.; Lin, Wenyu; Kaplan, Lee M.; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, GI Unit, Boston, MA 02114 USA.
[Hatoum, Ida J.; Kaplan, Lee M.] Massachusetts Gen Hosp, Obes Metab & Nutr Inst, Boston, MA 02114 USA.
[Greenawalt, Danielle M.] Merck Res Labs, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1593
BP 976A
EP 976A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204376
ER
PT J
AU Berry, K
Ioannou, GN
AF Berry, Kristin
Ioannou, George N.
TI The association between transjugular intrahepatic portosystemic shunt
and survival
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1634
BP 996A
EP 996A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252204417
ER
PT J
AU Tarlow, B
Naugler, WE
Orloff, SL
Haft, A
Grompe, M
AF Tarlow, Branden
Naugler, Willscott E.
Orloff, Susan L.
Haft, Annelise
Grompe, Markus
TI Repopulation of mouse liver with human hepatocytes from core biopsies: a
new approach to modeling human liver diseases
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Tarlow, Branden; Naugler, Willscott E.; Haft, Annelise; Grompe, Markus] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1664
BP 1010A
EP 1010A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205014
ER
PT J
AU Watanabe, T
Tokumoto, Y
Hirooka, M
Abe, M
Onji, M
Chung, RT
Hiasa, Y
AF Watanabe, Takao
Tokumoto, Yoshio
Hirooka, Masashi
Abe, Masanori
Onji, Morikazu
Chung, Raymond T.
Hiasa, Yoichi
TI Protein kinase R modulates c-Fos and c-Jun signaling to promote
proliferation of hepatocellular carcinoma with hepatitis C virus
infection
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Watanabe, Takao; Tokumoto, Yoshio; Hirooka, Masashi; Abe, Masanori; Onji, Morikazu; Hiasa, Yoichi] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon, Japan.
[Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Chung, Raymond T.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1822
BP 1082A
EP 1082A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205172
ER
PT J
AU Chen, YC
Huang, YH
Reiberger, T
Huang, PG
Lauwers, GY
Zhu, AX
Jain, RK
Duda, DG
AF Chen, Yunching
Huang, Yuhui
Reiberger, Thomas
Huang, Peigen
Lauwers, Gregory Y.
Zhu, Andrew X.
Jain, Rakesh K.
Duda, Dan G.
TI Differential effects of sorafenib on liver and hepatocellular carcinoma
fibrosis mediated by SDF1 alpha/CXCR4 axis and Gr-1+myeloid cell
infiltration
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Chen, Yunching; Huang, Yuhui; Reiberger, Thomas; Huang, Peigen; Jain, Rakesh K.; Duda, Dan G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab Tumor Biol, Boston, MA 02114 USA.
[Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Zhu, Andrew X.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1839
BP 1089A
EP 1090A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205189
ER
PT J
AU Basu, P
Shah, NJ
Siriki, R
Rahman, MA
Farhat, S
AF Basu, Patrick
Shah, Niraj J.
Siriki, Ravi
Rahman, Md A.
Farhat, Sakina
TI Romiplostim's Effect to Optimize SVR with Telaprevir, Ribavirin, And Peg
Interferon-alfa 2a in Thrombocytopenic Cirrhotics with Chronic Hepatitis
C. A Placebo Controlled Prospective Clinical Trial: RESTRAINT C Trial
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Basu, Patrick; Farhat, Sakina] Columbia Univ Sch Phys & Surg, New York, NY USA.
[Basu, Patrick; Siriki, Ravi; Rahman, Md A.] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj J.] Mt Sinai, Icahn Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1886
BP 1117A
EP 1117A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205236
ER
PT J
AU Saxena, V
Yee, HS
Catalli, L
Wayne, EM
Chua, J
Monto, A
Terrault, N
AF Saxena, Varun
Yee, Helen S.
Catalli, Lisa
Wayne, Elizabeth M.
Chua, Joshua
Monto, Alexander
Terrault, Norah
TI Protease-Inhibitor (PI) Triple Therapy (TT) in Mildly Decompensated
Cirrhotics: Predictors of Treatment Discontinuation, Worsening
Decompensation and Sustained Virologic Response
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Saxena, Varun; Yee, Helen S.; Catalli, Lisa; Wayne, Elizabeth M.; Monto, Alexander; Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yee, Helen S.; Chua, Joshua; Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 1969
BP 1161A
EP 1161A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205319
ER
PT J
AU Jang, JY
Kim, SJ
Cho, EK
Jeong, SW
Lee, YN
Lee, SH
Kim, SG
Cha, SW
Kim, YS
Cho, YD
Kim, HS
Kim, BS
Lin, WY
Chung, RT
AF Jang, Jae Young
Kim, Seong-Jun
Cho, Eun Kyung
Jeong, Soung Won
Lee, Yun Nah
Lee, Sae Hwan
Kim, Sang Gyune
Cha, Sang-Woo
Kim, Young Seok
Cho, Young Deok
Kim, Hong Soo
Kim, Boo Sung
Lin, Wenyu
Chung, Raymond T.
TI Hepatitis C virus infection elevates TRAIL-DR4/DR5-induced apoptosis via
caspase-8 activation
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Jang, Jae Young; Cho, Eun Kyung; Jeong, Soung Won; Cha, Sang-Woo; Cho, Young Deok; Kim, Boo Sung] Soonchunhyang Univ, Inst Digest Res, Ctr Digest Dis, Dept Internal Med,Coll Med, Seoul, South Korea.
[Lee, Sae Hwan; Kim, Hong Soo] Soonchunhyang Univ, Dept Internal Med, Coll Med, Cheonan, South Korea.
[Lee, Yun Nah; Kim, Sang Gyune; Kim, Young Seok] Soonchunhyang Univ, Dept Internal Med, Coll Med, Puchon, South Korea.
[Kim, Seong-Jun] Univ Calif San Diego, Dept Med, Div Infect Dis, San Diego, CA 92103 USA.
[Lin, Wenyu; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2008
BP 1180A
EP 1180A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205358
ER
PT J
AU Ojiro, K
Kikuchi, M
Park, JJ
Bunchorntavakul, C
Jones, LM
Valiga, ME
Kaplan, DE
Nunes, F
Reddy, R
Chang, KM
AF Ojiro, Keisuke
Kikuchi, Masahiro
Park, Jang-June
Bunchorntavakul, Chalermrat
Jones, Lisa M.
Valiga, Mary E.
Kaplan, David E.
Nunes, Frederick
Reddy, Rajender
Chang, Kyong-Mi
TI IL28B genotype defines differential immune costimulatory receptor
expression in acute hepatitis C
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Ojiro, Keisuke; Kikuchi, Masahiro; Park, Jang-June; Bunchorntavakul, Chalermrat; Jones, Lisa M.; Valiga, Mary E.; Kaplan, David E.; Nunes, Frederick; Reddy, Rajender; Chang, Kyong-Mi] Univ Penn, Philadelphia, PA 19104 USA.
[Ojiro, Keisuke; Kikuchi, Masahiro; Park, Jang-June; Valiga, Mary E.; Kaplan, David E.; Chang, Kyong-Mi] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2024
BP 1187A
EP 1187A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205374
ER
PT J
AU Beste, LA
Ioannou, GN
Yang, Y
Chang, MF
Ross, D
Dominitz, JA
AF Beste, Lauren A.
Ioannou, George N.
Yang, Yin
Chang, Michael F.
Ross, David
Dominitz, Jason A.
TI Improvement in use of hepatocellular carcinoma surveillance by a
primary-care oriented computerized clinical reminder
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Primary Care, Seattle, WA USA.
[Beste, Lauren A.; Ioannou, George N.; Dominitz, Jason A.] Univ Washington, Seattle, WA 98195 USA.
[Ioannou, George N.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol, Seattle, WA USA.
[Chang, Michael F.] Portland VA Med Ctr, Hepatol, Portland, OR USA.
[Ross, David] VA Cent Off, HIV Hepatitis C & Publ Hlth Pathogens Program, Washington, DC USA.
[Chang, Michael F.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Yang, Yin] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2037
BP 1193A
EP 1193A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205387
ER
PT J
AU Johnson, KB
Campbell, EJ
Chi, H
Zheng, H
King, LY
Wu, Y
deLemos, A
Hurairah, A
Corey, KE
Richter, JM
Chung, RT
AF Johnson, Kara B.
Campbell, Emily J.
Chi, Heng
Zheng, Hui
King, Lindsay Y.
Wu, Ying
deLemos, Andrew
Hurairah, Abu
Corey, Kathleen E.
Richter, James M.
Chung, Raymond T.
TI Diuretic Use is the Most Important Factor that Predicts Hospital
Admissions in an Ambulatory Cirrhosis Cohort
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Johnson, Kara B.] Harvard Univ, Sch Med, Boston, MA USA.
[Johnson, Kara B.; Campbell, Emily J.; King, Lindsay Y.; Wu, Ying; deLemos, Andrew; Corey, Kathleen E.; Richter, James M.; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Div Gastroenterol, Boston, MA 02114 USA.
[Chi, Heng] Erasmus MC Med Ctr Rotterdam, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
[Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Hurairah, Abu] Mt Auburn Hosp, Dept Med, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2038
BP 1193A
EP 1194A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252205388
ER
PT J
AU Beste, LA
Harp, BK
Blais, RK
Zickmund, S
AF Beste, Lauren A.
Harp, Bonnie K.
Blais, Rebecca K.
Zickmund, Susan
TI "They Gotta Want to Live More Than They Want to Die": Primary Care
Attitudes and Beliefs about Cirrhosis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Primary Care, Seattle, WA USA.
[Harp, Bonnie K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Blais, Rebecca K.] VA Puget Sound Hlth Care Syst, Mental Hlth, Seattle, WA USA.
[Beste, Lauren A.] Univ Washington, Seattle, WA 98195 USA.
[Zickmund, Susan] VA Pittsburgh Hlth Care Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA.
[Zickmund, Susan] Univ Pittsburgh, Dept Med & Clin & Translat Sci, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2061
BP 1204A
EP 1205A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206013
ER
PT J
AU King, LY
Khalili, H
Huang, E
Chung, RT
Chan, AT
AF King, Lindsay Y.
Khalili, Hamed
Huang, Edward
Chung, Raymond T.
Chan, Andrew T.
TI Statins Are Associated With a Reduced Risk of Liver Cancer: Data from a
Large US Prospective Cohort Study
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [King, Lindsay Y.; Khalili, Hamed; Chung, Raymond T.; Chan, Andrew T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chan, Andrew T.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Huang, Edward] Good Samaritan Hosp, San Jose, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2085
BP 1216A
EP 1217A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206037
ER
PT J
AU Fox, RK
Marcus, S
Merchante, N
Kikuchi, L
Minguez, B
Vispo, E
Harris, M
Badshah, MB
Jain, MK
Page, EE
Kaplan, DE
Nelson, M
Barrero, P
Pineda, JA
Brau, N
AF Fox, Rena K.
Marcus, Sonja
Merchante, Nicolas
Kikuchi, Luciana
Minguez, Beatriz
Vispo, Eugenia
Harris, Marianne
Badshah, Maaz B.
Jain, Mamta K.
Page, Emma E.
Kaplan, David E.
Nelson, Mark
Barrero, Pablo
Pineda, Juan A.
Brau, Norbert
TI Impact of Screening on Staging and Survival of Hepatocellular Carcinoma
(HCC) in HIV/HCV-Coinfected Patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Fox, Rena K.] Univ Calif San Francicso, San Francisco, CA USA.
[Marcus, Sonja; Badshah, Maaz B.; Brau, Norbert] Bronx VA Med Ctr, Bronx, NY USA.
[Merchante, Nicolas; Pineda, Juan A.] Hosp Univ Valme, Seville, Spain.
[Kikuchi, Luciana] Univ Sao Paulo, Sao Paulo, Brazil.
[Minguez, Beatriz] Hosp Univ Vall dHebron, Barcelona, Spain.
[Vispo, Eugenia; Barrero, Pablo] Hosp Carlos III, Madrid, Spain.
[Harris, Marianne] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada.
[Harris, Marianne] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Jain, Mamta K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Page, Emma E.; Nelson, Mark] Chelsea & Westminster Hosp, London, England.
[Page, Emma E.; Nelson, Mark] Univ London Imperial Coll Sci Technol & Med, London, England.
[Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, David E.] Univ Penn, Philadelphia, PA 19104 USA.
[Brau, Norbert] Mt Sinai Sch Med, New York, NY USA.
RI Minguez, Beatriz/N-4456-2014
OI Minguez, Beatriz/0000-0002-7276-9666
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2125
BP 1236A
EP 1236A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206077
ER
PT J
AU Marks, KM
Page, EE
Merchante, N
Kikuchi, LO
Minguez, B
Vispo, E
Harris, M
Badshah, MB
Jain, MK
Marcus, S
Kaplan, DE
Nelson, M
Barrero, P
Pineda, JA
Brau, N
AF Marks, Kristen M.
Page, Emma E.
Merchante, Nicolas
Kikuchi, Luciana O.
Minguez, Beatriz
Vispo, Eugenia
Harris, Marianne
Badshah, Maaz B.
Jain, Mamta K.
Marcus, Sonja
Kaplan, David E.
Nelson, Mark
Barrero, Pablo
Pineda, Juan A.
Brau, Norbert
TI Trends of Hepatocellular Carcinoma (HCC) in HIV-Infected Patients over
Time, 1995-2013
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Marks, Kristen M.] Weill Cornell Coll Med, New York, NY USA.
[Badshah, Maaz B.; Marcus, Sonja; Brau, Norbert] Bronx VA Med Ctr, Bronx, NY USA.
[Merchante, Nicolas; Pineda, Juan A.] Hosp Univ Valme, Seville, Spain.
[Harris, Marianne] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada.
[Harris, Marianne] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Kikuchi, Luciana O.] Univ Sao Paulo, Sao Paulo, Brazil.
[Minguez, Beatriz] Hosp Univ Vall dHebron, Barcelona, Spain.
[Vispo, Eugenia; Barrero, Pablo] Hosp Carlos III, Madrid, Spain.
[Jain, Mamta K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Nelson, Mark] Chelsea & Westminster Hosp, London, England.
[Nelson, Mark] Univ London Imperial Coll Sci Technol & Med, London, England.
[Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, David E.] Univ Penn, Philadelphia, PA 19104 USA.
[Brau, Norbert] Mt Sinai Sch Med, New York, NY USA.
RI Minguez, Beatriz/N-4456-2014
OI Minguez, Beatriz/0000-0002-7276-9666
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2151
BP 1249A
EP 1249A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206103
ER
PT J
AU Ioannou, GN
Bryson, C
Weiss, NS
Boyko, EJ
AF Ioannou, George N.
Bryson, Christopher
Weiss, Noel S.
Boyko, Edward J.
TI Antiretroviral medications, lipodystrophy and cirrhosis in HIV-infected
patients
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Ioannou, George N.; Bryson, Christopher; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Ioannou, George N.; Bryson, Christopher; Weiss, Noel S.; Boyko, Edward J.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2216
BP 1279A
EP 1280A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206168
ER
PT J
AU Yu, L
Morishima, C
Ioannou, GN
AF Yu, Lei
Morishima, Chihiro
Ioannou, George N.
TI Dietary cholesterol intake is associated with death and liver
transplantation in chronic hepatitis C virus infection: Analysis of
extended follow-up data from the HALT-C trial
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Yu, Lei; Morishima, Chihiro; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
[Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2219
BP 1281A
EP 1281A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206171
ER
PT J
AU Dieperink, E
Fuller, B
Ho, SB
Thuras, P
McMaken, K
Shira, K
Lenox, R
Wasil, MM
Isenhart, C
Morgan, TR
Hauser, P
AF Dieperink, Eric
Fuller, Bret
Ho, Samuel B.
Thuras, Paul
McMaken, Kelly
Shira, Kern
Lenox, Rebecca
Wasil, Michelene M.
Isenhart, Carl
Morgan, Timothy R.
Hauser, Peter
TI Association of self-reported change in alcohol use behavior with changes
in percent carbohydrate deficient transferring (%CDT), ethyl glucuronide
(EtG) and ethyl sulfate (EtS) levels in Veterans with Hepatitis C
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Ho, Samuel B.; Wasil, Michelene M.] VA San Diego Healthcare Syst, San Diego, CA USA.
[Fuller, Bret; Lenox, Rebecca] Portland VA Med Ctr, Portland, OR USA.
[Dieperink, Eric; Thuras, Paul; McMaken, Kelly; Isenhart, Carl] Minneapolis VA Med Ctr, Minneapolis, MN USA.
[Shira, Kern; Morgan, Timothy R.; Hauser, Peter] Long Beach VA Med Ctr, Long Beach, CA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2229
BP 1286A
EP 1286A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206181
ER
PT J
AU Onofrey, S
Aneja, J
Haney, GA
Nagami, EH
DeMaria, A
Bowen, MJ
Cocoros, N
McGovern, BH
Church, DR
Kim, AY
AF Onofrey, Shauna
Aneja, Jasneet
Haney, Gillian A.
Nagami, Ellen H.
DeMaria, Alfred
Bowen, Melinda J.
Cocoros, Noelle
McGovern, Barbara H.
Church, Daniel R.
Kim, Arthur Y.
TI Acute HCV in Massachusetts: Evidence of Systematic Underreporting to CDC
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 64th Annual Meeting and Postgraduate Course of the
American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2013
CL Washington, DC
SP Amer Assoc Study Liver Dis
C1 [Onofrey, Shauna; Haney, Gillian A.; DeMaria, Alfred; Cocoros, Noelle; Church, Daniel R.] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA.
[Aneja, Jasneet; Kim, Arthur Y.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Kim, Arthur Y.] Harvard Univ, Sch Med, Boston, MA USA.
[Nagami, Ellen H.; DeMaria, Alfred] Harvard Ctr AIDS Res, Boston, MA USA.
[Nagami, Ellen H.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Bowen, Melinda J.] Univ Massachusetts Correct Healthcare, Worcester, MA USA.
[McGovern, Barbara H.] Tufts Med Sch, Boston, MA USA.
[McGovern, Barbara H.] Abbvie Pharmaceut, N Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2013
VL 58
SU 1
SI SI
MA 2270
BP 1306A
EP 1306A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 297JR
UT WOS:000330252206222
ER
PT J
AU Nambudiri, VE
Bigby, ME
AF Nambudiri, Vinod E.
Bigby, Michael E.
TI Risk of Malignant Disease and Biologic Response Modifiers Fact, Fiction,
and Future Concerns
SO JAMA DERMATOLOGY
LA English
DT Editorial Material
ID TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; CANCER
C1 [Nambudiri, Vinod E.; Bigby, Michael E.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Nambudiri, Vinod E.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Bigby, Michael E.] Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02215 USA.
RP Nambudiri, VE (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 55 Fruit St,Bartlett Hall,Sixth Floor, Boston, MA 02114 USA.
EM vnambudiri@partners.org
NR 7
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD OCT
PY 2013
VL 149
IS 10
BP 1221
EP 1223
DI 10.1001/jamadermatol.2013.5738
PG 3
WC Dermatology
SC Dermatology
GA AA3DT
UT WOS:000330973800023
PM 23986262
ER
PT J
AU Chapman, LW
Hsiao, JL
Sarantopoulos, P
Chiu, MW
AF Chapman, Lance W.
Hsiao, Jennifer L.
Sarantopoulos, Peter
Chiu, Melvin W.
TI Reddish-Brown Nodules and Papules in an Elderly Man Progressive nodular
histiocytosis
SO JAMA DERMATOLOGY
LA English
DT Editorial Material
C1 [Chapman, Lance W.; Hsiao, Jennifer L.; Chiu, Melvin W.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA.
[Sarantopoulos, Peter] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Chiu, Melvin W.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA.
RP Chiu, MW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, 200 UCLA Med Plaza,Ste 450, Los Angeles, CA 90095 USA.
EM mchiu@mednet.ucla.edu
NR 9
TC 0
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD OCT
PY 2013
VL 149
IS 10
BP 1229
EP 1230
DI 10.1001/jamadermatol.2013.4040
PG 2
WC Dermatology
SC Dermatology
GA AA3DT
UT WOS:000330973800025
PM 23945611
ER
PT J
AU Munier, S
Rolland, T
Diot, C
Jacob, Y
Naffakh, N
AF Munier, Sandie
Rolland, Thomas
Diot, Cedric
Jacob, Yves
Naffakh, Nadia
TI Exploration of Binary Virus-Host Interactions Using an Infectious
Protein Complementation Assay
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID INFLUENZA-A VIRUS; POLYMERASE COMPLEX; NUCLEAR IMPORT; MESSENGER-RNAS;
NEUTRALIZING ANTIBODIES; LIFE-CYCLE; REPLICATION; SUBUNIT; H1N1; PB2
AB A precise mapping of pathogen-host interactions is essential for comprehensive understanding of the processes of infection and pathogenesis. The most frequently used techniques for interactomics are the yeast two-hybrid binary methodologies, which do not recapitulate the pathogen life cycle, and the tandem affinity purification mass spectrometry co-complex methodologies, which cannot distinguish direct from indirect interactions. New technologies are thus needed to improve the mapping of pathogen-host interactions. In the current study, we detected binary interactions between influenza A virus polymerase and host proteins during the course of an actual viral infection, using a new strategy based on trans-complementation of the Gluc1 and Gluc2 fragments of Gaussia princeps luciferase. Infectious recombinant influenza viruses that encode a Gluc1-tagged polymerase subunit were engineered to infect cultured cells transiently expressing a selected set of Gluc2-tagged cellular proteins involved in nucleocytoplasmic trafficking pathways. A random set and a literature-curated set of Gluc2-tagged cellular proteins were tested in parallel. Our assay allowed the sensitive and accurate recovery of previously described interactions, and it revealed 30% of positive, novel viral-host protein-protein interactions within the exploratory set. In addition to cellular proteins involved in the nuclear import pathway, components of the nuclear pore complex such as NUP62 and mRNA export factors such as NXF1, RMB15B, and DDX19B were identified for the first time as interactors of the viral polymerase. Gene silencing experiments further showed that NUP62 is required for efficient viral replication. Our findings give new insights regarding the subversion of host nucleocytoplasmic trafficking pathways by influenza A viruses. They also demonstrate the potential of our infectious protein complementation assay for high-throughput exploration of influenza virus interactomics in infected cells. With more infectious reverse genetics systems becoming available, this strategy should be widely applicable to numerous pathogens.
C1 [Munier, Sandie; Diot, Cedric; Jacob, Yves; Naffakh, Nadia] Inst Pasteur, Unite Genet Mol Virus ARN, Dept Virol, F-75015 Paris, France.
[Munier, Sandie; Diot, Cedric; Jacob, Yves; Naffakh, Nadia] CNRS, UMR3569, F-75015 Paris, France.
[Munier, Sandie; Diot, Cedric; Jacob, Yves; Naffakh, Nadia] Univ Paris Diderot, Sorbonne Paris Cite, Unite Genet Mol Virus ARN, EA302, F-75015 Paris, France.
[Rolland, Thomas; Jacob, Yves] Dana Farber Canc Inst, CCSB, Boston, MA 02215 USA.
[Rolland, Thomas; Jacob, Yves] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Rolland, Thomas; Jacob, Yves] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Naffakh, N (reprint author), Inst Pasteur, Unite Genet Mol Virus ARN, Dept Virol, F-75015 Paris, France.
EM yves_jacob@DFCI.HARVARD.edu; nadia.naffakh@pasteur.fr
RI Munier, Sandie/F-6826-2016;
OI Munier, Sandie/0000-0001-7819-128X; Naffakh, Nadia/0000-0002-0424-0277
FU Institut Pasteur (DARRI) [2010-790294]; European Commission [259751,
278433]; National Human Genome Research Institute [U01-HG001715,
R01-HG006061]
FX This work was funded by the Institut Pasteur (DARRI Project 2010-790294)
and by the European Commission funded FP7 projects FLUPHARM (Grant
Agreement No. 259751) and PREDEMICS (Grant Agreement No. 278433). Thomas
Rolland was supported by Grant Nos. U01-HG001715 and R01-HG006061 from
the National Human Genome Research Institute.
NR 54
TC 16
Z9 16
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD OCT
PY 2013
VL 12
IS 10
BP 2845
EP 2855
DI 10.1074/mcp.M113.028688
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 301MS
UT WOS:000330537000014
PM 23816991
ER
PT J
AU Heuer, HW
Mirsky, JB
Kong, EL
Dickerson, BC
Miller, BL
Kramer, JH
Boxer, AL
AF Heuer, Hilary W.
Mirsky, Jacob B.
Kong, Erwin L.
Dickerson, Bradford C.
Miller, Bruce L.
Kramer, Joel H.
Boxer, Adam L.
TI Antisaccade task reflects cortical involvement in mild cognitive
impairment
SO NEUROLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; EYE-MOVEMENTS; DEMENTIA;
SCHIZOPHRENIA; INDIVIDUALS; DEGENERATION; PERFORMANCE; COMMUNITY;
DECLINE
AB Objective: The aims of this study were to examine executive dysfunction using an antisaccade (AS) task in normal elderly (NE) and patients with mild cognitive impairment (MCI) and Alzheimer disease (AD) as well as to evaluate the relationship between AS performance and cortical thinning within AD-associated regions.
Methods: We recorded eye movements in 182 subjects (NE: 118; MCI: 36; AD: 28) during an AS task. We also performed neuropsychological measures of executive function for comparison. Brain MRI scans were collected on most subjects, and cortical thickness was determined in 9 regions known to exhibit atrophy in AD dementia ("AD signature"). We investigated the relationships between AS and neuropsychological performance, as well as possible correlations between AS performance and cortical thickness.
Results: AS performance in MCI resembled that in NE; subjects with AD were impaired relative to both MCI and NE. In all subjects, AS performance correlated with neuropsychological measures of executive function, even after controlling for disease severity. In the subjects with MCI but not in NE, cortical thickness in frontoparietal AD signature regions correlated with AS performance.
Conclusions: The AS task is a useful measure of executive function across the AD spectrum. In MCI, AS performance may reflect disease burden within cortical brain regions involved in oculomotor control; however, AS impairments in NE may have etiologies other than incipient AD.
C1 [Heuer, Hilary W.; Mirsky, Jacob B.; Kong, Erwin L.; Miller, Bruce L.; Kramer, Joel H.; Boxer, Adam L.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Frontotemporal Disorders Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Heuer, HW (reprint author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA.
EM hheuer@memory.ucsf.edu
FU NIH [R01AG031278, R01AG038791, R01AG032289]; Hellman Family Foundation;
John Douglas French Foundation; Silicon Valley Foundation; Tau Research
Consortium; Larry L. Hillblom Foundation; NIH National Institute on
Aging [P01AG019724, P50AG023501]
FX Supported in part by NIH grants R01AG031278 and R01AG038791 to Dr.
Boxer, as well as the Hellman Family Foundation, the John Douglas French
Foundation, the Silicon Valley Foundation, and the Tau Research
Consortium. Dr. Kramer was supported by NIH grant R01AG032289 and the
Larry L. Hillblom Foundation. Dr. Dickerson's contribution was supported
in part by AGP50-AG005134 and the Alzheimer's Association. The project
described was supported by grant numbers P01AG019724 and P50AG023501
from NIH National Institute on Aging. The contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the National Institute on Aging or the NIH.
NR 31
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 1
PY 2013
VL 81
IS 14
BP 1235
EP 1243
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA AA0EN
UT WOS:000330768200013
PM 23986300
ER
PT J
AU Quesnel, AM
Moonis, G
Appel, J
O'Malley, JT
Curtin, HD
McKenna, MJ
AF Quesnel, Alicia Marie
Moonis, Gul
Appel, Jason
O'Malley, Jennifer T.
Curtin, Hugh D.
McKenna, Michael J.
TI IN RESPONSE TO LETTER TO THE EDITOR: "CORRELATION OF COMPUTED TOMOGRAPHY
WITH HISTOPATHOLOGY IN OTOSLCEROSIS", QUESNEL ET AL. OTOL NEUROTOL 2013;
34(1):22-8
SO OTOLOGY & NEUROTOLOGY
LA English
DT Letter
ID SPIRAL LIGAMENT; OTOSCLEROSIS
C1 [Quesnel, Alicia Marie; O'Malley, Jennifer T.; McKenna, Michael J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Quesnel, Alicia Marie; O'Malley, Jennifer T.; McKenna, Michael J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Moonis, Gul; Appel, Jason; Curtin, Hugh D.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
[Moonis, Gul] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
RP Quesnel, AM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1531-7129
EI 1537-4505
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD OCT
PY 2013
VL 34
IS 8
BP 1546
EP 1547
PG 3
WC Clinical Neurology; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 301HO
UT WOS:000330523600037
PM 24026031
ER
PT J
AU Basu, S
Andrews, J
AF Basu, Sanjay
Andrews, Jason
TI Complexity in Mathematical Models of Public Health Policies: A Guide for
Consumers of Models
SO PLOS MEDICINE
LA English
DT Review
ID TRANSMISSION MODEL; CHOLERA EPIDEMIC; HIV PREVENTION; INFECTION; HAITI;
COMPUTATION; INFERENCE; SELECTION; DYNAMICS; STRATEGY
C1 [Basu, Sanjay] Stanford Univ, Prevent Res Ctr, Stanford, CA 94305 USA.
[Basu, Sanjay] Stanford Univ, Ctr Hlth Policy Primary Care & Outcomes Res, Stanford, CA 94305 USA.
[Basu, Sanjay] Stanford Univ, Ctr Poverty & Inequal, Stanford, CA 94305 USA.
[Basu, Sanjay] London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1, England.
[Andrews, Jason] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Andrews, Jason] Harvard Univ, Sch Med, Boston, MA USA.
RP Basu, S (reprint author), Stanford Univ, Prevent Res Ctr, Stanford, CA 94305 USA.
EM basus@stanford.edu
RI Barley, Kamal/F-9579-2011;
OI Barley, Kamal/0000-0003-1874-9813; Andrews, Jason/0000-0002-5967-251X
NR 29
TC 19
Z9 19
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD OCT
PY 2013
VL 10
IS 10
AR e1001540
DI 10.1371/journal.pmed.1001540
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 299BU
UT WOS:000330370600020
PM 24204214
ER
PT J
AU Matthews, LT
Kaida, A
Kanters, S
Byakwagamd, H
Mocello, AR
Muzoora, C
Kembabazi, A
Haberer, JE
Martin, JN
Bangsberg, DR
Hunt, PW
AF Matthews, Lynn T.
Kaida, Angela
Kanters, Steven
Byakwagamd, Helen
Mocello, A. Rain
Muzoora, Conrad
Kembabazi, Annet
Haberer, Jessica E.
Martin, Jeffrey N.
Bangsberg, David R.
Hunt, Peter W.
TI HIV-infected women on antiretroviral treatment have increased mortality
during pregnant and postpartum periods
SO AIDS
LA English
DT Article
DE Africa; antiretroviral therapy; HIV; immune reconstitution; maternal
health; maternal mortality; mortality; postpartum; pregnancy; women
ID MATERNAL MORTALITY; SOUTH-AFRICA; REPRODUCTIVE INTENTIONS; POSITIVE
WOMEN; FOLLOW-UP; THERAPY; UGANDA; CHILD; PREVENTION; ZIMBABWE
AB Objective: To assess the impact of pregnancy on mortality among HIV-infected Ugandan women initiating ART.
Design: Prospective cohort study.
Methods: HIV-infected women initiating ART in the Uganda AIDS Rural Treatment Outcomes study were assessed quarterly for self-reported pregnancy. The association between pregnancy and postpartum ('pregnancy-related') follow-up periods and mortality was assessed with Cox proportional hazards models adjusted for age, CD4 cell count, plasma HIV-1 RNA levels, and ART duration.
Results: Three hundred and fifty-four women with median age 33 years (IQR: 27-37) and CD4 142 cells/ml (IQR: 82-213) were followed for a median of 4.0 years (IQR: 2.5-4.8) after ART initiation, with 3 and 7% loss-to-follow-up at years 1 and 5. One hundred and nine women experienced pregnancy. Five deaths occurred during pregnancy-related follow-up and 16 during nonpregnancy-related follow-up, for crude mortality rates during the first year after ART initiation of 12.57/100 PYs and 3.53/100 PYs (rate ratio 3.56, 95% CI: 0.97-11.07). In adjusted models, the impact of pregnancy-related follow-up on mortality was highest at ART initiation (aHR: 21.48, 95% CI: 3.73-123.51), decreasing to 13.44 (95% CI 3.28-55.11) after 4 months, 8.28 (95% CI 2.38-28.88) after 8 months, 5.18 (95% CI: 1.36-19.71) after 1 year, and 1.25 (95% CI: 0.10-15.58) after 2 years on ART. Four of five maternal deaths occurred postpartum.
Conclusion: Pregnancy and the postpartum period were associated with increased mortality in HIV-infected women initiating ART, particularly during early ART. Contraception proximate to ART initiation, earlier ART initiation, and careful monitoring during the postpartum period may reduce maternal mortality in this setting. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Matthews, Lynn T.; Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Div Infect Dis, Boston, MA 02114 USA.
[Matthews, Lynn T.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
[Kaida, Angela] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.
[Byakwagamd, Helen; Mocello, A. Rain; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kanters, Steven] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada.
[Byakwagamd, Helen; Muzoora, Conrad; Kembabazi, Annet; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Haberer, Jessica E.] Massachusetts Gen Hosp, Ctr Global Hlth, Dept Med, Boston, MA 02114 USA.
[Martin, Jeffrey N.; Hunt, Peter W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Matthews, LT (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM ltmatthews@partners.org
FU Sullivan Family Foundation; Doris Duke Clinical Scientist Development
Award [2008047]; [MH54907]; [AI100765]; [HD069194]; [NIAID P30
027763]; [NIMH 095655]; [087228]; [NIMH 87227]
FX This project was supported by R01 (Bangsberg MH54907), R56 (Hunt
AI100765), R21 (Kaida HD069194), NIAID P30 027763 funds, and The
Sullivan Family Foundation. Lynn Matthews and Jessica Haberer are
supported by K23 awards (NIMH 095655 and 087228). David Bangsberg is
supported by a K24 award (NIMH 87227). Peter Hunt is supported by Doris
Duke Clinical Scientist Development Award (2008047). The content of this
manuscript is the responsibility of the authors and does not necessarily
represent the official views of the NIH.
NR 45
TC 8
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD OCT
PY 2013
VL 27
SU 1
BP S105
EP S112
DI 10.1097/QAD.0000000000000040
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 298UD
UT WOS:000330349100012
PM 24088676
ER
PT J
AU Ajayi, T
Richter, J
Campbell, E
Namias, J
AF Ajayi, Tokunbo
Richter, James
Campbell, Emily
Namias, Joshua
TI Quality of Colonoscopy Prep in Inpatients versus Outpatients at a
Community-based Hospital
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Ajayi, Tokunbo; Namias, Joshua] Salem Hosp, Salem, MA USA.
[Richter, James; Campbell, Emily] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1991
BP S605
EP S605
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102321
ER
PT J
AU Alishahi, Y
Kundrotas, L
AF Alishahi, Yasmin
Kundrotas, Leon
TI A Retrospective Review of the Clinical Impact of Hydrogen Breath Testing
for Small Bowel Bacterial Overgrowth in South Texas Veterans Health Care
System
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Alishahi, Yasmin] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Kundrotas, Leon] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1643
BP S493
EP S493
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101795
ER
PT J
AU Anderson, J
Goel, G
Cohen, H
Leung, F
AF Anderson, Joshua
Goel, Gati
Cohen, Hartley
Leung, Felix
TI Water Infusion Distension during Colonoscopy Is a Safe Alternative
Technique to Facilitate Polypectomy in a "Difficult Location"
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Anderson, Joshua; Goel, Gati; Cohen, Hartley; Leung, Felix] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1484
BP S440
EP S440
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101636
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, M
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, Md
Farhat, S.
TI Romiplostim's Effect to Optimize SVR with Telaprevir, Ribavirin, and PEG
Interferon-alfa 2a in Thrombocytopenic Cirrhotics with Chronic Hepatitis
C: A Placebo-controlled Prospective Clinical Trial: RESTRAINT C Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Physicians & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra N Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 506
BP S150
EP S150
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100506
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, M
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, Md
Farhat, S.
TI Telaprevir with Adjusted Dose of Ribavirin in Naive CHC-G1: Efficacy and
Treatment in CHC in Hemodialysis Population TARGET C Trial: A Placebo
Randomized Control Clinical Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra N Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 513
BP S152
EP S152
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100513
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, M
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, Md
Farhat, S.
TI Curcumin, Antioxidant, and Pioglitazone Therapy with Inclusion of
Vitamin E In Non-Alcoholic Fatty Liver Disease: A Randomized,
Open-label, Placebo-controlled Clinical Prospective Trial (CAPTIVE)
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 505
BP S149
EP S150
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100505
ER
PT J
AU Basu, P
Shah, N
Rahaman, M
Siriki, R
Farhat, S
AF Basu, Patrick
Shah, Niraj
Rahaman, Md
Siriki, Ravi
Farhat, S.
TI Prevalence of Small Bowel Bacterial Overgrowth (SIBO) in Decompensated
Cirrhosis with Portal Hypertension: A Clinical Pilot Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Rahaman, Md; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 486
BP S144
EP S145
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100486
ER
PT J
AU Basu, P
Shah, N
Farhat, S
Siriki, R
Rahaman, M
AF Basu, Patrick
Shah, Niraj
Farhat, S.
Siriki, Ravi
Rahaman, Md
TI Restless Leg Syndrome (RLS) is Associated with Hepatic Encephalopathy
(HE) in Decompensated Cirrhosis: A Clinical Pilot Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 485
BP S144
EP S144
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100485
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, M
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, Md
Farhat, S.
TI Effect of N Acetylcysteine (NAC) in Hypoxia-Induced Liver Injury (HILI):
A Randomized Placebo Control Clinical Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 484
BP S144
EP S144
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100484
ER
PT J
AU Basu, P
Shah, N
Rahaman, MD
Siriki, R
Farhat, S
AF Basu, Patrick
Shah, Niraj
Rahaman, M. D.
Siriki, Ravi
Farhat, S.
TI Rifabutin, Omeprazole, Alinia, and Doxycycline Therapy for Prior
Treatment Failure Helicobacter pylori Population: A Randomized,
Open-Label Clinical Pilot Study ROAD Trial
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Rahaman, M. D.; Siriki, Ravi] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 157
BP S49
EP S49
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100158
ER
PT J
AU Basu, P
Shah, N
Siriki, R
Rahaman, MD
Farhat, S
AF Basu, Patrick
Shah, Niraj
Siriki, Ravi
Rahaman, M. D.
Farhat, S.
TI Latent Eosinophilic Esophagitis (LEOE) Is a Unraveled Novel Clinical
Entity: A Randomized, Open Clinical Pilot Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Basu, Patrick; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Siriki, Ravi; Rahaman, M. D.] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 68
BP S23
EP S24
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100069
ER
PT J
AU Blackshear, L
Aranda-Michel, E
Wolfsen, H
Wallace, M
Tearney, G
AF Blackshear, Leslie
Aranda-Michel, Edgar
Wolfsen, Herbert
Wallace, Michael
Tearney, Gary
TI Volumetric Laser Endomicroscopy (VLE): An OFDI Case Study of Barrett's
Esophagus with Dysplasia
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Blackshear, Leslie; Aranda-Michel, Edgar; Wolfsen, Herbert; Wallace, Michael] Mayo Clin Florida, Jacksonville, FL USA.
[Tearney, Gary] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 3
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 2163
BP S656
EP S656
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102489
ER
PT J
AU Chen, XH
Lu, L
Xu, H
Sears, P
Kelly, C
AF Chen, Xinhua
Lu, Lei
Xu, Hua
Sears, Pam
Kelly, Ciaran
TI Steroid Therapy Exacerbates Clostridium difficile Infection in a Mouse
Model
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Chen, Xinhua; Lu, Lei; Xu, Hua; Kelly, Ciaran] Harvard Univ, Sch Med, BIDMC, Div Gastroenterol, Boston, MA USA.
[Sears, Pam] Optimer Pharmaceut Inc, San Diego, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1820
BP S549
EP S549
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102151
ER
PT J
AU Clifford, D
McAuliffe, M
Stephens, K
Major, E
Fox, I
Milch, C
Sankoh, S
Provenzale, J
Lev, M
Freedland, E
Berger, J
Parikh, A
AF Clifford, David
McAuliffe, Megan
Stephens, Kristin
Major, Eugene
Fox, Irving
Milch, Catherine
Sankoh, Serap
Provenzale, James
Lev, Michael
Freedland, Eric
Berger, Joseph
Parikh, Asit
TI Risk Assessment and Minimization for Progressive Multifocal
Leukoencephalopathy (PML RAMP): A Program to Assess for Potential Early
Signs and Symptoms of PML during Clinical Development of Vedolizumab
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Clifford, David] Washington Univ, Sch Med, St Louis, MO USA.
[McAuliffe, Megan; Stephens, Kristin; Fox, Irving; Sankoh, Serap; Freedland, Eric] Millennium Pharmaceut Inc, Cambridge, MA USA.
[Major, Eugene] NINDS, NIH, Bethesda, MD 20892 USA.
[Milch, Catherine; Provenzale, James] Duke Univ, Med Ctr, Durham, NC USA.
[Lev, Michael] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Berger, Joseph] Univ Kentucky, Lexington, KY USA.
[Parikh, Asit] Takeda Pharmaceut Int Inc, Deerfield, IL USA.
NR 0
TC 3
Z9 3
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1673
BP S502
EP S502
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102007
ER
PT J
AU Hotte, C
Vela, M
AF Hotte, Charles
Vela, Marcelo
TI Body Mass Index (BMI) and Percent Fat Are Not Associated with Increased
Reflux in a Veteran Hospital Review
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Hotte, Charles] Baylor Coll Med, Houston, TX 77030 USA.
[Vela, Marcelo] Michael E Debakey Vet Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 38
BP S14
EP S14
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100039
ER
PT J
AU Ihunnah, C
Khoruts, A
Fischer, M
Afzali, A
Aroniadis, O
Barto, A
Borody, T
Brandt, L
Giovanelli, A
Gordon, S
Hohmann, E
Kao, DN
Kao, J
McQuillen, D
Mellow, M
Rank, K
Ray, A
Schwartz, M
Singh, N
Stollman, N
Surawicz, C
Suskind, D
Vindigni, S
Youngster, I
Kelly, C
AF Ihunnah, Chioma
Khoruts, Alexander
Fischer, Monika
Afzali, Anita
Aroniadis, Olga
Barto, Amy
Borody, Thomas
Brandt, Lawrence
Giovanelli, Andrea
Gordon, Shelley
Hohmann, Elizabeth
Kao, Dina
Kao, John
McQuillen, Daniel
Mellow, Mark
Rank, Kevin
Ray, Arnab
Schwartz, Margot
Singh, Namita
Stollman, Neil
Surawicz, Christina
Suskind, David
Vindigni, Stephen
Youngster, Ilan
Kelly, Colleen
TI Fecal Microbiota Transplantation (FMT) for Treatment of Clostridium
difficile Infection (CDI) in Immunocompromised Patients
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Ihunnah, Chioma; Kelly, Colleen] Brown Alpert Med Sch, Providence, RI USA.
[Hohmann, Elizabeth; Youngster, Ilan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fischer, Monika] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Kao, John] Univ Michigan, Ann Arbor, MI 48109 USA.
[Singh, Namita; Suskind, David] Seattle Childrens Hosp, Seattle, WA USA.
[Aroniadis, Olga; Brandt, Lawrence] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Mellow, Mark] INTEGRIS Baptist Med Ctr, Oklahoma City, OK USA.
[Ray, Arnab] Ochsner Clin Fdn, New Orleans, LA USA.
[Barto, Amy; McQuillen, Daniel] Lahey Clin Med Ctr, Burlington, MA 01803 USA.
[Khoruts, Alexander; Rank, Kevin] Univ Minnesota, Minneapolis, MN USA.
[Giovanelli, Andrea; Stollman, Neil] Northern Calif Gastroenterol Consultants Inc, Oakland, CA USA.
[Gordon, Shelley] Calif Pacific Med Ctr, San Francisco, CA USA.
[Kao, Dina] Univ Alberta, Edmonton, AB, Canada.
[Schwartz, Margot] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
[Borody, Thomas] Ctr Digest Dis, Sydney, NSW, Australia.
[Afzali, Anita; Surawicz, Christina; Vindigni, Stephen] Univ Washington, Sch Med, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 611
BP S179
EP S180
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100611
ER
PT J
AU Kaung, A
Chak, E
Cohen, H
Ohning, G
Leung, F
AF Kaung, Aung
Chak, Eric
Cohen, Hartley
Ohning, Gordon
Leung, Felix
TI Water Exchange Colonoscopy without Air Insufflation May Facilitate
Terminal Ileum Intubation
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Kaung, Aung; Cohen, Hartley; Ohning, Gordon; Leung, Felix] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
[Chak, Eric] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1483
BP S439
EP S440
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101635
ER
PT J
AU Konijeti, G
Khalili, H
Ananthakrishnan, A
Higuchi, L
Fuchs, C
Richter, J
Chan, A
AF Konijeti, Gauree
Khalili, Hamed
Ananthakrishnan, Ashwin
Higuchi, Leslie
Fuchs, Charles
Richter, James
Chan, Andrew
TI Does Parental Age Influence the Risk of Inflammatory Bowel Disease in
Offspring?
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Konijeti, Gauree; Khalili, Hamed; Ananthakrishnan, Ashwin; Richter, James; Chan, Andrew] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Higuchi, Leslie] Childrens Hosp, Div Gastroenterol & Nutr, Boston, MA 02115 USA.
[Fuchs, Charles] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1814
BP S547
EP S547
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102146
ER
PT J
AU Konijeti, G
Sauk, J
Shrime, M
Ananthakrishnan, A
AF Konijeti, Gauree
Sauk, Jenny
Shrime, Mark
Ananthakrishnan, Ashwin
TI Cost-effectiveness of Competing Strategies for Recurrent Clostridium
difficile Infection ACG/AstraZeneca Fellow Award
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Konijeti, Gauree; Sauk, Jenny; Ananthakrishnan, Ashwin] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Shrime, Mark] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1579
BP S473
EP S473
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101731
ER
PT J
AU Korant, A
Shaik, M
Saha, S
Gay, G
Saha, S
AF Korant, Alpesh
Shaik, Mohammed
Saha, Supriya
Gay, Greer
Saha, Sukamal
TI Tumor Size Predicts Long-Term Survival in Colon Cancer Patients:
Analysis of National Cancer Database (NCDB)
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Korant, Alpesh; Saha, Sukamal] McLaren Flint Med Ctr, Flint, MI USA.
[Shaik, Mohammed] Hurley Med Ctr, Flint, MI USA.
[Saha, Supriya] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gay, Greer] Amer Coll Surg Commiss Canc, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 550
BP S162
EP S162
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100550
ER
PT J
AU Kovacs, T
Jensen, D
Ohning, G
Ghassemi, K
Dulai, G
Machicado, G
Jutabha, R
AF Kovacs, Thomas
Jensen, Dennis
Ohning, Gordon
Ghassemi, Kevin
Dulai, Gareth
Machicado, Gustavo
Jutabha, Rome
TI A Prospective Study of Patients with Bleeding Mallory Weiss Tears: Does
Portal Hypertension Matter?
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Ghassemi, Kevin; Jutabha, Rome] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Dulai, Gareth] CURE DDRC GI Hemostasis Res Unit, Los Angeles, CA USA.
[Ohning, Gordon] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Kovacs, Thomas; Jensen, Dennis; Machicado, Gustavo] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA.
[Kovacs, Thomas; Jensen, Dennis; Machicado, Gustavo] VA WLA Med Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 2029
BP S615
EP S615
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102357
ER
PT J
AU Lopez, J
Konijeti, G
Nguyen, D
Sauk, J
Yajnik, V
Ananthakrishnan, A
AF Lopez, Joanna
Konijeti, Gauree
Nguyen, Deanna
Sauk, Jenny
Yajnik, Vijay
Ananthakrishnan, Ashwin
TI Natural History of Crohn's Disease Following Permanent Ileostomy:
Implications for Endoscopic Surveillance
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Lopez, Joanna; Konijeti, Gauree; Nguyen, Deanna; Sauk, Jenny; Yajnik, Vijay; Ananthakrishnan, Ashwin] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1695
BP S510
EP S510
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102029
ER
PT J
AU Mahmood, S
Campbell, E
Richter, J
AF Mahmood, Syed
Campbell, Emily
Richter, James
TI Non-bleeding Indications for Inpatient Colonoscopy
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Mahmood, Syed] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Campbell, Emily; Richter, James] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 2041
BP S619
EP S619
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102369
ER
PT J
AU Mahmood, S
Campbell, E
Richter, J
AF Mahmood, Syed
Campbell, Emily
Richter, James
TI Frequency and Cost of Repeating Inpatient Colonoscopy Secondary to
Suboptimal Bowel Preparation
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Mahmood, Syed] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Campbell, Emily; Richter, James] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1970
BP S599
EP S599
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102300
ER
PT J
AU Mahmood, S
Campbell, E
Richter, J
AF Mahmood, Syed
Campbell, Emily
Richter, James
TI Mid-afternoon versus Evening Start Time for Polyethylene Glycol
Preparation in Hospitalized Patients Undergoing Next Day Colonoscopy
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Mahmood, Syed] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Campbell, Emily; Richter, James] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1928
BP S583
EP S584
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102258
ER
PT J
AU McPhaul, C
Sonnenberg, A
Genta, R
AF McPhaul, Christopher
Sonnenberg, Amnon
Genta, Robert
TI Low Prevalence of Colon Polyps in Patients with Diarrhea and Microscopic
Colitis
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Genta, Robert] Miraca Life Sci Res Inst, GI Pathol, Irving, TX USA.
[McPhaul, Christopher] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon] OHSU, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 558
BP S164
EP S164
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100558
ER
PT J
AU Mehrzad, R
Leung, J
Alejos, A
Hundal, N
Katz, A
Yuan, Q
Hesterberg, P
Shreffler, W
AF Mehrzad, Raman
Leung, John
Alejos, Alexandra
Hundal, Navneet
Katz, Aubrey
Yuan, Qian
Hesterberg, Paul
Shreffler, Wayne
TI Serial Diagnostic EGDs Used to Identify Food Trigger(s) in Eosinophilic
Esophagitis Are Safe
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Mehrzad, Raman; Leung, John; Alejos, Alexandra; Hesterberg, Paul; Shreffler, Wayne] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Immunol & Allergy, Boston, MA USA.
[Hundal, Navneet; Katz, Aubrey; Yuan, Qian] Harvard Univ, Sch Med, Massachusetts Gen Hosp Children, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 65
BP S23
EP S23
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100066
ER
PT J
AU Nguyen, K
Jacobs, J
Cao, WW
Chak, E
Cohen, H
Leung, F
AF Nguyen, Ken
Jacobs, Jonathan
Cao, Weiwei
Chak, Eric
Cohen, Hartley
Leung, Felix
TI Water Exchange Colonoscopy for Evaluation of Severe Ulcerative Colitis:
A Case Series
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Cohen, Hartley; Leung, Felix] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA.
[Nguyen, Ken] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.
[Jacobs, Jonathan; Cao, Weiwei; Chak, Eric] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1405
BP S416
EP S417
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101557
ER
PT J
AU Raza, MQ
Trang, T
Qureshi, W
AF Raza, Mohammad Qasim
Trang, Tony
Qureshi, Waqar
TI Colo-colonic Intussusception Presenting as Intermittent Testicular Pain
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Raza, Mohammad Qasim; Qureshi, Waqar] Baylor Coll Med, Houston, TX 77030 USA.
[Trang, Tony] VA Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1324
BP S394
EP S394
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101476
ER
PT J
AU Scoville, E
Konijeti, G
Yajnik, V
Nguyen, D
Sauk, J
Ananthakrishnan, A
AF Scoville, Elizabeth
Konijeti, Gauree
Yajnik, Vijay
Nguyen, Deanna
Sauk, Jenny
Ananthakrishnan, Ashwin
TI Preventability of Venous Thromboembolism in Patients with Inflammatory
Bowel Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Scoville, Elizabeth; Konijeti, Gauree; Yajnik, Vijay; Nguyen, Deanna; Sauk, Jenny; Ananthakrishnan, Ashwin] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1700
BP S511
EP S512
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102034
ER
PT J
AU Sharma, A
Smith, D
AF Sharma, Anurag
Smith, David
TI Autoimmune Hemolytic Anemia: A Part of the Hematological Spectrum of
Celiac Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Sharma, Anurag] Mt Sinai Sch Med, St Josephs Reg Med Ctr Program, Paterson, NJ USA.
[Smith, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Hematol & Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 954
BP S285
EP S285
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178101106
ER
PT J
AU Sonnenberg, A
Byrd-Clark, D
AF Sonnenberg, Amnon
Byrd-Clark, Danita
TI US Hospitalizations for Colorectal Cancer: 1970-2010
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, GI P3, Portland, OR USA.
[Byrd-Clark, Danita] Social & Sci Syst, Silver Spring, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 557
BP S164
EP S164
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100557
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Time Trends of US Hospitalization for Esophageal Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 13
BP S5
EP S5
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100014
ER
PT J
AU Taydas, E
Malik, M
Russell, S
Latt, N
Gurakar, A
AF Taydas, Eren
Malik, Mohammad
Russell, Stuart
Latt, Nyan
Gurakar, Ahmet
TI The Role of Coronary Artery Calcium Score and Age in Early
Identification of Occult Coronary Artery Disease among Patients
Undergoing Liver Transplant Work-up for End-stage Liver Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Taydas, Eren] MedStar Franklin Sq Med Ctr, Baltimore, MD USA.
[Malik, Mohammad; Russell, Stuart; Gurakar, Ahmet] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Latt, Nyan] W Los Angeles Vet Affairs Med Ctr, Dept Gastroenterol & Hepatol, Los Angeles, CA 90073 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 500
BP S148
EP S148
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178100500
ER
PT J
AU Wang, MH
Fiocchi, C
Zhu, XF
Ripke, S
Kamboh, I
Rebert, N
Duerr, R
Achkar, JP
AF Wang, Ming-Hsi
Fiocchi, Claudio
Zhu, Xiaofeng
Ripke, Stephan
Kamboh, Ilyas
Rebert, Nancy
Duerr, Richard
Achkar, Jean-Paul
TI Novel Gene-Gene and Gene-Environment Interactions in Ulcerative Colitis
ACG IBD Research Award
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT 78th Annual Scientific Meeting of the
American-College-of-Gastroenterology
CY OCT 11-16, 2013
CL San Diego, CA
SP Amer Coll Gastroenterol
C1 [Wang, Ming-Hsi; Fiocchi, Claudio; Rebert, Nancy; Achkar, Jean-Paul] Cleveland Clin, Inst Digest Dis, Cleveland, OH 44106 USA.
[Zhu, Xiaofeng] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Ripke, Stephan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kamboh, Ilyas; Duerr, Richard] Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2013
VL 108
SU 1
MA 1690
BP S508
EP S508
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 296II
UT WOS:000330178102024
ER
PT J
AU Maust, DT
Oslin, DW
Thase, ME
AF Maust, Donovan T.
Oslin, David W.
Thase, Michael E.
TI Going Beyond Antidepressant Monotherapy for Incomplete Response in
Nonpsychotic Late-Life Depression: A Critical Review
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Review
DE Antidepressant; augmentation; depression; pharmacotherapy
ID TREATMENT-RESISTANT DEPRESSION; RECURRENT MAJOR DEPRESSION; LITHIUM
AUGMENTATION; GERIATRIC DEPRESSION; PRIMARY-CARE; REFRACTORY DEPRESSION;
UNIPOLAR DEPRESSION; ELDERLY-PATIENTS; CONTROLLED-TRIAL; OLDER PATIENTS
AB Many older adults with major depressive disorder (MDD) do not respond to antidepressant monotherapy. Although there are evidence-based treatment options to support treatment beyond monotherapy for adults, the evidence for such strategies, specifically in late-life MDD, is relatively scarce. This review examines the published data describing strategies for antidepressant augmentation or acceleration studied specifically in older adults, including lithium, stimulants, and second-generation antipsychotics. In addition, the authors suggest strategies for future research, such as study of specific agents, refining understanding of the impact of medical or cognitive comorbidity in late-life depression, and comparative effectiveness to examine methods already used in clinical practice.
C1 [Maust, Donovan T.; Oslin, David W.; Thase, Michael E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Oslin, David W.; Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Oslin, David W.; Thase, Michael E.] VISN 4 Mental Illness Res Educ & Clin Ctr MIREC, Philadelphia, PA USA.
[Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA.
RP Maust, DT (reprint author), Univ Penn, Sect Geriatr Psychiat, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM Donovan.Maust@uphs.upenn.edu
FU NIMH [R25-MH060490]
FX Dr. Maust is supported through the NIMH-funded Clinical Research
Scholars Program (R25-MH060490) of the Department of Psychiatry,
University of Pennsylvania, Perelman School of Medicine.
NR 58
TC 10
Z9 10
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD OCT
PY 2013
VL 21
IS 10
BP 973
EP 986
DI 10.1016/j.jagp.2013.01.030
PG 14
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 298YZ
UT WOS:000330362300007
PM 23567381
ER
PT J
AU Liang, WY
Chang, WC
Hsu, CY
Arnason, T
Berger, D
Hawkins, AT
Sylla, P
Lauwers, GY
AF Liang, Wen-Yih
Chang, Wei-Chin
Hsu, Chih-Yi
Arnason, Thomas
Berger, David
Hawkins, Alexander T.
Sylla, Patricia
Lauwers, Gregory Y.
TI Retrospective Evaluation of Elastic Stain in the Assessment of Serosal
Invasion of pT3N0 Colorectal Cancers
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE colorectal cancer; elastic stain; elastic lamina invasion; peritoneal
involvement; CK7
ID COLON-CANCER; PERITONEAL INVOLVEMENT; 7TH EDITION; HIGH-RISK; CARCINOMA;
CLASSIFICATION; CATEGORIZATION; SURVIVAL; OUTCOMES; LAMINA
AB Peritoneal involvement is an important adverse prognostic factor in colorectal cancer (CRC) and determines a shift in the pathologic tumor node metastasis stage. Because peritoneal involvement is difficult to identify, use of special stains highlighting the peritoneal elastic lamina and mesothelial surface has been proposed. This study aims to determine whether use of elastic stain or CK7 immunohistochemistry on a single tissue section can refine the level of tumor invasion and determine whether restaging based on this assessment has prognostic significance in pT3N0 CRCs. Elastic stains were applied to 1 block per case from 244 consecutively resected pT3N0M0 CRCs. CK7 was evaluated in a 169-case subset. The elastic lamina was identified in only 101 cases (41%). Of those, 60 cases (24.6%) displayed elastic lamina invasion (ELI). This finding was associated with significantly worse (P < 0.001) disease-free survival (DFS) (5-y DFS = 60%) and significantly worse (P = 0.01) overall survival (OS) (5-y OS = 66.7%) compared with patients with no ELI (5-y DFS = 87.8%, OS = 92.7%) and those for whom no elastic lamina was identified (5-y DFS= 82.5%, OS = 86.0%). CK7 staining highlighted mesothelial cells in only 27 of 169 cases tested and helped demonstrate serosal invasion in only 5 cases (3%). In summary, the use of a single elastic stain is a useful and inexpensive method to demonstrate peritoneal involvement by tumor and should be considered for routine use in all pT3N0 CRCs. As tumors with ELI have an adverse prognosis, we propose that they should be upstaged compared with pT3N0 tumors without ELI.
C1 [Liang, Wen-Yih; Chang, Wei-Chin; Hsu, Chih-Yi] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei 112, Taiwan.
[Liang, Wen-Yih; Chang, Wei-Chin; Hsu, Chih-Yi] Natl Yang Ming Univ, Dept Pathol, Sch Med, Taipei, Taiwan.
[Liang, Wen-Yih; Arnason, Thomas; Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Gastrointestinal Pathol Serv, Boston, MA 02114 USA.
[Berger, David; Hawkins, Alexander T.; Sylla, Patricia] Massachusetts Gen Hosp, Dept Surg, Div Gastrointestinal Surg, Boston, MA 02114 USA.
[Berger, David; Hawkins, Alexander T.; Sylla, Patricia] Harvard Univ, Sch Med, Boston, MA USA.
RP Liang, WY (reprint author), Taipei Vet Gen Hosp, Dept Pathol, 201,Sec 2,Shi Pai Rd, Taipei 112, Taiwan.
EM wyliang@vghtpe.gov.tw
FU Royal College of Physicians and Surgeons of Canada (Detweiler Traveling
Fellowship); Dalhousie University (McLoughlin Scholarship); NIH NHLBI
T32 Harvard/Longwood Vascular Surgery Training Program [HL007734]
FX T.A.'s fellowship funding was provided through scholarships from the
Royal College of Physicians and Surgeons of Canada (Detweiler Traveling
Fellowship) and Dalhousie University (McLoughlin Scholarship). Dr
Hawkins is supported by the NIH NHLBI T32 (HL007734) Harvard/Longwood
Vascular Surgery Training Program. The authors have disclosed that they
have no significant relationships with, or financial interest in, any
commercial companies pertaining to this article.
NR 20
TC 8
Z9 9
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
EI 1532-0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD OCT
PY 2013
VL 37
IS 10
BP 1565
EP 1570
PG 6
WC Pathology; Surgery
SC Pathology; Surgery
GA 299YB
UT WOS:000330430500010
PM 23774172
ER
PT J
AU Mason, EF
Sadow, PM
Wagner, AJ
Remillard, SP
Flood, TA
Belanger, EC
Hornick, JL
Barletta, JA
AF Mason, Emily F.
Sadow, Peter M.
Wagner, Andrew J.
Remillard, Stephen P.
Flood, Trevor A.
Belanger, Eric C.
Hornick, Jason L.
Barletta, Justine A.
TI Identification of Succinate Dehydrogenase-deficient Bladder
Paragangliomas
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE bladder paragangliomas; succinate dehydrogenase; immunohistochemistry
ID GASTROINTESTINAL STROMAL TUMORS; CARNEY-STRATAKIS-SYNDROME; RENAL-CELL
CARCINOMA; SDHD GENE-MUTATIONS; GERM-LINE MUTATIONS; COMPLEX-II GENE;
MALIGNANT PHEOCHROMOCYTOMAS; FAMILIAL PHEOCHROMOCYTOMA;
CLINICAL-IMPLICATIONS; PULMONARY CHONDROMA
AB A significant number of patients with paragangliomas harbor germline mutations in one of the succinate dehydrogenase (SDH) genes (SDHA, B, C, or D). Tumors with mutations in SDH genes can be identified using immunohistochemistry. Loss of SDHB staining is seen in tumors with a mutation in any one of the SDH genes, whereas loss of both SDHB and SDHA expression is seen only in the context of an SDHA mutation. Identifying an SDH-deficient tumor can be prognostically significant, as tumors with SDHB mutations are more likely to pursue a malignant course. Although the rate of SDH deficiency in paragangliomas in general is known to be approximately 30%, there are only rare reports of SDH-deficient bladder paragangliomas. Therefore, the aim of this study was to determine the rate of SDH deficiency in bladder paragangliomas. Eleven cases of bladder paragangliomas were identified. Hematoxylin and eosin-stained slides of all tumors were reviewed, and immunohistochemical analysis for SDHB and SDHA was performed. For cases with loss of SDHA expression by immunohistochemistry, mutation analysis of the SDHA gene was performed. Loss of SDHB staining was seen in 3 (27%) cases (2 with loss of SDHB only, 1 with loss of SDHB and SDHA). Patients with SDH-deficient tumors were younger than those with tumors with intact SDH expression (mean age at presentation 39 y and 58 y, respectively). Of the 2 patients with SDHB-deficient and SDHA-intact tumors, one was found to have a germline SDHB mutation, and the other had a family history of a malignant paraganglioma. Both patients developed metastatic disease. The one patient with a tumor that was deficient for both SDHB and SDHA had no family history of paragangliomas and no evidence of metastatic disease. Sequencing of this tumor revealed a deleterious heterozygous single-base pair substitution in exon 10 of SDHA (c. 1340 A > G; p.His447Arg) in both the tumor and normal tissue, indicative of a germline SDHA mutation, and a deleterious singlebase pair substitution in exon 5 of SDHA (c. 484 A > T; p.Arg162*) in 1 allele of the tumor only. No patients with intact SDH expression had a family history of paragangliomas; 1 had a synchronous paraganglioma, but none developed metastatic disease. A significant subset of bladder paragangliomas is SDH deficient. It is essential to identify SDH-deficient tumors, as the presence of an SDH mutation has prognostic implications and is important in guiding genetic counseling.
C1 [Mason, Emily F.; Hornick, Jason L.; Barletta, Justine A.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Sadow, Peter M.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Wagner, Andrew J.; Remillard, Stephen P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA.
[Flood, Trevor A.; Belanger, Eric C.] Ottawa Hosp, Dept Pathol, Ottawa, ON, Canada.
RP Barletta, JA (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM jbarletta@partners.org
OI Flood, Trevor/0000-0002-5227-2708
NR 36
TC 3
Z9 3
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
EI 1532-0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD OCT
PY 2013
VL 37
IS 10
BP 1612
EP 1618
PG 7
WC Pathology; Surgery
SC Pathology; Surgery
GA 299YB
UT WOS:000330430500016
PM 23797725
ER
PT J
AU Wanderer, JP
Anderson-Dam, J
AF Wanderer, Jonathan P.
Anderson-Dam, John
TI ANESTHESIA INFORMATION MANAGEMENT SYSTEM RECORDS AND OPERATIVE NOTES: A
COMPARISON OF ESTIMATED BLOOD LOSS
SO ANESTHESIA AND ANALGESIA
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Technology-in-Anesthesia (STA)
CY JAN 09-12, 2013
CL Scottsdale, AZ
SP Soc Technol Anesthesia, Int Anesthesia Res Soc, Soc Cardiovascular Anesthesiologists, Soc Pediat Anesthesia, Soc Ambulatory Anesthesia, Int Soc Anaesthet Pharmacol, Anesthesia Patient Safety Fdn, Soc Crit Care Anesthesiologists, Soc Obstet Anesthesia & Perinatol
C1 [Wanderer, Jonathan P.] Vanderbilt Univ, Dept Anesthesia, Nashville, TN 37235 USA.
[Anderson-Dam, John] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 2013
VL 117
SU 1
BP 72
EP 73
PG 2
WC Anesthesiology
SC Anesthesiology
GA 300CZ
UT WOS:000330443300037
ER
PT J
AU Yuki, K
Bu, WM
Xi, J
Shimaoka, M
Eckenhoff, R
AF Yuki, Koichi
Bu, Weiming
Xi, Jin
Shimaoka, Motomu
Eckenhoff, Roderic
TI Propofol Shares the Binding Site with Isoflurane and Sevoflurane on
Leukocyte Function-Associated Antigen-1
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID HUMAN SERUM-ALBUMIN; GENERAL-ANESTHETICS; I-DOMAIN; INTEGRIN LFA-1;
CARDIOPULMONARY BYPASS; INFLAMMATORY RESPONSE; CRYSTAL-STRUCTURES;
RECEPTOR FUNCTION; GABA(A) RECEPTOR; STRUCTURAL BASIS
AB BACKGROUND: We previously demonstrated that propofol interacted with the leukocyte adhesion molecule leukocyte function-associated antigen-1 (LFA-1) and inhibited the production of interleukin-2 via LFA-1 in a dependent manner. However, the binding site(s) of propofol on LFA-1 remains unknown.
METHODS: First, the inhibition of LFA-1's ligand binding by propofol was confirmed in an enzyme-linked immunosorbent assay (ELISA) ELISA-type assay. The binding site of propofol on LFA-1 was probed with a photolabeling experiment using a photoactivatable propofol analog called azi-propofol-m. The adducted residues of LFA-1 by this compound were determined using liquid chromatography-mass spectrometry. In addition, the binding of propofol to the ligand-binding domain of LFA-1 was examined using 1-aminoanthracene (1-AMA) displacement assay. Furthermore, the binding site(s) of 1-AMA and propofol on LFA-1 was studied using the docking program GLIDE.
RESULTS: We demonstrated that propofol impaired the binding of LFA-1 to its ligand intercellular adhesion molecule-1. The photolabeling experiment demonstrated that the adducted residues were localized in the allosteric cavity of the ligand-binding domain of LFA-1 called "lovastatin site." The shift of fluorescence spectra was observed when 1-AMA was coincubated with the low-affinity conformer of LFA-1 ligand-binding domain (wild-type [WT] alpha L I domain), not with the high-affinity conformer, suggesting that 1-AMA bound only to WT alpha L I domain. In the 1-AMA displacement assay, propofol decreased 1-AMA fluorescence signal (at 520 nm), suggesting that propofol competed with 1-AMA and bound to the WT alpha L I domain. The docking simulation demonstrated that both 1-AMA and propofol bound to the lovastatin site, which agreed with the photolabeling experiment.
CONCLUSIONS: We demonstrated that propofol bound to the lovastatin site in LFA-1. Previously we showed that the volatile anesthetics isoflurane and sevoflurane bound to this site. Taken together, the lovastatin site is an example of the common binding sites for anesthetics currently used clinically.
C1 [Yuki, Koichi; Shimaoka, Motomu] Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
[Yuki, Koichi; Shimaoka, Motomu] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Yuki, Koichi; Shimaoka, Motomu] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA.
[Bu, Weiming; Xi, Jin; Eckenhoff, Roderic] Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Shimaoka, Motomu] Mie Univ, Dept Mol Pathobiol & Cell Adhes Biol, Grad Sch Med, Tsu, Mie 514, Japan.
RP Yuki, K (reprint author), Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM yuki.koichi@gmail.com
FU National Institutes of Health (NIH) [P01GM55876, K08GM101345]; CHMC
Anesthesia Foundation
FX Funding: This work is in part supported by National Institutes of Health
(NIH) grants P01GM55876 (RE), K08GM101345 (KY), and CHMC Anesthesia
Foundation (KY).
NR 55
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 2013
VL 117
IS 4
BP 803
EP 811
DI 10.1213/ANE.0b013e3182a00ae0
PG 9
WC Anesthesiology
SC Anesthesiology
GA 299ZU
UT WOS:000330435000009
PM 23960033
ER
PT J
AU Bauer, ME
Bateman, BT
Bauer, ST
Shanks, AM
Mhyre, JM
AF Bauer, Melissa E.
Bateman, Brian T.
Bauer, Samuel T.
Shanks, Amy M.
Mhyre, Jill M.
TI Maternal Sepsis Mortality and Morbidity During Hospitalization for
Delivery: Temporal Trends and Independent Associations for Severe Sepsis
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; UNITED-STATES; SEPTIC SHOCK; MULTIPLE
PREGNANCIES; CESAREAN DELIVERY; EPIDEMIOLOGY; INFECTIONS; CARE;
NETHERLANDS; GUIDELINES
AB BACKGROUND: Sepsis is currently the leading cause of direct maternal death in the United Kingdom. In this study, we aimed to determine frequency, temporal trends, and independent associations for severe sepsis during hospitalization for delivery in the United States.
METHODS: Data were obtained from the Nationwide Inpatient Sample for the years 1998 through 2008. The presence of severe sepsis was identified by the appropriate International Classification of Diseases, Ninth Revision, Clinical Modification codes. Logistic regression analysis was used to assess temporal trends for sepsis, severe sepsis, and sepsis-related death and also to identify independent associations of severe sepsis.
RESULTS: Of an estimated 44,999,260 hospitalizations for delivery, sepsis complicated 1: 3333 (95% confidence interval [CI], 1: 3151-1: 3540) deliveries, severe sepsis complicated 1: 10,823 (95% CI, 1: 10,000-1: 11,792) deliveries, and sepsis-related death complicated 1: 105,263 (95% CI, 1: 83,333-1: 131,579) deliveries. While the overall frequency of sepsis was stable (P = 0.95), the risk of severe sepsis and sepsis-related death increased during the study period, (P < 0.001) and (P = 0.02), respectively. Independent associations for severe sepsis, with an adjusted odds ratio and lower bound 95% CI higher than 3, include congestive heart failure, chronic liver disease, chronic renal disease, systemic lupus erythematous, and rescue cerclage placement.
CONCLUSIONS: Maternal severe sepsis and sepsis-related deaths are increasing in the United States. Severe sepsis often occurs in the absence of a recognized risk factor and underscores the need for developing systems of care that increase sensitivity for disease detection across the entire population. Physicians should enhance surveillance in patients with congestive heart failure, chronic liver disease, chronic renal disease, and systemic lupus erythematous and institute early treatment when signs of sepsis are emerging.
C1 [Bauer, Melissa E.; Mhyre, Jill M.] Univ Michigan Hlth Syst, Dept Anesthesiol, Div Obstet Anesthesia, Ann Arbor, MI 48109 USA.
[Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Bateman, Brian T.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
[Bateman, Brian T.] Harvard Univ, Sch Med, Boston, MA USA.
[Bauer, Samuel T.] Oakland Univ, William Beaumont Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Royal Oak, MI USA.
Univ Michigan Hlth Syst, Dept Anesthesiol, Ann Arbor, MI 48109 USA.
RP Bauer, ME (reprint author), Univ Michigan Hlth Syst, Dept Anesthesiol, Neurosci Hosp L3622, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM mbalun@med.umich.edu
FU University of Michigan Department of Anesthesiology
FX Funding: This study was funded by University of Michigan Department of
Anesthesiology.
NR 30
TC 29
Z9 30
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 2013
VL 117
IS 4
BP 944
EP 950
DI 10.1213/ANE.0b013e3182a009c3
PG 7
WC Anesthesiology
SC Anesthesiology
GA 299ZU
UT WOS:000330435000024
PM 24023020
ER
PT J
AU Gordon, CR
Swanson, EW
Susarla, SM
Coon, D
Rada, E
Al Rakan, M
Santiago, GF
Shores, JT
Bonawitz, SC
Fishman, EK
Murphy, R
Armand, M
Liacouras, P
Grant, GT
Brandacher, G
Lee, WPA
AF Gordon, Chad R.
Swanson, Edward W.
Susarla, Srinivas M.
Coon, Devin
Rada, Erin
Al Rakan, Mohammed
Santiago, Gabriel F.
Shores, Jaimie T.
Bonawitz, Steven C.
Fishman, Elliot K.
Murphy, Ryan
Armand, Mehran
Liacouras, Peter
Grant, Gerald T.
Brandacher, Gerald
Lee, Wei-Ping Andrew
TI Overcoming Cross-Gender Differences and Challenges in Le Fort-Based,
Craniomaxillofacial Transplantation With Enhanced Computer-Assisted
Technology
SO ANNALS OF PLASTIC SURGERY
LA English
DT Article; Proceedings Paper
CT 3rd Biennial Meeting of the
American-Society-for-Reconstructive-Transplantation
CY NOV, 2012
CL Chicago, IL
SP Amer Soc Reconstruct Transplantat
DE face transplant; craniomaxillofacial; vascularized composite
allotransplantation (VCA); sex; cross-gender; intraoperative cutting
guide
ID DONOR GENDER; ALLOTRANSPLANTATION; CYTOMEGALOVIRUS; RECOMMENDATIONS;
SURVIVAL; PROTOCOL; MODEL; FACE
AB Background: Sex-specific anthropometrics, skin texture/adnexae mismatch, and social apprehension have prevented cross-gender facial transplantation from evolving. However, the scarce donor pool and extreme waitlist times are currently suboptimal. Our objective was to (1) perform and assess cadaveric facial transplantation for each sex-mismatched scenario using virtual planning with cutting guide fabrication and (2) review the advantages/disadvantages of cross-gender facial transplantation.
Methods: Cross-gender facial transplantation feasibility was evaluated through 2 mock, double-jaw, Le Fort-based cadaveric allotransplants, including female donor-to-male recipient and male donor-to-female recipient. Hybrid facial-skeletal relationships were investigated using cephalometric measurements, including sellion-nasion-A point and sellion-nasion-B point angles, and lower-anterior-facial-height to total-anterior-facial-height ratio. Donor and recipient cutting guides were designed with virtual planning based on our team's experience in swine dissections and used to optimize the results.
Results: Skeletal proportions and facial-aesthetic harmony of the transplants (n = 2) were found to be equivalent to all reported experimental/clinical sex-matched cases by using custom guides and Mimics technology. Cephalometric measurements relative to Eastman Normal Values are shown.
Conclusions: On the basis of our results, we believe that cross-gender facial transplantation can offer equivalent, anatomical skeletal outcomes to those of sex-matched pairs using preoperative planning and custom guides for execution. Lack of literature discussion of cross-gender facial transplantation highlights the general stigmata encompassing the subject. We hypothesize that concerns over sex-specific anthropometrics, skin texture/adnexae disparity, and increased immunological resistance have prevented full acceptance thus far. Advantages include an increased donor pool with expedited reconstruction, as well as size-matched donors.
C1 [Gordon, Chad R.; Swanson, Edward W.; Susarla, Srinivas M.; Coon, Devin; Rada, Erin; Al Rakan, Mohammed; Santiago, Gabriel F.; Shores, Jaimie T.; Bonawitz, Steven C.; Brandacher, Gerald; Lee, Wei-Ping Andrew] Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Plast & Reconstruct Surg, Baltimore, MD 21287 USA.
[Susarla, Srinivas M.] Harvard Univ, Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA.
[Fishman, Elliot K.] Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Radiol, Baltimore, MD 21287 USA.
[Murphy, Ryan; Armand, Mehran] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA.
[Liacouras, Peter; Grant, Gerald T.] Walter Reed Natl Mil Med Ctr, Med Applicat Ctr 3D, Dept Radiol, Bethesda, MD USA.
RP Gordon, CR (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Plast & Reconstruct Surg, JHOC 8161,601 N Caroline St, Baltimore, MD 21287 USA.
EM cgordon@jhmi.edu
RI Brandacher, Gerald/L-7540-2016;
OI Murphy, Ryan/0000-0003-3065-7700; fishman, elliot/0000-0002-2567-1658;
Susarla, Srinivas/0000-0003-0155-8260
FU NCATS NIH HHS [UL1 TR000424, UL1TR000424-06]
NR 15
TC 10
Z9 10
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-7043
EI 1536-3708
J9 ANN PLAS SURG
JI Ann. Plast. Surg.
PD OCT
PY 2013
VL 71
IS 4
BP 421
EP 428
DI 10.1097/SAP.0b013e3182a0df45
PG 8
WC Surgery
SC Surgery
GA 300GX
UT WOS:000330453500023
PM 24025655
ER
PT J
AU Conrad, MF
Kang, J
Mukhopadhyay, S
Patel, VI
LaMuraglia, GM
Cambria, RP
AF Conrad, Mark F.
Kang, Jeanwan
Mukhopadhyay, Shankha
Patel, Virendra I.
LaMuraglia, Glenn M.
Cambria, Richard P.
TI A Risk Prediction Model for Determining Appropriateness of CEA in
Patients with Asymptomatic Carotid Artery Stenosis
SO ANNALS OF SURGERY
LA English
DT Article; Proceedings Paper
CT 133rd Annual Meeting of the American-Surgical-Association (ASA)
CY APR 04-06, 2013
CL Indianapolis, IN
SP Amer Surg Assoc
DE asymptomatic carotid; carotid artery; carotid endarterectomy; risk
prediction; stroke
ID STROKE PREVENTION; VASCULAR-SURGERY; ENDARTERECTOMY; TRIAL;
OCTOGENARIANS; METAANALYSIS; MANAGEMENT; SURVIVAL; EFFICACY; OUTCOMES
AB Objective: The benefit of carotid endarterectomy (CEA) overmedical therapy in patients with asymptomatic carotid artery stenosis is predicated upon a life expectancy of at least 5 years after the procedure. The goal of this study was to create a scoring system for prediction of 5-year survival after CEA that can be used to triage patients with ACAS.
Methods: All patients who underwent CEA for severe asymptomatic carotid stenosis from 1989 to 2005 were identified. Long-term survival was determined by a review of hospital records and the social security death index. Because all patients had at least 5-year follow-up, a logistic regression of predictors of survival at 5 years was performed and the odds ratios associated with particular significant comorbidities were used to create a scoring system to predict survival. The scoring system was then validated within the cohort using the Hosmer-Lemeshow Test and a derivation/validation receiver operating characteristic (ROC) curve.
Results: There were 2004 CEA performed in 1791 patients. The average follow-upwas 130 +/- 49 months. The clinical profile of the cohort data included 84% hypertension, 56% coronary artery disease (CAD), 24% diabetes, and 71% on statins. The 30-day stroke rate was 1.1% and the death rate was 0.7%. The actual 5-year survival was 73%. Logistic regression yielded the following predictors of mortality: age (by decade) (odds ratio [OR] = 1.8, P < 0.0001), CAD(OR = 1.5, P = 0.0007), chronic obstructive pulmonary disease (OR = 2.5; P < 0.0001), diabetes (OR = 1.7, P < 0.0001), neck radiation (OR = 2.6, P = 0.005), no statin (OR = 2.1, P < 0.0001), and creatinine more than 1.5 (OR = 2.6, P < 0.0001). These variables were then assigned a hierarchal point scoring system in accordance with the OR value. The 5-year survival based on the scoring system was as follows: 0 to 5 points = 92.5%, 6 to 8 points = 83.6%, 9 to 11 points = 63.7%, 12 to 14 points = 46.5%, and more than 15 points = 33.8%. The Hosmer-Lemeshow test validated the scoring system (P = 0.26) and there was no difference in the ROC curves (C statistic = 0.74 vs 0.73).
Conclusions: This validated scoring system can be a useful tool for determining which patients are likely to benefit most from CEA based on the probability of long-term survival. Given that the 5-year survival of patients in the medical arm of the asymptomatic CEA trials was 60% to 70%, it is reasonable to conclude that patients who score 0 to 8 points are excellent candidates for CEA whereas most patients with >= 12 points should be managed with medical therapy alone.
C1 [Conrad, Mark F.; Kang, Jeanwan; Mukhopadhyay, Shankha; Patel, Virendra I.; LaMuraglia, Glenn M.; Cambria, Richard P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Conrad, MF (reprint author), Massachusetts Gen Hosp, 55 Fruit St,WAC 440, Boston, MA 02114 USA.
EM mconrad@partners.org
NR 31
TC 8
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD OCT
PY 2013
VL 258
IS 4
BP 534
EP 540
DI 10.1097/SLA.0b013e3182a5007b
PG 7
WC Surgery
SC Surgery
GA 300LB
UT WOS:000330464300003
PM 23979268
ER
PT J
AU Creutzberg, CL
Kitchener, HC
Birrer, MJ
Landoni, F
Lu, KH
Powell, M
Aghajanian, C
Edmondson, R
Goodfellow, PJ
Quinn, M
Salvesen, HB
Thomas, G
AF Creutzberg, Carien L.
Kitchener, Henry C.
Birrer, Michael J.
Landoni, Fabio
Lu, Karen H.
Powell, Melanie
Aghajanian, Carol
Edmondson, Richard
Goodfellow, Paul J.
Quinn, Michael
Salvesen, Helga B.
Thomas, Gillian
CA Second GCIG Endometrial Canc
TI Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials
Planning Meeting Taking Endometrial Cancer Trials Into the Translational
Era
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Article
DE Endometrial cancer; Randomised trials; Clinical trials planning meeting;
International collaboration; Gynecological Cancer Intergroup
ID OVARIAN-CANCER; ONCOLOGY-GROUP; CHEMOTHERAPY; RADIOTHERAPY; CARCINOMA;
METAANALYSIS
AB Objective: The second Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting was held on December 1, 2012, and included international multidisciplinary representatives of the 24 member groups. The aims were to review recent advances in molecular pathology of endometrial cancer, focusing on molecular-based therapy, and to identify key hypotheses and issues to be addressed through international collaborative clinical trials.
Methods: Reviews and summaries of current knowledge were presented followed by parallel working group sessions for surgery, adjuvant and systemic therapy, and translational research. Plenary discussions were held to integrate translational and clinical issues, and a final discussion session to agree on key trial concepts.
Results and Conclusions: Proposals to take forward on the following trials were agreed: (1) lymphadenectomy to direct adjuvant treatment in women with high-risk endometrial cancer, including a sentinel node substudy; (2) conservative therapy for low-risk endometrial cancers in morbidly obese women with high surgical risks and for fertility-sparing treatment in premenopausal patients; (3) adjuvant therapy for women with early-stage carcinosarcoma. A proposal was made that a GCIG Early Phase Consortium be developed to serve as an international platform for rapid assessment of biomarkers.
C1 [Creutzberg, Carien L.; Second GCIG Endometrial Canc] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands.
[Kitchener, Henry C.] Univ Manchester, Inst Canc Sci, Manchester M13 9PL, Lancs, England.
[Birrer, Michael J.] Harvard Univ, Sch Med, Div Hematol & Oncol, Boston, MA USA.
[Birrer, Michael J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Landoni, Fabio] European Inst Oncol, Div Gynaecol, Milan, Italy.
[Lu, Karen H.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA.
[Powell, Melanie] Barts Hlth NHS Trust, Dept Clin Oncol, London, England.
[Aghajanian, Carol] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10021 USA.
[Edmondson, Richard] Newcastle Univ, Dept Gynaecol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Edmondson, Richard] Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England.
[Goodfellow, Paul J.] Ohio State Univ, Coll Med, Dept Obstet & Gynecol, Columbus, OH 43210 USA.
[Quinn, Michael] Royal Womens Hosp, Dept Gynaecol Oncol, Melbourne, Vic, Australia.
[Quinn, Michael] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic 3010, Australia.
[Salvesen, Helga B.] Haukeland Hosp, Dept Obstet & Gynecol, Bergen, Norway.
[Salvesen, Helga B.] Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway.
[Thomas, Gillian] Sunnybrook Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada.
RP Creutzberg, CL (reprint author), Leiden Univ, Med Ctr, Dept Clin Oncol, Postzone K1-P,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.
EM c.l.creutzberg@lumc.nl
RI Miller, David/H-4604-2011; Mahner, Sven/F-3560-2014; Piovano,
Elisa/J-6846-2016; Lorusso, Domenica/K-6523-2016; salvesen,
Helga/C-1187-2017;
OI Quinn, Michael/0000-0003-0694-3870; Miller, David/0000-0002-8215-5887;
Piovano, Elisa/0000-0002-5629-703X; Lorusso,
Domenica/0000-0003-0981-0598; salvesen, Helga/0000-0002-4438-8831;
Glasspool, Rosalind/0000-0002-5000-1680
FU Gynecological Cancer InterGroup; National Cancer Institute, USA; Leiden
University Fund-van Walsum; Nucletron BV
FX The GCIG Endometrial Cancer Clinical Trials Planning meeting was funded
by unrestricted grants from the Gynecological Cancer InterGroup
(www.gcig.igcs.org); the National Cancer Institute, USA; Leiden
University Fund-van Walsum; and Nucletron BV.
NR 21
TC 3
Z9 3
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD OCT
PY 2013
VL 23
IS 8
BP 1528
EP 1534
DI 10.1097/IGC.0b013e3182a26edb
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 299CY
UT WOS:000330373900030
PM 24257568
ER
PT J
AU Chan, J
Brady, M
Penson, R
Monk, B
Boente, M
Walker, J
Davidson, S
DiSilvestro, P
O'Malley, D
Morgan, M
Pearl, M
De Geest, K
Michael, H
AF Chan, J.
Brady, M.
Penson, R.
Monk, B.
Boente, M.
Walker, J.
Davidson, S.
DiSilvestro, P.
O'Malley, D.
Morgan, M.
Pearl, M.
De Geest, K.
Michael, H.
TI PHASE III TRIAL OF EVERY-3-WEEKS PACLITAXEL VS. DOSE DENSE WEEKLY
PACLITAXEL WITH CARBOPLATIN plus /- BEVACIZUMAB IN EPITHELIAL OVARIAN,
PERITONEAL, FALLOPIAN TUBE CANCER: GOG 262 (NCT01167712)
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Meeting Abstract
C1 [Chan, J.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, San Francisco, CA USA.
[Brady, M.] Stat & Data Ctr, Gynecol Oncol Grp, Buffalo, NY USA.
[Penson, R.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Monk, B.] Creighton Univ, Sch Med, Dept Obstet & Gynecol, Phoenix, AZ USA.
[Boente, M.] Metrominnesota CCOP, Dept Hematol Oncol, Edina, MN USA.
[Walker, J.] Univ Oklahoma, Dept Obstet & Gynecol, Norman, OK 73019 USA.
[Davidson, S.] Univ Colorado, Ctr Canc, Anschutz Ctr Adv Med Fitzsimons, Dept Obstet & Gynecol, Aurora, CO USA.
[DiSilvestro, P.] Brown Univ, Women & Infants Hosp, Dept Obstet & Gynecol, Providence, RI USA.
[O'Malley, D.] Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA.
[Morgan, M.] Fox Chase Canc Ctr, Dept Surg Oncol, Gynecol Oncol Sect, Philadelphia, PA 19111 USA.
[Pearl, M.] Stony Brook Univ Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Stony Brook, NY USA.
[De Geest, K.] Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA.
[Michael, H.] Indiana Univ, Ctr Canc, Clarian North Med Ctr, Dept Pathol, Carmel, IN USA.
RI OMalley, David/E-3789-2011
NR 0
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD OCT
PY 2013
VL 23
IS 8
SU 1
PG 2
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 299EW
UT WOS:000330379500008
ER
PT J
AU Kristeleit, R
Burris, H
LoRusso, P
Patel, M
Giordano, H
Isaacson, J
Borrow, J
Allen, A
Jaw-Tsai, S
Shapiro, G
AF Kristeleit, R.
Burris, H., III
LoRusso, P.
Patel, M.
Giordano, H.
Isaacson, J.
Borrow, J.
Allen, A.
Jaw-Tsai, S.
Shapiro, G.
TI PHASE 1 STUDY OF CONTINUOUS ORAL RUCAPARIB: ANALYSIS OF PATIENT SUBGROUP
WITH OVARIAN/PERITONEAL CANCER
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Meeting Abstract
C1 [Kristeleit, R.] UCL, Inst Canc, London, England.
[Burris, H., III] Sarah Cannon Res Inst, Nashville, TN USA.
[LoRusso, P.] Karmanos Canc Inst, Detroit, MI USA.
[Patel, M.] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA.
[Giordano, H.; Borrow, J.; Allen, A.; Jaw-Tsai, S.] Clovis Oncol Inc, San Francisco, CA USA.
[Isaacson, J.] Clovis Oncol Inc, Boulder, CO USA.
[Shapiro, G.] Dana Farber Canc Inst, Ctr Early Drug Dev, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD OCT
PY 2013
VL 23
IS 8
SU 1
PG 1
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 299EW
UT WOS:000330379501235
ER
PT J
AU Minion, L
Tewari, KS
Chan, JK
Penson, RT
Cohn, DE
Monk, BJ
AF Minion, L.
Tewari, K. S.
Chan, J. K.
Penson, R. T.
Cohn, D. E.
Monk, B. J.
TI A TRIAL-BASED ECONOMIC ASSESSMENT OF BEVACIZUAMB AND CHEMOTHERAPY VERSUS
CHEMOTHERAPY ALONE FOR ADVANCED CERVICAL CANCER: COST-EFFECTIVE ANALYSIS
OF GYNECOLOGIC ONCOLOGY GROUP (GOG) PROTOCOL 240
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Meeting Abstract
C1 [Minion, L.] St Josephs Hosp, Phoenix, AZ USA.
[Tewari, K. S.] Univ Calif Irvine, Med Ctr, Div Gynecol Oncol, Orange, CA USA.
[Chan, J. K.] Univ Calif San Francisco, Div Gynecol Oncol, San Francisco, CA 94143 USA.
[Penson, R. T.] Massachusetts Gen Hosp, Dept Med Hematol & Oncol, Boston, MA 02114 USA.
[Cohn, D. E.] Ohio State Univ, Div Gynecol Oncol, Columbus, OH 43210 USA.
[Monk, B. J.] Creighton Univ, Sch Med, Div Gynecol Oncol, Phoenix, AZ USA.
[Monk, B. J.] Univ Arizona, Ctr Canc, St Josephs Hosp, Phoenix, AZ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD OCT
PY 2013
VL 23
IS 8
SU 1
PG 1
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 299EW
UT WOS:000330379500209
ER
PT J
AU Philpott, S
Rizzuto, I
Fraser, L
Manchanda, R
Hadwin, R
Burnell, M
Mackay, S
Skates, S
Menon, U
Jacobs, I
Rosenthal, A
AF Philpott, S.
Rizzuto, I.
Fraser, L.
Manchanda, R.
Hadwin, R.
Burnell, M.
Mackay, S.
Skates, S.
Menon, U.
Jacobs, I.
Rosenthal, A.
TI DETECTION OF NON-OVARIAN CANCERS ON PHASE 2 OF THE UK FAMILIAL OVARIAN
CANCER SCREENING STUDY (UKFOCSS)
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Meeting Abstract
C1 [Philpott, S.; Rizzuto, I.; Fraser, L.; Manchanda, R.; Hadwin, R.; Burnell, M.; Mackay, S.; Menon, U.] UCL, London, England.
[Skates, S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Skates, S.] Harvard Univ, Sch Med, Boston, MA USA.
[Jacobs, I.] Univ Manchester, Manchester, Lancs, England.
[Rosenthal, A.] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England.
NR 0
TC 0
Z9 0
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD OCT
PY 2013
VL 23
IS 8
SU 1
PG 1
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 299EW
UT WOS:000330379501264
ER
PT J
AU Kanyago, S
Riding, DM
Mutakooha, E
de la O, AL
Siedner, MJ
AF Kanyago, Samuel
Riding, David M.
Mutakooha, Elichum
de la O, Alcides Lopez
Siedner, Mark J.
TI Shang Ring Versus Forceps-Guided Adult Male Circumcision: A Randomized,
Controlled Effectiveness Study in Southwestern Uganda
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV/AIDS; Uganda; sub-Saharan Africa; adult male circumcision; HIV
prevention; acceptability; feasibility
ID HIV PREVENTION; TRIAL; MEN; INTERVENTION; DEVICE; RAKAI
AB Adult male circumcision (AMC) reduces HIV transmission, but uptake is limited in part by current surgical methods. We randomized HIV-uninfected men (n = 138) to receive Shang Ring (SR)- or forceps-guided AMC from a locally trained surgeon. In as-treated analyses, more SR procedures were completed within 10 minutes (79% versus 0%, P < 0.01) and more subjects reported high satisfaction (77% versus 58%, P = 0.03). Healing time and pain scores were similar, though minor complication rates were higher in SR subjects (56% versus 24%, P < 0.01). SR circumcision is a rapid and acceptable method of AMC and should be further evaluated to increase uptake of AMC.
C1 [Kanyago, Samuel; Mutakooha, Elichum; de la O, Alcides Lopez; Siedner, Mark J.] Mbarara Univ Sci & Technol, Fac Med, Dept Surg, Mbarara, Uganda.
[Kanyago, Samuel] Good Shepherd Hosp, Siteki, Swaziland.
[Riding, David M.] North West Deanery, Manchester, Lancs, England.
[Riding, David M.] Mbarara Reg Referral Hosp, Mbarara, Uganda.
[Siedner, Mark J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Global Hlth, Boston, MA USA.
RP Kanyago, S (reprint author), Good Shepherd Hosp, 3 Km,Siteki Maphungwane Rd, Siteki, Swaziland.
EM kanyagosamuel@gmail.com
FU Fogarty International Clinical Research Scholars and Fellows Program at
Vanderbilt University [R24 TW007988]; NIH [T32 AI007433]
FX M.J.S. received salary support from the Fogarty International Clinical
Research Scholars and Fellows Program at Vanderbilt University (R24
TW007988), and NIH (T32 AI007433).
NR 15
TC 6
Z9 12
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2013
VL 64
IS 2
BP 130
EP 133
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300GP
UT WOS:000330452700008
PM 23599013
ER
PT J
AU Kanyago, S
Riding, DM
Siedner, MJ
AF Kanyago, Samuel
Riding, David M.
Siedner, Mark J.
TI Authors' Reply: Proper Surgical Training and Grading of Complications
for Shang Ring Circumcision Are Necessary
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
C1 [Kanyago, Samuel] Mbarara Univ Sci & Technol, Fac Med, Dept Surg, Mbarara, Uganda.
[Kanyago, Samuel] Good Shepherd Hosp, Dept Surg, Siteki, Swaziland.
[Riding, David M.] North West Deanery, Manchester, Lancs, England.
[Siedner, Mark J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Siedner, Mark J.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Siedner, Mark J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Kanyago, S (reprint author), Mbarara Univ Sci & Technol, Fac Med, Dept Surg, Mbarara, Uganda.
FU FIC NIH HHS [R24 TW007988]; NIAID NIH HHS [T32 AI007433]; NIMH NIH HHS
[K23 MH099916]
NR 4
TC 0
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2013
VL 64
IS 2
BP E12
EP E12
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300GP
UT WOS:000330452700002
PM 24043119
ER
PT J
AU Mackay, DD
Huesmann, GR
Wu, RI
Stone, JR
Pless, ML
AF Mackay, Devin D.
Huesmann, Graham R.
Wu, Roseann I.
Stone, James R.
Pless, Misha L.
TI Giant Cell Arteritis Causing Symmetric Bilateral Posterior Circulation
Infarcts
SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
LA English
DT Article
DE giant cell arteritis; stroke; posterior circulation; temporal arteritis
ID VERTEBRAL ARTERY; ISCHEMIC COMPLICATIONS; TEMPORAL ARTERITIS; OCCLUSION;
DIAGNOSIS; DISEASE
AB An 82-year-old woman presented with bilateral, symmetric posterior circulation infarctions secondary to giant cell arteritis (GCA). Her atypical clinical presentation included a lack of headache and fever, but she exhibited signs of systemic illness including generalized weakness, cachexia, apathy, and anemia. Laboratory testing revealed a markedly elevated erythrocyte sedimentation rate, but only a borderline elevated C-reactive protein. Head and neck vascular imaging demonstrated a pattern of vertebral arterial narrowing consistent with GCA-a diagnosis confirmed by temporal artery biopsy. Her unusual symptomatic, laboratory, and imaging presentation highlights the importance of considering GCA in the differential diagnosis of unusual bilateral stroke syndromes, where early treatment decreases morbid outcomes.
C1 [Mackay, Devin D.; Huesmann, Graham R.; Pless, Misha L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 01945 USA.
[Wu, Roseann I.; Stone, James R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 01945 USA.
[Pless, Misha L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Pless, ML (reprint author), Massachusetts Gen Hosp, Dept Neurol, 15 Parkman St, Boston, MA 01945 USA.
EM Pless.Misha@mgh.harvard.edu
NR 12
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-1608
EI 1536-7355
J9 JCR-J CLIN RHEUMATOL
JI JCR-J. Clin. Rheumatol.
PD OCT
PY 2013
VL 19
IS 7
BP 393
EP 396
DI 10.1097/RHU.0b013e3182a6ffc1
PG 4
WC Rheumatology
SC Rheumatology
GA 300KF
UT WOS:000330462100008
PM 24048110
ER
PT J
AU Fostvedt, S
Bruinsma, WE
Neuhaus, V
Stone, JH
Mudgal, CS
AF Fostvedt, Sigrid
Bruinsma, Wendy E.
Neuhaus, Valentin
Stone, John H.
Mudgal, Chaitanya S.
TI Manifestations and Treatment of the Hand in Adult Congenital
Erythropoietic Porphyria
SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
LA English
DT Article
DE congenital erythropoietic porphyria; finger; PIP arthrodesis; Gunther
disease
ID RADIOLOGICAL FEATURES; GUNTHERS-DISEASE; MANAGEMENT
AB Congenital erythropoietic porphyria (CEP) is a rare enzymatic disorder of heme metabolism, leading to the accumulation of porphyrins in the skin and subdermal structures. We present the case of a 34-year-old, right-hand-dominant, male patient with CEP. The patient had developed a chronic open subluxation of the left index finger proximal interphalangeal joint due to skin necrosis. We successfully treated the patient with proximal interphalangeal arthrodesis. This case demonstrates that childhood-onset CEP can also manifest in the adult hand. Considering the patient's age, the destructive nature of the disease, and the poor quality of function in older patients with childhood CEP, surgical intervention was necessary to avoid further digital length loss. Although the treatment described in this case report is not uncommon, we found it essential to present this case because the clinical presentation of CEP is rare.
C1 [Fostvedt, Sigrid; Bruinsma, Wendy E.; Neuhaus, Valentin; Mudgal, Chaitanya S.] Massachusetts Gen Hosp, Orthopaed Hand Serv, Boston, MA 02114 USA.
[Stone, John H.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
RP Mudgal, CS (reprint author), Massachusetts Gen Hosp, Orthopaed Hand Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM cmudgal@partners.org
OI Neuhaus, Valentin/0000-0003-4012-5628
FU Gottfried und Julia Bangerter-Rhyner-Stiftung, Switzerland, for
Scientific Research
FX No relevant benefits in any form have been received or will be received
related directly or indirectly to the subject of this article. V.N. is
currently receiving a grant from the Gottfried und Julia
Bangerter-Rhyner-Stiftung, Switzerland, for Scientific Research.
NR 10
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-1608
EI 1536-7355
J9 JCR-J CLIN RHEUMATOL
JI JCR-J. Clin. Rheumatol.
PD OCT
PY 2013
VL 19
IS 7
BP 402
EP 404
DI 10.1097/RHU.0b013e3182a70073
PG 3
WC Rheumatology
SC Rheumatology
GA 300KF
UT WOS:000330462100011
PM 24048109
ER
PT J
AU Nichols, CR
Roth, B
Albers, P
Einhorn, LH
Foster, R
Daneshmand, S
Jewett, M
Warde, P
Sweeney, CJ
Beard, C
Powles, T
Tyldesley, S
So, A
Porter, C
Olgac, S
Fizazi, K
Hayes-Lattin, B
Grimison, P
Toner, G
Cathomas, R
Bokemeyer, C
Kollmannsberger, C
AF Nichols, Craig R.
Roth, Bruce
Albers, Peter
Einhorn, Lawrence H.
Foster, Richard
Daneshmand, Siamak
Jewett, Michael
Warde, Padraig
Sweeney, Christopher J.
Beard, Clair
Powles, Tom
Tyldesley, Scott
So, Alan
Porter, Christopher
Olgac, Semra
Fizazi, Karim
Hayes-Lattin, Brandon
Grimison, Peter
Toner, Guy
Cathomas, Richard
Bokemeyer, Carsten
Kollmannsberger, Christian
TI Active Surveillance Is the Preferred Approach to Clinical Stage I
Testicular Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID GERM-CELL TUMORS; LYMPH-NODE DISSECTION; SEMINOMA; RISK; MANAGEMENT;
SURVIVORS; TESTIS; TRIAL
C1 [Nichols, Craig R.; Porter, Christopher; Olgac, Semra] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
[Roth, Bruce] Washington Univ, Sch Med, St Louis, MO USA.
[Albers, Peter] Univ Dusseldorf, Univ Hosp Heinrich Heine, Dusseldorf, Germany.
[Einhorn, Lawrence H.; Foster, Richard] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA.
[Daneshmand, Siamak] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
[Jewett, Michael; Warde, Padraig] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
[Sweeney, Christopher J.; Beard, Clair] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Powles, Tom] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, London, England.
[Tyldesley, Scott; So, Alan; Kollmannsberger, Christian] Univ British Columbia, Vancouver Canc Ctr, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada.
[Fizazi, Karim] Univ Paris 11, Inst Gustave Roussy, Paris, France.
[Hayes-Lattin, Brandon] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Grimison, Peter] Univ Sydney, Sydney Canc Ctr, Royal Prince Alfred Hosp, Sydney, NSW 2006, Australia.
[Toner, Guy] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Cathomas, Richard] Kantonsspital Graubuenden, Chur, Switzerland.
[Bokemeyer, Carsten] Univ Hamburg, Univ Med Ctr Eppendorf, Hamburg, Germany.
RP Nichols, CR (reprint author), Virginia Mason Med Ctr, Seattle, WA 98101 USA.
OI Daneshmand, Siamak/0000-0001-6224-9598; Toner, Guy/0000-0001-9873-3592
NR 27
TC 52
Z9 52
U1 1
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 1
PY 2013
VL 31
IS 28
BP 3490
EP 3493
DI 10.1200/JCO.2012.47.6010
PG 4
WC Oncology
SC Oncology
GA 301NM
UT WOS:000330539000006
PM 24002502
ER
PT J
AU Cespedes, EM
McDonald, J
Haines, J
Bottino, CJ
Schmidt, ME
Taveras, EM
AF Cespedes, Elizabeth M.
McDonald, Julia
Haines, Jess
Bottino, Clement J.
Schmidt, Marie Evans
Taveras, Elsie M.
TI Obesity-related Behaviors of US- and Non-US-born Parents and Children in
Low-income Households
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
LA English
DT Article
DE childhood obesity; behavior; immigrant families; routines; home
environment
ID RANDOMIZED CONTROLLED-TRIAL; PRESCHOOL-AGED CHILDREN; BODY-MASS INDEX;
SLEEP DURATION; WEIGHT STATUS; YOUNG-CHILDREN; UNITED-STATES; SCREENING
QUESTIONNAIRE; IMMIGRANT CHILDREN; PHYSICAL-ACTIVITY
AB Objective: To examine differences in obesity-related behaviors by parental US-born status among low-income, minority families participating in Healthy Habits, Happy Homes, an intervention trial to improve household routines for childhood obesity prevention. Evidence suggests lower obesity risk among adult immigrants, but research is inconclusive regarding the influence of having a non-US-born parent on childhood obesity. Method: We sampled 57 US-born and 64 non-US-born families of children aged 2 to 5.9 years living in the Boston area. At baseline, parents reported their own screen time, physical activity, diet, and sleep as well as their children's behaviors. We used linear and logistic regression to examine the association of parental US-born status with obesity-related behaviors. Results: Mean (SD) body mass index z score was 0.94 (1.16), and it did not differ between the groups. After adjusting for parental education and child race/ethnicity, children of non-US-born (vs US-born) parents had later bedtimes (0.81 hours later; 95% confidence interval [CI], 0.37-1.25) and wake-up times (0.56 hours later; 95% CI, 0.16-0.95) and engaged in less active play (0.15 fewer hr/d; 95% CI, -0.28 to -0.01). Non-US-born (vs US-born) parents had less screen exposure. Conclusion: In this cross-section of low-income, urban families, having a parent born outside the United States was associated with a profile of risk and protective behavior; adjustment for education and race/ethnicity removed the protective associations of parental nativity with child behavior. Obesity-related differences in behaviors and home environments should be considered when designing interventions targeting low-income communities with a high proportion of non-US-born participants.
C1 [Cespedes, Elizabeth M.; McDonald, Julia; Taveras, Elsie M.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA USA.
[Cespedes, Elizabeth M.; McDonald, Julia; Taveras, Elsie M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Cespedes, Elizabeth M.; Taveras, Elsie M.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Cespedes, Elizabeth M.; Taveras, Elsie M.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Haines, Jess] Univ Guelph, Dept Family Relat & Appl Nutr, Guelph, ON N1G 2W1, Canada.
[Bottino, Clement J.; Schmidt, Marie Evans] Boston Childrens Hosp, Dept Med, Boston, MA USA.
[Taveras, Elsie M.] MassGen Hosp Children, Div Gen Pediat, Boston, MA USA.
RP Cespedes, EM (reprint author), Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM emc611@mail.harvard.edu
OI Cespedes Feliciano, Elizabeth/0000-0003-1192-4017
FU Centers for Disease Control and Prevention's National Center for Chronic
Disease Prevention and Health Promotion (Prevention Research Centers)
[1U48DP00194]
FX Supported by the Centers for Disease Control and Prevention's National
Center for Chronic Disease Prevention and Health Promotion (Prevention
Research Centers Grants, 1U48DP00194).
NR 48
TC 2
Z9 2
U1 5
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0196-206X
EI 1536-7312
J9 J DEV BEHAV PEDIATR
JI J. Dev. Behav. Pediatr.
PD OCT
PY 2013
VL 34
IS 8
BP 541
EP 548
PG 8
WC Behavioral Sciences; Psychology, Developmental; Pediatrics
SC Behavioral Sciences; Psychology; Pediatrics
GA 298XZ
UT WOS:000330359300002
PM 24131876
ER
PT J
AU Nillni, YI
Nosen, E
Williams, PA
Tracy, M
Coffey, SF
Galea, S
AF Nillni, Yael I.
Nosen, Elizabeth
Williams, Patrick A.
Tracy, Melissa
Coffey, Scott F.
Galea, Sandro
TI Unique and Related Predictors of Major Depressive Disorder,
Posttraumatic Stress Disorder, and Their Comorbidity After Hurricane
Katrina
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE Posttraumatic stress disorder; major depressive disorder; comorbidity;
disasters
ID MENTAL-HEALTH PROBLEMS; DISASTER VICTIMS; NATURAL DISASTER;
PSYCHIATRIC-DISORDERS; PREVALENCE; PTSD; POPULATION; SYMPTOMS; ANDREW;
PHQ-9
AB The current study examined demographic and psychosocial factors that predict major depressive disorder (MDD) and comorbid MDD/posttraumatic stress disorder (MDD/PTSD) diagnostic status after Hurricane Katrina, one of the deadliest and costliest hurricanes in the history of the United States. This study expanded on the findings published in the article by Galea, Tracy, Norris, and Coffey (J Trauma Stress 21: 357-368, 2008), which examined the same predictors for PTSD, to better understand related and unique predictors of MDD, PTSD, and MDD/PTSD comorbidity. A total of 810 individuals representative of adult residents living in the 23 southern-most counties of Mississippi before Hurricane Katrina were interviewed. Ongoing hurricane-related stressors, low social support, and hurricane-related financial loss were common predictors of MDD, PTSD, and MDD/PTSD, whereas educational and marital status emerged as unique predictors of MDD. Implications for postdisaster relief efforts that address the risk for both MDD and PTSD are discussed.
C1 [Nillni, Yael I.; Nosen, Elizabeth; Williams, Patrick A.; Coffey, Scott F.] Univ Mississippi, Med Ctr, Jackson, MS USA.
[Nillni, Yael I.] Univ Vermont, Burlington, VT 05405 USA.
[Nosen, Elizabeth] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Tracy, Melissa; Galea, Sandro] Columbia Univ, New York, NY USA.
RP Nillni, YI (reprint author), Vet Affairs Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA.
EM yael.nillni2@va.gov
RI Kilic, Cengiz/I-9145-2013
FU National Institutes of Health [MH 078152]
FX This study was supported by grant MH 078152 from the National Institutes
of Health.
NR 35
TC 10
Z9 10
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD OCT
PY 2013
VL 201
IS 10
BP 841
EP 847
DI 10.1097/NMD.0b013e3182a430a0
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 299DR
UT WOS:000330375900002
PM 24080670
ER
PT J
AU Knouse, LE
Traeger, L
O'Cleirigh, C
Safren, SA
AF Knouse, Laura E.
Traeger, Lara
O'Cleirigh, Conall
Safren, Steven A.
TI Adult Attention Deficit Hyperactivity Disorder Symptoms and Five-Factor
Model Traits in a Clinical Sample A Structural Equation Modeling
Approach
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE Attention deficit hyperactivity disorder; ADHD; personality; five-factor
model; NEO-FFI; neuroticism; conscientiousness
ID COVARIANCE STRUCTURE-ANALYSIS; DEFICIT/HYPERACTIVITY DISORDER;
PERSONALITY-TRAITS; DISEASE PROGRESSION; EXECUTIVE FUNCTIONS; ADHD
SYMPTOMS; PROFILES; THERAPY; HIV
AB Relationships among attention deficit hyperactivity disorder (ADHD) symptoms and adult personality traits have not been examined in larger clinically diagnosed samples. We collected multisource ADHD symptom and self-report NEO Five-Factor Inventory (Costa and McCrae [Odessa, FL: Psychological Assessment Resources, Inc, 1992) data from 117 adults with ADHD and tested symptom-trait associations using structural equation modeling. The final model fit the data. Inattention was positively associated with neuroticism and negatively associated with conscientiousness. On the basis of ADHD expression in adulthood, hyperactivity and impulsivity were estimated as separate constructs and showed differential relationships to extraversion and agreeableness. A significant positive relationship between hyperactivity and conscientiousness arose in the context of other pathways. ADHD symptoms are reliably associated with personality traits, suggesting a complex interplay across development that warrants prospective study into adulthood.
C1 [Safren, Steven A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Safren, SA (reprint author), Massachusetts Gen Hosp, One Bowdoin Sq,7th Floor, Boston, MA 02114 USA.
EM ssafren@partners.org
FU NIH [5R01MH69812, 1R03MH60940]
FX This research was supported by NIH Grants 5R01MH69812 and 1R03MH60940 to
Steven A. Safren.
NR 45
TC 4
Z9 4
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD OCT
PY 2013
VL 201
IS 10
BP 848
EP 854
DI 10.1097/NMD.0b013e3182a5bf33
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 299DR
UT WOS:000330375900003
PM 24080671
ER
PT J
AU Lewis-Fernandez, R
Raggio, GA
Gorritz, M
Duan, N
Marcus, S
Cabassa, LJ
Humensky, J
Becker, AE
Alarcon, RD
Oquendo, MA
Hansen, H
Like, RC
Weiss, M
Desai, PN
Jacobsen, FM
Foulks, EF
Primm, A
Lu, F
Kopelowicz, A
Hinton, L
Hinton, DE
AF Lewis-Fernandez, Roberto
Raggio, Greer A.
Gorritz, Magdaliz
Duan, Naihua
Marcus, Sue
Cabassa, Leopoldo J.
Humensky, Jennifer
Becker, Anne E.
Alarcon, Renato D.
Oquendo, Maria A.
Hansen, Helena
Like, Robert C.
Weiss, Mitchell
Desai, Prakash N.
Jacobsen, Frederick M.
Foulks, Edward F.
Primm, Annelle
Lu, Francis
Kopelowicz, Alex
Hinton, Ladson
Hinton, Devon E.
TI GAP-REACH A Checklist to Assess Comprehensive Reporting of Race,
Ethnicity, and Culture in Psychiatric Publications
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE Race; ethnicity; culture; checklist; psychiatric literature
ID RANDOMIZED CONTROLLED-TRIALS; SOCIOECONOMIC-STATUS; CONSORT STATEMENT;
CLINICAL-TRIALS; SOCIAL-CLASS; QUALITY; HEALTH; RACE/ETHNICITY;
POPULATIONS; ARTICLES
AB Growing awareness of health and health care disparities highlights the importance of including information about race, ethnicity, and culture (REC) in health research. Reporting of REC factors in research publications, however, is notoriously imprecise and unsystematic. This article describes the development of a checklist to assess the comprehensiveness and the applicability of REC factor reporting in psychiatric research publications. The 16-itemGAP-REACH (c) checklist was developed through a rigorous process of expert consensus, empirical content analysis in a sample of publications (N = 1205), and interrater reliability (IRR) assessment (N = 30). The items assess each section in the conventional structure of a health research article. Data from the assessment may be considered on an item-by-item basis or as a total score ranging from 0% to 100%. The final checklist has excellent IRR (kappa = 0.91). The GAP-REACH may be used by multiple research stakeholders to assess the scope of REC reporting in a research article.
C1 [Lewis-Fernandez, Roberto; Duan, Naihua; Marcus, Sue; Cabassa, Leopoldo J.; Humensky, Jennifer; Oquendo, Maria A.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
[Lewis-Fernandez, Roberto; Gorritz, Magdaliz; Duan, Naihua; Marcus, Sue; Cabassa, Leopoldo J.; Humensky, Jennifer; Oquendo, Maria A.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Raggio, Greer A.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA.
[Duan, Naihua; Marcus, Sue] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10027 USA.
[Cabassa, Leopoldo J.] Columbia Univ, Sch Social Work, New York, NY 10027 USA.
[Becker, Anne E.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Alarcon, Renato D.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA.
[Hansen, Helena] NYU, Dept Psychiat, New York, NY 10016 USA.
[Hansen, Helena] NYU, Dept Anthropol, New York, NY 10003 USA.
[Like, Robert C.] UMDNJY Robert Wood Johnson Med Sch, Dept Family Med & Community Hlth, New Brunswick, NJ USA.
[Weiss, Mitchell] Swiss Trop Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland.
[Weiss, Mitchell] Univ Basel, CH-4003 Basel, Switzerland.
[Desai, Prakash N.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA.
[Jacobsen, Frederick M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA.
[Foulks, Edward F.] Tulane Univ, Dept Psychiat, New Orleans, LA 70118 USA.
[Primm, Annelle] Amer Psychiat Assoc, Arlington, VA USA.
Johns HopkinsMed Sch, Dept Psychiat, Baltimore, MD USA.
[Lu, Francis; Hinton, Ladson] Univ Calif Davis, Dept Psychiat, Davis, CA 95616 USA.
[Kopelowicz, Alex] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
[Hinton, Devon E.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
RP Lewis-Fernandez, R (reprint author), New York State Psychiat Inst & Hosp, Unit 69,1051 Riverside Dr, New York, NY 10032 USA.
EM rlewis@nyspi.columbia.edu
OI kopelowicz, alex/0000-0002-1728-4105
FU National Institute of Mental Health [R21 MH066388, R34 MH073087, R01
MH077226]; Brain and Behavior Research Foundation; New York State
Psychiatric Institute
FX This study was supported by grants R21 MH066388, R34 MH073087, and R01
MH077226 from the National Institute of Mental Health and a grant award
from the Brain and Behavior Research Foundation to Dr. Lewis-Fernandez
and institutional funds from the New York State Psychiatric Institute.
NR 49
TC 6
Z9 7
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
EI 1539-736X
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD OCT
PY 2013
VL 201
IS 10
BP 860
EP 871
DI 10.1097/NMD.0b013e3182a5c184
PG 12
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 299DR
UT WOS:000330375900005
PM 24080673
ER
PT J
AU Jacobsen, HB
Caban-Martinez, A
Onyebeke, LC
Sorensen, G
Dennerlein, JT
Reme, SE
AF Jacobsen, Henrik Borsting
Caban-Martinez, Alberto
Onyebeke, Lynn C.
Sorensen, Glorian
Dennerlein, Jack T.
Reme, Silje Endresen
TI Construction Workers Struggle With a High Prevalence of Mental Distress,
and This Is Associated With Their Pain and Injuries
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID LOW-BACK-PAIN; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW;
NATIONAL-COMORBIDITY-SURVEY; UNITED-STATES; OLDER CONSTRUCTION;
RISK-FACTORS; PSYCHOLOGICAL DISTRESS; PSYCHIATRIC-DISORDERS; SCREENING
SCALES; AGING WORKFORCE
AB Objectives: We aimed to investigate how mental distress was associated with pain and injuries in a convenience sample of construction workers. Methods: A cross-sectional, mental health assessment was conducted in a convenience sample of construction workers (N = 172). A subsample participated in a clinical interview (n = 10). We used a cutoff (1.50 or greater) on Hopkins Symptom Checklist-25 to determine substantial mental distress and determined associations with pain and injury outcomes. Results: The prevalence of substantial mental distress was 16% in the workers. This was supported by follow-up clinical interviews where 9 of 10 workers fulfilled the criteria for a mental disorder. Substantial mental distress was associated with both injury rate and self-reported pain. Conclusion: This pilot study strongly suggests the need for rigorous studies on construction worker mental health and how it affects their work and well-being.
C1 [Jacobsen, Henrik Borsting; Caban-Martinez, Alberto; Onyebeke, Lynn C.; Sorensen, Glorian; Dennerlein, Jack T.; Reme, Silje Endresen] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Dennerlein, Jack T.] Northeastern Univ, Boston, MA 02115 USA.
[Sorensen, Glorian] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Reme, Silje Endresen] Uni Hlth, Uni Res, Bergen, Norway.
[Jacobsen, Henrik Borsting] Norwegian Univ Sci & Technol, N-7034 Trondheim, Norway.
RP Jacobsen, HB (reprint author), NTNU, Fac Med, Dept Publ Hlth, MTFS, POB 8905, N-7491 Trondheim, Norway.
EM henrik.b.jacobsen@ntnu.no
OI Dennerlein, Jack/0000-0001-7703-643X; Caban-Martinez,
Alberto/0000-0002-5960-1308
FU National Institute for Occupational Safety and Health [U19 OH008861];
National Institute of Arthritis and Musculoskeletal and Skin Diseases
[T32 AR055885]
FX This work was supported by a grant from the National Institute for
Occupational Safety and Health (U19 OH008861) for the Harvard School of
Public Health Center for Work, Health and Well-being, and a grant from
the National Institute of Arthritis and Musculoskeletal and Skin
Diseases (grant T32 AR055885) to the Clinical Orthopedic and
Musculoskeletal Education and Training Program at Brigham and Women's
Hospital, Harvard Medical School and Harvard School of Public Health,
and the Liberty Mutual Harvard School of Public Health Program for
Occupational Safety and Health.
NR 42
TC 6
Z9 6
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD OCT
PY 2013
VL 55
IS 10
BP 1197
EP 1204
DI 10.1097/JOM.0b013e31829c76b3
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 300FC
UT WOS:000330448800011
PM 24064778
ER
PT J
AU Mejaddam, AY
Birkhan, OA
Sideris, AC
Van der Wilden, GM
Imam, AM
Hwabejire, JO
Chang, YC
Velmahos, GC
Fagenholz, PJ
Yeh, DD
de Moya, MA
King, DR
AF Mejaddam, Ali Y.
Birkhan, Oscar A.
Sideris, Antonis C.
Van der Wilden, Gwendolyn M.
Imam, Ayesha M.
Hwabejire, John O.
Chang, Yuchiao
Velmahos, George C.
Fagenholz, Peter J.
Yeh, Daniel D.
de Moya, Marc A.
King, David Richard
TI Real-time heart rate entropy predicts the need for lifesaving
interventions in trauma activation patients
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Entropy; combat; triage; complexity; variability
ID DIMINISHED PHYSIOLOGICAL RESERVE; RATE-VARIABILITY; PERIOD VARIABILITY;
HEMORRHAGIC-SHOCK; RATE COMPLEXITY; MORTALITY; TRIAGE; INDICATOR
AB BACKGROUND: Heart rate complexity (HRC), commonly described as a "new vital sign," has shown promise in predicting injury severity, but its use in clinical practice has been precluded by the absence of real-time data. This study was conducted to evaluate the utility of real-time, automated, instantaneous, hand-held heart rate entropy analysis in predicting the need for lifesaving interventions (LSIs). We hypothesized that real-time HRC would predict LSIs.
METHODS: Prospective enrollment of patients who met criteria for trauma team activation was conducted at a Level I trauma center (September 2011 to February 2012). A novel, hand-held, portable device was used to measure HRC (by sample entropy) and time-domain heart rate variability continuously in real time for 2 hours after the moment of presentation. Electric impedance cardiography was used to determine cardiac output. Patients who received an LSI were compared with patients without any intervention (non-LSI). Multivariable analysis was performed to control for differences between the groups.
RESULTS: Of 82 patients enrolled, 21 (26%) received 67 LSIs within 24 hours of hospital arrival. Initial systolic blood pressure was similar in both groups. LSI patients had a lower Glasgow Coma Scale (GCS) score (9.2 [5.1] vs. 14.9 [0.2], p < 0.0001). The mean (SD) HRC value on presentation was 0.8 (0.6) in the LSI group compared with 1.5 (0.6) in the non-LSI group (p G 0.0001). With the use of logistic regression, initial HRC was the only significant predictor of LSI. A cutoff value for HRC of 1.1 yields sensitivity, specificity, negative predictive value, and positive predictive value of 86%, 74%, 94%, and 53%, respectively, with an accuracy of 77% for predicting an LSI.
CONCLUSION: Decreased HRC on hospital arrival is an independent predictor of the need for LSI in trauma activation patients. Real-time HRC may be a useful adjunct to standard vital signs monitoring and predicts LSIs. Copyright (C) 2013 by Lippincott Williams & Wilkins
C1 [King, David Richard] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02141 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP King, DR (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02141 USA.
EM Dking3@partners.org
OI King, David/0000-0003-1028-1478
NR 29
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD OCT
PY 2013
VL 75
IS 4
BP 607
EP 612
DI 10.1097/TA.0b013e31829bb991
PG 6
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 300IK
UT WOS:000330457400010
PM 24064873
ER
PT J
AU Scott, NS
AF Scott, Nandita S.
TI Hypertensive pregnancy, menopausal symptoms, and heart disease: a motley
crew of characters
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Editorial Material
ID CARDIOVASCULAR-DISEASE; PREECLAMPSIA; WOMEN; ASSOCIATION; RISK;
DYSFUNCTION; HISTORY; UPDATE; AGE
C1 Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Scott, NS (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
NR 14
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
EI 1530-0374
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD OCT
PY 2013
VL 20
IS 10
BP 993
EP 994
DI 10.1097/gme.0b013e3182a34c12
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 300LC
UT WOS:000330464400002
PM 23982112
ER
PT J
AU Darney, BG
Snowden, JM
Cheng, YW
Jacob, L
Nicholson, JM
Kaimal, A
Dublin, S
Getahun, D
Caughey, AB
AF Darney, Blair G.
Snowden, Jonathan M.
Cheng, Yvonne W.
Jacob, Lorie
Nicholson, James M.
Kaimal, Anjali
Dublin, Sascha
Getahun, Darios
Caughey, Aaron B.
TI Elective Induction of Labor at Term Compared With Expectant Management
Maternal and Neonatal Outcomes
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID CESAREAN DELIVERY; NULLIPAROUS WOMEN; GESTATIONAL-AGE; UNITED-STATES;
RISK; COHORT; PROGRESSION; PREGNANCY
AB OBJECTIVE: To test the association of elective induction of labor at term compared with expectant management and maternal and neonatal outcomes.
METHODS: This was a retrospective cohort study of all deliveries without prior cesarean delivery in California in 2006 using linked hospital discharge and vital statistics data. We compared elective induction at each term gestational age (37-40 weeks) as defined by The Joint Commission with expectant management in vertex, non-anomalous, singleton deliveries. We used multivariable logistic regression to test the association of elective induction and cesarean delivery, operative vaginal delivery, maternal third- or fourth-degree lacerations, perinatal death, neonatal intensive care unit admission, respiratory distress, shoulder dystocia, hyperbilirubinemia, and macrosomia (birth weight greater than 4,000 g) at each gestational week, stratified by parity.
RESULTS: The cesarean delivery rate was 16%, perinatal mortality was 0.2%, and neonatal intensive care unit admission was 6.2% (N=362,154). The odds of cesarean delivery were lower among women with elective induction compared with expectant management across all gestational ages and parity (37 weeks [odds ratio (OR) 0.44, 95% confidence interval (CI) 0.34-0.57], 38 weeks [OR 0.43, 95% CI 0.38-0.50], 39 weeks [OR 0.46, 95% CI 0.41-0.52], 40 weeks [OR 0.57, CI 0.50-0.65]). Elective induction was not associated with increased odds of severe lacerations, operative vaginal delivery, perinatal death, neonatal intensive care unit admission, respiratory distress, shoulder dystocia, or macrosomia at any term gestational age. Elective induction was associated with increased odds of hyperbilirubinemia at 37 and 38 weeks of gestation and shoulder dystocia at 39 weeks of gestation.
CONCLUSION: Elective induction of labor is associated with decreased odds of cesarean delivery when compared with expectant management.
C1 Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Penn State Univ, Coll Med, Hershey, PA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Grp Hlth Res Inst, Seattle, WA USA.
Kaiser Permanente So Calif, Pasadena, CA 91101 USA.
RP Darney, BG (reprint author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Dept Med Informat & Clin Epidemiol, Mail Code L-466,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM darneyb@ohsu.edu
FU Agency for Healthcare Research and Quality T32 postdoctoral award
[HS017582]; National Institute on Aging [K23AG028954]; Health Resources
and Services Administration/Maternal and Child Health
[R40MC25694-01-00]; University of California, San Francisco Women's
Reproductive Health Research Career Development Award, National
Institutes of Health; Eunice Kennedy Shriver National Institute of Child
Health and Human Development [K12 HD001262]
FX Dr. Darney was supported by an Agency for Healthcare Research and
Quality T32 postdoctoral award (HS017582). Dr Dublin was supported by
National Institute on Aging grant K23AG028954. Drs. Caughey and Snowden
were supported by a Health Resources and Services
Administration/Maternal and Child Health grant R40MC25694-01-00. Dr.
Cheng is supported by the University of California, San Francisco
Women's Reproductive Health Research Career Development Award, National
Institutes of Health, and the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (K12 HD001262).
NR 31
TC 44
Z9 44
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
EI 1873-233X
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD OCT
PY 2013
VL 122
IS 4
BP 761
EP 769
DI 10.1097/AOG.0b013e3182a6a4d0
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 300EJ
UT WOS:000330446900006
PM 24084532
ER
PT J
AU Shanechi, MM
Chemali, JJ
Liberman, M
Solt, K
Brown, EN
AF Shanechi, Maryam M.
Chemali, Jessica J.
Liberman, Max
Solt, Ken
Brown, Emery N.
TI A Brain-Machine Interface for Control of Medically-Induced Coma
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID CLOSED-LOOP CONTROL; MODEL-PREDICTIVE CONTROL; DELIVERY-SYSTEM
CLADS(TM); QUANTITATIVE EEG ANALYSIS; BISPECTRAL INDEX;
BURST-SUPPRESSION; PERFORMANCE ASSESSMENT; PROPOFOL ANESTHESIA;
FEEDBACK-CONTROL; GENERAL-ANESTHESIA
AB Medically-induced coma is a drug-induced state of profound brain inactivation and unconsciousness used to treat refractory intracranial hypertension and to manage treatment-resistant epilepsy. The state of coma is achieved by continually monitoring the patient's brain activity with an electroencephalogram (EEG) and manually titrating the anesthetic infusion rate to maintain a specified level of burst suppression, an EEG marker of profound brain inactivation in which bursts of electrical activity alternate with periods of quiescence or suppression. The medical coma is often required for several days. A more rational approach would be to implement a brain-machine interface (BMI) that monitors the EEG and adjusts the anesthetic infusion rate in real time to maintain the specified target level of burst suppression. We used a stochastic control framework to develop a BMI to control medically-induced coma in a rodent model. The BMI controlled an EEG-guided closed-loop infusion of the anesthetic propofol to maintain precisely specified dynamic target levels of burst suppression. We used as the control signal the burst suppression probability (BSP), the brain's instantaneous probability of being in the suppressed state. We characterized the EEG response to propofol using a two-dimensional linear compartment model and estimated the model parameters specific to each animal prior to initiating control. We derived a recursive Bayesian binary filter algorithm to compute the BSP from the EEG and controllers using a linear-quadratic-regulator and a model-predictive control strategy. Both controllers used the estimated BSP as feedback. The BMI accurately controlled burst suppression in individual rodents across dynamic target trajectories, and enabled prompt transitions between target levels while avoiding both undershoot and overshoot. The median performance error for the BMI was 3.6%, the median bias was -1.4% and the overall posterior probability of reliable control was 1 (95% Bayesian credibility interval of [0.87, 1.0]). A BMI can maintain reliable and accurate real-time control of medically-induced coma in a rodent model suggesting this strategy could be applied in patient care.
C1 [Shanechi, Maryam M.] Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY 14850 USA.
[Shanechi, Maryam M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA.
[Chemali, Jessica J.; Liberman, Max; Solt, Ken; Brown, Emery N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Brown, Emery N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
[Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
RP Shanechi, MM (reprint author), Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY 14850 USA.
EM shanechi@cornell.edu; enb@neurostat.mit.edu
OI Solt, Ken/0000-0001-5328-2062
FU National Institutes of Health, Bethesda, Maryland [DP1-OD003646, R01
GM104948, NIH K08-GM094394]; Department of Anesthesia, Critical Care,
and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts
FX Support was provided by NIH Director's Pioneer Award DP1-OD003646 and
NIH Director's Transformative Award R01 GM104948 (to ENB) and NIH
K08-GM094394 (to KS) from the National Institutes of Health, Bethesda,
Maryland, and by the Department of Anesthesia, Critical Care, and Pain
Medicine, Massachusetts General Hospital, Boston, Massachusetts. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 63
TC 12
Z9 12
U1 3
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD OCT
PY 2013
VL 9
IS 10
AR e1003284
DI 10.1371/journal.pcbi.1003284
PG 17
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 298WN
UT WOS:000330355300041
PM 24204231
ER
PT J
AU Davis, LK
Yu, DM
Keenan, CL
Gamazon, ER
Konkashbaev, AI
Derks, EM
Neale, BM
Yang, J
Lee, SH
Evans, P
Barr, CL
Bellodi, L
Benarroch, F
Berrio, GB
Bienvenu, OJ
Bloch, MH
Blom, RM
Bruun, RD
Budman, CL
Camarena, B
Campbell, D
Cappi, C
Silgado, JCC
Cath, DC
Cavallini, MC
Chavira, DA
Chouinard, S
Conti, DV
Cook, EH
Coric, V
Cullen, BA
Deforce, D
Delorme, R
Dion, Y
Edlund, CK
Egberts, K
Falkai, P
Fernandez, TV
Gallagher, PJ
Garrido, H
Geller, D
Girard, SL
Grabe, HJ
Grados, MA
Greenberg, BD
Gross-Tsur, V
Haddad, S
Heiman, GA
Hemmings, SMJ
Hounie, AG
Illmann, C
Jankovic, J
Jenike, MA
Kennedy, JL
King, RA
Kremeyer, B
Kurlan, R
Lanzagorta, N
Leboyer, M
Leckman, JF
Lennertz, L
Liu, C
Lochner, C
Lowe, TL
Macciardi, F
McCracken, JT
McGrath, LM
Restrepo, SCM
Moessner, R
Morgan, J
Muller, H
Murphy, DL
Naarden, AL
Ochoa, WC
Ophoff, RA
Osiecki, L
Pakstis, AJ
Pato, MT
Pato, CN
Piacentini, J
Pittenger, C
Pollak, Y
Rauch, SL
Renner, TJ
Reus, VI
Richter, MA
Riddle, MA
Robertson, MM
Romero, R
Rosario, MC
Rosenberg, D
Rouleau, GA
Ruhrmann, S
Ruiz-Linares, A
Sampaio, AS
Samuels, J
Sandor, P
Sheppard, B
Singer, HS
Smit, JH
Stein, DJ
Strengman, E
Tischfield, JA
Duarte, AVV
Vallada, H
Van Nieuwerburgh, F
Veenstra-VanderWeele, J
Walitza, S
Wang, Y
Wendland, JR
Westenberg, HGM
Shugart, YY
Miguel, EC
McMahon, W
Wagner, M
Nicolini, H
Posthuma, D
Hanna, GL
Heutink, P
Denys, D
Arnold, PD
Oostra, BA
Nestadt, G
Freimer, NB
Pauls, DL
Wray, NR
Stewart, SE
Mathews, CA
Knowles, JA
Cox, NJ
Scharf, JM
AF Davis, Lea K.
Yu, Dongmei
Keenan, Clare L.
Gamazon, Eric R.
Konkashbaev, Anuar I.
Derks, Eske M.
Neale, Benjamin M.
Yang, Jian
Lee, S. Hong
Evans, Patrick
Barr, Cathy L.
Bellodi, Laura
Benarroch, Fortu
Berrio, Gabriel Bedoya
Bienvenu, Oscar J.
Bloch, Michael H.
Blom, Rianne M.
Bruun, Ruth D.
Budman, Cathy L.
Camarena, Beatriz
Campbell, Desmond
Cappi, Carolina
Silgado, Julio C. Cardona
Cath, Danielle C.
Cavallini, Maria C.
Chavira, Denise A.
Chouinard, Sylvain
Conti, David V.
Cook, Edwin H.
Coric, Vladimir
Cullen, Bernadette A.
Deforce, Dieter
Delorme, Richard
Dion, Yves
Edlund, Christopher K.
Egberts, Karin
Falkai, Peter
Fernandez, Thomas V.
Gallagher, Patience J.
Garrido, Helena
Geller, Daniel
Girard, Simon L.
Grabe, Hans J.
Grados, Marco A.
Greenberg, Benjamin D.
Gross-Tsur, Varda
Haddad, Stephen
Heiman, Gary A.
Hemmings, Sian M. J.
Hounie, Ana G.
Illmann, Cornelia
Jankovic, Joseph
Jenike, Michael A.
Kennedy, James L.
King, Robert A.
Kremeyer, Barbara
Kurlan, Roger
Lanzagorta, Nuria
Leboyer, Marion
Leckman, James F.
Lennertz, Leonhard
Liu, Chunyu
Lochner, Christine
Lowe, Thomas L.
Macciardi, Fabio
McCracken, James T.
McGrath, Lauren M.
Restrepo, Sandra C. Mesa
Moessner, Rainald
Morgan, Jubel
Muller, Heike
Murphy, Dennis L.
Naarden, Allan L.
Ochoa, William Cornejo
Ophoff, Roel A.
Osiecki, Lisa
Pakstis, Andrew J.
Pato, Michele T.
Pato, Carlos N.
Piacentini, John
Pittenger, Christopher
Pollak, Yehuda
Rauch, Scott L.
Renner, Tobias J.
Reus, Victor I.
Richter, Margaret A.
Riddle, Mark A.
Robertson, Mary M.
Romero, Roxana
Rosario, Maria C.
Rosenberg, David
Rouleau, Guy A.
Ruhrmann, Stephan
Ruiz-Linares, Andres
Sampaio, Aline S.
Samuels, Jack
Sandor, Paul
Sheppard, Brooke
Singer, Harvey S.
Smit, Jan H.
Stein, Dan J.
Strengman, E.
Tischfield, Jay A.
Duarte, Ana V. Valencia
Vallada, Homero
Van Nieuwerburgh, Filip
Veenstra-VanderWeele, Jeremy
Walitza, Susanne
Wang, Ying
Wendland, Jens R.
Westenberg, Herman G. M.
Shugart, Yin Yao
Miguel, Euripedes C.
McMahon, William
Wagner, Michael
Nicolini, Humberto
Posthuma, Danielle
Hanna, Gregory L.
Heutink, Peter
Denys, Damiaan
Arnold, Paul D.
Oostra, Ben A.
Nestadt, Gerald
Freimer, Nelson B.
Pauls, David L.
Wray, Naomi R.
Stewart, S. Evelyn
Mathews, Carol A.
Knowles, James A.
Cox, Nancy J.
Scharf, Jeremiah M.
TI Partitioning the Heritability of Tourette Syndrome and Obsessive
Compulsive Disorder Reveals Differences in Genetic Architecture
SO PLOS GENETICS
LA English
DT Article
ID MISSING HERITABILITY; TIC DISORDERS; NEUROPSYCHIATRIC DISORDERS; COMPLEX
DISEASES; COMMON SNPS; GILLES; FAMILY; BRAIN; EXPRESSION; AUTISM
AB The direct estimation of heritability from genome-wide common variant data as implemented in the program Genome-wide Complex Trait Analysis (GCTA) has provided a means to quantify heritability attributable to all interrogated variants. We have quantified the variance in liability to disease explained by all SNPs for two phenotypically-related neurobehavioral disorders, obsessive-compulsive disorder (OCD) and Tourette Syndrome (TS), using GCTA. Our analysis yielded a heritability point estimate of 0.58 (se = 0.09, p = 5.64e-12) for TS, and 0.37 (se = 0.07, p = 1.5e-07) for OCD. In addition, we conducted multiple genomic partitioning analyses to identify genomic elements that concentrate this heritability. We examined genomic architectures of TS and OCD by chromosome, MAF bin, and functional annotations. In addition, we assessed heritability for early onset and adult onset OCD. Among other notable results, we found that SNPs with a minor allele frequency of less than 5% accounted for 21% of the TS heritability and 0% of the OCD heritability. Additionally, we identified a significant contribution to TS and OCD heritability by variants significantly associated with gene expression in two regions of the brain (parietal cortex and cerebellum) for which we had available expression quantitative trait loci (eQTLs). Finally we analyzed the genetic correlation between TS and OCD, revealing a genetic correlation of 0.41 (se = 0.15, p = 0.002). These results are very close to previous heritability estimates for TS and OCD based on twin and family studies, suggesting that very little, if any, heritability is truly missing (i.e., unassayed) from TS and OCD GWAS studies of common variation. The results also indicate that there is some genetic overlap between these two phenotypically-related neuropsychiatric disorders, but suggest that the two disorders have distinct genetic architectures.
C1 [Davis, Lea K.; Gamazon, Eric R.; Konkashbaev, Anuar I.; Evans, Patrick; Cox, Nancy J.] Univ Chicago, Dept Med, Med Genet Sect, Chicago, IL 60637 USA.
[Yu, Dongmei; Haddad, Stephen; Illmann, Cornelia; McGrath, Lauren M.; Osiecki, Lisa; Pauls, David L.; Scharf, Jeremiah M.] Harvard Univ, Massachusetts Gen Hosp, Dept Psychiat,Sch Med, Psychiat & Neurodev Genet Unit,Ctr Human Genet Re, Boston, MA USA.
[Yu, Dongmei; Neale, Benjamin M.; Scharf, Jeremiah M.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Keenan, Clare L.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Keenan, Clare L.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
[Derks, Eske M.; Blom, Rianne M.; Denys, Damiaan] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands.
[Neale, Benjamin M.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Yang, Jian] Univ Queensland, Diamantina Inst, Brisbane, Qld 4072, Australia.
[Yang, Jian; Lee, S. Hong; Wray, Naomi R.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.
[Barr, Cathy L.] Univ Hlth Network, Toronto Western Res Inst, Toronto, ON, Canada.
[Barr, Cathy L.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Bellodi, Laura] Univ Vita Salute San Raffaele, Milan, Italy.
[Benarroch, Fortu] Hadassah Hebrew Univ Med Ctr, Herman Dana Div Child & Adolescent Psychiat, Jerusalem, Israel.
[Berrio, Gabriel Bedoya; Silgado, Julio C. Cardona; Restrepo, Sandra C. Mesa; Ochoa, William Cornejo; Duarte, Ana V. Valencia] Univ Pontificia Bolivariana, Univ Antioquia, Medellin, Colombia.
[Bienvenu, Oscar J.; Cullen, Bernadette A.; Gallagher, Patience J.; Grados, Marco A.; Riddle, Mark A.; Samuels, Jack; Wang, Ying; Nestadt, Gerald] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
[Bloch, Michael H.; Coric, Vladimir] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
[Bloch, Michael H.; Fernandez, Thomas V.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA.
[Bruun, Ruth D.] North Shore Long Isl Jewish Med Ctr, Manhasset, NY USA.
[Bruun, Ruth D.] NYU Med Ctr, New York, NY 10016 USA.
[Budman, Cathy L.] North Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA.
[Budman, Cathy L.] Hofstra Univ, Sch Med, Hempstead, NY 11550 USA.
[Camarena, Beatriz] Inst Nacl Psiquiatria Ramon de la Fuente Muniz, Mexico City, DF, Mexico.
[Campbell, Desmond; Kremeyer, Barbara; Muller, Heike; Robertson, Mary M.; Ruiz-Linares, Andres] UCL, London, England.
[Campbell, Desmond] Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China.
[Cappi, Carolina; Vallada, Homero; Miguel, Euripedes C.] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil.
[Cath, Danielle C.; Smit, Jan H.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands.
[Cath, Danielle C.] Univ Utrecht, Dept Clin & Hlth Psychol, Utrecht, Netherlands.
[Cath, Danielle C.] Altrecht Acad Anxiety Ctr, Utrecht, Netherlands.
[Cavallini, Maria C.] Univ Milan, Osped San Raffaele, I-20127 Milan, Italy.
[Chavira, Denise A.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
[Chavira, Denise A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Chouinard, Sylvain; Girard, Simon L.] Univ Montreal, Montreal, PQ, Canada.
[Conti, David V.; Edlund, Christopher K.] Univ Calif Los Angeles, Keck Sch Med, Div Biostat, Dept Preventat Med, Los Angeles, CA USA.
[Cook, Edwin H.] Univ Illinois, Dept Psychiat, Inst Juvenile Res, Chicago, IL 60612 USA.
[Deforce, Dieter; Van Nieuwerburgh, Filip] Univ Ghent, Lab Pharmaceut Biotechnol, B-9000 Ghent, Belgium.
[Delorme, Richard] Inst Pasteur, Paris, France.
[Delorme, Richard; Leboyer, Marion] French Natl Sci Fdn, Fondat Fondamental, Creteil, France.
[Delorme, Richard; Leboyer, Marion] Hop Robert Debre, AP HP, Dept Child & Adolescent Psychiat, F-75019 Paris, France.
[Dion, Yves] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada.
[Egberts, Karin; Renner, Tobias J.] Univ Wurzburg, Dept Child & Adolescent Psychiat Psychosomat & Ps, D-97070 Wurzburg, Germany.
[Falkai, Peter] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany.
[Fernandez, Thomas V.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp,OCD Program, Boston, MA 02115 USA.
[Grabe, Hans J.] Univ Med Greifswald, Helios Hosp Stralsund, Dept Psychiat & Psychotherapy, Greifswald, Germany.
[Garrido, Helena; Greenberg, Benjamin D.] Butler Hosp, Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
[Geller, Daniel; Gross-Tsur, Varda; Pollak, Yehuda] Shaare Zedek Med Ctr, Neuropediatr Unit, Jerusalem, Israel.
[Heiman, Gary A.; Tischfield, Jay A.] Rutgers State Univ, Dept Genet, Human Genet Inst New Jersey, Piscataway, NJ USA.
[Hemmings, Sian M. J.] Univ Stellenbosch, Dept Psychiat, ZA-7600 Stellenbosch, South Africa.
[Hounie, Ana G.; Sampaio, Aline S.] Univ Sao Paulo, Fac Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil.
[Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Parkinsons Dis Ctr, Houston, TX 77030 USA.
[Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA.
[Jenike, Michael A.; Stewart, S. Evelyn] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Kennedy, James L.] Ctr Addict & Mental Hlth, Neurogenet Sect, Toronto, ON, Canada.
[Kennedy, James L.; Richter, Margaret A.; Arnold, Paul D.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
[King, Robert A.] Yale Univ, Sch Med, Dept Genet, Yale Child Study Ctr, New Haven, CT 06510 USA.
[Kurlan, Roger] Overlook Hosp, Atlantic Neurosci Inst, Summit, NJ USA.
[Lanzagorta, Nuria] Carracci Med Grp, Mexico City, DF, Mexico.
[Leboyer, Marion] Inst Mondor Rech Biomed, Creteil, France.
[Leckman, James F.] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.
[Lennertz, Leonhard; Moessner, Rainald; Wagner, Michael] Univ Bonn, Dept Psychiat & Psychotherapy, Bonn, Germany.
[Liu, Chunyu] Univ Illinois, Dept Psychiat, Inst Human Genet, Chicago, IL 60612 USA.
[Lochner, Christine] Univ Stellenbosch, Dept Psychiat, MRC Unit Anxiety & Stress Disorders, ZA-7600 Stellenbosch, South Africa.
[Lowe, Thomas L.; Reus, Victor I.; Sheppard, Brooke; Mathews, Carol A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Macciardi, Fabio; McCracken, James T.] UCI, Sch Med, Dept Psychiat & Human Behav, Irvine, CA USA.
[Morgan, Jubel] Univ Utah, Salt Lake City, UT USA.
[Murphy, Dennis L.; Wendland, Jens R.] NIMH Intramural Res Program, Clin Sci Lab, Bethesda, MD USA.
[Naarden, Allan L.] Med City Dallas Hosp, Dept Clin Res, Dallas, TX USA.
[Ophoff, Roel A.] Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Psychiat, Utrecht, Netherlands.
[Ophoff, Roel A.; Freimer, Nelson B.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Ctr Neurobehav Genet, Los Angeles, CA 90024 USA.
[Pakstis, Andrew J.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.
[Pato, Michele T.; Pato, Carlos N.; Knowles, James A.] Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.
[Piacentini, John] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Pittenger, Christopher] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
[Pittenger, Christopher] Yale Univ, Dept Psychol, New Haven, CT 06520 USA.
[Pittenger, Christopher] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.
[Rauch, Scott L.] Partners Psychiat & McLean Hosp, Boston, MA USA.
[Richter, Margaret A.] Sunnybrook Hlth Sci Ctr, Frederick W Thompson Anxiety Disorders Ctr, Toronto, ON M4N 3M5, Canada.
[Robertson, Mary M.] St George Hosp, London, England.
[Robertson, Mary M.] Sch Med, London, England.
[Romero, Roxana] Hosp Nacl Ninos Dr Carlos Saenz Herrera, San Jose, Costa Rica.
[Rosario, Maria C.] Univ Fed Sao Paulo, Dept Psychiat, Child & Adolescent Psychiat Unit UPIA, Sao Paulo, Brazil.
[Rosenberg, David] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI 48207 USA.
[Rosenberg, David] Detroit Med Ctr, Detroit, MI USA.
[Rouleau, Guy A.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
[Ruhrmann, Stephan] Univ Cologne, Dept Psychiat & Psychotherapy, D-50931 Cologne, Germany.
[Sampaio, Aline S.] Univ Fed Bahia, Univ Hlth Care Serv SMURB, Salvador, BA, Brazil.
[Sandor, Paul] Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
[Sandor, Paul] Univ Hlth Network, Toronto Western Res Inst, Toronto, ON, Canada.
[Sandor, Paul] Youthdale Treatment Ctr, Toronto, ON, Canada.
[Singer, Harvey S.] Johns Hopkins Univ Sch Med, Baltimore, MD USA.
[Stein, Dan J.] Univ Cape Town, ZA-7925 Cape Town, South Africa.
[Strengman, E.] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands.
[Veenstra-VanderWeele, Jeremy] Vanderbilt Univ, Kennedy Ctr Res Human Dev, Dept Psychiat, Nashville, TN 37235 USA.
[Veenstra-VanderWeele, Jeremy] Vanderbilt Univ, Kennedy Ctr Res Human Dev, Dept Pediat & Pharmacol, Nashville, TN 37235 USA.
[Veenstra-VanderWeele, Jeremy] Vanderbilt Univ, Inst Brain, Nashville, TN 37235 USA.
[Walitza, Susanne] Univ Zurich, Dept Child & Adolescent Psychiat, Zurich, Switzerland.
[Walitza, Susanne] Univ Wurzburg, Dept Child & Adolescent Psychiat, D-97070 Wurzburg, Germany.
[Westenberg, Herman G. M.] Univ Amsterdam, Acad Med Ctr, Ctr Psychiat, NL-1105 BC Amsterdam, Netherlands.
[Westenberg, Herman G. M.; Denys, Damiaan] Inst Royal Netherlands Acad Arts & Sci NIN KNAW, Netherlands Inst Neurosci, Amsterdam, Netherlands.
[Shugart, Yin Yao] NIMH Intramural Res Program, Unit Stat Genom, Bethesda, MD USA.
[McMahon, William] Univ Utah, Dept Psychiat, Salt Lake City, UT USA.
[Nicolini, Humberto] Natl Inst Genom Med SAP, Carracci Med Grp, Mexico City, DF, Mexico.
[Posthuma, Danielle] Vrije Univ Amsterdam, Ctr Neurogen & Cognit Res, Dept Funct Genom, Amsterdam, Netherlands.
[Posthuma, Danielle] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
[Posthuma, Danielle] Erasmus Univ, Med Ctr, Dept Child & Adolescent Psychiat, Rotterdam, Netherlands.
[Hanna, Gregory L.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Heutink, Peter] Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet, Sect Med Genom, Amsterdam, Netherlands.
[Heutink, Peter] German Ctr Neurodegenerat Dis, Tubingen, Germany.
[Arnold, Paul D.] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada.
[Oostra, Ben A.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
[Stewart, S. Evelyn] Univ British Columbia, British Columbia Mental Hlth & Addict Res Inst, Vancouver, BC V5Z 1M9, Canada.
[Scharf, Jeremiah M.] Brigham & Womens Hosp, Div Cognit & Behav Neurol, Boston, MA 02115 USA.
[Scharf, Jeremiah M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Davis, LK (reprint author), Univ Chicago, Dept Med, Med Genet Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM lea.k.davis@gmail.com; jscharf@partners.org
RI Renner, Tobias/I-2120-2013; Lee, Sang Hong/A-2569-2011; Wray,
Naomi/C-8639-2015; Macciardi, Fabio/N-3768-2014; Wagner,
Michael/E-2325-2011; Van Nieuwerburgh, Filip/H-9697-2015; reus,
victor/I-7923-2015; Yang, Jian/A-5852-2010; Stein, Dan/A-1752-2008;
Derks, Eske/A-1652-2017; Veenstra-VanderWeele, Jeremy/K-1935-2015;
Vallada, Homero/D-1333-2014
OI Hemmings, Sian/0000-0001-8461-1017; Gamazon, Eric/0000-0003-4204-8734;
Lanzagorta, Nuria/0000-0001-6769-6813; Campbell,
Desmond/0000-0003-1085-714X; Nicolini, Humberto/0000-0003-2494-0067;
Hanna, Gregory/0000-0002-0742-6990; Samuels, Jack/0000-0002-6715-7905;
Walitza, Susanne/0000-0002-8161-8683; Barr, Cathy/0000-0003-0361-0106;
Fernandez, Thomas V/0000-0003-0830-022X; Tischfield,
Jay/0000-0003-3217-8287; Lee, Sang Hong/0000-0001-9701-2718; Wray,
Naomi/0000-0001-7421-3357; Macciardi, Fabio/0000-0003-0537-4266; Wagner,
Michael/0000-0003-2589-6440; Van Nieuwerburgh,
Filip/0000-0001-8815-5485; reus, victor/0000-0002-8193-5697; Yang,
Jian/0000-0003-2001-2474; Stein, Dan/0000-0001-7218-7810; Derks,
Eske/0000-0002-6292-6883; Veenstra-VanderWeele,
Jeremy/0000-0002-6349-1076; Vallada, Homero/0000-0001-5123-8295
FU Judah Foundation; NIH [NS40024, NS16648, MH079489, MH073250, NS037484,
1R01MH079487-01A1, K20 MH01065, R01 MH58376, MH085057, MH079494,
HHSN268200782096C]; Tourette Syndrome Association International
Consortium for Genetics (TSAICG); New Jersey Center for Tourette
Syndrome and Associated Disorders; NIMH [R01MH092293]; Obsessive
Compulsive Foundation; Ontario Mental Health Foundation; Tourette
Syndrome Association; American Academy of Child and Adolescent
Psychiatry (AACAP); Anxiety Disorders Association of America (ADAA);
University of British Columbia; Michael Smith Foundation; American
Recovery and Re-investment Act (ARRA) [NS40024-07S1, NS16648-29S1];
Australian Research Council [FT0991360, DE130100614]; Australian
National Health and Medical Research Council [1047956, 1052684]; German
Research Foundation [DFG GR 1912/1-1]; NIH Genes, Environment and Health
Initiative [GEI] [U01 HG004422]; Gene Environment Association Studies
(GENEVA) under GEI; NIH GEI [U01HG004438]; National Institute on Alcohol
Abuse and Alcoholism; National Institute on Drug Abuse; [R01 MH090937];
[P50MH094267]
FX This work was supported by a grant from the Judah Foundation, NIH grant
NS40024 to DLP/JMS and the Tourette Syndrome Association International
Consortium for Genetics (TSAICG), NIH grant NS16648, MH079489, and
MH073250 to DLP, NIH grant NS037484 to NBF, NIH grant 1R01MH079487-01A1
to JTM, New Jersey Center for Tourette Syndrome and Associated Disorders
and NIMH (R01MH092293) to GAH/RAK/JAT, NIH grant K20 MH01065 and R01
MH58376 and a grant from the Obsessive Compulsive Foundation to GLH,
Ontario Mental Health Foundation grant to PR and JLK, and a grant from
the Tourette Syndrome Association and NIH grant MH085057 to JMS,
MH079494 to JAK and the OCD Collaborative Genetics Association Study
which supported the imputation, by an American Academy of Child and
Adolescent Psychiatry (AACAP) Early Investigator Research Grant, an
Anxiety Disorders Association of America (ADAA) Junior Investigator
Research Grant, the University of British Columbia and a Michael Smith
Foundation Clinical Research Scholar Award to SES, and American Recovery
and Re-investment Act (ARRA) awards NS40024-07S1 to DLP/JMS and
NS16648-29S1 to DLP. Additional support for analysis was provided by R01
MH090937 and P50MH094267 awarded to NJC. Support was also provided by
the Australian Research Council FT0991360 (NRW), DE130100614 (SHL) and
the Australian National Health and Medical Research Council: 1047956
(NRW), 1052684 (JY), and the German Research Foundation (DFG GR
1912/1-1) to HJG and to PF, SR, MW. Funding support for the Study of
Addiction: Genetics and Environment (SAGE) was provided through the NIH
Genes, Environment and Health Initiative [GEI] (U01 HG004422). SAGE is
one of the genome-wide association studies funded as part of the Gene
Environment Association Studies (GENEVA) under GEI. Assistance with
phenotype harmonization and genotype cleaning, as well as with general
study coordination, was provided by the GENEVA Coordinating Center (U01
HG004446). Assistance with data cleaning was provided by the National
Center for Biotechnology Information. Support for collection of datasets
and samples was provided by the Collaborative Study on the Genetics of
Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of
Nicotine Dependence (COGEND; P01 CA089392), and the Family Study of
Cocaine Dependence (FSCD; R01 DA013423), and R01-MH-50214 (GN). Funding
support for genotyping, which was performed at the Johns Hopkins
University Center for Inherited Disease Research, was provided by the
NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and
Alcoholism, the National Institute on Drug Abuse, and the NIH contract
"High throughput genotyping for studying the genetic contributions to
human disease" (HHSN268200782096C). The datasets used for the analyses
described in this manuscript were obtained from dbGaP at
http://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs00
0092.v1.p1 through dbGaP accession number phs000092.v1.p. None of the
funding agencies for this project (NINDS, NIMH, the Tourette Syndrome
Association and the Judah Foundation) had any influence or played any
role in a) the design or conduct of the study; b) management, analysis
or interpretation of the data; c) preparation, review or approval of the
manuscript.
NR 61
TC 74
Z9 74
U1 5
U2 37
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD OCT
PY 2013
VL 9
IS 10
AR e1003864
DI 10.1371/journal.pgen.1003864
PG 14
WC Genetics & Heredity
SC Genetics & Heredity
GA 299AR
UT WOS:000330367200041
PM 24204291
ER
PT J
AU Pinto, RM
Dragileva, E
Kirby, A
Lloret, A
Lopez, E
St Claire, J
Panigrahi, GB
Hou, CX
Holloway, K
Gillis, T
Guide, JR
Cohen, PE
Li, GM
Pearson, CE
Daly, MJ
Wheeler, VC
AF Pinto, Ricardo Mouro
Dragileva, Ella
Kirby, Andrew
Lloret, Alejandro
Lopez, Edith
St Claire, Jason
Panigrahi, Gagan B.
Hou, Caixia
Holloway, Kim
Gillis, Tammy
Guide, Jolene R.
Cohen, Paula E.
Li, Guo-Min
Pearson, Christopher E.
Daly, Mark J.
Wheeler, Vanessa C.
TI Mismatch Repair Genes Mlh1 and Mlh3 Modify CAG Instability in
Huntington's Disease Mice: Genome-Wide and Candidate Approaches
SO PLOS GENETICS
LA English
DT Article
ID TRINUCLEOTIDE REPEAT INSTABILITY; KNOCK-IN MICE; AGE-OF-ONSET;
DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; SOMATIC EXPANSION; MOUSE MODEL;
QUANTITATIVE TRAITS; FUNCTIONAL-ANALYSIS; PROTEIN EXPRESSION
AB The Huntington's disease gene (HTT) CAG repeat mutation undergoes somatic expansion that correlates with pathogenesis. Modifiers of somatic expansion may therefore provide routes for therapies targeting the underlying mutation, an approach that is likely applicable to other trinucleotide repeat diseases. Huntington's disease Hdh(Q111) mice exhibit higher levels of somatic HTT CAG expansion on a C57BL/6 genetic background (B6.Hdh(Q111)) than on a 129 background (129.Hdh(Q111)). Linkage mapping in (B6x129).Hdh(Q111) F2 intercross animals identified a single quantitative trait locus underlying the strain-specific difference in expansion in the striatum, implicating mismatch repair (MMR) gene Mlh1 as the most likely candidate modifier. Crossing B6.Hdh(Q111) mice onto an Mlh1 null background demonstrated that Mlh1 is essential for somatic CAG expansions and that it is an enhancer of nuclear huntingtin accumulation in striatal neurons. Hdh(Q111) somatic expansion was also abolished in mice deficient in the Mlh3 gene, implicating MutL gamma (MLH1-MLH3) complex as a key driver of somatic expansion. Strikingly, Mlh1 and Mlh3 genes encoding MMR effector proteins were as critical to somatic expansion as Msh2 and Msh3 genes encoding DNA mismatch recognition complex MutS beta (MSH2-MSH3). The Mlh1 locus is highly polymorphic between B6 and 129 strains. While we were unable to detect any difference in base-base mismatch or short slipped-repeat repair activity between B6 and 129 MLH1 variants, repair efficiency was MLH1 dose-dependent. MLH1 mRNA and protein levels were significantly decreased in 129 mice compared to B6 mice, consistent with a dose-sensitive MLH1-dependent DNA repair mechanism underlying the somatic expansion difference between these strains. Together, these data identify Mlh1 and Mlh3 as novel critical genetic modifiers of HTT CAG instability, point to Mlh1 genetic variation as the likely source of the instability difference in B6 and 129 strains and suggest that MLH1 protein levels play an important role in driving of the efficiency of somatic expansions.
C1 [Pinto, Ricardo Mouro; Dragileva, Ella; Lloret, Alejandro; Lopez, Edith; St Claire, Jason; Gillis, Tammy; Guide, Jolene R.; Wheeler, Vanessa C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Kirby, Andrew; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Kirby, Andrew; Daly, Mark J.] MIT, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02139 USA.
[Kirby, Andrew; Daly, Mark J.] Harvard, Cambridge, MA USA.
[Panigrahi, Gagan B.; Pearson, Christopher E.] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada.
[Panigrahi, Gagan B.; Pearson, Christopher E.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
[Hou, Caixia; Li, Guo-Min] Univ Kentucky, Grad Ctr Toxicol, Coll Med, Lexington, KY 40536 USA.
[Hou, Caixia; Li, Guo-Min] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40536 USA.
[Holloway, Kim; Cohen, Paula E.] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA.
RP Pinto, RM (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
EM wheeler@chgr.mgh.harvard.edu
RI Li, Guo-Min/I-5016-2014;
OI Li, Guo-Min/0000-0002-9842-4578
FU National Institutes of Health [NS049206, GM089684]; Huntington's Society
of Canada; Hereditary disease foundation
FX This work was supported by the National Institutes of Health [NS049206
to VCW; GM089684 to GML], the Huntington's Society of Canada
(www.huntingtonsociety.ca) [VCW] and a Hereditary disease foundation
(www.hdfoundation.org) postdoctoral fellowship [KH]. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 97
TC 31
Z9 31
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7390
EI 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD OCT
PY 2013
VL 9
IS 10
AR e1003930
DI 10.1371/journal.pgen.1003930
PG 19
WC Genetics & Heredity
SC Genetics & Heredity
GA 299AR
UT WOS:000330367200083
PM 24204323
ER
PT J
AU Sakurai, D
Zhao, J
Deng, Y
Kelly, JA
Brown, EE
Harley, JB
Bae, SC
Alarcon-Riqueime, ME
Edberg, JC
Kimberly, RP
Ramsey-Goldman, R
Petri, MA
Reveille, JD
Vila, LM
Alarcon, GS
Kaufman, KM
Vyse, TJ
Jacob, CO
Gaffney, PM
Sivils, KM
James, JA
Kamen, DL
Gilkeson, GS
Niewold, TB
Merrill, JT
Scofield, RH
Criswell, LA
Stevens, AM
Boackle, SA
Kim, JH
Choi, J
Pons-Estel, BA
Freedman, BI
Anaya, JM
Martin, J
Yu, CY
Chang, DM
Song, YW
Langefeld, CD
Chen, WL
Grossman, JM
Cantor, RM
Hahn, BH
Tsao, BP
AF Sakurai, Daisuke
Zhao, Jian
Deng, Yun
Kelly, Jennifer A.
Brown, Elizabeth E.
Harley, John B.
Bae, Sang-Cheol
Alarcon-Riqueime, Marta E.
Edberg, Jeffrey C.
Kimberly, Robert P.
Ramsey-Goldman, Rosalind
Petri, Michelle A.
Reveille, John D.
Vila, Luis M.
Alarcon, Graciela S.
Kaufman, Kenneth M.
Vyse, Timothy J.
Jacob, Chaim O.
Gaffney, Patrick M.
Sivils, Kathy Moser
James, Judith A.
Kamen, Diane L.
Gilkeson, Gary S.
Niewold, Timothy B.
Merrill, Joan T.
Scofield, R. Hal
Criswell, Lindsey A.
Stevens, Anne M.
Boackle, Susan A.
Kim, Jae-Hoon
Choi, Jiyoung
Pons-Estel, Bernardo A.
Freedman, Barry I.
Anaya, Juan-Manuel
Martin, Javier
Yu, C. Yung
Chang, Deh-Ming
Song, Yeong Wook
Langefeld, Carl D.
Chen, Weiling
Grossman, Jennifer M.
Cantor, Rita M.
Hahn, Bevra H.
Tsao, Betty P.
CA BIOLUPUS & GENLES networks
Argentine Collaborative Grp
TI Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele
Upregulates IL10 Expression
SO PLOS GENETICS
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION;
INFLAMMATORY-BOWEL-DISEASE; HUMAN B-LYMPHOCYTES; CELL-DERIVED IL-10;
RHEUMATOID-ARTHRITIS; SUSCEPTIBILITY LOCI; AUTOIMMUNE-DISEASE;
INTERLEUKIN-10 PRODUCTION; 1ST-DEGREE RELATIVES
AB Immunoregulatory cytokine interleukin-10 (IL-10) is elevated in sera from patients with systemic lupus erythematosus (SLE) correlating with disease activity. The established association of IL10 with SLE and other autoimmune diseases led us to fine map causal variant(s) and to explore underlying mechanisms. We assessed 19 tag SNPs, covering the IL10 gene cluster including IL19, IL20 and IL24, for association with SLE in 15,533 case and control subjects from four ancestries. The previously reported IL10 variant, rs3024505 located at 1 kb downstream of IL10, exhibited the strongest association signal and was confirmed for association with SLE in European American (EA) (P = 2.7x10(-8), OR = 1.30), but not in non-EA ancestries. SNP imputation conducted in EA dataset identified three additional SLE-associated SNPs tagged by rs3024505 (rs3122605, rs3024493 and rs3024495 located at 9.2 kb upstream, intron 3 and 4 of IL10, respectively), and SLE-risk alleles of these SNPs were dose-dependently associated with elevated levels of IL10 mRNA in PBMCs and circulating IL-10 protein in SLE patients and controls. Using nuclear extracts of peripheral blood cells from SLE patients for electrophoretic mobility shift assays, we identified specific binding of transcription factor Elk-1 to oligodeoxynucleotides containing the risk (G) allele of rs3122605, suggesting rs3122605 as the most likely causal variant regulating IL10 expression. Elk-1 is known to be activated by phosphorylation and nuclear localization to induce transcription. Of interest, phosphorylated Elk-1 (p-Elk-1) detected only in nuclear extracts of SLE PBMCs appeared to increase with disease activity. Co-expression levels of p-Elk-1 and IL-10 were elevated in SLE T, B cells and monocytes, associated with increased disease activity in SLE B cells, and were best downregulated by ERK inhibitor. Taken together, our data suggest that preferential binding of activated Elk-1 to the IL10 rs3122605-G allele upregulates IL10 expression and confers increased risk for SLE in European Americans.
C1 [Sakurai, Daisuke; Zhao, Jian; Deng, Yun; Chen, Weiling; Grossman, Jennifer M.; Hahn, Bevra H.; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
[Kelly, Jennifer A.; Alarcon-Riqueime, Marta E.; Gaffney, Patrick M.; Sivils, Kathy Moser; James, Judith A.; Scofield, R. Hal] Oklahoma Med Res Fdn, Arthritis & Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Brown, Elizabeth E.; Edberg, Jeffrey C.; Kimberly, Robert P.; Alarcon, Graciela S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
[Harley, John B.; Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA.
[Harley, John B.; Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA.
[Harley, John B.; Kaufman, Kenneth M.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
[Bae, Sang-Cheol; Kim, Jae-Hoon; Choi, Jiyoung] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea.
[Alarcon-Riqueime, Marta E.] Univ Granada Junta Andalucia, Pfizer, GENYO, Ctr Genom & Invest Oncol, Granada, Spain.
[Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA.
[Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Reveille, John D.] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA.
[Vila, Luis M.] Univ Puerto Rico, Dept Med, San Juan, PR 00936 USA.
[Vyse, Timothy J.] Kings Coll London, Div Genet, London WC2R 2LS, England.
[Vyse, Timothy J.] Kings Coll London, Div Mol Med, London WC2R 2LS, England.
[Vyse, Timothy J.] Kings Coll London, Div Immunol, London WC2R 2LS, England.
[Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA.
[James, Judith A.; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Kamen, Diane L.; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
[Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA.
[Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN USA.
[Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA.
[Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthritis, Dept Med, San Francisco, CA 94143 USA.
[Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA.
[Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA.
[Boackle, Susan A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA.
[Pons-Estel, Bernardo A.] Sanatorio Parque, Dept Med, Rosario, Argentina.
[Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA.
[Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia.
[Martin, Javier] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain.
[Yu, C. Yung] Nationwide Childrens Hosp, Ctr Mol & Human Genet, Res Inst, Columbus, OH USA.
[Yu, C. Yung] Ohio State Univ, Columbus, OH 43210 USA.
[Chang, Deh-Ming] Natl Def Med Ctr, Taipei, Taiwan.
[Song, Yeong Wook] Seoul Natl Univ, Div Rheumatol, Seoul, South Korea.
[Langefeld, Carl D.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA.
RP Sakurai, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
EM btsao@mednet.ucla.edu
RI Martin, Javier/B-8141-2008; Yu, Chack-Yung/E-4360-2011; Anaya,
Juan-Manuel/J-1960-2016;
OI Kimberly, Robert/0000-0002-5330-3086; Niewold,
Timothy/0000-0003-3532-6660; Anaya, Juan-Manuel/0000-0002-6444-1249;
Catoggio, Luis Jose/0000-0002-4047-4863; Universidad del Rosario,
Biblioteca/0000-0003-3491-9392; Silva, Berta/0000-0001-6579-5068
FU US National Institutes of Health [R01AR043814, P30AR48311, R01CA141700,
RC1AR058621, P01AI083194, P01AR049084, R01AR33062, K24AR002138,
P602AR30692, UL1RR025741, R01AR43727, P01AR052915, U01AI090909]; Lupus
Research Institute; Alliance for Lupus Research grants; U.S. Department
of Defense [PR094002]; US Department of Veterans Affairs; Arthritis
National Research Foundation; Charles Barkley Research Award; Ministry
for Health and Welfare, Republic of Korea [A120404]; Swedish Research
Council of Medicine; Arthritis Research UK; Arthritis Foundation;
National Center for Advancing Translational Sciences (NCATS)
[UL1RR025014-02, UL1TR000165, UL1RR025005]; National Center for Research
Resources (NCRR) component of the National Institutes of Health (NIH);
Kirkland Scholar Award; Federico Wilhelm Agricola Foundation; Wake
Forest University Health Sciences Center for Public Health Genomics;
MKE/KEIT [10035615]; UCLA Clinical and Translational Science Institute
(CTSI) [UL1RR033176, UL1TR000124]; US NIH [R01AR057172, R01AI063274,
RC2AR058959, R01AR043274, P30AR053483, P30GM103510, U19AI082714,
U01AI101934, P60AR049459, UL1RR029882, K08AI083790, L30AI071651,
UL1RR024999, P60AR053308, UL1TR000004, R01AR051545-01A2, R21AI070304,
1R01AR054459]
FX Support for this work was provided by the US National Institutes of
Health grants: R01AR043814 (BPT), P30AR48311 (EEB), R01CA141700 and
RC1AR058621 (MEAR), P01AI083194 (JBH KMS RPK LAC TJV MEAR COJ BPT PMG),
P01AR049084 (RPK JBH EEB JCE RRG LMV MAP), R01AR33062 (RPK),
K24AR002138, P602AR30692 and UL1RR025741 (RRG), R01AR43727 (MAP),
P01AR052915 and U01AI090909 (JDR), R01AR057172 (COJ), R01AI063274 and
RC2AR058959 (PMG), R01AR043274 (KMS), P30AR053483, P30GM103510,
U19AI082714 and U01AI101934 (JAJ), P60AR049459 and UL1RR029882 (GSG
DLK), K08AI083790, L30AI071651 and UL1RR024999 (TBN), P60AR053308 and
UL1TR000004 (LAC), R01AR051545-01A2 (AMS), R21AI070304 (SAB), and
1R01AR054459 (CYY). Additional support was provided by the Lupus
Research Institute grant (BPT); the Alliance for Lupus Research grants
(BPT YD KMS TBN LAC COJ); the U.S. Department of Defense PR094002 and
the US Department of Veterans Affairs Merit Award (JBH); the Arthritis
National Research Foundation Eng Tan Scholar Award (TBN JZ); Charles
Barkley Research Award (EEB); the Korea Healthcare Technology R&D
Project, Ministry for Health and Welfare, Republic of Korea (A120404;
SCB); funding from the Swedish Research Council of Medicine (MEAR); the
Arthritis Research UK (TJV); the Arthritis Foundation (AMS PMG);
Clinical and Translational Science Grant Number UL1RR025014-02 (AMS),
UL1TR000165 (JCE) and UL1RR025005 (MAP) from the National Center for
Advancing Translational Sciences (NCATS) and National Center for
Research Resources (NCRR) component of the National Institutes of Health
(NIH); Kirkland Scholar Award (LAC); the Federico Wilhelm Agricola
Foundation Research grant (BAPE); Wake Forest University Health Sciences
Center for Public Health Genomics (CDL); the Korean Research and
Development Program of MKE/KEIT (10035615; YWS); and UCLA Clinical and
Translational Science Institute (CTSI) grants: UL1RR033176 and
UL1TR000124. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 89
TC 13
Z9 13
U1 321
U2 327
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD OCT
PY 2013
VL 9
IS 10
AR e1003870
DI 10.1371/journal.pgen.1003870
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 299AR
UT WOS:000330367200046
PM 24130510
ER
PT J
AU Soukas, AA
Carr, CE
Ruvkun, G
AF Soukas, Alexander A.
Carr, Christopher E.
Ruvkun, Gary
TI Genetic Regulation of Caenorhabditis elegans Lysosome Related Organelle
Function
SO PLOS GENETICS
LA English
DT Article
ID C. ELEGANS; FAT STORAGE; LIFE-SPAN; LIPID DROPLETS; BIOGENESIS;
SEROTONIN; MECHANISMS; KYNURENINE; MUTANTS; METABOLISM
AB Lysosomes are membrane-bound organelles that contain acid hydrolases that degrade cellular proteins, lipids, nucleic acids, and oligosaccharides, and are important for cellular maintenance and protection against age-related decline. Lysosome related organelles (LROs) are specialized lysosomes found in organisms from humans to worms, and share many of the features of classic lysosomes. Defective LROs are associated with human immune disorders and neurological disease. Caenorhabditis elegans LROs are the site of concentration of vital dyes such as Nile red as well as age-associated autofluorescence. Even though certain short-lived mutants have high LRO Nile red and high autofluorescence, and other long-lived mutants have low LRO Nile red and low autofluorescence, these two biologies are distinct. We identified a genetic pathway that modulates aging-related LRO phenotypes via serotonin signaling and the gene kat-1, which encodes a mitochondrial ketothiolase. Regulation of LRO phenotypes by serotonin and kat-1 in turn depend on the proton-coupled, transmembrane transporter SKAT-1. skat-1 loss of function mutations strongly suppress the high LRO Nile red accumulation phenotype of kat-1 mutation. Using a systems approach, we further analyzed the role of 571 genes in LRO biology. These results highlight a gene network that modulates LRO biology in a manner dependent upon the conserved protein kinase TOR complex 2. The results implicate new genetic pathways involved in LRO biology, aging related physiology, and potentially human diseases of the LRO.
C1 [Soukas, Alexander A.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Soukas, Alexander A.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Carr, Christopher E.; Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Carr, Christopher E.] MIT, Dept Earth & Interplanetary Sci, Cambridge, MA 02139 USA.
[Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
RP Soukas, AA (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
EM asoukas@chgr.mgh.harvard.edu; ruvkun@molbio.mgh.harvard.edu
OI Carr, Christopher/0000-0002-7946-5622
FU NIH/NIDDK [K08DK087941, R01DK070147]; New Scholar in Aging Award from
the Ellison Medical Foundation; NIH Office of Research Infrastructure
Programs [P40 OD010440]
FX This work was supported by grants from the NIH/NIDDK (K08DK087941 to AAS
and R01DK070147 to GR) and a New Scholar in Aging Award from the Ellison
Medical Foundation (to AAS). Some strains were provided by the CGC,
which is funded by NIH Office of Research Infrastructure Programs (P40
OD010440). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 44
TC 6
Z9 9
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD OCT
PY 2013
VL 9
IS 10
AR e1003908
DI 10.1371/journal.pgen.1003908
PG 16
WC Genetics & Heredity
SC Genetics & Heredity
GA 299AR
UT WOS:000330367200072
PM 24204312
ER
PT J
AU Hatano, H
Yukl, SA
Ferre, AL
Graf, EH
Somsouk, M
Sinclair, E
Abdel-Mohsen, M
Liegler, T
Harvill, K
Hoh, R
Palmer, S
Bacchetti, P
Hunt, PW
Martin, JN
McCune, JM
Tracy, RP
Busch, MP
O'Doherty, U
Shacklett, BL
Wong, JK
Deeks, SG
AF Hatano, Hiroyu
Yukl, Steven A.
Ferre, April L.
Graf, Erin H.
Somsouk, Ma
Sinclair, Elizabeth
Abdel-Mohsen, Mohamed
Liegler, Teri
Harvill, Kara
Hoh, Rebecca
Palmer, Sarah
Bacchetti, Peter
Hunt, Peter W.
Martin, Jeffrey N.
McCune, Joseph M.
Tracy, Russell P.
Busch, Michael P.
O'Doherty, Una
Shacklett, Barbara L.
Wong, Joseph K.
Deeks, Steven G.
TI Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected
Controllers
SO PLOS PATHOGENS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL-ACTIVATION;
POLYMERASE-CHAIN-REACTION; HIV-1 ELITE CONTROLLERS; BLOOD
MONONUCLEAR-CELLS; LOW-LEVEL VIREMIA; RALTEGRAVIR INTENSIFICATION;
IMMUNE ACTIVATION; RECTAL MUCOSA; TYPE-1 RNA
AB The study of HIV-infected "controllers'' who are able to maintain low levels of plasma HIV RNA in the absence of antiretroviral therapy (ART) may provide insights for HIV cure and vaccine strategies. Despite maintaining very low levels of plasma viremia, controllers have elevated immune activation and accelerated atherosclerosis. However, the degree to which low-level replication contributes to these phenomena is not known. Sixteen asymptomatic controllers were prospectively treated with ART for 24 weeks. Controllers had a statistically significant decrease in ultrasensitive plasma and rectal HIV RNA levels with ART. Markers of T cell activation/dysfunction in blood and gut mucosa also decreased substantially with ART. Similar reductions were observed in the subset of "elite'' controllers with pre-ART plasma HIV RNA levels below conventional assays (<40 copies/mL). These data confirm that HIV replication persists in controllers and contributes to a chronic inflammatory state. ART should be considered for these individuals (ClinicalTrials.gov NCT01025427).
C1 [Hatano, Hiroyu; Yukl, Steven A.; Somsouk, Ma; Sinclair, Elizabeth; Abdel-Mohsen, Mohamed; Liegler, Teri; Harvill, Kara; Hoh, Rebecca; Hunt, Peter W.; McCune, Joseph M.; Wong, Joseph K.; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Yukl, Steven A.; Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Ferre, April L.; Shacklett, Barbara L.] Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.
[Graf, Erin H.; O'Doherty, Una] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Palmer, Sarah] Karolinska Inst, Solna, Sweden.
[Palmer, Sarah] Swedish Inst Infect Dis Control, Solna, Sweden.
[Palmer, Sarah] Westmead Millennium Inst, Ctr Virus Res, Westmead, NSW, Australia.
[Palmer, Sarah] Univ Sydney, Westmead, NSW 2145, Australia.
[Bacchetti, Peter; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Tracy, Russell P.] Univ Vermont, Dept Pathol, Colchester, VT USA.
[Tracy, Russell P.] Univ Vermont, Dept Biochem, Colchester, VT USA.
[Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA.
[Busch, Michael P.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
RP Hatano, H (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM hhatano@php.ucsf.edu
RI Shacklett, Barbara/A-7288-2009
OI Shacklett, Barbara/0000-0002-7067-732X
FU National Institute of Allergy and Infectious Diseases [R01 AI087145, K23
AI075985, K24 AI069994, R56 AI091573, R01 NS051132, R01 AI057020];
National Cancer Institute [K23 CA157929]; Delaney AIDS Research
Enterprise (DARE) [U19 AI0961090]; California HIV/AIDS Research Program
[ID08-SF-004]; American Foundation for AIDS Research [106710-40-RGRL,
107170-44-RGRL, 108073-50-RGRL]; UCSF/Gladstone Institute of Virology &
Immunology CFAR [P30 AI027763]; UCSF Clinical and Translational Research
Institute Clinical Research Center [UL1 RR024131]; Center for AIDS
Prevention Studies [P30 MH62246]; CFAR Network of Integrated Systems
[R24 AI067039]; U.S. Department of Veterans Affairs [1 IK2 CX000520-01,
5101BX001048]
FX This work was supported by grants from the National Institute of Allergy
and Infectious Diseases (R01 AI087145, K23 AI075985, K24 AI069994, R56
AI091573, R01 NS051132, R01 AI057020), the National Cancer Institute
(K23 CA157929), the Delaney AIDS Research Enterprise (DARE; U19
AI0961090), California HIV/AIDS Research Program (ID08-SF-004), the
American Foundation for AIDS Research (106710-40-RGRL, 107170-44-RGRL,
and 108073-50-RGRL), the UCSF/Gladstone Institute of Virology &
Immunology CFAR (P30 AI027763), the UCSF Clinical and Translational
Research Institute Clinical Research Center (UL1 RR024131), the Center
for AIDS Prevention Studies (P30 MH62246), the CFAR Network of
Integrated Systems (R24 AI067039), and the U.S. Department of Veterans
Affairs (1 IK2 CX000520-01, 5101BX001048). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 67
TC 35
Z9 35
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2013
VL 9
IS 10
AR e1003691
DI 10.1371/journal.ppat.1003691
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 299GJ
UT WOS:000330383800060
PM 24130489
ER
PT J
AU Lucas-Hourani, M
Dauzonne, D
Jorda, P
Cousin, G
Lupan, A
Helynck, O
Caignard, G
Janvier, G
Andre-Leroux, G
Khiar, S
Escriou, N
Despres, P
Jacob, Y
Munier-Lehmann, H
Tangy, F
Vidalain, PO
AF Lucas-Hourani, Marianne
Dauzonne, Daniel
Jorda, Pierre
Cousin, Gaelle
Lupan, Alexandru
Helynck, Olivier
Caignard, Gregory
Janvier, Genevieve
Andre-Leroux, Gwenaelle
Khiar, Samira
Escriou, Nicolas
Despres, Philippe
Jacob, Yves
Munier-Lehmann, Helene
Tangy, Frederic
Vidalain, Pierre-Olivier
TI Inhibition of Pyrimidine Biosynthesis Pathway Suppresses Viral Growth
through Innate Immunity
SO PLOS PATHOGENS
LA English
DT Article
ID IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE; TOLL-LIKE RECEPTORS;
VIRUS-INFECTION; GENE INDUCTION; RNA VIRUSES; DIHYDROOROTATE
DEHYDROGENASE; ANTIVIRAL ACTIVITY; MYCOPHENOLIC-ACID; IN-VITRO; IRF-1
AB Searching for stimulators of the innate antiviral response is an appealing approach to develop novel therapeutics against viral infections. Here, we established a cell-based reporter assay to identify compounds stimulating expression of interferon-inducible antiviral genes. DD264 was selected out of 41,353 compounds for both its immuno-stimulatory and antiviral properties. While searching for its mode of action, we identified DD264 as an inhibitor of pyrimidine biosynthesis pathway. This metabolic pathway was recently identified as a prime target of broad-spectrum antiviral molecules, but our data unraveled a yet unsuspected link with innate immunity. Indeed, we showed that DD264 or brequinar, a well-known inhibitor of pyrimidine biosynthesis pathway, both enhanced the expression of antiviral genes in human cells. Furthermore, antiviral activity of DD264 or brequinar was found strictly dependent on cellular gene transcription, nuclear export machinery, and required IRF1 transcription factor. In conclusion, the antiviral property of pyrimidine biosynthesis inhibitors is not a direct consequence of pyrimidine deprivation on the virus machinery, but rather involves the induction of cellular immune response.
C1 [Lucas-Hourani, Marianne; Caignard, Gregory; Janvier, Genevieve; Khiar, Samira; Escriou, Nicolas; Tangy, Frederic; Vidalain, Pierre-Olivier] Inst Pasteur, Unite Genom Virale & Vaccinat, Paris, France.
[Lucas-Hourani, Marianne; Caignard, Gregory; Janvier, Genevieve; Khiar, Samira; Escriou, Nicolas; Jacob, Yves; Tangy, Frederic; Vidalain, Pierre-Olivier] CNRS, UMR3569, Paris, France.
[Dauzonne, Daniel; Jorda, Pierre; Cousin, Gaelle] Inst Curie, Ctr Rech, Paris, France.
[Dauzonne, Daniel; Jorda, Pierre; Cousin, Gaelle] CNRS, UMR176, Paris, France.
[Lupan, Alexandru; Helynck, Olivier; Munier-Lehmann, Helene] Inst Pasteur, Unite Chim & Biocatalyse, Paris, France.
[Lupan, Alexandru; Helynck, Olivier; Munier-Lehmann, Helene] CNRS, UMR3523, Paris, France.
[Andre-Leroux, Gwenaelle] Inst Pasteur, Unite Biochim Struct, Paris, France.
[Andre-Leroux, Gwenaelle] CNRS, UMR 3528, Paris, France.
[Despres, Philippe] Inst Pasteur, Unite Interact Mol Flavivirus Hotes, Paris, France.
[Jacob, Yves] Inst Pasteur, Unite Genet Mol Virus ARN, Paris, France.
[Jacob, Yves] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA.
[Jacob, Yves] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
RP Lucas-Hourani, M (reprint author), Inst Pasteur, Unite Genom Virale & Vaccinat, Paris, France.
EM helene.munier-lehmann@pasteur.fr; frederic.tangy@pasteur.fr;
pierre-olivier.vidalain@pasteur.fr
RI Lupan, Alexandru/A-3142-2012; Escriou, Nicolas/A-2392-2016
OI Lupan, Alexandru/0000-0002-9353-7629; Escriou,
Nicolas/0000-0002-1224-6839
FU Institut Pasteur; Centre National de la Recherche Scientifique (CNRS);
Institut National de la Sante Et de la Recherche Medicale (INSERM);
Institut Carnot - Pasteur Maladies Infectieuses (Programme STING);
Institut Carnot - Pasteur Maladies Infectieuses (HML); Agence Nationale
pour la Recherche (ANR-RPIB, Programme STING 2.0); "Conseil Regional
d'Ile-de-France'' (Chemical Library Project) [I 06-222/R, I 09-1739/R];
project ArbOAS (ANR) [2010-INTB-1601-02]
FX This work was supported by the Institut Pasteur (www.pasteur.fr), the
Centre National de la Recherche Scientifique (CNRS; www.cnrs.fr), the
Institut National de la Sante Et de la Recherche Medicale (INSERM;
www.inserm.fr), the Institut Carnot - Pasteur Maladies Infectieuses
(Programme STING to POV and HML), the Agence Nationale pour la Recherche
(ANR-RPIB, Programme STING 2.0 to POV), and the "Conseil Regional
d'Ile-de-France'' (Chemical Library Project, grants no I 06-222/R and I
09-1739/R to HML). The work on CHIKV/Ren was supported by the project
ArbOAS (ANR grant 2010-INTB-1601-02). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 72
TC 18
Z9 19
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2013
VL 9
IS 10
AR e1003678
DI 10.1371/journal.ppat.1003678
PG 18
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 299GJ
UT WOS:000330383800048
PM 24098125
ER
PT J
AU Matreyek, KA
Yucel, SS
Li, X
Engelman, A
AF Matreyek, Kenneth A.
Yuecel, Sara S.
Li, Xiang
Engelman, Alan
TI Nucleoporin NUP153 Phenylalanine-Glycine Motifs Engage a Common Binding
Pocket within the HIV-1 Capsid Protein to Mediate Lentiviral Infectivity
SO PLOS PATHOGENS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-PORE COMPLEX; AMINO-TERMINAL
DOMAIN; PREINTEGRATION COMPLEX; REVERSE TRANSCRIPTION; NONDIVIDING
CELLS; TRIM5-ALPHA RESTRICTION; RETROTRANSPOSON TF1; TYPE-1 INFECTION;
IMPORT PATHWAYS
AB Lentiviruses can infect non-dividing cells, and various cellular transport proteins provide crucial functions for lentiviral nuclear entry and integration. We previously showed that the viral capsid (CA) protein mediated the dependency on cellular nucleoporin (NUP) 153 during HIV-1 infection, and now demonstrate a direct interaction between the CA N-terminal domain and the phenylalanine-glycine (FG)-repeat enriched NUP153 C-terminal domain (NUP153(C)). NUP153(C) fused to the effector domains of the rhesus Trim5 alpha restriction factor (Trim-NUP153(C)) potently restricted HIV-1, providing an intracellular readout for the NUP153(C)-CA interaction during retroviral infection. Primate lentiviruses and equine infectious anemia virus (EIAV) bound NUP153(C) under these conditions, results that correlated with direct binding between purified proteins in vitro. These binding phenotypes moreover correlated with the requirement for endogenous NUP153 protein during virus infection. Mutagenesis experiments concordantly identified NUP153(C) and CA residues important for binding and lentiviral infectivity. Different FG motifs within NUP153(C) mediated binding to HIV-1 versus EIAV capsids. HIV-1 CA binding mapped to residues that line the common alpha helix 3/4 hydrophobic pocket that also mediates binding to the small molecule PF-3450074 (PF74) inhibitor and cleavage and polyadenylation specific factor 6 (CPSF6) protein, with Asn57 (Asp58 in EIAV) playing a particularly important role. PF74 and CPSF6 accordingly each competed with NUP153(C) for binding to the HIV-1 CA pocket, and significantly higher concentrations of PF74 were needed to inhibit HIV-1 infection in the face of Trim-NUP153(C) expression or NUP153 knockdown. Correlation between CA mutant viral cell cycle and NUP153 dependencies moreover indicates that the NUP153(C)-CA interaction underlies the ability of HIV-1 to infect non-dividing cells. Our results highlight similar mechanisms of binding for disparate host factors to the same region of HIV-1 CA during viral ingress. We conclude that a subset of lentiviral CA proteins directly engage FG-motifs present on NUP153 to affect viral nuclear import.
C1 [Matreyek, Kenneth A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Matreyek, KA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.
EM alan_engelman@dfci.harvard.edu
OI Matreyek, Kenneth/0000-0001-9149-551X
FU US National Institutes of Health [AI052014]
FX US National Institutes of Health grant AI052014 provided the funding to
support this work. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 90
TC 55
Z9 57
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2013
VL 9
IS 10
AR e1003693
DI 10.1371/journal.ppat.1003693
PG 21
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 299GJ
UT WOS:000330383800062
PM 24130490
ER
PT J
AU Mehra, A
Zahra, A
Thompson, V
Sirisaengtaksin, N
Wells, A
Porto, M
Koster, S
Penberthy, K
Kubota, Y
Dricot, A
Rogan, D
Vidal, M
Hill, DE
Bean, AJ
Philips, JA
AF Mehra, Alka
Zahra, Aleena
Thompson, Victor
Sirisaengtaksin, Natalie
Wells, Ashley
Porto, Maura
Koester, Stefan
Penberthy, Kristen
Kubota, Yoshihisha
Dricot, Amelie
Rogan, Daniel
Vidal, Marc
Hill, David E.
Bean, Andrew J.
Philips, Jennifer A.
TI Mycobacterium tuberculosis Type VII Secreted Effector EsxH Targets Host
ESCRT to Impair Trafficking
SO PLOS PATHOGENS
LA English
DT Article
ID RECEPTOR DOWN-REGULATION; NF-KAPPA-B; PHAGOSOME MATURATION;
COMPLEX-FORMATION; EGF RECEPTOR; LIPOAMIDE DEHYDROGENASE; HRS PROTEIN;
BOVIS BCG; FAMILY; SYSTEM
AB Mycobacterium tuberculosis (Mtb) disrupts anti-microbial pathways of macrophages, cells that normally kill bacteria. Over 40 years ago, D'Arcy Hart showed that Mtb avoids delivery to lysosomes, but the molecular mechanisms that allow Mtb to elude lysosomal degradation are poorly understood. Specialized secretion systems are often used by bacterial pathogens to translocate effectors that target the host, and Mtb encodes type VII secretion systems (TSSSs) that enable mycobacteria to secrete proteins across their complex cell envelope; however, their cellular targets are unknown. Here, we describe a systematic strategy to identify bacterial virulence factors by looking for interactions between the Mtb secretome and host proteins using a high throughput, high stringency, yeast two-hybrid (Y2H) platform. Using this approach we identified an interaction between EsxH, which is secreted by the Esx-3 TSSS, and human hepatocyte growth factor-regulated tyrosine kinase substrate (Hgs/Hrs), a component of the endosomal sorting complex required for transport (ESCRT). ESCRT has a well-described role in directing proteins destined for lysosomal degradation into intraluminal vesicles (ILVs) of multivesicular bodies (MVBs), ensuring degradation of the sorted cargo upon MVB-lysosome fusion. Here, we show that ESCRT is required to deliver Mtb to the lysosome and to restrict intracellular bacterial growth. Further, EsxH, in complex with EsxG, disrupts ESCRT function and impairs phagosome maturation. Thus, we demonstrate a role for a TSSS and the host ESCRT machinery in one of the central features of tuberculosis pathogenesis.
C1 [Mehra, Alka; Zahra, Aleena; Thompson, Victor; Wells, Ashley; Porto, Maura; Koester, Stefan; Penberthy, Kristen; Rogan, Daniel; Philips, Jennifer A.] NYU, Sch Med, Dept Med, Dept Pathol,Div Infect Dis, New York, NY 10012 USA.
[Mehra, Alka; Zahra, Aleena; Thompson, Victor; Wells, Ashley; Porto, Maura; Koester, Stefan; Penberthy, Kristen; Rogan, Daniel; Philips, Jennifer A.] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.
[Sirisaengtaksin, Natalie; Kubota, Yoshihisha; Bean, Andrew J.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA.
[Sirisaengtaksin, Natalie; Kubota, Yoshihisha; Bean, Andrew J.] Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.
[Dricot, Amelie; Vidal, Marc; Hill, David E.] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA.
[Dricot, Amelie; Vidal, Marc; Hill, David E.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Dricot, Amelie; Vidal, Marc; Hill, David E.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Bean, Andrew J.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA.
RP Mehra, A (reprint author), NYU, Sch Med, Dept Med, Dept Pathol,Div Infect Dis, New York, NY 10012 USA.
EM Jennifer.Philips@nyumc.org
OI Sirisaengtaksin, Natalie/0000-0002-8791-722X; Penberthy,
Kristen/0000-0003-3178-0524
FU NIH/NIAID [AI087682]; Doris Duke Charitable Foundation; Infectious
Disease Society of America (IDSA); Michael Saperstein Medical Scholars
Research Fund; NIH [HG004233, HG001715]; Ellison Foundation (Boston,
MA); Institute Sponsored Research funds from the Dana-Farber Cancer
Institute Strategic Initiative; DEH Potts Memorial Foundation; American
Society of Microbiology; IDSA
FX This work was supported by grants from the NIH/NIAID (AI087682), the
Doris Duke Charitable Foundation, the Infectious Disease Society of
America (IDSA), and the Michael Saperstein Medical Scholars Research
Fund to JAP. It was supported by NIH (HG004233 and HG001715), Ellison
Foundation (Boston, MA), and Institute Sponsored Research funds from the
Dana-Farber Cancer Institute Strategic Initiative to MV and DEH Potts
Memorial Foundation provided support to AM, IDSA provided support to MP,
and the American Society of Microbiology supported AZ.
http://www.ddcf.org http://www.idsociety.org/Index.aspx
http://www.ellisonfoundation.org http://www.asm.org
http://www.dana-farber.org Pott's and Michael Saperstein Fund: URL not
available. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript
NR 67
TC 33
Z9 35
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2013
VL 9
IS 10
AR e1003734
DI 10.1371/journal.ppat.1003734
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 299GJ
UT WOS:000330383800092
PM 24204276
ER
PT J
AU Rollman, BL
Huffman, JC
AF Rollman, Bruce L.
Huffman, Jeff C.
TI Treating Anxiety in the Presence of Medical Comorbidity: Calmly Moving
Forward
SO PSYCHOSOMATIC MEDICINE
LA English
DT Editorial Material
DE chronic medical conditions; depression; anxiety; collaborative care;
interventions
ID RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE CARE; DEPRESSION; DISORDERS;
QUALITY
AB Patients with chronic medical conditions (CMCs) and a comorbid anxiety or mood disorder tend to report more symptoms and experience poorer treatment outcomes compared with those without mental health comorbidity. Although the benefits to be derived from treating depression in patients with CMCs have begun to be quantified, particularly among those with cardiovascular disease, our understanding of the benefits of treating anxiety in patients with CMCs is far less developed. Improving care for patients with CMCs is one of the major challenges facing medicine today because patients with multiple chronic diseases account for most health care costs. Emerging evidence indicates that integrated or "blended" collaborative care strategies that treat both the psychiatric and physical conditions together tend to produce greater improvements in mood symptoms and control of CMCs compared with programs that target the psychiatric condition alone. We review a new report, published in this issue of Psychosomatic Medicine, from the National Institutes of Mental Health-funded multisite Coordinated Anxiety Learning and Management trial, that shines new attention on anxiety disorders and medical comorbidity. We place their findings in context with these new blended care models that are potentially more powerful, scalable, cost-effective, and readily delivered through existing CMC programs.
C1 [Rollman, Bruce L.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA.
[Huffman, Jeff C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Psychiat & Med, Boston, MA USA.
RP Rollman, BL (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA.
FU NHLBI NIH HHS [R01 HL114016, 1R01HL113272]; NIMH NIH HHS [R01 MH093501]
NR 15
TC 3
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD OCT
PY 2013
VL 75
IS 8
BP 710
EP 712
DI 10.1097/PSY.0000000000000011
PG 3
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 300MZ
UT WOS:000330469300001
PM 24096773
ER
PT J
AU Feldt, B
Dion, GR
Weitzel, EK
McMains, KC
AF Feldt, Brent
Dion, Gregory R.
Weitzel, Erik K.
McMains, Kevin C.
TI Acute Sinusitis
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Review
DE acute sinusitis; bacterial sinusitis; nasal airway obstruction; purulent
rhinorrhea; sinusitis
ID ACUTE BACTERIAL RHINOSINUSITIS; ANTIMICROBIAL THERAPY; CONTROLLED TRIAL;
DOUBLE-BLIND; ADULTS; METAANALYSIS; ANTIBIOTICS; AMOXICILLIN; DIAGNOSIS;
RHINITIS
AB Sinusitis is a common patient complaint that carries with it a large economic burden. It is one of the most common reasons patients visit their primary care physician. Acute bacterial rhinosinusitis (ABRS) can be distinguished from other forms of rhinosinusitis based on symptom duration of <4 weeks in a patient with purulent rhinorrhea associated with facial pain or pressure. Native upper aerodigestive tract bacteria are the most common etiologic agents. Treatment of ABRS is targeted primarily at symptom improvement. Amoxicillin can be used based on the clinical scenario and patient comorbidities. Computed tomographic scans are reserved for complicated presentations or when there is concern for intracranial extension or other complications. A systematic approach to ABRS will allow for improved patient quality of life and a decreased overall economic burden of this common entity.
C1 Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA.
Brooke Army Med Ctr, San Antonio Mil Med Ctr, Ft Sam Houston, TX 78234 USA.
Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care, San Antonio, TX 78284 USA.
RP Dion, GR (reprint author), ATTN MCHE SDT Oto, Dept Otolaryngol, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
EM greg.r.dion@us.army.mil
NR 32
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0038-4348
EI 1541-8243
J9 SOUTH MED J
JI South.Med.J.
PD OCT
PY 2013
VL 106
IS 10
BP 577
EP 581
DI 10.1097/SMJ.0000000000000002
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 298UK
UT WOS:000330349800007
PM 24096952
ER
PT J
AU Reisenbichler, ES
Lester, SC
Richardson, AL
Dillon, DA
Ly, A
Brock, JE
AF Reisenbichler, Emily S.
Lester, Susan C.
Richardson, Andrea L.
Dillon, Deborah A.
Ly, Amy
Brock, Jane E.
TI lnterobserver Concordance in Implementing the 2010 ASCO/CAP
Recommendations for Reporting ER in Breast Carcinomas A Demonstration of
the Difficulties of Consistently Reporting Low Levels of ER Expression
by Manual Quantification
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE Estrogen receptor; Immunohistochemistry; Concordance; Breast carcinoma
ID ESTROGEN-RECEPTOR STATUS; LIGAND-BINDING ASSAY; PROGESTERONE-RECEPTOR;
PREDICTING RESPONSE; CANCER; IMMUNOHISTOCHEMISTRY; TAMOXIFEN; SURVIVAL;
THERAPY; RECURRENCE
AB Objectives: Endocrine therapy reduces recurrence risk by 30% to 50% in estrogen receptor (ER) positive breast cancer. The ER-positive threshold recommended by the American Society of Clinical Oncology/College of American Pathologists is 1% based on studies using the ER-6F11 antibody. ER-SP1 antibody has a higher sensitivity and is more widely used.
Methods: We report interobserver concordance manually measuring ER in 264 breast cancers using ER-SP1 and 1D5 and 2 scoring methods (H-score and Allred score).
Results: With both antibodies, 3% to 4% of cases have a low level of ER expression (1%-10%), more than previously reported (<1%). We find a high level of paired observer concordance with both antibodies and scoring methods (K = 0.892-0.943) with no significant difference with method of scoring. Despite excellent concordance, positive/negative discordance was almost 5% among 3 observers using either antibody, an underappreciated clinically significant rate.
Conclusions: Discordance overwhelmingly reflected differing opinions recording the proportion of tumor cells positive with low levels of expression (<10% staining; 12/13 cases).
C1 [Reisenbichler, Emily S.; Lester, Susan C.; Richardson, Andrea L.; Dillon, Deborah A.; Brock, Jane E.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Ly, Amy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Reisenbichler, ES (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, MCN C-3321,1161 21st Ave S, Nashville, TN 37232 USA.
EM Emily.s.reisenbiehler@vanderbilt.edu
NR 20
TC 11
Z9 12
U1 0
U2 1
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD OCT
PY 2013
VL 140
IS 4
BP 487
EP 494
DI 10.1309/AJCP1RF9FUIZRDPI
PG 8
WC Pathology
SC Pathology
GA 295EQ
UT WOS:000330099800004
PM 24045544
ER
PT J
AU Muehlschlegel, S
Kursun, O
Topcuoglu, MA
Fok, J
Singhal, AB
AF Muehlschlegel, Susanne
Kursun, Oguzhan
Topcuoglu, Mehmet A.
Fok, Joshua
Singhal, Aneesh B.
TI Differentiating Reversible Cerebral Vasoconstriction Syndrome With
Subarachnoid Hemorrhage From Other Causes of Subarachnoid Hemorrhage
SO JAMA NEUROLOGY
LA English
DT Article
ID INTRACRANIAL ANEURYSMS; CLINICAL PRESENTATION; ANGIOGRAPHY; VASOSPASM;
RISK; MANAGEMENT; HEADACHE; TIME
AB IMPORTANCE Reversible cerebral vasoconstriction syndrome (RCVS) is a clinical-angiographic syndrome characterized by recurrent thunderclap headaches and reversible segmental multifocal cerebral artery narrowing. More than 30% of patients with RCVS develop subarachnoid hemorrhage (SAH). Patients with RCVS with SAH (RCVS-SAH) are often misdiagnosed as having potentially ominous conditions such as aneurysmal SAH (aSAH) or cryptogenic "angiogram-negative" SAH (cSAH) owing to overlapping clinical and imaging features.
OBJECTIVE To identify predictors that can distinguish RCVS-SAH from aSAH and cSAH at the time of clinical presentation.
DESIGN Retrospective analysis of 3 patient cohorts: patients with RCVS (1998-2009), patients with aSAH (1995-2003), and patients with cSAH (1995-2003).
SETTING Academic hospital and tertiary referral center.
PARTICIPANTS Consecutive patients with RCVS-SAH (n = 38), aSAH (n = 515), or cSAH (n = 93) whose conditions were diagnosed using standard criteria.
MAIN OUTCOMES AND MEASURES Multivariate logistic regression analysis was used to identify predictors that differentiate RCVS-SAH from aSAH and cSAH.
RESULTS Predictors differentiating RCVS-SAH from aSAH were younger age, chronic headache disorder, prior depression, prior chronic obstructive pulmonary disease, lower Hunt-Hess grade, lower Fisher SAH group, higher number of affected arteries, and the presence of bilateral arterial narrowing. Predictors differentiating RCVS-SAH from cSAH were younger age, female sex, prior hypertension, chronic headache disorder, lower Hunt-Hess grade, lower Fisher SAH group, and the presence of bilateral arterial narrowing.
CONCLUSION AND RELEVANCE We identified important clinical and imaging differences between RCVS-SAH, aSAH, and cSAH that may be useful for improving diagnostic accuracy, clinical management, and resource utilization.
C1 [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Neurol, Div Neurocrit Care, Worcester, MA USA.
[Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Anesthesia Crit Care, Worcester, MA USA.
[Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA USA.
[Kursun, Oguzhan; Singhal, Aneesh B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Stroke Serv, Boston, MA 02114 USA.
[Topcuoglu, Mehmet A.] Hacettepe Univ, Dept Neurol, Ankara, Turkey.
[Fok, Joshua] Chinese Univ Hong Kong, Dept Neurol, Hong Kong, Hong Kong, Peoples R China.
RP Singhal, AB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Stroke Serv, ACC-729-C,55 Fruit St, Boston, MA 02114 USA.
EM asinghal@partners.org
FU American Heart Association [09SDG2030022]; Worcester Research
Foundation; University of Massachusetts Medical School
FX This work was funded in part by the American Heart Association (grant
09SDG2030022 to Dr Muehlschlegel), the Worcester Research Foundation,
and the University of Massachusetts Medical School (Faculty Scholar
Award to Dr Muehlschlegel).
NR 27
TC 8
Z9 9
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD OCT
PY 2013
VL 70
IS 10
BP 1254
EP 1260
DI 10.1001/jamaneurol.2013.3484
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 295KG
UT WOS:000330114400008
PM 23939614
ER
PT J
AU van der Wilden, GM
Velmahos, GC
Joseph, DK
Jacobs, L
DeBusk, G
Adams, CA
Gross, R
Burkott, B
Agarwal, S
Maung, AA
Johnson, DC
Gates, J
Kelly, E
Michaud, Y
Charash, WE
Winchell, RJ
Desjardins, SE
Rosenblatt, MS
Gupta, S
Gaeta, M
Chang, YC
de Moya, MA
AF van der Wilden, Gwendolyn M.
Velmahos, George C.
Joseph, D'Andrea K.
Jacobs, Lenworth
DeBusk, George
Adams, Charles A.
Gross, Ronald
Burkott, Barbara
Agarwal, Suresh
Maung, Adrian A.
Johnson, Dirk C.
Gates, Jonathan
Kelly, Edward
Michaud, Yvonne
Charash, William E.
Winchell, Robert J.
Desjardins, Steven E.
Rosenblatt, Michael S.
Gupta, Sanjay
Gaeta, Miguel
Chang, Yuchiao
de Moya, Marc A.
TI Successful Nonoperative Management of the Most Severe Blunt Renal
Injuries A Multicenter Study of the Research Consortium of New England
Centers for Trauma
SO JAMA SURGERY
LA English
DT Article
ID URINARY EXTRAVASATION; CONSERVATIVE MANAGEMENT; LACERATIONS; KIDNEY;
COMPLICATIONS; RECONECT; OUTCOMES; SPLEEN; LIVER
AB IMPORTANCE Severe renal injuries after blunt trauma cause diagnostic and therapeutic challenges for the treating clinicians. The need for an operative vs a nonoperative approach is debated.
OBJECTIVE To determine the rate, causes, predictors, and consequences of failure of nonoperative management (NOM) in grade IV and grade V blunt renal injuries (BRIs).
DESIGN Retrospective case series.
SETTING Twelve level I and II trauma centers in New England.
PARTICIPANTS A total of 206 adult patients with a grade IV or V BRI who were admitted between January 1, 2000, and December 31, 2011.
MAIN OUTCOMES AND MEASURES Failure of NOM, defined as the need for a delayed operation or death due to renal-related complications during NOM.
RESULTS Of 206 patients, 52 (25.2%) were operated on immediately, and 154 (74.8%) were managed nonoperatively (with the assistance of angiographic embolization for 25 patients). Nonoperative management failed for 12 of the 154 patients (7.8%) and was related to kidney injury in 10 (6.5%). None of these 10 patients had complications because of the delay in BRI management. The mean (SD) time from admission to failure was 17.6 (27.4) hours (median time, 7.5 hours; range, 4.5-102 hours), and the cause was hemodynamic instability in 10 of the 12 patients (83.3%). Multivariate analysis identified 2 independent predictors of NOM failure: older than 55 years of age and a road traffic crash as the mechanism of injury. When both risk factors were present, NOM failure occurred for 27.3% of the patients; when both were absent, there were no NOM failures. Of the 142 patients successfully managed nonoperatively, 46 (32.4%) developed renal-related complications, including hematuria (24 patients), urinoma (15 patients), urinary tract infection (8 patients), renal failure (7 patients), and abscess (2 patients). These patients were managed successfully with no loss of renal units (ie, kidneys). The renal salvage rate was 76.2% for the entire population and 90.3% among patients selected for NOM.
CONCLUSIONS AND RELEVANCE Hemodynamically stable patients with a grade IV or V BRI were safely managed nonoperatively. Nonoperative management failed for only 6.5% of patients owing to renal-related injuries, and three-fourths of the entire population retained their kidneys.
C1 [van der Wilden, Gwendolyn M.; Velmahos, George C.; de Moya, Marc A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[van der Wilden, Gwendolyn M.; Velmahos, George C.; Gates, Jonathan; Kelly, Edward; Michaud, Yvonne; de Moya, Marc A.] Harvard Univ, Sch Med, Boston, MA USA.
[Joseph, D'Andrea K.; Jacobs, Lenworth] Univ Connecticut, Hartford Hosp, Dept Surg, Hartford, CT 06112 USA.
[DeBusk, George; Adams, Charles A.] Brown Univ, Rhode Isl Hosp, Dept Surg, Providence, RI 02903 USA.
[DeBusk, George; Adams, Charles A.] Brown Univ, Providence, RI 02912 USA.
[Gross, Ronald; Burkott, Barbara] Baystate Med Ctr, Dept Surg, Springfield, MA 01107 USA.
[Agarwal, Suresh] Boston Med Ctr, Dept Surg, Boston, MA USA.
[Agarwal, Suresh] Boston Univ, Boston, MA 02215 USA.
[Maung, Adrian A.; Johnson, Dirk C.] Yale New Haven Med Ctr, Dept Surg, New Haven, CT 06504 USA.
[Maung, Adrian A.; Johnson, Dirk C.] Yale Univ, Sch Med, New Haven, CT USA.
[Gates, Jonathan; Kelly, Edward; Michaud, Yvonne] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Charash, William E.] Univ Vermont, Coll Med, Dept Surg, Burlington, VT USA.
[Winchell, Robert J.; Desjardins, Steven E.] Maine Med Ctr, Dept Surg, Portland, ME 04102 USA.
[Rosenblatt, Michael S.] Lahey Clin Fdn, Dept Surg, Burlington, MA USA.
[Gupta, Sanjay] Southern New Hampshire Med Ctr, Dept Surg, Nashua, NH USA.
[Gaeta, Miguel] Elliot Hosp, Dept Surg, Manchester, NH USA.
[Chang, Yuchiao] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA.
RP Velmahos, GC (reprint author), Massachusetts Gen Hosp, Dept Surg, 165 Cambridge St,Ste 810, Boston, MA 02114 USA.
EM gvelmahos@partners.org
NR 39
TC 12
Z9 13
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD OCT
PY 2013
VL 148
IS 10
BP 924
EP 931
DI 10.1001/jamasurg.2013.2747
PG 8
WC Surgery
SC Surgery
GA 295KL
UT WOS:000330114900005
PM 23945834
ER
PT J
AU Hwabejire, JO
Kaafarani, HMA
Imam, AM
Solis, CV
Verge, J
Sullivan, NM
DeMoya, MA
Alam, HB
Velmahos, GC
AF Hwabejire, John O.
Kaafarani, Haytham M. A.
Imam, Ayesha M.
Solis, Carolina V.
Verge, Justin
Sullivan, Nancy M.
DeMoya, Marc A.
Alam, Hasan B.
Velmahos, George C.
TI Excessively Long Hospital Stays After Trauma Are Not Related to the
Severity of Illness Let's Aim to the Right Target!
SO JAMA SURGERY
LA English
DT Article
ID CORONARY-BYPASS SURGERY; LENGTH-OF-STAY; ADVERSE EVENTS; CARE;
VARIABILITY; COST; RISK
AB IMPORTANCE Reduction in length of hospital stay is a veritable target in reducing the overall costs of health care. However, many existing approaches are flawed because the assumptions of what cause excessive length of stay are incorrect; we methodically identified the right targets in this study.
OBJECTIVE To identify the causes of excessively prolonged hospitalization (ExProH) in trauma patients.
DESIGN The trauma registry, billing databases, and medical records of trauma admissions were reviewed. Excessively prolonged hospitalization was defined by the standard method used by insurers, which is a hospital stay that exceeds the Diagnosis Related Group-based trim point. The causes of ExProH were explored in a unique potentially avoidable days database, used by our hospital's case managers to track discharge delays.
SETTING Level I academic trauma center.
PARTICIPANTS Adult trauma patients admitted between January 1, 2006, and December 31, 2010.
MAIN OUTCOMES AND MEASURES Excessively prolonged hospitalization and hospital cost.
RESULTS Of 3237 patients, 155 (5%) had ExProH. The patients with ExProH compared with non-ExProH patients were older (mean [SD] age, 53 [21] vs 47 [22] years, respectively; P = .001), were more likely to have blunt trauma (92% vs 84%, respectively; P = .03), were more likely to be self-payers (16% vs 11%, respectively; P = .02) or covered by Medicare/Medicaid (41% vs 30%, respectively; P = .002), were more likely to be discharged to post-acute care facilities than home (65% vs 35%, respectively; P < .001), and had higher hospitalization cost (mean, $54 646 vs $18 444, respectively; P < .001). Both groups had similar Injury Severity Scores, Revised Trauma Scores, baseline comorbidities, and in-hospital complication rates. Independent predictors of mortality were discharge to a rehabilitation facility (odds ratio = 4.66; 95% CI, 2.71-8.00; P < .001) or other post-acute care facility (odds ratio = 5.04; 95% CI, 2.52-10.05; P < .001) as well as insurance type that was Medicare/Medicaid (odds ratio = 1.70; 95% CI, 1.06-2.72; P = .03) or self-pay (odds ratio = 2.43; 95% CI, 1.35-4.37; P = .003). The reasons for discharge delays were clinical in only 20% of the cases. The remaining discharges were excessively delayed because of difficulties in rehabilitation facility placement (47%), in-hospital operational delays (26%), or payer-related issues (7%).
CONCLUSIONS AND RELEVANCE System-related issues, not severity of illness, prolong hospital stay excessively. Cost-reduction efforts should target operational bottlenecks between acute and postacute care.
C1 [Hwabejire, John O.; Kaafarani, Haytham M. A.; Imam, Ayesha M.; Solis, Carolina V.; Verge, Justin; DeMoya, Marc A.; Alam, Hasan B.; Velmahos, George C.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA.
[Hwabejire, John O.; Kaafarani, Haytham M. A.; Imam, Ayesha M.; Solis, Carolina V.; Verge, Justin; Sullivan, Nancy M.; DeMoya, Marc A.; Alam, Hasan B.; Velmahos, George C.] Harvard Univ, Sch Med, Boston, MA USA.
[Sullivan, Nancy M.] Massachusetts Gen Hosp, Case Management Dept, Boston, MA 02114 USA.
RP Velmahos, GC (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Ste 810, Boston, MA 02114 USA.
EM gvelmahos@partners.org
NR 20
TC 13
Z9 13
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD OCT
PY 2013
VL 148
IS 10
BP 956
EP 961
DI 10.1001/jamasurg.2013.2148
PG 6
WC Surgery
SC Surgery
GA 295KL
UT WOS:000330114900010
PM 23965602
ER
PT J
AU Ravicz, ME
Rosowski, JJ
AF Ravicz, Michael E.
Rosowski, John J.
TI Middle-ear velocity transfer function, cochlear input immittance, and
middle-ear efficiency in chinchilla
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID EXTERNAL-EAR; STAPES VELOCITY; DIFFUSE FIELD; IMPEDANCE; ADMITTANCE;
PRESSURE; GERBIL; CAT; TRANSMISSION; MOTION
AB The transfer function H-V between stapes velocity V-S and sound pressure near the tympanic membrane P-TM is a descriptor of sound transmission through the middle ear (ME). The ME power transmission efficiency (MEE), the ratio of sound power entering the cochlea to power entering the middle ear, was computed from H-V measured in seven chinchilla ears and previously reported measurements of ME input admittance Y-TM and ME pressure gain G(MEP) [Ravicz and Rosowski, J. Acoust. Soc. Am. 132, 2437-2454 (2012); J. Acoust. Soc. Am. 133, 2208-2223 (2013)] in the same ears. The ME was open, and a pressure sensor was inserted into the cochlear vestibule for most measurements. The cochlear input admittance Y-C computed from H-V and G(MEP) is controlled by a combination of mass and resistance and is consistent with a minimum-phase system up to 27 kHz. The real part Re{Y-C}, which relates cochlear sound power to inner-ear sound pressure, decreased gradually with frequency up to 25 kHz and more rapidly above that. MEE was about 0.5 between 0.1 and 8 kHz, higher than previous estimates in this species, and decreased sharply at higher frequencies. (C) 2013 Acoustical Society of America.
C1 [Ravicz, Michael E.; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Ravicz, Michael E.; Rosowski, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Rosowski, John J.] MA Inst Technol, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Ravicz, ME (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM mike_ravicz@meei.harvard.edu
FU NIDCD
FX We thank Michael Slama for helpful discussions, Melissa McKinnon for
animal surgery and assistance with experiments, and the staff of the
Eaton-Peabody Laboratory for technical support. Supported by NIDCD.
NR 39
TC 6
Z9 6
U1 0
U2 4
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
EI 1520-8524
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD OCT
PY 2013
VL 134
IS 4
BP 2852
EP 2865
DI 10.1121/1.4818745
PG 14
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA 295MH
UT WOS:000330119700040
PM 24116422
ER
PT J
AU Louapre, C
Govindarajan, ST
Gianni, C
Cohen-Adad, J
Tobyne, SM
Kinkel, RP
Mainero, C
AF Louapre, C.
Govindarajan, S. T.
Gianni, C.
Cohen-Adad, J.
Tobyne, S. M.
Kinkel, R. P.
Mainero, C.
TI Intracortical laminar pathology in the motor cortex is associated with
proximal underlying white matter injury in multiple sclerosis: a
multimodal 7 T and 3 T MRI study
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Meeting Abstract
CT 29th Congress of the
European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis /
18th Annual Conference of Rehabilitation in MS
CY OCT 02-05, 2013
CL Copenhagen, DENMARK
SP European Comm Treatment & Res Multiple Sclerosis
C1 [Louapre, C.; Govindarajan, S. T.; Gianni, C.; Mainero, C.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Cohen-Adad, J.] Ecole Polytech, Montreal, PQ H3C 3A7, Canada.
[Tobyne, S. M.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Kinkel, R. P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD OCT
PY 2013
VL 19
IS 11
SU S
BP 8
EP 8
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276LI
UT WOS:000328751400002
ER
PT J
AU Bove, R
Musallam, A
Healy, BC
Radhavan, K
Glanz, BI
Weiner, H
De Jager, PL
Miller, KK
Chitnis, T
AF Bove, R.
Musallam, A.
Healy, B. C.
Radhavan, K.
Glanz, B. I.
Weiner, H.
De Jager, P. L.
Miller, K. K.
Chitnis, T.
TI Testosterone is associated with worse disease severity in men with early
relapsing onset multiple sclerosis
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Meeting Abstract
CT 29th Congress of the
European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis /
18th Annual Conference of Rehabilitation in MS
CY OCT 02-05, 2013
CL Copenhagen, DENMARK
SP European Comm Treatment & Res Multiple Sclerosis
C1 [Bove, R.; Musallam, A.; Healy, B. C.; Radhavan, K.; Glanz, B. I.; Weiner, H.; De Jager, P. L.; Chitnis, T.] Partners Multiple Sclerosis Ctr, Brookline, MA USA.
[Miller, K. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD OCT
PY 2013
VL 19
IS 11
SU S
BP 110
EP 110
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276LI
UT WOS:000328751401074
ER
PT J
AU Tobyne, S
Klawiter, E
Boratyn, D
Govindarajan, ST
Sepulcre, J
Buckner, R
Kinkel, RP
Rosen, B
Mainero, C
AF Tobyne, S.
Klawiter, E.
Boratyn, D.
Govindarajan, S. T.
Sepulcre, J.
Buckner, R.
Kinkel, R. P.
Rosen, B.
Mainero, C.
TI Local and distant functional connectivity changes vary based on
functional network in multiple sclerosis
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Meeting Abstract
CT 29th Congress of the
European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis /
18th Annual Conference of Rehabilitation in MS
CY OCT 02-05, 2013
CL Copenhagen, DENMARK
SP European Comm Treatment & Res Multiple Sclerosis
C1 [Tobyne, S.; Klawiter, E.; Boratyn, D.; Govindarajan, S. T.; Sepulcre, J.; Rosen, B.; Mainero, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Buckner, R.] Harvard Univ, Cambridge, MA 02138 USA.
[Kinkel, R. P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD OCT
PY 2013
VL 19
IS 11
SU S
BP 174
EP 174
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276LI
UT WOS:000328751401205
ER
PT J
AU Vassilev, Z
Li, L
Falcone, G
Wallander, MA
Jick, S
Bromley, S
AF Vassilev, Z.
Li, L.
Falcone, G.
Wallander, M. -A.
Jick, S.
Bromley, S.
TI Mortality and risk factors for death in patients with multiple sclerosis
in a large population-based cohort
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Meeting Abstract
CT 29th Congress of the
European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis /
18th Annual Conference of Rehabilitation in MS
CY OCT 02-05, 2013
CL Copenhagen, DENMARK
SP European Comm Treatment & Res Multiple Sclerosis
C1 [Vassilev, Z.] Bayer Healthcare Pharmaceut, Montville, NJ USA.
[Li, L.; Jick, S.] Boston Univ, Sch Publ Hlth, Lexington, MA USA.
[Falcone, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Falcone, G.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Wallander, M. -A.] Bayer AB, Solna, Sweden.
[Wallander, M. -A.] Uppsala Univ, Solna, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD OCT
PY 2013
VL 19
IS 11
SU S
BP 343
EP 344
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276LI
UT WOS:000328751402210
ER
PT J
AU Bove, R
Musallam, A
Healy, BC
Soltany, P
Messina, S
Glanz, BI
Kivisakk, P
Weiner, H
De Jager, PL
Miller, KK
Chitnis, T
AF Bove, R.
Musallam, A.
Healy, B. C.
Soltany, P.
Messina, S.
Glanz, B. I.
Kivisakk, P.
Weiner, H.
De Jager, P. L.
Miller, K. K.
Chitnis, T.
TI Adiposity markers are associated with disease severity in early
relapsing remitting multiple sclerosis
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Meeting Abstract
CT 29th Congress of the
European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis /
18th Annual Conference of Rehabilitation in MS
CY OCT 02-05, 2013
CL Copenhagen, DENMARK
SP European Comm Treatment & Res Multiple Sclerosis
C1 [Bove, R.; Musallam, A.; Healy, B. C.; Glanz, B. I.; Weiner, H.; De Jager, P. L.; Chitnis, T.] Partners Multiple Sclerosis Ctr, Brookline, MA USA.
[Soltany, P.; Kivisakk, P.] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA.
[Messina, S.] Univ Catania, Catania, Italy.
[Miller, K. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD OCT
PY 2013
VL 19
IS 11
SU S
BP 404
EP 405
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276LI
UT WOS:000328751402336
ER
PT J
AU Mainero, C
Govindarajan, ST
Cohen-Adad, J
Louapre, C
Gianni', C
Nielsen, AS
Kinkel, RP
AF Mainero, C.
Govindarajan, S. T.
Cohen-Adad, J.
Louapre, C.
Gianni', C.
Nielsen, A. S.
Kinkel, R. P.
TI A gradient in intracortical laminar pathology in multiple sclerosis: an
in vivo study at 7 Tesla MRI
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Meeting Abstract
CT 29th Congress of the
European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis /
18th Annual Conference of Rehabilitation in MS
CY OCT 02-05, 2013
CL Copenhagen, DENMARK
SP European Comm Treatment & Res Multiple Sclerosis
C1 [Mainero, C.; Govindarajan, S. T.; Louapre, C.; Gianni', C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Cohen-Adad, J.] Ecole Polytech, Montreal, PQ H3C 3A7, Canada.
[Nielsen, A. S.] Oregon Med Ctr, Portland, ME USA.
[Kinkel, R. P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD OCT
PY 2013
VL 19
IS 11
SU S
BP 429
EP 429
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276LI
UT WOS:000328751402383
ER
PT J
AU Mrejen, S
Sarraf, D
Mukkamala, K
Freund, KB
AF Mrejen, Sarah
Sarraf, David
Mukkamala, Krishna
Freund, K. Bailey
TI MULTIMODAL IMAGING OF PIGMENT EPITHELIAL DETACHMENT A Guide to
Evaluation
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE retinal pigment epithelial detachment; age-related macular degeneration;
drusenoid pigment epithelial detachment; serous pigment epithelial
detachment; vascularized pigment epithelial detachment; retinal
angiomatous proliferation; polypoidal choroidal vasculopathy; multimodal
imaging; central serous chorioretinopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY; RETINAL
ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
INDOCYANINE-GREEN VIDEOANGIOGRAPHY; COMBINED INTRAVITREAL RANIBIZUMAB;
SCANNING LASER OPHTHALMOSCOPE; GROWTH-FACTOR THERAPY; TERM-FOLLOW-UP;
MACULAR DEGENERATION
AB Purpose: To describe the spectrum of pigment epithelial detachments (PEDs) occurring mainly in age-related macular degeneration and central serous chorioretinopathy and also in other inflammatory, neoplastic and iatrogenic, retinal, and systemic disorders.
Methods: Pigment epithelial detachments are divided into drusenoid, serous, vascularized, or mixed categories.
Results: The clinical presentation, classification, and natural history of PEDs are reviewed as illustrated with multimodal imaging combining traditional and novel imaging techniques, including fluorescein angiography, indocyanine green angiography, fundus autofluorescence, and spectral domain optical coherence tomography. Most PEDs occur because of pathophysiologic mechanisms taking place below the retinal pigment epithelium that are difficult to identify with conventional imaging modalities. Enhanced depth imaging optical coherence tomography and indocyanine green angiography allow a better analysis of the subretinal pigment epithelium compartment.
Conclusion: The differentiation between various kinds of PEDs is essential because each PED type is a distinct entity that has a specific pathogenesis, natural history, prognosis, and optimal treatment strategy.
C1 [Mrejen, Sarah; Mukkamala, Krishna; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
[Mrejen, Sarah; Mukkamala, Krishna; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
[Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
RP Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
FU Macula Foundation, Inc.
FX Supported in part by the Macula Foundation, Inc.
NR 151
TC 24
Z9 26
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1735
EP 1762
PG 28
WC Ophthalmology
SC Ophthalmology
GA 297DL
UT WOS:000330235500002
PM 23873168
ER
PT J
AU Schneider, EW
Elner, SG
van Kuijk, FJ
Goldberg, N
Lieberman, RM
Eliott, D
Johnson, MW
AF Schneider, Eric W.
Elner, Susan G.
van Kuijk, Frederik J.
Goldberg, Naomi
Lieberman, Ronni M.
Eliott, Dean
Johnson, Mark W.
TI CHRONIC RETINAL NECROSIS Cytomegalovirus Necrotizing Retinitis
Associated With Panretinal Vasculopathy in Non-HIV Patients
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE cytomegalovirus retinitis; acute retinal necrosis; progressive outer
retinal necrosis; infectious retinitis; retinal vasculitis; posterior
uveitis; neovascularization
ID CELL-MEDIATED-IMMUNITY; ACQUIRED-IMMUNODEFICIENCY-SYNDROME;
CHAIN-REACTION ANALYSIS; DIABETES-MELLITUS; STROMAL KERATITIS; VIRUS
RETINITIS; AIDS; INFECTION; COUNTS; DIAGNOSIS
AB Purpose: To characterize a unique cytomegalovirus (CMV)-associated retinopathy in patients with limited immune dysfunction.
Methods: Retrospective observational case series. CMV was confirmed as the pathogenic agent via polymerase chain reaction analysis of aqueous or vitreous humor samples or via immunohistochemical analysis of retinal biopsy specimens.
Results: Five non-HIV patients with granular necrotizing retinitis, vitritis, and severe occlusive vasculopathy were identified. Patient histories all suggested a basis for limited immune dysfunction including advanced age (n = 4), diabetes mellitus (n = 4), and noncytotoxic immunotherapy (n = 3). Diagnosis of CMV retinitis was delayed in all cases and patients received either no antiviral therapy (n = 2) or incorrect antiviral therapy (n = 3) for presumed herpes simplex/varicella zoster-related acute retinal necrosis. Retinitis subsequently regressed in all cases with introduction of systemic ganciclovir/valganciclovir (n = 5) and/or intravitreal foscarnet (n = 2). Four of five patients developed neovascularization because of extensive retinal ischemia.
Conclusion: The clinical expression of CMV-associated retinopathy is strongly related to immune status. In patients with limited immune dysfunction, a mixed clinical picture of intraocular inflammation with panretinal occlusive vasculopathy, more characteristic of acute retinal necrosis, and peripheral slowly progressive granular retinitis, more characteristic of classic CMV retinitis, is observed. Recognition of this atypical clinical presentation, which the authors term chronic retinal necrosis, should prompt molecular testing for CMV to determine the appropriate antiviral therapy. Consideration should also be given to prophylactic panretinal photocoagulation in such eyes, given the high risk of neovascular complications.
C1 [Schneider, Eric W.; Elner, Susan G.; Johnson, Mark W.] Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
[van Kuijk, Frederik J.] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
[Goldberg, Naomi; Lieberman, Ronni M.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA.
[Eliott, Dean] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
RP Johnson, MW (reprint author), Univ Michigan Hosp, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM markwj@umich.edu
FU Research to Prevent Blindness
FX Supported by Research to Prevent Blindness Unrestricted Grant (E.V.K.).
NR 35
TC 11
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1791
EP 1799
PG 9
WC Ophthalmology
SC Ophthalmology
GA 297DL
UT WOS:000330235500006
PM 23584702
ER
PT J
AU Rudolph, JW
Foldy, EG
Robinson, T
Kendall, S
Taylor, SS
Simon, R
AF Rudolph, Jenny W.
Foldy, Erica Gabrielle
Robinson, Traci
Kendall, Sandy
Taylor, Steven S.
Simon, Robert
TI Helping Without Harming The Instructor's Feedback Dilemma in
Debriefing-A Case Study
SO SIMULATION IN HEALTHCARE-JOURNAL OF THE SOCIETY FOR SIMULATION IN
HEALTHCARE
LA English
DT Article
DE Feedback; Debriefing; Faculty development; Debriefing the debriefer;
Inter-professional education
ID MEDICAL-EDUCATION; PATIENT SAFETY; PERFORMANCE; FAULTLINES; CONFLICT;
BEHAVIOR; IMPACT; THREAT; TEAMS; WORK
AB Introduction: Simulation instructors often feel caught in a task-versus-relationship dilemma. They must offer clear feedback on learners' task performance without damaging their relationship with those learners, especially in formative simulation settings. Mastering the skills to resolve this dilemma is crucial for simulation faculty development.
Methods: We conducted a case study of a debriefer stuck in this task-versus-relationship dilemma. Data: The "2-column case" captures debriefing dialogue and instructor's thoughts and feelings or the "subjective experience." Analysis: The "learning pathways grid" guides a peer group of faculty in a step-by-step, retrospective analysis of the debriefing. The method uses vivid language to highlight the debriefer's dilemmas and how to surmount them.
Results: The instructor's initial approach to managing the task-versus-relationship dilemma included (1) assuming that honest critiques will damage learners, (2) using vague descriptions of learner actions paired with guess-what-I-am-thinking questions, and (3) creating a context she worried would leave learners feeling neither safe nor clear how they could improve. This case study analysis identified things the instructor could do to be more effective including (1) making generous inferences about the learners' qualities, (2) normalizing the challenges posed by the simulation, (3) assuming there are different understandings of what it means to be a team.
Conclusions: There are key assumptions and ways of interacting that help instructors resolve the task-versus-relationship dilemma. The instructor can then provide honest feedback in a rigorous yet empathic way to help sustain good or improve suboptimal performance in the future.
C1 [Rudolph, Jenny W.; Simon, Robert] Ctr Med Simulat, Boston, MA USA.
[Rudolph, Jenny W.; Simon, Robert] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rudolph, Jenny W.; Simon, Robert] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Foldy, Erica Gabrielle] NYU, Wagner Sch Publ Serv, New York, NY 10003 USA.
[Robinson, Traci] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada.
[Kendall, Sandy] Wellesley Coll, Wellesley, MA 02181 USA.
[Taylor, Steven S.] Worcester Polytech Inst, Sch Business, Worcester, MA USA.
RP Rudolph, JW (reprint author), 100 1st Ave,Suite 400, Boston, MA 02129 USA.
EM JWRudolph@partners.org
NR 97
TC 16
Z9 16
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1559-2332
EI 1559-713X
J9 SIMUL HEALTHC
JI Simul. Healthc.
PD OCT
PY 2013
VL 8
IS 5
BP 304
EP 316
DI 10.1097/SIH.0b013e318294854e
PG 13
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 298EY
UT WOS:000330308100003
PM 24084647
ER
PT J
AU Weinberg, I
Jaff, MR
AF Weinberg, Ido
Jaff, Michael R.
TI Inferior Vena Cava Filters Truth or Dare?
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
DE Editorials; deep vein thrombosis; inferior vena cava filter; pulmonary
embolism; retrieval
ID DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM;
MANAGEMENT; COMPLICATIONS; REMOVAL; RISK
C1 [Weinberg, Ido; Jaff, Michael R.] Massachusetts Gen Hosp, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA.
RP Weinberg, I (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GB 852, Boston, MA 02114 USA.
EM iweinberg@partners.org
NR 18
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7640
EI 1941-7632
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD OCT
PY 2013
VL 6
IS 5
BP 498
EP 500
DI 10.1161/CIRCINTERVENTIONS.113.000818
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 292SQ
UT WOS:000329923100006
PM 24129933
ER
PT J
AU Armand, P
Oki, Y
Neuberg, DS
Faham, M
Cummings, C
Klinger, M
Weng, L
Bhattar, S
LaCasce, AS
Jacobsen, ED
Davids, MS
Jacobson, C
Fisher, DC
Brown, JR
Fowler, NH
Rodriguez, MA
Wallace, MJ
Neelapu, SS
Rodig, S
Younes, A
Freedman, AS
AF Armand, Philippe
Oki, Yasuhiro
Neuberg, Donna S.
Faham, Malek
Cummings, Craig
Klinger, Mark
Weng, Li
Bhattar, Sangeetha
LaCasce, Ann S.
Jacobsen, Eric D.
Davids, Matthew S.
Jacobson, Caron
Fisher, David C.
Brown, Jennifer R.
Fowler, Nathan H.
Rodriguez, M. Alma
Wallace, Michael J.
Neelapu, Sattva S.
Rodig, Scott
Younes, Anas
Freedman, Arnold S.
TI Detection of circulating tumour DNA in patients with aggressive B-cell
non-Hodgkin lymphoma
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter
DE minimal residual disease; sequences; lymphomas
ID RESIDUAL DISEASE DETECTION
C1 [Armand, Philippe; Bhattar, Sangeetha; LaCasce, Ann S.; Jacobsen, Eric D.; Davids, Matthew S.; Jacobson, Caron; Fisher, David C.; Brown, Jennifer R.; Freedman, Arnold S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Oki, Yasuhiro; Fowler, Nathan H.; Rodriguez, M. Alma; Neelapu, Sattva S.; Younes, Anas] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA.
[Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Faham, Malek; Cummings, Craig; Klinger, Mark; Weng, Li] Sequenta Inc, San Francisco, CA USA.
[Wallace, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA.
[Rodig, Scott] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Armand, P (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM parmand@partners.org
NR 8
TC 16
Z9 17
U1 3
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD OCT
PY 2013
VL 163
IS 1
BP 123
EP 126
DI 10.1111/bjh.12439
PG 4
WC Hematology
SC Hematology
GA 216YQ
UT WOS:000324323300016
PM 23795711
ER
PT J
AU Pezzolesi, MG
Krolewski, AS
AF Pezzolesi, Marcus G.
Krolewski, Andrzej S.
TI Diabetic Nephropathy: Is ESRD Its Only Heritable Phenotype?
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID RENAL-FUNCTION DECLINE; RISK; MICROALBUMINURIA; GENES
C1 Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Krolewski, AS (reprint author), Joslin Diabet Ctr, Sect Genet & Epidemiol, 1 Joslin Pl, Boston, MA 02215 USA.
EM Andrzej.Krolewski@joslin.harvard.edu
NR 13
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD OCT
PY 2013
VL 24
IS 10
BP 1505
EP 1507
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 277JN
UT WOS:000328815000002
PM 24029425
ER
PT J
AU Sandholm, N
McKnight, AJ
Salem, RM
Brennan, EP
Forsblom, C
Harjutsalo, V
Makinen, VP
McKay, GJ
Sadlier, DM
Williams, WW
Martin, F
Panduru, NM
Tarnow, L
Tuomilehto, J
Tryggvason, K
Zerbini, G
Comeau, ME
Langefeld, CD
Godson, C
Hirschhorn, JN
Maxwell, AP
Florez, JC
Groop, PH
AF Sandholm, Niina
McKnight, Amy Jayne
Salem, Rany M.
Brennan, Eoin P.
Forsblom, Carol
Harjutsalo, Valma
Makinen, Ville-Petteri
McKay, Gareth J.
Sadlier, Denise M.
Williams, Winfred W.
Martin, Finian
Panduru, Nicolae Mircea
Tarnow, Lise
Tuomilehto, Jaakko
Tryggvason, Karl
Zerbini, Gianpaolo
Comeau, Mary E.
Langefeld, Carl D.
Godson, Catherine
Hirschhorn, Joel N.
Maxwell, Alexander P.
Florez, Jose C.
Groop, Per-Henrik
CA FIND Consortium
FinnDiane Study Grp
GENIE Consortium
TI Chromosome 2q31.1 Associates with ESRD in Women with Type 1 Diabetes
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; SLIT DIAPHRAGM; CANCER-CELLS;
NEPHROPATHY; KIDNEY; COMPLICATIONS; INHIBITION; PROTEINS; PROMOTER
C1 [Sandholm, Niina; Forsblom, Carol; Harjutsalo, Valma; Makinen, Ville-Petteri; Groop, Per-Henrik] Folkhalsan Res Ctr, Folkhalsan Inst Genet, Helsinki, Finland.
[Sandholm, Niina; Forsblom, Carol; Harjutsalo, Valma; Makinen, Ville-Petteri; Groop, Per-Henrik] Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, FIN-00014 Helsinki, Finland.
[Sandholm, Niina] Aalto Univ, Dept Biomed Engn & Computat Sci, Espoo, Finland.
[McKnight, Amy Jayne; McKay, Gareth J.; Maxwell, Alexander P.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
[Salem, Rany M.; Hirschhorn, Joel N.; Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Salem, Rany M.; Hirschhorn, Joel N.] Childrens Hosp, Dept Endocrinol, Endocrine Res Unit, Boston, MA 02115 USA.
[Salem, Rany M.; Williams, Winfred W.; Hirschhorn, Joel N.; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Brennan, Eoin P.; Sadlier, Denise M.; Martin, Finian; Godson, Catherine] Univ Coll Dublin, Sch Med & Med Sci, Conway Inst, Diabet Res Ctr, Dublin 2, Ireland.
[Brennan, Eoin P.; Sadlier, Denise M.; Martin, Finian; Godson, Catherine] Mater Misericordiae Univ Hosp, Dublin 7, Ireland.
[Harjutsalo, Valma; Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Diabet Prevent Unit, Helsinki, Finland.
[Makinen, Ville-Petteri] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA USA.
[Williams, Winfred W.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Panduru, Nicolae Mircea] Carol Davila Univ Med & Pharm, Clin Dept 2, Bucharest, Romania.
[Tarnow, Lise] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark.
[Tarnow, Lise] Steno Diabet Ctr, DK-2820 Gentofte, Denmark.
[Tuomilehto, Jaakko] South Ostrobothnia Cent Hosp, Seinajoki, Finland.
[Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria.
[Tuomilehto, Jaakko] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia.
[Tryggvason, Karl] Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Stockholm, Sweden.
[Zerbini, Gianpaolo] Ist Sci San Raffaele, Div Metab & Cardiovasc Sci, Complicat Diabet Unit, I-20132 Milan, Italy.
[Comeau, Mary E.; Langefeld, Carl D.] Wake Forest Sch Med, Ctr Publ Hlth Genom, Dept Biostat, Winston Salem, NC USA.
[Maxwell, Alexander P.] Belfast City Hosp, Reg Nephrol Unit, Belfast BT9 7AD, Antrim, North Ireland.
[Groop, Per-Henrik] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia.
RP Groop, PH (reprint author), Univ Helsinki, Cent Hosp, Biomedicum Helsinki, Div Nephrol,Dept Med, Haartmaninkatu 8,POB 63, FIN-00014 Helsinki, Finland.
EM per-henrik.groop@helsinki.fi
OI McKnight, Amy Jayne/0000-0002-7482-709X; Makinen,
Ville-Petteri/0000-0002-7262-2656; Maxwell, Alexander
P./0000-0002-6110-7253
FU Eli Lilly; Roche
FX J.C.F. has received consulting honoraria from Novartis, Lilly, and
Pfizer. P.H.G. has received lecture honoraria from Abbott, Boehringer
Ingelheim, Cebix, Eli Lilly, Genzyme, Novartis, Novo Nordisk, and MSD
and research grants from Eli Lilly and Roche. P.H.G. is also an advisory
board member of Boehringer Ingelheim and Novartis.
NR 28
TC 20
Z9 21
U1 1
U2 2
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD OCT
PY 2013
VL 24
IS 10
BP 1537
EP 1543
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 277JN
UT WOS:000328815000008
PM 24029427
ER
PT J
AU Wen, LS
Kosowsky, JM
Gurrola, ER
Camargo, CA
AF Wen, Leana S.
Kosowsky, Joshua M.
Gurrola, Edith R.
Camargo, Carlos A., Jr.
TI The provision of diagnosis at emergency department discharge: a pilot
study
SO EMERGENCY MEDICINE JOURNAL
LA English
DT Article
ID UNSCHEDULED RETURNS; URBAN
AB Objectives Understanding the cause of patients' symptoms usually involves identification of a pathological diagnosis. Anecdotal reports suggest that emergency department (ED) providers do not prioritise giving pathological diagnoses, and often reiterate the patient's symptom as the discharge 'diagnosis'. Our pilot study sought to identify the proportion of patients at a large teaching hospital who receive a symptomatic versus pathological diagnosis at ED discharge.
Methods We performed a chart review of all adult patients who were discharged from an urban ED in the USA, with an 88 000 annual visit volume. All charts of patients presenting with the three most common ED chief complaints (chest pain, abdominal pain and headache) were reviewed by two reviewers. Charts were coded as either symptomatic or pathological diagnosis based on the discharge diagnosis provided by the attending physician. Those with discrepant coding by the two reviewers were subject to review by a third adjudicator.
Results 797 charts met the inclusion criteria. Five charts (0.6%) were coded differently by the two reviewers; a discussion with the third reviewer resulted in consensus in all cases. For patients presenting with chest pain, abdominal pain and headache, the proportion that received a pathological ED discharge diagnosis were 17%, 43% and 41%, respectively.
Conclusions According to our pilot study, most patients are discharged from the ED without a pathological diagnosis that explains the likely cause of their symptoms. Future studies will investigate whether this finding is consistent across institutions, and whether provision of a pathological diagnosis affects clinical outcomes and patient satisfaction.
C1 [Wen, Leana S.] Brigham & Womens Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA.
[Kosowsky, Joshua M.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
[Gurrola, Edith R.] Univ Arizona, Dept Emergency Med, Phoenix, AZ USA.
[Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
RP Wen, LS (reprint author), Brigham & Womens Hosp, Massachusetts Gen Hosp, Dept Emergency Med, Neville House,75 Francis St, Boston, MA 02115 USA.
EM wen.leana@gmail.com
OI Wen, Leana/0000-0003-0259-0537
FU Massachusetts American College of Emergency Physicians; Department of
Emergency Medicine at Brigham & Women's Hospital
FX This project is being funded by grants from the Massachusetts American
College of Emergency Physicians and Department of Emergency Medicine at
Brigham & Women's Hospital.
NR 10
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1472-0205
EI 1472-0213
J9 EMERG MED J
JI Emerg. Med. J.
PD OCT
PY 2013
VL 30
IS 10
BP 801
EP 803
DI 10.1136/emermed-2012-201749
PG 3
WC Emergency Medicine
SC Emergency Medicine
GA 267XI
UT WOS:000328131300007
PM 23100316
ER
PT J
AU Juillerat, P
Wasan, SK
Fowler, SA
Friedman, S
Pabby, VK
Coukas, JA
Barto, AE
Pellish, R
Germansky, KA
Cheifetz, AS
Korzenik, JR
Farraye, FA
Yajnik, V
AF Juillerat, Pascal
Wasan, Sharmeel K.
Fowler, Sharyle A.
Friedman, Sonia
Pabby, Vikas K.
Coukas, Jennifer A.
Barto, Amy E.
Pellish, Randall
Germansky, Katharine A.
Cheifetz, Adam S.
Korzenik, Joshua R.
Farraye, Francis A.
Yajnik, Vijay
TI Efficacy and Safety of Natalizumab in Crohn's Disease Patients Treated
at 6 Boston Academic Hospitals
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE Crohn's disease; inflammatory bowel disease; natalizumab; safety;
efficacy; clinical practice
ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; ANTIBODY;
THERAPY; TRIAL; INDEX; RISK
AB Background:Despite trials demonstrating its efficacy, many physicians harbor concerns regarding the use of natalizumab in the treatment of patients with refractory Crohn's disease (CD). The purpose of this study was to perform a descriptive analysis of a series of CD patients not currently enrolled in a clinical trial.
Methods: A retrospective case review of patients treated with natalizumab at 6 sites in Massachusetts: Boston Medical Center, Beth Israel Deaconess Medical Center, Brigham & Women's Hospital, Lahey Clinic, Massachusetts General Hospital, and UMass Medical Center.
Results: Data on 69 CD patients on natalizumab were collected. At the start of treatment, patients' disease duration was 12 years. A high proportion of patients were women (68%), presented with perianal disease (65%) and upper gastrointestinal tract involvement (14%). Prior nonbiologic therapies were steroids (96%), thiopurines (94%), antibiotics (74%), methotrexate (58%), and at least two anti-tumor necrosis factor agent failures (81%). Sixty-nine percent (44 of 64 patients) with available medical evaluation had a partial or complete clinical response. Loss of response was 13% after an average of 1 year of treatment. Adverse events were infusion reactions, headaches, fever, and infections. No case of progressive multifocal leukoencephalopathy was observed.
Conclusions: In our clinical experience outside the context of a clinical trial, natalizumab is largely reserved for CD patients with extensive ileocolonic disease who have failed conventional immunosuppressants and of at least 2 anti-tumor necrosis factor agents. This drug is, however, well tolerated and offers significant clinical improvement for more than a year in one-third of these difficult-to-treat CD patients.
C1 [Juillerat, Pascal; Fowler, Sharyle A.; Korzenik, Joshua R.; Yajnik, Vijay] Massachusetts Gen Hosp, Dept Gastroenterol & Hepatol, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA.
[Juillerat, Pascal; Fowler, Sharyle A.; Korzenik, Joshua R.; Yajnik, Vijay] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Juillerat, Pascal] Univ Bern, Inselspital, Univ Hosp Bern, Div Gastroenterol,Clin Visceral Surg & Med, CH-3010 Bern, Switzerland.
[Wasan, Sharmeel K.; Coukas, Jennifer A.; Farraye, Francis A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Friedman, Sonia; Pabby, Vikas K.; Korzenik, Joshua R.] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA.
[Barto, Amy E.] Lahey Clin Fdn, Burlington, MA USA.
[Pellish, Randall] Univ Massachusetts, Worcester, MA 01605 USA.
[Germansky, Katharine A.; Cheifetz, Adam S.] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA.
RP Juillerat, P (reprint author), Massachusetts Gen Hosp, Dept Gastroenterol & Hepatol, MGH Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA.
EM pascal_juillerat@post.harvard.edu
FU Swiss National Science Foundation (SNF) [PBLAP3-124341]
FX Supported by the Swiss National Science Foundation (SNF) Grant
PBLAP3-124341.
NR 19
TC 12
Z9 12
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD OCT
PY 2013
VL 19
IS 11
BP 2457
EP 2463
DI 10.1097/MIB.0b013e3182a32a0d
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 284XE
UT WOS:000329354500024
PM 23962896
ER
PT J
AU Sevc, J
Goldberg, D
van Gorp, S
Leerink, M
Juhas, S
Juhasova, J
Marsala, S
Hruska-Plochan, M
Hefferan, MP
Motlik, J
Rypacek, F
Machova, L
Kakinohana, O
Santucci, C
Johe, K
Lukacova, N
Yamada, K
Bui, JD
Marsala, M
AF Sevc, Juraj
Goldberg, Danielle
van Gorp, Sebastiaan
Leerink, Marjolein
Juhas, Stefan
Juhasova, Jana
Marsala, Silvia
Hruska-Plochan, Marian
Hefferan, Michael P.
Motlik, Jan
Rypacek, Frantisek
Machova, Ludka
Kakinohana, Osamu
Santucci, Camila
Johe, Karl
Lukacova, Nadezda
Yamada, Kazuhiko
Bui, Jack D.
Marsala, Martin
TI Effective long-term immunosuppression in rats by subcutaneously
implanted sustained-release tacrolimus pellet: Effect on spinally
grafted human neural precursor survival
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Immunosuppression; Xenograft; Human neural precursors; Spinal grafting;
Sprague-Dawley rat; T-lymphocyte; Tacrolimus pellet
ID STEM-CELLS; MYCOPHENOLATE-MOFETIL; ORGAN-TRANSPLANTATION;
PARKINSONS-DISEASE; FK506; MODEL; PHARMACOKINETICS; PHARMACODYNAMICS;
NEPHROTOXICITY; DIFFERENTIATION
AB Achievement of effective, safe and long-term immunosuppression represents one of the challenges in experimental allogeneic and xenogeneic cell and organ transplantation. The goal of the present study was to develop a reliable, long-term immunosuppression protocol in Sprague-Dawley (SD) rats by: 1) comparing the pharmacokinetics of four different subcutaneously delivered/implanted tacrolimus (TAC) formulations, including: i) caster oil/saline solution, ii) unilamellar or multilamellar liposomes, iii) biodegradable microspheres, and iv) biodegradable 3-month lasting pellets; and 2) defining the survival and immune response in animals receiving spinal injections of human neural precursors at 6 weeks to 3 months after cell grafting. In animals implanted with TAC pellets (3.4 mg/kg/day), a stable 3-month lasting plasma concentration of TAC averaging 19.1 +/- 4.9 ng/ml was measured. Analysis of grafted cell survival in SOD + or spinal trauma-injured SD rats immunosuppressed with 3-month lasting TAC pellets (3.4-5.1 mg/kg/day) showed the consistent presence of implanted human neurons with minimal or no local T-cell infiltration. These data demonstrate that the use of TAC pellets can represent an effective, long-lasting immunosuppressive drug delivery system that is safe, simple to implement and is associated with a long-term human neural precursor survival after grafting into the spinal cord of SOD+ or spinal trauma-injured SD rats. Published by Elsevier Inc.
C1 [Sevc, Juraj; Goldberg, Danielle; Leerink, Marjolein; Marsala, Silvia; Hruska-Plochan, Marian; Kakinohana, Osamu; Santucci, Camila; Marsala, Martin] UCSD, Dept Anesthesiol, Neuroregenerat Lab, La Jolla, CA 92037 USA.
[Sevc, Juraj] Safarik Univ, Fac Sci, Inst Biol & Ecol, Kosice 04001, Slovakia.
[van Gorp, Sebastiaan] Maastricht Univ, Med Ctr, Dept Anesthesiol, NL-6202 AZ Maastricht, Netherlands.
[Juhas, Stefan; Juhasova, Jana; Hruska-Plochan, Marian; Motlik, Jan] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov 27721, Czech Republic.
[Hruska-Plochan, Marian] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague, Czech Republic.
[Rypacek, Frantisek; Machova, Ludka] Acad Sci Czech Republic, Inst Macromol Chem, Prague 16206 6, Czech Republic.
[Hefferan, Michael P.; Johe, Karl] Neuralstem Inc, Rockville, MD 20850 USA.
[Lukacova, Nadezda] Slovak Acad Sci, Inst Neurobiol, Kosice 04001, Slovakia.
[Yamada, Kazuhiko] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
[Bui, Jack D.] UCSD, Dept Pathol, La Jolla, CA 92037 USA.
RP Marsala, M (reprint author), UCSD, Sanford Consortium Regenerat Med, Dept Anesthesiol, Neuroregenerat Lab, 2880 Torrey Pines Scen Dr, La Jolla, CA 92037 USA.
EM mmarsala@ucsd.edu
RI Juhasova, Jana/G-7144-2014; Rypacek, Frantisek/G-7872-2014; Motlik,
Jan/G-7148-2014; Juhas, Stefan/G-7141-2014; Hruska-Plochan,
Marian/I-3982-2014
OI Juhasova, Jana/0000-0001-7022-6812; Juhas, Stefan/0000-0002-2866-0727;
FU CIRM; Neuralstem Inc.; ITMS [26220220127]; [TA01011466];
[CZ.1.05./2.1.00/03.0124]; [RVO: 67985904]; [APVV-0314-06]
FX This study was funded by CIRM and by Neuralstem Inc. (M.M.), TA01011466,
CZ.1.05./2.1.00/03.0124 and RVO: 67985904 (S.J., J.J., J.M.), ITMS
26220220127 (Research & Development Operational Programme, ERDF) and
APVV-0314-06 (N.L). No relationship with Astellas Pharma exists for any
of the authors.
NR 41
TC 9
Z9 9
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 1090-2430
J9 EXP NEUROL
JI Exp. Neurol.
PD OCT
PY 2013
VL 248
BP 85
EP 99
DI 10.1016/j.expneurol.2013.05.017
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 261SJ
UT WOS:000327684600009
PM 23748136
ER
PT J
AU Leonardis, RL
Duvvuri, U
Mehta, D
AF Leonardis, Rachel L.
Duvvuri, Umamaheswar
Mehta, Deepak
TI Transoral Robotic-Assisted Lingual Tonsillectomy in the Pediatric
Population
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID OBSTRUCTIVE SLEEP-APNEA; SURGERY; HEAD; NECK; OTOLARYNGOLOGY; SAFETY
AB IMPORTANCE Since technologic advances allow the use of robotic assistance in various surgical interventions performed to treat pediatric otolaryngology patients, the feasibility and outcomes of potential procedures must be assessed.
OBJECTIVE To assess the feasibility and outcomes of robotic-assisted lingual tonsillectomy in the pediatric population.
DESIGN, SETTING, AND PARTICIPANTS Retrospective medical record review in a tertiary care children's hospital of 16 pediatric patients who underwent robotic-assisted lingual tonsillectomy from March 1, 2011, through December 31, 2012.
INTERVENTION All patients underwent robotic-assisted lingual tonsillectomy using the da Vinci Surgical System (Intuitive Surgical, Inc) at the Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center.
MAIN OUTCOMES AND MEASURES Demographic data, comorbidities, robot docking time, operative time, estimated blood loss, and postoperative course, including complications in the immediate and longer-term postoperative period, were collected and analyzed.
RESULTS All patients successfully underwent lingual tonsillectomy using the da Vinci Surgical System. Endotracheal intubation was performed in all patients and did not interfere with visualization of the oropharynx. Optimal retraction allowed visualization of pertinent structures and maximized transoral access. A significant learning curve from the first 5 surgical cases to subsequent cases with respect to robot docking time was observed (9 vs 3 minutes, respectively; P < .05). Operative time, estimated blood loss, and postoperative complication profiles are within the expected and acceptable limitations for performing lingual tonsillectomy in the pediatric population.
CONCLUSIONS AND RELEVANCE Technologic advances have allowed miniaturization of robotic instrumentation and have expanded the scope of surgical options for the pediatric airway. Robotic-assisted lingual tonsillectomy is well tolerated and can be performed in the pediatric population with excellent success. It should be considered a feasible option for implementation at an institution-based level.
C1 [Leonardis, Rachel L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Duvvuri, Umamaheswar] Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Syst, Med Ctr, Inst Eye & Ear,Dept Otolaryngol, Pittsburgh, PA 15213 USA.
[Mehta, Deepak] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
RP Duvvuri, U (reprint author), Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Syst, Med Ctr, Inst Eye & Ear,Dept Otolaryngol, 203 Lothrop St,Ste 300, Pittsburgh, PA 15213 USA.
EM duvvuriu@upmc.edu
NR 15
TC 8
Z9 8
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6181
EI 2168-619X
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD OCT
PY 2013
VL 139
IS 10
BP 1032
EP 1036
DI 10.1001/jamaoto.2013.4924
PG 5
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 279DU
UT WOS:000328941400007
PM 24135744
ER
PT J
AU Putman, MS
Yu, EW
Lee, H
Neer, RM
Schindler, E
Taylor, AP
Cheston, E
Bouxsein, ML
Finkelstein, JS
AF Putman, Melissa S.
Yu, Elaine W.
Lee, Hang
Neer, Robert M.
Schindler, Elizabeth
Taylor, Alexander P.
Cheston, Emily
Bouxsein, Mary L.
Finkelstein, Joel S.
TI Differences in Skeletal Microarchitecture and Strength in
African-American and White Women
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE HR-PQCT; BONE MICROARCHITECTURE; MICRO-FINITE ELEMENT ANALYSIS;
AFRICAN-AMERICAN; WHITE
ID QUANTITATIVE COMPUTED-TOMOGRAPHY; BONE-MINERAL DENSITY;
FINITE-ELEMENT-ANALYSIS; VIVO HR-PQCT; DISTAL RADIUS; CORTICAL BONE;
PROXIMAL FEMUR; FRACTURE RISK; POSTMENOPAUSAL WOMEN; ETHNIC VARIATION
AB African-American women have a lower risk of fracture than white women, and this difference is only partially explained by differences in dual-energy X-ray absorptiometry (DXA) areal bone mineral density (aBMD). Little is known about racial differences in skeletal microarchitecture and the consequences for bone strength. To evaluate potential factors underlying this racial difference in fracture rates, we used high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess cortical and trabecular bone microarchitecture and estimate bone strength using micro-finite element analysis (mu FEA) in African-American (n=100) and white (n=173) women participating in the Study of Women's Health Across the Nation (SWAN). African-American women had larger and denser bones than whites, with greater total area, aBMD, and total volumetric BMD (vBMD) at the radius and tibia metaphysis (p<0.05 for all). African-Americans had greater trabecular vBMD at the radius, but higher cortical vBMD at the tibia. Cortical microarchitecture tended to show the most pronounced racial differences, with higher cortical area, thickness, and volumes in African-Americans at both skeletal sites (p<0.05 for all), and lower cortical porosity in African-Americans at the tibia (p<0.05). African-American women also had greater estimated bone stiffness and failure load at both the radius and tibia. Differences in skeletal microarchitecture and estimated stiffness and failure load persisted even after adjustment for DXA aBMD. The densitometric and microarchitectural predictors of failure load at the radius and tibia were the same in African-American and white women. In conclusion, differences in bone microarchitecture and density contribute to greater estimated bone strength in African-Americans and probably explain, at least in part, the lower fracture risk of African-American women. (c) 2013 American Society for Bone and Mineral Research.
C1 [Putman, Melissa S.; Yu, Elaine W.; Neer, Robert M.; Schindler, Elizabeth; Taylor, Alexander P.; Cheston, Emily; Bouxsein, Mary L.; Finkelstein, Joel S.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Putman, Melissa S.; Yu, Elaine W.; Neer, Robert M.; Schindler, Elizabeth; Taylor, Alexander P.; Cheston, Emily; Bouxsein, Mary L.; Finkelstein, Joel S.] Harvard Univ, Sch Med, Boston, MA USA.
[Putman, Melissa S.] Boston Childrens Hosp, Div Endocrine, Boston, MA USA.
[Lee, Hang] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
RP Putman, MS (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,THR 1051, Boston, MA 02114 USA.
EM msputman@partners.org
FU National Institutes of Health (NIH); DHHS through the National Institute
on Aging (NIA); National Institute of Nursing Research (NINR); NIH
Office of Research on Women's Health (ORWH) [NR004061, AG012505,
AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495];
NCRR Shared Equipment Grant [1S10RR023405-01]
FX The Study of Women's Health Across the Nation (SWAN) has grant support
from the National Institutes of Health (NIH), DHHS, through the National
Institute on Aging (NIA), the National Institute of Nursing Research
(NINR) and the NIH Office of Research on Women's Health (ORWH)
(NR004061, AG012505, AG012535, AG012531, AG012539, AG012546, AG012553,
AG012554, AG012495). The HR-pQCT measurements were made possible by an
NCRR Shared Equipment Grant (1S10RR023405-01). The content of this
manuscript is solely the responsibility of the authors and does not
necessarily represent the official views of the NIA, NINR, ORWH, or the
NIH.
NR 39
TC 18
Z9 18
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD OCT
PY 2013
VL 28
IS 10
BP 2177
EP 2185
DI 10.1002/jbmr.1953
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 282EM
UT WOS:000329153100013
PM 23572415
ER
PT J
AU Catassi, C
Bai, JC
Bonaz, B
Bouma, G
Calabro, A
Carroccio, A
Castillejo, G
Ciacci, C
Cristofori, F
Dolinsek, J
Francavilla, R
Elli, L
Green, P
Holtmeier, W
Koehler, P
Koletzko, S
Meinhold, C
Sanders, D
Schumann, M
Schuppan, D
Ullrich, R
Vecsei, A
Volta, U
Zevallos, V
Sapone, A
Fasano, A
AF Catassi, Carlo
Bai, Julio C.
Bonaz, Bruno
Bouma, Gerd
Calabro, Antonio
Carroccio, Antonio
Castillejo, Gemma
Ciacci, Carolina
Cristofori, Fernanda
Dolinsek, Jernej
Francavilla, Ruggiero
Elli, Luca
Green, Peter
Holtmeier, Wolfgang
Koehler, Peter
Koletzko, Sibylle
Meinhold, Christof
Sanders, David
Schumann, Michael
Schuppan, Detlef
Ullrich, Reiner
Vecsei, Andreas
Volta, Umberto
Zevallos, Victor
Sapone, Anna
Fasano, Alessio
TI Non-Celiac Gluten Sensitivity: The New Frontier of Gluten Related
Disorders
SO NUTRIENTS
LA English
DT Review
DE gluten sensitivity; celiac disease; wheat allergy; gluten-related
disorders; gluten-free diet
ID AUTISM SPECTRUM DISORDERS; CONTROLLED-TRIAL; FREE DIET; DISEASE;
CHILDREN; BLIND; WHEAT; PREVALENCE; CHALLENGE; SYMPTOMS
AB Non Celiac Gluten sensitivity (NCGS) was originally described in the 1980s and recently a re-discovered disorder characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected with either celiac disease (CD) or wheat allergy (WA). Although NCGS frequency is still unclear, epidemiological data have been generated that can help establishing the magnitude of the problem. Clinical studies further defined the identity of NCGS and its implications in human disease. An overlap between the irritable bowel syndrome (IBS) and NCGS has been detected, requiring even more stringent diagnostic criteria. Several studies suggested a relationship between NCGS and neuropsychiatric disorders, particularly autism and schizophrenia. The first case reports of NCGS in children have been described. Lack of biomarkers is still a major limitation of clinical studies, making it difficult to differentiate NCGS from other gluten related disorders. Recent studies raised the possibility that, beside gluten, wheat amylase-trypsin inhibitors and low-fermentable, poorly-absorbed, short-chain carbohydrates can contribute to symptoms (at least those related to IBS) experienced by NCGS patients. In this paper we report the major advances and current trends on NCGS.
C1 [Catassi, Carlo] Univ Politecn Marche, Dept Pediat, I-60121 Ancona, Italy.
[Bai, Julio C.] Hosp Gastroenterol Dr Carlos Bonorino Udaondo, Dept Med, RA-1264 Buenos Aires, DF, Argentina.
[Bonaz, Bruno] CHU Grenoble, Dept Gastroenterol & Liver Dis, F-38043 Grenoble, France.
[Bouma, Gerd] Vrije Univ Med Ctr, Dept Gastroenterol & Hepatol, NL-1081 HV Amsterdam, Netherlands.
[Calabro, Antonio] Univ Florence, Dept Expt & Clin Biomed Sci, Gastroenterol Unit, I-50134 Florence, Italy.
[Carroccio, Antonio] Giovanni Paolo II Hosp, Dept Internal Med, Sciacca, AG, Italy.
[Carroccio, Antonio] Univ Palermo, I-92019 Sciacca, Italy.
[Castillejo, Gemma] Univ Rovira & Virgili, Hosp Univ St Joan de Reus, Pediat Gastroenterol Unit, Tarragona 43204, Spain.
[Ciacci, Carolina] Univ Salerno, Dept Med & Surg, I-84081 Salerno, Italy.
[Cristofori, Fernanda; Francavilla, Ruggiero] Univ Bari, Interdisciplinary Dept Med, I-70124 Bari, Italy.
[Dolinsek, Jernej] Univ Med Ctr Maribor, Dept Pediat, Gastroenterol Unit, Maribor 2000, Slovenia.
[Elli, Luca] Ctr Prevenz & Diagnosi Malattia Celiaca Fdn IRCCS, I-20122 Milan, Italy.
[Green, Peter] Columbia Univ Med Ctr, Dept Med, Celiac Dis Ctr, New York, NY 10032 USA.
[Holtmeier, Wolfgang] Hosp Porz Rhein, Div Gastroenterol & Internal Med, D-51149 Cologne, Germany.
[Koehler, Peter] Leibniz Inst, German Res Ctr Food Chem, D-85354 Freising Weihenstephan, Germany.
[Koletzko, Sibylle] Univ Munich Med Ctr, Dr von Hauner Childrens Hosp, Div Pediat Gastroenterol & Hepatol, D-80337 Munich, Germany.
[Meinhold, Christof] Practice Nutr Therapy Meinhold & Team, D-50674 Cologne, Germany.
[Sanders, David] Royal Hallamshire Hosp, Dept Gastroenterol & Hepatol, Sheffield S10 2JF, S Yorkshire, England.
[Sanders, David] Univ Sheffield Med Sch, Sheffield S10 2JF, S Yorkshire, England.
[Schumann, Michael; Ullrich, Reiner] Charite, Dept Gastroenterol Rheumatol & Infectiol, D-10203 Berlin, Germany.
[Schuppan, Detlef; Zevallos, Victor] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 1, D-55131 Mainz, Germany.
[Schuppan, Detlef] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA.
[Schuppan, Detlef] Beth Israel Deaconess Med Ctr, Celiac Ctr, Boston, MA 02215 USA.
[Schuppan, Detlef] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Vecsei, Andreas] St Anna Childrens Hosp, A-1090 Vienna, Austria.
[Volta, Umberto] Univ Bologna, Dept Med & Surg Sci, I-40138 Bologna, Italy.
[Sapone, Anna] Univ Naples 2, Dept Gastroenterol, I-80136 Naples, Italy.
[Fasano, Alessio] MassGen Hosp Children, Boston, MA 02129 USA.
RP Fasano, A (reprint author), MassGen Hosp Children, Boston, MA 02129 USA.
EM catassi@tin.it; jbai@intramed.net; bbonaz@chu-grenoble.fr;
g.bouma@vumc.nl; a.calabro@dfc.unifi.it; acarroccio@hotmail.com;
gcv@tinet.cat; cciacci@unisa.it; fernandacristofori@gmail.com;
jernej.dolinsek@ukc-mb.si; rfrancavilla@gmail.com; lucelli@yahoo.com;
pg11@columbia.edu; w.holtmeier@khporz.de; peter.koehler@tum.de;
sybille.koletzko@med.uni-muenchen.de; praxis@christof-meinhold.de;
david.sanders@sth.nhs.uk; michael.schumann@charite.de;
dschuppa@bidmc.harvard.edu; reiner.ullrich@charite.de;
andreas.vecsei@stanna.at; uvolt@yahoo.com; zevallos@uni-mainz.de;
annasapone@yahoo.it; afasano@partners.org
RI ciacci, carolina/A-2594-2012; bouma, gerd/E-2520-2013; Carroccio,
Antonio/K-4484-2016; Schumann, Michael/K-6426-2013;
OI ciacci, carolina/0000-0002-7426-1145; Carroccio,
Antonio/0000-0001-8913-7916; Schumann, Michael/0000-0001-6391-9979;
Volta, Umberto/0000-0003-3405-3808; Francavilla,
Ruggiero/0000-0002-4603-974X; Elli, Luca/0000-0002-0873-0759
FU Schar; Menarini Diagnostics
FX Carlo Catassi received consulting fees from Schar and Menarini
Diagnostics. Luca Elli and Anna Sapone received consulting fees from
Schar. Peter Green is a member of the scientific advisory board of
Alvine Pharmaceuticals and Alba Therapeutics. Alessio Fasano owns stock
in Alba Therapeutics. The other authors declared no conflict of
interest.
NR 40
TC 153
Z9 157
U1 15
U2 150
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2013
VL 5
IS 10
BP 3839
EP 3853
DI 10.3390/nu5103839
PG 15
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 274TA
UT WOS:000328627900003
PM 24077239
ER
PT J
AU Azzam, PN
Gopalan, PR
AF Azzam, Pierre N.
Gopalan, Priya R.
TI A 44-Year-Old Man with Agitation after Stroke
SO PSYCHIATRIC ANNALS
LA English
DT Editorial Material
ID SUBARACHNOID HEMORRHAGE; BRAIN-INJURY; AMNESIA; IMPAIRMENT; LESIONS;
MEMORY; VOLUME
C1 [Azzam, Pierre N.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Cambridge, MA 02138 USA.
[Azzam, Pierre N.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Gopalan, Priya R.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA.
RP Azzam, PN (reprint author), VA Med Ctr West, Roxbury Campus,GD 110,1400 VFW Pkwy, Boston, MA 02132 USA.
EM pierre.azzam@va.gov
NR 17
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD OCT
PY 2013
VL 43
IS 10
BP 470
EP 472
DI 10.3928/00485713-20131003-09
PG 3
WC Psychiatry
SC Psychiatry
GA 282SG
UT WOS:000329192600009
ER
PT J
AU West, JS
Price, M
Gros, KS
Ruggiero, KJ
AF West, Jenny S.
Price, Matthew
Gros, Kirstin Stauffacher
Ruggiero, Kenneth J.
TI Community Support as a Moderator of Postdisaster Mental Health Symptoms
in Urban and Nonurban Communities
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE community support; urban nonurban; PTSD; depression
ID SOCIAL SUPPORT; NATURAL DISASTER; HURRICANE IKE; PSYCHOLOGICAL DISTRESS;
VIOLENT CRIME; STRESS; INTERVENTION; PTSD; ADULTS; CONSERVATION
AB Objective We examined the association between disaster exposure, community support, and mental health outcomes in urban and nonurban participants of Galveston and Chambers counties after Hurricane Ike. The moderating effect of community support was evaluated as a protective factor relative to postdisaster mental health.
Methods A representative population-based sample of 157 urban and 714 nonurban adults were interviewed 12 to 17 months after the hurricane about their mental health functioning, disaster exposure, and perceptions of community support.
Results A series of multiple regressions demonstrated that disaster exposure was associated with mental health outcomes for both groups. The strength of the association varied across population samples.Community support moderated the association between interpersonal effects of the disaster and posttraumatic stress disorder (PTSD) and depression outcomes in nonurban participants and the association between property damage and PTSD in urban participants.
Conclusions Community support played a larger role in reducing PTSD and depression symptoms associated with the interpersonal effects of a disaster in the nonurban sample only. Communities may play a more beneficial role in the recovery process in nonurban areas that have elevated levels of injury or death attributed to a disaster.
C1 [West, Jenny S.; Price, Matthew; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Price, Matthew; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[West, Jenny S.] Univ Calif Irvine, Irvine, CA USA.
RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, 67 President St, Charleston, SC 29425 USA.
EM prima@musc.edu
FU National Institutes of Mental Health [R34MH77149]; [T32MH018869]
FX This study is supported by the National Institutes of Mental Health
Grant R34MH77149 (Dr Ruggiero). Dr. Price is supported by T32MH018869.
NR 34
TC 2
Z9 2
U1 2
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD OCT
PY 2013
VL 7
IS 5
BP 443
EP 451
DI 10.1017/dmp.2013.74
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 273PC
UT WOS:000328546700003
PM 24274123
ER
PT J
AU Yoo, JW
Kim, S
Seol, H
Kim, SJ
Yang, JM
Ryu, WS
Min, TJ
Choi, JB
Kwon, M
Nakagawa, S
AF Yoo, Ji Won
Kim, Sulgi
Seol, Haesun
Kim, Sun Jung
Yang, Janet Miyoung
Ryu, Woo Sang
Min, Too Jae
Choi, Jong Bum
Kwon, Minkyung
Nakagawa, Shunichi
TI Effects of an internal medicine floor interdisciplinary team on hospital
and clinical outcomes of seniors with acute medical illness
SO GERIATRICS & GERONTOLOGY INTERNATIONAL
LA English
DT Article
DE clinical education; geriatric assessment; hospital medicine;
interdisciplinary team; quality improvement
ID CONFUSION ASSESSMENT METHOD; LENGTH-OF-STAY; PROSPECTIVE-PAYMENT;
DELIRIUM; GERIATRICS; RELIABILITY; RESIDENTS; TRENDS; RISK; CARE
AB AimTo examine whether an internal medicine interdisciplinary floor team enhances the hospital and clinical outcomes for seniors with acute medical illness.
MethodsSeniors admitted to medical floor teaching services of a USA teaching hospital were recruited and allocated to the interdisciplinary (ITD; n=236) and usual care teams (n=248). Compared with the usual care team, the interdisciplinary team physicians carried out daily geriatric assessment and management, and led the interdisciplinary team meeting designed for improving interprofessional collaboration.
ResultsAfter controlling for patient and physician characteristics, the mean hospital length of stay in the ITD team (6.1 days; 95% CI 5.2-7.7 days) was 0.7 days shorter than that in the usual care team (6.8 days; 95% CI 5.7-8.3 days; P=0.008). There was no significant difference in delirium and 30-day hospital readmission between care groups.
ConclusionsNotwithstanding partly positive associations, the results from the present study suggest that interdisciplinary team-based care is, at best, associated with enhancing the clinical and hospital outcomes for seniors with acute medical illness. Geriatr Gerontol Int 2013; 13: 942-948.
C1 [Yoo, Ji Won] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Yoo, Ji Won] Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA.
[Yang, Janet Miyoung] St Joseph Mercy, Dept Internal Med, Ann Arbor, MI USA.
[Kim, Sulgi] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Seol, Haesun] VNA Hlth Ctr, Federally Qualified Hlth Ctr, Bensenville, IL USA.
[Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA.
[Yoo, Ji Won] Korea Univ, Coll Med, Dept Internal Med, Seoul 136705, South Korea.
[Ryu, Woo Sang; Min, Too Jae] Korea Univ, Coll Med, Ctr Clin Educ, Seoul 136705, South Korea.
[Kim, Sun Jung] Yonsei Univ, Sch Publ Hlth, Seoul 120749, South Korea.
[Choi, Jong Bum; Kwon, Minkyung] Yonsei Univ, Coll Med, Ctr Clin Educ, Seoul, South Korea.
RP Yoo, JW (reprint author), Univ Michigan, Sch Med, Dept Internal Med, 300 North Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA.
EM yoojiw@trinity-health.org
RI Kwon, Minkyung/H-3787-2012
OI Kwon, Minkyung/0000-0003-2437-7606
FU Junior Researcher Seed Grant (American Geriatrics Society); Excellence
for Graduate Medical Education Grant (Ministry of Education, Science and
Technology, Republic of Korea)
FX This study was funded by a Junior Researcher Seed Grant (American
Geriatrics Society) and an Excellence for Graduate Medical Education
Grant (Ministry of Education, Science and Technology, Republic of
Korea).
NR 31
TC 2
Z9 2
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-1586
EI 1447-0594
J9 GERIATR GERONTOL INT
JI Geriatr. Gerontol. Int.
PD OCT
PY 2013
VL 13
IS 4
BP 942
EP 948
DI 10.1111/ggi.12035
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 271LE
UT WOS:000328392600016
PM 23441847
ER
PT J
AU Nogueira, RG
Bayrlee, A
Hirsch, JA
Yoo, AJ
Copen, WA
AF Nogueira, Raul G.
Bayrlee, Ahmad
Hirsch, Joshua A.
Yoo, Albert J.
Copen, William A.
TI Dynamic Contrast-Enhanced MRA at 1.5 T for Detection of Arteriovenous
Shunting Before and After Onyx Embolization of Cerebral Arteriovenous
Malformations
SO JOURNAL OF NEUROIMAGING
LA English
DT Article
DE Cerebral arteriovenous malformation; Onyx; MRI; TRICKS
ID MAGNETIC-RESONANCE ANGIOGRAPHY
AB BACKGROUNDConventional non-invasive angiographic techniques for evaluating cerebral Arteriovenous Malformations (cAVMs) after embolization treatment are limited by their inability to acquire time-resolved images. We describe the use of dynamic contrast-enhanced magnetic resonance angiography (MRA) in the evaluation of residual arteriovenous shunting in cAVMs following Onyx embolization.
METHODSSix subjects who underwent multimodal MR imaging including dynamic MRA after different stages of endovascular treatment with Onyx were included. Each MRA was assessed for the presence of residual arteriovenous shunting. The results were compared with digital subtraction angiography (DSA).
RESULTSMean age was 41 years (range, 25-63) and the mean maximum AVM diameter was 5.3 cm (range, 4.7-6.0). Fourteen dynamic MRA were performed using a 1.5 T scanner. Arteriovenous shunting was detected in thirteen of fourteen patients by both dynamic MRA and DSA, with complete agreement between the two techniques. The only MRA without detectable residual arteriovenous shunting was for a subject who had complete treatment with no residual cAVM as confirmed by the DSA images.
CONCLUSIONSDynamic contrast-enhanced MRA is a promising non-invasive modality in identifying residual arteriovenous shunting after different stages of AVM embolization, achieving 100% agreement in this small study. Embolization with Onyx caused no significant image artifact.
C1 [Nogueira, Raul G.; Bayrlee, Ahmad] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Hirsch, Joshua A.; Yoo, Albert J.; Copen, William A.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Nogueira, Raul G.] Emory Univ, Sch Med, Dept Neurol, Marcus Stroke & Neurosci Ctr,Grady Mem Hosp, Atlanta, GA 30322 USA.
[Nogueira, Raul G.] Emory Univ, Sch Med, Dept Neurosurg, Marcus Stroke & Neurosci Ctr,Grady Mem Hosp, Atlanta, GA 30322 USA.
[Nogueira, Raul G.] Emory Univ, Sch Med, Dept Radiol, Marcus Stroke & Neurosci Ctr,Grady Mem Hosp, Atlanta, GA 30322 USA.
RP Nogueira, RG (reprint author), Emory Fac Off Bldg,80 Jesse Hill Dr SE,Room 398, Atlanta, GA 30303 USA.
EM rnoguei@emory.edu
FU Penumbra, Inc.
FX RGN is a member of the Scientific Advisory Boards (SAB) for Concentric
Medical Inc., ev3 Neurovascular Inc., CoAxia Inc., Rapid Medical, Inc.,
and Neurointervention, Inc. AJY receives a research grant support from
Penumbra, Inc.
NR 9
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1051-2284
EI 1552-6569
J9 J NEUROIMAGING
JI J. Neuroimaging
PD OCT
PY 2013
VL 23
IS 4
BP 514
EP 517
DI 10.1111/j.1552-6569.2012.00780.x
PG 4
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 269XM
UT WOS:000328277200009
PM 23317169
ER
PT J
AU Matreyek, KA
Engelman, A
AF Matreyek, Kenneth A.
Engelman, Alan
TI Viral and Cellular Requirements for the Nuclear Entry of Retroviral
Preintegration Nucleoprotein Complexes
SO VIRUSES-BASEL
LA English
DT Review
DE HIV; lentivirus; nuclear import; nuclear pore complex; capsid; TNPO3;
CPSF6; NUP153; NUP358
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; CENTRAL DNA FLAP;
REVERSE TRANSCRIPTION COMPLEXES; HIV-1 MATRIX PROTEIN; INTEGRATION
IN-VIVO; C-TERMINAL DOMAIN; PORE COMPLEX; NONDIVIDING CELLS; CAPSID
PROTEIN
AB Retroviruses integrate their reverse transcribed genomes into host cell chromosomes as an obligate step in virus replication. The nuclear envelope separates the chromosomes from the cell cytoplasm during interphase, and different retroviral groups deal with this physical barrier in different ways. Gammaretroviruses are dependent on the passage of target cells through mitosis, where they are believed to access chromosomes when the nuclear envelope dissolves for cell division. Contrastingly, lentiviruses such as HIV-1 infect non-dividing cells, and are believed to enter the nucleus by passing through the nuclear pore complex. While numerous virally encoded elements have been proposed to be involved in HIV-1 nuclear import, recent evidence has highlighted the importance of HIV-1 capsid. Furthermore, capsid was found to be responsible for the viral requirement of various nuclear transport proteins, including transportin 3 and nucleoporins NUP153 and NUP358, during infection. In this review, we describe our current understanding of retroviral nuclear import, with emphasis on recent developments on the role of the HIV-1 capsid protein.
C1 [Engelman, Alan] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Engelman, A (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
EM matreyek@fas.harvard.edu; alan_engelman@dfci.harvard.edu
OI Matreyek, Kenneth/0000-0001-9149-551X
FU NIH [AI052014, GM082251]
FX Research in the authors' laboratory is supported by NIH grants AI052014
and GM082251.
NR 189
TC 40
Z9 40
U1 0
U2 12
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD OCT
PY 2013
VL 5
IS 10
BP 2483
EP 2511
DI 10.3390/v5102483
PG 29
WC Virology
SC Virology
GA 274SL
UT WOS:000328626400009
PM 24103892
ER
PT J
AU Wang, J
Boutin, KG
Abdulhadi, O
Personnat, LD
Shazly, T
Langer, R
Channick, CL
Borenstein, JT
AF Wang, Jane
Boutin, Kyle G.
Abdulhadi, Omar
Personnat, Lyndia D.
Shazly, Tarek
Langer, Robert
Channick, Colleen L.
Borenstein, Jeffrey T.
TI Fully Biodegradable Airway Stents Using Amino Alcohol-Based Poly(ester
amide) Elastomers
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE airway stents; biodegradable; elastomer; implant; polymer
ID TISSUE-ENGINEERING SCAFFOLDS; TRACHEOBRONCHIAL STENT; OBSTRUCTION;
TECHNOLOGY; STENOSIS; OUTCOMES; POLYMER; DISEASE; CULTURE
AB Airway stents are often used to maintain patency of the tracheal and bronchial passages in patients suffering from central airway obstruction caused by malignant tumors, scarring, and injury. Like most conventional medical implants, they are designed to perform their functions for a limited period of time, after which surgical removal is often required. Two primary types of airway stents are in general use, metal mesh devices and elastomeric tubes; both are constructed using permanent materials, and must be removed when no longer needed, leading to potential complications. This paper describes the development of process technologies for bioresorbable prototype elastomeric airway stents that would dissolve completely after a predetermined period of time or by an enzymatic triggering mechanism. These airway stents are constructed from biodegradable elastomers with high mechanical strength, flexibility and optical transparency. This work combines microfabrication technology with bioresorbable polymers, with the ultimate goal of a fully biodegradable airway stent ultimately capable of improving patient safety and treatment outcomes.
C1 [Wang, Jane; Boutin, Kyle G.; Personnat, Lyndia D.; Borenstein, Jeffrey T.] Ctr Biomed Engn, Charles Stark Draper Lab, Cambridge, MA 02139 USA.
[Wang, Jane; Langer, Robert] MIT, David H Koch Inst, Cambridge, MA 02139 USA.
[Abdulhadi, Omar; Shazly, Tarek] Univ S Carolina, Columbia, SC USA.
[Channick, Colleen L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Borenstein, JT (reprint author), Ctr Biomed Engn, Charles Stark Draper Lab, Mail Stop 32,555 Technol Sq, Cambridge, MA 02139 USA.
EM jborenstein@draper.com
FU Draper Laboratory; Center of Integration of Medicine and Innovative
Technology [US Army DAMD17-02-2-0006]
FX Funding for this work, provided by Draper Laboratory and by the Center
of Integration of Medicine and Innovative Technology, Contract Number US
Army DAMD17-02-2-0006, is gratefully acknowledged. We are indebted to G.
C. Engelmayr, C.J. Bettinger, L. E. Freed, J. Hsiao, M. E. Kolewe and H.
S. Park for many useful discussions and assistance with the
instrumentation and polymer synthesis.
NR 34
TC 7
Z9 8
U1 3
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD OCT
PY 2013
VL 2
IS 10
BP 1329
EP 1336
DI 10.1002/adhm.201200348
PG 8
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA 264RY
UT WOS:000327899400005
PM 23526787
ER
PT J
AU Namba, T
Tian, F
Chu, KK
Hwang, SY
Yoon, KW
Byun, S
Hiraki, M
Mandinova, A
Lee, SW
AF Namba, Takushi
Tian, Fang
Chu, Kiki
Hwang, So-Young
Yoon, Kyoung Wan
Byun, Sanguine
Hiraki, Masatsugu
Mandinova, Anna
Lee, Sam W.
TI CDIP1-BAP31 Complex Transduces Apoptotic Signals from Endoplasmic
Reticulum to Mitochondria under Endoplasmic Reticulum Stress
SO CELL REPORTS
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; CELL-DEATH; BAP31 COMPLEX; BAX; BCL-2;
PROCASPASE-8; IRE1-ALPHA; NETWORK
AB Resolved endoplasmic reticulum (ER) stress response is essential for intracellular homeostatic balance, but unsettled ER stress can lead to apoptosis. Here, we show that a proapoptotic p53 target, CDIP1, acts as a key signal transducer of ER-stress-mediated apoptosis. We identify B-cell-receptor-associated protein 31 (BAP31) as an interacting partner of CDIP1. Upon ER stress, CDIP1 is induced and enhances an association with BAP31 at the ER membrane. We also show that CDIP1 binding to BAP31 is required for BAP31 cleavage upon ER stress and for BAP31-Bcl-2 association. The recruitment of Bcl-2 to the BAP31-CDIP1 complex, as well as CDIP1-dependent truncated Bid (tBid) and caspase-8 activation, contributes to BAX oligomerization. Genetic knockout of CDIP1 in mice leads to impaired response to ER-stress-mediated apoptosis. Altogether, our data demonstrate that the CDIP1/BAP31-mediated regulation of mitochondrial apoptosis pathway represents a mechanism for establishing an ER-mitochondrial crosstalk for ER-stress-mediated apoptosis signaling.
C1 [Namba, Takushi; Tian, Fang; Chu, Kiki; Hwang, So-Young; Yoon, Kyoung Wan; Byun, Sanguine; Hiraki, Masatsugu; Mandinova, Anna; Lee, Sam W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
[Mandinova, Anna; Lee, Sam W.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
RP Lee, SW (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
EM swlee@partners.org
FU National Institutes of Health [CA142805, CA080058, CA127247]; Japan
Society for the Promotion of Science; AACR-Bristol-Myers Squibb Oncology
Scholar-in-Training grant; Korean Government Research Foundation
[KRF-2008-357-E00023]
FX LC-MS/MS analysis was performed by the Taplin Biological Mass
Spectrometry Facility of Harvard Medical School. We thank S. Aaronson
for helpful advice and suggestions during the project. This work was
partially supported by National Institutes of Health grants CA142805,
CA080058, and CA127247. T.N. was supported by a fellowship for research
abroad from Japan Society for the Promotion of Science and is a
recipient of an AACR-Bristol-Myers Squibb Oncology Scholar-in-Training
grant. S.-Y.H. was supported by the Korean Government Research
Foundation (KRF-2008-357-E00023).
NR 25
TC 20
Z9 22
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD OCT
PY 2013
VL 5
IS 2
BP 331
EP 339
DI 10.1016/j.celrep.2013.09.020
PG 9
WC Cell Biology
SC Cell Biology
GA 269SU
UT WOS:000328263000006
PM 24139803
ER
PT J
AU Huang, YY
Nagata, K
Tedford, CE
McCarthy, T
Hamblin, MR
AF Huang, Ying-Ying
Nagata, Kazuya
Tedford, Clark E.
McCarthy, Thomas
Hamblin, Michael R.
TI Low-level laser therapy (LLLT) reduces oxidative stress in primary
cortical neurons in vitro
SO JOURNAL OF BIOPHOTONICS
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; NEAR-INFRARED LIGHT; TERM NEUROLOGICAL DEFICITS;
RAT-LIVER MITOCHONDRIA; BIPHASIC DOSE-RESPONSE; CYTOCHROME-C-OXIDASE;
HELIUM-NEON LASER; DIFFERENT WAVELENGTHS; DOPAMINERGIC-NEURONS;
COGNITIVE DEFICITS
C1 [Huang, Ying-Ying; Nagata, Kazuya; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Huang, Ying-Ying] Guangxi Med Univ, Dept Pathol, Nanning, Guangxi, Peoples R China.
[Nagata, Kazuya] Univ Tokyo, Grad Sch Med, Tokyo 1138654, Japan.
[Tedford, Clark E.; McCarthy, Thomas] PhotoThera Inc, Carlsbad, CA USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU Photothera Inc; NIH [R01AI050875]; Center for Integration of Medicine
and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI
[W81XWH-09-1-0514]; Air Force Office of Scientific Research
[FA9950-04-1-0079]
FX This work was supported by sponsored research funding from Photothera
Inc and by NIH grant R01AI050875, Center for Integration of Medicine and
Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI
(W81XWH-09-1-0514) and Air Force Office of Scientific Research
(FA9950-04-1-0079)
NR 80
TC 26
Z9 27
U1 0
U2 7
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1864-063X
EI 1864-0648
J9 J BIOPHOTONICS
JI J. Biophotonics
PD OCT
PY 2013
VL 6
IS 10
SI SI
BP 829
EP 838
PG 10
WC Biochemical Research Methods; Biophysics; Optics
SC Biochemistry & Molecular Biology; Biophysics; Optics
GA 264NL
UT WOS:000327884800009
PM 23281261
ER
PT J
AU Sperandio, FF
Giudice, FS
Correa, L
Pinto, DS
Hamblin, MR
de Sousa, SCOM
AF Sperandio, Felipe F.
Giudice, Fernanda S.
Correa, Luciana
Pinto, Decio S., Jr.
Hamblin, Michael R.
de Sousa, Suzana C. O. M.
TI Low-level laser therapy can produce increased aggressiveness of
dysplastic and oral cancer cell lines by modulation of Akt/mTOR
signaling pathway
SO JOURNAL OF BIOPHOTONICS
LA English
DT Article
ID IN-VITRO; TYROSINE KINASE; IRRADIATION; HEAD; INHIBITION; PROLIFERATION;
MUCOSITIS; MECHANISM; MELANOMA; PROTEIN
C1 [Sperandio, Felipe F.; Giudice, Fernanda S.; Correa, Luciana; Pinto, Decio S., Jr.; de Sousa, Suzana C. O. M.] Univ Sao Paulo, Sch Dent, Dept Oral Pathol, BR-05508000 Sao Paulo, Brazil.
[Sperandio, Felipe F.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Sperandio, Felipe F.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Sperandio, FF (reprint author), Univ Sao Paulo, Sch Dent, Dept Oral Pathol, 2227 Prof Lineu Prestes Av,Cidade Univ, BR-05508000 Sao Paulo, Brazil.
EM sperandio@usp.br
RI Correa, Luciana/H-3875-2012; Sousa, Suzana/H-6154-2012;
OI Hamblin, Michael/0000-0001-6431-4605
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2009/08452-2,
2009/16183-1]; US NIH [R01AI050875]
FX Contract grant sponsor: Fundacao de Amparo a Pesquisa do Estado de Sao
Paulo - Grant numbers: 2009/08452-2 and 2009/16183-1. MR Hamblin was
supported by US NIH grant R01AI050875.
NR 55
TC 17
Z9 17
U1 1
U2 5
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1864-063X
EI 1864-0648
J9 J BIOPHOTONICS
JI J. Biophotonics
PD OCT
PY 2013
VL 6
IS 10
SI SI
BP 839
EP 847
PG 9
WC Biochemical Research Methods; Biophysics; Optics
SC Biochemistry & Molecular Biology; Biophysics; Optics
GA 264NL
UT WOS:000327884800010
PM 23554211
ER
PT J
AU Keuthen, NJ
Fama, J
Altenburger, EM
Allen, A
Raff, A
Pauls, D
AF Keuthen, Nancy J.
Fama, Jeanne
Altenburger, Erin M.
Allen, Amanda
Raff, Anna
Pauls, David
TI Family environment in adolescent trichotillomania
SO JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS
LA English
DT Article
DE Trichotillomania; Hair pulling; Family environment
ID OBSESSIVE-COMPULSIVE DISORDER; EXPRESSED EMOTION; CHILDREN; ANXIETY;
PSYCHOPATHOLOGY; DEPRESSION
AB We examined family environment variables and parenting stress in a cohort of adolescents with trichotillomania (TTM; N=49), their parents (N=55) and matched control adolescents (N=23) and their parents (N=23). TTM youth vs. controls endorsed significantly more expression of anger, aggression and conflict in their families and less family support on the Family Relationship Index (FRI) of the Family Environment Scale (FES). Pulling distress but not severity was correlated with these variables. Greater pulling severity, distress or both were correlated with impairment on the cohesion subscale of the FES and the task accomplishment and affective expression subscales of the Family Assessment Measure (FAM). Mothers of TTM youth vs. controls endorsed more anxiety, depression and anger, plus more total parenting stress and problems in their offspring on the Stress Index for Parents of Adolescents (SIPA). On the FES, mothers of TTM youth vs. controls reported less emphasis on intellectual and cultural orientation and less organization in the family. TTM youth and their mothers were discordant in their ratings of several family environment variables. These findings warrant further study and merit attention when designing treatment interventions for adolescents with TTM. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Keuthen, Nancy J.; Fama, Jeanne; Altenburger, Erin M.; Pauls, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Allen, Amanda] Boston Univ, Sch Social Work, Boston, MA 02215 USA.
[Raff, Anna] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Keuthen, NJ (reprint author), Massachusetts Gen Hosp, Trichotillomania Clin, Simches Res Bldg,Fl 2,185 Cambridge St, Boston, MA 02114 USA.
EM nkeuthen@partners.org
FU Greater Kansas City Foundation
FX This research was financially supported by a grant from the Greater
Kansas City Foundation. We would like to express our gratitude to Liz
Loerke, Nicole Dacuyan and Brianne Campbell for their assistance with
data collection and input. We would also like to express our thanks to
Lisa Osiecki for her assistance with database management and to Irina
Kasarskis for support with statistical analysis.
NR 32
TC 1
Z9 1
U1 6
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2211-3649
J9 J OBSESS-COMPULS REL
JI J. Obsessive-Compuls. Relat. Disord.
PD OCT
PY 2013
VL 2
IS 4
BP 366
EP 374
DI 10.1016/j.jocrd.2013.07.001
PG 9
WC Psychiatry
SC Psychiatry
GA 269JR
UT WOS:000328238100002
ER
PT J
AU Wamsley, MA
Julian, KA
O'Sullivan, P
McCance-Katz, EF
Batki, SL
Satre, DD
Satterfield, J
AF Wamsley, Maria A.
Julian, Katherine A.
O'Sullivan, Patricia
McCance-Katz, Elinore F.
Batki, Steven L.
Satre, Derek D.
Satterfield, Jason
TI Team-Based Learning Exercise Efficiently Teaches Brief Intervention
Skills to Medicine Residents
SO SUBSTANCE ABUSE
LA English
DT Article
DE Curriculum development and evaluation; graduate medical education;
substance use; team-based learning
ID PATIENTS ALCOHOL-USE; PRIMARY-CARE; SUBSTANCE-ABUSE; TREATMENT SBIRT;
DRUG-USE; IMPACT; CURRICULUM; EDUCATION; PERFORMANCE; SETTINGS
AB Background: Evaluations of substance use screening and brief intervention (SBI) curricula typically focus on learner attitudes and knowledge, although effects on clinical skills are of greater interest and utility. Moreover, these curricula often require large amounts of training time and teaching resources. This study examined whether a 3-hour SBI curriculum for internal medicine residents utilizing a team-based learning (TBL) format is effective for SBI skills as measured by a standardized patient (SP) assessment. Methods: A waitlist-controlled design was employed. Results: Twenty-four postgraduate year 2 (PGY-2) and PGY-3 residents participated in a SP assessment prior to the TBL session (waitlist control group) and 32 participated in a SP assessment after the TBL session (intervention group). The intervention residents demonstrated better brief intervention skills than waitlist control residents, but there were no differences between the groups in screening and assessment skills. Residents receiving the TBL curriculum prior to the SP assessment reported increased confidence in all SBI skills. Conclusion: Findings indicate that a brief educational intervention can improve brief intervention skills. However, more intensive education may be needed to improve substance use screening and assessment.
C1 [Wamsley, Maria A.; Julian, Katherine A.; O'Sullivan, Patricia; Satterfield, Jason] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[McCance-Katz, Elinore F.; Batki, Steven L.; Satre, Derek D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Batki, Steven L.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
[Satre, Derek D.] Kaiser Permanente, Div Res, San Francisco, CA USA.
RP Wamsley, MA (reprint author), Univ Calif San Francisco, Div Gen Internal Med, 1545 Divisadero St,Room 322,Campus Box 0320, San Francisco, CA 94143 USA.
EM maria.wamsley@ucsf.edu
RI Herring, Anna/L-7859-2014
FU SAMHSA [U79T1020295]
FX This research was funded by SAMHSA grant U79T1020295 awarded to Dr.
Satterfield.
NR 41
TC 4
Z9 4
U1 1
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0889-7077
EI 1547-0164
J9 SUBST ABUS
JI Subst. Abus.
PD OCT 1
PY 2013
VL 34
IS 4
BP 344
EP 349
DI 10.1080/08897077.2013.787958
PG 6
WC Substance Abuse
SC Substance Abuse
GA 269LB
UT WOS:000328241700003
PM 24159904
ER
PT J
AU Wakeman, SE
Baggett, MV
Pham-Kanter, G
Campbell, EG
AF Wakeman, Sarah E.
Baggett, Meridale V.
Pham-Kanter, Genevieve
Campbell, Eric G.
TI Internal Medicine Residents' Training in Substance Use Disorders: A
Survey of the Quality of Instruction and Residents' Self-Perceived
Preparedness to Diagnose and Treat Addiction
SO SUBSTANCE ABUSE
LA English
DT Article
DE Addiction; medical education; preparedness; residency training;
substance use disorder
ID PRIMARY-CARE; DRUG-USERS; PREVALENCE; PHYSICIANS; ALCOHOL;
BUPRENORPHINE; DISCHARGE; ADVICE; ABUSE
AB Background: Resident physicians are the direct care providers for many patients with addiction. This study assesses residents' self-perceived preparedness to diagnose and treat addiction, measures residents' perceptions of the quality of addictions instruction, and evaluates basic knowledge of addictions. Methods: A survey was e-mailed to 184 internal medicine residents at Massachusetts General Hospital in May 2012. Results: Responses were obtained from 55% of residents. Residents estimated that 26% of inpatients they cared for met criteria for a substance use disorder (SUD). Twenty-five percent of residents felt unprepared to diagnose and 62% felt unprepared to treat addiction. Only 13% felt very prepared to diagnose addiction. No residents felt very prepared to treat addiction. Preparedness to diagnose or treat addiction did not differ significantly across postgraduate year (PGY) level. Fifty-five percent rated the overall instruction in addictions as poor or fair. Seventy-two percent of residents rated the quality of addictions training as poor or fair in the outpatient clinical setting, and 56% in the inpatient setting. No resident answered all 6 knowledge questions correctly. Slightly more than half correctly identified the mechanism of buprenorphine and 19% correctly answered a question about naltrexone. Nine percent of residents responded that someone had expressed concern about the respondent's substance use. Conclusions: Despite providing care for a substantial population with addiction, the majority of internal medicine residents in this study feel unprepared to treat SUDs. More than half rate the quality of addictions instruction as fair or poor. Structured and comprehensive addictions curriculum and faculty development are needed to address the deficiencies of the current training system.
C1 [Wakeman, Sarah E.; Baggett, Meridale V.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Wakeman, Sarah E.; Campbell, Eric G.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Pham-Kanter, Genevieve; Campbell, Eric G.] Mongan Inst Hlth Policy, Boston, MA USA.
[Pham-Kanter, Genevieve] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA.
[Pham-Kanter, Genevieve] Univ Colorado, Colorado Sch Publ Hlth, Dept Hlth Syst Management & Policy, Denver, CO 80202 USA.
RP Wakeman, SE (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRB 740, Boston, MA 02114 USA.
EM swakeman@partners.org
OI Pham-Kanter, Genevieve/0000-0002-3044-7829
NR 18
TC 17
Z9 17
U1 1
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0889-7077
EI 1547-0164
J9 SUBST ABUS
JI Subst. Abus.
PD OCT 1
PY 2013
VL 34
IS 4
BP 363
EP 370
DI 10.1080/08897077.2013.797540
PG 8
WC Substance Abuse
SC Substance Abuse
GA 269LB
UT WOS:000328241700006
PM 24159907
ER
PT J
AU Drucker, A
Arnason, T
Yan, SR
Aljawad, M
Thompson, K
Huang, WY
AF Drucker, Arik
Arnason, Thomas
Yan, Sen Rong
Aljawad, Mohammed
Thompson, Kara
Huang, Weei-Yuarn
TI Ephrin B2 Receptor and Microsatellite Status in Lymph Node-Positive
Colon Cancer Survival
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID COLORECTAL-CANCER; ADJUVANT THERAPY; COST-EFFECTIVENESS; TISSUE
MICROARRAY; CETUXIMAB; EPHB2; CHEMOTHERAPY; EXPRESSION; INTEGRINS;
ADHESION
AB BACKGROUND: Ephrin B2 receptor (EphB2) is a target of the canonical wnt pathway implicated in colorectal carcinogenesis, and its down-regulation may be associated with adverse prognosis. We evaluated its prognostic value in resected colon cancer stratified by microsatellite status and other clinicopathologic characteristics. METHODS: We identified all cases of resected stage III colon cancer from 1995 to 2009 managed in the Capital Health district of Nova Scotia. Tissue microarrays were constructed and immunohistochemistry (IHC) for tumor EphB2 staining assigned into quartiles. Microsatellite status was evaluated by IHC for MutL homolog 1 (MLH1) and MutS homolog 2 (MSH2). Microsatellite stable tumors were defined as both MLH1/MSH2 (+/+); tumors staining otherwise were classified with microsatellite instability (MSI-H). Primary and secondary outcomes were disease-free survival (DFS) and overall survival (OS), respectively. RESULTS: We identified 159 cases with sufficient tissue for microarray analysis having a median follow-up of 3.47 years (range, 0.14-14). Median age was 61, 52% were male, 40% had an event, and 29% died. MSI-H was present in 18 (13%). Univariate analysis of EphB2 expression on DFS and OS showed a hazard ratio (HR) of 2.00 (P = .01) and 2.14 (P = .03), respectively. Multivariate analysis of EphB2 expression on DFS and OS showed an HR of 2.24 and 2.23, respectively, with tumor IHC <= 50%. CONCLUSIONS: In this cohort, decreased EphB2 expression was an independent prognostic factor for recurrence and death and may have prognostic relevance in tumors with MSI-H. However, this would require prospective validation in a larger study.
C1 [Drucker, Arik; Arnason, Thomas; Thompson, Kara; Huang, Weei-Yuarn] Dalhousie Univ, Capital Hlth, Halifax, NS B3H 1V8, Canada.
[Drucker, Arik] Dalhousie Univ, Dept Med, Div Med Oncol, Halifax, NS B3H 1V8, Canada.
[Arnason, Thomas; Huang, Weei-Yuarn] Dalhousie Univ, Dept Pathol & Lab Med, Halifax, NS B3H 1V8, Canada.
[Arnason, Thomas] Massachusetts Gen Hosp, Pathol Serv, Boston, MA 02114 USA.
[Arnason, Thomas] Harvard Univ, Sch Med, Boston, MA USA.
[Yan, Sen Rong] Dr Everett Chalmers Hosp, Fredericton, NB, Canada.
[Aljawad, Mohammed] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada.
[Aljawad, Mohammed] Univ Western Ontario, Div Gastroenterol, London, ON, Canada.
[Thompson, Kara] Dalhousie Univ, Res Methods Unit, Halifax, NS B3H 1V8, Canada.
[Thompson, Kara] Dalhousie Univ, Dept Med, Halifax, NS B3H 1V8, Canada.
RP Huang, WY (reprint author), Dalhousie Univ, Capital Hlth, 5788 Univ Ave, Halifax, NS B3H 1V8, Canada.
EM huangw@cdha.nshealth.ca
FU Capital Health Category 3 Competitive Research grant; Department of
Pathology and Laboratory Medicine, Halifax; Queen Elizabeth II Health
Sciences Centre, Halifax; Nova Scotia
FX This study was funded by the Capital Health Category 3 Competitive
Research grant and the Department of Pathology and Laboratory Medicine,
Queen Elizabeth II Health Sciences Centre, both in Halifax, Nova Scotia.
None of the authors have any financial or other conflicts of interest to
disclose.
NR 28
TC 0
Z9 0
U1 0
U2 0
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
USA
SN 1944-7124
EI 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD OCT
PY 2013
VL 6
IS 5
BP 520
EP 527
DI 10.1593/tlo.13385
PG 8
WC Oncology
SC Oncology
GA 271AQ
UT WOS:000328362800003
PM 24151532
ER
PT J
AU Engineer, DR
Burney, BO
Hayes, TG
Garcia, JM
AF Engineer, Diana R.
Burney, Basil O.
Hayes, Teresa G.
Garcia, Jose M.
TI Exposure to ACEI/ARB and beta-Blockers Is Associated with Improved
Survival and Decreased Tumor Progression and Hospitalizations in
Patients with Advanced Colon Cancer
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; HEART-FAILURE; CELLS; ANGIOGENESIS;
PROPRANOLOL; INHIBITION; EXPRESSION; RECEPTOR; MODEL; PROLIFERATION
AB BACKGROUND: Advanced colon cancer is associated with weight loss and decreased survival. Studies suggest that angiotensin and beta-adrenergic blockade decrease colon cancer progression and ameliorate weight loss. This study aims to determine whether exposure to beta-adrenoceptor blockers (BBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) is associated with decreased mortality, tumor progression, number of hospitalizations, or weight loss in colorectal cancer. METHODS: Retrospective chart review included patients with advanced colorectal cancer. Survival, stage, hospitalization, cancer progression, cancer treatment, and body weight history were collected. RESULTS: Two hundred sixty-two of 425 new stage III to IV colorectal cancer cases reviewed met the study criteria. Those exposed to ACEI/ARB, BB, or both were more likely to have diabetes, hypertension, and stage III colorectal cancer. Adjusting for age, presence of hypertension and diabetes, and stage, ACEI/ARB + BB exposure was associated with decreased mortality compared to unexposed individuals [hazard ratio (HR) = 0.5, confidence interval (CI) = 0.29-0.85; Cox regression, P =.01]. Fewer total and cancer-related hospitalizations and decreased cancer progression in the ACEI/ARB + BB group versus the unexposed group (HR = 0.59, CI = 0.36-0.99, P =.047) were seen. Exposure did not affect weight changes; furthermore, body weight changes from both prediagnosis and at diagnosis to 6, 12, 18, and 24 months postdiagnosis predicted survival. CONCLUSIONS: We have observed an association between exposure to a combination of ACEI/ ARB + BB and increased survival, decreased hospitalizations, and decreased tumor progression in advanced colorectal cancer. Future studies will be needed to replicate these results and generalize them to broader populations. Determination of causality will require a randomized controlled trial.
C1 [Engineer, Diana R.; Burney, Basil O.; Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Div Diabet Endocrinol & Metab, Ctr Translat Res Inflammatory Dis, Houston, TX USA.
[Engineer, Diana R.; Garcia, Jose M.] Baylor Coll Med, Houston, TX 77030 USA.
[Engineer, Diana R.] St Lukes Episcopal Hosp, Houston, TX 77030 USA.
[Hayes, Teresa G.] Baylor Coll Med, Div Hematol & Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.
RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, Rm 210,Bldg 109,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM jgarcia1@bcm.edu
FU Veterans Affairs Medical Center (Houston, TX); Department of Veterans
Affairs (MERIT awards) [BX000507, CX000174]; National Institutes of
Health [AG040583]
FX This material is based on the work supported by the Michael E. DeBakey
Veterans Affairs Medical Center (Houston, TX), Department of Veterans
Affairs (MERIT awards BX000507 and CX000174), and the National
Institutes of Health (AG040583) to J.M.G. The authors report no
conflicts of interest.
NR 32
TC 17
Z9 18
U1 0
U2 2
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
USA
SN 1944-7124
EI 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD OCT
PY 2013
VL 6
IS 5
BP 539
EP 545
DI 10.1593/tlo.13346
PG 7
WC Oncology
SC Oncology
GA 271AQ
UT WOS:000328362800005
PM 24151534
ER
PT J
AU Fishman, JA
AF Fishman, Jay A.
TI Opportunistic Infections-Coming to the Limits of Immunosuppression?
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID ORGAN-TRANSPLANT RECIPIENTS; HEPATITIS-C-VIRUS;
HUMAN-IMMUNODEFICIENCY-VIRUS; MUSCULOSKELETAL TISSUE DONORS; TRANSMITTED
VIRAL-INFECTIONS; CYTOMEGALOVIRUS DISEASE; LIVER-TRANSPLANTATION;
HETEROLOGOUS IMMUNITY; LUNG TRANSPLANTATION; BLOOD-DONORS
AB Possible etiologies of infection in the solid organ recipient are diverse, ranging from common bacterial and viral pathogens to opportunistic pathogens that cause invasive disease only in immunocompromised hosts. The recognition of infectious syndromes in this population is limited by alterations in the clinical manifestations by immunosuppression. The risk of serious infections in the organ transplant patient is determined by the interaction between the patients' recent and distant epidemiological exposures and all factors that contribute to the patient's net state of immune suppression. This risk is altered by antimicrobial prophylaxis and changes in immunosuppressive therapies. In addition to the direct effects of infection, opportunistic infections, and the microbiome may adversely shape the host immune responses with diminished graft and patient survivals. Antimicrobial therapies are more complex than in the normal host with a significant incidence of drug toxicity and a propensity for drug interactions with the immunosuppressive agents used to maintain graft function. Rapid and specific microbiologic diagnosis is essential. Newer microbiologic assays have improved the diagnosis and management of opportunistic infections. These tools coupled with assays that assess immune responses to infection and to graft antigens may allow optimization of management for graft recipients in the future.
C1 Harvard Univ, Massachusetts Gen Hosp, Transplant Infect Dis & Compromised Host Program, Infect Dis Div,MGH Transplantat Ctr,Med Sch, Boston, MA 02114 USA.
RP Fishman, JA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Transplant Infect Dis & Compromised Host Program, Infect Dis Div,MGH Transplantat Ctr,Med Sch, Boston, MA 02114 USA.
EM jfishman@partners.org
NR 52
TC 10
Z9 10
U1 0
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD OCT
PY 2013
VL 3
IS 10
AR a015669
DI 10.1101/cshperspect.a015669
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 269XK
UT WOS:000328277000004
PM 24086067
ER
PT J
AU Vashishta, R
Soler, ZM
Nguyen, SA
Schlosser, RJ
AF Vashishta, Rishi
Soler, Zachary M.
Nguyen, Shaun A.
Schlosser, Rodney J.
TI A systematic review and meta-analysis of asthma outcomes following
endoscopic sinus surgery for chronic rhinosinusitis
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE asthma; chronic rhinosinusitis; endoscopic sinus surgery; ESS; FESS
ID ALLERGEN-INDUCED RHINITIS; ASPIRIN TRIAD PATIENTS; NASAL POLYPS;
INTRANASAL CORTICOSTEROIDS; BRONCHIAL RESPONSIVENESS; TISSUE
EOSINOPHILIA; SURGICAL-TREATMENT; MESSENGER-RNA; MILD ASTHMA;
PROVOCATION
AB BackgroundPatients suffering from both chronic rhinosinusitis (CRS) and asthma demonstrate improved asthma outcomes when upper airway inflammation is controlled with medications. It is unclear if similar benefits exist when the upper airway is treated surgically. This study presents a systematic review and meta-analysis to assess the effects of endoscopic sinus surgery (ESS) on asthma outcomes.
MethodsOvid MEDLINE and the Cochrane databases were searched to identify studies examining asthma outcomes in patients with CRS following ESS. Included studies involved a cohort of at least 5 patients and reported at least 1 postoperative asthma outcome.
ResultsTwenty-two studies involving a total of 891 patients were identified. Mean follow-up across all studies was 26.4 months. Patients reported improved overall asthma control in 76.1% (95% confidence interval [CI], 71.9% to 80.3%) of cases. The frequency of asthma attacks decreased in 84.8% (95% CI, 76.6% to 93.0%) of patients and the number of hospitalizations decreased in 64.4% (95% CI, 53.3% to 75.6%). Decreased use of oral corticosteroids was seen in 72.8% (95% CI, 67.5% to 78.1%) of patients; inhaled corticosteroid use decreased in 28.5% (95% CI, 22.6% to 34.5%) and bronchodilator use decreased in 36.3% (95% CI, 28.9% to 43.7%) of patients. Mean improvement in predicted forced expiratory volume at 1 second (FEV1) was 1.62%, but was not statistically significant (p = 0.877).
ConclusionESS in patients with concomitant bronchial asthma improves clinical asthma outcome measures, but not lung function testing. Difficulty conducting controlled clinical trials of ESS limits the strength of conclusions which can be reached.
C1 [Vashishta, Rishi; Soler, Zachary M.; Nguyen, Shaun A.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
[Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg Otolaryngol, Charleston, SC USA.
RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.
EM schlossr@musc.edu
FU Merit Award from the Clinical Sciences Research and Development program
of the Department of Veterans Affairs at the Ralph H. Johnson VA Medical
Center, Charleston, SC
FX Funding sources for the study: Merit Award from the Clinical Sciences
Research and Development program of the Department of Veterans Affairs
at the Ralph H. Johnson VA Medical Center, Charleston, SC.
NR 42
TC 24
Z9 25
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD OCT
PY 2013
VL 3
IS 10
BP 788
EP 794
DI 10.1002/alr.21182
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 269EG
UT WOS:000328223500003
PM 23818462
ER
PT J
AU Evertts, AG
Manning, AL
Wang, X
Dyson, NJ
Garcia, BA
Coller, HA
AF Evertts, Adam G.
Manning, Amity L.
Wang, Xin
Dyson, Nicholas J.
Garcia, Benjamin A.
Coller, Hilary A.
TI H4K20 methylation regulates quiescence and chromatin compaction
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID HISTONE METHYLTRANSFERASE SET8; CELL-CYCLE PROGRESSION; CONSTITUTIVE
HETEROCHROMATIN; GENE-EXPRESSION; S-PHASE; MUSCLE DIFFERENTIATION; MOUSE
DEVELOPMENT; POTENTIAL ROLE; DNA-DAMAGE; STEM-CELLS
AB The transition between proliferation and quiescence is frequently associated with changes in gene expression, extent of chromatin compaction, and histone modifications, but whether changes in chromatin state actually regulate cell cycle exit with quiescence is unclear. We find that primary human fibroblasts induced into quiescence exhibit tighter chromatin compaction. Mass spectrometry analysis of histone modifications reveals that H4K20me2 and H4K20me3 increase in quiescence and other histone modifications are present at similar levels in proliferating and quiescent cells. Analysis of cells in S, G(2)/M, and G(1) phases shows that H4K20me1 increases after S phase and is converted to H4K20me2 and H4K20me3 in quiescence. Knockdown of the enzyme that creates H4K20me3 results in an increased fraction of cells in S phase, a defect in exiting the cell cycle, and decreased chromatin compaction. Overexpression of Suv4-20h1, the enzyme that creates H4K20me2 from H4K20me1, results in G(2) arrest, consistent with a role for H4K20me1 in mitosis. The results suggest that the same lysine on H4K20 may, in its different methylation states, facilitate mitotic functions in M phase and promote chromatin compaction and cell cycle exit in quiescent cells.
C1 [Evertts, Adam G.; Wang, Xin] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
[Manning, Amity L.; Dyson, Nicholas J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp Canc Ctr, Charlestown, MA 02129 USA.
[Garcia, Benjamin A.] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.
[Coller, Hilary A.] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.
[Coller, Hilary A.] David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
RP Coller, HA (reprint author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.
EM hcoller@ucla.edu
FU American Cancer Society; National Institutes of Health [R01 CA155202];
National Science Foundation Early Faculty CAREER award; National Science
Foundation [CBET-0941143]; Office of the Director, National Institutes
of Health [DP2OD007447]; National Institute of General Medical Sciences
Center of Excellence Grant [P50 GM071508]; Cancer Institute of New
Jersey; New Jersey Commission on Cancer Research; National Cancer
Institute [1RC1 CA147961-01]; Johnson & Johnson Foundation; National
Institutes of Health/National Institute of General Medical Sciences
[1R01 GM081686, 1R01 GM086465]
FX We thank Eric Neeley (Novus Biologicals) for providing reagents and all
of the members of the Coller and Garcia laboratories for helpful
discussions. A. L. M. is supported in part by an American Cancer Society
Postdoctoral Fellowship. A. L. M. and N.J.D. are supported by National
Institutes of Health Grant R01 CA155202. B. A. G. is supported by a
National Science Foundation Early Faculty CAREER award, National Science
Foundation Grant CBET-0941143, and a grant supported by Award
DP2OD007447 from the Office of the Director, National Institutes of
Health. H. A. C. is supported by National Institute of General Medical
Sciences Center of Excellence Grant P50 GM071508, the Cancer Institute
of New Jersey, the New Jersey Commission on Cancer Research, National
Cancer Institute 1RC1 CA147961-01, a Focused Funding Grant from the
Johnson & Johnson Foundation, and National Institutes of Health/National
Institute of General Medical Sciences Grants 1R01 GM081686 and 1R01
GM086465. H. A. C. was a Milton E. Cassel Scholar of the Rita Allen
Foundation.
NR 72
TC 23
Z9 23
U1 2
U2 16
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
EI 1939-4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD OCT 1
PY 2013
VL 24
IS 19
BP 3025
EP 3037
DI 10.1091/mbc.E12-07-0529
PG 13
WC Cell Biology
SC Cell Biology
GA 267UH
UT WOS:000328123200003
PM 23924899
ER
PT J
AU Khaleghi, M
Lu, WN
Dobrev, I
Cheng, JT
Furlong, C
Rosowski, JJ
AF Khaleghi, Morteza
Lu, Weina
Dobrev, Ivo
Cheng, Jeffrey Tao
Furlong, Cosme
Rosowski, John J.
TI Digital holographic measurements of shape and three-dimensional
sound-induced displacements of tympanic membrane
SO OPTICAL ENGINEERING
LA English
DT Article
DE digital holography; middle-ear mechanics; shape and three-dimensional
displacement measurements; sound-induced response; thin-shell theory;
tympanic membrane
ID SURFACE; MOTION
AB Acoustically induced vibrations of the tympanic membrane (TM) play a primary role in the hearing process, in that these motions are the initial mechanical response of the ear to airborne sound. Characterization of the shape and three-dimensional (3-D) displacement patterns of the TM is a crucial step to a better understanding of the complicated mechanics of sound reception by the ear. Sound-induced 3-D displacements of the TM are estimated from shape and one-dimensional displacements measured in cadaveric chinchillas using a lensless dual-wavelength digital holography system (DWDHS). The DWDHS consists of laser delivery, optical head, and computing platform subsystems. Shape measurements are performed in double-exposure mode with the use of two wavelengths of a tunable laser, while nanometer-scale displacements are measured along a single sensitivity direction with a constant wavelength. Taking into consideration the geometrical and dimensional constrains imposed by the anatomy of the TM, we combine principles of thin-shell theory together with displacement measurements along a single sensitivity vector and TM surface shape to extract the three principal components of displacement in the full-field-of-view. We test, validate, and identify limitations of this approach via the application of finite element method to artificial geometries. (C) The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License.
C1 [Khaleghi, Morteza; Lu, Weina; Dobrev, Ivo; Furlong, Cosme] Worcester Polytech Inst, Ctr Holog Studies & Laser MicromechaTron, Worcester, MA 01609 USA.
[Khaleghi, Morteza; Lu, Weina; Dobrev, Ivo; Furlong, Cosme] Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA.
[Cheng, Jeffrey Tao; Furlong, Cosme; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Cheng, Jeffrey Tao; Furlong, Cosme; Rosowski, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
RP Khaleghi, M (reprint author), Worcester Polytech Inst, Ctr Holog Studies & Laser MicromechaTron, Worcester, MA 01609 USA.
EM mkm@wpi.edu
FU National Institute on Deafness and Other Communication Disorders; Mass
Eye Ear Infirmary; Worcester Polytechnic Institute, Mechanical
Engineering Department
FX This work was supported by the National Institute on Deafness and Other
Communication Disorders, the Mass Eye & Ear Infirmary, and the Worcester
Polytechnic Institute, Mechanical Engineering Department. We would also
like to acknowledge the support of all of the members of the Center for
Holographic Studies and Laser micro-mechaTronics laboratories and
particularly of Peter Hefti and Ellery Harrington.
NR 30
TC 15
Z9 15
U1 0
U2 5
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 0091-3286
EI 1560-2303
J9 OPT ENG
JI Opt. Eng.
PD OCT
PY 2013
VL 52
IS 10
AR 101916
DI 10.1117/1.OE.52.10.101916
PG 11
WC Optics
SC Optics
GA 269PR
UT WOS:000328254600021
PM 24790255
ER
PT J
AU Maia, Q
Grandner, MA
Findley, J
Gurubhagavatula, I
AF Maia, Querino
Grandner, Michael A.
Findley, James
Gurubhagavatula, Indira
TI Short and long sleep duration and risk of drowsy driving and the role of
subjective sleep insufficiency
SO ACCIDENT ANALYSIS AND PREVENTION
LA English
DT Article
DE Sleep; Driving; Accidents; Sleep duration; Insufficient sleep;
Epidemiology
ID MOTOR-VEHICLE CRASH; METAANALYSIS; PERFORMANCE; DEPRIVATION; ADULTS;
STATES; APNEA
AB Experimental sleep restriction increases sleepiness and impairs driving performance. However, it is unclear whether short sleep duration in the general population is associated with drowsy driving. The goal of the present study was to evaluate whether individuals in the general population who obtained sleep of 6 h or less are more likely to report drowsy driving, and evaluate the role of perceived sleep sufficiency. Data exploring whether subgroups of short sleepers (those who report the most or least unmet sleep need) show different risk profiles for drowsy driving are limited. From the 2009 Behavioral Risk Factor Surveillance System (N = 31,522), we obtained the following self-reported data: (1) sleep duration (<= 5, 6, 7, 8, 9, or >= 10h/night); (2) number of days/week of perceived insufficient sleep; (3) among drivers, yes/no response to: "During the past 30 days, have you ever nodded off or fallen asleep, even just for a brief moment, while driving?" (4) demographics, physical/mental health. Using 7 h/night as reference, logistic regression analyses evaluated whether self-reported sleep duration was associated with drowsy driving. Overall, 3.6% reported drowsy driving. Self-identified short-sleepers reported drowsy driving more often, and long sleepers, less often. Among those who perceived sleep as always insufficient, drowsy driving was reported more often when sleep duration was <= 5 h, 6 h, or >= 10 h. Among those who perceived sleep as always sufficient, drowsy driving was reported more often among <= 5 h and 6 h sleepers. Overall, drowsy driving was common, particularly in self-identified short-sleepers as a whole, as well as subgroups based on sleep insufficiency. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Maia, Querino; Grandner, Michael A.; Findley, James; Gurubhagavatula, Indira] Univ Penn, Ctr Sleep & Circadian Neurobiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Grandner, Michael A.; Findley, James] Univ Penn, Dept Psychiat, Behav Sleep Med Program, Philadelphia, PA 19104 USA.
[Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm Crit Care Sleep Sect, Philadelphia, PA USA.
RP Grandner, MA (reprint author), Univ Penn, Ctr Sleep & Circadian Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA.
EM grandner@upenn.edu
FU NCRR NIH HHS [UL1 RR024134, UL1RR024134]; NHLBI NIH HHS [K23 HL110216,
K23HL110216]; NIEHS NIH HHS [R21 ES022931, R21ES022931]; NIOSH CDC HHS
[R01 OH009149, R01OH009149]
NR 23
TC 16
Z9 16
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0001-4575
EI 1879-2057
J9 ACCIDENT ANAL PREV
JI Accid. Anal. Prev.
PD OCT
PY 2013
VL 59
BP 618
EP 622
DI 10.1016/j.aap.2013.07.028
PG 5
WC Ergonomics; Public, Environmental & Occupational Health; Social
Sciences, Interdisciplinary; Transportation
SC Engineering; Public, Environmental & Occupational Health; Social
Sciences - Other Topics; Transportation
GA 261SX
UT WOS:000327686000071
PM 23973762
ER
PT J
AU Sano, M
Egelko, S
Donohue, M
Ferris, S
Kaye, J
Hayes, TL
Mundt, JC
Sun, CK
Paparello, S
Aisen, PS
AF Sano, Mary
Egelko, Susan
Donohue, Michael
Ferris, Steven
Kaye, Jeffrey
Hayes, Tamara L.
Mundt, James C.
Sun, Chung-Kai
Paparello, Silvia
Aisen, Paul S.
CA Alzheimer Disease Cooperative
TI Developing Dementia Prevention Trials Baseline Report of the Home-Based
Assessment Study
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article
DE Alzheimer disease; clinical trials; in-home assessment; prevention
studies
ID INSTRUMENT PROJECT; CLINICAL-TRIALS
AB This report describes the baseline experience of the multicenter, Home-Based Assessment study, designed to develop methods for dementia prevention trials using novel technologies for test administration and data collection. Nondemented individuals of 75 years of age or more were recruited and evaluated in-person using established clinical trial outcomes of cognition and function, and randomized to one of 3 assessment methodologies: (1) mail-in questionnaire/live telephone interviews [mail-in/phone (MIP)]; (2) automated telephone with interactive voice recognition; and (3) internet-based computer Kiosk. Brief versions of cognitive and noncognitive outcomes were adapted to each methodology and administered at baseline and repeatedly over a 4-year period. Efficiency measures assessed the time from screening to baseline, and staff time required for each methodology. A total of 713 individuals signed consent and were screened; 640 met eligibility and were randomized to one of 3 assessment arms; and 581 completed baseline. Dropout, time from screening to baseline, and total staff time were highest among those assigned to internet-based computer Kiosk. However, efficiency measures were driven by nonrecurring start-up activities suggesting that differences may be mitigated over a long trial. Performance among Home-Based Assessment instruments collected through different technologies will be compared with established outcomes over this 4-year study.
C1 [Sano, Mary; Egelko, Susan] Mt Sinai Sch Med, New York, NY USA.
[Ferris, Steven] NYU, Langone Med Ctr, New York, NY USA.
[Sano, Mary; Egelko, Susan] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Donohue, Michael; Sun, Chung-Kai; Paparello, Silvia; Aisen, Paul S.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Kaye, Jeffrey; Hayes, Tamara L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Kaye, Jeffrey] Portland VA Med Ctr, Portland, OR USA.
[Mundt, James C.] Ctr Psychol Consultat, Madison, WI USA.
[Mundt, James C.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
RP Sano, M (reprint author), James J Peters VA Med Ctr, 130 Kingsbridge Rd,Code 151 Room 1F01, Bronx, NY 10468 USA.
EM mary.sano@mssm.edu
OI Kaye, Jeffrey/0000-0002-9971-3478; Ferris, Steven/0000-0001-8641-6223
FU NIA [U01AG10483, P50AG005138, P30AG008051, P30AG024978, P30AG08017];
Intel Corporation
FX Supported by the following NIA Grants: U01AG10483, P50AG005138,
P30AG008051, and P30AG024978. Development of the Kiosk and MedTracker
was supported in part by Grants from NIA (P30AG024978; P30AG08017) and
Intel Corporation.
NR 18
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0893-0341
EI 1546-4156
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD OCT-DEC
PY 2013
VL 27
IS 4
BP 356
EP 362
DI 10.1097/WAD.0b013e3182769c05
PG 7
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA 262NR
UT WOS:000327742800010
PM 23151596
ER
PT J
AU Torchiana, DF
Colton, DG
Rao, SK
Lenz, SK
Meyer, GS
Ferris, TG
AF Torchiana, David F.
Colton, Deborah G.
Rao, Sandhya K.
Lenz, Sarah K.
Meyer, Gregg S.
Ferris, Timothy G.
TI INNOVATION PROFILE Massachusetts General Physicians Organization's
Quality Incentive Program Produces Encouraging Results
SO HEALTH AFFAIRS
LA English
DT Article
ID OF-CARE; HEALTH-CARE; PERFORMANCE; PAY; DECISION; SUPPORT
AB Physicians are increasingly becoming salaried employees of hospitals or large physician groups. Yet few published reports have evaluated provider-driven quality incentive programs for salaried physicians. In 2006 the Massachusetts General Physicians Organization began a quality incentive program for its salaried physicians. Eligible physicians were given performance targets for three quality measures every six months. The incentive payments could be as much as 2 percent of a physician's annual income. Over thirteen six-month terms, the program used 130 different quality measures. Although quality-of-care improvements and cost reductions were difficult to calculate, anecdotal evidence points to multiple successes. For example, the program helped physicians meet many federal health information technology meaningful-use criteria and produced $15.5 million in incentive payments. The program also facilitated the adoption of an electronic health record, improved hand hygiene compliance, increased efficiency in radiology and the cancer center, and decreased emergency department use. The program demonstrated that even small incentives tied to carefully structured metrics, priority setting, and clear communication can help change salaried physicians' behavior in ways that improve the quality and safety of health care and ease the physicians' sense of administrative burden.
C1 [Torchiana, David F.; Colton, Deborah G.; Rao, Sandhya K.; Ferris, Timothy G.] MGPO, Boston, MA USA.
[Torchiana, David F.; Rao, Sandhya K.; Ferris, Timothy G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lenz, Sarah K.] MGPO, Phys Incent Programs, Boston, MA USA.
[Meyer, Gregg S.] Dartmouth Hitchcock Med Ctr, Hanover, NH USA.
RP Torchiana, DF (reprint author), MGPO, Boston, MA USA.
EM dcolton@partners.org
NR 23
TC 9
Z9 9
U1 0
U2 3
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD OCT
PY 2013
VL 32
IS 10
BP 1748
EP 1756
DI 10.1377/hlthaff.2013.0377
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 250GG
UT WOS:000326837900009
PM 24101064
ER
PT J
AU Herring, AA
Johnson, B
Ginde, AA
Camargo, CA
Feng, L
Alter, HJ
Hsia, R
AF Herring, Andrew A.
Johnson, Brian
Ginde, Adit A.
Camargo, Carlos A.
Feng, Lin
Alter, Harrison J.
Hsia, Renee
TI High-Intensity Emergency Department Visits Increased In California,
2002-09
SO HEALTH AFFAIRS
LA English
DT Article
ID UNITED-STATES; CARE-UNIT; ADMISSIONS; TRENDS; IMPACT
AB Increasing use of the emergency department (ED) is well documented, but little is known about the type and severity of ED visits or their distribution across safety-net and non-safety-net hospitals. We examined the rates of high-intensity ED visits-characterized by their use of advanced imaging, consultations with specialists, the evaluation of multiple systems, and highly complex medical decision making-by patients with a severe, potentially life-threatening illness in California from 2002 through 2009. Total annual ED visits increased by 25 percent, from 9.0 million to 11.3 million, but high-intensity ED visits nearly doubled, increasing 87 percent from 778,000 to 1.5 million per year. The percentage of ED visits with high-intensity care increased from 9 percent to 13 percent (a relative increase of 44 percent). Annual ED admissions increased by 39 percent overall; most of this increase was attributable to high-intensity ED admissions, which increased by 88 percent. Safety-net EDs experienced an increase in high-intensity visits of 157 percent, compared to an increase of 61 percent at non-safety-net EDs. These findings suggest a trend toward intensification of ED care, particularly at safety-net hospitals, whose patients may have limited access to care outside the ED.
C1 [Herring, Andrew A.; Johnson, Brian; Alter, Harrison J.] Alameda Hlth Syst, Highland Hosp, Oakland, CA USA.
[Ginde, Adit A.] Univ Colorado, Dept Emergency Med, Sch Med, Aurora, CO USA.
[Camargo, Carlos A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Camargo, Carlos A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Feng, Lin] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA.
[Alter, Harrison J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hsia, Renee] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA.
RP Herring, AA (reprint author), Alameda Hlth Syst, Highland Hosp, Oakland, CA USA.
EM aherring@alamedahealthsystem.org
RI bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017
FU National Center for Research Resources, National Institutes of Health
[KL2 RR024130]; Robert Wood Johnson Foundation Physician Faculty
Scholars
FX The research reported here was supported by Grant No. KL2 RR024130 from
the National Center for Research Resources, National Institutes of
Health, to the Clinical and Translational Science Institute at the
University of California, San Francisco, and by the Robert Wood Johnson
Foundation Physician Faculty Scholars. The article's contents are solely
the responsibility of the authors and do not necessarily represent the
official views of any of the funding agencies.
NR 39
TC 3
Z9 3
U1 0
U2 2
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD OCT
PY 2013
VL 32
IS 10
BP 1811
EP 1819
DI 10.1377/hlthaff.2013.0397
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 250GG
UT WOS:000326837900018
PM 24101073
ER
PT J
AU Anderson, EC
Dryman, MT
Worthington, J
Hoge, EA
Fischer, LE
Pollack, MH
Barrett, LF
Simon, NM
AF Anderson, Eric C.
Dryman, M. Taylor
Worthington, John
Hoge, Elizabeth A.
Fischer, Laura E.
Pollack, Mark H.
Barrett, Lisa Feldman
Simon, Naomi M.
TI Smiles may go unseen in generalized social anxiety disorder: Evidence
from binocular rivalry for reduced visual consciousness of positive
facial expressions
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Visual perception; Motivation and emotion; Psychological disorder's;
Affective disorders; Neuroses and anxiety disorders
ID THREATENING FACES; PERCEPTION; PHOBIA; BIAS; IMPACT
AB Research has demonstrated increased attention to negative social cues and reduced attention to positive social cues in generalized social anxiety disorder (GSAD), but little is known about whether GSAD also involves differences in lower levels of visual processing. This study explored visual experience in GSAD compared to participants with generalized anxiety disorder (GAD) and healthy controls using binocular rivalry. Participants were presented with dissimilar images to each eye, and the two images competed for perceptual dominance. Consistent with the hypothesis that GSAD involves a reduced visual salience for positive social cues, we found that smiling faces were dominant for significantly shorter durations in GSAD compared to GAD and controls. Contrasting with our hypothesis of greater visual salience of negative social cues, we found no difference in negative stimuli salience. These findings are consistent with the broader view that a perceiver's affective state directly influences the content of visual consciousness. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Anderson, Eric C.; Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
[Dryman, M. Taylor; Worthington, John; Hoge, Elizabeth A.; Fischer, Laura E.; Barrett, Lisa Feldman; Simon, Naomi M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA.
[Pollack, Mark H.] Rush Univ, Med Ctr, Dept Psychiat, Chicago, IL 60612 USA.
RP Simon, NM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM NSIMON@partners.org
RI Hoge, Elizabeth/H-5879-2012;
OI Hoge, Elizabeth/0000-0002-5513-2292; Anderson, Eric/0000-0002-4215-6308
NR 42
TC 6
Z9 6
U1 2
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD OCT
PY 2013
VL 27
IS 7
BP 619
EP 626
DI 10.1016/j.janxdis.2013.07.004
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 261ST
UT WOS:000327685600001
PM 24064330
ER
PT J
AU White, S
Acierno, R
Ruggiero, KJ
Koenen, KC
Kilpatrick, DG
Galea, S
Gelernter, J
Williamson, V
McMichael, O
Vladimirov, VI
Amstadter, AB
AF White, Simone
Acierno, Ron
Ruggiero, Kenneth J.
Koenen, Karestan C.
Kilpatrick, Dean G.
Galea, Sandro
Gelernter, Joel
Williamson, Vernell
McMichael, Omari
Vladimirov, Vladimir I.
Amstadter, Ananda B.
TI Association of CRHR1 variants and posttraumatic stress symptoms in
hurricane exposed adults
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Posttraumatic stress disorder; CRHR1; HPA axis; Disasters; Trauma
ID POPULATION GROUP ASSIGNMENT; DISORDER SYMPTOMS; COMBAT VETERANS;
TRAUMATIC EVENT; RECEPTOR GENE; GENOTYPE DATA; RISK; TWIN; DEPRESSION;
MARKERS
AB Posttraumatic stress disorder (PTSD) is a moderately heritable anxiety disorder that may develop after exposure to trauma. However, only few genetic variants that relate to PTSD have been studied. This study examined the relationship between 12 single nucleotide polymorphisms (SNPs) in the corticotropin-releasing hormone receptor 1 gene (CRHR1) and post-disaster PTSD symptoms and diagnosis in adults exposed to 2004 Florida hurricanes. CRHR1 regulates the hypothalamic-pituitary-adrenal (HPA) axis; dysregulation of the HPA axis is characteristic of stress phenotypes. Final analyses were conducted in the European-American (EA) subsample (n = 564) due to population stratification. After correction for multiple testing, rs12938031 and rs4792887 remained associated with post-hurricane PTSD symptoms. Additionally, rs12938031 was associated with post-hurricane diagnosis of PTSD. This study is the first to examine CRHR1 in relation to PTSD in adults, and provides evidence for the importance of CRHR1 variation in the etiology of PTSD. Although results are preliminary and require replication, they justify follow-up efforts to characterize how this gene relates to PTSD. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [White, Simone; Williamson, Vernell; McMichael, Omari; Vladimirov, Vladimir I.; Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23298 USA.
[Acierno, Ron; Ruggiero, Kenneth J.; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Acierno, Ron; Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Koenen, Karestan C.; Galea, Sandro] Columbia Univ, Dept Epidemiol, New York, NY USA.
[Gelernter, Joel] Yale Univ, Sch Med, Div Human Genet Psychiat, New Haven, CT USA.
RP Amstadter, AB (reprint author), Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, 800 E Leigh St,Biotech 1,POB 980126, Richmond, VA 23298 USA.
EM slw257@cornell.edu; abamstadter@vcu.edu
FU NIAAA NIH HHS [R01 AA020179]; NIGMS NIH HHS [R25 GM089614]; NIMH NIH HHS
[R21 MH074469]; PHS HHS [NIGMS 089614, NIMH 05220]
NR 47
TC 14
Z9 15
U1 3
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD OCT
PY 2013
VL 27
IS 7
BP 678
EP 683
DI 10.1016/j.janxdis.2013.08.003
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 261ST
UT WOS:000327685600008
PM 24077033
ER
PT J
AU Gutner, CA
Nillni, YI
Suvak, M
Wiltsey-Stirman, S
Resick, PA
AF Gutner, Cassidy A.
Nillni, Yael I.
Suvak, Michael
Wiltsey-Stirman, Shannon
Resick, Patricia A.
TI Longitudinal course of anxiety sensitivity and PTSD symptoms in
cognitive-behavioral therapies for PTSD
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Anxiety sensitivity; Posttraumatic stress disorder; Treatment; Cognitive
therapy
ID POSTTRAUMATIC-STRESS-DISORDER; PROCESSING THERAPY; PANIC-ATTACKS; FEMALE
VICTIMS; DIMENSIONS; EXPOSURE; PREVENTION; PREDICTION; CLUSTERS;
VIOLENCE
AB Anxiety sensitivity (AS) has been conceptualized as trait-like vulnerability and maintenance factor for PTSD. Although recent literature has demonstrated its malleability during treatment, few have examined its influence on and effect from PTSD treatment. Using multilevel regression analyses we examined: (a) changes in AS during treatment and (b) whether pre-treatment AS predicted PTSD treatment response, in sample of female victims of interpersonal trauma receiving one of three treatments (cognitive processing therapy, cognitive processing therapy-cognitive, and written accounts). Participants exhibited reductions in total ASI scores from pre- to post-treatment. Growth curve modeling revealed slightly different trajectories of PTSD symptoms as a function of pre-treatment AS, and overall decreases in PTSD symptoms during treatment were not associated with pretreatment AS. Pretreatment AS dimensions impacted PTSD total scores and symptoms clusters differentially. Clinical and theoretical implications for these results are discussed. Published by Elsevier Ltd.
C1 [Gutner, Cassidy A.; Nillni, Yael I.; Suvak, Michael; Wiltsey-Stirman, Shannon; Resick, Patricia A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA.
[Gutner, Cassidy A.; Nillni, Yael I.; Wiltsey-Stirman, Shannon; Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA.
[Suvak, Michael] Suffolk Univ, Dept Psychol, Boston, MA 02108 USA.
RP Gutner, CA (reprint author), VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA.
EM cassidy.gutner@va.gov
OI Gutner, Cassidy A./0000-0002-9406-6638; Wiltsey Stirman,
Shannon/0000-0001-9917-5078
FU NIMH NIH HHS [R01 MH051509, T32 MH019836, T32MH019836-15A2, 1
R01-MH51509]
NR 41
TC 3
Z9 3
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD OCT
PY 2013
VL 27
IS 7
BP 728
EP 734
DI 10.1016/j.janxdis.2013.09.010
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 261ST
UT WOS:000327685600014
PM 24176804
ER
PT J
AU MacDonald, DE
Rapuano, BE
Vyas, P
Lane, JM
Meyers, K
Wright, T
AF MacDonald, Daniel E.
Rapuano, Bruce E.
Vyas, Parth
Lane, Joseph M.
Meyers, Kathleen
Wright, Timothy
TI Heat and Radiofrequency Plasma Glow Discharge Pretreatment of a Titanium
Alloy Promote Bone Formation and Osseointegration
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE DENTAL IMPLANT; FIBRONECTIN; OSTEOBLAST; CELL DIFFERENTIATION; BONE
MINERALIZATION; OSSEOINTEGRATION
ID OXIDE NET CHARGE; OSTEOBLAST ADHESION; DENTAL IMPLANTS; CELL-ADHESION;
SURFACE; FIBRONECTIN; TOPOGRAPHY; SITES; DIFFERENTIATION; INTEGRATION
AB Orthopedic and dental implants manifest increased failure rates when inserted into low density bone. We determined whether chemical pretreatments of a titanium alloy implant material stimulated new bone formation to increase osseointegration in vivo in trabecular bone using a rat model. Titanium alloy rods were untreated or pretreated with heat (600 degrees C) or radiofrequency plasma glow discharge (RFGD). The rods were then coated with the extracellular matrix protein fibronectin (1nM) or left uncoated and surgically implanted into the rat femoral medullary cavity. Animals were euthanized 3 or 6 weeks later, and femurs were removed for analysis. The number of trabeculae in contact with the implant surface, surface contact between trabeculae and the implant, and the length and area of bone attached to the implant were measured by histomorphometry. Implant shear strength was measured by a pull-out test. Both pretreatments and fibronectin enhanced the number of trabeculae bonding with the implant and trabeculae-to-implant surface contact, with greater effects of fibronectin observed with pretreated compared to untreated implants. RFGD pretreatment modestly increased implant shear strength, which was highly correlated (r(2)=0.87-0.99) with measures of trabecular bonding for untreated and RFGD-pretreated implants. In contrast, heat pretreatment increased shear strength 3-5-fold for both uncoated and fibronectin-coated implants at 3 and 6 weeks, suggesting a more rapid increase in implant-femur bonding compared to the other groups. In summary, our findings suggest that the heat and RFGD pretreatments can promote the osseointegration of a titanium alloy implant material. J. Cell. Biochem. 114: 2363-2374, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [MacDonald, Daniel E.; Rapuano, Bruce E.; Vyas, Parth; Lane, Joseph M.; Meyers, Kathleen; Wright, Timothy] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA.
[MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA.
RP MacDonald, DE (reprint author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
EM dem14@columbia.edu
FU National Center for Research Resources, NIH [C06-RR12538-01]
FX The sponsor did not have any role in the study design; the collection,
analysis and interpretation of data; the writing of the report; or the
decision to submit the article for publication. This material also
resulted from work supported with resources and the use of facilities at
the James J. Peters VA Medical Center, Bronx, New York. This
investigation was also conducted at the HSS research facility
constructed with support of Grant C06-RR12538-01 from the National
Center for Research Resources, NIH. We thank Dr. Hannes Schniepp for the
AFM surface analyses, Dr. Stephen Doty, and Tony Labissiere for
technical assistance with the SEM analyses, Dr. Adele Boskey and
Lyudmila Spevak for assistance with FTIR, and Kyle Hackshaw, Carrie
Guan, and Jenny Lee for help with preparation of the alloy implants.
NR 50
TC 4
Z9 4
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2013
VL 114
IS 10
BP 2363
EP 2374
DI 10.1002/jcb.24585
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 263NP
UT WOS:000327815600017
PM 23649564
ER
PT J
AU Kacmarek, RM
Villar, J
AF Kacmarek, R. M.
Villar, J.
TI Management of refractory hypoxemia in ARDS
SO MINERVA ANESTESIOLOGICA
LA English
DT Article
DE Respiratory distress syndrome, adult; Respiration, artificial; Patient
positioning
ID RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; ACUTE LUNG
INJURY; RANDOMIZED CONTROLLED-TRIAL; INHALED NITRIC-OXIDE;
EXTRACORPOREAL MEMBRANE-OXYGENATION; FREQUENCY OSCILLATORY VENTILATION;
SEVERE PULMONARY-HYPERTENSION; 2009 INFLUENZA A(H1N1); RECRUITMENT
MANEUVERS
AB Severe hypoxemia is the hallmark of ARDS. However, unmanageable refractory hypoxemia fortunately is a rare occurrence in patients with ARDS and an infrequent cause of death in ARDS. However, in some patients, in spite of the application of lung protective ventilation with moderate to high levels of end-expiratory pressure (PEEP), refractory hypoxemia remains unresolved. When refractory hypoxemia persists, we first recommend the use of lung recruitment maneuvers and a decremental PEEP trial, if this does not resolve the refractory hypoxemia prone positioning should be attempted. The use of aerosolized pulmonary vasodilators can be used to buy time when these approaches fail as the patient is transitioned to extracorporeal membrane oxygenation. We also find that there is now sufficient evidence to recommend against the use of high frequency oscillation in the management of refractory hypoxemia.
C1 [Kacmarek, R. M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
[Kacmarek, R. M.] Harvard Univ, Dept Anesthesia, Boston, MA 02115 USA.
[Villar, J.] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
[Villar, J.] Hosp Univ Dr Negrin, Res Unit, Las Palmas Gran Canaria, Spain.
[Villar, J.] St Michaels Hosp, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada.
[Villar, J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
RP Kacmarek, RM (reprint author), Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
EM rkacmarek@partners.org
FU Instituto de Salud Carlos III, Spain [PI10/0393]
FX The present study was supported in part by and Instituto de Salud Carlos
III, Spain (PI10/0393).
NR 43
TC 11
Z9 13
U1 0
U2 6
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0375-9393
EI 1827-1596
J9 MINERVA ANESTESIOL
JI Minerva Anestesiol.
PD OCT
PY 2013
VL 79
IS 10
BP 1173
EP 1179
PG 7
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA 263KS
UT WOS:000327808100013
PM 23857446
ER
PT J
AU Boissel, L
Betancur-Boissel, M
Lu, WQ
Krause, DS
Van Etten, RA
Wels, WS
Klingemann, H
AF Boissel, Laurent
Betancur-Boissel, Monica
Lu, Weiquan
Krause, Daniela S.
Van Etten, Richard A.
Wels, Winfried S.
Klingemann, Hans
TI Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric
antigen receptors compares favorably with antibody-dependent cellular
cytotoxicity
SO ONCOIMMUNOLOGY
LA English
DT Article
DE CAR; lentiviral vector; lymphoid malignancies; NK cells; NK-92
ID NATURAL-KILLER-CELLS; EX-VIVO EXPANSION; LINE NK-92; NK CELLS;
STEM-CELLS; CANCER; LYMPHOMA; IMMUNOTHERAPY; LEUKEMIA; DIFFERENTIATION
AB Multiple natural killer (NK) cell-based anticancer therapies are currently under development. Here, we compare the efficiency of genetically modified NK-92 cells expressing chimeric antigen receptors (CARs) at killing NK cell-resistant B-lymphoid leukemia cells to the antibody-dependent cell-mediated cytotoxicity (ADCC) of NK-92 cells expressing a high affinity variant of the IgG Fc receptor (FcRIII). First, we compared in vitro the abilities of NK-92 cells expressing CD20-targeting CARs to kill primary chronic lymphocytic leukemia (CLL) cells derived from 9 patients with active, untreated disease to the cytotoxicity of NK-92 cells expressing FcRIII combined with either of the anti-CD20 monoclonal antibodies (mAbs) rituximab or ofatumumab. We found that CAR-expressing NK-92 cells effectively kill NK cell-resistant primary CLL cells and that such a cytotoxic response is significantly stronger than that resulting from ADCC. For studying CAR-expressing NK cell-based immunotherapy in vivo, we established xenograft mouse models of residual leukemia using the human BCR-ABL1(+) cell lines SUP-B15 (CD19(+)CD20(-)) and TMD-5 (CD19(+)CD20(+)), two acute lymphoblastic leukemia (ALL) lines that are resistant to parental NK-92 cells. Intravenous injection of NK-92 cells expressing CD19-targeting CARs eliminated SUP-B15 cells, whereas they had no such effect on TMD-5 cells. However, the intrafemoral injection of NK-92 cells expressing CD19-targeting CAR resulted in the depletion of TMD-5 cells from the bone marrow environment. Comparative studies in which NK-92 cells expressing either CD19- or CD20-targeting CARs were directly injected into subcutaneous CD19(+)CD20(+) Daudi lymphoma xenografts revealed that CD20-targeting CAR is superior to its CD19-specific counterpart in controlling local tumor growth. In summary, we show here that CAR-expressing NK-92 cells can be functionally superior to ADCC (as mediated by anti-CD20 mAbs) in the elimination of primary CLL cells. Moreover, we provide data demonstrating that the systemic administration of CAR-expressing NK-92 cells can control lymphoblastic leukemia in immunocompromised mice. Our results also suggest that the direct injection of CAR-expressing NK-92 cells to neoplastic lesions could be an effective treatment modality against lymphoma.
C1 [Boissel, Laurent; Betancur-Boissel, Monica; Lu, Weiquan; Van Etten, Richard A.; Klingemann, Hans] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA.
[Lu, Weiquan; Van Etten, Richard A.; Klingemann, Hans] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA.
[Krause, Daniela S.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Krause, Daniela S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Wels, Winfried S.] Chemotherapeut Forschungsinst Georg Speyer Haus, Frankfurt, Germany.
RP Klingemann, H (reprint author), Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA.
EM hans.klingemann@tufts.edu
FU National Institutes of Health [R01 CA090576, R01 HL093981, K08 CA138916]
FX The authors thank the staff at Flow Cytometry and Small Animal Services
Core Facilities of the Tufts Medical Center Cancer Center for
assistance. This work was supported by grants from the National
Institutes of Health (R01 CA090576 to R. A. V., R01 HL093981 to H. K.
and R. A. V., and K08 CA138916 to D.S.K.)
NR 33
TC 39
Z9 42
U1 1
U2 10
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD OCT 1
PY 2013
VL 2
IS 10
AR e26527
DI 10.4161/onci.26527
PG 8
WC Oncology; Immunology
SC Oncology; Immunology
GA 262LO
UT WOS:000327737000002
PM 24404423
ER
PT J
AU Cooper, ZA
Frederick, DT
Juneja, VR
Sullivan, RJ
Lawrence, DP
Piris, A
Sharpe, AH
Fisher, DE
Flaherty, KT
Wargo, JA
AF Cooper, Zachary A.
Frederick, Dennie T.
Juneja, Vikram R.
Sullivan, Ryan J.
Lawrence, Donald P.
Piris, Adriano
Sharpe, Arlene H.
Fisher, David E.
Flaherty, Keith T.
Wargo, Jennifer A.
TI BRAF inhibition is associated with increased clonality in
tumor-infiltrating lymphocytes
SO ONCOIMMUNOLOGY
LA English
DT Article
DE BRAF; T cells; TILs; melanoma; vemurafenib
ID RAF INHIBITION; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; MUTATIONS;
MEK; BRAF(V600E); VEMURAFENIB; CANCER; MICROENVIRONMENT; RECOGNITION
AB There have been significant advances with regard to BRAF-targeted therapies against metastatic melanoma. However, the majority of patients receiving BRAF inhibitors (BRAFi) manifest disease progression within a year. We have recently shown that melanoma patients treated with BRAFi exhibit an increase in melanoma-associated antigens and in CD8+ tumor-infiltrating lymphocytes in response to therapy. To characterize such a T-cell infiltrate, we analyzed the complementarity-determining region 3 (CDR3) of rearranged T-cell receptor (TCR) chain-coding genes in tumor biopsies obtained before the initiation of BRAFi and 10-14 d later. We observed an increase in the clonality of tumor-infiltrating lymphocytes in 7 of 8 patients receiving BRAFi, with a statistically significant 21% aggregate increase in clonality. Over 80% of individual T-cell clones detected after initiation of BRAFi treatment were new clones. Interestingly, the comparison of tumor infiltrates with clinical responses revealed that patients who had a high proportion of pre-existing dominant clones after the administration of BRAFi responded better to therapy than patients who had a low proportion of such pre-existing dominant clones following BRAFi. These data suggest that although the inhibition of BRAF in melanoma patients results in tumor infiltration by new lymphocytes, the response to treatment appears to be related to the presence of a pre-existing population of tumor-infiltrating T-cell clones.
C1 [Cooper, Zachary A.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
[Cooper, Zachary A.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
[Frederick, Dennie T.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
[Juneja, Vikram R.; Sharpe, Arlene H.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA USA.
[Juneja, Vikram R.] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Sullivan, Ryan J.; Lawrence, Donald P.; Flaherty, Keith T.] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA.
[Sullivan, Ryan J.; Lawrence, Donald P.; Piris, Adriano; Fisher, David E.; Flaherty, Keith T.] Harvard Univ, Sch Med, Boston, MA USA.
[Piris, Adriano] Massachusetts Gen Hosp, Div Dermatopathol, Boston, MA 02114 USA.
[Fisher, David E.] Massachusetts Gen Hosp, Div Dermatol, Boston, MA 02114 USA.
RP Wargo, JA (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
EM jwargo@mdanderson.org
OI Cooper, Zachary/0000-0003-1059-0940
FU NCI NIH HHS [P01 CA163222]; NIAMS NIH HHS [R01 AR043369]
NR 32
TC 38
Z9 39
U1 0
U2 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD OCT 1
PY 2013
VL 2
IS 10
AR UNSP e26615
DI 10.4161/onci.26615
PG 7
WC Oncology; Immunology
SC Oncology; Immunology
GA 262LO
UT WOS:000327737000028
PM 24251082
ER
PT J
AU Duraiswamy, J
Freeman, G
Coukos, G
AF Duraiswamy, Jaikumar
Freeman, Gordon
Coukos, George
TI Replenish the source within Rescuing tumor-infiltrating lymphocytes by
double checkpoint blockade
SO ONCOIMMUNOLOGY
LA English
DT Editorial Material
DE CTLA4; PD-1; regulatory T cells; tumor-infiltrating lymphocytes; vaccine
ID T-CELLS; OVARIAN-CANCER; REGULATORY T; MELANOMA; PD-1
AB We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and regulatory T cells, causing profound immune dysfunctions in the tumor microenvironment. In line with this notion, the dual blockade of PD-1- and CTLA4-conveyed signals may exert robust therapeutic effects. Here, we discuss the mechanisms possibly underlying such a synergic interaction.
C1 [Duraiswamy, Jaikumar; Coukos, George] Univ Penn, Perelman Sch Med, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.
[Freeman, Gordon] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Coukos, George] Univ Lausanne Hosp, Dept Oncol, Lausanne, Switzerland.
[Coukos, George] Univ Lausanne Hosp, Ludwig Ctr Canc Res, Lausanne, Switzerland.
RP Coukos, G (reprint author), Univ Penn, Perelman Sch Med, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.
EM gcks@mail.med.upenn.edu
FU NCI NIH HHS [P50 CA083638]; NIAID NIH HHS [P01 AI056299]
NR 10
TC 4
Z9 4
U1 1
U2 3
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD OCT 1
PY 2013
VL 2
IS 10
AR e25912
DI 10.4161/onci.25912
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA 262LO
UT WOS:000327737000012
PM 24404420
ER
PT J
AU Lin, DT
Lin, AC
AF Lin, Derrick T.
Lin, Alice C.
TI Surgical Treatment of Traumatic Injuries of the Cranial Base
SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Skull base trauma; Craniofacial trauma; Skull base fractures; Basilar
skull fractures; Surgical treatment of skull fractures; CSF leak
ID CEREBROSPINAL-FLUID RHINORRHEA; ANTIBIOTIC-PROPHYLAXIS; ENDOSCOPIC
REPAIR; MANAGEMENT; FRACTURES; FISTULAS; LEAKS; DIAGNOSIS; EXPERIENCE
AB Skull-base fractures involve one or more of the bones that constitute the cranial base; the cribriform plate. the orbital plate of the frontal bone, sphenoid bone, occipital bone, and petrous or temporal bone. Although the fractures only require reduction and reconstruction when the skull base is severely comminuted or altered, even small fractures are associated with traumatic shear forces which create tears in the meninges and thus predispose to cerebrospinal fluid leaks. This article explores the preoperative, intraoperative, and postoperative management of skull-base fractures, which most commonly involves resolution of the cerebrospinal fluid leak and the prevention of future leaks or meningoencephaloceles.
C1 [Lin, Derrick T.; Lin, Alice C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Massachusetts Gen Hosp, Div Head & Neck Oncol,Med Sch, Boston, MA 02114 USA.
RP Lin, DT (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Massachusetts Gen Hosp, Div Head & Neck Oncol,Med Sch, 243 Charles St, Boston, MA 02114 USA.
EM Derrick_Lin@meei.harvard.edu
NR 34
TC 3
Z9 5
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0030-6665
EI 1557-8259
J9 OTOLARYNG CLIN N AM
JI Otolaryngol. Clin. N. Am.
PD OCT
PY 2013
VL 46
IS 5
BP 749
EP +
DI 10.1016/j.otc.2013.06.008
PG 10
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 264UB
UT WOS:000327905400004
PM 24138735
ER
PT J
AU Garrido, MM
Idler, EL
Leventhal, H
Carr, D
AF Garrido, Melissa M.
Idler, Ellen L.
Leventhal, Howard
Carr, Deborah
TI Pathways From Religion to Advance Care Planning: Beliefs About Control
Over Length of Life and End-of-Life Values
SO GERONTOLOGIST
LA English
DT Article
DE Advance directive; living wills; durable power of attorney for
healthcare
ID TREATMENT PREFERENCES; DECISION-MAKING; RACIAL-DIFFERENCES;
CANCER-PATIENTS; DIRECTIVES; HEALTH; DEATH; PHYSICIANS; RESIDENTS;
ATTITUDES
AB Purpose of the Study: To evaluate the extent to which religious affiliation and self-identified religious importance affect advance care planning (ACP) via beliefs about control over life length and end-of-life values. Design and Methods: Three hundred and five adults aged 55 and older from diverse racial and socioeconomic groups seeking outpatient care in New Jersey were surveyed. Measures included discussion of end-of-life preferences; living will (LW) completion; durable power of attorney for healthcare (DPAHC) appointment; religious affiliation; importance of religion; and beliefs about who/what controls life length, end-of-life values, health status, and sociodemographics. Results: Of the sample, 68.9% had an informal discussion and 46.2% both discussed their preferences and did formal ACP (LW and/or DPAHC). Conservative Protestants and those placing great importance on religion/spirituality had a lower likelihood of ACP. These associations were largely accounted for by beliefs about God's controlling life length and values for using all available treatments. Implications: Beliefs and values about control account for relationships between religiosity and ACP. Beliefs and some values differ by religious affiliation. As such, congregations may be one nonclinical setting in which ACP discussions could be held, as individuals with similar attitudes toward the end of life could discuss their treatment preferences with those who share their views.
C1 [Garrido, Melissa M.] GRECC, James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Garrido, Melissa M.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA.
[Idler, Ellen L.] Emory Univ, Dept Sociol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Idler, Ellen L.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Leventhal, Howard] Rutgers State Univ, Dept Psychol, New Brunswick, NJ 08903 USA.
[Leventhal, Howard] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA.
[Carr, Deborah] Rutgers State Univ, Dept Sociol, New Brunswick, NJ 08903 USA.
[Carr, Deborah] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA.
RP Garrido, MM (reprint author), GRECC, James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM melissa.garrido@mssm.edu
FU NIA NIH HHS [AG023958]; NIMH NIH HHS [T32 MH16242-29]
NR 38
TC 11
Z9 11
U1 4
U2 22
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
EI 1758-5341
J9 GERONTOLOGIST
JI Gerontologist
PD OCT
PY 2013
VL 53
IS 5
BP 801
EP 816
DI 10.1093/geront/gns128
PG 16
WC Gerontology
SC Geriatrics & Gerontology
GA 258DL
UT WOS:000327439300010
PM 23161430
ER
PT J
AU Bradley, KA
Chavez, LJ
Lapham, GT
Williams, EC
Achtmeyer, CE
Rubinsky, AD
Hawkins, EJ
Saitz, R
Kivlahan, DR
AF Bradley, Katharine A.
Chavez, Laura J.
Lapham, Gwendolyn T.
Williams, Emily C.
Achtmeyer, Carol E.
Rubinsky, Anna D.
Hawkins, Eric J.
Saitz, Richard
Kivlahan, Daniel R.
TI When Quality Indicators Undermine Quality: Bias in a Quality Indicator
of Follow-Up for Alcohol Misuse
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID SERVICES-TASK-FORCE; PRIMARY-CARE; HEALTH-CARE; PREVENTIVE-SERVICES;
MENTAL-HEALTH; PERFORMANCE-MEASURES; MEANINGFUL USE; INTERVENTIONS;
ACCOUNTABILITY; IMPROVEMENT
AB Objective: Valid quality indicators are needed to monitor and encourage identification and management of mental health and substance use conditions (behavioral conditions). Because behavioral conditions are frequently underidentified, quality indicators often evaluate the proportion of patients who screen positive for a condition who also have appropriate follow-up care documented. However, these "positive-screen-based" quality indicators of follow-up for behavioral conditions could be biased by differences in the denominator due to differential screening quality ("denominator bias") and could reward identification of fewer patients with the behavioral conditions of interest. This study evaluated denominator bias in the performance of Veterans Health Administration (VHA) networks on a quality indicator of follow-up for alcohol misuse that used the number of patients with positive alcohol screens as the denominator. Methods: Two quality indicators of follow-up for alcohol misuse-a positive-screen-based quality indicator and a population-based quality indicator-were compared among 21 VHA networks by review of 219,119 medical records. Results: Results for the two quality indicators were inconsistent. For example, two networks performed similarly on the quality indicators (64.7% and 65.4% follow-up) even though one network identified and documented follow-up for almost twice as many patients (5,411 and 2,899 per 100,000 eligible, respectively). Networks that performed better on the positive-screen-based quality indicator identified fewer patients with alcohol misuse than networks that performed better on the population-based quality indicator (mean 4.1% versus 7.4%, respectively). Conclusions: A positive-screen-based quality indicator of follow-up for alcohol misuse preferentially rewarded networks that identified fewer patients with alcohol misuse.
C1 [Bradley, Katharine A.; Lapham, Gwendolyn T.] Grp Hlth Res Inst, Seattle, WA 98101 USA.
[Chavez, Laura J.; Williams, Emily C.; Achtmeyer, Carol E.; Rubinsky, Anna D.; Kivlahan, Daniel R.] Vet Affairs VA Hlth Serv Res & Dev, Northwest Ctr Excellence, Seattle, WA USA.
[Chavez, Laura J.; Williams, Emily C.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA.
[Hawkins, Eric J.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Saitz, Richard] Boston Univ, Dept Gen Internal Med, Boston, MA 02215 USA.
RP Bradley, KA (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
EM bradley.k@ghc.org
FU Substance Use Disorders Quality Enhancement Research Initiative from VA
Health Services Research and Development [SUB98-000]; National Institute
on Alcohol Abuse and Alcoholism [NIAAA R21 AA020894-01A1]; Group Health
Research Institute
FX This study was supported by the Substance Use Disorders Quality
Enhancement Research Initiative SUB98-000 from VA Health Services
Research and Development, by grant NIAAA R21 AA020894-01A1 from the
National Institute on Alcohol Abuse and Alcoholism, and by the Group
Health Research Institute. Funders had no role in the conduct or
reporting of research. Data were provided via a data use agreement with
the VA OABI (formerly the VA Office of Quality and Performance), which
had no role in design or analyses but reviewed the manuscript before
submission to ensure accurate use and reporting of data.
NR 51
TC 9
Z9 9
U1 4
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD OCT
PY 2013
VL 64
IS 10
BP 1018
EP 1025
DI 10.1176/appi.ps.201200449
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255ZH
UT WOS:000327278200022
PM 23852137
ER
PT J
AU Stirman, SW
Calloway, A
Toder, K
Miller, CJ
DeVito, AK
Meisel, SN
Xhezo, R
Evans, AC
Beck, AT
Crits-Christoph, P
AF Stirman, Shannon Wiltsey
Calloway, Amber
Toder, Katherine
Miller, Christopher J.
DeVito, Andrea K.
Meisel, Samuel N.
Xhezo, Regina
Evans, Arthur C.
Beck, Aaron T.
Crits-Christoph, Paul
TI Community Mental Health Provider Modifications to Cognitive Therapy:
Implications for Sustainability
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID PSYCHOLOGICAL TREATMENTS; BEHAVIORAL THERAPY; DISSEMINATION; SYSTEM
AB Objective: This study identified modifications to an evidence-based psychosocial treatment (cognitive therapy) within a community mental health system after clinicians had received intensive training and consultation. Methods: A coding system, consisting of four types of contextual modifications, 12 types of content-related-modifications, seven levels at which modifications can occur, and a code for changes to training or evaluation processes, was applied to data from interviews with 27 clinicians who treat adult consumers within a mental health system. Results: Nine of 12 content modifications were endorsed, and four (tailoring, integration into other therapeutic approaches, loosening structure, and drift) accounted for 65% of all modifications identified. Contextual modifications were rarely endorsed by clinicians in this sample. Modifications typically occurred at the client or clinician level. Conclusions: Clinicians in community mental health settings made several modifications to an evidence-based practice (EBP), often in an effort to improve the fit of the intervention to the client's needs or to the clinician's therapeutic style. These findings have implications for implementation and sustainability of EBPs in community settings, client-level outcomes, and training and consultation.
C1 [Stirman, Shannon Wiltsey] VA Boston Healthcare Syst, Vet Affairs VA Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA.
[Stirman, Shannon Wiltsey; DeVito, Andrea K.; Meisel, Samuel N.] Boston Univ, Dept Psychiat, Boston, MA 02130 USA.
[Calloway, Amber] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
[Toder, Katherine; Beck, Aaron T.; Crits-Christoph, Paul] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Miller, Christopher J.] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA 02130 USA.
RP Stirman, SW (reprint author), VA Boston Healthcare Syst, Vet Affairs VA Natl Ctr PTSD, Womens Hlth Sci Div, 150 S Huntington Ave 116B3, Boston, MA 02130 USA.
EM sws@bu.edu
FU National Institute of Mental Health (NIMH) [R00 MH01800, R25
MH080916-01A2]
FX The preparation of this report was supported through grant R00 MH01800
from the National Institute of Mental Health (NIMH). While the study was
being conducted, Dr. Wiltsey Stirman was receiving training from the
Implementation Research Institute at the George Warren Brown School of
Social Work, Washington University in St. Louis, which is funded through
NIMH award R25 MH080916-01A2 and the Department of Veterans Affairs,
Health Services Research and Development Service, Quality Enhancement
Research Initiative. The authors are grateful to the providers who
participated in the interviews and the agencies that participated in the
adult outpatient training program. J. Bryce McLaulin, M.D., and Matthew
Hurford, M.D., and the program's mentors and consultants also played
important roles in facilitating this research. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of NIMH, the National Institutes of Health, or the
Department of Veterans Affairs.
NR 11
TC 9
Z9 9
U1 1
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD OCT
PY 2013
VL 64
IS 10
BP 1056
EP 1059
DI 10.1176/appi.ps.201200456
PG 4
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255ZH
UT WOS:000327278200029
ER
PT J
AU Ostergaard, SD
AF Ostergaard, Soren Dinesen
TI The Evidence-Based Guide to Antidepressant Medications
SO PSYCHIATRIC SERVICES
LA English
DT Book Review
C1 [Ostergaard, Soren Dinesen] Aalborg Psychiat Hosp, Unit Psychiat Res, Aalborg, Denmark.
[Ostergaard, Soren Dinesen] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
RP Ostergaard, SD (reprint author), Aalborg Psychiat Hosp, Unit Psychiat Res, Aalborg, Denmark.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD OCT
PY 2013
VL 64
IS 10
BP E3
EP E3
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255ZH
UT WOS:000327278200003
ER
PT J
AU Gradl, G
Jupiter, JB
AF Gradl, G.
Jupiter, J. B.
TI Current Concepts Review - Fractures of the Shaft of the Humerus
SO ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA
LA English
DT Review
ID SHOULDER ARTHROPLASTY; DIAPHYSEAL FRACTURES; PLATE FIXATION; COMPRESSION
PLATE; FUNCTIONAL BRACE; ANTEGRADE; COMPLICATIONS; EPIDEMIOLOGY;
NONUNIONS; NAIL
AB Fractures of the shaft of the humerus are common injuries. Historically, the treatment of choice has been functional bracing. Recent technical advances such as angular stable plate and nail constructs lead to a shift in the treatment algorithm for this type of fracture. Surgical treatment is recommended in high grade open fractures, multilevel injury, polytrauma patients, nerve and serious vascular injuries, pathological fractures, and delayed or nonunions. This article aims to describe the published scientific data and current treatment modalities most suitable for each type of fracture.
C1 [Gradl, G.] Univ Aachen, Med Ctr, Dept Trauma & Reconstruct Surg, D-52074 Aachen, Germany.
[Jupiter, J. B.] Massachussetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA USA.
RP Gradl, G (reprint author), Univ Aachen, Med Ctr, Dept Trauma & Reconstruct Surg, Pauwelsstr 30, D-52074 Aachen, Germany.
EM ggradl@ukaachen.de
NR 34
TC 0
Z9 0
U1 2
U2 9
PU GALEN SRO
PI PRAGUE 5
PA NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC
SN 0001-5415
J9 ACTA CHIR ORTHOP TR
JI Acta Chir. Orthop. Traumatol. Cechoslov.
PD OCT
PY 2013
VL 80
IS 5
BP 321
EP 327
PG 7
WC Orthopedics
SC Orthopedics
GA 250JH
UT WOS:000326848600002
PM 25105672
ER
PT J
AU Hosoya, Y
Ando, S
Otani, H
Yukinari, T
Miyazaki, M
Garcia-Godoy, F
AF Hosoya, Yumiko
Ando, Susumu
Otani, Hedeji
Yukinari, Tetsubiro
Miyazaki, Masashi
Garcia-Godoy, Franklin
TI Ability of Barrier Coat S-PRG coating to arrest artificial enamel
lesions in primary teeth
SO AMERICAN JOURNAL OF DENTISTRY
LA English
DT Article
ID ELASTIC-MODULUS; NANO-HARDNESS; CANINE DENTIN; FLUORIDE; FILLER;
DEMINERALIZATION; REMINERALIZATION; PREVENTION; CARIES; LEVEL
AB Purpose: To evaluate the effects of a surface pre-reacted glass-ionomer (S-PRO) filled coating material to arrest artificial enamel lesions in primary teeth. Methods: Buccal and lingual enamel was demineralized in 0.1 M lactic acid buffer solution (pH 4.75) for 5 days and then divided in the PRO-applied and non-PRG areas. Proximal surfaces were used as a control area without demineralization and coating application. Teeth were divided into three groups (n= 4) according to the 1-week immersion in different solutions: Group 1 (distilled water), Group 2 (demineralizing solution) and Group 3 (artificial saliva). Hardness and Young's modulus by nano-indentation test, and elemental contents and ultrastructure by SEM/EDX analysis were obtained. Data were statistically analyzed using ANOVA and Fisher's PLSD at alpha= 0.05. Results: Only for the non-PRG area in Group 1, the hardness and Young's modulus of the demineralized surface enamel were significantly lower than those of the enamel 30-60 mu m beneath the surface. Demineralized enamel of non-PRG and PRO-applied areas showed similar SEM views. Only for the non-PRO area in Group 2 and control area in Group 3, the Ca/P of the surface enamel was significantly higher than that of the enamel 5-10 mu m beneath the surface. There was no significant difference of the Ca/P among the measuring points from the surface to 10 mu m depth of enamel for the PRG applied area in Group 2.
C1 [Hosoya, Yumiko] Nagasaki Univ, Grad Sch Biomed Sci, Course Med & Dent Sci, Dept Pediat Dent,Unit Translat Med, Nagasaki 8528588, Japan.
[Ando, Susumu; Miyazaki, Masashi] Nihon Univ, Sch Dent, Dept Operat Dent, Tokyo 101, Japan.
[Otani, Hedeji] Otani Dent Clin, Nayoro, Hokkaido, Japan.
[Yukinari, Tetsubiro] Yukinari Pediat & Orthodont Dent Clin, Nagasaki, Japan.
[Garcia-Godoy, Franklin] Univ Tennessee, Biosci Res Ctr, Coll Dent, Memphis, TN USA.
[Garcia-Godoy, Franklin] Forsyth Ctr, Cambridge, MA USA.
RP Hosoya, Y (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Course Med & Dent Sci, Dept Pediat Dent,Unit Translat Med, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.
EM hosoya@nagasaki-u.ac.jp
NR 19
TC 1
Z9 2
U1 1
U2 4
PU MOSHER & LINDER, INC
PI WESTON
PA 318 INDIAN TRACE SUITE 500, WESTON, FL 33326 USA
SN 0894-8275
J9 AM J DENT
JI Am. J. Dent.
PD OCT
PY 2013
VL 26
IS 5
BP 286
EP 290
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 251CP
UT WOS:000326905700010
PM 24479282
ER
PT J
AU Brumpton, B
Leivseth, L
Romundstad, PR
Langhammer, A
Chen, Y
Camargo, CA
Mai, XM
AF Brumpton, Ben Michael
Leivseth, Linda
Romundstad, Pal Richard
Langhammer, Arnulf
Chen, Yue
Camargo, Carlos Arturo, Jr.
Mai, Xiao-Mei
TI The joint association of anxiety, depression and obesity with incident
asthma in adults: the HUNT Study
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Body mass index; epidemiology; interaction; psychological distress
ID MENTAL-DISORDERS; PSYCHOSOCIAL FACTORS; GENERAL-POPULATION; HOSPITAL
ANXIETY; HEALTH SURVEY; COHORT; RISK; SYMPTOMS; STRESS; METAANALYSIS
AB Background Anxiety or depression symptoms may increase the risk of developing asthma, and their interaction with obesity is not known. We aimed to assess the association of anxiety or depression symptoms and the joint association of these symptoms and obesity with incident asthma.
Methods We conducted a prospective cohort study of 23 599 adults who were 19-55 years old and free from asthma at baseline in the Norwegian Nord-Tr circle divide ndelag Health Study. The Hospital Anxiety and Depression Scale was used to measure anxiety or depression symptoms. Obesity was defined as a body mass index epsilon 30.0 kg/m(2). Incident asthma was self-reported new cases of asthma during the 11-year follow-up.
Results Having anxiety or depression symptoms was associated with incident asthma [odds ratio (OR) 1.39, 95% confidence interval (CI) 1.09-1.78). Obese participants with anxiety or depression symptoms had a substantially higher risk of incident asthma (OR 2.93, 95% CI 2.20-3.91) than any other group (non-obese participants without anxiety or depression symptoms [reference], non-obese participants with anxiety or depression symptoms (OR 1.20, 95% CI 1.00-1.45) and obese participants without anxiety or depression symptoms (OR 1.47, 95% CI 1.19-1.82)]. The relative excess risk for incident asthma due to interaction between anxiety or depression symptoms and obesity was 1.26 (95% CI 0.39-2.12).
Conclusions This study suggests that having anxiety or depression symptoms contributes to the development of asthma in adults. The risk of asthma may be further increased by the interaction between anxiety or depression symptoms and obesity.
C1 [Brumpton, Ben Michael; Leivseth, Linda; Romundstad, Pal Richard; Langhammer, Arnulf; Mai, Xiao-Mei] Norwegian Univ Sci & Technol, Fac Med, Dept Publ Hlth & Gen Practice, N-7034 Trondheim, Norway.
[Chen, Yue] Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
[Camargo, Carlos Arturo, Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Brumpton, B (reprint author), NTNU, Fak Med, Inst Samfunnsmed, MTFS, Postboks 8905, N-7491 Trondheim, Norway.
EM ben.brumpton@ntnu.no
RI Osborne, Nicholas/N-4915-2015;
OI Osborne, Nicholas/0000-0002-6700-2284; Romundstad, Pal
Richard/0000-0003-2061-4336
FU Research Council of Norway [201895/V50]; Faculty of Medicine at the
Norwegian University of Science and Technology
FX This study was supported by the Research Council of Norway (project no.
201895/V50) and the Faculty of Medicine at the Norwegian University of
Science and Technology.
NR 48
TC 8
Z9 8
U1 2
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD OCT
PY 2013
VL 42
IS 5
BP 1455
EP 1463
DI 10.1093/ije/dyt151
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 248TI
UT WOS:000326726000037
PM 24008330
ER
PT J
AU Kendler, DL
Borges, JLC
Fielding, RA
Itabashi, A
Krueger, D
Mulligan, K
Camargos, BM
Sabowitz, B
Wu, CH
Yu, EW
Shepherd, J
AF Kendler, David L.
Borges, Joao L. C.
Fielding, Roger A.
Itabashi, Akira
Krueger, Diane
Mulligan, Kathleen
Camargos, Bruno M.
Sabowitz, Brian
Wu, Chih-Hsing
Yu, Elaine W.
Shepherd, John
TI The Official Positions of the International Society for Clinical
Densitometry: Indications of Use and Reporting of DXA for Body
Composition
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE Body composition; DXA; obesity; sarcopenia
ID X-RAY ABSORPTIOMETRY; BONE-MINERAL DENSITY; PLACEBO-CONTROLLED TRIAL;
VISCERAL ADIPOSE-TISSUE; GASTRIC BYPASS-SURGERY; HIV-INFECTED PATIENTS;
OBESE OLDER-ADULTS; TRANSCRIPTASE INHIBITOR THERAPY; HORMONE-RELEASING
FACTOR; PLUS DUAL NUCLEOSIDES
AB The technique of body composition by dual-energy X-ray absorptiometry (DXA) has been used for several years in the research environment. Its ability to accurately, and precisely measure lean, fat, and mineral composition in various body compartments has been well validated. Furthermore, the technique is widely available to clinical patients on existing DXA instruments throughout the world through the use of specific software packages and scanning algorithms. There have been few clear statements regarding the clinical indications for body composition measurement in patients outside the research setting. This is in part because of the lack of specific documented interventions that would be affected by body composition test results, beyond usual clinical advice. We have examined a few of the most common, specific scenarios (HIV therapy, sarcopenia, bariatric surgery, obesity) and proposed indications for body composition assessment. We have also discussed contraindications to body composition testing.
C1 [Kendler, David L.] Univ British Columbia, Vancouver, BC V5Z 4E1, Canada.
[Borges, Joao L. C.] Univ Catolica Brasilia, Brasilia, DF, Brazil.
[Fielding, Roger A.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr Exercise Physiol & Sarcopenia Lab, Boston, MA 02111 USA.
[Krueger, Diane] Univ Wisconsin, Madison, WI USA.
[Mulligan, Kathleen; Shepherd, John] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Camargos, Bruno M.] Hosp Mater Dei, Belo Horizonte, MG, Brazil.
[Wu, Chih-Hsing] Natl Cheng Kung Univ Hosp, Dept Family Med, Tainan 70428, Taiwan.
[Yu, Elaine W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Kendler, DL (reprint author), Univ British Columbia, 150-943 W Broadway, Vancouver, BC V5Z 4E1, Canada.
EM davidkendler@gmail.com
OI Camargos, Bruno/0000-0002-3132-6455; Kendler, David/0000-0001-7679-3965
FU US Department of Agriculture [58-1950-0-014]
FX The contribution by RAF is partially supported by the US Department of
Agriculture under agreement no. 58-1950-0-014. Any opinions, findings,
conclusion, or recommendations expressed in this publication are those
of the authors and do not necessarily reflect the view of the US
Department of Agriculture.
NR 139
TC 18
Z9 18
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1094-6950
EI 1559-0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD OCT-DEC
PY 2013
VL 16
IS 4
BP 496
EP 507
DI 10.1016/j.jocd.2013.08.020
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 250KK
UT WOS:000326851500019
PM 24090645
ER
PT J
AU Petak, S
Barbu, CG
Yu, EW
Fielding, R
Mulligan, K
Sabowitz, B
Wu, CH
Shepherd, JA
AF Petak, Steven
Barbu, Carmen G.
Yu, Elaine W.
Fielding, Roger
Mulligan, Kathleen
Sabowitz, Brian
Wu, Chih-Hsing
Shepherd, John A.
TI The Official Positions of the International Society for Clinical
Densitometry: Body Composition Analysis Reporting
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE Adipose mass; body composition; bone mineral density; lean mass; whole
body
ID ENERGY X-RAY; CARDIOVASCULAR RISK-FACTORS; SKELETAL-MUSCLE MASS;
FAT-FREE MASS; ADIPOSE-TISSUE; LEAN MASS; VISCERAL FAT; ALTERNATIVE
DEFINITIONS; CARDIOMETABOLIC RISK; WAIST CIRCUMFERENCE
AB Dual-energy x-ray absorptiometry (DXA) measurements of body composition increasingly are used in the evaluation of clinical disorders, but there has been little guidance on how to effectively report these measures. Uniformity in reporting of body composition measures will aid in the diagnosis of clinical disorders such as obesity, sarcopenia, and lipodystrophy. At the 2013 International Society for Clinical Densitometry Position Development Conference on body composition, the reporting section recommended that all DXA body composition reports should contain parameters of body mass index, bone mineral density, BMC, total mass, total lean mass, total fat mass, and percent fat mass The inclusion of additional measures of adiposity and lean mass are optional, including visceral adipose tissue, appendicular lean mass index, android/gynoid percent fat ratio, trunk to leg fat mass ratio, lean mass index, and fat mass index. Within the United States, we recommend the use of the National Health and Nutrition Examination Survey 1999-2004 body composition dataset as an age-, gender-, and race-specific reference and to calibrate BMC in 4-compartment models. Z-scores and percentiles of body composition measures may be useful for clinical interpretation if methods are used to adjust for non-normality. In particular, DXA body composition measures may be useful for risk-stratification of obese and sarcopenia patients, but there needs to be validation of thresholds to define obesity and sarcopenia. To summarize, these guidelines provide evidence-based standards for the reporting and clinical application of DXA-based measures of body, composition.
C1 [Petak, Steven] Houston Methodist Hosp, Dept Med, Houston, TX 77030 USA.
[Barbu, Carmen G.] Carol Davila Univ, Elias Hosp, Dept Endocrinol, Bucharest, Romania.
[Yu, Elaine W.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
[Fielding, Roger] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr Exercise Physiol & Sarcopenia Lab, Boston, MA 02111 USA.
[Mulligan, Kathleen; Shepherd, John A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Sabowitz, Brian] Univ Texas Hlth Sci Ctr San Antonio, Dept Endocrinol Diabet & Metab, San Antonio, TX 78229 USA.
[Wu, Chih-Hsing] Natl Cheng Kung Univ Hosp, Dept Family Med, Tainan 70428, Taiwan.
RP Petak, S (reprint author), Houston Methodist Hosp, Dept Med, Smith Tower Suite 1001, Houston, TX 77030 USA.
EM spetak@petak.com
FU US Department of Agriculture [58-1950-0-014]
FX RF was supported by the US Department of Agriculture, agreement No.
58-1950-0-014. Any opinions, findings, conclusion, or recommendations
expressed in this publication are those of the author and do not
necessarily reflect the view of the US Department of Agriculture. We
appreciate the comments received from representatives of instrument
manufacturers, including Kevin Wilson, Tom Kelly, Tom Sanchez, and David
Ergun.
NR 91
TC 23
Z9 23
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1094-6950
EI 1559-0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD OCT-DEC
PY 2013
VL 16
IS 4
BP 508
EP 519
DI 10.1016/j.jocd.2013.08.018
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 250KK
UT WOS:000326851500020
PM 24183640
ER
PT J
AU Chapman, S
Dobrovolskai, M
Farahani, K
Goodwin, A
Joshi, A
Lee, H
Meade, T
Pomper, M
Ptak, K
Rao, JH
Singh, R
Sridhar, S
Stern, S
Wang, A
Weaver, JB
Woloschak, G
Yang, L
AF Chapman, Sandra
Dobrovolskai, Marina
Farahani, Keyvan
Goodwin, Andrew
Joshi, Amit
Lee, Hakho
Meade, Thomas
Pomper, Martin
Ptak, Krzysztof
Rao, Jianghong
Singh, Ravi
Sridhar, Srinivas
Stern, Stephan
Wang, Andrew
Weaver, John B.
Woloschak, Gayle
Yang, Lily
TI Nanoparticles for cancer imaging: The good, the bad, and the promise
SO NANO TODAY
LA English
DT Article
DE Nanonnedicine; Cancer; Imaging; Detection; Screening
ID PARTICLES; CLEARANCE; MOLECULES
AB Recent advances in molecular imaging and nanotechnology are providing new opportunities for biomedical imaging with great promise for the development of novel imaging agents. The unique optical, magnetic, and chemical properties of materials at the scale of nanometers allow the creation of imaging probes with better contrast enhancement, increased sensitivity, controlled biodistribution, better spatial and temporal information, multi-functionality and multi-modal imaging across MRI, PET, SPECT, and ultrasound. These features could ultimately translate to clinical advantages such as earlier detection, real time assessment of disease progression and personalized medicine. However, several years of investigation into the application of these materials to cancer research has revealed challenges that have delayed the successful application of these agents to the field of biomedical imaging. Understanding these challenges is critical to take full advantage of the benefits offered by nano-sized imaging agents. Therefore, this article presents the lessons learned and challenges encountered by a group of leading researchers in this field, and suggests ways forward to develop nanoparticle probes for cancer imaging. Published by Elsevier Ltd.
C1 [Chapman, Sandra] NCI, Off Canc Nanotechnol Res, Ctr Strateg Sci Initiat, NIH, Bethesda, MD 20892 USA.
[Dobrovolskai, Marina; Stern, Stephan] SAIC Frederick Inc, Nanotechnol Characterizat Lab, Adv Technol Res Facil, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
[Farahani, Keyvan] NCI, Image Guided Intervent Branch, Canc Imaging Program, Rockville, MD 20852 USA.
[Goodwin, Andrew] Univ Colorado Boulder, Dept Chem & Biol Engn, Boulder, CO 80303 USA.
[Joshi, Amit] Baylor Coll Med, Dept Radiol, TBMM Grad Program, Houston, TX 77030 USA.
[Joshi, Amit] Baylor Coll Med, Dept Mol Physiol & Biophys, TBMM Grad Program, Houston, TX 77030 USA.
[Lee, Hakho] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA.
[Meade, Thomas] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA.
[Meade, Thomas] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA.
[Meade, Thomas] Northwestern Univ, Dept Radiol, Evanston, IL 60208 USA.
[Pomper, Martin] Johns Hopkins Med Sch, Baltimore, MD 21287 USA.
[Ptak, Krzysztof] NCI, Off Canc Ctr, Off Director, NIH, Bethesda, MD 20892 USA.
[Rao, Jianghong] Stanford Univ, Mol Imaging Program Stanford, Dept Radiol, Stanford, CA 94305 USA.
[Singh, Ravi] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.
[Sridhar, Srinivas] Northeastern Univ, Nanomedicine Sci & Technol Ctr, Boston, MA 02115 USA.
[Sridhar, Srinivas] Northeastern Univ, Dept Phys, Boston, MA 02115 USA.
[Wang, Andrew] Univ N Carolina, Dept Radiat Oncol, Carolina Ctr Nanotechnol Excellence, Chapel Hill, NC 27599 USA.
[Weaver, John B.] Dartmouth Coll, Geisel Sch Med, Dept Radiol, Hanover, NH 03755 USA.
[Woloschak, Gayle] Northwestern Univ, Dept Radiat Oncol, Robert E Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Woloschak, Gayle] Northwestern Univ, Dept Radiol, Robert E Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Woloschak, Gayle] Northwestern Univ, Dept Cell & Mol Biol, Robert E Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Yang, Lily] Emory Univ Sch Med, Dept Surg, Atlanta, GA 30322 USA.
RP Chapman, S (reprint author), NCI, Off Canc Nanotechnol Res, Ctr Strateg Sci Initiat, NIH, Bethesda, MD 20892 USA.
EM chapmansandra.e@gmail.com; jrao@stanford.edu; s.sridhar@neu.edu;
g-woloschak@northwestern.edu
RI Chapman, Sandra/I-8889-2014; Nanotechnology Characterization Lab,
NCL/K-8454-2012; Singh, Ravi/A-5740-2011; Woloschak, Gayle/A-3799-2017;
OI Chapman, Sandra/0000-0002-9202-336X; Singh, Ravi/0000-0003-0750-1804;
Woloschak, Gayle/0000-0001-9209-8954; Wang, Andrew/0000-0002-9781-4494
FU CCR NIH HHS [HHSN261200800001C]; NCI NIH HHS [R01 CA178748,
HHSN261200800001E, R00 CA154006]
NR 16
TC 37
Z9 37
U1 6
U2 70
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1748-0132
EI 1878-044X
J9 NANO TODAY
JI Nano Today
PD OCT
PY 2013
VL 8
IS 5
BP 454
EP 460
DI 10.1016/j.nantod.2013.06.001
PG 7
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 252HK
UT WOS:000326995500005
PM 25419228
ER
PT J
AU Benacerraf, B
AF Benacerraf, Beryl
TI The use of obstetrical ultrasound in the obese gravida
SO SEMINARS IN PERINATOLOGY
LA English
DT Review
DE Ultrasound; Obesity; Fetal anomalies; Ultrasound technique
ID MATERNAL OBESITY; OVERWEIGHT; VISUALIZATION; SONOGRAPHY; WOMEN
AB Obesity is an epidemic in the United States, especially among the pregnant population. Obesity is responsible for an increase in fetal anomalies and adverse outcome of both mother and fetus. Due to difficulty in penetrating to the depth of the uterus, the ultrasound image in obese patients is inadequate, fuzzy, and high in artifacts. Hence, obese patients often require multiple scans as well as special scanning techniques just to get borderline image quality. These techniques and the data regarding quality and frequency of scans for the obese pregnant population are discussed in this paper. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Benacerraf, Beryl] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Benacerraf, Beryl] Brigham & Womens Hosp, Dept OB GYN, Boston, MA 02115 USA.
[Benacerraf, Beryl] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept OBGYN, Boston, MA USA.
RP Benacerraf, B (reprint author), 1 Brookline Pl, Brookline, MA 02445 USA.
EM bbsono@aol.com
NR 11
TC 5
Z9 5
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0146-0005
EI 1558-075X
J9 SEMIN PERINATOL
JI Semin. Perinatol.
PD OCT
PY 2013
VL 37
IS 5
BP 345
EP 347
DI 10.1053/j.semperi.2013.06.012
PG 3
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 251FG
UT WOS:000326912600013
PM 24176158
ER
PT J
AU Mananga, ES
AF Mananga, Eugene Stephane
TI Applications of Floquet-Magnus expansion, average Hamiltonian theory and
Fer expansion to study interactions in solid state NMR when irradiated
with the magic-echo sequence
SO SOLID STATE NUCLEAR MAGNETIC RESONANCE
LA English
DT Article
DE Solid-state NMR; Floquet-Magnus expansion; Fer expansion; Average
Hamiltonian theory; Magic-echo sequence; NMR interactions
ID QUADRUPOLAR NUCLEI; SAMPLE ROTATION; SPIN SYSTEMS; SPECTROSCOPY;
RESONANCE; SIMULATION; DYNAMICS; I=1
AB This work presents the possibility of applying the Floquet-Magnus expansion and the For expansion approaches to the most useful interactions known in solid-state nuclear magnetic resonance using the magic-echo scheme. The results of the effective Hamiltonians of these theories and average Hamiltonian theory are presented. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Mananga, Eugene Stephane] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Mananga, Eugene Stephane] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging Phys, Dept Radiol, Boston, MA 02114 USA.
RP Mananga, ES (reprint author), Harvard Univ, Sch Med, 55 Fruit St, Boston, MA 02114 USA.
EM emananga@pet.mgh.harvard.edu
FU National Institute of Health (NIH) [R01-HL110241, T32 EB013180]
FX E.S. Mananga acknowledges assistance from Harvard University, Harvard
Medical School, Massachusetts General Hospital, and the National
Institute of Health (NIH), under Grants R01-HL110241 and T32 EB013180.
The contents of this paper are solely the responsibility of the author
and do not represent the official views of NIH.
NR 43
TC 8
Z9 8
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0926-2040
EI 1527-3326
J9 SOLID STATE NUCL MAG
JI Solid State Nucl. Magn. Reson.
PD OCT-NOV
PY 2013
VL 55-56
BP 54
EP 62
DI 10.1016/j.ssnmr.2013.08.002
PG 9
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical; Physics,
Condensed Matter; Spectroscopy
SC Chemistry; Physics; Spectroscopy
GA 254AQ
UT WOS:000327132700006
PM 24034855
ER
PT J
AU Mananga, ES
AF Mananga, Eugene Stephane
TI Criteria to average out the chemical shift anisotropy in solid-state NMR
when irradiated with BABA I, BABA II, and C7 radiofrequency pulse
sequences
SO SOLID STATE NUCLEAR MAGNETIC RESONANCE
LA English
DT Article
DE Solid-state NMR; Floquet-Magnus expansion; CSA; BABA pulse sequence; C7
pulse sequence
ID ANGLE-SPINNING NMR; NUCLEAR-MAGNETIC-RESONANCE; ROTATING SOLIDS; QUANTUM
NMR; DISTANCE MEASUREMENTS; SPECTROSCOPY; SIMULATION
AB Floquet-Magnus expansion is used to study the effect of chemical shift anisotropy in solid-state NMR of rotating solids. The chemical shift interaction is irradiated with two types of radiofrequency pulse sequences: BABA and C7. The criteria for the chemical shift anisotropy to be averaged out in each rotor period are obtained. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Mananga, Eugene Stephane] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Mananga, Eugene Stephane] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging Phys, Dept Radiol, Boston, MA 02114 USA.
RP Mananga, ES (reprint author), Harvard Univ, Sch Med, 55 Fruit St, Boston, MA 02114 USA.
EM emananga@pet.mgh.harvard.edu
FU National Institute of Health (NIH) [R01-HL110241, T32 EB013180]
FX E.S. Mananga acknowledges assistance from Massachusetts General
Hospital, Harvard Medical School, and the National Institute of Health
(NIH), under Grants R01-HL110241 and T32 EB013180. The contents of this
paper are solely the responsibility of the authors and do not represent
the official views of NIH.
NR 34
TC 6
Z9 6
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0926-2040
EI 1527-3326
J9 SOLID STATE NUCL MAG
JI Solid State Nucl. Magn. Reson.
PD OCT-NOV
PY 2013
VL 55-56
BP 63
EP 72
DI 10.1016/j.ssnmr.2013.08.003
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical; Physics,
Condensed Matter; Spectroscopy
SC Chemistry; Physics; Spectroscopy
GA 254AQ
UT WOS:000327132700007
ER
PT J
AU Cayabyab, MJ
Qin, LZ
Kashino, SS
Izzo, A
Campos-Neto, A
AF Cayabyab, Mark J.
Qin, Lizeng
Kashino, Suely S.
Izzo, Angelo
Campos-Neto, Antonio
TI An unbiased peptide-wide discovery approach to select Mycobacterium
tuberculosis antigens that target CD8+T cell response during infection
SO VACCINE
LA English
DT Article
DE Tuberculosis; CD8 associated antigen; MT0401; Immunogenicity
ID CD8(+) T-CELLS; RECOMBINANT ADENOVIRAL VECTORS; IN-VIVO; GAMMA; GENE;
VACCINATION; VIRUS; PROTECTION; INDUCTION; PRIMATES
AB Accruing data strongly support the possible role of CD8+ T cells in immunity against tuberculosis (TB). Multivalent vaccines against Mycobacterium tuberculosis (Mtb) that incorporate CD8+ T cell antigens with those that elicit CD4+ T cells are therefore highly desirable. To screen for potential CD8+ T cell antigens that are produced by Mtb during infection, we isolated pathogen-derived peptides that bound to MHC Class I molecules expressed in adherent splenocytes obtained from Mtb-infected mice. Mass spectroscopy analysis revealed the following four nonamer peptides that had 100% homology with Mtb proteins: DGYVGAPAH (MT_0401), TTMPLFAD (MT_1164), RSGAATPVR (MT_2160.1) and LAAVVGVVL (MT_0078). The gene MT_0401 codes the protein 5'-phosphoribosylglycinamide transformylase 2 and the other three genes code for hypothetical proteins with unknown function. The NCBI/Blast analysis showed that among the four peptides DGYVGAPAH had the highest maximum alignment score and lowest E value (number of alignments expected by chance). Therefore, we assessed whether MT_0401 expressed in two genetic vaccine formulations was capable of stimulating CD8+ T cell response that is specific to DGYVGAPAH peptide. When mice were immunized with a recombinant plasmid DNA and an E1/E3-deleted Adenovirus 5 expressing MT0401 protein, using both homologous and heterologous prime-boost protocols, they developed strong DGYVGAPAH-specific CD8+ T cell response as well as antibody and CD4+ specific T cell response to the full length MT0401 protein. Equally important was the observation that mice infected with Mtb developed DGYVGAPAH-specific CD8+ T cell responses in both spleen and lungs. These results demonstrate that Mtb antigens that are processed and presented via MHC Class I machinery can be readily identified by the described approach and may be useful candidate antigens to stimulate specific CD8+ T cell responses in vaccine development programs. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Cayabyab, Mark J.; Campos-Neto, Antonio] Forsyth Inst, Global Infect Dis Res Ctr, Cambridge, MA 02142 USA.
[Cayabyab, Mark J.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Izzo, Angelo] Colorado State Univ, Dept Pathol & Immunol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA.
[Qin, Lizeng] Novartis Corp, Cambridge, MA USA.
[Kashino, Suely S.] Adolpho Lutz Inst, Sao Paulo, Brazil.
RP Campos-Neto, A (reprint author), Forsyth Inst, Global Infect Dis Res Ctr, 245 1st St, Cambridge, MA 02142 USA.
EM acampos@forsyth.org
RI Izzo, Angelo/F-1229-2017
OI Izzo, Angelo/0000-0003-3208-2330
FU National Institutes of Health [R01AI076425]; Harvard University Center
for AIDS Research
FX This work was supported by a grant from the National Institutes of
Health to A.C-N (R01AI076425). MC was supported in part by the Harvard
University Center for AIDS Research.
NR 33
TC 2
Z9 4
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 1
PY 2013
VL 31
IS 42
BP 4834
EP 4840
DI 10.1016/j.vaccine.2013.07.077
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 249IY
UT WOS:000326772100025
PM 23933335
ER
PT J
AU Jung, M
Lin, L
Viswanath, K
AF Jung, Minsoo
Lin, Leesa
Viswanath, K.
TI Associations between health communication behaviors, neighborhood social
capital, vaccine knowledge, and parents' H1N1 vaccination of their
children
SO VACCINE
LA English
DT Article
DE H1N1; Vaccination; Child; Social determinants; Health communication;
Social capital
ID INFLUENZA VACCINATION; RISK PERCEPTION; TEACHERS; INEQUALITIES;
POPULATION; PREDICTORS; MONOVALENT; STUDENTS; BELIEFS; CANCER
AB During the H1N1 pandemic in 2009-10, the vaccination behavior of parents played a critical role in preventing and containing the spread of the disease and the subsequent health outcomes among children. Several studies have examined the relationship between parents' health communication behaviors and vaccinations for children in general. Little is known, however, about the link between parents' health communication behaviors and the vaccination of their children against the H1N1 virus, and their level of vaccine-related knowledge. We drew on a national survey among parents with at least one child less than 18 years of age (n = 639) to investigate Parents' H1N1-related health communication behaviors including sources of information, media exposure, information-seeking behaviors, H1N1-related knowledge, and neighborhood social capital, as well as the H1N1 vaccination rates of their children. Findings showed that there is a significant association between the degree at which parents obtained H1N1 vaccination for their children and health communication variables: watching the national television news and actively seeking H1N1 information. And this association was moderated by the extent of the parents' H1N1-related knowledge. In addition, the parents' degree of neighborhood social capital mediated the association between H1N1 knowledge of the parents and H1N1 vaccination acceptance for their children. We found, compared to those with a low-level of neighborhood social capital, parents who have a high-level of neighborhood social capital are more likely to vaccinate their children. These findings suggest that it is necessary to design a strategic health communication campaign segmented by parent health communication behaviors. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Jung, Minsoo; Lin, Leesa; Viswanath, K.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
[Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, Seoul, South Korea.
[Lin, Leesa; Viswanath, K.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
RP Jung, M (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave,LW 601, Boston, MA 02215 USA.
EM minsoo_jung@dfci.harvard.edu
OI Jung, Minsoo/0000-0003-3317-6507
FU Harvard School of Public Health Preparedness and Emergency Response
Center (Harvard PERRC), CDC [5PO1TP000307-05]
FX This project was funded by the Harvard School of Public Health
Preparedness and Emergency Response Center (Harvard PERRC) - Linking
Assessment and Measurement to Performance in PHEP Systems (LAMPS), CDC
grant number: 5PO1TP000307-05. The content of this publication as well
as the views and discussions expressed in this paper are solely those of
the authors and do not necessarily represent the views of any partner
organizations, the CDC or the U.S. Department of Health and Human
Services nor does mention of trade names, commercial practices, or
organizations imply endorsement by the U.S. Government.
NR 37
TC 15
Z9 15
U1 1
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 1
PY 2013
VL 31
IS 42
BP 4860
EP 4866
DI 10.1016/j.vaccine.2013.07.068
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 249IY
UT WOS:000326772100029
PM 23954379
ER
PT J
AU Robinson, TN
Wu, DS
Pointer, L
Dunn, CL
Cleveland, JC
Moss, M
AF Robinson, Thomas N.
Wu, Daniel S.
Pointer, Lauren
Dunn, Christina L.
Cleveland, Joseph C., Jr.
Moss, Marc
TI Simple frailty score predicts postoperative complications across
surgical specialties
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Geriatric surgery; Preoperative risk assessment; Surgical morbidity
ID OLDER-ADULTS; NONCARDIAC SURGERY; ELDERLY-PATIENTS; CO-MORBIDITY; CARE;
MORTALITY; RISK; POPULATION; VALIDATION; SEVERITY
AB BACKGROUND: Our purpose was to determine the relationship between preoperative frailty and the occurrence of postoperative complications after colorectal and cardiac operations.
METHODS: Patients 65 years or older undergoing elective colorectal or cardiac surgery were enrolled. Seven baseline frailty traits were measured preoperatively: Katz score less than or equal to 5, Timed Up and Go test greater than or equal to 15 seconds, Charlson Index greater than or equal to 3, anemia less than 35%, Mini-Cog score less than or equal to 3, albumin less than 3.4 g/dL, and 1 or more falls within 6 months. Patients were categorized by the number of positive traits as follows: non-frail: 0 to 1 traits, prefrail: 2 to 3 traits, and frail: 4 or more traits.
RESULTS: Two hundred one subjects (age 74 +/- 6 years) were studied. Preoperative frailty was associated with increased postoperative complications after colorectal (nonfrail: 21%, prefrail: 40%, frail: 58%; P = .016) and cardiac operations (nonfrail: 17%, prefrail: 28%, frail: 56%; P < .001). This finding in both groups was independent of advancing age. Frail individuals in both groups had longer hospital stays and higher 30-day readmission rates. Receiver operating characteristic curves examining frailty's ability to forecast complications were colorectal (.702, P = .004) and cardiac (. 711, P < .001).
CONCLUSIONS: A simple preoperative frailty score defines older adults at higher risk for postoperative complications across surgical specialties. Published by Elsevier Inc.
C1 [Robinson, Thomas N.; Wu, Daniel S.; Dunn, Christina L.; Cleveland, Joseph C., Jr.] Univ Colorado Denver Sch Med, Dept Surg, Aurora, CO 80045 USA.
[Moss, Marc] Univ Colorado Denver Sch Med, Dept Med, Aurora, CO 80045 USA.
[Robinson, Thomas N.; Wu, Daniel S.; Cleveland, Joseph C., Jr.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA.
[Pointer, Lauren] Denver Vet Affairs Med Ctr, Dept Biostat, Denver, CO USA.
RP Robinson, TN (reprint author), Univ Colorado Denver Sch Med, Dept Surg, 12631 East 17th Ave,MS C313, Aurora, CO 80045 USA.
EM thomas.robinson@ucdenver.edu
FU Paul B. Beeson Award [NIA K23AG034632]; Dennis W. Jahnigen Award;
American Geriatrics Society; National Institutes of Health
[K24-HL-089223]
FX Supported by the Paul B. Beeson Award (NIA K23AG034632 [TNR]), Dennis W.
Jahnigen Award, American Geriatrics Society (TNR) and National
Institutes of Health (K24-HL-089223 [MM]).
NR 26
TC 76
Z9 76
U1 3
U2 11
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
EI 1879-1883
J9 AM J SURG
JI Am. J. Surg.
PD OCT
PY 2013
VL 206
IS 4
BP 544
EP 550
DI 10.1016/j.amjsurg.2013.03.012
PG 7
WC Surgery
SC Surgery
GA 246BF
UT WOS:000326510500016
PM 23880071
ER
PT J
AU An, HM
Tan, YL
Shi, J
Wang, ZR
Li, J
Wang, YC
Kosten, TR
Zhou, DF
Yang, FD
Zhang, XY
AF An, Hui-Mei
Tan, Yun-Long
Shi, Jing
Wang, Zhi-Ren
Li, Jia
Wang, Yue-Chan
Kosten, Thomas R.
Zhou, Dong Feng
Yang, Fu-De
Zhang, Xiang-Yang
TI Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and
preventing vacuous chewing movements in a rat model of tardive
dyskinesia
SO BEHAVIOURAL PHARMACOLOGY
LA English
DT Article
DE animal model; antioxidant; extract of Ginkgo biloba; free radical; rat;
tardive dyskinesia; vacuous chewing movements; vitamin E
ID INDUCED OROFACIAL DYSKINESIA; PLACEBO-CONTROLLED TRIAL; LONG-TERM
TREATMENT; DOUBLE-BLIND; JAW MOVEMENTS; POSSIBLE INVOLVEMENT;
ANIMAL-MODELS; SUPEROXIDE-DISMUTASE; PARKINSONIAN TREMOR; OXIDATIVE
STRESS
AB Free radical-mediated abnormalities may contribute toward the pathogenesis of tardive dyskinesia (TD). Many studies have reported the protective antioxidant and free radical-scavenging activities of extract of Ginkgo biloba (EGb761) against free radical-induced cell damage and dysfunction. This study aimed to compare the efficacy of EGb761 with that of vitamin E for the prevention and treatment of TD in a rat model. We carried out two studies. First, rats were injected with haloperidol (2 mg/kg intraperitoneally) daily for 5 weeks. EGb761 (50mg/kg/day) or vitamin E (20mg/kg/day) were then administered for another 5 weeks, and their effects on vacuous chewing movements (VCMs) were compared. Second, we compared 10 weeks of haloperidol alone with 10 weeks of haloperidol plus EGb761 or vitamin E. The administration of haloperidol led to a progressive increase in VCMs, which peaked at week 5. In study one, EGb761 and vitamin E, administered by an oral gavage for 5 weeks during withdrawal from chronic haloperidol treatment, decreased VCMs significantly, showing 83.8 and 91.0% reduction, respectively, compared with the haloperidol-alone group. In study two, the concomitant administration of EGb761 and vitamin E led to significantly fewer VCMs, by 64.4 and 73.9%, respectively, compared with the haloperidol-alone group. There was no significant difference in either study between EGb761 and vitamin E treatment. EGb761 shows promise for the prevention and treatment of TD in a rat model with a magnitude that was similar to that of vitamin E. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [An, Hui-Mei; Tan, Yun-Long; Shi, Jing; Wang, Zhi-Ren; Li, Jia; Wang, Yue-Chan; Yang, Fu-De; Zhang, Xiang-Yang] Peking Univ, Beijing Huilongguan Hosp, Psychiat Res Ctr, Beijing 100871, Peoples R China.
[Zhou, Dong Feng] Peking Univ, Inst Mental Hlth, Beijing 100871, Peoples R China.
[Kosten, Thomas R.; Zhang, Xiang-Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Kosten, Thomas R.; Zhang, Xiang-Yang] Michael E DeBakey VA Med Ctr, Houston, TX USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu
FU National Natural Science Foundation of China [30770782, 81071086];
Stanley Medical Research Institute [03T-459, 05T-726]; United States
National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639]
FX This work was supported by grants from the National Natural Science
Foundation of China (30770782, 81071086), the Stanley Medical Research
Institute (03T-459 and 05T-726), and the United States National
Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639.
NR 71
TC 3
Z9 3
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0955-8810
EI 1473-5849
J9 BEHAV PHARMACOL
JI Behav. Pharmacol.
PD OCT
PY 2013
VL 24
IS 7
BP 610
EP 616
DI 10.1097/FBP.0b013e3283656d87
PG 7
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 251YP
UT WOS:000326971200008
PM 23994817
ER
PT J
AU Johnson, GJ
Leis, LA
Slater, BCS
Bach, RR
AF Johnson, Gerhard J.
Leis, Linda A.
Slater, Billie C. S.
Bach, Ronald R.
TI Elevated platelet count, C-reactive protein and thromboxane
analog-induced platelet aggregation in patients with Gulf War veterans'
illnesses: evidence of a chronic inflammatory state?
SO BLOOD COAGULATION & FIBRINOLYSIS
LA English
DT Article
DE C-reactive protein; Gulf War illness; platelet aggregation; platelet
secretion; thromboxane A(2)
ID CHRONIC-FATIGUE-SYNDROME; THROMBOCYTOSIS; DYSFUNCTION; ACTIVATION; LINK
AB A previous study of Gulf War veteran's illnesses (GWVI) observed evidence of platelet activation in a majority of patients with GWVI. To further characterize platelet function, we studied 43 patients (40 men) with GWVI (GWVI+) and 21 veterans who served concurrently in the Gulf War but who lacked criteria for GWVI (GWVI-). All participants were free of infection and known inflammatory diseases. Studies performed included platelet count, immature platelet fraction (IPF), plasma thrombopoietin (TPO), C-reactive protein (CRP), platelet aggregation and ATP secretion in response to six agonists, and spontaneous aggregation. Platelet counts and CRP were significantly elevated in GWVI+ compared to GWVI- patients without elevation in IPF or TPO. Platelet aggregation did not differ between GWVI+ and GWVI- patients except for spontaneous aggregation that was significantly greater in GWVI+ patients. Platelet ATP secretion was similar in the two groups, except the response to 50mol/l thrombin receptor agonist peptide 6 (TRAP 6) was significantly greater in GWVI+ patients. When platelet aggregation was analyzed in relation to CRP, the response to 0.5mol/l U46619 was significantly greater in patients whose CRP was at least 2g/ml. Therefore, GWVI+ patients had elevated platelet counts, spontaneous aggregation, TRAP 6-induced secretion, and CRP, but no impairment of platelet function. The increased platelet counts and U46619-induced aggregation appear to be consequences of an underlying inflammatory state in GWVI. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Johnson, Gerhard J.; Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] VA Healthcare Syst, Minneapolis, MN 55417 USA.
[Johnson, Gerhard J.; Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] Univ Minnesota, Minneapolis, MN USA.
[Leis, Linda A.; Slater, Billie C. S.; Bach, Ronald R.] Univ Minnesota, US Dept Vet Affairs, Res Serv, Minneapolis, MN USA.
[Johnson, Gerhard J.] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplant, Minneapolis, MN 55455 USA.
RP Johnson, GJ (reprint author), VA Healthcare Syst, Hematol Oncol 111E,1 Vet Dr, Minneapolis, MN 55417 USA.
EM johns337@umn.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development; US Department of Defense, Gulf War Illness
Research Programs
FX Source of support for the work: This material is based upon work
supported by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, and by the US
Department of Defense, Gulf War Illness Research Programs.
NR 25
TC 5
Z9 5
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0957-5235
EI 1473-5733
J9 BLOOD COAGUL FIBRIN
JI Blood Coagul. Fibrinolysis
PD OCT
PY 2013
VL 24
IS 7
BP 736
EP 741
DI 10.1097/MBC.0b013e328362627f
PG 6
WC Hematology
SC Hematology
GA 247EM
UT WOS:000326598300011
PM 23751609
ER
PT J
AU Singh, H
AF Singh, Hardeep
TI Diagnostic errors: moving beyond 'no respect' and getting ready for
prime time
SO BMJ QUALITY & SAFETY
LA English
DT Editorial Material
DE Accreditation; Adverse events; epidemiology and detection; Ambulatory
care
ID PRIMARY-CARE; INFORMATION-TECHNOLOGY; MISSED OPPORTUNITIES; MALPRACTICE
CLAIMS; CANCER DIAGNOSIS; PATIENT-SAFETY; SETTINGS; MEDICINE; AUTOPSY;
RECORDS
C1 [Singh, Hardeep] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, VA Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, VA Med Ctr, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Singh, H (reprint author), Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, VA Med Ctr, 152 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
FU AHRQ HHS [R18HS017820, R13 HS019252, R13 HS19252-01, R18 HS017820]; NCI
NIH HHS [K23 CA125585, K23CA125585]
NR 39
TC 9
Z9 9
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
EI 2044-5423
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD OCT
PY 2013
VL 22
IS 10
BP 789
EP 792
DI 10.1136/bmjqs-2013-002387
PG 4
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 247XU
UT WOS:000326659100001
PM 24048615
ER
PT J
AU Hariri, LP
Mino-Kenudson, M
Applegate, MB
Mark, EJ
Tearney, GJ
Lanuti, M
Channick, CL
Chee, A
Suter, MJ
AF Hariri, Lida P.
Mino-Kenudson, Mari
Applegate, Matthew B.
Mark, Eugene J.
Tearney, Guillermo J.
Lanuti, Michael
Channick, Colleen L.
Chee, Alex
Suter, Melissa J.
TI Toward the Guidance of Transbronchial Biopsy Identifying Pulmonary
Nodules With Optical Coherence Tomography
SO CHEST
LA English
DT Article
ID GUIDELINES 2ND EDITION; LUNG-CANCER; IN-VIVO; BARRETTS-ESOPHAGUS;
BRONCHIAL LESIONS; NEEDLE; DIAGNOSIS; BRONCHOSCOPY; MICROSCOPY;
METAANALYSIS
AB Background: Solitary pulmonary nodules (SPNs) frequently require transbronchial needle aspiration (TBNA) or biopsy to determine malignant potential, but have variable diagnostic yields. Confirming needle placement within SPNs during TBNA could significantly increase diagnostic yield. Optical coherence tomography (OCT) provides nondestructive, high-resolution, microstructural imaging with potential to distinguish SPN from parenchyma. We have developed needle-based OCT probes compatible with TBNA. Before OCT can play any significant role in guiding clinical TBNA, OCT interpretation criteria for differentiating SPN from lung parenchyma must be developed and validated.
Methods: OCT of SPN and parenchyma was performed on 111 ex vivo resection specimens. OCT criteria for parenchyma and SPN were developed and validated in a blinded assessment. Six blinded readers (two pulmonologists, two pathologists, and two OCT experts) were trained on imaging criteria in a 15-min training session prior to interpreting the validation data set.
Results: OCT of lung parenchyma displayed evenly spaced signal-void alveolar spaces, signal-intense backreflections at tissue-air interfaces, or both. SPNs lacked both of these imaging features. Independent validation of OCT criteria by the six blinded readers demonstrated sensitivity and specificity of 95.4% and 98.2%, respectively.
Conclusions: We have developed and validated OCT criteria for lung parenchyma and SPN with sensitivity and specificity. 95% in this ex vivo study. We anticipate that OCT could be a useful complementary imaging modality to confirm needle placement during TBNA to potentially increase diagnostic yield.
C1 [Hariri, Lida P.; Mino-Kenudson, Mari; Mark, Eugene J.; Tearney, Guillermo J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Applegate, Matthew B.; Channick, Colleen L.; Chee, Alex; Suter, Melissa J.] Massachusetts Gen Hosp, Dept Pulm, Boston, MA 02114 USA.
[Applegate, Matthew B.; Channick, Colleen L.; Chee, Alex; Suter, Melissa J.] Massachusetts Gen Hosp, Crit Care Unit, Boston, MA 02114 USA.
[Hariri, Lida P.; Applegate, Matthew B.; Tearney, Guillermo J.; Chee, Alex; Suter, Melissa J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Lanuti, Michael] Massachusetts Gen Hosp, Dept Thorac Surg, Boston, MA 02114 USA.
[Hariri, Lida P.; Mino-Kenudson, Mari; Mark, Eugene J.; Tearney, Guillermo J.; Lanuti, Michael; Channick, Colleen L.; Suter, Melissa J.] Harvard Univ, Sch Med, Boston, MA USA.
[Tearney, Guillermo J.] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA.
RP Suter, MJ (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Warren Bldg,Room 407, Boston, MA 02114 USA.
EM msuter@partners.org
FU National Institutes of Heath [R00CA134920, R01CA167827, P41EB01593];
American Lung Association [RG-194681-N]
FX This work was funded in part by the National Institutes of Heath [Grants
R00CA134920, R01CA167827, P41EB01593] and the American Lung Association
[Grant RG-194681-N].
NR 47
TC 10
Z9 10
U1 0
U2 12
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD OCT
PY 2013
VL 144
IS 4
BP 1261
EP 1268
DI 10.1378/chest.13-0534
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 241JJ
UT WOS:000326162600031
PM 23828441
ER
PT J
AU Daniel, S
Soleymani, T
Garvey, WT
AF Daniel, Sunil
Soleymani, Taraneh
Garvey, W. Timothy
TI A complications-based clinical staging of obesity to guide treatment
modality and intensity
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Review
DE cardiometabolic disease; complications; obesity; treatment algorithm;
weight loss
ID BODY-MASS INDEX; OBSTRUCTIVE SLEEP-APNEA; QUALITY-OF-LIFE;
POLYCYSTIC-OVARY-SYNDROME; FATTY LIVER-DISEASE; BINGE-EATING DISORDER;
CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; GASTROESOPHAGEAL-REFLUX
DISEASE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL
AB Purpose of reviewThe current medical model for obesity management is BMI-centric because BMI is the predominant measure used to gauge disease severity, as well as indications for various treatment modalities. Recent advancements in therapy and understanding of the relationship between BMI and obesity-related complications call for a re-examination of this approach.Recent findingsAdvancements in treatment, including the recent approval of two new weight loss medications in the USA, have enabled development of new medical models for management of obesity. On the basis of accumulating data demonstrating the benefits of weight loss regarding multiple obesity-related complications (e.g., diabetes prevention, type 2 diabetes mellitus, cardiovascular disease risk, nonalcoholic steatohepatitis, sleep apnea), a complications-centric model is proposed that employs weight loss as a tool to treat and prevent obesity comorbidities. This model assures that the aggressiveness of therapy is commensurate with disease severity, and that therapy is directed at those obese patients who will benefit most from weight loss therapy. The treatment algorithm is comprehensive in addressing complications and quantitative when possible in the staging of risk or disease severity.SummaryA complications-centric approach to obesity management identifies patients who will benefit most from weight loss, and optimizes patient outcomes, benefit/risk ratio, and the cost-effectiveness of interventions.
C1 [Daniel, Sunil] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
Birmingham VA Med Ctr, Birmingham, MA USA.
RP Daniel, S (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 232,1720 2nd Ave South, Birmingham, AL 35294 USA.
EM sunild@uab.edu
FU Department of Veterans Affairs; National Institutes of Health
[DK-038765, DK-083562]; UAB Diabetes Research Center [P60-DK079626];
Merck; Amylin; Weight Watchers
FX This work was supported by the Merit Review program of the Department of
Veterans Affairs, the National Institutes of Health (DK-038765 and
DK-083562), and the UAB Diabetes Research Center (P60-DK079626).; W.T.G.
is a speaker for Merck, Amylin, and Liposcience. He is on the advisory
boards of Daiichi-Sankyo, Vivus, Alkermes, Eisai, Liposcience, Tethys
Bioscience, and Janssen. He receives research support from Merck,
Amylin, and Weight Watchers. S. D. is a speaker for Vivus. T. S. is a
speaker for Vivus.
NR 130
TC 11
Z9 11
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1752-296X
EI 1752-2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD OCT
PY 2013
VL 20
IS 5
BP 377
EP 388
DI 10.1097/01.med.0000433067.01671.f5
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 247BG
UT WOS:000326587900003
PM 23974764
ER
PT J
AU Nichols, JJ
Willcox, MDP
Bron, AJ
Belmonte, C
Ciolino, JB
Craig, JP
Dogru, M
Foulks, GN
Jones, L
Nelson, JD
Nichols, KK
Purslow, C
Schaumberg, DA
Stapleton, F
Sullivan, DA
AF Nichols, Jason J.
Willcox, Mark D. P.
Bron, Anthony J.
Belmonte, Carlos
Ciolino, Joseph B.
Craig, Jennifer P.
Dogru, Murat
Foulks, Gary N.
Jones, Lyndon
Nelson, J. Daniel
Nichols, Kelly K.
Purslow, Christine
Schaumberg, Debra A.
Stapleton, Fiona
Sullivan, David A.
CA TFOS Int Workshop Contact Lens
TI The TFOS International Workshop on Contact Lens Discomfort: Executive
Summary
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Editorial Material
DE contact lenses; dry eye; discomfort; dryness; discontinuation
C1 [Nichols, Jason J.; Nichols, Kelly K.] Univ Houston, Coll Optometry, Ocular Surface Inst, Houston, TX 77204 USA.
[Willcox, Mark D. P.; Stapleton, Fiona] Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
[Bron, Anthony J.] Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX2 6AW, England.
[Belmonte, Carlos] Univ Miguel Hernandez, Inst Neurociencias, CSIC, Alicante, Spain.
[Belmonte, Carlos] Fdn Invest Oftalmol, Inst Fernandez Vega, Oviedo, Spain.
[Ciolino, Joseph B.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Craig, Jennifer P.] Univ Auckland, Dept Ophthalmol, Auckland 1, New Zealand.
[Dogru, Murat] Ichikawa Hosp, Tokyo Dent Coll, Tokyo, Japan.
[Foulks, Gary N.] Univ Louisville, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40292 USA.
[Jones, Lyndon] Univ Waterloo, Sch Optometry & Vis Sci, Ctr Contact Lens Res, Waterloo, ON N2L 3G1, Canada.
[Nelson, J. Daniel] Hlth Partners Med Grp, Minneapolis, MN USA.
[Purslow, Christine] Univ Plymouth, Peninsula Allied Hlth Ctr, Plymouth PL4 8AA, Devon, England.
[Schaumberg, Debra A.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Ctr Translat Med,John A Moran Eye Ctr, Salt Lake City, UT USA.
[Sullivan, David A.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Eye & Ear, Boston, MA USA.
RP Nichols, JJ (reprint author), Univ Houston, Coll Optometry, Ocular Surface Inst, 505 J Davis Armistead Bldg,4901 Calhoun Rd, Houston, TX 77204 USA.
EM jnichols@optometry.uh.edu
OI Golebiowski, Blanka/0000-0002-9348-6470; Nichols,
Jason/0000-0003-1519-7734
NR 0
TC 27
Z9 27
U1 2
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2013
VL 54
IS 11
SI SI
BP 7
EP 13
DI 10.1167/iovs.13-13212
PG 7
WC Ophthalmology
SC Ophthalmology
GA 247KW
UT WOS:000326617300002
ER
PT J
AU Stapleton, F
Marfurt, C
Golebiowski, B
Rosenblatt, M
Bereiter, D
Begley, C
Dartt, D
Gallar, J
Belmonte, C
Hamrah, P
Willcox, M
AF Stapleton, Fiona
Marfurt, Carl
Golebiowski, Blanka
Rosenblatt, Mark
Bereiter, David
Begley, Carolyn
Dartt, Darlene
Gallar, Juana
Belmonte, Carlos
Hamrah, Pedram
Willcox, Mark
CA TFOS Int Workshop Contact Lens
TI The TFOS International Workshop on Contact Lens Discomfort: Report of
the Subcommittee on Neurobiology
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 7th International Conference on the Tear Film and Ocular Surface-Basic
Science and Clinical Relevance (TFOS)
CY SEP 18-21, 2013
CL Taormina, ITALY
DE contact lens; dry eye; discomfort; neurobiology
ID NERVE GROWTH-FACTOR; IN-SITU KERATOMILEUSIS; SPINAL TRIGEMINAL NUCLEUS;
NONCONTACT CORNEAL AESTHESIOMETER; PLATELET-ACTIVATING-FACTOR; FOS-LIKE
IMMUNOREACTIVITY; VIVO CONFOCAL MICROSCOPY; DRY EYE SYMPTOMS;
POLYMORPHONUCLEAR LEUKOCYTE RESPONSE; PHOTOREFRACTIVE KERATECTOMY PAIN
AB This report characterizes the neurobiology of the ocular surface and highlights relevant mechanisms that may underpin contact lens-related discomfort. While there is limited evidence for the mechanisms involved in contact lens-related discomfort, neurobiological mechanisms in dry eye disease, the inflammatory pathway, the effect of hyperosmolarity on ocular surface nociceptors, and subsequent sensory processing of ocular pain and discomfort have been at least partly elucidated and are presented herein to provide insight in this new arena. The stimulus to the ocular surface from a contact lens is likely to be complex and multifactorial, including components of osmolarity, solution effects, desiccation, thermal effects, inflammation, friction, and mechanical stimulation. Sensory input will arise from stimulation of the lid margin, palpebral and bulbar conjunctiva, and the cornea.
C1 [Stapleton, Fiona; Golebiowski, Blanka; Willcox, Mark] Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
[Marfurt, Carl] Indiana Univ Sch Med Northwest, Gary, IN USA.
[Rosenblatt, Mark] Cornell Univ, Weill Cornell Med Coll, Ithaca, NY USA.
[Bereiter, David] Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA.
[Begley, Carolyn] Indiana Univ, Sch Optometry, Bloomington, IN USA.
[Dartt, Darlene] Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Eye & Ear, Boston, MA USA.
[Gallar, Juana; Belmonte, Carlos] Univ Miguel Hernandez, Inst Neurociencias Alicante, CSIC, Alicante, Spain.
[Hamrah, Pedram] Massachusetts Eye & Ear Infirm, Stoneham, MA USA.
RP Willcox, M (reprint author), Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
EM mdpwillcox@gmail.com
RI Gallar, Juana/B-4563-2011;
OI Gallar, Juana/0000-0002-3559-3649; Golebiowski,
Blanka/0000-0002-9348-6470
NR 401
TC 20
Z9 20
U1 0
U2 16
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2013
VL 54
IS 11
SI SI
BP 71
EP 97
DI 10.1167/iovs.13-13226
PG 27
WC Ophthalmology
SC Ophthalmology
GA 247KW
UT WOS:000326617300006
ER
PT J
AU Papas, EB
Ciolino, JB
Jacobs, D
Miller, WS
Pult, H
Sahin, A
Srinivasan, S
Tauber, J
Wolffsohn, JS
Nelson, JD
AF Papas, Eric B.
Ciolino, Joseph B.
Jacobs, Deborah
Miller, William S.
Pult, Heiko
Sahin, Afsun
Srinivasan, Sruthi
Tauber, Joseph
Wolffsohn, James S.
Nelson, J. Daniel
CA TFOS Int Workshop Contact Lens
TI The TFOS International Workshop on Contact Lens Discomfort: Report of
the Management and Therapy Subcommittee
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 7th International Conference on the Tear Film and Ocular Surface-Basic
Science and Clinical Relevance (TFOS)
CY SEP 18-21, 2013
CL Taormina, ITALY
DE contact; dry eyes; tears; discomfort
ID MEIBOMIAN GLAND DYSFUNCTION; SILICONE-HYDROGEL LENSES; DRY EYE SYNDROME;
QUALITY-OF-LIFE; TOPICAL CYCLOSPORINE 0.05-PERCENT; CONJUNCTIVAL
IMPRESSION CYTOLOGY; CONTROLLED ADVERSE ENVIRONMENT; OPHTHALMIC SOLUTION
1-PERCENT; PATIENT-RELATED FACTORS; OCULAR SURFACE DISEASE
C1 [Papas, Eric B.] Brien Holden Vis Inst, Sydney, NSW, Australia.
[Papas, Eric B.] Vis CRC, Sydney, NSW, Australia.
[Papas, Eric B.] Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
[Ciolino, Joseph B.; Jacobs, Deborah] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Jacobs, Deborah] Boston Fdn Sight, Needham, MA USA.
[Miller, William S.] Univ Houston, Coll Optometry, Dept Clin Sci, Ocular Surface Inst, Houston, TX USA.
[Pult, Heiko] Dr Heiko Pult Optometry & Vis Res, Weinheim, Germany.
[Pult, Heiko] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, S Glam, Wales.
[Sahin, Afsun] Eskisehir Osmangazi Univ, Sch Med, Dept Ophthalmol, Eskisehir, Turkey.
[Srinivasan, Sruthi] Univ Waterloo, Sch Optometry & Vis Sci, Ctr Contact Lens Res, Waterloo, ON N2L 3G1, Canada.
[Tauber, Joseph] Tauber Eye Ctr, Kansas City, MO USA.
[Wolffsohn, James S.] Aston Univ, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
[Nelson, J. Daniel] HealthPartners Med Grp, Minneapolis, MN 55440 USA.
RP Nelson, JD (reprint author), HealthPartners Med Grp, Mail Stop 21110R,POB 1309, Minneapolis, MN 55440 USA.
EM j.d.nelson@healthpartners.com
RI Pult, Heiko/I-3596-2015
OI Pult, Heiko/0000-0003-4371-8007
NR 278
TC 11
Z9 11
U1 1
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2013
VL 54
IS 11
SI SI
BP 183
EP 203
DI 10.1167/iovs.13-13166
PG 21
WC Ophthalmology
SC Ophthalmology
GA 247KW
UT WOS:000326617300010
ER
PT J
AU Parissi, M
Karanis, G
Randjelovic, S
Germundsson, J
Poletti, E
Ruggeri, A
Utheim, TP
Lagali, N
AF Parissi, Marlen
Karanis, Georgios
Randjelovic, Stefan
Germundsson, Johan
Poletti, Enea
Ruggeri, Alfredo
Utheim, Tor Paaske
Lagali, Neil
TI Standardized Baseline Human Corneal Subbasal Nerve Density for Clinical
Investigations With Laser-Scanning in Vivo Confocal Microscopy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE subbasal nerve; imaging; confocal microscopy
ID STEM-CELL DEFICIENCY; FLUORESCENCE MICROSCOPY; DIABETIC-NEUROPATHY;
INNERVATION; PLEXUS; IMAGES; SENSITIVITY; TORTUOSITY; DYSTROPHY
AB PURPOSE. We established a baseline value for central corneal subbasal nerve density in a large, healthy cohort.
METHODS. A total of 106 healthy volunteers (207 eyes) underwent full ophthalmic examination, including laser-scanning in vivo confocal microscopy (IVCM) of the central cornea. Images of the corneal subbasal nerve plexus were acquired and analyzed based on defined criteria. Nerve tracing was performed by two human observers and by a fully automated method. Subbasal nerve density was stratified by eye, observer, tracing method, calculation method, and age group. Association of nerve density with age was examined by linear regression and population distribution was examined by nonlinear regression.
RESULTS. We analyzed 892 distinct, high quality images of the subbasal nerve plexus (mean, 4.3 images/eye) from 207 eyes. An overall mean central subbasal nerve density of 19 mm/mm(2) was found in 106 subjects aged 15 to 88 years, independent of eye, sex, or nerve tracing method, while the SD was a consistent 4 to 5 mm/mm2. Subbasal nerve density followed a normal Gaussian distribution, and correlated negatively with age, with a mean decline of 0.25% to 0.30% per year, independent of eye, observer, or nerve tracing method. Moreover, the use of automated tracing techniques and randomized sampling may improve the speed and reproducibility of subbasal nerve density assessment for clinical applications.
CONCLUSIONS. A baseline human corneal subbasal nerve density has been determined by laser-scanning IVCM using rigorous methods. The methods and results could aid in the future assessment of corneal nerves in various patient populations.
C1 [Parissi, Marlen; Utheim, Tor Paaske] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway.
[Parissi, Marlen; Randjelovic, Stefan; Utheim, Tor Paaske] Norwegian Dry Eye Clin, Oslo, Norway.
[Karanis, Georgios; Germundsson, Johan; Lagali, Neil] Linkoping Univ, Dept Clin & Expt Med, S-58183 Linkoping, Sweden.
[Poletti, Enea; Ruggeri, Alfredo] Univ Padua, Dept Informat Engn, Padua, Italy.
[Utheim, Tor Paaske] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
RP Lagali, N (reprint author), Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med Ophthalmol, S-58183 Linkoping, Sweden.
EM neil.lagali@liu.se
OI Lagali, Neil/0000-0003-1079-4361
FU Cronqvist Foundation; Swedish Research Council; Princess Margaretas
Foundation for the Visually Impaired; Norwegian Research Council
FX Supported by the Cronqvist Foundation, the Swedish Research Council, and
Princess Margaretas Foundation for the Visually Impaired (NL), and
funding from the Norwegian Research Council (MP). The authors alone are
responsible for the content and writing of the paper.
NR 38
TC 15
Z9 15
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2013
VL 54
IS 10
BP 7091
EP 7102
DI 10.1167/iovs.13-12999
PG 12
WC Ophthalmology
SC Ophthalmology
GA 246VI
UT WOS:000326567700074
PM 24084094
ER
PT J
AU Tabach, Y
Golan, T
Hernandez-Hernandez, A
Messer, AR
Fukuda, T
Kouznetsova, A
Liu, JG
Lilienthal, I
Levy, C
Ruvkun, G
AF Tabach, Yuval
Golan, Tamar
Hernandez-Hernandez, Abrahan
Messer, Arielle R.
Fukuda, Tomoyuki
Kouznetsova, Anna
Liu, Jian-Guo
Lilienthal, Ingrid
Levy, Carmit
Ruvkun, Gary
TI Human disease locus discovery and mapping to molecular pathways through
phylogenetic profiling
SO MOLECULAR SYSTEMS BIOLOGY
LA English
DT Article
ID RBP-J; FUNCTIONAL-RELATIONSHIPS; PROTEIN INTERACTIONS; GENE-EXPRESSION;
COMPLEX; EVOLUTION; MELANOMA; ONCOGENE; CANCER; CILIA
AB Genes with common profiles of the presence and absence in disparate genomes tend to function in the same pathway. By mapping all human genes into about 1000 clusters of genes with similar patterns of conservation across eukaryotic phylogeny, we determined that sets of genes associated with particular diseases have similar phylogenetic profiles. By focusing on those human phylogenetic gene clusters that significantly overlap some of the thousands of human gene sets defined by their coexpression or annotation to pathways or other molecular attributes, we reveal the evolutionary map that connects molecular pathways and human diseases. The other genes in the phylogenetic clusters enriched for particular known disease genes or molecular pathways identify candidate genes for roles in those same disorders and pathways. Focusing on proteins coevolved with the microphthalmia-associated transcription factor (MITF), we identified the Notch pathway suppressor of hairless (RBP-Jk/SuH) transcription factor, and showed that RBP-Jk functions as an MITF cofactor.
C1 [Tabach, Yuval; Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Tabach, Yuval; Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Golan, Tamar; Messer, Arielle R.; Levy, Carmit] Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Biochem, IL-69978 Tel Aviv, Israel.
[Hernandez-Hernandez, Abrahan; Fukuda, Tomoyuki; Kouznetsova, Anna; Liu, Jian-Guo; Lilienthal, Ingrid] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.
RP Tabach, Y (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM tabach@molbio.mgh.harvard.edu; carmitlevy@post.tau.ac.il;
ruvkun@molbio.mgh.harvard.edu
FU NIH [R01GM44619]; Israeli Centers for Research Excellence (I-CORE);
Israel Cancer Association (ICA), Israel Cancer Research Fund (ICRF);
USIsrael Binational Science Fund (BSF); Fritz Thyssen Stiftung, Marie
Curie Career Integration Grants (CIG); German Cancer Research Center
(DKFZ)
FX We thank Jonathan Urbach, Sunil Wadhwa, and the Ruvkun laboratory
members for the comments and suggestions that have been helpful to
improve the manuscript. YTand GR supported by NIH R01GM44619. CL thanks
Meenhard Herlyn and Levi Garraway forsupplying melanoma short-term
cultures. TG and CL supported by grants from the Israeli Centers for
Research Excellence (I-CORE), Israel Cancer Association (ICA), Israel
Cancer Research Fund (ICRF), USIsrael Binational Science Fund (BSF),
Fritz Thyssen Stiftung, Marie Curie Career Integration Grants (CIG),
German Cancer Research Center (DKFZ).
NR 59
TC 9
Z9 9
U1 2
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1744-4292
J9 MOL SYST BIOL
JI Mol. Syst. Biol.
PD OCT
PY 2013
VL 9
AR UNSP 692
DI 10.1038/msb.2013.50
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 248VR
UT WOS:000326733900003
PM 24084807
ER
PT J
AU Cheng, CS
Rai, K
Garber, M
Hollinger, A
Robbins, D
Anderson, S
Macbeth, A
Tzou, A
Carneiro, MO
Raychowdhury, R
Russ, C
Hacohen, N
Gershenwald, JE
Lennon, N
Nusbaum, C
Chin, L
Regev, A
Amit, I
AF Cheng, Christine S.
Rai, Kunal
Garber, Manuel
Hollinger, Andrew
Robbins, Dana
Anderson, Scott
Macbeth, Alyssa
Tzou, Austin
Carneiro, Mauricio O.
Raychowdhury, Raktima
Russ, Carsten
Hacohen, Nir
Gershenwald, Jeffrey E.
Lennon, Niall
Nusbaum, Chad
Chin, Lynda
Regev, Aviv
Amit, Ido
TI Semiconductor-based DNA sequencing of histone modification states
SO NATURE COMMUNICATIONS
LA English
DT Article
ID EMBRYONIC STEM-CELLS; LIMITED NUMBERS; CHIP-SEQ; CANCER; INFLAMMATION;
REGULATORS; SIGNATURE; POLYCOMB; ENCODE
AB The recent development of a semiconductor-based, non-optical DNA sequencing technology promises scalable, low-cost and rapid sequence data production. The technology has previously been applied mainly to genomic sequencing and targeted re-sequencing. Here we demonstrate the utility of Ion Torrent semiconductor-based sequencing for sensitive, efficient and rapid chromatin immunoprecipitation followed by sequencing (ChIP-seq) through the application of sample preparation methods that are optimized for ChIP-seq on the Ion Torrent platform. We leverage this method for epigenetic profiling of tumour tissues.
C1 [Cheng, Christine S.; Garber, Manuel; Hollinger, Andrew; Robbins, Dana; Anderson, Scott; Macbeth, Alyssa; Tzou, Austin; Carneiro, Mauricio O.; Raychowdhury, Raktima; Russ, Carsten; Hacohen, Nir; Lennon, Niall; Nusbaum, Chad; Regev, Aviv; Amit, Ido] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Rai, Kunal; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
[Garber, Manuel] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA.
[Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA.
[Hacohen, Nir] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Gershenwald, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
[Regev, Aviv] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02142 USA.
[Amit, Ido] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.
RP Chin, L (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
EM lchin@mdanderson.org; aregev@broadinstitute.org; ido.amit@weizmann.ac.il
FU Human Frontiers Science Program Career Development Award; ISF Bikura
Institutional Research Grant Program; ERC starting Grant [309788]; NHGRI
[1P50HG006193-01, U54HG003067]; NIH Pioneer Award [DP1OD003958-01];
Klarman Cell Observatory; NCI [R01 CA93947, U01 CA1411508]; NIH [P50
CA093459]; NIH Ruth L. Kirschstein National Research Service awards for
individual Postdoctoral Fellowships
FX We thank R. Satija and S. Schwartz for helpful discussions. We thank J.
Bochicchio for project management, A. Wysoker for the development of the
data transfer pipeline and the Broad's Genomics Platform for sequencing.
We also thank T. L. Calderone for preparing and sending the melanoma
tumours. We thank L. Gaffney for production of the graphical abstract.
This work was supported by the Human Frontiers Science Program Career
Development Award (I. A.), the ISF Bikura Institutional Research Grant
Program (I. A.), ERC starting Grant 309788 (I. A.), NHGRI
(1P50HG006193-01 to I. A. and A. R.), NIH Pioneer Award (DP1OD003958-01
to A. R.), Klarman Cell Observatory (A. R.), NCI (R01 CA93947 to L. C.),
NCI (U01 CA1411508 to L. C.), NHGRI (U54HG003067 to C. R.), NIH (P50
CA093459 to J. G.) and NIH Ruth L. Kirschstein National Research Service
awards for individual Postdoctoral Fellowships (C.S.C.).
NR 30
TC 5
Z9 5
U1 1
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT
PY 2013
VL 4
AR 2672
DI 10.1038/ncomms3672
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245OP
UT WOS:000326473500004
PM 24157732
ER
PT J
AU Sethi, DK
Gordo, S
Schubert, DA
Wucherpfennig, KW
AF Sethi, Dhruv K.
Gordo, Susana
Schubert, David A.
Wucherpfennig, Kai W.
TI Crossreactivity of a human autoimmune TCR is dominated by a single TCR
loop
SO NATURE COMMUNICATIONS
LA English
DT Article
ID T-CELL-RECEPTOR; MYELIN BASIC-PROTEIN; MAJOR HISTOCOMPATIBILITY COMPLEX;
CLASS-II MOLECULE; MULTIPLE-SCLEROSIS; PEPTIDE-MHC; STRUCTURAL BASIS;
SELF-PEPTIDE; CRYSTAL-STRUCTURE; RECOGNITION
AB Self-reactive CD4 T cells are thought to have a central role in the pathogenesis of many chronic inflammatory human diseases. Microbial peptides can activate self-reactive T cells, but the structural basis for such crossreactivity is not well understood. The Hy.1B11 T cell receptor (TCR) originates from a patient with multiple sclerosis and recognizes the self-antigen myelin basic protein. Here we report the structural mechanism of TCR crossreactivity with two distinct peptides from human pathogens. The structures show that a single TCR residue (CDR3 alpha F95) makes the majority of contacts with the self-peptide and both microbial peptides (66.7-80.6%) due to a highly tilted TCR-binding topology on the peptide-MHC surface. Further, a neighbouring residue located on the same TCR loop (CDR3 alpha E98) forms an energetically critical interaction with the MHC molecule. These data show how binding by a self-reactive TCR favors crossreactivity between self and microbial antigens.
C1 [Sethi, Dhruv K.; Gordo, Susana; Schubert, David A.; Wucherpfennig, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Wucherpfennig, Kai W.] Harvard Univ, Sch Med, Program Immunol, Boston, MA 02115 USA.
RP Wucherpfennig, KW (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
EM kai_wucherpfennig@dfci.harvard.edu
FU NIH [PO1 AI045757, RO1 AI064177]; National Multiple Sclerosis Society;
Cancer Research Institute; National Center for Research Resources
[5P41RR015301-10]; National Institute of General Medical Sciences from
the National Institutes of Health [8P41 GM103403-10]; U.S. DOE
[DE-AC02-06CH11357]
FX This work was supported by grants from the NIH (PO1 AI045757 and RO1
AI064177 to K. W. W.) and postdoctoral fellowships from the National
Multiple Sclerosis Society (to D. K. S. and S. G.) and the Cancer
Research Institute (to D. A. S.). Diffraction data were collected at the
Advanced Photon Source using beamlines allocated to the Northeastern
Collaborative Access Team. These beamlines are supported by grants from
the National Center for Research Resources (5P41RR015301-10) and the
National Institute of General Medical Sciences (8P41 GM103403-10) from
the National Institutes of Health. Use of the Advanced Photon Source, an
Office of Science User Facility operated for the U.S. Department of
Energy (DOE) Office of Science by Argonne National Laboratory, was
supported by the U.S. DOE under Contract No. DE-AC02-06CH11357.
NR 58
TC 9
Z9 9
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT
PY 2013
VL 4
AR 2623
DI 10.1038/ncomms3623
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245OE
UT WOS:000326472200012
PM 24136005
ER
PT J
AU Koch, R
Demant, M
Guntsch, A
Cicholas, A
Aung, T
Venkataramani, V
Diering, N
Wenzel, D
Chapuy, B
Trumper, L
Wulf, G
AF Koch, R.
Demant, M.
Guentsch, A.
Cicholas, A.
Aung, T.
Venkataramani, V.
Diering, N.
Wenzel, D.
Chapuy, B.
Truemper, L.
Wulf, G.
TI Exosome mediated Wnt-Signaling augments side population in diffuse large
B-cell lymphomas
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Koch, R.; Demant, M.; Guentsch, A.; Cicholas, A.; Aung, T.; Venkataramani, V.; Diering, N.; Truemper, L.; Wulf, G.] Univ Med, Gottingen, Germany.
[Wenzel, D.] Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany.
[Chapuy, B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
EI 1423-0240
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2013
VL 36
SU 7
BP 134
EP 134
PG 1
GA 244BA
UT WOS:000326360900325
ER
PT J
AU Koch, R
Cicholas, A
Aung, T
Demant, M
Venkataramani, V
Chapuy, B
Trumper, L
Wulf, G
AF Koch, R.
Cicholas, A.
Aung, T.
Demant, M.
Venkataramani, V.
Chapuy, B.
Truemper, L.
Wulf, G.
TI SFRP4 inhibits proliferation of DLBCL by antagonizing wnt-signaling
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Koch, R.; Cicholas, A.; Aung, T.; Demant, M.; Venkataramani, V.; Truemper, L.; Wulf, G.] Univ Med, Gottingen, Germany.
[Chapuy, B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
EI 1423-0240
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2013
VL 36
SU 7
BP 134
EP 135
PG 2
GA 244BA
UT WOS:000326360900326
ER
PT J
AU Reichardt, P
Demetri, G
Kang, YK
Blay, JY
Joensuu, H
Maki, RG
Rutkowski, P
Hohenberger, P
Gelderblom, H
Leahy, MG
von Mehren, M
Schoffski, P
Blackstein, ME
Le Cesne, A
Badalamenti, G
Xu, J
Nishida, T
Kuss, I
Casali, PG
AF Reichardt, P.
Demetri, G.
Kang, Y-K
Blay, J-Y
Joensuu, H.
Maki, R. G.
Rutkowski, P.
Hohenberger, P.
Gelderblom, H.
Leahy, M. G.
von Mehren, M.
Schoffski, P.
Blackstein, M. E.
Le Cesne, A.
Badalamenti, G.
Xu, J.
Nishida, T.
Kuss, I
Casali, P. G.
TI Mutational analysis of plasma DNA from patients (pts) in the phase III
GRID study of regorafenib vs placebo in tyrosine kinase inhibitor
(TKI)-refractory GIST: Correlating genotype with clinical outcomes
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Reichardt, P.] Helios Klinikum Berlin Buch, Klin Interdisziplinare Onkol, Berlin, Germany.
[Demetri, G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kang, Y-K] Asan Med Ctr, Seoul, South Korea.
[Blay, J-Y] Ctr Leon Berard, F-69373 Lyon, France.
[Joensuu, H.] Univ Helsinki, Cent Hosp, Helsinki, Finland.
[Maki, R. G.] Mt Sinai Sch Med, New York, NY USA.
[Rutkowski, P.] Maria Sklodowska Curie Mem Canc Ctr & Inst, Warsaw, Poland.
[Hohenberger, P.] Univ Mannheim, Med Ctr, D-68131 Mannheim, Germany.
[Gelderblom, H.] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Leahy, M. G.] Christie NHS Trust Fdn, Manchester, Lancs, England.
[von Mehren, M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Schoffski, P.] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium.
[Blackstein, M. E.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Le Cesne, A.] Inst Gustav Roussy, Villejuif, France.
[Badalamenti, G.] Univ Palermo, Palermo, Italy.
[Xu, J.] Acad Mil Med Sci, Affiliated Hosp, Beijing, Peoples R China.
[Nishida, T.] Osaka Police Hosp, Osaka, Japan.
[Kuss, I] Bayer HealthCare, Berlin, Germany.
[Casali, P. G.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
EI 1423-0240
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2013
VL 36
SU 7
BP 179
EP 180
PG 2
GA 244BA
UT WOS:000326360900445
ER
PT J
AU Bauer, S
Joensuu, H
Casali, P
Reichardt, P
Kang, YK
Blay, JY
Rutkowski, P
Gelderblom, H
Hohenberger, P
Leahy, M
von Mehren, M
Badalamenti, G
Blackstein, M
Le Cesne, A
Schoffski, P
Maki, RG
Xu, J
Nishida, T
Kappeler, C
Kuss, I
Demetri, GD
AF Bauer, S.
Joensuu, H.
Casali, P.
Reichardt, P.
Kang, Y-K
Blay, J-Y
Rutkowski, P.
Gelderblom, H.
Hohenberger, P.
Leahy, M.
von Mehren, M.
Badalamenti, G.
Blackstein, M.
Le Cesne, A.
Schoffski, P.
Maki, R. G.
Xu, J.
Nishida, T.
Kappeler, C.
Kuss, I
Demetri, G. D.
TI Results from a phase III trial (GRID) evaluating regorafenib in
metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of
outcomes based on pretreatment characteristics
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Bauer, S.] Univ Klinikum Essen, Essen, Germany.
[Joensuu, H.] Univ Helsinki, Cent Hosp, Helsinki, Finland.
[Casali, P.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
[Reichardt, P.] Helios Klinikum Berlin Buch, Berlin, Germany.
[Kang, Y-K] Asan Med Ctr, Seoul, South Korea.
[Blay, J-Y] Ctr Leon Berard, F-69373 Lyon, France.
[Rutkowski, P.] Maria Sklodowska Curie Mem Canc Ctr & Inst, Warsaw, Poland.
[Gelderblom, H.] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Hohenberger, P.] Univ Mannheim, Med Ctr, D-68131 Mannheim, Germany.
[Leahy, M.] Christie NHS Trust Fdn, Manchester, Lancs, England.
[von Mehren, M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Badalamenti, G.] Univ Palermo, Palermo, Italy.
[Blackstein, M.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Le Cesne, A.] Inst Gustav Roussy, Villejuif, France.
[Schoffski, P.] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium.
[Maki, R. G.] Mt Sinai Sch Med, New York, NY USA.
[Xu, J.] Acad Mil Med Sci, Affiliated Hosp, Beijing, Peoples R China.
[Nishida, T.] Osaka Police Hosp, Osaka, Japan.
[Kappeler, C.; Kuss, I] Bayer HealthCare, Berlin, Germany.
[Demetri, G. D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
EI 1423-0240
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2013
VL 36
SU 7
BP 180
EP 181
PG 2
GA 244BA
UT WOS:000326360900446
ER
PT J
AU Koch, R
Aung, T
Vogel, D
Menck, K
Venkataramani, V
Mohring, S
Chapuy, B
Trumper, L
Wulf, G
AF Koch, R.
Aung, T.
Vogel, D.
Menck, K.
Venkataramani, V.
Mohring, S.
Chapuy, B.
Truemper, L.
Wulf, G.
TI Association of Exosome Secretion and Drug Resistance in Diffuse Large
B-cell Lymphomas
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Koch, R.; Aung, T.; Vogel, D.; Menck, K.; Venkataramani, V.; Mohring, S.; Truemper, L.; Wulf, G.] UMG, Gottingen, Germany.
[Chapuy, B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
EI 1423-0240
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2013
VL 36
SU 7
BP 199
EP 199
PG 1
GA 244BA
UT WOS:000326360900494
ER
PT J
AU Fan, F
Tonon, G
Bashari, HM
Vallet, S
Antonini, E
Goldschmidt, H
Schulze-Bergkamen, H
Opferman, J
Settler, M
Anderson, KC
Jager, D
Podar, K
AF Fan, F.
Tonon, G.
Bashari, H. M.
Vallet, S.
Antonini, E.
Goldschmidt, H.
Schulze-Bergkamen, H.
Opferman, J.
Settler, M.
Anderson, K. C.
Jaeger, D.
Podar, K.
TI Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced
generation of Mcl-1 fragment Mcl-1128-350 triggers MM cell death via
c-Jun upregulation
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Fan, F.; Bashari, H. M.; Vallet, S.; Goldschmidt, H.; Schulze-Bergkamen, H.; Jaeger, D.; Podar, K.] Heidelberg Univ, Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
[Fan, F.; Bashari, H. M.; Vallet, S.; Schulze-Bergkamen, H.; Jaeger, D.; Podar, K.] German Canc Res Ctr, Heidelberg, Germany.
[Tonon, G.; Antonini, E.] Ist Sci San Raffaele, Div Mol Oncol, Funct Genom Canc Unit, I-20132 Milan, Italy.
[Goldschmidt, H.] Heidelberg Univ, German Canc Res Ctr DKFZ, Heidelberg, Germany.
[Goldschmidt, H.] Heidelberg Univ, Dept Hematol & Oncol, Heidelberg, Germany.
[Opferman, J.] St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA.
[Settler, M.; Anderson, K. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
EI 1423-0240
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2013
VL 36
SU 7
BP 213
EP 213
PG 1
GA 244BA
UT WOS:000326360900532
ER
PT J
AU Niemeyer, E
Kamoun, WS
Han, HS
Huang, Y
Bhaumik, J
Chen, Y
Gillisen, M
Martin, JD
Roberge, S
Lanning, RM
Cui, J
Munn, LL
Nocera, DG
Padera, T
Fukumura, D
Jain, RK
Bawendi, MG
Dunst, J
Duda, DG
AF Niemeyer, E.
Kamoun, W. S.
Han, H. -S.
Huang, Y.
Bhaumik, J.
Chen, Y.
Gillisen, M.
Martin, J. D.
Roberge, S.
Lanning, R. M.
Cui, J.
Munn, L. L.
Nocera, D. G.
Padera, T.
Fukumura, D.
Jain, R. K.
Bawendi, M. G.
Dunst, J.
Duda, D. G.
TI Multiphoton microscopy and in-situ labeling techniques allow detection
of endogenous hematopoetic stem cells and measurement of functional
parameters in the stem cell niche
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Niemeyer, E.; Dunst, J.] Med Univ Lubeck, Klin Strahlentherapie, D-23538 Lubeck, Germany.
[Niemeyer, E.; Kamoun, W. S.; Huang, Y.; Bhaumik, J.; Chen, Y.; Gillisen, M.; Martin, J. D.; Roberge, S.; Lanning, R. M.; Munn, L. L.; Padera, T.; Fukumura, D.; Jain, R. K.; Duda, D. G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
[Niemeyer, E.; Kamoun, W. S.; Huang, Y.; Bhaumik, J.; Chen, Y.; Gillisen, M.; Martin, J. D.; Roberge, S.; Lanning, R. M.; Munn, L. L.; Padera, T.; Fukumura, D.; Jain, R. K.; Duda, D. G.] Harvard Univ, Sch Med, Boston, MA USA.
[Han, H. -S.; Cui, J.; Nocera, D. G.; Bawendi, M. G.] MIT, Dept Chem, Cambridge, MA 02139 USA.
RI Munn, Lance/L-3950-2016; Dunst, Juergen/D-2138-2010
OI Munn, Lance/0000-0003-0698-7232;
NR 0
TC 0
Z9 0
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
EI 1423-0240
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2013
VL 36
SU 7
BP 229
EP 230
PG 2
GA 244BA
UT WOS:000326360900577
ER
PT J
AU Garza, JLB
Eijckelhof, BHW
Huysmans, MA
Catalano, PJ
Katz, JN
Johnson, PW
van Dieen, JH
van der Beek, AJ
Dennerlein, JT
AF Garza, Jennifer L. Bruno
Eijckelhof, Belinda H. W.
Huysmans, Maaike A.
Catalano, Paul J.
Katz, Jeffrey N.
Johnson, Peter W.
van Dieen, Jaap H.
van der Beek, Allard J.
Dennerlein, Jack T.
TI The effect of over-commitment and reward on trapezius muscle activity
and shoulder, head, neck, and torso postures during computer use in the
field
SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE
LA English
DT Article
DE psychosocial; VDT; MSDs; exposure assessment; office ergonomics
ID UPPER-LIMB SYMPTOMS; MUSCULOSKELETAL SYMPTOMS; OCCUPATIONAL-HEALTH;
OFFICE WORKERS; RISK-FACTORS; DISORDERS; EXPOSURE; PATHOPHYSIOLOGY;
INTERVENTIONS; VARIABILITY
AB Background Because of reported associations of psychosocial factors and computer related musculoskeletal symptoms, we investigated the effects of a workplace psychosocial factor, reward, in the presence of over-commitment, on trapezius muscle activity and shoulder, head, neck, and torso postures during computer use.
Methods We measured 120 office workers across four groups (lowest/highest reward/over-commitment), performing their own computer work at their own workstations over a 2-hr period.
Results Median trapezius muscle activity (P=0.04) and median neck flexion (P=0.03) were largest for participants reporting simultaneously low reward and high over-commitment. No differences were observed for other muscle activities or postures.
Conclusions These data suggest that the interaction of reward and over-commitment can affect upper extremity muscle activity and postures during computer use in the real work environment. This finding aligns with the hypothesized biomechanical pathway connecting workplace psychosocial factors and musculoskeletal symptoms of the neck and shoulder. Am. J. Ind. Med. 56:1190-1200, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Garza, Jennifer L. Bruno; Katz, Jeffrey N.; Dennerlein, Jack T.] Harvard Univ, Dept Environm Hlth, Boston, MA 02115 USA.
[Eijckelhof, Belinda H. W.; Huysmans, Maaike A.; van der Beek, Allard J.] Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands.
[Eijckelhof, Belinda H. W.; Huysmans, Maaike A.; van Dieen, Jaap H.; van der Beek, Allard J.; Dennerlein, Jack T.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
[Eijckelhof, Belinda H. W.; Huysmans, Maaike A.; van der Beek, Allard J.] TNO VU VUmc, Body Work Res Ctr Phys Act Work & Hlth, Amsterdam, Netherlands.
[Catalano, Paul J.] Harvard Univ, Cambridge, MA 02138 USA.
[Catalano, Paul J.] Dana Farber Canc Inst Boston, Boston, MA USA.
[Katz, Jeffrey N.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Katz, Jeffrey N.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Katz, Jeffrey N.] Brigham & Womens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA.
[Johnson, Peter W.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA.
[van Dieen, Jaap H.] Vrije Univ Amsterdam, Fac Human Movement Sci, Res Inst MOVE, Amsterdam, Netherlands.
[Dennerlein, Jack T.] Northeastern Univ, Dept Phys Therapy, Boston, MA 02115 USA.
RP Dennerlein, JT (reprint author), Northeastern Univ, 6 Robinson Hall Off 308F,360 Huntington Ave, Boston, MA 02115 USA.
EM j.dennerlein@neu.edu
RI Johnson, Peter/C-3046-2011;
OI Johnson, Peter/0000-0001-5583-5919; Dennerlein,
Jack/0000-0001-7703-643X; van Dieen, Jaap/0000-0002-7719-5585
FU CDC/NIOSH [RO1-0H-08781]
FX This study was funded in part by Grant sponsor: CDC/NIOSH; Grant number:
RO1-0H-08781 (PI: Dennerlein). The authors would like to thank Sachin
Raina, Patrik Rynell, and Birgette Blatter for their contributions to
the design, data collection, and analysis for this study. The authors
would like to thank Paul Landsbergis for his assistance and suggestions
regarding the definition of over-commitment and the different ways in
which over-commitment may affect biomechanical loading.
NR 39
TC 8
Z9 8
U1 1
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0271-3586
EI 1097-0274
J9 AM J IND MED
JI Am. J. Ind. Med.
PD OCT
PY 2013
VL 56
IS 10
BP 1190
EP 1200
DI 10.1002/ajim.22192
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 210JT
UT WOS:000323829200008
ER
PT J
AU Mohammad-Taheri, Z
Nadji, SA
Raisi, F
Mohammadi, F
Bahadori, M
Mark, EJ
AF Mohammad-Taheri, Zohreh
Nadji, Seyed Alireza
Raisi, Farshid
Mohammadi, Forouzan
Bahadori, Moslem
Mark, Eugene Jerome
TI No association between simian virus 40 and diffuse malignant
mesothelioma of the pleura in Iranian patients: A molecular and
epidemiologic case-control study of 60 patients
SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE
LA English
DT Article
DE mesothelioma malignant; PCR; simian virus 40; etiology
ID LARGE T-ANTIGEN; SV40; DNA; EXPRESSION; CANCER; CELLS; PATHOGENESIS;
SEQUENCES; ASBESTOS; VACCINE
AB Background Diffuse malignant mesothelioma (DMM) is increasing in incidence on a worldwide basis and is linked to exposure to asbestos. Simian virus 40 (SV40), a DNA virus, was introduced inadvertently to human populations through contaminated polio vaccine during the years 1956-1963. It has been associated with various types of malignancy in animal experiments. There have been suggestions that SV40 might play a role in the pathogenesis of DMM.
Objective To evaluate the association between SV40 and DMM in Iranian patients.
Method In a case-control study between the years 2007-2008, isolated DNA from 60 paraffin blocks of patients with DMM and 60 controls was assessed to detect three human polyomaviruses (JCV, BKV, and SV40) using three different sets of primers by multiplex nested PCR analysis. We related the patients with diffuse malignant mesotheioma to possible sites of exposure to asbestos.
Results None of the DMMs nor any patient in the control group had SV40 genome on polymerase chain reaction (PCR). All of the cases were SV40 T antigen negative.
Conclusion This study suggests that DMM is independent of SV40 infection in Iran. Am. J. Ind. Med. 56:1221-1225, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Mohammad-Taheri, Zohreh; Nadji, Seyed Alireza] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis, Virol Res Ctr, Tehran, Iran.
[Raisi, Farshid] Shahid Beheshti Univ Med Sci, Dept Pathol & Lab Med, Masih Daneshvari Hosp, NRITLD, Tehran, Iran.
[Mohammadi, Forouzan] Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr, Natl Res Inst TB & Lung Dis, Tehran, Iran.
[Bahadori, Moslem] Shahid Beheshti Univ Med Sci, Clin TB & Epidemiol Res Ctr, Natl Res Inst TB & Lung Dis, Tehran, Iran.
[Mark, Eugene Jerome] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Mohammad-Taheri, Z (reprint author), Daneshvary Hosp, NRITLD, Tehran, Iran.
EM zohrehmt@yahoo.com
RI Nadji, Seyed Alireza/C-4172-2016;
OI Nadji, Seyed Alireza/0000-0002-8823-384X; Bahadori,
Moslem/0000-0001-7050-6320
NR 31
TC 2
Z9 2
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0271-3586
EI 1097-0274
J9 AM J IND MED
JI Am. J. Ind. Med.
PD OCT
PY 2013
VL 56
IS 10
BP 1221
EP 1225
DI 10.1002/ajim.22160
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 210JT
UT WOS:000323829200011
PM 23828611
ER
PT J
AU Ryan, ET
AF Ryan, Edward T.
TI Eyes on the Prize: Lessons from the Cholera Wars for Modern Scientists,
Physicians, and Public Health Officials
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Editorial Material
C1 [Ryan, Edward T.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Ryan, ET (reprint author), Massachusetts Gen Hosp, Jackson 504,55 Fruit St, Boston, MA 02114 USA.
EM etryan@partners.org
NR 0
TC 1
Z9 1
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2013
VL 89
IS 4
BP 610
EP 614
DI 10.4269/ajtmh.13-0173
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 240UB
UT WOS:000326122100002
PM 24106185
ER
PT J
AU Oh, S
Go, GW
Choi, NJ
Oh, S
Kim, Y
AF Oh, Sangnarn
Go, Gwang-woong
Choi, Nag-Jin
Oh, Sejong
Kim, Younghoon
TI Possible Involvement of Mycoplasma hominis in Inhibiting the Formation
of Biofilms by Uropathogenic Escherichia coli (UPEC)
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE biofilm formation; Mycoplasma hominis; uropathogenic Escherichia coli;
whole transcriptome analysis
ID URINARY-TRACT-INFECTIONS; CELLS; EXOPOLYSACCHARIDE; COMMUNITIES;
EXPRESSION; VIRULENCE; STRAINS; O157-H7; INDOLE; CFT073
AB Here we examined the involvement of Mycoplasma hominis in the formation of biofilms by uropathogenic Escherichia coli (UPEC) strain CFT073. Initially, we thought that M. hominis does not affect the fitness of UPEC, including the growth and production of signaling molecules, such as autoinducer-2 and indole. We found, however, that the presence of M. hominis significantly decreased the degree of biofilm formation by UPEC CFT073 (approximately a 60% reduction for 10(5) ccu/mL of M. hominis as compared with UPEC alone). We also found that it had a slight effect in inhibiting the attachment and cytotoxicity of UPEC CFT073. These findings are specific to these UPEC strains rather than to enterohemorrhagic E. coli (EHEC) strains, found in normal intestinal flora. In addition, we performed whole-transcriptome profiling and quantitative realtime polymerase chain reaction (qRT-PCR) analysis. This indicated that the PhoPQ system and the anti-termination protein (encoded by ybcQ) were involved in the reduction of biofilm formation by M. hominis (corroborated by qRT-PCR). Furthermore, our results indicate that M. hominis raises the degree of transcription of toxin genes, including hha and pasT. Hence, we suggest a possible role of M. hominis in affecting the formation of biofilms by UPEC in the urinary tract.
C1 [Oh, Sangnarn] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA.
[Go, Gwang-woong] Yale Univ, Sch Med, Cardiovasc Res Ctr, New Haven, CT 06511 USA.
[Choi, Nag-Jin; Kim, Younghoon] Chonbuk Natl Univ, Dept Anim Sci, Jeonju 561756, South Korea.
[Choi, Nag-Jin; Kim, Younghoon] Chonbuk Natl Univ, Inst Rare Earth Biol Applicat, Jeonju 561756, South Korea.
[Oh, Sejong] Chonnam Natl Univ, Inst Agr Sci & Technol, Div Anim Sci, Kwangju 500757, South Korea.
RP Kim, Y (reprint author), Chonbuk Natl Univ, Dept Anim Sci, Jeonju 561756, South Korea.
EM ykeys2584@jbnu.ac.kr
FU Cooperative Research Program for Agriculture Science and Technology
Development, Rural Development Administration, Republic of Korea
[PJ007963]
FX We are grateful to Dr. Harry L. Mobley (University of Michigan Medical
School) and to Dr. Indal Park (Kosin University College of Medicine) for
providing us with the UPEC CFT073 and M. hominis PG21 strains
respectively. This work was supported by the Cooperative Research
Program for Agriculture Science and Technology Development, Rural
Development Administration, Republic of Korea (project no. PJ007963).
NR 29
TC 0
Z9 0
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD OCT
PY 2013
VL 77
IS 10
BP 2025
EP 2029
DI 10.1271/bbb.130320
PG 5
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Chemistry; Food Science & Technology
GA 245TK
UT WOS:000326486500008
PM 24096662
ER
PT J
AU Frankel, HL
Kaplan, LJ
AF Frankel, Heidi L.
Kaplan, Lewis J.
TI In brief
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Editorial Material
C1 [Frankel, Heidi L.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA.
RP Frankel, HL (reprint author), Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 414
EP 417
DI 10.1067/j.cpsurg.2013.07.002
PG 4
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300002
ER
PT J
AU Tinti, MS
Gracias, VH
Kaplan, LJ
AF Tinti, Meridith S.
Gracias, Vincente H.
Kaplan, Lewis J.
TI Adjuncts to ventilation part II: Monitoring, fluid management, bundles,
and positioning
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Review
ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; CENTRAL
VENOUS CATHETER; ACUTE LUNG INJURY; COMPARTMENT SYNDROME;
PULMONARY-ARTERY; FAILURE; PNEUMONIA; THERAPY
C1 [Tinti, Meridith S.] UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA.
[Tinti, Meridith S.; Gracias, Vincente H.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA.
[Gracias, Vincente H.] UMDNJ Robert Wood Johnson Med Sch, Div Trauma & Acute Care Surg, New Brunswick, NJ USA.
[Gracias, Vincente H.] Univ Illinois, Chicago, IL 60680 USA.
[Gracias, Vincente H.] Univ Penn, Surg ICU, Philadelphia, PA 19104 USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA.
RP Tinti, MS (reprint author), UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA.
NR 22
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 433
EP 437
DI 10.1067/j.cpsurg.2013.08.006
PG 5
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300004
PM 24156840
ER
PT J
AU Maung, AA
Kaplan, LJ
AF Maung, Adrian A.
Kaplan, Lewis J.
TI Waveform analysis during mechanical ventilation
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Review
ID RECRUITMENT; PRESSURE
C1 [Maung, Adrian A.; Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA.
[Maung, Adrian A.] Univ Maryland, R Adams Cowley Shock Trauma Ctr, College Pk, MD 20742 USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Maung, AA (reprint author), Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA.
NR 10
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 438
EP 446
DI 10.1067/j.cpsurg.2013.08.007
PG 9
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300005
PM 24156841
ER
PT J
AU Jung, HS
Kaplan, LJ
Park, PK
AF Jung, Hee Soo
Kaplan, Lewis J.
Park, Pauline K.
TI Reviewing the studies of the National Heart, Lung, and Blood Institute
Acute Respiratory Distress Syndrome Network: Outcomes and clinical
findings
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Review
ID GAMMA-LINOLENIC ACID; MECHANICALLY VENTILATED PATIENTS; RANDOMIZED
CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; PULMONARY-ARTERY
CATHETERS; CRITICALLY-ILL PATIENTS; EICOSAPENTAENOIC ACID;
CALORIC-INTAKE; SURGICAL PATIENTS; AIRWAY PRESSURE
C1 [Jung, Hee Soo] Univ Wisconsin Madison, Madison, WI USA.
[Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA.
[Park, Pauline K.] Univ Michigan, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA.
RP Jung, HS (reprint author), Univ Wisconsin Madison, Madison, WI USA.
NR 56
TC 0
Z9 0
U1 1
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 451
EP 462
DI 10.1067/j.cpsurg.2013.08.009
PG 12
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300007
PM 24156843
ER
PT J
AU Kaplan, LJ
Toevs, CC
AF Kaplan, Lewis J.
Toevs, Christine C.
TI Weaning from mechanical ventilation
SO CURRENT PROBLEMS IN SURGERY
LA English
DT Review
ID SPONTANEOUS-BREATHING TRIAL; EXTUBATION FAILURE; INDEX; METAANALYSIS;
LIBERATION; SEDATION; PROTOCOL; PREDICT; TRAUMA
C1 [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kaplan, Lewis J.] Yale Univ, Sch Med, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT USA.
[Toevs, Christine C.] E Carolina Univ, Sch Med, Greenville, NC 27858 USA.
RP Kaplan, LJ (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 22
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0011-3840
EI 1535-6337
J9 CURR PROB SURG
JI Curr. Probl. Surg.
PD OCT
PY 2013
VL 50
IS 10
BP 489
EP 494
DI 10.1067/j.cpsurg.2013.08.014
PG 6
WC Surgery
SC Surgery
GA 245QQ
UT WOS:000326479300012
PM 24156848
ER
PT J
AU Loftis, JM
Hauser, P
AF Loftis, Jennifer M.
Hauser, Peter
TI Pain and Opioid Use in Chronic Liver Disease: Optimal Treatment Must
Address the Mental Health Care Needs of the Patient
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Editorial Material
ID SUBSTANCE USE DISORDERS; CHRONIC HEPATITIS-C; PSYCHIATRIC-DISORDERS;
DEPRESSED-PATIENTS; VETERANS; INFECTION
C1 [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA.
[Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
[Hauser, Peter] VISN 22 Network Off, Long Beach, CA 90802 USA.
RP Hauser, P (reprint author), VISN 22 Network Off, 300 Oceangate,Suite 700, Long Beach, CA 90802 USA.
EM Peter.Hauser2@va.gov
FU BLRD VA [I01 BX002061]; NIDA NIH HHS [P50 DA018165]
NR 21
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD OCT
PY 2013
VL 58
IS 10
BP 2753
EP 2755
DI 10.1007/s10620-013-2809-4
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 223BO
UT WOS:000324778900044
PM 23959213
ER
PT J
AU Sonnenberg, A
Genta, RM
AF Sonnenberg, Amnon
Genta, Robert M.
TI Lymphocytic and Collagenous Colitis: Epidemiologic Differences and
Similarities
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Adenomatous polyps; Collagenous colitis; Geographic distribution;
Epidemiology; Lymphocytic colitis; Microscopic colitis
ID MICROSCOPIC COLITIS; DISORDERS; DISEASE
AB Background It is unknown whether the subtypes of microscopic colitis (MC) represent distinct nosologic entities or related presentations of the same disease. Our aim was to search for epidemiologic differences among its various histopathologic subtypes.
Methods In a computerized database of 789,568 colon pathology reports, we compared the characteristics of 8,745 MC patients with those of the remaining population.
Results MC was diagnosed as three distinct histopathologic subtypes: lymphocytic colitis (LC) in 51 %, collagenous colitis (CC) in 43 %, and incomplete colitis (IC) in 6 % of patients. Only 0.65 % was simultaneously diagnosed with more than one subtype of MC. The prevalence of all three subtypes showed an age-dependent rise, with the average age (SD) being 63.3 (14.3) years in LC, 66.4 (12.1) years in CC, and 67.3 (12.7) years in IC (p < 0.0001). There was a striking female predominance in all three subtypes, the female fraction being 72 % in LC, 82 % in CC, and 79 % in IC (p < 0.0001). All three subtypes showed similar geographic distributions among different US states. They were similarly associated with diarrhea and weight loss, the odds ratios for all MC being 45.92 (43.35-48.63) and 5.12 (4.68-5.60), respectively, compared to control patients without MC. All three subtypes also harbored significantly less colonic adenomas, the overall odds ratio being 0.11 (0.10-0.12).
Conclusion MC comes in three distinct histopathologic entities, which show striking similarities of their general epidemiologic features. The slight differences in their demographic characteristics could point at varying sets of environmental influences that affect the occurrence of subtypes.
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Dept Gastroenterol, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Genta, Robert M.] Miraca Life Sci, Irving, TX USA.
[Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
FU Takeda Pharmaceuticals
FX Amnon Sonnenberg was supported by a grant from Takeda Pharmaceuticals.
No funding was obtained for this study.
NR 14
TC 11
Z9 11
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD OCT
PY 2013
VL 58
IS 10
BP 2970
EP 2975
DI 10.1007/s10620-013-2718-6
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 223BO
UT WOS:000324778900010
PM 23709158
ER
PT J
AU Schafer, CM
Campbell, NG
Cai, GQ
Yu, F
Makarov, V
Yoon, S
Daly, MJ
Gibbs, RA
Schellenberg, GD
Devlin, B
Sutcliffe, JS
Buxbaum, JD
Roeder, K
AF Schafer, Chad M.
Campbell, Nicholas G.
Cai, Guiqing
Yu, Fei
Makarov, Vladimir
Yoon, Seungtai
Daly, Mark J.
Gibbs, Richard A.
Schellenberg, Gerard D.
Devlin, Bernie
Sutcliffe, James S.
Buxbaum, Joseph D.
Roeder, Kathryn
TI Whole exome sequencing reveals minimal differences between cell line and
whole blood derived DNA
SO GENOMICS
LA English
DT Article
DE Graphical diagnostics; Lymphoblastoid cell line; Mosaicism; Sequence
variant call; Strand bias; Somatic mutation
ID DE-NOVO MUTATIONS; COPY NUMBER; GENOME; DISORDERS; FRAMEWORK; NETWORK;
RATES
AB Two common sources of DNA for whole exome sequencing (WES) are whole blood (WB) and immortalized lymphoblastoid cell line (LCL). However, it is possible that LCLs have a substantially higher rate of mutation than WB, causing concern for their use in sequencing studies. We compared results from paired WB and LCL DNA samples for 16 subjects, using LCLs of low passage number (<5). Using a standard analysis pipeline we detected a large number of discordant genotype calls (approximately 50 per subject) that we segregated into categories of "confidence" based on read-level quality metrics. From these categories and validation by Sanger sequencing, we estimate that the vast majority of the candidate differences were false positives and that our categories were effective in predicting valid sequence differences, including LCLs with putative mosaicism for the non-reference allele (3-4 per exome). These results validate the use of DNA from LCLs of low passage number for exome sequencing. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Schafer, Chad M.; Yu, Fei; Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
[Campbell, Nicholas G.; Sutcliffe, James S.] Vanderbilt Univ, Vanderbilt Brain Inst, Dept Mol Physiol & Biophys, Nashville, IN 37232 USA.
[Cai, Guiqing; Makarov, Vladimir; Yoon, Seungtai; Buxbaum, Joseph D.] Mt Sinai, Seaver Autism Ctr Res & Treatment, Icahn Sch Med, New York, NY 10029 USA.
[Cai, Guiqing; Makarov, Vladimir; Yoon, Seungtai; Buxbaum, Joseph D.] Mt Sinai, Dept Psychiat, Icahn Sch Med, New York, NY 10029 USA.
[Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Dept Med, Boston, MA 02114 USA.
[Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Gibbs, Richard A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Schellenberg, Gerard D.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Devlin, Bernie] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Buxbaum, Joseph D.] Mt Sinai, Dept Genet & Genom Sci, Icahn Sch Med, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Mt Sinai, Friedman Brain Inst, Icahn Sch Med, New York, NY 10029 USA.
[Roeder, Kathryn] Carnegie Mellon Univ, Ray & Stephanie Lane Ctr Computat Biol, Pittsburgh, PA 15213 USA.
[Campbell, Nicholas G.; Sutcliffe, James S.] Vanderbilt Univ, Vanderbilt Brain Inst, Dept Psychiatiy, Nashville, TN 37232 USA.
RP Roeder, K (reprint author), Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
EM roeder@stat.cmu.edu
RI Sutcliffe, James/C-1348-2012;
OI Sutcliffe, James/0000-0001-5200-6007; Buxbaum,
Joseph/0000-0001-8898-8313
FU ARRA Autism Sequencing Consortium [R01MH089208, R01MH089025,
R01MH089004, R01MH089175, R01 MH089482]; NIH [RO1 MH057881, R01
MH061009]; Seaver Foundation; NIH NCRR [UL1 RR024975]; Vanderbilt
Kennedy Center for Research on Human Development [P30 HD015052]
FX This work was directly supported by the ARRA Autism Sequencing
Consortium grants (R01MH089208, R01MH089025-J.D.B., R01MH089004,
R01MH089175 and R01 MH089482-J.S.S.), and supported in part by NIH
grants RO1 MH057881 (B.D.) and R01 MH061009 (J.S.S.). J.D.B. is
supported by the Seaver Foundation. We thank T. Lehner, A. Felsenfeld
and P. Bender for their support and contribution to the project. We
acknowledge the assistance of M. Potter, A. McGrew and G. Crockett
without whom these studies would not be possible, and the Center for
Human Genetics Research resources: Computational Genomics Core, Genetic
Studies Ascertainment Core and DNA Resources Core, supported in part by
NIH NCRR grant UL1 RR024975, and the Vanderbilt Kennedy Center for
Research on Human Development (P30 HD015052). We acknowledge the
clinicians and organizations that contributed to samples used in this
study and particularly the support of families and clinicians of the
Icahn School of Medicine at Mount Sinai and Vanderbilt University.
M.J.D., R.A.G., G.D.S., B.D., J.S.S., J.D.B. and K.R., are lead
investigators in the Autism Sequencing Consortium (ASC).
NR 15
TC 4
Z9 4
U1 1
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
EI 1089-8646
J9 GENOMICS
JI Genomics
PD OCT
PY 2013
VL 102
IS 4
BP 270
EP 277
DI 10.1016/j.ygeno.2013.05.005
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 244YE
UT WOS:000326425300013
PM 23743231
ER
PT J
AU Vegh, EM
Sood, N
Singh, JP
AF Vegh, Eszter M.
Sood, Nitesh
Singh, Jagmeet P.
TI The Role of Ablation of the Atrioventricular Junction in Patients with
Heart Failure and Atrial Fibrillation
SO HEART FAILURE CLINICS
LA English
DT Article
DE AV junction ablation; Cardiac resynchronization therapy; Therapy
refractory atrial fibrillation
ID CARDIAC RESYNCHRONIZATION THERAPY; VENTRICULAR SYSTOLIC DYSFUNCTION;
RADIOFREQUENCY CATHETER ABLATION; AV NODAL ABLATION; TACHYCARDIA-INDUCED
CARDIOMYOPATHY; CARDIOVERTER-DEFIBRILLATOR SHOCKS; LONG-TERM SURVIVAL;
RHYTHM CONTROL; INTRAMURAL DYSSYNCHRONY; MYOCARDIAL-INFARCTION
AB Ablation of the atrioventricular junction (AVJ) is a technically easy procedure that is safe and has a high success rate as an intervention for effective ventricular rate control in patients in symptomatic atrial fibrillation. AVJ ablation has been reported to improve quality of life, left ventricular ejection fraction, and exercise duration in these patients and minimize the incidence of inappropriate shocks. Because right ventricular pacing after AVJ ablation may result in decrease in left ventricular function and worsening of heart failure symptoms, there is increasing evidence to support the effectiveness of cardiac resynchronization therapy in atrial fibrillation populations.
C1 [Vegh, Eszter M.; Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
[Sood, Nitesh] Tufts Univ, Lahey Clin, Div Cardiol, Burlington, MA 01805 USA.
RP Singh, JP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, 55 Fruit St, Boston, MA 02114 USA.
EM jsingh@partners.org
FU Biotronik; Boston Scientific; Medtronic; Sorin Group; St. Jude Medical
FX EMV and NS have no disclosures. JPS: Lectures, consulting and research
grants from Biotronik, Boston Scientific, Medtronic, Sorin Group, and
St. Jude Medical.
NR 78
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7136
J9 HEART FAIL CLIN
JI Heart Fail. Clin.
PD OCT
PY 2013
VL 9
IS 4
BP 489
EP +
DI 10.1016/j.hfc.2013.07.003
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 241XS
UT WOS:000326202600013
PM 24054481
ER
PT J
AU Wagner, AJ
AF Wagner, Andrew J.
TI Sarcoma Preface
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Wagner, AJ (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM andrew_wagner@dfci.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD OCT
PY 2013
VL 27
IS 5
BP XI
EP XII
DI 10.1016/j.hoc.2013.08.001
PG 2
WC Oncology; Hematology
SC Oncology; Hematology
GA 244CL
UT WOS:000326364600001
PM 24093177
ER
PT J
AU Barnett, CM
Corless, CL
Heinrich, MC
AF Barnett, Christine M.
Corless, Christopher L.
Heinrich, Michael C.
TI Gastrointestinal Stromal Tumors Molecular Markers and Genetic Subtypes
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE GIST; KIT; PDGFRA; RTK-wild-type; SDH
ID SUCCINATE-DEHYDROGENASE SUBUNIT; RECEPTOR TYROSINE KINASE; OF-FUNCTION
MUTATIONS; C-KIT; PDGFRA MUTATIONS; SDHA MUTATIONS; INTERSTITIAL-CELLS;
CARNEY-STRATAKIS; STRUCTURAL BASIS; BRAF MUTATIONS
AB Mutation-activated signaling from the KIT and PDGFRA kinases has been successfully targeted in gastrointestinal stromal tumors (GISTs), with subtle differences between the mutations serving to refine prognosis and more precisely tailor therapy. There is a growing understanding of the molecular drivers of GISTs lacking mutations in KIT or PDGFRA, so called wild-type GISTs, further aiding in management decisions. This article provides an overview of all the known molecular subtypes of GIST and provides information about clinical correlates, treatment, and prognosis depending on the subtype.
C1 [Barnett, Christine M.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Portland VA Med Ctr, Portland, OR 97239 USA.
[Corless, Christopher L.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Dept Pathol, Portland, OR 97239 USA.
[Heinrich, Michael C.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Portland VA Med Ctr,Dept Med, Portland, OR 97239 USA.
[Heinrich, Michael C.] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Dept Cell & Dev Biol,Portland VA Med Ctr, Portland, OR 97239 USA.
RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol Oncol, Dept Cell & Dev Biol,Portland VA Med Ctr, R&D-19 3710,US Vet Hosp Rd, Portland, OR 97239 USA.
EM heinrich@ohsu.edu
FU Novartis; Pfizer; Bayer; Ariad; MolecularMD; AROG; Imclone
FX None (C.M. Barnett); honoraria from Novartis; consulting fees from
Novartis and Pfizer; research support from Novartis, Pfizer, and Bayer
(C.L. Corless); honoraria from Onyx; consulting fees from Novartis,
Pfizer, Ariad, MolecularMD; research support from Novartis, Pfizer,
AROG, Ariad, Imclone; equity interest: MolecularMD (M.C. Heinrich).
NR 78
TC 13
Z9 13
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD OCT
PY 2013
VL 27
IS 5
BP 871
EP 888
DI 10.1016/j.hoc.2013.07.003
PG 18
WC Oncology; Hematology
SC Oncology; Hematology
GA 244CL
UT WOS:000326364600002
PM 24093165
ER
PT J
AU Gronchi, A
Raut, CP
AF Gronchi, Alessandro
Raut, Chandrajit P.
TI Treatment of Localized Sarcomas
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Sarcoma; GIST; Surgery; Radiation therapy; Chemotherapy; Tyrosine kinase
inhibitors; Survival; Outcome
ID SOFT-TISSUE SARCOMAS; GASTROINTESTINAL STROMAL TUMORS;
RADIATION-ASSOCIATED ANGIOSARCOMA; ISOLATED LIMB PERFUSION; LONG-TERM
OUTCOMES; SINGLE INSTITUTION; PROGNOSTIC-FACTORS; RETROPERITONEAL
SARCOMAS; PREOPERATIVE RADIATION; ADJUVANT CHEMOTHERAPY
AB Surgery remains the only potentially curative therapy in the management of localized adult soft tissue sarcomas and gastrointestinal stromal tumors. There are over 50 different unique histologic types of soft tissue sarcomas, With different patterns of recurrence and prognosis. Surgical principles and sensitivity to locoregional and systemic treatments vary considerably based on the histologic type and anatomic location, as discussed in detail in this review.
C1 [Gronchi, Alessandro] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Sarcoma Serv, I-20133 Milan, Italy.
[Raut, Chandrajit P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Surg,Brigham & Womens Hosp,Ctr Sarcoma & Bon, Boston, MA 02115 USA.
RP Raut, CP (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Surg,Brigham & Womens Hosp,Ctr Sarcoma & Bon, 75 Francis St, Boston, MA 02115 USA.
EM craut@partners.org
OI Gronchi, Alessandro/0000-0002-4703-3534
NR 62
TC 5
Z9 5
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD OCT
PY 2013
VL 27
IS 5
BP 921
EP 938
DI 10.1016/j.hoc.2013.07.006
PG 18
WC Oncology; Hematology
SC Oncology; Hematology
GA 244CL
UT WOS:000326364600005
PM 24093168
ER
PT J
AU Serrano, C
George, S
AF Serrano, Cesar
George, Suzanne
TI Leiomyosarcoma
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Leiomyosarcoma; Chemotherapy; Targeted therapy; Prognostic factors;
Uterine leiomyosarcoma
ID SOFT-TISSUE SARCOMAS; PHASE-II TRIAL; GYNECOLOGIC-ONCOLOGY-GROUP;
INFERIOR VENA-CAVA; GEMCITABINE PLUS DOCETAXEL; FIXED-DOSE-RATE;
UTERINE-SARCOMAS; PROGNOSTIC-FACTORS; EUROPEAN ORGANIZATION;
RADIATION-THERAPY
AB This article presents an overview of the current literature about the biology, pathology, and the clinical management of leiomyosarcoma. In addition, the article emphasizes and discusses the current systemic treatment options available for patients with leiomyosarcoma, which range from cytotoxic chemotherapy to target therapies. Particular leiomyosarcoma subtypes, such as uterine leiomyosarcoma and inferior vena cava leiomyosarcoma, are discussed separately.
C1 [Serrano, Cesar] Brigham & Womens Hosp, Fletcher Lab, Dept Pathol, Boston, MA 02115 USA.
[Serrano, Cesar; George, Suzanne] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02215 USA.
RP George, S (reprint author), Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM sgeorge2@partners.org
FU Spanish Society of Medical Oncology; Driscoll Family Leiomyosarcoma
Research Fund
FX Spanish Society of Medical Oncology (SEOM) Translational Award (C.
Serrano); Driscoll Family Leiomyosarcoma Research Fund (S. George).
NR 101
TC 13
Z9 15
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD OCT
PY 2013
VL 27
IS 5
BP 957
EP 974
DI 10.1016/j.hoc.2013.07.002
PG 18
WC Oncology; Hematology
SC Oncology; Hematology
GA 244CL
UT WOS:000326364600007
PM 24093170
ER
PT J
AU Cote, GM
Choy, E
AF Cote, Gregory M.
Choy, Edwin
TI Update in Treatment and Targets in Ewing Sarcoma
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Ewing sarcoma; Chemotherapy; Oncology; Treatment; Tumor
ID CHILDRENS-ONCOLOGY-GROUP; PRIMITIVE NEUROECTODERMAL TUMOR; GROUP
PHASE-II; MONOCLONAL-ANTIBODY; CANCER GROUP; NEOADJUVANT CHEMOTHERAPY;
STANDARD CHEMOTHERAPY; TRANSCRIPTION FACTOR; MULTIMODAL THERAPY;
RECURRENT SARCOMAS
AB The improvement in outcome for patients with localized and metastatic Ewing sarcoma since the development of cytotoxic chemotherapy remains one of the most profound advances in oncology and one of the proudest achievements of sarcoma researchers. Identification of molecular targets for new treatments has become an intense area within Ewing sarcoma research. The development of improved preclinical Ewing sarcoma models and advanced molecular techniques will build on knowledge of EWS/FLI1 function, EWS/FLI1 transcription targets, and the other critical driver events in these tumors.
C1 [Cote, Gregory M.; Choy, Edwin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Yawkey Ctr Outpatient Care, Boston, MA 02114 USA.
RP Choy, E (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Yawkey Ctr Outpatient Care, 32 Fruit St, Boston, MA 02114 USA.
EM echoy@partners.org
OI Cote, Gregory/0000-0003-0181-886X
NR 58
TC 2
Z9 2
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD OCT
PY 2013
VL 27
IS 5
BP 1007
EP 1019
DI 10.1016/j.hoc.2013.07.001
PG 13
WC Oncology; Hematology
SC Oncology; Hematology
GA 244CL
UT WOS:000326364600010
PM 24093173
ER
PT J
AU Galka, A
Wong, KKF
Stephani, U
Ozaki, T
Siniatchkin, M
AF Galka, Andreas
Wong, Kevin K. F.
Stephani, Ulrich
Ozaki, Tohru
Siniatchkin, Michael
TI BLIND SIGNAL SEPARATION OF MIXTURES OF CHAOTIC PROCESSES: A COMPARISON
BETWEEN INDEPENDENT COMPONENT ANALYSIS AND STATE SPACE MODELING
SO INTERNATIONAL JOURNAL OF BIFURCATION AND CHAOS
LA English
DT Article
DE Blind signal separation; independent component analysis; state space
modeling
ID NONSTATIONARY TIME-SERIES; LEAST-SQUARES ESTIMATION; MAXIMUM-LIKELIHOOD;
DYNAMIC FACTOR; EEG; DECOMPOSITION; ALGORITHM; SYSTEMS; DECONVOLUTION;
INFORMATION
AB We perform a systematic comparison between different algorithms for solving the Blind Signal Separation problem. In particular, we compare five well-known algorithms for Independent Component Analysis (ICA) with a recently proposed algorithm based on linear state space modeling (IC-LSS). The comparison is based on simulated mixtures of six source signals, five of which are generated by nonlinear deterministic processes evolving on chaotic attractors. The quality of the reconstructed sources is quantified by two measures, one based on a distance measure implemented by a Frobenius norm, and one based on residual mutual information. We find that the IC-LSS modeling algorithm offers several advantages over the ICA algorithms: it succeeds in unmixing Gaussian sources, on short time series it performs, on average, better than static ICA algorithms, it does not try to remove coincidental dependencies resulting from finite data set size, and it shows the potential to reconstruct the sources even in the case of noninvertible mixing. As expected, for the case of non-Gaussian sources, invertible mixing and sufficient time series length, the ICA algorithms typically outperform IC-LSS modeling.
C1 [Galka, Andreas; Stephani, Ulrich] Univ Kiel, Dept Neuropediat, D-24098 Kiel, Germany.
[Galka, Andreas] Univ Kiel, Inst Expt & Appl Phys, D-24098 Kiel, Germany.
[Wong, Kevin K. F.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ozaki, Tohru] Tohoku Univ, Aoba Ku, Sendai, Miyagi 9808576, Japan.
[Siniatchkin, Michael] Goethe Univ Frankfurt, Dept Psychiat Psychosomat Med & Psychotherapy, D-60528 Frankfurt, Germany.
RP Galka, A (reprint author), Univ Kiel, Dept Neuropediat, D-24098 Kiel, Germany.
RI Wong, Kin Foon Kevin/C-7896-2014; Stephani, Ulrich/D-1004-2010
FU German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)
[Sonderforschungsbereich SFB 855]
FX The work of A. Galka was supported by the German Research Foundation
(Deutsche Forschungsgemeinschaft, DFG) through Sonderforschungsbereich
SFB 855 "Biomagnetic Sensing".
NR 70
TC 2
Z9 2
U1 1
U2 11
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0218-1274
EI 1793-6551
J9 INT J BIFURCAT CHAOS
JI Int. J. Bifurcation Chaos
PD OCT
PY 2013
VL 23
IS 10
AR 1350165
DI 10.1142/S0218127413501654
PG 24
WC Mathematics, Interdisciplinary Applications; Multidisciplinary Sciences
SC Mathematics; Science & Technology - Other Topics
GA 245MT
UT WOS:000326468500003
ER
PT J
AU Abbasi, SA
Ertel, A
Shah, RV
Dandekar, V
Chung, J
Bhat, G
Desai, AA
Kwong, RY
Farzaneh-Far, A
AF Abbasi, Siddique A.
Ertel, Andrew
Shah, Ravi V.
Dandekar, Vineet
Chung, Jaehoon
Bhat, Geetha
Desai, Ankit A.
Kwong, Raymond Y.
Farzaneh-Far, Afshin
TI Impact of cardiovascular magnetic resonance on management and clinical
decision-making in heart failure patients
SO JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
LA English
DT Article
ID NONINVASIVE DETECTION; DISEASE; CARDIOMYOPATHY; DYSFUNCTION; INFARCTION;
TRIAL
AB Background: Cardiovascular magnetic resonance (CMR) can provide important diagnostic and prognostic information in patients with heart failure. However, in the current health care environment, use of a new imaging modality like CMR requires evidence for direct additive impact on clinical management. We sought to evaluate the impact of CMR on clinical management and diagnosis in patients with heart failure.
Methods: We prospectively studied 150 consecutive patients with heart failure and an ejection fraction <= 50% referred for CMR. Definitions for "significant clinical impact" of CMR were pre-defined and collected directly from medical records and/or from patients. Categories of significant clinical impact included: new diagnosis, medication change, hospital admission/discharge, as well as performance or avoidance of invasive procedures (angiography, revascularization, device therapy or biopsy).
Results: Overall, CMR had a significant clinical impact in 65% of patients. This included an entirely new diagnosis in 30% of cases and a change in management in 52%. CMR results directly led to angiography in 9% and to the performance of percutaneous coronary intervention in 7%. In a multivariable model that included clinical and imaging parameters, presence of late gadolinium enhancement (LGE) was the only independent predictor of "significant clinical impact" (OR 6.72, 95% CI 2.56-17.60, p=0.0001).
Conclusions: CMR made a significant additive clinical impact on management, decision-making and diagnosis in 65% of heart failure patients. This additive impact was seen despite universal use of prior echocardiography in this patient group. The presence of LGE was the best independent predictor of significant clinical impact following CMR.
C1 [Abbasi, Siddique A.; Shah, Ravi V.; Kwong, Raymond Y.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA.
[Abbasi, Siddique A.; Shah, Ravi V.] Harvard Univ, Sch Med, Boston, MA USA.
[Abbasi, Siddique A.; Ertel, Andrew; Dandekar, Vineet; Chung, Jaehoon; Bhat, Geetha; Desai, Ankit A.; Farzaneh-Far, Afshin] Univ Illinois, Dept Med, Sect Cardiol, Chicago, IL 60612 USA.
[Shah, Ravi V.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Bhat, Geetha] Advocate Christ Med Ctr, Ctr Heart Transplant & Assist Devices, Oak Lawn, IL USA.
[Farzaneh-Far, Afshin] Univ Illinois, Dept Radiol, Chicago, IL 60612 USA.
RP Farzaneh-Far, A (reprint author), Univ Illinois, Dept Med, Sect Cardiol, 840 South Wood St M-C 715,Suite 920 S, Chicago, IL 60612 USA.
EM afshin@uic.edu
OI Abbasi, Siddique/0000-0002-9601-7565
NR 23
TC 17
Z9 17
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1097-6647
EI 1532-429X
J9 J CARDIOVASC MAGN R
JI J. Cardiov. Magn. Reson.
PD OCT 1
PY 2013
VL 15
AR 89
DI 10.1186/1532-429X-15-89
PG 8
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 245LX
UT WOS:000326466300002
PM 24083836
ER
PT J
AU Walcott, BP
Boehm, KM
Stapleton, CJ
Mehta, BP
Nahed, BV
Ogilvy, CS
AF Walcott, Brian P.
Boehm, Kevin M.
Stapleton, Christopher J.
Mehta, Brijesh P.
Nahed, Brian V.
Ogilvy, Christopher S.
TI Retrievable stent thrombectomy in the treatment of acute ischemic
stroke: Analysis of a revolutionizing treatment technique
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Review
DE Endovascular; Ischemia; Neurosurgery; Solitaire; Stent; Stroke; Trevo
ID TISSUE-PLASMINOGEN-ACTIVATOR; CEREBRAL-ARTERY OCCLUSION; SINGLE-CENTER
EXPERIENCE; RT-PA STROKE; MECHANICAL THROMBECTOMY; ANTERIOR CIRCULATION;
FLOW RESTORATION; PENUMBRA SYSTEM; SOLITAIRE STENT; MERCI RETRIEVER
AB Acute ischemic stroke resulting from intracranial vessel occlusion is associated with high morbidity and mortality. The mainstays of therapy are fibrinolytics and mechanical thrombectomy in properly selected patients. A new Food and Drug Administration-approved technology to perform thrombectomy, retrievable stenting, may provide superior revascularization rates and improved patient outcomes. We analyzed the cumulative human experience reported for the Trevo Pro Retrieval System (Stryker, Kalamazoo, MI, USA) and the Solitaire FR Revascularization Device (ev3, Irvine, CA, USA) as the definitive treatment for acute ischemic stroke. A literature search was undertaken to identify studies using the retrievable stents published up to September 2012. Nineteen studies identified a total of 576 patients treated with either the Trevo (n = 221) or Solitaire (n = 355) devices. Pooled data analysis identified median baseline National Institutes of Health Stroke Scale scores of 18.5 +/- 0.289 (standard error of the mean) and 17.9 +/- 0.610, and time to recanalization of 53.9 +/- 23.6 minutes and 59.0 +/- 8.0 minutes for the Trevo and Solitaire groups, respectively. Recanalization was variably defined by individual studies, most commonly achieving at least a thrombolysis in cerebral infarction score of 2a-3 or a thrombolysis in myocardial infarction score of 2-3. Revascularization (83%, 82%), mortality (31%, 14%), hemorrhage (8%, 6%), device complications (5%, 6%), and good patient outcomes (51%, 47%) were found with the Trevo and Solitaire devices, respectively. Preliminary analysis reveals excellent clinical outcomes for retrievable stent technology. This may be attributable to both high rates of revascularization with a relatively short time to perfusion restoration. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Walcott, Brian P.; Boehm, Kevin M.; Stapleton, Christopher J.; Nahed, Brian V.; Ogilvy, Christopher S.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Walcott, Brian P.; Boehm, Kevin M.; Stapleton, Christopher J.; Mehta, Brijesh P.; Nahed, Brian V.; Ogilvy, Christopher S.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Boehm, Kevin M.] Yale Univ, New Haven, CT USA.
[Mehta, Brijesh P.] Massachusetts Gen Hosp, Dept Intervent Neuroradiol, Boston, MA 02114 USA.
RP Walcott, BP (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA.
EM walcott.brian@mgh.harvard.edu
FU NINDS NIH HHS [R25 NS065743]
NR 38
TC 11
Z9 11
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
EI 1532-2653
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD OCT
PY 2013
VL 20
IS 10
BP 1346
EP 1349
DI 10.1016/j.jocn.2013.03.015
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 244XC
UT WOS:000326422500003
PM 23938012
ER
PT J
AU Freeman, MP
Walker, R
Laughren, TP
Miller, KK
Fava, M
AF Freeman, Marlene P.
Walker, Rosemary
Laughren, Thomas P.
Miller, Karen K.
Fava, Maurizio
TI Female Reproductive Life Cycle and Hormones: Methodology to Improve
Clinical Trials
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Editorial Material
ID PREMENSTRUAL-SYNDROME; MENOPAUSAL STATUS; SEX-DIFFERENCES; DEPRESSION;
WOMEN; DISORDERS; ESTRADIOL; EFFICACY; STEROIDS; HISTORY
C1 [Freeman, Marlene P.] Massachusetts Gen Hosp, Ctr Womens Mental Hlth, Boston, MA 02114 USA.
[Walker, Rosemary] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Laughren, Thomas P.] Massachusetts Gen Hosp, Clin Trials Network & Inst, Boston, MA 02114 USA.
[Miller, Karen K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
[Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
RP Freeman, MP (reprint author), Massachusetts Gen Hosp, Ctr Womens Hlth, Simches Res Bldg,Fl 2,185 Cambridge St, Boston, MA 02114 USA.
EM mfreeman@partners.org
FU NIMH NIH HHS [R34 MH099315]
NR 31
TC 1
Z9 1
U1 1
U2 1
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD OCT
PY 2013
VL 74
IS 10
BP 1018
EP 1021
DI 10.4088/JCP.13com08742
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 243KU
UT WOS:000326316100011
PM 24229755
ER
PT J
AU Fonarow, GC
Liang, L
Smith, EE
Reeves, MJ
Saver, JL
Xian, Y
Hernandez, AF
Peterson, ED
Schwamm, LH
AF Fonarow, Gregg C.
Liang, Li
Smith, Eric E.
Reeves, Mathew J.
Saver, Jeffrey L.
Xian, Ying
Hernandez, Adrian F.
Peterson, Eric D.
Schwamm, Lee H.
CA GWTG-Stroke Steering Comm Investi
TI Comparison of Performance Achievement Award Recognition With Primary
Stroke Center Certification for Acute Ischemic Stroke Care
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE acute stroke; measures registry; Primary Stroke Center certification
ID AMERICAN-HEART-ASSOCIATION; QUALITY-OF-CARE; GUIDELINES-STROKE;
CARDIOVASCULAR-RADIOLOGY; ATTACK; RECOMMENDATIONS; ESTABLISHMENT;
OUTCOMES; PROGRAM; DISEASE
AB Background-Hospital certification and recognition programs represent 2 independent but commonly used systems to distinguish hospitals, yet they have not been directly compared. This study assessed acute ischemic stroke quality of care measure conformity by hospitals receiving Primary Stroke Center (PSC) certification and those receiving the American Heart Association's Get With The Guidelines-Stroke (GWTG-Stroke) Performance Achievement Award (PAA) recognition.
Methods and Results-The patient and hospital characteristics as well as performance/quality measures for acute ischemic stroke from 1356 hospitals participating in the GWTG-Stroke Program 2010-2012 were compared. Hospitals were classified as PAA+/PSC+ (hospitals n=410, patients n=169 302), PAA+/PSC- (n=415, n=129 454), PAA-/PSC+ (n=88, n=26 386), and PAA-/PSC- (n=443, n=75 565). A comprehensive set of stroke measures were compared with adjustment for patient and hospital characteristics. Patient characteristics were similar by PAA and PSC status but PAA-/PSC- hospitals were more likely to be smaller and nonteaching. Measure conformity was highest for PAA+/PSC+ and PAA+/PSC- hospitals, intermediate for PAA-/PSC+ hospitals, and lowest for PAA-/PSC- hospitals (all-or-none care measure 91.2%, 91.2%, 84.3%, and 76.9%, respectively). After adjustment for patient and hospital characteristics, PAA+/PSC+, PAA+/PSC-, and PAA-/PSC+ hospitals had 3.15 (95% CIs 2.86 to 3.47); 3.23 (2.93 to 3.56) and 1.72 (1.47 to 2.00), higher odds for providing all indicated stroke performance measures to patients compared with PAA-/PSC- hospitals.
Conclusions-While both PSC certification and GWTG-Stroke PAA recognition identified hospitals providing higher conformity with care measures for patients hospitalized with acute ischemic stroke, PAA recognition was a more robust identifier of hospitals with better performance.
C1 [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
[Saver, Jeffrey L.] Univ Calif Los Angeles, Div Neurol, Los Angeles, CA USA.
[Liang, Li; Xian, Ying; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Ctr, Durham, NC USA.
[Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB, Canada.
[Reeves, Mathew J.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.
[Schwamm, Lee H.] Massachusetts Gen Hosp, Div Neurol, Boston, MA 02114 USA.
RP Fonarow, GC (reprint author), Univ Calif Los Angeles, Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, 10833 LeConte Ave,Room 47-123 CHS, Los Angeles, CA 90095 USA.
EM gfonarow@mednet.ucla.edu
RI Smith, Eric/C-5443-2012
OI Smith, Eric/0000-0003-3956-1668
FU Boeringher-Ingelheim; Merck; Bristol-Myers Squib/Sanofi Pharmaceutical
Partnership; Janssen Pharmaceutical Companies of Johnson Johnson;
American Heart Association Pharmaceutical Roundtable
FX The Get With The Guidelines-Stroke (GWTG-Stroke) program is provided by
the American Heart Association/American Stroke Association. GWTG-Stroke
has been funded in the past through support from Boeringher-Ingelheim,
Merck, Bristol-Myers Squib/Sanofi Pharmaceutical Partnership, Janssen
Pharmaceutical Companies of Johnson & Johnson and the American Heart
Association Pharmaceutical Roundtable. The industry sponsors did not
participate in the design, analysis, manuscript preparation, review, or
approval of this manuscript.
NR 27
TC 11
Z9 11
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD OCT
PY 2013
VL 2
IS 5
AR UNSP e000451
DI 10.1161/JAHA.113.000451
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243UL
UT WOS:000326343200014
PM 24125846
ER
PT J
AU Lubitz, SA
Moser, C
Sullivan, L
Rienstra, M
Fontes, JD
Villalon, ML
Pai, M
McManus, DD
Schnabel, RB
Magnani, JW
Yin, XY
Levy, D
Pencina, MJ
Larson, MG
Ellinor, PT
Benjamin, EJ
AF Lubitz, Steven A.
Moser, Carlee
Sullivan, Lisa
Rienstra, Michiel
Fontes, Joao D.
Villalon, Mark L.
Pai, Manju
McManus, David D.
Schnabel, Renate B.
Magnani, Jared W.
Yin, Xiaoyan
Levy, Daniel
Pencina, Michael J.
Larson, Martin G.
Ellinor, Patrick T.
Benjamin, Emelia J.
TI Atrial Fibrillation Patterns and Risks of Subsequent Stroke, Heart
Failure, or Death in the Community
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE atrial fibrillation; heart failure; mortality; pattern; risk; stroke
ID FOLLOW-UP; PROGRESSION; MANAGEMENT; INTERMITTENT; DIAGNOSIS; PROGNOSIS;
SURVIVAL; FEATURES; OUTCOMES; COHORT
AB Background-Atrial fibrillation (AF) patterns and their relations with long-term prognosis are uncertain, partly because pattern definitions are challenging to implement in longitudinal data sets. We developed a novel AF classification algorithm and examined AF patterns and outcomes in the community.
Methods and Results-We characterized AF patterns between 1980 and 2005 among Framingham Heart Study participants who survived >= 1 year after diagnosis. We classified participants based on their pattern within the first 2 years after detection as having AF without recurrence, recurrent AF, or sustained AF. We examined associations between AF patterns and 10-year survival using proportional hazards regression. Among 612 individuals with AF, mean age was 72.5 +/- 10.8 years, and 53% were men. Of these, 478 participants had >= 2 electrocardiograms (median, 3; limits 2 to 23) within 2 years after initial AF and were classified as having AF without 2-year recurrence (n=63, 10%), recurrent AF (n=162, 26%) or sustained AF (n=207, 34%), although some (n=46, 8%) were indeterminate. Of 432 classified participants, 363 died, 75 had strokes, and 110 were diagnosed with heart failure during the next 10 years. Relative to individuals without AF recurrence, the multivariable-adjusted mortality was higher among people with recurrent AF (hazard ratio [HR], 2.04; 95% confidence interval [CI], 1.26 to 3.29) and sustained AF (HR, 2.36; 95% CI, 1.49 to 3.75).
Conclusions-In our community-based AF sample, only 10% had AF without early-term (2-year) recurrence. Compared with individuals without 2-year AF recurrences, the 10-year prognosis was worse for individuals with either sustained or recurrent AF. Our proposed AF classification algorithm may be applicable in longitudinal datas ets.
C1 [Lubitz, Steven A.; Rienstra, Michiel; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Lubitz, Steven A.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
[Moser, Carlee; Sullivan, Lisa; Pencina, Michael J.; Larson, Martin G.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Fontes, Joao D.; Magnani, Jared W.; Benjamin, Emelia J.] Boston Univ, Sch Med, Sect Cardiovasc Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Prevent Med Sect, Boston, MA 02118 USA.
[Villalon, Mark L.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Rienstra, Michiel] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[Fontes, Joao D.; Schnabel, Renate B.; Magnani, Jared W.; Yin, Xiaoyan; Levy, Daniel; Pencina, Michael J.; Larson, Martin G.; Benjamin, Emelia J.] Boston Univ, Framingham, MA USA.
[Fontes, Joao D.; Schnabel, Renate B.; Magnani, Jared W.; Yin, Xiaoyan; Levy, Daniel; Pencina, Michael J.; Larson, Martin G.; Benjamin, Emelia J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Pai, Manju] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[McManus, David D.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[McManus, David D.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Schnabel, Renate B.] Univ Heart Ctr Hamburg Eppendorf, Dept Gen & Intervent Cardiol, Hamburg, Germany.
[Levy, Daniel] NHLBI, Ctr Populat Studies, Bethesda, MD USA.
RP Lubitz, SA (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St,GRB 109, Boston, MA 02114 USA.
EM slubitz@partners.org
OI Larson, Martin/0000-0002-9631-1254; Sullivan, Lisa/0000-0003-0726-7149;
Benjamin, Emelia/0000-0003-4076-2336; Rienstra,
Michiel/0000-0002-2581-070X
FU Evans Center for Interdisciplinary Biomedical Research ARC on Atrial
Fibrillation at Boston University; AHA [13EIA14220013]; [N01-HC 25195];
[6R01-NS 17950]; [1RC1HL101056]; [1R01HL102214]; [1R01AG028321];
[1RO1HL092577]; [5R21DA027021]; [1RO1HL104156]; [1K24HL105780];
[1K23HL114724]; [U01HL105268]; [KL2RR031981]; [12FTF11350014];
[09FTF2190028]
FX This work was funded by N01-HC 25195, 6R01-NS 17950, grants to Dr
Benjamin (1RC1HL101056; 1R01HL102214, 1R01AG028321), Drs Benjamin and
Ellinor (1RO1HL092577), Dr Ellinor (5R21DA027021, 1RO1HL104156,
1K24HL105780), Dr Lubitz (1K23HL114724), and Dr McManus (U01HL105268,
KL2RR031981), and in part by the Evans Center for Interdisciplinary
Biomedical Research ARC on Atrial Fibrillation at Boston University
(http://www.bumc.bu.edu/evanscenteribr/). Dr Lubitz (12FTF11350014), Dr
Magnani (09FTF2190028), and Dr Ellinor (13EIA14220013) were supported by
AHA awards.
NR 28
TC 9
Z9 9
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD OCT
PY 2013
VL 2
IS 5
AR UNSP e000126
DI 10.1161/JAHA.113.000126
PG 18
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243UL
UT WOS:000326343200024
PM 24002369
ER
PT J
AU McCabe, JM
Armstrong, EJ
Ku, I
Kulkarni, A
Hoffmayer, KS
Bhave, PD
Waldo, SW
Hsue, P
Stein, JC
Marcus, GM
Kinlay, S
Ganz, P
AF McCabe, James M.
Armstrong, Ehrin J.
Ku, Ivy
Kulkarni, Ameya
Hoffmayer, Kurt S.
Bhave, Prashant D.
Waldo, Stephen W.
Hsue, Priscilla
Stein, John C.
Marcus, Gregory M.
Kinlay, Scott
Ganz, Peter
TI Physician Accuracy in Interpreting Potential ST-Segment Elevation
Myocardial Infarction Electrocardiograms
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE electrocardiogram; myocardial infarction; quality; telemedicine
ID DOOR-TO-BALLOON; PERCUTANEOUS CORONARY INTERVENTION; CATHETERIZATION
LABORATORY ACTIVATION; CARDIAC-CATHETERIZATION; 12-LEAD
ELECTROCARDIOGRAM; EMERGENCY-DEPARTMENT; WIRELESS TECHNOLOGY; TIME;
RECOMMENDATIONS; CARDIOLOGIST
AB Background-With adoption of telemedicine, physicians are increasingly asked to diagnose ST-segment elevation myocardial infarctions (STEMIs) based on electrocardiograms (ECGs) with minimal associated clinical information. We sought to determine physicians' diagnostic agreement and accuracy when interpreting potential STEMI ECGs.
Methods and Results-A cross-sectional survey was performed consisting of 36 deidentified ECGs that had previously resulted in putative STEMI diagnoses. Emergency physicians, cardiologists, and interventional cardiologists participated in the survey. For each ECG, physicians were asked, "based on the ECG above, is there a blocked coronary artery present causing a STEMI?" The reference standard for ascertaining the STEMI diagnosis was subsequent emergent coronary arteriography. Responses were analyzed with generalized estimating equations to account for nested and repeated measures. One hundred twenty-four physicians interpreted a total of 4392 ECGs. Among all physicians, interreader agreement (kappa) for ECG interpretation was 0.33, reflecting poor agreement. The sensitivity to identify "true" STEMIs was 65% (95% CI: 63 to 67) and the specificity was 79% (95% CI: 77 to 81). There was a 6% increase in the odds of accurate ECG interpretation for every 5 years of experience since medical school graduation (OR 1.06, 95% CI: 1.02 to 1.10, P=0.01). After adjusting for experience, there was no significant difference in the odds of accurate interpretation by specialty-Emergency Medicine (reference), General Cardiology (AOR 0.97, 95% CI: 0.79 to 1.2, P=0.80), or Interventional Cardiology physicians (AOR 1.24, 95% CI: 0.93 to 1.7, P=0.15).
Conclusions-There is significant physician disagreement in interpreting ECGs with features concerning for STEMI. Such ECGs lack the necessary sensitivity and specificity to act as a suitable "stand-alone" diagnostic test.
C1 [McCabe, James M.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Armstrong, Ehrin J.] Univ Colorado, Div Cardiol, Denver, CO 80202 USA.
[Armstrong, Ehrin J.] VA Colorado Healthcare Syst, Denver, CO USA.
[Ku, Ivy] Kaiser Permanente, Dept Cardiol, San Francisco, CA USA.
[Kulkarni, Ameya] Kaiser Permanante Mid Atlant Med Grp, Div Cardiol, Washington, DC USA.
[Hoffmayer, Kurt S.] Univ Wisconsin, Div Cardiol, Madison, WI 53706 USA.
[Bhave, Prashant D.] Univ Iowa, Div Cardiol, Iowa City, IA USA.
[Waldo, Stephen W.] Massachusetts Gen Hosp, Div Cardiovasc Med, Boston, MA 02114 USA.
[Hsue, Priscilla; Ganz, Peter] Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA.
[Marcus, Gregory M.] Univ Calif San Francisco, Div Electrophysiol, San Francisco, CA 94143 USA.
[Stein, John C.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA.
[Hsue, Priscilla; Ganz, Peter] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
[Kinlay, Scott] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA.
[Kinlay, Scott] VA Boston Healthcare Syst, Div Cardiovasc, Boston, MA USA.
RP McCabe, JM (reprint author), 1959 NE Pacific St,Box 356422, Seattle, WA 98195 USA.
EM mccabe@aya.yale.edu
NR 28
TC 6
Z9 6
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD OCT
PY 2013
VL 2
IS 5
AR UNSP e000268
DI 10.1161/JAHA.113.000268
PG 47
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243UL
UT WOS:000326343200027
PM 24096575
ER
PT J
AU Kilpatrick, DG
Resnick, HS
Milanak, ME
Miller, MW
Keyes, KM
Friedman, MJ
AF Kilpatrick, Dean G.
Resnick, Heidi S.
Milanak, Melissa E.
Miller, Mark W.
Keyes, Katherine M.
Friedman, Matthew J.
TI National Estimates of Exposure to Traumatic Events and PTSD Prevalence
Using DSM-IV and DSM-5 Criteria
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; COMORBIDITY SURVEY REPLICATION; WOMEN;
SYMPTOMS; COLLEGE; SAMPLE
AB Prevalence of posttraumatic stress disorder (PTSD) defined according to the American Psychiatric Association's Diagnostic and Statistical Manual fifth edition (DSM-5; 2013) and fourth edition (DSM-IV; 1994) was compared in a national sample of U.S. adults (N = 2,953) recruited from an online panel. Exposure to traumatic events, PTSD symptoms, and functional impairment were assessed online using a highly structured, self-administered survey. Traumatic event exposure using DSM-5 criteria was high (89.7%), and exposure to multiple traumatic event types was the norm. PTSD caseness was determined using Same Event (i.e., all symptom criteria met to the same event type) and Composite Event (i.e., symptom criteria met to a combination of event types) definitions. Lifetime, past-12-month, and past 6-month PTSD prevalence using the Same Event definition for DSM-5 was 8.3%, 4.7%, and 3.8% respectively. All 6 DSM-5 prevalence estimates were slightly lower than their DSM-IV counterparts, although only 2 of these differences were statistically significant. DSM-5 PTSD prevalence was higher among women than among men, and prevalence increased with greater traumatic event exposure. Major reasons individuals met DSM-IV criteria, but not DSM-5 criteria were the exclusion of nonaccidental, nonviolent deaths from Criterion A, and the new requirement of at least 1 active avoidance symptom.
C1 [Kilpatrick, Dean G.; Resnick, Heidi S.; Milanak, Melissa E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Miller, Mark W.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Miller, Mark W.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Keyes, Katherine M.] Columbia Univ, Dept Epidemiol, New York, NY USA.
[Friedman, Matthew J.] Geisel Sch Med Dartmouth, Hanover, NH USA.
[Friedman, Matthew J.] Natl Ctr PTSD, White River Jct, VT USA.
RP Kilpatrick, DG (reprint author), 67 President St,South Bldg,Suite 200, Charleston, SC 29425 USA.
EM kilpatdg@musc.edu
RI Miller, Mark/G-7322-2011
OI Miller, Mark/0000-0001-6393-8563
FU CSRD VA [I01 CX000431]; NCATS NIH HHS [UL1 TR000062]; NCRR NIH HHS [UL1
RR029882]; NIDA NIH HHS [R01 DA023099]; NIMH NIH HHS [T32 MH018869]
NR 28
TC 105
Z9 105
U1 11
U2 43
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2013
VL 26
IS 5
BP 537
EP 547
DI 10.1002/jts.21848
PG 11
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 242ZF
UT WOS:000326284900002
PM 24151000
ER
PT J
AU Harb, GC
Phelps, AJ
Forbes, D
Ross, RJ
Gehrman, PR
Cook, JM
AF Harb, Gerlinde C.
Phelps, Andrea J.
Forbes, David
Ross, Richard J.
Gehrman, Philip R.
Cook, Joan M.
TI A Critical Review of the Evidence Base of Imagery Rehearsal for
Posttraumatic Nightmares: Pointing the Way for Future Research
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIALS; SEXUAL
ASSAULT SURVIVORS; STRESS-DISORDER; CONSORT STATEMENT; CLINICAL-TRIALS;
PTSD; VETERANS; INSOMNIA; QUALITY
AB In this article, the authors provide information on key characteristics of imagery rehearsal treatment protocols and examine the quality of reporting of randomized controlled and uncontrolled trials of imagery rehearsal for treating posttraumatic nightmares. Using a reliable and valid scale, two independent psychologists rated 16 trials. Most reports provided insufficient information on a range of variables including the definition of treatment delivery (e.g., therapist supervision, treatment fidelity), description of the participant sample, data analysis (e.g., determination of sample size), and treatment assignment (e.g., randomization procedures). Low methodological quality and poor reporting can lead to inflation of estimates of treatment effects and inadequately substantiated conclusions, such as inflated effect sizes in meta-analytic studies. Numerous imagery rehearsal protocols exist, but in some cases are given different names and tested in pilot studies, slowing progression in the field. Randomized controlled trials of imagery rehearsal with credible comparison conditions, examination of predictors of dropout and outcome, as well as dismantling studies of imagery rehearsal treatment components are needed.
C1 [Harb, Gerlinde C.; Ross, Richard J.; Gehrman, Philip R.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA.
[Phelps, Andrea J.; Forbes, David] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Melbourne, Vic, Australia.
[Ross, Richard J.; Gehrman, Philip R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Cook, Joan M.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA.
[Cook, Joan M.] Natl Ctr PTSD, West Haven, CT USA.
RP Cook, JM (reprint author), Yale Univ, Sch Med, Dept Psychiat, NEPEC 182,950 Campbell Ave, West Haven, CT 06516 USA.
EM Joan.Cook@yale.edu
NR 46
TC 6
Z9 6
U1 3
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2013
VL 26
IS 5
BP 570
EP 579
DI 10.1002/jts.21854
PG 10
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 242ZF
UT WOS:000326284900008
PM 24114887
ER
PT J
AU Kachadourian, LK
Taft, CT
Holowka, DW
Woodward, H
Marx, BP
Burns, A
AF Kachadourian, Lorig K.
Taft, Casey T.
Holowka, Darren W.
Woodward, Halley
Marx, Brian P.
Burns, Anthony
TI Maladaptive Dependency Schemas, Posttraumatic Stress Hyperarousal
Symptoms, and Intimate Partner Aggression Perpetration
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID PSYCHOMETRIC PROPERTIES; DISORDER SYMPTOMS; DOMESTIC VIOLENCE;
QUESTIONNAIRE; BATTERERS; VETERANS; VALIDITY; FORCES; SCALE; PTSD
AB This study examined the associations between maladaptive dependency-related schemas, posttraumatic stress disorder (PTSD) hyperarousal symptoms, and intimate-partner psychological and physical aggression in a sample of court-referred men (N = 174) participating in a domestic-abuser-intervention program. The men were largely African American; average age was 33.5years. The extent to which hyperarousal symptoms moderated the association between dependency schemas and aggression was also examined. Maladaptive dependency-related schemas were positively associated with severe psychological, and mild and severe physical aggression perpetration. Hyperarousal symptoms were positively associated with mild and severe psychological aggression, and mild physical aggression perpetration. Multiple regression analyses showed a significant interaction for mild physical aggression: For those with high levels of hyperarousal symptoms, greater endorsement of maladaptive dependency schemas was associated with the perpetration of aggression (B = 0.98, p = .001). For those with low levels of hyperarousal symptoms, there was no association between dependency schemas and aggression (B = 0.04, ns). These findings suggest that focusing on problematic dependency and PTSD-hyperarousal symptoms in domestic-abuser-intervention programs may be helpful, and that examining related variables as possible moderators between dependency schemas and intimate aggression would be a fruitful area for future research.
C1 [Kachadourian, Lorig K.; Taft, Casey T.; Holowka, Darren W.; Marx, Brian P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Kachadourian, Lorig K.; Taft, Casey T.; Holowka, Darren W.; Marx, Brian P.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Woodward, Halley] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA.
[Burns, Anthony] Common Purpose Inc, Boston, MA USA.
RP Kachadourian, LK (reprint author), VA Connecticut Healthcare Syst 116B 2, Natl Ctr PTSD, 950 Campbell Ave, West Haven, CT 06516 USA.
EM lorig.kachadourian@va.gov
NR 43
TC 0
Z9 0
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2013
VL 26
IS 5
BP 580
EP 587
DI 10.1002/jts.21850
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 242ZF
UT WOS:000326284900009
PM 24030885
ER
PT J
AU Dekel, S
Ein-Dor, T
Gordon, KM
Rosen, JB
Bonanno, GA
AF Dekel, Sharon
Ein-Dor, Tsachi
Gordon, Kathleen M.
Rosen, Jeffrey B.
Bonanno, George A.
TI Cortisol and PTSD Symptoms Among Male and Female High-Exposure 9/11
Survivors
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; METAANALYSIS; RESPONSES; GENDER; ADULTS
AB Only a few studies have examined cortisol response to trauma-related stressors in relation to posttraumatic stress disorder (PTSD). We followed a sample of high-exposure survivors of the attacks on September 11, 2001 (9/11; 32 men and 29 women) and examined their cortisol response after recalling the escape from the attack, 7 and 18 months post-9/11. PTSD symptoms and saliva cortisol levels were assessed before and after trauma recollection. Hierarchical regression analyses revealed that PTSD symptoms and male sex predicted increased cortisol response following recollections. For men, elevated cortisol was associated with greater severity of reexperiencing symptoms (p < .001) and lower severity of avoidance symptoms (p < .001). For women, recall-induced cortisol was minimal and unrelated to PTSD symptoms (p = .164 and p = .331, respectively). These findings suggest that augmented cortisol response to trauma-related stressors may be evident in men reporting symptoms of PTSD. Thus, as cortisol abnormalities related to PTSD symptoms appear sex-specific, future research on mechanisms of sex differences in response to trauma is warranted.
C1 [Dekel, Sharon] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
[Dekel, Sharon] Harvard Univ, Sch Med, Charlestown, MA USA.
[Dekel, Sharon] Tel Aviv Univ, Bob Shapell Sch Social Work, IL-69978 Tel Aviv, Israel.
[Ein-Dor, Tsachi] Interdisciplinary Ctr IDC, Sch Psychol, Herzliyya, Israel.
[Gordon, Kathleen M.; Rosen, Jeffrey B.] Univ Delaware, Dept Psychol, Newark, DE USA.
[Bonanno, George A.] Columbia Univ Teachers Coll, New York, NY 10027 USA.
RP Dekel, S (reprint author), Massachusetts Gen Hosp East, PTSD Res Lab, 120 2nd Ave, Charlestown, MA 02129 USA.
EM sharon.dekel@gmail.com
NR 18
TC 10
Z9 12
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2013
VL 26
IS 5
BP 621
EP 625
DI 10.1002/jts.21839
PG 5
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 242ZF
UT WOS:000326284900014
PM 24030869
ER
PT J
AU Sledge, J
Graham, WA
Westmoreland, S
Sejdic, E
Miller, A
Hoggatt, A
Nesathurai, S
AF Sledge, J.
Graham, W. Andrew
Westmoreland, S.
Sejdic, E.
Miller, A.
Hoggatt, A.
Nesathurai, S.
TI Spinal cord injury models in non human primates: Are lesions created by
sharp instruments relevant to human injuries?
SO MEDICAL HYPOTHESES
LA English
DT Letter
ID MACACA-FASCICULARIS; MONKEY; CAT
AB The worldwide incidence of traumatic spinal cord injury (SCI) is approximated at 180,000 new cases per year. Experiments using nonhuman primates (NHP) are often used to replicate the human condition in order to advance the understanding of SCI and to assist in the development of new treatments. Experimental spinal cord lesions in NHP have been created by a number of methods including blunt trauma, epidural balloons, circumferential cuffs, and dropping a precision weight over the spinal cord. As well, experimental lesions have been created with sharp instruments after opening the dura mater. However, spinal cord lesions that are created with a sharp instrument in NHP experiments may not replicate the clinical and pathological features of human spinal cord injury. Researchers should recognize the challenges associated with making clinical inferences in human SCIs based on NHP experiments that created experimental lesions with a sharp surgical instrument. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Sledge, J.] Lafayette Bone & Joint Clin, Lafayette, LA USA.
[Graham, W. Andrew; Nesathurai, S.] McMaster Univ, Div Phys Med & Rehabil, Hamilton, ON L8S 4K1, Canada.
[Graham, W. Andrew] St Josephs Healthcare, Hamilton, ON, Canada.
[Westmoreland, S.; Sejdic, E.] Univ Pittsburgh, Dept Elect & Comp Engn, Pittsburgh, PA USA.
[Miller, A.; Hoggatt, A.] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.
[Nesathurai, S.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA.
[Graham, W. Andrew; Nesathurai, S.] Hamilton Hlth Sci, Dept Phys Med & Rehabil, Hamilton, ON, Canada.
RP Graham, WA (reprint author), McMaster Univ, Dept Med, Div Phys Med & Rehabil, 1280 Main St West, Hamilton, ON L8S 4K1, Canada.
EM grahaman@hhsc.ca
OI Sejdic, Ervin/0000-0003-4987-8298
NR 18
TC 3
Z9 4
U1 0
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2013
VL 81
IS 4
BP 747
EP 748
DI 10.1016/j.mehy.2013.07.040
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 243ZO
UT WOS:000326357100050
PM 23948598
ER
PT J
AU Ageta-Ishihara, N
Miyata, T
Ohshima, C
Watanabe, M
Sato, Y
Hamamura, Y
Higashiyama, T
Mazitschek, R
Bito, H
Kinoshita, M
AF Ageta-Ishihara, Natsumi
Miyata, Takaki
Ohshima, Chika
Watanabe, Masahiko
Sato, Yoshikatsu
Hamamura, Yuki
Higashiyama, Tetsuya
Mazitschek, Ralph
Bito, Haruhiko
Kinoshita, Makoto
TI Septins promote dendrite and axon development by negatively regulating
microtubule stability via HDAC6-mediated deacetylation
SO NATURE COMMUNICATIONS
LA English
DT Article
ID BINDING PROTEIN; MAMMALIAN SEPTINS; NEUROTRANSMITTER RELEASE;
CAENORHABDITIS-ELEGANS; FLUORESCENT PROTEIN; MOUSE MODEL; HDAC6;
TUBULIN; NEURONS; GROWTH
AB Neurite growth requires two guanine nucleotide-binding protein polymers of tubulins and septins. However, whether and how those cytoskeletal systems are coordinated was unknown. Here we show that the acute knockdown or knockout of the pivotal septin subunit SEPT7 from cerebrocortical neurons impairs their interhemispheric and cerebrospinal axon projections and dendritogenesis in perinatal mice, when the microtubules are severely hyperacetylated. The resulting hyperstabilization and growth retardation of microtubules are demonstrated in vitro. The phenotypic similarity between SEPT7 depletion and the pharmacological inhibition of a-tubulin deacetylase HDAC6 reveals that HDAC6 requires SEPT7 not for its enzymatic activity, but to associate with acetylated a-tubulin. These and other findings indicate that septins provide a physical scaffold for HDAC6 to achieve efficient microtubule deacetylation, thereby negatively regulating microtubule stability to an optimal level for neuritogenesis. Our findings shed light on the mechanisms underlying the HDAC6-mediated coupling of the two ubiquitous cytoskeletal systems during neural development.
C1 [Ageta-Ishihara, Natsumi; Ohshima, Chika; Hamamura, Yuki; Kinoshita, Makoto] Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan.
[Miyata, Takaki] Nagoya Univ, Grad Sch Med, Dept Anat & Cell Biol, Nagoya, Aichi 4668550, Japan.
[Watanabe, Masahiko] Hokkaido Univ, Grad Sch Med, Dept Anat, Sapporo, Hokkaido 0608638, Japan.
[Sato, Yoshikatsu; Higashiyama, Tetsuya] Nagoya Univ, Inst Transformat Bio Mol, Nagoya, Aichi 4648602, Japan.
[Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Mazitschek, Ralph] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Bito, Haruhiko] Univ Tokyo, Grad Sch Med, Dept Neurochem, Tokyo 1130033, Japan.
RP Kinoshita, M (reprint author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan.
EM kinoshita.makoto@c.mbox.nagoya-u.ac.jp
RI Bito, Haruhiko/A-8635-2008; Sato, Yoshikatsu/I-6129-2014; MIYATA,
TAKAKI/I-7066-2014
FU Comprehensive Brain Science Network; Ministry of Education, Science,
Sports and Culture of Japan; Takeda Science Foundation; Astellas
Foundation; Suzuken Memorial Foundation; Narishige Neuroscience Research
Foundation; NIH [P50A086355]
FX We thank M. Masaoka and Y. Enomoto (Nagoya University), respectively for
the technical help in in utero electroporation and FACS analysis, T-P.
Yao and Y-S. Gao (Duke University) for HDAC6 antibody, E. T. Spiliotis
(Drexel University) for polyglutamylated tubulin antibody, Y. Kiyosue
(RIKEN CDB) for GFP-EB1 plasmid, M. Yoshida (RIKEN) for HDAC6-HA
plasmid, and R. Y. Tsien (University of California, San Diego) for
mCherry cDNA. A part of the microscopic analysis was done at Nagoya
University Advanced Live Imaging Center funded by Japan Advanced Plant
Science Network. This work was supported in part by Grant-in-Aid for
Scientific Research (B) (to M. K.), Grant-in-Aid for Young Investigator
(B) (to N.A.-I.), Grants-in-Aid for Scientific Research on Innovative
Areas 'Synapse Neurocircuit Pathology' and 'Micro Psychopathology' (to
M. K.), 'Cross-talk between moving cells and microenvironment as a basis
of emerging order in multicellular system' (to T. M.), Technical
Supports for Fluorescent Probes and Imaging and for Antibody Production
from Comprehensive Brain Science Network (to N.A.-I., M. W., H. B., M.
K.), each from the Ministry of Education, Science, Sports and Culture of
Japan, and by the research grants from Takeda Science Foundation,
Astellas Foundation, Suzuken Memorial Foundation, Narishige Neuroscience
Research Foundation (to N.A.-I.), and NIH grant P50A086355 (to R. M.).
NR 55
TC 24
Z9 25
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT
PY 2013
VL 4
AR 2532
DI 10.1038/ncomms3532
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245MO
UT WOS:000326468000002
PM 24113571
ER
PT J
AU Ahveninen, J
Huang, S
Nummenmaa, A
Belliveau, JW
Hung, AY
Jaaskelainen, IP
Rauschecker, JP
Rossi, S
Tiitinen, H
Raij, T
AF Ahveninen, Jyrki
Huang, Samantha
Nummenmaa, Aapo
Belliveau, John W.
Hung, An-Yi
Jaaskelainen, Iiro P.
Rauschecker, Josef P.
Rossi, Stephanie
Tiitinen, Hannu
Raij, Tommi
TI Evidence for distinct human auditory cortex regions for sound location
versus identity processing
SO NATURE COMMUNICATIONS
LA English
DT Article
ID TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; HUMAN BRAIN;
CEREBRAL CONNECTIONS; HEMISPHERIC LESIONS; FUNCTIONAL IMPACT; PARIETAL
CORTEX; TEMPORAL-LOBE; LOCALIZATION; SPEECH
AB Neurophysiological animal models suggest that anterior auditory cortex (AC) areas process sound identity information, whereas posterior ACs specialize in sound location processing. In humans, inconsistent neuroimaging results and insufficient causal evidence have challenged the existence of such parallel AC organization. Here we transiently inhibit bilateral anterior or posterior AC areas using MRI-guided paired-pulse transcranial magnetic stimulation (TMS) while subjects listen to Reference/Probe sound pairs and perform either sound location or identity discrimination tasks. The targeting of TMS pulses, delivered 55-145 ms after Probes, is confirmed with individual-level cortical electric-field estimates. Our data show that TMS to posterior AC regions delays reaction times (RT) significantly more during sound location than identity discrimination, whereas TMS to anterior AC regions delays RTs significantly more during sound identity than location discrimination. This double dissociation provides direct causal support for parallel processing of sound identity features in anterior AC and sound location in posterior AC.
C1 [Ahveninen, Jyrki; Huang, Samantha; Nummenmaa, Aapo; Belliveau, John W.; Hung, An-Yi; Rossi, Stephanie; Raij, Tommi] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Belliveau, John W.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Jaaskelainen, Iiro P.; Tiitinen, Hannu] Aalto Univ, Sch Sci, Dept Biomed Engn & Computat Sci BECS, FIN-00076 Espoo, Aalto, Finland.
[Rauschecker, Josef P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Integrat Neurosci & Cognit, Washington, DC 20057 USA.
RP Ahveninen, J (reprint author), Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Massachusetts Gen Hosp, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM jyrki@nmr.mgh.harvard.edu
RI Jaaskelainen, Iiro/C-7392-2012
OI Jaaskelainen, Iiro/0000-0001-6001-6950
FU National Institutes of Health (NIH) [R21DC010060, R01MH083744,
R01HD040712, R01NS037462, R01NS048279, K99EB015445]; NIH/National
Institute of Biomedical Imaging and Bioengineering (NIBIB)
[P41EB015896]; Center for Functional Neuroimaging Techniques, CFNT; NIH
Shared Instrumentation Grant S10-RR024694; Harvard Clinical and
Translational Science Center [NCRR-NIH UL1 RR025758, NCRR-NIH UL1
TR000170]; Academy Of Finland [130412]; NIH [R56NS052494]; National
Science Foundation [PIRE-OISE-0730255]
FX We thank Mary O'Hara, Nancy Shearer, Chinmayi Tengshe and Lawrence
White, as well as Drs Wei- Tang Chang, Sharon Furtak, Matti Ha "ma "la
"inen and Norbert Kopc. o. This research was supported by the National
Institutes of Health (NIH) Grants R21DC010060, R01MH083744, R01HD040712,
R01NS037462, R01NS048279 and K99EB015445. The research environment was
supported by the NIH/National Institute of Biomedical Imaging and
Bioengineering (NIBIB) Grant P41EB015896 (Center for Functional
Neuroimaging Techniques, CFNT), NIH Shared Instrumentation Grant
S10-RR024694, and the Harvard Clinical and Translational Science Center
(Harvard Catalyst; NCRR-NIH UL1 RR025758; NCRR-NIH UL1 TR000170). I. P.
J. was supported by the Academy Of Finland Grant 130412, and J. P. R was
supported by the NIH Grant R56NS052494 and by the National Science
Foundation Grant NSF PIRE-OISE-0730255. The content is solely the
responsibility of the authors and does not necessarily represent
NR 60
TC 22
Z9 22
U1 2
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT
PY 2013
VL 4
AR 2585
DI 10.1038/ncomms3585
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245NM
UT WOS:000326470400029
PM 24121634
ER
PT J
AU Chauhan, VP
Martin, JD
Liu, H
Lacorre, DA
Jain, SR
Kozin, SV
Stylianopoulos, T
Mousa, AS
Han, XX
Adstamongkonkul, P
Popovic, Z
Huang, PG
Bawendi, MG
Boucher, Y
Jain, RK
AF Chauhan, Vikash P.
Martin, John D.
Liu, Hao
Lacorre, Delphine A.
Jain, Saloni R.
Kozin, Sergey V.
Stylianopoulos, Triantafyllos
Mousa, Ahmed S.
Han, Xiaoxing
Adstamongkonkul, Pichet
Popovic, Zoran
Huang, Peigen
Bawendi, Moungi G.
Boucher, Yves
Jain, Rakesh K.
TI Angiotensin inhibition enhances drug delivery and potentiates
chemotherapy by decompressing tumour blood vessels
SO NATURE COMMUNICATIONS
LA English
DT Article
ID II TYPE-2 RECEPTOR; GROWTH-FACTOR-BETA; INTERSTITIAL FLUID PRESSURE;
PANCREATIC STELLATE CELLS; BREAST-CANCER; SOLID STRESS; TGF-BETA;
GENE-EXPRESSION; AORTIC-ANEURYSM; MOUSE MODEL
AB Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-beta 1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors - inexpensive drugs with decades of safe use - could be rapidly repurposed as cancer therapeutics.
C1 [Chauhan, Vikash P.; Martin, John D.; Liu, Hao; Lacorre, Delphine A.; Jain, Saloni R.; Kozin, Sergey V.; Stylianopoulos, Triantafyllos; Mousa, Ahmed S.; Han, Xiaoxing; Adstamongkonkul, Pichet; Huang, Peigen; Boucher, Yves; Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
[Chauhan, Vikash P.; Martin, John D.; Liu, Hao; Lacorre, Delphine A.; Jain, Saloni R.; Kozin, Sergey V.; Stylianopoulos, Triantafyllos; Mousa, Ahmed S.; Han, Xiaoxing; Adstamongkonkul, Pichet; Huang, Peigen; Boucher, Yves; Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Chauhan, Vikash P.; Adstamongkonkul, Pichet] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Martin, John D.; Jain, Saloni R.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Liu, Hao] Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA.
[Stylianopoulos, Triantafyllos] Univ Cyprus, Dept Mech & Mfg Engn, CY-1678 Nicosia, Cyprus.
[Popovic, Zoran; Bawendi, Moungi G.] MIT, Dept Chem, Cambridge, MA 02139 USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
RI Martin, John/L-6892-2016;
OI Martin, John/0000-0002-9828-8203; Stylianopoulos,
Triantafyllos/0000-0002-3093-1696
FU U.S. National Cancer Institute [P01-CA080124, R01-CA126642,
R01-CA085140, R01-CA115767, R01-CA098706]; U.S. Department of Defense
Breast Cancer Research Program Innovator Award [W81XWH-10-1-0016];
Dana-Farber Harvard Cancer Center/MIT Koch Institute Bridge Project
grant from the Lustgarten Foundation; Ruth L. Kirschstein NRSA
Post-doctoral Fellowship from the NIH [T32-CA073479]
FX We thank Julia Kahn, Sylvie Roberge, Christina Koppel, Carolyn Smith and
Eve Smith for technical assistance. We also thank Drs Dan G. Duda,
Jeffrey Clark and Pieter Timmermans for helpful discussions, and Dr
Nabeel Bardeesy for providing us with AK4.4 cells. This research was
primarily supported by the U.S. National Cancer Institute Grants
P01-CA080124, R01-CA126642, R01-CA085140, R01-CA115767 and R01-CA098706,
and by the U.S. Department of Defense Breast Cancer Research Program
Innovator Award W81XWH-10-1-0016. Additional support was provided by a
Dana-Farber Harvard Cancer Center/MIT Koch Institute Bridge Project
grant from the Lustgarten Foundation. V.P.C. is supported by a Ruth L.
Kirschstein NRSA Post-doctoral Fellowship from the NIH, T32-CA073479.
NR 63
TC 123
Z9 124
U1 8
U2 68
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT
PY 2013
VL 4
AR 2516
DI 10.1038/ncomms3516
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245MK
UT WOS:000326467600001
PM 24084631
ER
PT J
AU Sander, JD
Ramirez, CL
Linder, SJ
Pattanayak, V
Shoresh, N
Ku, MC
Foden, JA
Reyon, D
Bernstein, BE
Liu, DR
Joung, JK
AF Sander, Jeffry D.
Ramirez, Cherie L.
Linder, Samantha J.
Pattanayak, Vikram
Shoresh, Noam
Ku, Manching
Foden, Jennifer A.
Reyon, Deepak
Bernstein, Bradley E.
Liu, David R.
Joung, J. Keith
TI In silico abstraction of zinc finger nuclease cleavage profiles reveals
an expanded landscape of off-target sites
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID GENOME; CELLS; CAS9
AB Gene-editing nucleases enable targeted modification of DNA sequences in living cells, thereby facilitating efficient knockout and precise editing of endogenous loci. Engineered nucleases also have the potential to introduce mutations at off-target sites of action. Such unintended alterations can confound interpretation of experiments and can have implications for development of therapeutic applications. Recently, two improved methods for identifying the off-target effects of zinc finger nucleases (ZFNs) were described-one using an in vitro cleavage site selection method and the other exploiting the insertion of integration-defective lentiviruses into nuclease-induced double-stranded DNA breaks. However, application of these two methods to a ZFN pair targeted to the human CCR5 gene led to identification of largely non-overlapping off-target sites, raising the possibility that additional off-target sites might exist. Here, we show that in silico abstraction of ZFN cleavage profiles obtained from in vitro cleavage site selections can greatly enhance the ability to identify potential off-target sites in human cells. Our improved method should enable more comprehensive profiling of ZFN specificities.
C1 [Sander, Jeffry D.; Ramirez, Cherie L.; Linder, Samantha J.; Ku, Manching; Foden, Jennifer A.; Reyon, Deepak; Bernstein, Bradley E.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Mol Pathol Unit, Charlestown, MA 02129 USA.
[Sander, Jeffry D.; Ramirez, Cherie L.; Linder, Samantha J.; Foden, Jennifer A.; Reyon, Deepak; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA.
[Sander, Jeffry D.; Ku, Manching; Reyon, Deepak; Bernstein, Bradley E.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Ramirez, Cherie L.; Joung, J. Keith] Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA.
[Pattanayak, Vikram; Liu, David R.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 01238 USA.
[Shoresh, Noam; Bernstein, Bradley E.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Bernstein, Bradley E.; Liu, David R.] Howard Hughes Med Inst, Chevy Chase, MD 02815 USA.
RP Sander, JD (reprint author), Massachusetts Gen Hosp, Ctr Canc Res, Mol Pathol Unit, Charlestown, MA 02129 USA.
EM jsander@alumni.iastate.edu
FU National Institutes of Health (NIH) [DP1 GM105378, NIH P50 HG005550];
Defense Advanced Research Projects Agency (DARPA) [W911NF-11-2-0056];
Jim and Ann Orr Massachusetts General Hospital (MGH) Research Scholar
Award; NIH [DP1 GM105378, T32 CA009216]; National Science Foundation
Graduate Research Fellowship; Ford Foundation Predoctoral Fellowship;
National Science Foundation (NSF) [DBI-0923827]; DARPA
[HR0011-11-2-0003, N66001-12-C-4207]; Howard Hughes Medical Institute;
National Institute of General Medical Sciences [T32GM007753]; National
Human Genome Research Institute [U54 HG004570]
FX National Institutes of Health (NIH) Director's Pioneer Award [DP1
GM105378], [NIH P50 HG005550] and Defense Advanced Research Projects
Agency (DARPA) [W911NF-11-2-0056 to J.K.J.]; The Jim and Ann Orr
Massachusetts General Hospital (MGH) Research Scholar Award (to J.K.J.);
[NIH T32 CA009216 to J.D.S.]; National Science Foundation Graduate
Research Fellowship and a Ford Foundation Predoctoral Fellowship (to C.
L. R.); National Science Foundation (NSF) ward [DBI-0923827 to D. R.];
[DARPA HR0011-11-2-0003, DARPA N66001-12-C-4207] and the Howard Hughes
Medical Institute (to V. P. and D. R. L.); Award number [T32GM007753 to
V. P.] from the National Institute of General Medical Sciences. National
Human Genome Research Institute Grant [U54 HG004570 to N.S., M. K., B.
E. B.]. Funding for open access charge: NIH [DP1 GM105378].
NR 14
TC 26
Z9 27
U1 1
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD OCT
PY 2013
VL 41
IS 19
AR e181
DI 10.1093/nar/gkt716
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 239SC
UT WOS:000326044700004
PM 23945932
ER
PT J
AU Chi, AS
AF Chi, Andrew S.
TI Is There a Role for Bevacizumab in the Treatment of Glioblastoma?
SO ONCOLOGIST
LA English
DT Editorial Material
C1 [Chi, Andrew S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
RP Chi, AS (reprint author), 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM chi.andrew@mgh.harvard.edu
NR 10
TC 3
Z9 3
U1 0
U2 0
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD OCT
PY 2013
VL 18
IS 10
BP 1080
EP 1082
DI 10.1634/theoncologist.2013-0296
PG 3
WC Oncology
SC Oncology
GA 243NK
UT WOS:000326322900003
PM 24056893
ER
PT J
AU Tucker, RP
Judah, MR
O'Keefe, VM
Mills, AC
Lechner, WV
Davidson, CL
Grant, DM
Wingate, LR
AF Tucker, Raymond P.
Judah, Matt R.
O'Keefe, Victoria M.
Mills, Adam C.
Lechner, William V.
Davidson, Collin L.
Grant, DeMond M.
Wingate, LaRicka R.
TI Humor styles impact the relationship between symptoms of social anxiety
and depression
SO PERSONALITY AND INDIVIDUAL DIFFERENCES
LA English
DT Article
DE Humor styles; Humor; Social anxiety; Depression; Dysphoria
ID SUICIDAL IDEATION; PHOBIA; RISK; DISORDER; ADULTS; COMORBIDITY;
LONELINESS; VALIDATION; PREDICTORS; MODEL
AB Recent research suggests that examining humor styles may contribute to our understanding of clinical problems, such as risk and resiliency. The goal of the current study was to examine whether humor styles moderate the association between social anxiety and depressive symptoms in an unselected sample. Three-hundred and six participants (66% female) at a large Southern US university completed self-report measures of humor styles and symptoms of social anxiety and depression. Regression analyses suggested that affiliative and self-defeating humor styles individually moderated the relationship between social anxiety and depressive symptoms. Clinical implications regarding the monitoring of humor use as a means of understanding the maintenance of depressive symptoms among socially anxious individuals are discussed. (C) 2013 Published by Elsevier Ltd.
C1 [Tucker, Raymond P.; Judah, Matt R.; O'Keefe, Victoria M.; Mills, Adam C.; Lechner, William V.; Grant, DeMond M.; Wingate, LaRicka R.] Oklahoma State Univ, Stillwater, OK 74078 USA.
[Davidson, Collin L.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA.
RP Wingate, LR (reprint author), Oklahoma State Univ, Dept Psychol, 116 North Murray Hall, Stillwater, OK 74078 USA.
EM laricka.wingate@okstate.edu
OI Grant, DeMond/0000-0002-5231-6563
NR 35
TC 3
Z9 4
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0191-8869
J9 PERS INDIV DIFFER
JI Pers. Individ. Differ.
PD OCT
PY 2013
VL 55
IS 7
BP 823
EP 827
DI 10.1016/j.paid.2013.07.008
PG 5
WC Psychology, Social
SC Psychology
GA 214SL
UT WOS:000324156000018
ER
PT J
AU Logue, MW
Solovieff, N
Leussis, MP
Wolf, EJ
Melista, E
Baldwin, C
Koenen, KC
Petryshen, TL
Miller, MW
AF Logue, Mark W.
Solovieff, Nadia
Leussis, Melanie P.
Wolf, Erika J.
Melista, Efthymia
Baldwin, Clinton
Koenen, Karestan C.
Petryshen, Tracey L.
Miller, Mark W.
TI The ankyrin-3 gene is associated with posttraumatic stress disorder and
externalizing comorbidity
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE ANK3; Posttraumatic stress disorder; Externalizing; Genetic association;
Candidate gene
ID GENOME-WIDE ASSOCIATION; LONGITUDINAL DATA-ANALYSIS; MULTILOCUS GENOTYPE
DATA; BIPOLAR-DISORDER; ANK3; SCHIZOPHRENIA; INDIVIDUALS; INFERENCE;
VARIANTS; BRAIN
AB Background: The ankyrin 3 gene (ANK3) produces the ankyrin G protein that plays an integral role in regulating neuronal activity. Previous studies have linked ANK3 to bipolar disorder and schizophrenia. A recent mouse study suggests that ANK3 may regulate behavioral disinhibition and stress reactivity. This led us to hypothesize that ANK3 might also be associated with stress-related psychopathology such as posttraumatic stress disorder (PTSD), as well as disorders of the externalizing spectrum such as antisocial personality disorder and substance-related disorders that are etiologically linked to impulsivity and temperamental disinhibition.
Methods: We examined the possibility of association between ANK3 SNPs and both PTSD and externalizing (defined by a factor score representing a composite of adult antisociality and substance abuse) in a cohort of white non-Hispanic combat veterans and their intimate partners (n = 554). Initially, we focused on rs9804190-a SNP previously reported to be associated With bipolar disorder, schizophrenia, and ankyrin G expression in brain. Then we examined 358 additional ANK3 SNPs utilizing a multiple-testing correction.
Results: rs9804190 was associated with both externalizing and PTSD (p = 0.028 and p = 0.042 respectively). Analysis of other ANK3 SNPs identified several that were more strongly associated with either trait. The most significant association with externalizing was observed at rs1049862 (p = 0.00040, p(corrected) = 0.60). The most significant association with PTSD (p = 0.00060, p(corrected) = 0.045) was found with three SNPs in complete linkage disequilibrium (LD)-rs28932171, rs11599164, and rs17208576.
Conclusions: These findings support a role of ANK3 in risk of stress-related and externalizing disorders, beyond its previous associations with bipolar disorder and schizophrenia. Published by Elsevier Ltd.
C1 [Logue, Mark W.; Melista, Efthymia; Baldwin, Clinton] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Logue, Mark W.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Solovieff, Nadia; Leussis, Melanie P.; Petryshen, Tracey L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA.
[Solovieff, Nadia; Leussis, Melanie P.; Petryshen, Tracey L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Solovieff, Nadia; Petryshen, Tracey L.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Solovieff, Nadia; Leussis, Melanie P.; Petryshen, Tracey L.] Broad Inst Harvard & Massachusetts Inst Technol, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Wolf, Erika J.; Miller, Mark W.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Leussis, Melanie P.] Emmanuel Coll, Dept Psychol, Boston, MA USA.
[Wolf, Erika J.; Miller, Mark W.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Koenen, Karestan C.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
RP Miller, MW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 2, 150 South Huntington Ave, Boston, MA 02130 USA.
EM petryshen@chgr.mgh.harvard.edu; mark.miller5@va.gov
RI Miller, Mark/G-7322-2011; Koenen, Karestan/K-5402-2014;
OI Miller, Mark/0000-0001-6393-8563; Koenen, Karestan/0000-0003-3293-4281;
Wolf, Erika/0000-0003-2666-2435
FU Department of Veterans Affairs, the Stanley National Institute of Mental
Health
FX Funding was provided by the Department of Veterans Affairs, the Stanley
National Institute of Mental Health. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 39
TC 14
Z9 15
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD OCT
PY 2013
VL 38
IS 10
BP 2249
EP 2257
DI 10.1016/j.psyneuen.2013.04.013
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 242BZ
UT WOS:000326213700031
PM 23796624
ER
PT J
AU Hess, DR
AF Hess, Dean R.
TI Science and Evidence: Separating Fact from Fiction
SO RESPIRATORY CARE
LA English
DT Article
DE clinical practice guideline; evidence-base medicine; meta-analysis;
systematic review
ID RESPIRATORY-DISTRESS-SYNDROME; CLINICAL-PRACTICE GUIDELINES; ACUTE LUNG
INJURY; RANDOMIZED CONTROLLED-TRIAL; HIGH-FREQUENCY OSCILLATION;
EVIDENCE-BASED MEDICINE; CONVENTIONAL MECHANICAL VENTILATION; AIR-FLOW
LIMITATION; LOWER TIDAL VOLUMES; NONINVASIVE VENTILATION
AB Evidence-based medicine (EBM) is the integration of individual clinical expertise with the best available research evidence from systematic research and the patient's values and expectations. A hierarchy of evidence can be used to assess the strength upon which clinical decisions are made. The efficient approach to finding the best evidence is to identify systematic reviews or evidence-based clinical practice guidelines. Respiratory therapies that evidence supports include noninvasive ventilation for appropriately selected patients, lung-protective ventilation, and ventilator discontinuation protocols. Evidence does not support use of weaning parameters, albuterol for ARDS, and high frequency oscillatory ventilation for adults. Therapy with equivocal evidence includes airway clearance, selection of an aerosol delivery device, and PEEP for ARDS. Although all tenets of EBM are not universally accepted, the principles of EBM nonetheless provide a valuable approach to respiratory care practice.
C1 [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
[Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.
RP Hess, DR (reprint author), Massachusetts Gen Hosp, Ellison 401,55 Fruit St, Boston, MA 02114 USA.
EM dhess@partners.org
NR 73
TC 1
Z9 1
U1 0
U2 5
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD OCT
PY 2013
VL 58
IS 10
BP 1649
EP 1661
DI 10.4187/respcare.02591
PG 13
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 245RH
UT WOS:000326481000012
PM 24064624
ER
PT J
AU Fernandez, JF
Restrepo, MI
AF Fernandez, Juan Felipe
Restrepo, Marcos I.
TI Too Passive to Prevent Ventilator-Associated Pneumonia
SO RESPIRATORY CARE
LA English
DT Editorial Material
ID SUBGLOTTIC SECRETION DRAINAGE; CARE SAFETY NETWORK; ENDOTRACHEAL-TUBES;
METAANALYSIS; CUFF
C1 [Fernandez, Juan Felipe; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Restrepo, Marcos I.] Evidence Based Res Disseminat & Implementat Ctr, San Antonio, TX USA.
RP Restrepo, MI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care, 7400 Merton Minter St,MC 111E, San Antonio, TX 78229 USA.
EM Restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
FU NHLBI NIH HHS [K23 HL096054]
NR 13
TC 0
Z9 0
U1 0
U2 0
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD OCT
PY 2013
VL 58
IS 10
BP 1704
EP 1706
DI 10.4187/respcare.02803
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 245RH
UT WOS:000326481000017
PM 24064628
ER
PT J
AU Kim, HG
Tan, L
Weisberg, EL
Liu, FY
Canning, P
Choi, HG
Ezell, SA
Wu, H
Zhao, Z
Wang, JH
Mandinova, A
Griffin, JD
Bullock, AN
Liu, QS
Lee, SW
Gray, NS
AF Kim, Hyung-Gu
Tan, Li
Weisberg, Ellen L.
Liu, Feiyang
Canning, Peter
Choi, Hwan Geun
Ezell, Scott A.
Wu, Hong
Zhao, Zheng
Wang, Jinhua
Mandinova, Anna
Griffin, James D.
Bullock, Alex N.
Liu, Qingsong
Lee, Sam W.
Gray, Nathanael S.
TI Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase
Inhibitor
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID DISCOIDIN DOMAIN RECEPTOR-1; SOMATIC MUTATIONS; ABL INHIBITORS;
ACTIVATION; EXPRESSION; GENES; OVEREXPRESSION; DASATINIB; CARCINOMA;
NILOTINIB
AB The DDR1 receptor tyrosine kinase is activated by matrix collagens and has been implicated in numerous cellular functions such as proliferation, differentiation, adhesion, migration, and invasion. Here we report the discovery of a potent and selective DDR1 inhibitor, DDR1-IN-1, and present the 2.2 angstrom DDR1 co-crystal structure. DDR1-IN-1 binds to DDR1 in the 'DFG-out' conformation and inhibits DDR1 autophosphorylation in cells at submicromolar concentrations with good selectivity as assessed against a panel of 451 kinases measured using the KinomeScan technology. We identified a mutation in the hinge region of DDR1, G707A, that confers >20-fold resistance to the ability of DDR1-IN-1 to inhibit DDR1 autophosphorylation and can be used to establish what pharmacology is DDR1-dependent. A combinatorial screen of DDR1-IN-1 with a library of annotated kinase inhibitors revealed that inhibitors of PI3K and mTOR such as GSK2126458 potentiate the antiproliferative activity of DDR1-IN-1 in colorectal cancer cell lines. DDR1-IN-1 provides a useful pharmacological probe for DDR1-dependent signal transduction.
C1 [Kim, Hyung-Gu; Ezell, Scott A.; Mandinova, Anna; Lee, Sam W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
[Kim, Hyung-Gu; Ezell, Scott A.; Mandinova, Anna; Lee, Sam W.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Tan, Li; Weisberg, Ellen L.; Liu, Feiyang; Choi, Hwan Geun; Wu, Hong; Wang, Jinhua; Griffin, James D.; Liu, Qingsong; Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tan, Li; Wang, Jinhua; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Liu, Feiyang; Wu, Hong; Zhao, Zheng; Liu, Qingsong] Chinese Acad Sci, High Field Magnet Lab, Hefei 230031, Anhui, Peoples R China.
[Canning, Peter; Bullock, Alex N.] Univ Oxford, Struct Genom Consortium, Oxford OX3 7DQ, England.
RP Liu, QS (reprint author), Chinese Acad Sci, High Field Magnet Lab, POB 1110, Hefei 230031, Anhui, Peoples R China.
EM Qsliu97@hmfl.ac.cn; swlee@partners.org; nathanael_gray@dfci.harvard.edu
OI Canning, Peter/0000-0001-9678-4169; liu, qing song/0000-0002-7829-2547
FU National Institutes of Health [U54 HG006097, CA154303]; Chinese Academy
of Sciences; NIH; MGH; AbbVie; Boehringer Ingelheim; Canada Foundation
for Innovation; Canadian Institutes for Health Research; Genome Canada;
GlaxoSmithKline; Janssen; Lilly Canada; Novartis Research Foundation;
Ontario Ministry of Economic Development and Innovation; Pfizer; Takeda;
Wellcome Trust [092809/Z/10/Z]
FX We thank National Institutes of Health (U54 HG006097 and CA154303) for
support of L.T., H.G.C., J.W., Q.L., and N.S.G. and the Chinese Academy
of Sciences for training grant in support of F.L. and W.H.; H.-G.K,
S.A.E., and S.W.L. were supported by NIH grants and MGH Interim funds.
The SGC is a registered charity (number 1097737) that receives funds
from AbbVie, Boehringer Ingelheim, the Canada Foundation for Innovation,
the Canadian Institutes for Health Research, Genome Canada,
GlaxoSmithKline, Janssen, Lilly Canada, the Novartis Research
Foundation, the Ontario Ministry of Economic Development and Innovation,
Pfizer, Takeda, and the Wellcome Trust [092809/Z/10/Z]
NR 21
TC 32
Z9 35
U1 2
U2 36
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD OCT
PY 2013
VL 8
IS 10
BP 2145
EP 2150
DI 10.1021/cb400430t
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 240TU
UT WOS:000326121400007
PM 23899692
ER
PT J
AU Grant, SS
Kawate, T
Nag, PP
Silvis, MR
Gordon, K
Stanley, SA
Kazyanskaya, E
Nietupski, R
Golas, A
Fitzgerald, M
Cho, S
Franzblau, SG
Hung, DT
AF Grant, Sarah Schmidt
Kawate, Tomohiko
Nag, Partha P.
Silvis, Melanie R.
Gordon, Katherine
Stanley, Sarah A.
Kazyanskaya, Edward
Nietupski, Raymond
Golas, Aaron
Fitzgerald, Michael
Cho, Sanghyun
Franzblau, Scott G.
Hung, Deborah T.
TI Identification of Novel Inhibitors of Nonreplicating Mycobacterium
tuberculosis Using a Carbon Starvation Model
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID IN-VITRO; STRINGENT RESPONSE; TUBERCLE-BACILLI; ATP HOMEOSTASIS; MURINE
MODEL; PERSISTENCE; DORMANT; GROWTH; DIARYLQUINOLINES; METABOLISM
AB During Mycobacterium tuberculosis infection, a population of bacteria is thought to exist in a nonreplicating state, refractory to antibiotics, which may contribute to the need for prolonged antibiotic therapy. The identification of inhibitors of the nonreplicating state provides tools that can be used to probe this hypothesis and the physiology of this state. The development of such inhibitors also has the potential to shorten the duration of antibiotic therapy required. Here we describe the development of a novel nonreplicating assay amenable to high-throughput chemical screening coupled with secondary assays that use carbon starvation as the in vitro model. Together these assays identify compounds with activity against replicating and nonreplicating M. tuberculosis as well as compounds that inhibit the transition from nonreplicating to replicating stages of growth. Using these assays we successfully screened over 300,000 compounds and identified 786 inhibitors of nonreplicating M. tuberculosis In order to understand the relationship among different nonreplicating models, we tested 52 of these molecules in a hypoxia model, and four different chemical scaffolds in a stochastic persister model, and a streptomycin-dependent model. We found that compounds display varying levels of activity in different models for the nonreplicating state, suggesting important differences in bacterial physiology between models. Therefore, chemical tools identified in this assay may be useful for determining the relevance of different nonreplicating in vitro models to in vivo M. tuberculosis infection. Given our current limited understanding, molecules that are active across multiple models may represent more promising candidates for further development.
C1 [Grant, Sarah Schmidt; Kawate, Tomohiko; Nag, Partha P.; Silvis, Melanie R.; Gordon, Katherine; Stanley, Sarah A.; Kazyanskaya, Edward; Nietupski, Raymond; Golas, Aaron; Fitzgerald, Michael; Hung, Deborah T.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Grant, Sarah Schmidt] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
[Grant, Sarah Schmidt; Kawate, Tomohiko; Stanley, Sarah A.; Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Grant, Sarah Schmidt; Kawate, Tomohiko; Stanley, Sarah A.; Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Grant, Sarah Schmidt; Kawate, Tomohiko; Stanley, Sarah A.; Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
[Cho, Sanghyun; Franzblau, Scott G.] Univ Illinois, Coll Pharm, Inst TB Res, Chicago, IL 60621 USA.
RP Hung, DT (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
EM hung@molbio.mgh.harvard.edu
OI Franzblau, Scott/0000-0002-8698-0243; Silvis,
Melanie/0000-0002-0732-9744
FU National Institutes of Health [K08AI085033, R03MH087444]; Bill and
Melinda Gates Foundation; National Institutes of Health Molecular
Libraries Production Centers Network (MLPCN)
FX We thank J. Bittker, C. Mulrooney, and the Broad Institute Chemical
Biology platform for technical assistance and data management; R.
Goldman, B. Laughon, T. Parker, the NIAID and TAACF/SRI for providing
the 1113 compound set; Lucille White and SRSBSC for completing the
primary starvation screen and secondary logarithmic screen against the
324,545 MLSMR library; J. Gomez for helpful discussion and advice
throughout the project; A. Campos-Neto for the M. tuberculosis 18b
strain. S.S.G. gratefully acknowledges the National Institutes of Health
K08AI085033 for funding. This work was supported through funding from
the Bill and Melinda Gates Foundation to D.T.H., National Institutes of
Health R03MH087444 to D.T.H., and by the National Institutes of Health
Molecular Libraries Production Centers Network (MLPCN; www.mli.nih.gov),
which funded primary screening of a 324,545-compound library against M.
tuberculosis strain H37Rv at SRI.
NR 50
TC 18
Z9 18
U1 2
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD OCT
PY 2013
VL 8
IS 10
BP 2224
EP 2234
DI 10.1021/cb4004817
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 240TU
UT WOS:000326121400017
PM 23898841
ER
PT J
AU Flynn, JM
O'Leary, MN
Zambataro, CA
Academia, EC
Presley, MP
Garrett, BJ
Zykovich, A
Mooney, SD
Strong, R
Rosen, CJ
Kapahi, P
Nelson, MD
Kennedy, BK
Melov, S
AF Flynn, James M.
O'Leary, Monique N.
Zambataro, Christopher A.
Academia, Emmeline C.
Presley, Michael P.
Garrett, Brittany J.
Zykovich, Artem
Mooney, Sean D.
Strong, Randy
Rosen, Clifford J.
Kapahi, Pankaj
Nelson, Michael D.
Kennedy, Brian K.
Melov, Simon
TI Late-life rapamycin treatment reverses age-related heart dysfunction
SO AGING CELL
LA English
DT Article
DE RNA-seq; rapamycin; aging; strain echocardiography; RAD; hypertrophy;
mTOR
ID CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; MAMMALIAN TARGET; MTOR
INHIBITION; SPAN; BETA; RAD; DIFFERENTIATION; PERFORMANCE; MODULATION
AB Summary
Rapamycin has been shown to extend lifespan in numerous model organisms including mice, with the most dramatic longevity effects reported in females. However, little is known about the functional ramifications of this longevity-enhancing paradigm in mammalian tissues. We treated 24-month-old female C57BL/6J mice with rapamycin for 3 months and determined health outcomes via a variety of noninvasive measures of cardiovascular, skeletal, and metabolic health for individual mice. We determined that while rapamycin has mild transient metabolic effects, there are significant benefits to late-life cardiovascular function with a reversal or attenuation of age-related changes in the heart. RNA-seq analysis of cardiac tissue after treatment indicated inflammatory, metabolic, and antihypertrophic expression changes in cardiac tissue as potential mechanisms mediating the functional improvement. Rapamycin treatment also resulted in beneficial behavioral, skeletal, and motor changes in these mice compared with those fed a control diet. From these findings, we propose that late-life rapamycin therapy not only extends the lifespan of mammals, but also confers functional benefits to a number of tissues and mechanistically implicates an improvement in contractile function and antihypertrophic signaling in the aged heart with a reduction in age-related inflammation.
C1 [Flynn, James M.; O'Leary, Monique N.; Zambataro, Christopher A.; Academia, Emmeline C.; Presley, Michael P.; Garrett, Brittany J.; Zykovich, Artem; Mooney, Sean D.; Kapahi, Pankaj; Kennedy, Brian K.; Melov, Simon] Buck Inst Res Aging, Novato, CA 94945 USA.
[Strong, Randy] UTHSC, South Texas Vet Hlth Care Syst, Dept Pharmacol, San Antonio, TX 78229 USA.
[Strong, Randy] UTHSC, South Texas Vet Hlth Care Syst, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Rosen, Clifford J.] Maine Med Ctr, Res Inst, Ctr Clin & Translat Res, Scarborough, ME 04074 USA.
[Nelson, Michael D.] Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA.
RP Melov, S (reprint author), Buck Inst Res Aging, 8001 Redwood Blvd, Novato, CA 94945 USA.
EM smelov@buckinstitute.org
FU Larry L. Hillblom Foundation [2007 2/F]; Ellison Medical Foundation;
Glenn Foundation for Medical Research; Investigator Initiated Studies
Program [39326, 50196]; [PO1 AG025901]; [RO1 AG033373];
[1U01-AG022307]; [T32AG000266]
FX Funding support for this research was generously provided by the
following grants; PO1 AG025901(SM), RO1 AG033373 (BKK), 1U01-AG022307
(RS), T32AG000266 (Buck Institute), and partial support from the Larry
L. Hillblom Foundation Network grant (2007 2/F), the Ellison Medical
Foundation (BKK), and the Glenn Foundation for Medical Research (SM and
JF). This research was also supported in part by grants from Merck to SM
(Investigator Initiated Studies Program, # 39326, and #50196).
NR 45
TC 75
Z9 77
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD OCT
PY 2013
VL 12
IS 5
BP 851
EP 862
DI 10.1111/acel.12109
PG 12
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 217RA
UT WOS:000324376300013
PM 23734717
ER
PT J
AU Stein, NR
Schorr, Y
Krantz, L
Dickstein, BD
Solomon, Z
Horesh, D
Litz, BT
AF Stein, Nathan R.
Schorr, Yonit
Krantz, Lillian
Dickstein, Benjamin D.
Solomon, Zahava
Horesh, Danny
Litz, Brett T.
TI The Differential Impact of Terrorism on Two Israeli Communities
SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY
LA English
DT Article
DE Israeli communities; terrorism; exposure to terror; stress-related
symptoms; posttraumatic stress disorder; depression; dose-response
relationship; rocket attacks; kibbutz; moshav
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH SYMPTOMS; PSYCHOMETRIC
PROPERTIES; REPRESENTATIVE SAMPLE; EXPOSURE; TRAUMA; CHECKLIST; ARABS;
PTSD; RISK
AB The authors evaluated 2 cohorts of individuals from different Israeli communities (Sderot and Otef Aza) that are repeatedly subjected to potentially lethal missile attacks. Although both communities border the Gaza Strip and face similar levels of threat, the authors hypothesized that the Sderot cohort would endorse higher rates of stress-related symptoms because it has fewer mitigating economic and psychosocial resources. The authors further hypothesized that there would be a significant relationship between exposure to terror and psychopathology regardless of community context. To test these predictions, the authors compared the levels of exposure to terror, posttraumatic stress disorder (PTSD), and depression in representative samples of adults from the 2 communities (n=298 and n=152, respectively). Residents of Sderot had a much higher rate of probable PTSD (35.2% vs. 6.6%), and community context was the most important predictor of PTSD and depression. The study also revealed a significant relationship between exposure and psychopathology, but for Sderot residents only. The conclusion is that researchers, mental health workers, and policy makers should pay attention to the influence of community characteristics, such as the availability of resources, the general sense of support, and the level of solidarity, on the mental health response to exposure to terror.
C1 [Solomon, Zahava; Horesh, Danny] Tel Aviv Univ, IL-69978 Tel Aviv, Israel.
RP Stein, NR (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave 116B-4, Boston, MA 02130 USA.
EM nathan.stein@va.gov
OI Horesh, Danny/0000-0003-3574-4301
FU National Institute of Mental Health [R21 MH074501]
FX This research was supported by Grant R21 MH074501 from the National
Institute of Mental Health awarded to Brett Litz. Its contents are
solely the responsibility of the authors and do not necessarily
represent the official views of the National Institute of Mental Health.
NR 29
TC 2
Z9 2
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-9432
EI 1939-0025
J9 AM J ORTHOPSYCHIAT
JI Am. J. Orthopsychiatr.
PD OCT
PY 2013
VL 83
IS 4
BP 528
EP 535
DI 10.1111/ajop.12044
PG 8
WC Psychiatry; Social Work
SC Psychiatry; Social Work
GA 241OP
UT WOS:000326176900009
PM 24164524
ER
PT J
AU Adrianto, I
Dozmorov, MG
Wiley, GB
Ice, JA
Li, H
Kelly, JA
Rasmussen, A
Stone, DU
Anaya, JM
Segal, BM
Rhodus, NL
Radfar, L
Harley, JB
James, JA
Montgomery, CG
Scofield, RH
Gaffney, PM
Wren, JD
Sivils, KL
Lessard, CJ
AF Adrianto, Indra
Dozmorov, Mikhail G.
Wiley, Graham B.
Ice, John A.
Li, He
Kelly, Jennifer A.
Rasmussen, Astrid
Stone, Donald U.
Anaya, Juan-Manuel
Segal, Barbara M.
Rhodus, Nelson L.
Radfar, Lida
Harley, John B.
James, Judith A.
Montgomery, Courtney G.
Scofield, R. Hal
Gaffney, Patrick M.
Wren, Jonathan D.
Sivils, Kathy L.
Lessard, Christopher J.
TI RNA-Sequencing Identifies Novel Differentially Expressed Coding and
Non-Coding Transcripts In Sjogren's Syndrome
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Adrianto, Indra; Dozmorov, Mikhail G.; Wiley, Graham B.; Ice, John A.; Kelly, Jennifer A.; Rasmussen, Astrid; Montgomery, Courtney G.; Gaffney, Patrick M.; Wren, Jonathan D.; Sivils, Kathy L.; Lessard, Christopher J.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Li, He; Stone, Donald U.; Radfar, Lida; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Anaya, Juan-Manuel] Univ Rosario, Sch Med & Hlth Sci, Bogota, Colombia.
[Segal, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Rhodus, Nelson L.] Univ Minnesota, Minneapolis, MN USA.
[Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
RI Anaya, Juan-Manuel/J-1960-2016
OI Anaya, Juan-Manuel/0000-0002-6444-1249
NR 0
TC 1
Z9 1
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1489
BP S632
EP S633
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203467
ER
PT J
AU Anyanwu, CO
Fiorentino, D
Chung, L
Wang, YL
Propert, KJ
Werth, VP
AF Anyanwu, Cynthia O.
Fiorentino, David
Chung, Lorinda
Wang, Yanli
Propert, Kathleen J.
Werth, Victoria P.
TI Validation Of The Cutaneous Dermatomyositis Disease Area and Severity
Index: Characterizing Severity and Assessing Responsiveness To Clinical
Change
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Anyanwu, Cynthia O.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Fiorentino, David] Stanford Univ, Sch Med, Redwood City, CA USA.
[Chung, Lorinda] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA.
[Wang, Yanli; Propert, Kathleen J.] Univ Penn, Philadelphia, PA 19104 USA.
[Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1935
BP S824
EP S824
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204393
ER
PT J
AU Aquino-Beaton, C
Persselin, JE
Weinreb, A
Fang, MA
Singh, JA
Duffy, E
Elashoff, D
Khanna, P
Khanna, D
AF Aquino-Beaton, Cleopatra
Persselin, Jay E.
Weinreb, Ari
Fang, Meika A.
Singh, Jasvinder A.
Duffy, Erin
Elashoff, David
Khanna, Puja
Khanna, Dinesh
TI Impact Of Educational Attainment On Health-Related Quality Of Life and
Healthcare Utilization Among Veterans With Gout
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Aquino-Beaton, Cleopatra; Persselin, Jay E.; Weinreb, Ari; Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med Stat Core, Los Angeles, CA USA.
[Khanna, Puja] Ann Arbor VA, Ann Arbor, MI USA.
[Khanna, Dinesh] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1984
BP S846
EP S846
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204442
ER
PT J
AU Arvikar, SL
Strle, K
Collier, DS
Fisher, MC
Kawai, T
Scher, JU
Steere, AC
AF Arvikar, Sheila L.
Strle, Klemen
Collier, Deborah S.
Fisher, Mark C.
Kawai, Toshihisa
Scher, Jose U.
Steere, Allen C.
TI Association Of High Serum Interleukin-23 Levels With Porphyromonas
Gingivalis Antibodies In Patients With Early Rheumatoid Arthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Arvikar, Sheila L.; Strle, Klemen; Collier, Deborah S.; Fisher, Mark C.; Steere, Allen C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kawai, Toshihisa] Forsyth Inst, Cambridge, MA USA.
[Scher, Jose U.] NYU, Hosp Joint Dis, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2409
BP S1029
EP S1029
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359205354
ER
PT J
AU Barker, AM
Battistone, MJ
Beck, JP
Butler, J
Grotzke, M
Huhtala, TA
Cannella, AC
Daikh, DI
Fang, MA
Lazzari, AA
Roldan, P
Von Feldt, JM
Cannon, GW
AF Barker, Andrea M.
Battistone, Michael J.
Beck, J. Peter
Butler, Jorie
Grotzke, Marissa
Huhtala, Timothy A.
Cannella, Amy C.
Daikh, David I.
Fang, Meika A.
Lazzari, Antonio A.
Roldan, Pedro
Von Feldt, Joan Marie
Cannon, Grant W.
TI Objective Assessment Of Musculoskeletal Physical Examination Skills
During Continuing Education Programs For Primary Care Providers Adds
Significant Information Not Obtained Through Self-Assessment
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Barker, Andrea M.; Battistone, Michael J.; Beck, J. Peter; Butler, Jorie; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA.
[Barker, Andrea M.; Battistone, Michael J.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA.
[Cannella, Amy C.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA.
[Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA.
[Von Feldt, Joan Marie] Univ Penn Philadelphia VAMC, Philadelphia, PA USA.
RI Beck, James Peter/F-9407-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2817
BP S1206
EP S1207
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206246
ER
PT J
AU Battistone, MJ
Barker, AM
Beck, JP
Grotzke, M
Huhtala, TA
Butler, J
Cannella, AC
Daikh, DI
Fang, MA
Lazzari, AA
Roldan, P
Von Feldt, JM
Cannon, GW
AF Battistone, Michael J.
Barker, Andrea M.
Beck, J. Peter
Grotzke, Marissa
Huhtala, Timothy A.
Butler, Jorie
Cannella, Amy C.
Daikh, David I.
Fang, Meika A.
Lazzari, Antonio A.
Roldan, Pedro
Von Feldt, Joan Marie
Cannon, Grant W.
TI Retrospective Self-Assessment Of Pre-Course Competency: A Useful Tool
For Musculoskeletal Curriculum Assessment In a Multi-Center,
Interprofessional Cohort.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Battistone, Michael J.; Barker, Andrea M.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Butler, Jorie; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA.
[Battistone, Michael J.; Barker, Andrea M.; Beck, J. Peter; Grotzke, Marissa; Huhtala, Timothy A.; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA.
[Cannella, Amy C.] Univ Nebraska, Med Ctr, Omaha, NE USA.
[Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA.
[Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA.
[Von Feldt, Joan Marie] Univ Penn, Philadelphia, PA 19104 USA.
[Von Feldt, Joan Marie] Philadelphia VAMC, Philadelphia, PA USA.
RI Beck, James Peter/F-9407-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 972
BP S415
EP S415
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202476
ER
PT J
AU Bharat, A
Singh, JA
Khanna, P
Aquino-Beaton, C
Persselin, JE
Duffy, E
Elashoff, D
Khanna, D
AF Bharat, Aseem
Singh, Jasvinder A.
Khanna, Puja
Aquino-Beaton, Cleopatra
Persselin, Jay E.
Duffy, Erin
Elashoff, David
Khanna, Dinesh
TI Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL),
Functional Ability and Health Care Utilization In Gout Patients
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Bharat, Aseem] Univ Alabama Birmingham, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Aquino-Beaton, Cleopatra; Persselin, Jay E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA.
[Khanna, Dinesh] Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1996
BP S851
EP S852
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204454
ER
PT J
AU Brown, LE
Frits, MA
Iannaccone, CK
Weinblatt, ME
Shadick, NA
Liao, KP
AF Brown, Lindsay E.
Frits, Michelle A.
Iannaccone, Christine K.
Weinblatt, Michael E.
Shadick, Nancy A.
Liao, Katherine P.
TI Clinical Characteristics of Rheumatoid Arthritis Patients with Secondary
Sjogren's Syndrome and Association with Joint Damage
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Brown, Lindsay E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Frits, Michelle A.; Iannaccone, Christine K.; Weinblatt, Michael E.; Shadick, Nancy A.; Liao, Katherine P.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2883
BP S1236
EP S1237
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206310
ER
PT J
AU Cannon, GW
DuVall, SL
Hayden, CL
Caplan, L
Curtis, JR
Michaud, K
Mikuls, TR
Reimold, AM
Collier, DH
Joseph, G
Harrison, DJ
Sauer, BC
AF Cannon, Grant W.
DuVall, Scott L.
Hayden, Candace L.
Caplan, Liron
Curtis, Jeffrey R.
Michaud, Kaleb
Mikuls, Ted R.
Reimold, Andreas M.
Collier, David H.
Joseph, George
Harrison, David J.
Sauer, Brian C.
TI US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis
Factor Blocking Agents Have No Additional Clinical Benefit With The
Change In Therapy and Incur Higher Costs
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA.
[Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[DuVall, Scott L.; Hayden, Candace L.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA.
[DuVall, Scott L.; Hayden, Candace L.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Michaud, Kaleb] Natl Data Bank Rheumat Dis, Omaha, NE USA.
[Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Mikuls, Ted R.] Omaha VA, Omaha, NE USA.
[Reimold, Andreas M.] Dallas VA, Dallas, TX USA.
[Reimold, Andreas M.] Univ Texas Southwestern, Dallas, TX USA.
[Collier, David H.; Joseph, George; Harrison, David J.] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Sauer, Brian C.] George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 427
BP S184
EP S185
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359201426
ER
PT J
AU Carruthers, M
Topazian, M
Khosroshahi, A
Witzig, T
Oakley, J
Hart, P
Kelly, L
Bergstrom, L
Chari, S
Stone, J
AF Carruthers, Mollie
Topazian, Mark
Khosroshahi, Arezou
Witzig, Thomas
Oakley, Judith
Hart, Philip
Kelly, Lauren
Bergstrom, Lori
Chari, Suresh
Stone, John
TI Rituximab For The Treatment Of IgG4-Related Disease: A Prospective
Clinical Trial
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Carruthers, Mollie; Oakley, Judith; Kelly, Lauren] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Topazian, Mark] Mayo Clin, Rochester, MA USA.
[Khosroshahi, Arezou] Emory Univ, Sch Med, Atlanta, GA USA.
[Witzig, Thomas; Hart, Philip; Bergstrom, Lori; Chari, Suresh] Mayo Clin, Rochester, MN USA.
[Stone, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2649
BP S1128
EP S1129
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206078
ER
PT J
AU Carruthers, M
Mattoo, H
Wallace, ZS
Mahajan, V
Pillai, S
Stone, JH
AF Carruthers, Mollie
Mattoo, Hamid
Wallace, Zachary S.
Mahajan, Vinay
Pillai, Shiv
Stone, John H.
TI IgG4+Plasmablasts Are A Novel Biomarker In IgG4-Related Disease.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Carruthers, Mollie; Wallace, Zachary S.; Pillai, Shiv; Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mattoo, Hamid; Mahajan, Vinay] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 784
BP S332
EP S332
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202289
ER
PT J
AU Criscione-Schreiber, LG
Bolster, MB
Jonas, BL
Sloane, R
Hawley, J
O'Rourke, KS
AF Criscione-Schreiber, Lisa G.
Bolster, Marcy B.
Jonas, Beth L.
Sloane, Richard
Hawley, Jeffrey
O'Rourke, Kenneth S.
TI Expert Panel Consensus On Content Of a Rheumatology Objective Structured
Clinical Examination
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Criscione-Schreiber, Lisa G.; Sloane, Richard] Duke Univ Hlth Syst, Durham, NC USA.
[Bolster, Marcy B.] Massachussetts Gen Hosp, Boston, MA USA.
[Jonas, Beth L.] Univ N Carolina, Chapel Hill, NC USA.
[Hawley, Jeffrey] Duke Univ, Sch Nursing, Durham, NC USA.
[O'Rourke, Kenneth S.] Wake Forest Sch Med, Winston Salem, NC USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2813
BP S1204
EP S1205
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206242
ER
PT J
AU Daikh, DI
Battistone, MJ
Barker, AM
Avins, AL
Grotzke, M
Fang, MA
Lazzari, AA
Cannella, AC
Roldan, P
Von Feldt, JM
Cannon, GW
AF Daikh, David I.
Battistone, Michael J.
Barker, Andrea M.
Avins, Andy L.
Grotzke, Marissa
Fang, Meika A.
Lazzari, Antonio A.
Cannella, Amy C.
Roldan, Pedro
Von Feldt, Joan Marie
Cannon, Grant W.
TI Inter-Professional Training Programs For Primary Care Providers Can
Successfully Educate Practitioners With Dramatically Different
Educational and Training Background Through a Common Mini-Residency
Training Program.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Daikh, David I.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Battistone, Michael J.; Barker, Andrea M.; Grotzke, Marissa; Cannon, Grant W.] Salt Lake City VA, Salt Lake City, UT USA.
[Battistone, Michael J.; Barker, Andrea M.; Grotzke, Marissa; Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Avins, Andy L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Lazzari, Antonio A.] Boston VA Med Ctr, Boston, MA USA.
[Cannella, Amy C.] Omaha Vet Affairs Hosp, Omaha, NE USA.
[Cannella, Amy C.] Univ Nebraska, Med Ctr, Omaha, NE USA.
[Roldan, Pedro] Leesburg VA CBOC, Leesburg, FL USA.
[Von Feldt, Joan Marie] Univ Penn, Philadelphia, PA 19104 USA.
[Von Feldt, Joan Marie] Philadelphia VAMC, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 978
BP S417
EP S418
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202482
ER
PT J
AU Davis, LA
Luong, P
Bobba, S
Dischinger, H
Quinzanos, I
Caplan, L
AF Davis, Lisa A.
Phat Luong
Bobba, Sushmitha
Dischinger, Hannah
Quinzanos, Itziar
Caplan, Liron
TI Acceptability Of Various Technology-Based Communication Modalities In a
Rheumatology Clinic
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Davis, Lisa A.] Denver Hlth & Hosp Author, Denver, CO USA.
[Phat Luong; Bobba, Sushmitha; Dischinger, Hannah; Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Quinzanos, Itziar] Univ Colorado, Sch Med, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1907
BP S812
EP S813
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204366
ER
PT J
AU Della Torre, E
Krause, D
Deshpande, V
Mahajan, V
Mattoo, H
Pillai, S
Stone, J
AF Della Torre, Emanuel
Krause, Donald
Deshpande, Vikram
Mahajan, Vinay
Mattoo, Hamid
Pillai, Shiv
Stone, John
TI IgG4-Related Midline Destructive Lesion: Expanding The Spectrum Of Organ
Involvement In IgG4-Related Disease
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Della Torre, Emanuel; Deshpande, Vikram; Pillai, Shiv] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Krause, Donald] St Josephs Hosp, Bangor, ME USA.
[Mahajan, Vinay; Mattoo, Hamid; Stone, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2023
BP S863
EP S863
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204481
ER
PT J
AU Ding, YN
Hsu, HC
Li, J
Yang, PA
Wu, Q
Zajac, AJ
Mountz, JD
AF Ding, Yanna
Hsu, Hui-Chen
Li, Jun
Yang, PingAr
Wu, Qi
Zajac, Allan J.
Mountz, John D.
TI IL-21 Inhibited Follicular Regulatory T Cells To Promote Autoreactive
Germinal Center Development In Autoimmune BXD2 Mice
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Ding, Yanna; Li, Jun; Yang, PingAr; Wu, Qi; Zajac, Allan J.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2713
BP S1159
EP S1159
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206143
ER
PT J
AU Grammatikos, AP
Ghosh, D
Kyttaris, VC
AF Grammatikos, Alexandros P.
Ghosh, Debjani
Kyttaris, Vasileios C.
TI Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T
Cell Signaling
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Grammatikos, Alexandros P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Ghosh, Debjani] E Carolina Univ, Brody Sch Med, Greenville, NC USA.
[Kyttaris, Vasileios C.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2701
BP S1154
EP S1154
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206131
ER
PT J
AU Hedrich, CM
Crispin, JC
Rauen, T
Ioannidis, C
Koga, T
Rodriguez, NR
Apostolidis, SA
Kyttaris, VC
Tsokos, GC
AF Hedrich, Christian M.
Crispin, Jose C.
Rauen, Thomas
Ioannidis, Christina
Koga, Tomohiro
Rodriguez, Noe Rodriguez
Apostolidis, Sokratis A.
Kyttaris, Vasileios C.
Tsokos, George C.
TI cAMP Responsive Element Modulator (CREM) alpha Governs CD8 Expression
and Contributes to the Generation of CD3(+) CD4(-)CD8(-) T Cells in
Lupus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Hedrich, Christian M.; Crispin, Jose C.; Rauen, Thomas; Ioannidis, Christina; Rodriguez, Noe Rodriguez; Kyttaris, Vasileios C.; Tsokos, George C.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
[Koga, Tomohiro; Apostolidis, Sokratis A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2724
BP S1163
EP S1163
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206153
ER
PT J
AU Henderson, LA
Frugoni, F
Hopkins, G
de Boer, H
Pai, SY
Lee, YN
Walter, JE
Hazen, MM
Notarangelo, LD
AF Henderson, Lauren A.
Frugoni, Francesco
Hopkins, Gregory
de Boer, Helen
Pai, Sung-Yun
Lee, Yu Nee
Walter, Jolan E.
Hazen, Melissa M.
Notarangelo, Luigi D.
TI Expanding The Spectrum Of Recombination Activating Gene-1 Deficiency To
Include Early Onset Autoimmunity
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Henderson, Lauren A.; Frugoni, Francesco; Hopkins, Gregory; de Boer, Helen; Lee, Yu Nee; Hazen, Melissa M.; Notarangelo, Luigi D.] Boston Childrens Hosp, Boston, MA USA.
[Pai, Sung-Yun] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Walter, Jolan E.] Massachusetts Gen Hosp Children, Boston, MA USA.
RI Notarangelo, Luigi/F-9718-2016
OI Notarangelo, Luigi/0000-0002-8335-0262
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2195
BP S935
EP S936
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359205143
ER
PT J
AU Hill, E
Higgs, JB
Sky, K
Sit, M
Collamer, AN
AF Hill, Erica
Higgs, Jay B.
Sky, Karen
Sit, Michelle
Collamer, Angelique N.
TI Does Starting Allopurinol Prolong Acute Treated Gout?
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Hill, Erica; Higgs, Jay B.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA.
[Sky, Karen] Alaska VA Healthcare Syst, US Dept Vet Affairs, Anchorage, AK USA.
[Sit, Michelle] David Grant Med Ctr, Travis AFB, CA USA.
[Collamer, Angelique N.] Langley AFB Hosp, Langley AFB, VA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1722
BP S730
EP S730
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204182
ER
PT J
AU Hirsh, JM
Davis, LA
Quinzanos, I
Keniston, A
Caplan, L
AF Hirsh, Joel M.
Davis, Lisa A.
Quinzanos, Itziar
Keniston, Angela
Caplan, Liron
TI Health Literacy Predicts Discrepancies Between Traditional Written
Rheumatoid Arthritis Patient Assessments and Verbally-Administered
Assessments
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Hirsh, Joel M.; Keniston, Angela] Denver Hlth, Denver, CO USA.
[Hirsh, Joel M.; Keniston, Angela] Hosp Author, Denver, CO USA.
[Davis, Lisa A.; Quinzanos, Itziar] Univ Colorado, Sch Med, Aurora, CO USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1031
BP S439
EP S440
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203017
ER
PT J
AU Ichinose, K
Ushigusa, T
Koga, T
Tsokos, GC
Kawakami, A
AF Ichinose, Kunihiro
Ushigusa, Takeshi
Koga, Tomohiro
Tsokos, George C.
Kawakami, Atsushi
TI Role of Calcium/Calmodulin Kinase IV On Podocyte Function in Lupus
Nephritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Ichinose, Kunihiro] Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Unit Translat Med, Nagasaki 852, Japan.
[Ushigusa, Takeshi; Kawakami, Atsushi] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 852, Japan.
[Koga, Tomohiro] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Tsokos, George C.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 888
BP S381
EP S381
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202393
ER
PT J
AU Kay, J
Bossaller, L
Schmidt-Lauber, C
Abujudeh, HH
Vladimer, G
Latz, E
Fitzgerald, KA
Marshak-Rothstein, A
Gravallese, EM
AF Kay, Jonathan
Bossaller, Lukas
Schmidt-Lauber, Christian
Abujudeh, Hani H.
Vladimer, Gregory
Latz, Eicke
Fitzgerald, Katherine A.
Marshak-Rothstein, Ann
Gravallese, Ellen M.
TI Gadolinium-Based Compounds Induce NLRP3-Dependent IL-1 beta Production
and Peritoneal Inflammation.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Kay, Jonathan] UMass Mem Med Ctr, Worcester, MA USA.
[Kay, Jonathan; Bossaller, Lukas; Schmidt-Lauber, Christian; Vladimer, Gregory; Latz, Eicke; Fitzgerald, Katherine A.; Marshak-Rothstein, Ann; Gravallese, Ellen M.] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Abujudeh, Hani H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Abujudeh, Hani H.] Harvard Univ, Sch Med, Boston, MA USA.
RI Latz, Eicke/H-3951-2014
OI Latz, Eicke/0000-0003-1488-5666
NR 0
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2904
BP S1246
EP S1246
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206331
ER
PT J
AU Khanna, D
Gladue, H
Fitzgerald, JD
Channick, RN
Chung, L
Distler, O
Furst, D
Hachulla, E
Humbert, M
Langleben, D
Mathai, SC
Saggar, R
Visovatti, SH
McLaughlin, V
AF Khanna, Dinesh
Gladue, Heather
Fitzgerald, John D.
Channick, Richard N.
Chung, Lorinda
Distler, Oliver
Furst, Daniel
Hachulla, Eric
Humbert, Marc
Langleben, David
Mathai, Stephen C.
Saggar, Rajeev
Visovatti, Scott H.
McLaughlin, Vallerie
TI Recommendations For Screening and Detection Of Connective-Tissue Disease
Associated Pulmonary Arterial Hypertension
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Khanna, Dinesh] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Gladue, Heather; Visovatti, Scott H.; McLaughlin, Vallerie] Univ Michigan, Ann Arbor, MI 48109 USA.
[Fitzgerald, John D.] Univ Calif Los Angeles, Sch Med Rehab 32 59, Los Angeles, CA USA.
[Channick, Richard N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chung, Lorinda] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA.
[Distler, Oliver] Univ Zurich Hosp, Dept Rheumatol, CH-8091 Zurich, Switzerland.
[Furst, Daniel] Univ Calif Los Angeles, Los Angeles, CA USA.
[Hachulla, Eric] Claude Huriez Univ Hosp, Lille, France.
[Humbert, Marc] Ctr Chirurg Marie Lannelongue, Le Plessis Robinson, France.
[Langleben, David] McGill Univ, Montreal, PQ, Canada.
[Mathai, Stephen C.] Johns Hopkins Univ, Baltimore, MD USA.
[Saggar, Rajeev] St Josephs Hosp, Phoenix, AZ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2579
BP S1100
EP S1101
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206012
ER
PT J
AU Khanna, P
Aquino-Beaton, C
Singh, JA
Duffy, E
Elashoff, D
Khanna, D
AF Khanna, Puja
Aquino-Beaton, Cleopatra
Singh, Jasvinder A.
Duffy, Erin
Elashoff, David
Khanna, Dinesh
TI Predictors Of Outcomes In Tophaceous Gout-Results From a Prospective
Cohort At The Veterans Affairs
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Khanna, Puja] Ann Arbor VA, Ann Arbor, MI USA.
[Aquino-Beaton, Cleopatra] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA.
[Khanna, Dinesh] Univ Michigan, Med Ctr, Div Rheumatol, Ann Arbor, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2005
BP S856
EP S856
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204463
ER
PT J
AU Khanna, P
Aquino-Beaton, C
Singh, JA
Duffy, E
Elashoff, D
Khanna, D
AF Khanna, Puja
Aquino-Beaton, Cleopatra
Singh, Jasvinder A.
Duffy, Erin
Elashoff, David
Khanna, Dinesh
TI Performance Of Gout Impact Scale Of The Gout Assessment Questionnaire In
a Longitudinal Observational Study Of Patients With Gout
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Aquino-Beaton, Cleopatra] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA.
[Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1994
BP S850
EP S851
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204452
ER
PT J
AU Kim, SC
Schneeweiss, S
Glynn, RJ
Doherty, M
Goldfine, A
Solomon, DH
AF Kim, Seoyoung C.
Schneeweiss, Sebastian
Glynn, Robert J.
Doherty, Michael
Goldfine, Allison
Solomon, Daniel H.
TI Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk
Of Autoimmune Diseases
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Kim, Seoyoung C.; Schneeweiss, Sebastian; Glynn, Robert J.; Doherty, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Goldfine, Allison] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Solomon, Daniel H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol,Div Pharmacoepidemiol, Boston, MA 02115 USA.
RI Schneeweiss, Sebastian/C-2125-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2658
BP S1133
EP S1133
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206088
ER
PT J
AU Kohler, MJ
Rempell, J
Seton, M
AF Kohler, Minna J.
Rempell, Joshua
Seton, Margaret
TI Medical Student Perceptions Of Point-Of-Care Ultrasound In
Musculoskeletal Education.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Kohler, Minna J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Rempell, Joshua; Seton, Margaret] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 974
BP S416
EP S416
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202478
ER
PT J
AU Kohler, MJ
Rastalsky, N
Fraenkel, L
AF Kohler, Minna J.
Rastalsky, Naina
Fraenkel, Liana
TI Variable Imaging Characteristics Identified By Point-Of-Care Ultrasound
For Greater Trochanteric Pain Syndrome
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Kohler, Minna J.; Rastalsky, Naina] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Fraenkel, Liana] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 231
BP S94
EP S95
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359201230
ER
PT J
AU Koristka, S
Cartellieri, M
Arndt, C
Feldmann, A
Michalk, I
Bippes, CC
Berndt, N
Hermsdorf, A
Stamova, S
Kurien, BT
Scofield, RH
Farris, AD
James, JA
Bartsch, H
Bachmann, M
AF Koristka, Stefanie
Cartellieri, Marc
Arndt, Claudia
Feldmann, Anja
Michalk, Irene
Bippes, Claudia C.
Berndt, Nicole
Hermsdorf, Anne
Stamova, Slava
Kurien, Biji T.
Scofield, Robert Hal
Farris, A. Darise
James, Judith A.
Bartsch, Holger
Bachmann, Michael
TI Bispecific Antibodies For Redirection Of Human Regulatory T Cells To
Surface-Inducible Autoantigen La/SS-B
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Koristka, Stefanie; Cartellieri, Marc; Arndt, Claudia; Feldmann, Anja; Michalk, Irene; Bippes, Claudia C.; Berndt, Nicole; Hermsdorf, Anne; Stamova, Slava; Bartsch, Holger; Bachmann, Michael] Carl Gustav Carus TU Dresden, Dresden, Germany.
[Kurien, Biji T.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Scofield, Robert Hal] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Scofield, Robert Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Scofield, Robert Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Farris, A. Darise] Oklahoma Med Res Foun, Oklahoma City, OK USA.
[James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
RI Bachmann, Michael/E-8850-2010; Feldmann, Anja/D-7843-2014
OI Bachmann, Michael/0000-0002-8029-5755; Feldmann,
Anja/0000-0001-5099-2448
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1641
BP S696
EP S696
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204105
ER
PT J
AU Lee, P
Sykes, D
Ameri, S
Kalaitzidis, D
Nigrovic, PA
Cardona, A
AF Lee, Pui
Sykes, David
Ameri, Sarah
Kalaitzidis, Demetrios
Nigrovic, Peter A.
Cardona, Astrid
TI Distinct Pathways Of Ly6C(hi) Monocyte Development Identified By a Novel
Dual-Reporter Murine Myeloid Progenitor Cell Line
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Lee, Pui; Nigrovic, Peter A.] Boston Childrens Hosp, Boston, MA USA.
[Sykes, David; Kalaitzidis, Demetrios] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ameri, Sarah] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Cardona, Astrid] Univ Texas San Antonio, San Antonio, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1142
BP S485
EP S485
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203128
ER
PT J
AU Li, H
Hsu, HC
Wu, Q
Li, J
Yang, PA
Fu, YX
Mountz, JD
AF Li, Hao
Hsu, Hui-Chen
Wu, Qi
Li, Jun
Yang, PingAr
Fu, Yang-Xin
Mountz, John D.
TI Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon
Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic
Autoimmunity
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Li, Hao; Wu, Qi; Li, Jun; Yang, PingAr; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA.
[Fu, Yang-Xin] Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 37
BP S15
EP S16
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359201037
ER
PT J
AU Li, H
Ice, JA
Kelly, JA
Adrianto, I
Glenn, SB
Hefner, KS
Vista, EG
Stone, DU
Gopalakrishnan, R
Houston, GD
Lewis, DM
Rohrer, M
Hughes, P
Harley, JB
Montgomery, CG
Chodosh, J
Lessard, JA
Anaya, JM
Segal, BM
Rhodus, NL
Radfar, L
Scofield, RH
Lessard, CJ
Sivils, KL
AF Li, He
Ice, John A.
Kelly, Jennifer A.
Adrianto, Indra
Glenn, Stuart B.
Hefner, Kimberly S.
Vista, Evan G.
Stone, Donald U.
Gopalakrishnan, Raj
Houston, Glen D.
Lewis, David M.
Rohrer, Michael
Hughes, Pamela
Harley, John B.
Montgomery, Courtney G.
Chodosh, James
Lessard, James A.
Anaya, Juan-Manuel
Segal, Barbara M.
Rhodus, Nelson L.
Radfar, Lida
Scofield, R. Hal
Lessard, Christopher J.
Sivils, Kathy L.
TI Identification Of a Sjogren's Syndrome-Associated Variant That
Influences OAS1 Isoform Switching
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Li, He; Stone, Donald U.; Houston, Glen D.; Lewis, David M.; Lessard, Christopher J.] Univ Oklahoma Hlth Sci Ctr, Oklahoma City, OK USA.
[Ice, John A.; Kelly, Jennifer A.; Adrianto, Indra; Glenn, Stuart B.; Montgomery, Courtney G.; Scofield, R. Hal; Sivils, Kathy L.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Hefner, Kimberly S.] Hefner Eye Care & Opt Ctr, Oklahoma City, OK USA.
[Vista, Evan G.] Univ Santo Tomas, Taguig City, Philippines.
[Gopalakrishnan, Raj; Rohrer, Michael; Hughes, Pamela; Rhodus, Nelson L.] Univ Minnesota, Minneapolis, MN USA.
[Harley, John B.] US Dept Vet Affairs Med Ctr, Cincinnati, OH USA.
[Chodosh, James] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Lessard, James A.] Valley Bone & Joint Clin, Grand Forks, ND USA.
[Anaya, Juan-Manuel] Univ Rosario, Sch Med & Hlth Sci, Bogota, Colombia.
[Segal, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
RI Anaya, Juan-Manuel/J-1960-2016
OI Anaya, Juan-Manuel/0000-0002-6444-1249
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2772
BP S1185
EP S1186
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206201
ER
PT J
AU Li, J
Hsu, HC
Yang, PA
Wu, Q
Luo, B
Rowse, AL
Spalding, DM
Mobley, JA
Bridges, SL
Mountz, JD
AF Li, Jun
Hsu, Hui-Chen
Yang, PingAr
Wu, Qi
Luo, Bao
Rowse, Amber L.
Spalding, David M.
Mobley, James A.
Bridges, S. Louis, Jr.
Mountz, John D.
TI Reshaping Inflammatory Macrophage Development and Functions by a
Monosaccharide Analogue In Rheumatoid Arthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Li, Jun; Yang, PingAr; Wu, Qi; Luo, Bao; Rowse, Amber L.; Spalding, David M.; Mobley, James A.; Bridges, S. Louis, Jr.; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2745
BP S1171
EP S1172
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206174
ER
PT J
AU Liu, ML
Bashir, M
Sharma, M
Xu, HH
Williams, K
Anyanwu, CO
Okawa, J
Werth, VP
AF Liu, Ming-Lin
Bashir, Muhammad
Sharma, Meena
Xu, Honghui
Williams, Kevin
Anyanwu, Cynthia O.
Okawa, Joyce
Werth, Victoria P.
TI Novel Proinflammatory Microvesicles That Carry LL-37 In Patients With
Cutaneous Lupus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Liu, Ming-Lin; Sharma, Meena] Univ Penn, Philadelphia, PA 19104 USA.
[Bashir, Muhammad; Xu, Honghui; Okawa, Joyce] Philadelphia VA Hosp, Philadelphia, PA USA.
[Williams, Kevin] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
[Anyanwu, Cynthia O.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1860
BP S793
EP S793
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204319
ER
PT J
AU Michalk, I
Berndt, N
Bippes, CC
Bartsch, H
Koristka, S
Arndt, C
Feldmann, A
Kurien, BT
Scofield, RH
Farris, AD
James, JA
Cartellieri, M
Bachmann, M
AF Michalk, Irene
Berndt, Nicole
Bippes, Claudia C.
Bartsch, Holger
Koristka, Stefanie
Arndt, Claudia
Feldmann, Anja
Kurien, Biji T.
Scofield, Robert Hal
Farris, A. Darise
James, Judith A.
Cartellieri, Marc
Bachmann, Michael
TI Redox Dependent Conformational Changes Of The Autoantigen La Are
Responsible For Its Shuttling, Translocation and a Pathophysiological
Role Of Anti-La Autoantibodies
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Michalk, Irene; Berndt, Nicole; Bippes, Claudia C.; Bartsch, Holger; Koristka, Stefanie; Arndt, Claudia; Feldmann, Anja; Cartellieri, Marc; Bachmann, Michael] Carl Gustav Carus TU Dresden, Dresden, Germany.
[Kurien, Biji T.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Scofield, Robert Hal] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Scofield, Robert Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Scofield, Robert Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Farris, A. Darise] Oklahoma Med Res Foun, Oklahoma City, OK USA.
[James, Judith A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
RI Bachmann, Michael/E-8850-2010; Feldmann, Anja/D-7843-2014
OI Bachmann, Michael/0000-0002-8029-5755; Feldmann,
Anja/0000-0001-5099-2448
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 923
BP S396
EP S396
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202428
ER
PT J
AU Miloslavsky, E
Sullivan, A
Richards, J
McSparron, JI
Roberts, D
Puig, A
AF Miloslavsky, Eli
Sullivan, Amy
Richards, Jeremy
McSparron, Jakob I.
Roberts, David
Puig, Alberto
TI The Resident-Fellow Interaction: Limiting Barriers and Maximizing
Learning
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Miloslavsky, Eli] Massachusetts Gen Hopsital, Boston, MA USA.
[Sullivan, Amy; Richards, Jeremy; Roberts, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[McSparron, Jakob I.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Puig, Alberto] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2814
BP S1205
EP S1205
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206243
ER
PT J
AU Miloslavsky, E
Specks, U
Merkel, PA
Seo, P
Spiera, RF
Langford, CA
Hoffman, GS
Kallenberg, CGM
St Clair, EW
Tchao, N
Ding, L
Ikle, D
Jepson, B
Brunetta, P
Stone, JH
AF Miloslavsky, Eli
Specks, Ulrich
Merkel, Peter A.
Seo, Philip
Spiera, Robert F.
Langford, Carol A.
Hoffman, Gary S.
Kallenberg, Cees G. M.
St Clair, E. William
Tchao, Nadia
Ding, Linna
Ikle, David
Jepson, Brett
Brunetta, Paul
Stone, John H.
TI Retreatment With Rituximab In The Rituximab In ANCA-Associated
Vasculitis (RAVE) Trial
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Miloslavsky, Eli] Massachusetts Gen Hopsital, Boston, MA USA.
[Specks, Ulrich] Mayo Clin, Rochester, MN USA.
[Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA.
[Merkel, Peter A.] VA Med Ctr, Philadelphia, PA USA.
[Seo, Philip] Johns Hopkins Vasculitis Ctr, Baltimore, MD USA.
[Spiera, Robert F.] Hosp Special Surg, New York, NY 10021 USA.
[Langford, Carol A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Hoffman, Gary S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Kallenberg, Cees G. M.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[St Clair, E. William] Duke Unvers Med Ctr, Durham, NC USA.
[Tchao, Nadia] Immune Tolerance Network, Bethesda, MD USA.
[Ding, Linna] NIAID, Bethesda, MD 20892 USA.
[Ikle, David; Jepson, Brett] Rho, Chapel Hill, NC USA.
[Brunetta, Paul] Genentech Inc, So San Francisco, CA USA.
[Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2782
BP S1190
EP S1190
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206211
ER
PT J
AU Miloslavsky, E
Specks, U
Merkel, PA
Seo, P
Spiera, RF
Langford, CA
Hoffman, GS
Kallenberg, CGM
St Clair, EW
Tchao, N
Ding, LN
Ikle, D
Jepson, B
Brunetta, P
Stone, JH
AF Miloslavsky, Eli
Specks, Ulrich
Merkel, Peter A.
Seo, Philip
Spiera, Robert F.
Langford, Carol A.
Hoffman, Gary S.
Kallenberg, Cees G. M.
St Clair, E. William
Tchao, Nadia
Ding, Linna
Ikle, David
Jepson, Brett
Brunetta, Paul
Stone, John H.
TI Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated
Vasculitis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Miloslavsky, Eli] Massachusetts Gen Hopsital, Boston, MA USA.
[Specks, Ulrich] Mayo Clin, Rochester, MN USA.
[Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA.
[Seo, Philip] Johns Hopkins Vasculitis Ctr, Baltimore, MD USA.
[Spiera, Robert F.] Hosp Special Surg, New York, NY 10021 USA.
[Langford, Carol A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Hoffman, Gary S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Kallenberg, Cees G. M.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[St Clair, E. William] Duke Univ, Med Ctr, Durham, NC USA.
[Tchao, Nadia] Immune Tolerance Network, Bethesda, MD USA.
[Ding, Linna] NIAID, Bethesda, MD 20892 USA.
[Ikle, David; Jepson, Brett] Rho, Chapel Hill, NC USA.
[Brunetta, Paul] Genentech Inc, So San Francisco, CA USA.
[Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 747
BP S315
EP S316
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202252
ER
PT J
AU Miloslavsky, E
Specks, U
Merkel, PA
Seo, P
Spiera, RF
Langford, CA
Hoffman, GS
Kallenberg, CGM
St Clair, EW
Tchao, N
Ding, LN
Ikle, D
Jepson, B
Brunetta, P
Stone, JH
AF Miloslavsky, Eli
Specks, Ulrich
Merkel, Peter A.
Seo, Philip
Spiera, Robert F.
Langford, Carol A.
Hoffman, Gary S.
Kallenberg, Cees G. M.
St Clair, E. William
Tchao, Nadia
Ding, Linna
Ikle, David
Jepson, Brett
Brunetta, Paul
Stone, John H.
TI Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In
Patients 65 and Older With Severe ANCA-Associated Vasculitis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Miloslavsky, Eli; Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Specks, Ulrich] Mayo Clin, Rochester, MN USA.
[Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA.
[Merkel, Peter A.] VA Med Ctr, Philadelphia, PA USA.
[Seo, Philip] Johns Hopkins Vasculitis Ctr, Baltimore, MD USA.
[Spiera, Robert F.] Hosp Special Surg, New York, NY 10021 USA.
[Langford, Carol A.] Cleveland Clin, Cleveland, OH 44106 USA.
[Hoffman, Gary S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Kallenberg, Cees G. M.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[St Clair, E. William] Duke Univ, Med Ctr, Durham, NC USA.
[Tchao, Nadia] Immune Tolerance Network, Bethesda, MD USA.
[Ding, Linna] NIAID, Bethesda, MD 20892 USA.
[Ikle, David; Jepson, Brett] Rho, Chapel Hill, NC USA.
[Brunetta, Paul] Genentech Inc, So San Francisco, CA USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 742
BP S313
EP S313
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202247
ER
PT J
AU Ritter, SY
Greenblatt, MB
Tsang, K
Hu, DZ
Wright, J
Aliprantis, AO
AF Ritter, Susan Y.
Greenblatt, Matthew B.
Tsang, Kelly
Hu, Dorothy Z.
Wright, John
Aliprantis, Antonios O.
TI Spontaneous Osteoarthritis In Mice By Genetic Deletion Of Nfatc1 and
Nfatc2
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Ritter, Susan Y.; Greenblatt, Matthew B.; Tsang, Kelly; Wright, John; Aliprantis, Antonios O.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Hu, Dorothy Z.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2733
BP S1166
EP S1167
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206162
ER
PT J
AU Ruth, NM
Kral, MC
Nowling, TK
Slan, S
Passo, MH
Gilkeson, GS
AF Ruth, Natasha M.
Kral, Mary C.
Nowling, Tamara K.
Slan, Stephanie
Passo, Murray H.
Gilkeson, Gary S.
TI The Usefulness Of Traditional Neurocognitive Testing and
N-Methyl-D-Aspartate Receptor Antibodies In Pediatric Lupus Patients
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Ruth, Natasha M.; Kral, Mary C.; Nowling, Tamara K.; Slan, Stephanie; Passo, Murray H.; Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Nowling, Tamara K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1261
BP S533
EP S533
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203244
ER
PT J
AU Sato, S
Williams, S
Karam, E
Zhang, X
AF Sato, Shuzo
Williams, Sarah
Karam, Eva
Zhang, Xian
TI Fli-1 Regulates Immune Cell Infiltration Through Affecting Local
Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone
Mice
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Sato, Shuzo; Karam, Eva; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA.
[Williams, Sarah; Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 558
BP S242
EP S242
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202070
ER
PT J
AU Schmajuk, G
Yazdany, J
Miao, YH
Daikh, DI
Steinman, M
AF Schmajuk, Gabriela
Yazdany, Jinoos
Miao, Yinghui
Daikh, David I.
Steinman, Michael
TI Folic Acid Prescription Among Older Adult Methotrexate Initiators Is
Poor
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Schmajuk, Gabriela] UCSF San Francisco VA Med Ctr, San Francisco, CA USA.
[Yazdany, Jinoos; Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Miao, Yinghui; Steinman, Michael] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1711
BP S725
EP S725
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204171
ER
PT J
AU Singh, JA
Bharat, A
Khanna, P
Aquino-Beaton, C
Persselin, JE
Duffy, E
Elashoff, D
Khanna, D
AF Singh, Jasvinder A.
Bharat, Aseem
Khanna, Puja
Aquino-Beaton, Cleopatra
Persselin, Jay E.
Duffy, Erin
Elashoff, David
Khanna, Dinesh
TI Health Care Utilization In Gout Patients: A Prospective Multicenter
Cohort Study
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Singh, Jasvinder A.] Univ Alabama, Tuscaloosa, AL USA.
[Bharat, Aseem] Univ Alabama Birmingham, Birmingham, AL USA.
[Khanna, Puja] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
[Aquino-Beaton, Cleopatra; Persselin, Jay E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Duffy, Erin] Univ Calif Los Angeles, Los Angeles, CA USA.
[Elashoff, David] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90024 USA.
[Khanna, Dinesh] Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1997
BP S852
EP S853
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204455
ER
PT J
AU Unizony, S
Stone, J
Keroack, B
AF Unizony, Sebastian
Stone, John
Keroack, Brian
TI Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Unizony, Sebastian; Stone, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Keroack, Brian] Tufts Univ, Sch Med, Maine Med Ctr, Maine, ME USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1685
BP S713
EP S713
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204147
ER
PT J
AU Vina, ER
Utset, TO
Hannon, MJ
Roberts, N
Masi, CM
Kwoh, CK
AF Vina, Ernest R.
Utset, Tammy O.
Hannon, Michael J.
Roberts, Nicole
Masi, Christopher M.
Kwoh, C. Kent
TI Racial Differences In Systemic Lupus Erythematosus Patients' Treatment
Preferences: A Two-Site Study
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Vina, Ernest R.; Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA.
[Vina, Ernest R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Utset, Tammy O.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Hannon, Michael J.; Roberts, Nicole] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Masi, Christopher M.] NorthShore Univ Hlth Syst, Evanston, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1069
BP S456
EP S457
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359203055
ER
PT J
AU Wallace, ZS
Mahajan, V
Carruthers, M
Mattoo, H
Pillai, S
Stone, JH
AF Wallace, Zachary S.
Mahajan, Vinay
Carruthers, Mollie
Mattoo, Hamid
Pillai, Shiv
Stone, John H.
TI Elevated IgG4+Plasmablasts In Patients With Active, Untreated
IgG4-Related Disease
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Wallace, Zachary S.; Carruthers, Mollie; Pillai, Shiv; Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mahajan, Vinay; Mattoo, Hamid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2024
BP S863
EP S864
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204482
ER
PT J
AU Wallace, ZS
Deshpande, V
Stone, JH
AF Wallace, Zachary S.
Deshpande, Vikram
Stone, John H.
TI Ophthalmic Manifestations Of IgG4-Related Disease: A Single-Center
Experience.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Wallace, Zachary S.; Deshpande, Vikram; Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 785
BP S332
EP S333
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359202290
ER
PT J
AU Werth, VP
Khamashta, MA
Illei, GG
Yoo, S
Wang, LW
Greth, W
AF Werth, Victoria P.
Khamashta, Munther A.
Illei, Gabor G.
Yoo, Stephen
Wang, Liangwei
Greth, Warren
TI Smoking Is Associated With More Severe Skin Disease In Subjects With
Moderate To Severe Systemic Lupus Erythematosus (SLE)
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Khamashta, Munther A.] Kings Coll London, Sch Med, Rayne Inst, Lupus Res Unit, London, England.
[Illei, Gabor G.; Yoo, Stephen; Wang, Liangwei; Greth, Warren] MedImmune LLC, Gaithersburg, MD USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2512
BP S1072
EP S1073
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359205457
ER
PT J
AU Werth, VP
Fiorentino, D
Cohen, SB
Fivenson, D
Hansen, C
Zoog, S
Arnold, G
Wang, C
Boedigheimer, M
Welcher, A
Chung, J
Sullivan, B
Martin, DA
AF Werth, Victoria P.
Fiorentino, David
Cohen, Stanley B.
Fivenson, David
Hansen, Chris
Zoog, Steve
Arnold, Greg
Wang, Christine
Boedigheimer, Michael
Welcher, Andrew
Chung, James
Sullivan, Barbara
Martin, David A.
TI A Phase I Single-Dose Crossover Study To Evaluate The Safety,
Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy
Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Fiorentino, David] Stanford Univ, Sch Med, Redwood City, CA USA.
[Cohen, Stanley B.] Metroplex Clin Res Ctr, Dallas, TX USA.
[Fivenson, David] Dermatology PLLC, MD, Ann Arbor, MI USA.
[Hansen, Chris] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Zoog, Steve; Arnold, Greg; Wang, Christine; Boedigheimer, Michael; Welcher, Andrew; Chung, James; Sullivan, Barbara] Amgen Inc, Thousand Oaks, CA USA.
[Martin, David A.] Amgen Inc, Seattle, WA USA.
NR 0
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 1608
BP S682
EP S683
PG 2
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359204072
ER
PT J
AU Yang, WH
Bloch, EG
Berenson, DF
Galdos, RL
Arora, P
Wu, CN
Bloch, DB
AF Yang, Wei-Hong
Bloch, Emily G.
Berenson, Daniel F.
Galdos, Rita L.
Arora, Pankaj
Wu, Connie
Bloch, Donald B.
TI The Use Of "Autoantigenomics" To Rapidly Identify Targets Of Human
Autoantibodies
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 158
BP S63
EP S63
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359201157
ER
PT J
AU Young, K
Benissan-Messan, D
Duryee, MJ
Anderson, D
Caplan, L
Davis, LA
Sayles, H
Hunter, CD
Klassen, LW
O'Dell, JR
Mikuls, TR
Thiele, GM
AF Young, Kathleen
Benissan-Messan, Dathe
Duryee, Michael J.
Anderson, Daniel
Caplan, Liron
Davis, Lisa A.
Sayles, Harlan
Hunter, Carlos D.
Klassen, Lynell W.
O'Dell, James R.
Mikuls, Ted R.
Thiele, Geoffrey M.
TI Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of
Inflammation and Is Correlated With The Disease Activity In Rheumatoid
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Young, Kathleen; Benissan-Messan, Dathe; Duryee, Michael J.; Anderson, Daniel; Sayles, Harlan; Hunter, Carlos D.; Klassen, Lynell W.; O'Dell, James R.; Mikuls, Ted R.; Thiele, Geoffrey M.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Davis, Lisa A.] Denver Hlth & Hosp Author, Denver, CO USA.
[Klassen, Lynell W.; Thiele, Geoffrey M.] Omaha VA Med Ctr, Omaha, NE USA.
[Mikuls, Ted R.] Omaha VA, Omaha, NE USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2262
BP S962
EP S962
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359205209
ER
PT J
AU Zhao, J
Giles, BM
Taylor, RL
Yette, GA
Lough, KM
Abraham, LJ
Wu, H
Gaffney, PM
Kelly, JA
Kaufman, KM
Harley, JB
Langefeld, CD
Brown, EE
Edberg, JC
Kimberly, RP
Ulgiati, D
Tsao, BP
Boackle, SA
AF Zhao, Jian
Giles, Brendan M.
Taylor, Rhonda L.
Yette, Gabriel A.
Lough, Kara M.
Abraham, Lawrence J.
Wu, Hui
Gaffney, Patrick M.
Kelly, Jennifer A.
Kaufman, Kenneth M.
Harley, John B.
Langefeld, Carl D.
Brown, Elizabeth E.
Edberg, Jeffrey C.
Kimberly, Robert P.
Ulgiati, Daniela
Tsao, Betty P.
Boackle, Susan A.
TI An Intronic CR2 Polymorphism Associated With Systemic Lupus
Erythematosus Alters CTCF Binding and CR1 Expression
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th
Annual Meeting of the Association-of-Rheumatology-Health-Professionals
CY OCT 25-30, 2013
CL San Diego, CA
SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess
C1 [Zhao, Jian; Wu, Hui; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Giles, Brendan M.; Yette, Gabriel A.; Lough, Kara M.; Boackle, Susan A.] Univ Colorado, Sch Med, Aurora, CO USA.
[Taylor, Rhonda L.; Abraham, Lawrence J.; Ulgiati, Daniela] Univ Western Australia, Perth, WA 6009, Australia.
[Gaffney, Patrick M.; Kelly, Jennifer A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Kaufman, Kenneth M.] Univ Cincinnati, Cincinnati, OH USA.
[Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
[Langefeld, Carl D.] Wake Forest Sch Med, Winston Salem, NC USA.
[Brown, Elizabeth E.; Kimberly, Robert P.] Univ Alabama Birmingham, Birmingham, AL USA.
[Edberg, Jeffrey C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2013
VL 65
SU 10
SI SI
MA 2703
BP S1155
EP S1155
PG 1
WC Rheumatology
SC Rheumatology
GA 230RF
UT WOS:000325359206133
ER
PT J
AU Caplan, D
Michaud, J
Hufford, R
AF Caplan, David
Michaud, Jennifer
Hufford, Rebecca
TI Dissociations and associations of performance in syntactic comprehension
in aphasia and their implications for the nature of aphasic deficits
SO BRAIN AND LANGUAGE
LA English
DT Article
DE Aphasia; Syntactic comprehension; Task effects; Deficits
ID SPOKEN-LANGUAGE COMPREHENSION; MOVING-WINDOW TECHNIQUE; SENTENCE
COMPREHENSION; BROCAS APHASIA; CAPACITY THEORY; WORKING-MEMORY; STROKE
APHASIA; EYE-MOVEMENTS; MODEL; DETERMINANTS
AB Sixty-one pwa were tested on syntactic comprehension in three tasks: sentence-picture matching, sentence-picture matching with auditory moving window presentation, and object manipulation. There were significant correlations of performances on sentences across tasks. First factors on which all sentence types loaded in unrotated factor analyses accounted for most of the variance in each task. Dissociations in performance between sentence types that differed minimally in their syntactic structures were not consistent across tasks. These results replicate previous results with smaller samples and provide important validation of basic aspects of aphasic performance in this area of language processing. They point to the role of a reduction in processing resources and of the interaction of task demands and parsing and interpretive abilities in the genesis of patient performance. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Caplan, David; Michaud, Jennifer; Hufford, Rebecca] Massachusetts Gen Hosp, Neuropsychol Lab, Dept Neurol, Boston, MA 02114 USA.
RP Caplan, D (reprint author), Neuropsychol Lab, 175 Cambridge St,Suite 340,Fruit St, Boston, MA 02114 USA.
EM dcaplan@partners.org
FU NIDCD [DC00942]
FX This research was supported by NIDCD Grant DC00942 to David Caplan.
NR 58
TC 13
Z9 13
U1 6
U2 27
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0093-934X
EI 1090-2155
J9 BRAIN LANG
JI Brain Lang.
PD OCT
PY 2013
VL 127
IS 1
BP 21
EP 33
DI 10.1016/j.bandl.2013.07.007
PG 13
WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences;
Psychology, Experimental
SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences &
Neurology; Psychology
GA 242BV
UT WOS:000326213300004
PM 24061104
ER
PT J
AU Yoshizawa, JM
Schafer, CA
Schafer, JJ
Farrell, JJ
Paster, BJ
Wong, DTW
AF Yoshizawa, Janice M.
Schafer, Christopher A.
Schafer, Jason J.
Farrell, James J.
Paster, Bruce J.
Wong, David T. W.
TI Salivary Biomarkers: Toward Future Clinical and Diagnostic Utilities
SO CLINICAL MICROBIOLOGY REVIEWS
LA English
DT Review
ID MICROBE IDENTIFICATION MICROARRAY; SQUAMOUS-CELL CARCINOMA; ORAL-CANCER
DETECTION; PANCREATIC-CANCER; BACTERIAL DIVERSITY; PROMOTER
HYPERMETHYLATION; REFRACTORY PERIODONTITIS; STREPTOCOCCUS-MUTANS;
HEALTHY-INDIVIDUALS; FLUID SPECIMENS
AB The pursuit of timely, cost-effective, accurate, and noninvasive diagnostic methodologies is an endeavor of urgency among clinicians and scientists alike. Detecting pathologies at their earliest stages can significantly affect patient discomfort, prognosis, therapeutic intervention, survival rates, and recurrence. Diagnosis and monitoring often require painful invasive procedures such as biopsies and repeated blood draws, adding undue stress to an already unpleasant experience. The discovery of saliva-based microbial, immunologic, and molecular biomarkers offers unique opportunities to bypass these measures by utilizing oral fluids to evaluate the condition of both healthy and diseased individuals. Here we discuss saliva and its significance as a source of indicators for local, systemic, and infectious disorders. We highlight contemporary innovations and explore recent discoveries that deem saliva a mediator of the body's physiological condition. Additionally, we examine the current state of salivary diagnostics and its associated technologies, future aspirations, and potential as the preferred route of disease detection, monitoring, and prognosis.
C1 [Yoshizawa, Janice M.; Schafer, Christopher A.; Wong, David T. W.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Yoshizawa, Janice M.; Schafer, Christopher A.; Wong, David T. W.] Ctr Oral Head & Neck Oncol Res, Los Angeles, CA 90024 USA.
[Schafer, Jason J.] Thomas Jefferson Univ, Jefferson Sch Pharm, Dept Pharm Practice, Philadelphia, PA 19107 USA.
[Farrell, James J.] Yale Univ, Sch Med, Yale Ctr Pancreat Dis & Endoscop Oncol, New Haven, CT USA.
[Paster, Bruce J.] Forsyth Inst, Cambridge, MA USA.
[Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Oral Biol Med, Boston, MA 02115 USA.
RP Wong, DTW (reprint author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
EM dtww@ucla.edu
FU NIDCR NIH HHS [T90 DE022734]
NR 120
TC 45
Z9 47
U1 4
U2 53
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0893-8512
EI 1098-6618
J9 CLIN MICROBIOL REV
JI Clin. Microbiol. Rev.
PD OCT
PY 2013
VL 26
IS 4
BP 781
EP 791
DI 10.1128/CMR.00021-13
PG 11
WC Microbiology
SC Microbiology
GA 229NF
UT WOS:000325272500006
PM 24092855
ER
PT J
AU Rahman, M
Baimbridge, C
Davis, BR
Barzilay, JI
Basile, JN
Henriquez, MA
Huml, A
Kopyt, N
Louis, GT
Pressel, SL
Rosendorr, C
Sastrasinh, S
Stanford, C
AF Rahman, Mahboob
Baimbridge, Charles
Davis, Barry R.
Barzilay, Joshua I.
Basile, Jan N.
Henriquez, Mario A.
Huml, Anne
Kopyt, Nelson
Louis, Gail T.
Pressel, Sara L.
Rosendorr, Clive
Sastrasinh, Sithiporn
Stanford, Carol
CA ALLHAT Collaborative Res Grp
TI Pravastatin and cardiovascular outcomes stratified by baseline eGFR in
the lipid-lowering component of ALLHAT
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE hyperlipidemia; kidney disease; cardiovascular outcomes; chronic renal
failure
ID CHRONIC KIDNEY-DISEASE; CHRONIC RENAL-INSUFFICIENCY;
GLOMERULAR-FILTRATION-RATE; ATTACK TRIAL ALLHAT; USUAL CARE; EVENTS;
HEART; ATORVASTATIN; HEMODIALYSIS; CHOLESTEROL
AB Background/Aims: The role of statins in preventing cardiovascular outcomes in patients with chronic kidney disease (CKD) is unclear. This paper compares cardiovascular outcomes with pravastatin vs. usual care, stratified by baseline estimated glomerular filtration rate (eGFR). Methods: Post-hoc analyses of a prospective randomized open-label clinical trial; 10,151 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid-lowering component) were randomized to pravastatin 40 mg/day or usual care. Mean follow-up was 4.8 years. Results: Through Year 6, total cholesterol declined in pravastatin (-20.7%) and usual-care groups (-11.2%). Use of statin therapy in the pravastatin group was 89.8% (Year 2) and 87.0% (Year 6). Usual-care group statin use increased from 8.2% (Year 2) to 23.5% (Year 6). By primary intention-to-treat analyses, no significant differences were seen between groups for coronary heart disease (CHD), total mortality or combined cardiovascular disease; findings were consistent across eGFR strata. In exploratory "as-treated" analyses (patients actually using pravastatin vs. not using), pravastatin therapy was associated with lower mortality (HR = 0.76 (0.68 - 0.85), p < 0.001) and lower CHID (HR = 0.84 (0.73 - 0.97), p = 0.01), but not combined cardiovascular disease (HR = 0.95 (0.88 - 1.04), p = 0.30). Total cholesterol reduction of 10 mg/dL from baseline to Year 2 was associated with 5% lower CHD risk. Conclusions: In hypertensive patients with moderate dyslipidemia, pravastatin was not superior to usual care in preventing total mortality or CHD independent of baseline eGFR level. However, exploratory "as-treated" analyses suggest improved mortality and CHD risk in participants using pravastatin, and decreased CHD events associated with achieved reduction in total cholesterol. Potential benefit from statin therapy may depend on degree of reduction achieved in total and LDL-cholesterol and adherence to therapy.
C1 [Rahman, Mahboob; Huml, Anne] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
[Baimbridge, Charles; Davis, Barry R.; Pressel, Sara L.] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA.
[Barzilay, Joshua I.] Kaiser Permanente Georgia, Tucker, GA USA.
[Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Henriquez, Mario A.] Bronx Nephrol Hypertens, Bronx, NY USA.
[Kopyt, Nelson] Lehigh Valley Hosp, Allentown, PA USA.
[Louis, Gail T.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA.
[Rosendorr, Clive] Mt Sinai Sch Med, New York, NY USA.
[Rosendorr, Clive] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Sastrasinh, Sithiporn] Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA.
[Stanford, Carol] Univ Missouri, Sch Med, Kansas City, MO 64108 USA.
RP Pressel, SL (reprint author), Univ Texas Houston, Sch Publ Hlth, Coordinating Ctr Clin Trials, 1200 Herman Pressler St,Suite W908, Houston, TX 77030 USA.
EM Sara.L.Pressel@uth.tmc.edu
FU National Heart, Lung, and Blood Institute [NO1-HC-35130]; Pfizer
FX This study was supported by contract NO1-HC-35130 with the National
Heart, Lung, and Blood Institute. The ALLHAT investigators acknowledge
contributions of study medications supplied by Pfizer (amlodipine and
doxazosin), AstraZeneca (atenolol and lisinopril) and Bristol-Myers
Squibb (pravastatin), and financial support provided by Pfizer.
NR 23
TC 2
Z9 2
U1 0
U2 4
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0301-0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD OCT
PY 2013
VL 80
IS 4
BP 235
EP 248
DI 10.5414/CN107922
PG 14
WC Urology & Nephrology
SC Urology & Nephrology
GA 241YS
UT WOS:000326205200001
PM 23816477
ER
PT J
AU Kang, RW
Mahony, GT
Harris, TC
Dines, JS
AF Kang, Richard W.
Mahony, Gregory T.
Harris, Thomas C.
Dines, Joshua S.
TI Posterior Instability Caused by Batter's Shoulder
SO CLINICS IN SPORTS MEDICINE
LA English
DT Article
DE Posterior instability; Posterior labral repair; Batter's shoulder;
Shoulder injury
ID SUBLUXATION; BASEBALL; LESION; REPAIR
AB The lead shoulder of a batter's swing can undergo tremendous forces, especially when a pitch is missed. Repetitive loads on the shoulder in this setting can lead to posterior instability also known as batter's shoulder. This article reviews the pathomechanics, clinical presentation, imaging, treatment options, and initial clinical results of batter's shoulder.
C1 [Kang, Richard W.; Mahony, Gregory T.; Dines, Joshua S.] Hosp Special Surg, Dept Sports Med & Shoulder Surg, New York, NY 10021 USA.
[Harris, Thomas C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Kang, RW (reprint author), Hosp Special Surg, Dept Sports Med & Shoulder Surg, 535 E 70th St, New York, NY 10021 USA.
EM rwkang.md@gmail.com
NR 13
TC 2
Z9 2
U1 2
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-5919
EI 1556-228X
J9 CLIN SPORT MED
JI Clin. Sports Med.
PD OCT
PY 2013
VL 32
IS 4
BP 797
EP +
DI 10.1016/j.csm.2013.07.012
PG 7
WC Sport Sciences
SC Sport Sciences
GA 243GW
UT WOS:000326305900014
PM 24079435
ER
PT J
AU Gwathmey, FW
Warner, JJP
AF Gwathmey, F. Winston, Jr.
Warner, Jon J. P.
TI Management of the Athlete with a Failed Shoulder Instability Procedure
SO CLINICS IN SPORTS MEDICINE
LA English
DT Article
DE Shoulder instability; Recurrence; Athlete; Bankart; Latarjet
ID ARTHROSCOPIC BANKART REPAIR; GLENOID BONE LOSS; ANTERIOR GLENOHUMERAL
INSTABILITY; HILL-SACHS LESION; 6-YEAR FOLLOW-UP; LATARJET PROCEDURE;
SUTURE-ANCHOR; RISK-FACTORS; SURGICAL-TREATMENT; EXTERNAL ROTATION
AB Athletes often expose their shoulders to significant forces and stresses and treatment of recurrent shoulder instability in this population is challenging. Recurrence after surgical shoulder stabilization in an athlete warrants a systematic approach to the diagnosis and treatment, The surgeon must develop a dear understanding of the etiology of the failure and take the necessary steps during the management algorithm to prevent a subsequent recurrence. When planning revision surgical stabilization, the surgeon must analyze and address risk factors for recurrence, which include younger age, contact/collision sports, higher level of competition, capsular laxity, glenoid bone loss, and engaging Hill-Sachs deformities. The surgeon must provide the athlete with the surgery that provides the best chance to return to sport and the lowest risk of recurrent instability. While revision arthroscopic Bankart repair may be appropriate in some cases in which there is minimal glenoid bone loss and robust labral and capsular tissue is available, an open procedure such as a Latarjet may be indicated for athletes at high risk for recurrence.
C1 [Gwathmey, F. Winston, Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Warner, Jon J. P.] Harvard Univ, Sch Med, MGH Shoulder Serv, Boston Shoulder Inst,Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Warner, JJP (reprint author), Harvard Univ, Sch Med, MGH Shoulder Serv, Boston Shoulder Inst,Massachusetts Gen Hosp, 55 Fruit St,Suite 3200, Boston, MA 02114 USA.
EM jwarner@partners.org
NR 127
TC 2
Z9 2
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-5919
EI 1556-228X
J9 CLIN SPORT MED
JI Clin. Sports Med.
PD OCT
PY 2013
VL 32
IS 4
BP 833
EP +
DI 10.1016/j.csm.2013.07.016
PG 33
WC Sport Sciences
SC Sport Sciences
GA 243GW
UT WOS:000326305900018
PM 24079439
ER
PT J
AU Grottkau, BE
Cai, XX
Wang, J
Yang, XM
Lin, YF
AF Grottkau, Brian E.
Cai, Xiaoxiao
Wang, Jing
Yang, Xingmei
Lin, Yunfeng
TI Polymeric Nanoparticles for a Drug Delivery System
SO CURRENT DRUG METABOLISM
LA English
DT Article
DE Polymeric nanoparticles; PHA; PLGA
ID PEG-PLGA NANOPARTICLES; IN-VITRO EVALUATION; BIODEGRADABLE
NANOPARTICLES; TARGETED NANOMEDICINES; VIVO EVALUATION; MODEL PROTEIN;
MICROSPHERES; TISSUE; POLYHYDROXYALKANOATES; BIOCOMPATIBILITY
AB In recent years, nanotechnology research has made great strides in the area of pharmacy, especially for drug delivery systems. Polymeric nanoparticles provide significant stability in anti-neoplastic drug research and have demonstrated the ability to solve the problems of therapeutic efficacy and diagnostic sensitivity. In this review, we describe the specific advantages of polymeric nanoparticles and their applications for a drug delivery system. The latest research on PHA-based polymeric nanoparticles and PLGA is also discussed.
C1 [Grottkau, Brian E.] Harvard Univ, Sch Med, MassGen Hosp Children, Dept Orthopaed Surg, Boston, MA USA.
[Grottkau, Brian E.] Harvard Univ, Sch Med, Pediat Orthopaed Lab Tissue Engn & Regenerat Med, Boston, MA USA.
[Cai, Xiaoxiao; Yang, Xingmei; Lin, Yunfeng] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
[Wang, Jing] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Stomatol, Shanghai 200092, Peoples R China.
RP Lin, YF (reprint author), Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, 14,3rd Sec,Ren Min Nan Rd, Chengdu 610041, Peoples R China.
EM yunfenglin@scu.edu.cn
RI Lin, Yunfeng/M-5438-2013; Lin, Yunfeng/H-3393-2011;
OI Lin, Yunfeng/0000-0003-1224-6561; Lin, Yunfeng/0000-0003-1224-6561; Cai,
Xiaoxiao/0000-0002-5654-7414
FU National Natural Science Foundation of China [81071273, 31170929,
81201211]; Foundation for the Author of National Excellent Doctoral
Dissertation of China [FANEDD 200977]; Doctoral Fund of Ministry of
Education of China [20110181120071]
FX This work was funded by National Natural Science Foundation of China
(81071273, 31170929, 81201211), Foundation for the Author of National
Excellent Doctoral Dissertation of China (FANEDD 200977), Doctoral Fund
of Ministry of Education of China (20110181120071).
NR 50
TC 12
Z9 12
U1 10
U2 61
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1389-2002
EI 1875-5453
J9 CURR DRUG METAB
JI Curr. Drug Metab.
PD OCT
PY 2013
VL 14
IS 8
SI SI
BP 840
EP 846
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 241LR
UT WOS:000326168900004
PM 24016112
ER
PT J
AU Uygun, BE
Yarmush, ML
AF Uygun, Basak E.
Yarmush, Martin L.
TI Engineered liver for transplantation
SO CURRENT OPINION IN BIOTECHNOLOGY
LA English
DT Review
ID PLURIPOTENT STEM-CELLS; HEPATOCYTE TRANSPLANTATION;
EXTRACELLULAR-MATRIX; REGENERATIVE MEDICINE; STEM/PROGENITOR CELLS;
DECELLULARIZED MATRIX; UNITED-STATES; FETAL LIVER; TISSUE; SCAFFOLDS
AB Orthotopic liver transplantation is the only definitive treatment for end stage liver failure and the shortage of donor organs severely limits the number of patients receiving transplants. Liver tissue engineering aims to address the donor liver shortage by creating functional tissue constructs to replace a damaged or failing liver. Despite decades of work, various bottoms-up, synthetic biomaterials approaches have failed to produce a functional construct suitable for transplantation. Recently, a new strategy has emerged using whole organ scaffolds as a vehicle for tissue engineering. This technique involves preparation of these organ scaffolds via perfusion decellularization with the resulting scaffold retaining the circulatory network of the native organ. This important phenomenon allows for the construct to be repopulated with cells and to be connected to the blood torrent upon transplantation. This opinion paper presents the current advances and discusses the challenges of creating fully functional transplantable liver grafts with this whole liver engineering approach.
C1 [Uygun, Basak E.; Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA.
[Uygun, Basak E.; Yarmush, Martin L.] Shriners Hosp Children Boston, Boston, MA 02114 USA.
[Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.
RP Yarmush, ML (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, 51 Blossom St, Boston, MA 02114 USA.
EM ireis@sbi.org
RI Uygun, Basak/I-1792-2012
OI Uygun, Basak/0000-0002-2600-7900
FU NIDDK NIH HHS [K99 DK088962, R00 DK088962, R01 DK084053]
NR 66
TC 12
Z9 13
U1 3
U2 41
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0958-1669
EI 1879-0429
J9 CURR OPIN BIOTECH
JI Curr. Opin. Biotechnol.
PD OCT
PY 2013
VL 24
IS 5
BP 893
EP 899
DI 10.1016/j.copbio.2013.05.008
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 241BP
UT WOS:000326141700011
PM 23791465
ER
PT J
AU Tegos, GP
Hamblin, MR
AF Tegos, George P.
Hamblin, Michael R.
TI Disruptive innovations: new anti-infectives in the age of resistance
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Editorial Material
C1 [Tegos, George P.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA.
[Tegos, George P.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA.
[Tegos, George P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Tegos, George P.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
RP Tegos, GP (reprint author), Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA.
EM gtegos@salud.unm.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU NIAID NIH HHS [R01 AI050875, R01AI050875]
NR 12
TC 8
Z9 9
U1 2
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD OCT
PY 2013
VL 13
IS 5
BP 673
EP 677
DI 10.1016/j.coph.2013.08.012
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 241BD
UT WOS:000326140500001
PM 24012294
ER
PT J
AU Bologa, CG
Ursu, O
Oprea, TI
Melancon, CE
Tegos, GP
AF Bologa, Cristian G.
Ursu, Oleg
Oprea, Tudor I.
Melancon, Charles E., III
Tegos, George P.
TI Emerging trends in the discovery of natural product antibacterials
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID I POLYKETIDE SYNTHASES; ESCHERICHIA-COLI; GENE CLUSTERS; BIOSYNTHESIS;
RESISTANCE; STREPTOMYCES; ANTIBIOTICS; BACTERIAL; INHIBITION; DIVERSITY
AB This article highlights current trends and advances in exploiting natural sources for the deployment of novel and potent anti-infective countermeasures. The key challenge is to therapeutically target bacterial pathogens that exhibit a variety of puzzling and evolutionarily complex resistance mechanisms. Special emphasis is given to the strengths, weaknesses, and opportunities in the natural product antibacterial drug discovery arena, and to emerging applications driven by advances in bioinformatics, chemical biology, and synthetic biology in concert with exploiting bacterial phenotypes. These efforts have identified a critical mass of natural product antibacterial lead compounds and discovery technologies with high probability of successful implementation against emerging bacterial pathogens.
C1 [Bologa, Cristian G.; Ursu, Oleg; Oprea, Tudor I.; Tegos, George P.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA.
[Bologa, Cristian G.; Ursu, Oleg; Oprea, Tudor I.] Univ New Mexico, Hlth Sci Ctr, Dept Internal Med, Translat Informat Div, Albuquerque, NM 87131 USA.
[Oprea, Tudor I.] Univ Gothenburg, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.
[Oprea, Tudor I.] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmark.
[Melancon, Charles E., III] Univ New Mexico, Dept Chem & Biol Chem, Albuquerque, NM 87131 USA.
[Melancon, Charles E., III] Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA.
[Tegos, George P.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA.
[Tegos, George P.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Tegos, George P.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
RP Melancon, CE (reprint author), Univ New Mexico, Dept Chem & Biol Chem, Albuquerque, NM 87131 USA.
EM gtegos@salud.unm.edu
RI Oprea, Tudor/A-5746-2011; Luan, Gan/B-3211-2015; Bologa,
Cristian/A-7952-2010
OI Oprea, Tudor/0000-0002-6195-6976; Bologa, Cristian/0000-0003-2232-4244
FU NIH [5U54MH084690-02]; DTRA [HDTRA1-13-C-0005]; NCRR [5P20RR016480-12];
NIGMS [8P20GM103451-12]
FX Work in the authors' laboratories was supported by the NIH (grant
5U54MH084690-02 to GPT), DTRA (contract number HDTRA1-13-C-0005 to GPT),
NCRR (5P20RR016480-12 to CGB) and NIGMS (8P20GM103451-12 to CGB)
NR 49
TC 14
Z9 14
U1 4
U2 45
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD OCT
PY 2013
VL 13
IS 5
BP 678
EP 687
DI 10.1016/j.coph.2013.07.002
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 241BD
UT WOS:000326140500002
PM 23890825
ER
PT J
AU Yin, R
Dai, TH
Avci, P
Jorge, AES
de Melo, WCMA
Vecchio, D
Huang, YY
Gupta, A
Hamblin, MR
AF Yin, Rui
Dai, Tianhong
Avci, Pinar
Serafim Jorge, Ana Elisa
de Melo, Wanessa C. M. A.
Vecchio, Daniela
Huang, Ying-Ying
Gupta, Asheesh
Hamblin, Michael R.
TI Light based anti-infectives: ultraviolet C irradiation, photodynamic
therapy, blue light, and beyond
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; DELTA-AMINOLEVULINIC-ACID;
GRAM-NEGATIVE BACTERIA; DERMATOPHYTE TRICHOPHYTON-RUBRUM; EXPERIMENTAL
PERIODONTAL-DISEASE; ANTIMICROBIAL CHEMOTHERAPY PACT;
HELICOBACTER-PYLORI INFECTION; CRUZI TRYPOMASTIGOTE FORMS; LOW
ENVIRONMENTAL-IMPACT; MYCOBACTERIUM-BOVIS BCG
AB Owing to the worldwide increase in antibiotic resistance, researchers are investigating alternative anti-infective strategies to which it is supposed microorganisms will be unable to develop resistance. Prominent among these strategies, is a group of approaches which rely on light to deliver the killing blow. As is well known, ultraviolet light, particularly UVC (200-280 nm), is germicidal, but it has not been much developed as an anti-infective approach until recently, when it was realized that the possible adverse effects to host tissue were relatively minor compared to its high activity in killing pathogens. Photodynamic therapy is the combination of non-toxic photosensitizing dyes with harmless visible light that together produce abundant destructive reactive oxygen species (ROS). Certain cationic dyes or photosensitizers have good specificity for binding to microbial cells while sparing host mammalian cells and can be used for treating many localized infections, both superficial and even deep-seated by using fiber optic delivered light. Many microbial cells are highly sensitive to killing by blue light (400-470 nm) due to accumulation of naturally occurring photosensitizers such as porphyrins and flavins. Near infrared light has also been shown to have antimicrobial effects against certain species. Clinical applications of these technologies include skin, dental, wound, stomach, nasal, toenail and other infections which are amenable to effective light delivery.
C1 [Yin, Rui; Dai, Tianhong; Avci, Pinar; Serafim Jorge, Ana Elisa; de Melo, Wanessa C. M. A.; Vecchio, Daniela; Huang, Ying-Ying; Gupta, Asheesh; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Yin, Rui; Dai, Tianhong; Avci, Pinar; Vecchio, Daniela; Huang, Ying-Ying; Gupta, Asheesh; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Yin, Rui] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing, Peoples R China.
[Avci, Pinar] Semmelweis Univ, Sch Med, Dept Dermatol Dermatooncol & Venerol, H-1085 Budapest, Hungary.
[Serafim Jorge, Ana Elisa] Univ Sao Paulo, EESC FMRP IQSC, Programa Posgrad Interunidades Bioengn, Sao Carlos, SP, Brazil.
[Serafim Jorge, Ana Elisa] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Pesquisa Opt & Foton, Sao Carlos, SP, Brazil.
[de Melo, Wanessa C. M. A.] Univ Sao Paulo, Sao Carlos, SP, Brazil.
[Huang, Ying-Ying] Guangxi Med Univ, Dept Pathol, Nanning, Guangxi, Peoples R China.
[Gupta, Asheesh] Def Inst Physiol & Allied Sci, Delhi, India.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
RI Sao Carlos Institute of Physics, IFSC/USP/M-2664-2016;
OI Hamblin, Michael/0000-0001-6431-4605
FU US NIH [R01AI050875]; National Natural Science Foundation of China
[81172495]; Airlift Research Foundation Extremity Trauma Research Grant
[109421]; CAPES (Coordination for the Improvement of Higher Level
Personnel) from Brazil; Department of Science and Technology, Government
of India [2010-11]
FX Research in the Hamblin laboratory is supported by US NIH grant
R01AI050875. Rui Yin was supported in part by National Natural Science
Foundation of China (No. 81172495) in this work. Tianhong Dai was
supported by an Airlift Research Foundation Extremity Trauma Research
Grant (No. 109421). Ana Jorge and Wanessa de Melo were supported by
CAPES (Coordination for the Improvement of Higher Level Personnel) from
Brazil. Asheesh Gupta was supported by BOYSCAST Fellowship 2010-11,
Department of Science and Technology, Government of India.
NR 283
TC 34
Z9 35
U1 3
U2 57
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD OCT
PY 2013
VL 13
IS 5
BP 731
EP 762
DI 10.1016/j.coph.2013.08.009
PG 32
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 241BD
UT WOS:000326140500008
PM 24060701
ER
PT J
AU Metra, M
Ponikowski, P
Cotter, G
Davison, BA
Felker, GM
Filippatos, G
Greenberg, BH
Hua, TA
Severin, T
Unemori, E
Voors, AA
Teerlink, JR
AF Metra, Marco
Ponikowski, Piotr
Cotter, Gad
Davison, Beth A.
Felker, G. Michael
Filippatos, Gerasimos
Greenberg, Barry H.
Hua, Tsushung A.
Severin, Thomas
Unemori, Elaine
Voors, Adriaan A.
Teerlink, John R.
TI Effects of serelaxin in subgroups of patients with acute heart failure:
results from RELAX-AHF
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Acute heart failure; Serelaxin; Mortality; Subgroups
ID NATRIURETIC PEPTIDE; CLINICAL-TRIALS; OUTCOMES; HOSPITALIZATION;
ANTAGONIST; PROGRAM; STATE
AB Aim Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial.
Methods and results Subgroups were based on pre-specified covariates (age, sex, race, geographic region, estimated glomerular filtration rate, time from presentation to randomization, baseline systolic blood pressure, history of diabetes, atrial fibrillation, ischaemic heart disease, cardiac devices, i.v. nitrates at randomization). Other covariates which may modify the efficacy of AHF treatment were also analysed. Subgroup analyses did not show any difference in the effects of serelaxin vs. placebo on dyspnoea relief or on the incidence of cardiovascular death or rehospitalizations for heart failure or renal failure at 60 days. Nominally significant interactions between some patient subgroups and the effects of serelaxin on 180 days cardiovascular and all-cause mortality were noted but should be interpreted cautiously due to the number of comparisons and the low incidence of deaths in the subgroups at lower risk.
Conclusion The effects of serelaxin vs. placebo appeared to be similar across subgroups of patients in RELAX-AHF.
C1 [Metra, Marco] Univ Brescia, Dept Med & Surg Specialties, Brescia, Italy.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
[Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
[Felker, G. Michael] Duke Univ, Sch Med, Duke Heart Ctr, Durham, NC USA.
[Filippatos, Gerasimos] Athens Univ Hosp, Athens, Greece.
[Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Hua, Tsushung A.] Novartis Pharmaceut, E Hanover, NJ USA.
[Severin, Thomas] Novartis Pharma AG, Basel, Switzerland.
[Unemori, Elaine] Corthera Inc, San Carlos, CA USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Metra, M (reprint author), Spedali Civil Brescia, Piazza Spedali Civili 1, I-25123 Brescia, Italy.
EM metramarco@libero.it
RI Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015;
OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568;
Davison, Beth/0000-0003-2374-6449
FU Corthera, Inc.; Novartis Pharma AG, Basel, Switzerland
FX The RELAX-AHF trial was supported by Corthera, Inc., a member of the
Novartis group of companies. Graham Allcock of CircleScience provided
editorial assistance, which was funded by Novartis Pharma AG, Basel,
Switzerland.
NR 29
TC 27
Z9 29
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD OCT
PY 2013
VL 34
IS 40
BP 3128
EP 3136
DI 10.1093/eurheartj/eht371
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243BX
UT WOS:000326292600012
PM 23999454
ER
PT J
AU Drubach, LA
Palmer, EL
Stamoulis, C
Jenkins, KJ
Marshall, AC
Cao, X
Lee, EY
AF Drubach, L. A.
Palmer, E. L.
Stamoulis, C.
Jenkins, K. J.
Marshall, A. C.
Cao, X.
Lee, E. Y.
TI Correlation of the Findings of Quantitative 99mTc MAA Lung Scintigraphy
and Cardiac Catheterization in pediatric patients with Pulmonary Vein
Stenosis
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Meeting Abstract
CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)
CY OCT 19-23, 2013
CL Lyon, FRANCE
SP European Assoc Nucl Med
C1 [Drubach, L. A.; Stamoulis, C.; Jenkins, K. J.; Marshall, A. C.; Cao, X.; Lee, E. Y.] Boston Childrens Hosp, Boston, MA USA.
[Palmer, E. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2013
VL 40
SU 2
BP S165
EP S165
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 237FG
UT WOS:000325853400217
ER
PT J
AU McQuaid, SJ
Kijewski, MF
Moore, SC
Park, M
Sitek, A
Gualtieri, E
Perkins, A
Daube-Witherspoon, M
Karp, JS
AF McQuaid, S. J.
Kijewski, M. F.
Moore, S. C.
Park, M.
Sitek, A.
Gualtieri, E.
Perkins, A.
Daube-Witherspoon, M.
Karp, J. S.
TI Estimating Cardiac Kinetic Parameters Using Dynamic Time-of-Flight PET
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Meeting Abstract
CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)
CY OCT 19-23, 2013
CL Lyon, FRANCE
SP European Assoc Nucl Med
C1 [McQuaid, S. J.] Royal Surrey Cty Hosp, Guildford, Surrey, England.
[Kijewski, M. F.; Moore, S. C.; Park, M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Kijewski, M. F.; Moore, S. C.; Park, M.; Sitek, A.] Harvard Univ, Sch Med, Boston, MA USA.
[Sitek, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gualtieri, E.; Daube-Witherspoon, M.; Karp, J. S.] Univ Penn, Philadelphia, PA 19104 USA.
[Perkins, A.] Philips Healthcare, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2013
VL 40
SU 2
BP S158
EP S158
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 237FG
UT WOS:000325853400192
ER
PT J
AU van der Lans, A
Lichtenbelt, WV
Hoeks, J
Vijgen, G
Visser, M
Vosselmans, M
Hansen, J
Jorgensen, J
Wu, J
Mottaghy, F
Schrauwen, P
Brans, B
AF van der Lans, A.
Lichtenbelt, W. van Marken
Hoeks, J.
Vijgen, G.
Visser, M.
Vosselmans, M.
Hansen, J.
Jorgensen, J.
Wu, J.
Mottaghy, F.
Schrauwen, P.
Brans, B.
TI Visualization of brown adipose tissue recruitment in human adults by
means of dynamic and static [F-18]FDG PET/CT-imaging
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Meeting Abstract
CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)
CY OCT 19-23, 2013
CL Lyon, FRANCE
SP European Assoc Nucl Med
C1 [van der Lans, A.; Lichtenbelt, W. van Marken; Hoeks, J.; Vosselmans, M.; Hansen, J.; Jorgensen, J.; Schrauwen, P.] Univ Maastricht, Maastricht, Netherlands.
[Vijgen, G.; Visser, M.; Brans, B.] Univ Maastricht, Med Ctr, Maastricht, Netherlands.
[Wu, J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wu, J.] Harvard Univ, Sch Med, Boston, MA USA.
[Mottaghy, F.] Univ Hosp RWTH Aachen, Aachen, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2013
VL 40
SU 2
BP S203
EP S203
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 237FG
UT WOS:000325853400359
ER
EF